PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 8694856-5 1996 A gel mobility-shift assay demonstrated that the 1,25-(OH)2D3-induced alteration of hsp28 gene expression was associated with decreased binding activity to the vitamin D3 receptor-vitamin D3 response element (VDR-VDRE), whereas binding to the heat shock transcription factor-heat shock element (HSF-HSE) was not altered. Cholecalciferol 160-170 heat shock protein family B (small) member 1 Homo sapiens 84-89 8663213-1 1996 Parathyroid hormone-related peptide (PTHRP) gene transcription is suppressed by 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active metabolite of vitamin D3. Cholecalciferol 94-104 parathyroid hormone-like hormone Rattus norvegicus 0-35 8663213-1 1996 Parathyroid hormone-related peptide (PTHRP) gene transcription is suppressed by 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active metabolite of vitamin D3. Cholecalciferol 94-104 parathyroid hormone-like hormone Rattus norvegicus 37-42 8869697-0 1996 Climatotherapy at the Dead Sea stimulates vitamin D3 metabolism. Cholecalciferol 42-52 S13 erythroblastosis (avian) oncogene homolog Homo sapiens 27-30 8698190-0 1996 Protein kinase C isoforms in the chemopreventive effects of a novel vitamin D3 analogue in rat colonic tumorigenesis. Cholecalciferol 68-78 protein kinase C, gamma Rattus norvegicus 0-16 8665483-4 1996 Thus, vitamin D3 treatment can stimulate the immune competence of tumor bearers when treatment is targeted to coincide with a heightened presence of GM-CSF-induced suppressor cells. Cholecalciferol 6-16 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 149-155 8672545-1 1996 We found that vitamin D3 up-regulates the expression of cytidine deaminase (CDD) gene in some human solid tumor cell lines as well as the monocytic leukemia cell lines. Cholecalciferol 14-24 cytidine deaminase Homo sapiens 56-74 8966142-1 1996 Active vitamin D3 pulse therapy effectively suppresses parathormone (PTH) synthesis in uremic hyperparathyroidism but high serum levels of calcitriol achieved can induce direct osteoclastic resorption and block bone formation. Cholecalciferol 7-17 parathyroid hormone Homo sapiens 69-72 8672545-1 1996 We found that vitamin D3 up-regulates the expression of cytidine deaminase (CDD) gene in some human solid tumor cell lines as well as the monocytic leukemia cell lines. Cholecalciferol 14-24 cytidine deaminase Homo sapiens 76-79 8672545-7 1996 Three of five gastric carcinoma cell lines and five of eight colorectal cancer lines had increased levels of CDD mRNA following 24 h treatment with vitamin D3. Cholecalciferol 148-158 cytidine deaminase Homo sapiens 109-112 8672545-9 1996 Our results demonstrate that CDD can be up-regulated by vitamin D3 in some solid tumor cell lines. Cholecalciferol 56-66 cytidine deaminase Homo sapiens 29-32 8660360-4 1996 The vitamin D3-elicited PSA increases were preceded by an induction of androgen receptor (AR) expression, as measured by Western blot analysis and by binding assays using [3H]R1881 as the ligand. Cholecalciferol 4-14 androgen receptor Homo sapiens 71-88 8660360-4 1996 The vitamin D3-elicited PSA increases were preceded by an induction of androgen receptor (AR) expression, as measured by Western blot analysis and by binding assays using [3H]R1881 as the ligand. Cholecalciferol 4-14 androgen receptor Homo sapiens 90-92 8660360-5 1996 These results are consistent with the hypothesis that the growth inhibitory effects of vitamin D3 is partially mediated through its ability to modulate PCNA expression. Cholecalciferol 87-97 proliferating cell nuclear antigen Homo sapiens 152-156 8809353-0 1996 Peroxidase activity of liver microsomal vitamin D 25-hydroxylase and cytochrome P450 1A2 catalyzes 25-hydroxylation of vitamin D3 and oxidation of dopamine to aminochrome. Cholecalciferol 119-129 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 40-64 8809353-0 1996 Peroxidase activity of liver microsomal vitamin D 25-hydroxylase and cytochrome P450 1A2 catalyzes 25-hydroxylation of vitamin D3 and oxidation of dopamine to aminochrome. Cholecalciferol 119-129 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 69-88 8809353-1 1996 Purified liver microsomal vitamin D 25-hydroxylase, a cytochrome P450, catalyzes 25-hydroxylation of vitamin D3 in the absence of NADPH and NADPH-cytochrome P450 reductase by using t-butyl hydroperoxide as electron donors. Cholecalciferol 101-111 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 26-50 11866799-6 1996 We also evaluated the in vitro inhibitory effects of macrolides on IL---8 production by vitamin D3-induced human monocytic cell line THP-1 cells when stimulated with lipopolysaccharide and serum. Cholecalciferol 88-98 C-X-C motif chemokine ligand 8 Homo sapiens 67-73 8776727-5 1996 One of these motifs resembles the negative VDRE (nVDRE) from the PTH gene, which is also down-regulated by vitamin D3. Cholecalciferol 107-117 parathyroid hormone Rattus norvegicus 65-68 8665568-5 1996 In mice that were first treated with vitamin D3 and then also with IL-12, there was stimulation of splenic T cell proliferation in response to immobilized anti-CD3 plus IL-2. Cholecalciferol 37-47 interleukin 2 Mus musculus 169-173 9081364-0 1996 Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089. Cholecalciferol 120-130 insulin Homo sapiens 14-21 9081364-0 1996 Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089. Cholecalciferol 120-130 insulin Homo sapiens 27-34 9081364-2 1996 The purpose of the present study was to investigate a possible interaction of 1,25-(OH)2D3 and the vitamin D3 analogue EB1089 with the insulin-IGF-I regulatory system. Cholecalciferol 99-109 insulin Homo sapiens 135-142 9081364-2 1996 The purpose of the present study was to investigate a possible interaction of 1,25-(OH)2D3 and the vitamin D3 analogue EB1089 with the insulin-IGF-I regulatory system. Cholecalciferol 99-109 insulin like growth factor 1 Homo sapiens 143-148 9081364-12 1996 Together, the present study demonstrates that vitamin D3 compounds can block the mitogenic activity of insulin and IGF-I, which may contribute to their tumour suppressive activity observed in vivo. Cholecalciferol 46-56 insulin Homo sapiens 103-110 9081364-12 1996 Together, the present study demonstrates that vitamin D3 compounds can block the mitogenic activity of insulin and IGF-I, which may contribute to their tumour suppressive activity observed in vivo. Cholecalciferol 46-56 insulin like growth factor 1 Homo sapiens 115-120 8676558-4 1996 BGP measurement is a clinically useful method to detect osteoblastic function after active vitamin D3 treatment. Cholecalciferol 91-101 CEA cell adhesion molecule 1 Homo sapiens 0-3 8676558-9 1996 These findings suggest that B-ALP is a more sensitive and stable marker than BGP in evaluating bone formation, although both markers have significant correlations with each other, and BGP is useful to detect the active vitamin D3 effect on osteoblastic function. Cholecalciferol 219-229 CEA cell adhesion molecule 1 Homo sapiens 184-187 8612541-0 1996 Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements. Cholecalciferol 59-69 bone gamma-carboxyglutamate protein Rattus norvegicus 85-96 8612541-0 1996 Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements. Cholecalciferol 59-69 secreted phosphoprotein 1 Rattus norvegicus 101-112 8928773-0 1996 Downregulation of the PTH/PTHrP receptor by vitamin D3 in the osteoblast-like ROS 17/2.8 cells. Cholecalciferol 44-54 parathyroid hormone Rattus norvegicus 22-25 8672415-0 1996 Changes in vitamin-D metabolites and parathyroid hormone in plasma following cholecalciferol administration to pre- and postmenopausal women in the Netherlands in early spring and to postmenopausal women in Curacao. Cholecalciferol 77-92 parathyroid hormone Homo sapiens 37-56 8672415-5 1996 Cholecalciferol administration increased 25(OH)D in all groups, 1,25(OH)2D in postmenopausal Curacao women and PTH in postmenopausal Curacao women and premenopausal Dutch women. Cholecalciferol 0-15 parathyroid hormone Homo sapiens 111-114 9627702-1 1996 Vitamin D3 derivative 1,25-dihydroxyvitamin D3 (1,25[OH]2D3) exerts various biological effects in cells that possess vitamin D3 receptor (VDR), including enhancement of cell differentiation and inhibition of cell proliferation. Cholecalciferol 0-10 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 117-136 8687373-1 1996 The biologically active metabolite of vitamin D (cholecalciferol), i.e. 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], is a secosteroid hormone whose mode of action involves stereospecific interaction with an intracellular receptor protein (vitamin D receptor; VDR). Cholecalciferol 49-64 vitamin D receptor Homo sapiens 234-252 9627702-1 1996 Vitamin D3 derivative 1,25-dihydroxyvitamin D3 (1,25[OH]2D3) exerts various biological effects in cells that possess vitamin D3 receptor (VDR), including enhancement of cell differentiation and inhibition of cell proliferation. Cholecalciferol 0-10 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 138-141 8687373-1 1996 The biologically active metabolite of vitamin D (cholecalciferol), i.e. 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], is a secosteroid hormone whose mode of action involves stereospecific interaction with an intracellular receptor protein (vitamin D receptor; VDR). Cholecalciferol 49-64 vitamin D receptor Homo sapiens 254-257 8867808-0 1996 Identification of a vitamin D3 response element in the fibronectin gene that is bound by a vitamin D3 receptor homodimer. Cholecalciferol 20-30 fibronectin 1 Homo sapiens 55-66 8867808-2 1996 Regulation of FN occurs at the transcriptional level by the active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3). Cholecalciferol 81-91 fibronectin 1 Homo sapiens 14-16 8622645-7 1996 Conversely, when VDR is overexpressed, vitamin D3 attenuates 9-cis RA induction from an RXR-responsive element. Cholecalciferol 39-49 vitamin D receptor Homo sapiens 17-20 8622645-7 1996 Conversely, when VDR is overexpressed, vitamin D3 attenuates 9-cis RA induction from an RXR-responsive element. Cholecalciferol 39-49 retinoid X receptor alpha Homo sapiens 88-91 8615881-3 1996 On the other hand, KCA-098 had no effect on the basal synthesis of osteocalcin but reduced the 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25(OH)(2)D3)-induced increase in osteocalcin synthesized by ROS 17/2.8 cells. Cholecalciferol 123-125 bone gamma-carboxyglutamate protein Rattus norvegicus 168-179 8593782-12 1996 Gel shift analyses indicate that nuclear extracts from MCF-7WT and MCF-7D3Res cells bind equally well to the DR3 consensus vitamin D3 response element. Cholecalciferol 123-133 TNF receptor superfamily member 25 Homo sapiens 109-112 8628015-2 1996 To ascertain whether the NM23 genes are involved in the differentiation processes of human cell lines, the NM23.H1 and NM23.H2 expression level has been determined during the monocyte-macrophage differentiation of HL-60 and U-937 cell lines induced by vitamin D3. Cholecalciferol 252-262 NME/NM23 nucleoside diphosphate kinase 1 Homo sapiens 25-29 8628015-3 1996 In both lines, vitamin D3 produced induction of differentiative markers, inhibition of cell proliferation and a decrease of the NM23.H1, NM23.H2 and c-myc genes, behaving both as a differentiative and an antiproliferative agent. Cholecalciferol 15-25 NME/NM23 nucleoside diphosphate kinase 1 Homo sapiens 128-135 8628015-3 1996 In both lines, vitamin D3 produced induction of differentiative markers, inhibition of cell proliferation and a decrease of the NM23.H1, NM23.H2 and c-myc genes, behaving both as a differentiative and an antiproliferative agent. Cholecalciferol 15-25 NME/NM23 nucleoside diphosphate kinase 1 Homo sapiens 128-132 8628015-3 1996 In both lines, vitamin D3 produced induction of differentiative markers, inhibition of cell proliferation and a decrease of the NM23.H1, NM23.H2 and c-myc genes, behaving both as a differentiative and an antiproliferative agent. Cholecalciferol 15-25 MYC proto-oncogene, bHLH transcription factor Homo sapiens 149-154 8628015-4 1996 The fact that the c-myc transcriptional factor PuF is identical to the NM23.H2 gene and that NM23 protein could be a transcriptional factor suggests that the regulatory action exerted by vitamin D3 on c-myc transcription is mediated by NM23.H2. Cholecalciferol 187-197 NME/NM23 nucleoside diphosphate kinase 2 Homo sapiens 47-50 8628015-4 1996 The fact that the c-myc transcriptional factor PuF is identical to the NM23.H2 gene and that NM23 protein could be a transcriptional factor suggests that the regulatory action exerted by vitamin D3 on c-myc transcription is mediated by NM23.H2. Cholecalciferol 187-197 NME/NM23 nucleoside diphosphate kinase 1 Homo sapiens 71-75 8628015-4 1996 The fact that the c-myc transcriptional factor PuF is identical to the NM23.H2 gene and that NM23 protein could be a transcriptional factor suggests that the regulatory action exerted by vitamin D3 on c-myc transcription is mediated by NM23.H2. Cholecalciferol 187-197 NME/NM23 nucleoside diphosphate kinase 1 Homo sapiens 93-97 8628015-4 1996 The fact that the c-myc transcriptional factor PuF is identical to the NM23.H2 gene and that NM23 protein could be a transcriptional factor suggests that the regulatory action exerted by vitamin D3 on c-myc transcription is mediated by NM23.H2. Cholecalciferol 187-197 MYC proto-oncogene, bHLH transcription factor Homo sapiens 201-206 8628015-4 1996 The fact that the c-myc transcriptional factor PuF is identical to the NM23.H2 gene and that NM23 protein could be a transcriptional factor suggests that the regulatory action exerted by vitamin D3 on c-myc transcription is mediated by NM23.H2. Cholecalciferol 187-197 NME/NM23 nucleoside diphosphate kinase 1 Homo sapiens 93-97 8566748-0 1996 Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Cholecalciferol 55-65 H3 histone pseudogene 16 Homo sapiens 48-51 8698545-8 1996 Vitamin D3 treatment also caused 25% increase in glucose 6-phosphate dehydrogenase (G6PD) activity. Cholecalciferol 0-10 glucose-6-phosphate dehydrogenase Rattus norvegicus 49-82 8598193-2 1996 mSUG1 also efficiently interacts with other nuclear receptors, including oestrogen (ER), thyroid hormone (TR), Vitamin D3 (VDR) and retinoid X (RXR) receptors. Cholecalciferol 111-121 protease (prosome, macropain) 26S subunit, ATPase 5 Mus musculus 0-5 9084640-6 1996 The TATA box is overlapped by a vitamin D3 response element (VDRE) which appears to mediate vitamin D suppression of BSP gene transcription by competing with the TATA-binding protein (TBP) for occupancy of the site of the pre-initiation complex formation. Cholecalciferol 32-42 integrin binding sialoprotein Homo sapiens 117-120 9084640-6 1996 The TATA box is overlapped by a vitamin D3 response element (VDRE) which appears to mediate vitamin D suppression of BSP gene transcription by competing with the TATA-binding protein (TBP) for occupancy of the site of the pre-initiation complex formation. Cholecalciferol 32-42 TATA-box binding protein Homo sapiens 184-187 9084648-3 1996 The present study determined whether there is an additive or synergistic effect of vitamin D3 metabolites and TGF beta on alkaline phosphatase and PKC specific activities and whether this effect is cell maturation-dependent. Cholecalciferol 83-93 protein kinase C, gamma Rattus norvegicus 147-150 9084648-6 1996 The addition of 24,25-(OH)2D3 with TGF beta to RC cells caused a synergistic effect on alkaline phosphatase activity; this result was not found if the vitamin D3 metabolite was replaced by 1,25-(OH)2D3. Cholecalciferol 151-161 transforming growth factor, beta 1 Rattus norvegicus 35-43 9371227-0 1996 Vitamin D3 and ceramide reduce the invasion of tumor cells through extracellular matrix components by elevating protein phosphatase-2A. Cholecalciferol 0-10 protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform Mus musculus 120-134 9371227-4 1996 The cellular PP-2A activity could be stimulated by addition of C2-ceramide to LLC-LN7 lysates, or by incubating cells with either C2-ceramide or with a noncalcemic analog of vitamin D3, which has previously been shown to stimulate the release of ceramide. Cholecalciferol 174-184 protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform Mus musculus 13-18 9371227-7 1996 Invasion by these cells was further reduced by additionally increasing PP-2A activity by incubation with C2-ceramide or the vitamin D3 analog. Cholecalciferol 124-134 protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform Mus musculus 71-76 9371227-8 1996 These results suggest a role of a vitamin D3/ceramide/PP-2A pathway in limiting the invasiveness of tumor cells through select ECM components. Cholecalciferol 34-44 protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform Mus musculus 54-59 8755104-3 1996 It is concluded that the lowering of the level of absorption of vitamin D3 by hepatocytes and its transportation to these cells from reticulocytes as well as the inhibition of vitamin D3-25-hydroxylase liver systems can be the most probable cause of these disturbances. Cholecalciferol 64-74 cytochrome P450, family 27, subfamily a, polypeptide 1 Rattus norvegicus 176-201 8614417-0 1995 Vitamin D3-retinoid X receptor dimerization, DNA binding, and transactivation are differentially affected by analogs of 1,25-dihydroxyvitamin D3. Cholecalciferol 0-10 retinoid X receptor alpha Homo sapiens 11-30 9627688-2 1996 The vitamin D receptor (VDR) mediates most, if not all, the effects of vitamin D3. Cholecalciferol 71-81 vitamin D receptor Homo sapiens 4-22 9627688-2 1996 The vitamin D receptor (VDR) mediates most, if not all, the effects of vitamin D3. Cholecalciferol 71-81 vitamin D receptor Homo sapiens 24-27 9627689-0 1996 Vitamin D3 regulation of transforming growth factor-beta system in epithelial and fibroblastic cells--relationships to plasminogen activation. Cholecalciferol 0-10 transforming growth factor beta 1 Homo sapiens 25-56 9627689-2 1996 A mechanism of action of vitamin D3 and other steroid hormones is to enhance the secretion of transforming growth factor-beta (TGF-beta) in target cells. Cholecalciferol 25-35 transforming growth factor beta 1 Homo sapiens 94-125 9627689-2 1996 A mechanism of action of vitamin D3 and other steroid hormones is to enhance the secretion of transforming growth factor-beta (TGF-beta) in target cells. Cholecalciferol 25-35 transforming growth factor beta 1 Homo sapiens 127-135 9627689-3 1996 In epidermal keratinocytes, vitamin D3 induced the expression of both TGF-beta 1 and TGF-beta 2 with minor changes in mRNA levels, while in BT-20 breast carcinoma cells the increase in TGF-beta activity was preceded by an induction of mRNA. Cholecalciferol 28-38 transforming growth factor beta 1 Homo sapiens 70-80 9627689-3 1996 In epidermal keratinocytes, vitamin D3 induced the expression of both TGF-beta 1 and TGF-beta 2 with minor changes in mRNA levels, while in BT-20 breast carcinoma cells the increase in TGF-beta activity was preceded by an induction of mRNA. Cholecalciferol 28-38 transforming growth factor beta 2 Homo sapiens 85-95 9627689-3 1996 In epidermal keratinocytes, vitamin D3 induced the expression of both TGF-beta 1 and TGF-beta 2 with minor changes in mRNA levels, while in BT-20 breast carcinoma cells the increase in TGF-beta activity was preceded by an induction of mRNA. Cholecalciferol 28-38 transforming growth factor beta 1 Homo sapiens 70-78 9627689-5 1996 A concomitant enhancement of secretion of the latent TGF-beta-binding protein by vitamin D3 was observed in BT-20 cells. Cholecalciferol 81-91 transforming growth factor beta 1 Homo sapiens 53-61 9627689-6 1996 Retinoic acid, which is known to interfere with vitamin D3 signaling, slightly decreased the levels of secreted TGF-beta 1 protein in BT-20 cells, but did not significantly affect the vitamin D3-induced increase. Cholecalciferol 48-58 transforming growth factor beta 1 Homo sapiens 112-122 9627689-12 1996 Our results indicate that vitamin D3 and its analogs are potent regulators of the TGF-beta and plasminogen activator systems in cells of epithelial and mesenchymal origin. Cholecalciferol 26-36 transforming growth factor beta 1 Homo sapiens 82-90 9627692-3 1996 Because 9-cis-retinoic acid receptors (RXRs) form heterodimers both with RARs and the vitamin D3 receptor (VDR), it is plausible that vitamin D3 may affect retinol metabolism if altered transcription is involved in the regulation of vitamin A-metabolizing enzymes. Cholecalciferol 86-96 vitamin D receptor Homo sapiens 107-110 8711172-14 1996 During treatment with vitamin D3 hypercalcemia tends to develop, serum alkaline phosphatase normalizes, elevated PTH serum level decreases. Cholecalciferol 22-32 parathyroid hormone Homo sapiens 113-116 8698545-8 1996 Vitamin D3 treatment also caused 25% increase in glucose 6-phosphate dehydrogenase (G6PD) activity. Cholecalciferol 0-10 glucose-6-phosphate dehydrogenase Rattus norvegicus 84-88 7639762-3 1995 Western blot analysis showed that vitamin D3 deficiency also resulted in increased c-myc protein levels in the hearts of vitamin D3-deficient rats. Cholecalciferol 34-44 MYC proto-oncogene, bHLH transcription factor Rattus norvegicus 83-88 7489414-3 1995 Active vitamin D3 acts via its receptor (VDR), and binding of the ligand-receptor complex to specific promoter regions of the PTH gene inhibits transcription. Cholecalciferol 7-17 vitamin D receptor Homo sapiens 41-44 7489414-3 1995 Active vitamin D3 acts via its receptor (VDR), and binding of the ligand-receptor complex to specific promoter regions of the PTH gene inhibits transcription. Cholecalciferol 7-17 parathyroid hormone Homo sapiens 126-129 7489414-4 1995 Active vitamin D3 constitutes a principal regulator of parathyroid cell growth, and polymorphism in the VDR gene has recently been related to bone mineral density and suggested as predisposing to osteoporosis. Cholecalciferol 7-17 vitamin D receptor Homo sapiens 104-107 7578252-0 1995 Molecular cloning of 25-hydroxyvitamin D-3 24-hydroxylase (Cyp-24) from mouse kidney: its inducibility by vitamin D-3. Cholecalciferol 31-42 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 59-65 7664636-1 1995 1 alpha, 25-Dihydroxyvitamin D3 [1 alpha, 25-(OH)2D3], the hormonal form of vitamin D3, is further metabolized in the kidney and intestine through the carbon 24 (C-24) oxidation pathway initiated by C-24 hydroxylation, and the carbon 23 (C-23) oxidation pathway initiated by C-23 hydroxylation. Cholecalciferol 21-31 nucleolin Homo sapiens 238-242 7664636-1 1995 1 alpha, 25-Dihydroxyvitamin D3 [1 alpha, 25-(OH)2D3], the hormonal form of vitamin D3, is further metabolized in the kidney and intestine through the carbon 24 (C-24) oxidation pathway initiated by C-24 hydroxylation, and the carbon 23 (C-23) oxidation pathway initiated by C-23 hydroxylation. Cholecalciferol 21-31 nucleolin Homo sapiens 275-279 7565732-0 1995 Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Cholecalciferol 56-66 interleukin 2 Homo sapiens 34-47 7565732-0 1995 Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Cholecalciferol 56-66 nuclear factor of activated T cells 2 Homo sapiens 89-94 7673731-8 1995 Treatment of monocytes with another combination of cytokines, IFN-gamma+ TNF-alpha + vitamin D3, markedly reduced bacterial viability, although this appeared to be due to decreased phagocytosis leading to extracellular death of the bacteria. Cholecalciferol 85-95 tumor necrosis factor Homo sapiens 73-82 7583583-5 1995 OP mRNA expression was not detected by Northern blot analysis of total RNA from subconfluent or confluent cultures of human VSMCs of any passage maintained in normal growth medium or after stimulation with TGF beta 1 (20 ng/mL), angiotensin II (1 mumol/L), or basic fibroblast growth factor (10 mg/mL) but was just detectable after stimulation with activation vitamin D3 (1 mumol/L). Cholecalciferol 360-370 secreted phosphoprotein 1 Homo sapiens 0-2 8590308-0 1995 Inhibition of vitamin D3-induced cell differentiation by interferon-gamma in HL-60 cells determined by a nitroblue tetrazolium reduction test. Cholecalciferol 14-24 interferon gamma Homo sapiens 57-73 7583386-9 1995 CONCLUSION: Vitamin D3 decreases N-myc expression in LA-N-5 human neuroblastoma cells, with extended treatment causing growth inhibition and differentiation. Cholecalciferol 12-22 MYCN proto-oncogene, bHLH transcription factor Homo sapiens 33-38 8643162-4 1995 The most potent vitamin D3 metabolite 1,25(OH)2 D3 (Vit D3) shares certain immunomodulatory properties with CsA. Cholecalciferol 16-26 vitrin Rattus norvegicus 52-55 7585485-5 1995 The association of 9-cis-retinoic acid, the ligand of RXR, with vitamin D3 derivatives modified the demonstrated effects, indicating in our model, a preferential effect of vitamin D3 derivatives via the heterodimeric form of the receptor. Cholecalciferol 64-74 retinoid X receptor alpha Homo sapiens 54-57 7585485-5 1995 The association of 9-cis-retinoic acid, the ligand of RXR, with vitamin D3 derivatives modified the demonstrated effects, indicating in our model, a preferential effect of vitamin D3 derivatives via the heterodimeric form of the receptor. Cholecalciferol 172-182 retinoid X receptor alpha Homo sapiens 54-57 7639762-3 1995 Western blot analysis showed that vitamin D3 deficiency also resulted in increased c-myc protein levels in the hearts of vitamin D3-deficient rats. Cholecalciferol 121-131 MYC proto-oncogene, bHLH transcription factor Rattus norvegicus 83-88 7639762-5 1995 Our data suggest a possible relationship between myocyte hyperplasia and increased c-myc levels in the vitamin D3-deficient rat heart. Cholecalciferol 103-113 MYC proto-oncogene, bHLH transcription factor Rattus norvegicus 83-88 7641218-3 1995 Treatment of mice having LLC-LN7 tumors with vitamin D3 reduced tumor production of GM-CSF and the frequency of myeloid progenitor cells. Cholecalciferol 45-55 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 84-90 7671162-0 1995 Resetting of parathyroid hormone secretion after vitamin D3 treatment in hypoparathyroidism and after parathyroid adenectomy in primary hyperparathyroidism. Cholecalciferol 49-59 parathyroid hormone Homo sapiens 13-32 7484280-3 1995 1,25-dihydroxyvitamin D3 (1,25[OH]2D3), an active form of vitamin D3, stimulated OC secretion from the human osteosarcoma cell line MG-63 in a dose-dependent manner. Cholecalciferol 14-24 bone gamma-carboxyglutamate protein Homo sapiens 81-83 8524170-3 1995 There is in vitro evidence that vitamin D3 (1,25 dihydrocholecalciferol) inhibits the production of elastin by smooth muscle cells. Cholecalciferol 32-42 elastin Homo sapiens 100-107 7566512-0 1995 Vitamin D3 effects on basal and cAMP modulated expression of cholecystokinin and somatostatin genes in a rat medullary thyroid carcinoma cell line [CA-77]. Cholecalciferol 0-10 cholecystokinin Rattus norvegicus 61-76 7566512-0 1995 Vitamin D3 effects on basal and cAMP modulated expression of cholecystokinin and somatostatin genes in a rat medullary thyroid carcinoma cell line [CA-77]. Cholecalciferol 0-10 somatostatin Rattus norvegicus 81-93 7797563-10 1995 Vitamin D3-induced monocytic differentiation resulted in an increased carboxypeptidase M expression in all three cell lines. Cholecalciferol 0-10 carboxypeptidase M Homo sapiens 70-88 7625727-2 1995 Receptors for retinoids, thyroid hormone, vitamin D3 and fatty acids/peroxisome proliferators bind their response elements as heterodimers with the retinoid X receptor. Cholecalciferol 42-52 retinoid X receptor alpha Homo sapiens 148-167 7786034-1 1995 Vitamin D-binding protein (DBP) is primarily involved in the binding and transportation of vitamin D3 and its various metabolites to target organs and tissues. Cholecalciferol 91-101 GC vitamin D binding protein Homo sapiens 0-25 7565732-1 1995 T-lymphocyte proliferation is suppressed by 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], the active metabolite of vitamin D3, and is associated with a decrease in interleukin 2 (IL-2), gamma interferon, and granulocyte-macrophage colony-stimulating factor mRNA levels. Cholecalciferol 58-68 interleukin 2 Homo sapiens 173-177 7565732-3 1995 We therefore examined vitamin D3-mediated repression of activated IL-2 expression by cotransfecting Jurkat cells with IL-2 promoter/reporter constructs and a VDR overexpression vector and by DNA binding. Cholecalciferol 22-32 interleukin 2 Homo sapiens 66-70 7565732-3 1995 We therefore examined vitamin D3-mediated repression of activated IL-2 expression by cotransfecting Jurkat cells with IL-2 promoter/reporter constructs and a VDR overexpression vector and by DNA binding. Cholecalciferol 22-32 interleukin 2 Homo sapiens 118-122 7565732-3 1995 We therefore examined vitamin D3-mediated repression of activated IL-2 expression by cotransfecting Jurkat cells with IL-2 promoter/reporter constructs and a VDR overexpression vector and by DNA binding. Cholecalciferol 22-32 vitamin D receptor Homo sapiens 158-161 7786034-1 1995 Vitamin D-binding protein (DBP) is primarily involved in the binding and transportation of vitamin D3 and its various metabolites to target organs and tissues. Cholecalciferol 91-101 D-box binding PAR bZIP transcription factor Homo sapiens 27-30 7786034-2 1995 This is manifested by the ability of DBP to bind vitamin D3 and its metabolites with high affinity. Cholecalciferol 49-59 D-box binding PAR bZIP transcription factor Homo sapiens 37-40 7786039-0 1995 The role of dietary calcium in the physiology of vitamin D toxicity: excess dietary vitamin D3 blunts parathyroid hormone induction of kidney 1-hydroxylase. Cholecalciferol 84-94 parathyroid hormone Rattus norvegicus 102-121 7786039-9 1995 Also, the metabolic clearance rate for 1,25(OH)2D3 was enhanced by feeding excess vitamin D3, which was likely a result of the substantial elevations in intestinal (25-fold) and renal (46-fold) 24-OHase activities in the LCT and NCT groups, respectively. Cholecalciferol 82-92 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 194-202 7579039-9 1995 Hence, other factors like ambient Ca2+ may be responsible for the perturbed secretory patterns of ALP and PRL seen in vitamin D3 treated rats. Cholecalciferol 118-128 PDZ and LIM domain 3 Rattus norvegicus 98-101 7579039-9 1995 Hence, other factors like ambient Ca2+ may be responsible for the perturbed secretory patterns of ALP and PRL seen in vitamin D3 treated rats. Cholecalciferol 118-128 prolactin Rattus norvegicus 106-109 7670562-4 1995 The cell growth of mEHE/CH1-5 cell lines was independent of TSH but was inhibited by c-AMP and vitamin D3. Cholecalciferol 95-105 immediate early response 2 Mus musculus 24-27 7670562-5 1995 c-Myc proto-oncogene expression was also suppressed by vitamin D3 treatment. Cholecalciferol 55-65 myelocytomatosis oncogene Mus musculus 0-20 7738187-3 1995 In addition, our laboratory has demonstrated that the major active metabolite of vitamin D3, 1,25(OH)2D3, also rapidly (seconds-minutes) activated PKC and increased intracellular calcium in isolated rat colonocytes. Cholecalciferol 81-91 protein kinase C, alpha Rattus norvegicus 147-150 7785896-6 1995 Expression of OPN mRNA is upregulated by growth and differentiation factors (PDGF, EGF, TGF-beta and BMP-7/OP-1) and by mechanical stress, which promote bone formation, as well as by osteotropic hormones (retinoic acid and vitamin D3), which can promote bone resorption and remodelling. Cholecalciferol 223-233 secreted phosphoprotein 1 Rattus norvegicus 14-17 7882362-5 1995 Vitamin D3 is growth inhibitory for the estrogen receptor-negative breast cancer cell line BT-20 and regulates TGF-beta expression in cultured keratinocytes. Cholecalciferol 0-10 transforming growth factor beta 1 Homo sapiens 111-119 7882362-6 1995 We studied here the effects of vitamin D3 and its analogues on TGF-beta expression and activity in BT-20 cells. Cholecalciferol 31-41 transforming growth factor beta 1 Homo sapiens 63-71 7882362-7 1995 It was found that vitamin D3 enhanced both TGF-beta 1 mRNA and secretion of the protein in a time- and dose-dependent manner. Cholecalciferol 18-28 transforming growth factor beta 1 Homo sapiens 43-53 7882362-8 1995 Analyses of the vitamin D3 responses in the presence of cycloheximide or actinomycin D indicated that the TGF-beta 1 mRNA induction was dependent on both protein and RNA synthesis. Cholecalciferol 16-26 transforming growth factor beta 1 Homo sapiens 106-116 7882362-10 1995 The amounts of active TGF-beta were enhanced in vitamin D3-treated cultures as well, suggesting autocrine or paracrine functions for the secreted growth factor. Cholecalciferol 48-58 transforming growth factor beta 1 Homo sapiens 22-30 7882362-11 1995 Some analogues of vitamin D3 (EB 1089, MC 903, and KH 1060) that are known to be potent inhibitors of breast cancer cell growth both in vitro and in vivo had similar or more pronounced inducing effects on TGF-beta 1 mRNA levels. Cholecalciferol 18-28 transforming growth factor beta 1 Homo sapiens 205-215 7882362-12 1995 The present results indicate that vitamin D3 and its analogues are potent inducers of both active and latent forms of TGF-beta 1 in BT-20 breast carcinoma cells and provide evidence for coordinated regulation of latent TGF-beta binding protein and TGF-beta 1. Cholecalciferol 34-44 transforming growth factor beta 1 Homo sapiens 118-128 7882362-12 1995 The present results indicate that vitamin D3 and its analogues are potent inducers of both active and latent forms of TGF-beta 1 in BT-20 breast carcinoma cells and provide evidence for coordinated regulation of latent TGF-beta binding protein and TGF-beta 1. Cholecalciferol 34-44 transforming growth factor beta 1 Homo sapiens 118-126 7882362-12 1995 The present results indicate that vitamin D3 and its analogues are potent inducers of both active and latent forms of TGF-beta 1 in BT-20 breast carcinoma cells and provide evidence for coordinated regulation of latent TGF-beta binding protein and TGF-beta 1. Cholecalciferol 34-44 transforming growth factor beta 1 Homo sapiens 248-258 7714065-8 1995 Supplementation with 400 IU vitamin D3 daily in elderly women slightly decreases PTH secretion and increases bone mineral density at the femoral neck. Cholecalciferol 28-38 parathyroid hormone Homo sapiens 81-84 7667104-0 1995 Calreticulin inhibits vitamin D3 signal transduction. Cholecalciferol 22-32 calreticulin Rattus norvegicus 0-12 7662562-7 1995 Our findings provide the first evidence that a strong vitamin D3 analogue triggers synthesis of skin connective tissue, possibly via vitamin D receptor activation and the paracrine action of epidermis-derived TGF-beta 1. Cholecalciferol 54-64 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 133-151 7662562-7 1995 Our findings provide the first evidence that a strong vitamin D3 analogue triggers synthesis of skin connective tissue, possibly via vitamin D receptor activation and the paracrine action of epidermis-derived TGF-beta 1. Cholecalciferol 54-64 transforming growth factor, beta 1 Mus musculus 209-219 7782931-8 1995 These actions of the vitamin D3 compounds suggest that it may have potential therapeutic applications in Th1-mediated clinical situations such as autoimmunity and transplantation. Cholecalciferol 21-31 negative elongation factor complex member C/D Homo sapiens 105-108 7539760-9 1995 When CD14 expression is induced on the myelomonocytic cell line U937 by treatment with vitamin D3 the cells concomittently acquire the capacity to bind bacteria. Cholecalciferol 87-97 CD14 molecule Homo sapiens 5-9 7606167-1 1995 During the course of our studies to probe the vitamin D ligand-binding domains of vitamin D-binding protein and vitamin D receptor, we developed a synthetic procedure to modify the 3 beta-hydroxyl group of vitamin D3 and its 25-hydroxy- and 1,25-dihydroxy metabolites with a 3"-aminopropylether group. Cholecalciferol 206-216 GC vitamin D binding protein Homo sapiens 82-107 7606167-1 1995 During the course of our studies to probe the vitamin D ligand-binding domains of vitamin D-binding protein and vitamin D receptor, we developed a synthetic procedure to modify the 3 beta-hydroxyl group of vitamin D3 and its 25-hydroxy- and 1,25-dihydroxy metabolites with a 3"-aminopropylether group. Cholecalciferol 206-216 vitamin D receptor Homo sapiens 112-130 7720709-3 1995 Using AP1 reporter cells, we also show that glucocorticoids or vitamin D3, together with either RA or these "dissociating" synthetic retinoids, can synergistically repress phorbol ester-induced AP1 activity. Cholecalciferol 63-73 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 6-9 7720709-3 1995 Using AP1 reporter cells, we also show that glucocorticoids or vitamin D3, together with either RA or these "dissociating" synthetic retinoids, can synergistically repress phorbol ester-induced AP1 activity. Cholecalciferol 63-73 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 194-197 7862109-0 1995 Natural vitamin D3 response elements formed by inverted palindromes: polarity-directed ligand sensitivity of vitamin D3 receptor-retinoid X receptor heterodimer-mediated transactivation. Cholecalciferol 8-18 retinoid X receptor alpha Homo sapiens 129-148 7887976-5 1995 Our study shows that vitamin D3 compounds that bind to the vitamin D receptor stimulate epidermal proliferation in mice. Cholecalciferol 21-31 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 59-77 7700077-1 1995 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] mediates its biological activities through specific binding to the vitamin D3 receptor (VDR) and subsequent association with vitamin D3 responsive elements (VDRE) in genes modulated by 1,25(OH)2D3. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 106-125 7700077-1 1995 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] mediates its biological activities through specific binding to the vitamin D3 receptor (VDR) and subsequent association with vitamin D3 responsive elements (VDRE) in genes modulated by 1,25(OH)2D3. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 127-130 7700077-10 1995 In contrast, biologically active vitamin D3 compounds (Cmpds HM, C, V) in a dose-dependent fashion enhanced the VDR/RXR (retinoid X receptor)-VDRE retarded band. Cholecalciferol 33-43 vitamin D receptor Homo sapiens 112-115 7700077-10 1995 In contrast, biologically active vitamin D3 compounds (Cmpds HM, C, V) in a dose-dependent fashion enhanced the VDR/RXR (retinoid X receptor)-VDRE retarded band. Cholecalciferol 33-43 retinoid X receptor alpha Homo sapiens 116-119 7700077-10 1995 In contrast, biologically active vitamin D3 compounds (Cmpds HM, C, V) in a dose-dependent fashion enhanced the VDR/RXR (retinoid X receptor)-VDRE retarded band. Cholecalciferol 33-43 retinoid X receptor alpha Homo sapiens 121-140 7530503-4 1995 Induction of monocytic differentiation in HL-60 cells by vitamin D3 resulted in rapid expression of HOX B7 mRNA, but stimulation with phorbol ester or dimethyl sulfoxide (DMSO) did not. Cholecalciferol 57-67 homeobox B7 Homo sapiens 100-106 7834638-4 1995 We show that p53-independent induction of WAF1/CIP1 occurs in human leukemia cells treated with 12-O-tetradecanoylphorbol-13-acetate, okadaic acid, or IFN-gamma but not with retinoic acid, vitamin D3, or DMSO. Cholecalciferol 189-199 tumor protein p53 Homo sapiens 13-16 7834638-4 1995 We show that p53-independent induction of WAF1/CIP1 occurs in human leukemia cells treated with 12-O-tetradecanoylphorbol-13-acetate, okadaic acid, or IFN-gamma but not with retinoic acid, vitamin D3, or DMSO. Cholecalciferol 189-199 cyclin dependent kinase inhibitor 1A Homo sapiens 42-46 7834638-4 1995 We show that p53-independent induction of WAF1/CIP1 occurs in human leukemia cells treated with 12-O-tetradecanoylphorbol-13-acetate, okadaic acid, or IFN-gamma but not with retinoic acid, vitamin D3, or DMSO. Cholecalciferol 189-199 cyclin dependent kinase inhibitor 1A Homo sapiens 47-51 7834638-4 1995 We show that p53-independent induction of WAF1/CIP1 occurs in human leukemia cells treated with 12-O-tetradecanoylphorbol-13-acetate, okadaic acid, or IFN-gamma but not with retinoic acid, vitamin D3, or DMSO. Cholecalciferol 189-199 interferon gamma Homo sapiens 151-160 7554919-4 1995 In contrast, however, vitamin D3 suppresses bone formation and abrogates the expression of BSP. Cholecalciferol 22-32 integrin binding sialoprotein Homo sapiens 91-94 7554919-7 1995 The promoters are characterized by a highly conserved region (BSP box) encompassing the immediate promoter region, which includes a unique inverted TATA box overlapped by a putative (DR3) vitamin D3 response element (VDRE). Cholecalciferol 188-198 integrin binding sialoprotein Homo sapiens 62-65 7876686-1 1994 The effects of a new derivative of vitamin D3, 22-oxa-1 alpha,25-dihydroxyvitamin D3 (OCT), on rheumatoid arthritis was investigated using collagen-induced arthritis in rat, as an experimental model of the disease. Cholecalciferol 35-45 plexin A2 Homo sapiens 86-89 7811238-0 1994 On the induction of 5-lipoxygenase expression and activity in HL-60 cells: effects of vitamin D3, retinoic acid, DMSO and TGF beta. Cholecalciferol 86-96 arachidonate 5-lipoxygenase Homo sapiens 20-34 7798277-1 1994 The present study was undertaken to clarify the pharmacokinetics of 22-oxa-1,25-dihydroxyvitamin D3 (22-oxa-1,25-(OH)2D3, OCT), a vitamin D3 analogue with little calcemic activity, and its effect on the transcription of parathyroid hormone-related peptide (PTHRP) gene in nude mice bearing a human carcinoma (FA-6) associated with humoral hypercalcemia. Cholecalciferol 89-99 parathyroid hormone-like peptide Mus musculus 220-255 7798277-1 1994 The present study was undertaken to clarify the pharmacokinetics of 22-oxa-1,25-dihydroxyvitamin D3 (22-oxa-1,25-(OH)2D3, OCT), a vitamin D3 analogue with little calcemic activity, and its effect on the transcription of parathyroid hormone-related peptide (PTHRP) gene in nude mice bearing a human carcinoma (FA-6) associated with humoral hypercalcemia. Cholecalciferol 89-99 parathyroid hormone-like peptide Mus musculus 257-262 7959906-6 1994 The protective effect observed against IL-1 beta-induced beta-cell dysfunction might be related to a beneficial action of vitamin D3 on the mitochondrial calcium metabolism of the beta-cells. Cholecalciferol 122-132 interleukin 1 beta Rattus norvegicus 39-48 7811384-0 1994 Identification and characterization of a vitamin D3 response element of chicken carbonic anhydrase-II. Cholecalciferol 41-51 carbonic anhydrase 2 Gallus gallus 80-101 8049143-0 1994 Vitamin D receptor binding and biological effects of cholecalciferol analogues in rat thyroid cells. Cholecalciferol 53-68 vitamin D receptor Rattus norvegicus 0-18 8049143-8 1994 In conclusion, the biological effects of these cholecalciferol analogues in rat thyroid FRTL-5 cells seem to be mainly determined by their binding affinity for the VDR, although non-genomic effects can not be excluded. Cholecalciferol 47-62 vitamin D receptor Rattus norvegicus 164-167 7536865-4 1995 In HL-60 cells, lacking constitutive TGF-alpha mRNA, vitamin D3 caused expression of the TGF-alpha gene and protein as demonstrated by Northern blot analysis and enzyme-linked immunoabsorbant assay (ELISA). Cholecalciferol 53-63 transforming growth factor alpha Homo sapiens 89-98 7855310-5 1994 AM from vitamin D3-deficient rats demonstrated reduced 5-LO metabolism of AA and a parallel reduction in FLAP expression compared to control rats. Cholecalciferol 8-18 arachidonate 5-lipoxygenase activating protein Rattus norvegicus 105-109 7888303-0 1994 Potentiation by cholesterol and vitamin D3 oxygenated derivatives of arachidonic acid release and prostaglandin E2 synthesis induced by the epidermal growth factor in NRK 49F cells: the role of protein kinase C. We have previously demonstrated that oxysterols and calcitriol potentiate arachidonic acid (AA) release and prostaglandin (PG) synthesis when NRK cells (fibroblastic clone 49F) are activated by foetal calf serum. Cholecalciferol 32-42 epidermal growth factor like 1 Rattus norvegicus 140-163 7519122-0 1994 PML/RAR alpha+ U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3. Cholecalciferol 112-122 PML nuclear body scaffold Homo sapiens 0-13 8172088-0 1994 Single-dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: a randomized trial. Cholecalciferol 12-27 parathyroid hormone Homo sapiens 62-81 8076440-2 1994 injection of vitamin D3 has a well known suppressive effect on the release of parathyroid hormone. Cholecalciferol 13-23 parathyroid hormone Homo sapiens 78-97 8033198-9 1994 Vitamin D3 also decreased the conduction velocity and increased CaBP of the vagus nerve and, by lipid analysis, was shown to increase and decrease its phosphatidylcholine and phosphatidylethanolamine content, respectively, and to decrease its phospholipid/cholesterol ratio. Cholecalciferol 0-10 S100 calcium binding protein G Homo sapiens 64-68 8188744-3 1994 Vitamin D3 and thyroid hormone T3, that activate retinoic acid receptor (RAR) cognates, forming heterodimers with retinoid X receptor (RXR), do not affect the potency of immunotoxins. Cholecalciferol 0-10 retinoic acid receptor alpha Homo sapiens 73-76 8142654-5 1994 The wt1 transcripts were also downregulated in HL60 cells during differentiation to monocytes by vitamin D3 or 12-o-tetradecanoyl-phorbol-13-acetate. Cholecalciferol 97-107 WT1 transcription factor Homo sapiens 4-7 8134128-6 1994 In contrast to these two genes the expression of mad was induced upon differentiation in the three cell lines by TPA, retinoic acid, vitamin D3, dimethyl sulfoxide, and interferon-gamma and remained elevated for at least 3 days. Cholecalciferol 133-143 MAX dimerization protein 1 Homo sapiens 49-52 8028822-2 1994 Evaluation of the gene coding for the vitamin D receptor (VDR) for the hormonally active form of vitamin D3, 1 alpha, 25(OH)2-vitamin D3, indicates the presence of two allelic variants. Cholecalciferol 97-107 vitamin D receptor Homo sapiens 38-56 8028822-2 1994 Evaluation of the gene coding for the vitamin D receptor (VDR) for the hormonally active form of vitamin D3, 1 alpha, 25(OH)2-vitamin D3, indicates the presence of two allelic variants. Cholecalciferol 97-107 vitamin D receptor Homo sapiens 58-61 8193081-0 1994 Regulatory effects of 1,25-dihydroxyvitamin D3 and a novel vitamin D3 analogue MC903 on secretion of interleukin-1 alpha (IL-1 alpha) and IL-8 by normal human keratinocytes and a human squamous cell carcinoma cell line (HSC-1). Cholecalciferol 36-46 interleukin 1 alpha Homo sapiens 122-132 7510956-1 1994 Pretreatment (4h) of human HL 60 leukemia cells with the topoisomerase I-inhibitor camptothecin (7-28 x 10(-9) Mol/l, single dose) enhanced vitamin D3-responsive CD 14 expression (10(-11)-10(-8) Mol/l vitamin D3) up to twofold, as measured by fluorescence activated flow cytometry after 1-3 days. Cholecalciferol 140-150 CD14 molecule Homo sapiens 162-167 7510956-5 1994 We conclude that inhibition of topoisomerase I enhances vitamin D3-stimulated CD 14 expression. Cholecalciferol 56-66 CD14 molecule Homo sapiens 78-83 7509804-11 1994 Furthermore, vitamin D3 completely dissociates the production of 92-kDa gelatinase and interstitial collagenase in human mononuclear phagocytes. Cholecalciferol 13-23 matrix metallopeptidase 1 Homo sapiens 87-111 8193081-0 1994 Regulatory effects of 1,25-dihydroxyvitamin D3 and a novel vitamin D3 analogue MC903 on secretion of interleukin-1 alpha (IL-1 alpha) and IL-8 by normal human keratinocytes and a human squamous cell carcinoma cell line (HSC-1). Cholecalciferol 36-46 C-X-C motif chemokine ligand 8 Homo sapiens 138-142 8188744-3 1994 Vitamin D3 and thyroid hormone T3, that activate retinoic acid receptor (RAR) cognates, forming heterodimers with retinoid X receptor (RXR), do not affect the potency of immunotoxins. Cholecalciferol 0-10 retinoid X receptor alpha Homo sapiens 114-133 7508534-6 1994 CD14 expression was significantly (p = 0.035) enhanced with the combination of bryostatin 5 and vitamin D3. Cholecalciferol 96-106 CD14 molecule Homo sapiens 0-4 7508534-8 1994 A loss of CD34 expression occurred during cell culture; this loss was enhanced by vitamin D3, but prevented partly by bryostatin 5. Cholecalciferol 82-92 CD34 molecule Homo sapiens 10-14 8190177-2 1994 PBMC from HD patients without prior therapy with hydroxylated vitamin D3 analogs and from normal controls produced similar amounts of TNF-alpha, either spontaneously or after stimulation with lipopolysaccharide (LPS). Cholecalciferol 62-72 tumor necrosis factor Homo sapiens 134-143 8190177-7 1994 These results suggest that therapy with 1 alpha-hydroxylated vitamin D3 analogs normally given to HD patients for the management of renal osteodystrophy may also regulate the in vivo activity of TNF-alpha. Cholecalciferol 61-71 tumor necrosis factor Homo sapiens 195-204 7505123-8 1993 Vitamin D3, which increases the functional capacity of beta-glucan receptors, increased IL-1Ra production induced by particulate beta-glucan, whereas dexamethasone suppressed IL-1Ra synthesis. Cholecalciferol 0-10 interleukin 1 receptor antagonist Homo sapiens 88-94 8253854-3 1993 Similar to controls, OI bone cells produced predominantly collagen type I with traces of collagen types III and V. The 1,25(OH)2 vitamin D3-stimulated synthesis of osteocalcin, a specific osteoblastic marker protein, was similar in OI bone cells and age-matched controls. Cholecalciferol 129-139 bone gamma-carboxyglutamate protein Homo sapiens 164-175 8227160-0 1993 Maturation-dependent regulation of protein kinase C activity by vitamin D3 metabolites in chondrocyte cultures. Cholecalciferol 64-74 protein kinase C, gamma Rattus norvegicus 35-51 8227160-7 1993 The specificity of PKC stimulation by the vitamin D3 metabolites was verified using a specific pseudosubstrate region peptide inhibitor, which reduced PKC activity when included in the reaction mixture. Cholecalciferol 42-52 protein kinase C, gamma Rattus norvegicus 19-22 8227160-7 1993 The specificity of PKC stimulation by the vitamin D3 metabolites was verified using a specific pseudosubstrate region peptide inhibitor, which reduced PKC activity when included in the reaction mixture. Cholecalciferol 42-52 protein kinase C, gamma Rattus norvegicus 151-154 8228332-7 1993 A decrease was observed also in extracellular matrix and membrane-associated u-PA activity of vitamin D3 and calcipotriol treated cells. Cholecalciferol 94-104 plasminogen activator, urokinase Homo sapiens 77-81 8366134-5 1993 The biologically less potent metabolite of vitamin D3, 25 (OH) D3, also augmented 125I-interleukin 1 alpha binding but at steroid levels 2-3 log orders greater than 1,25 (OH)2 D3. Cholecalciferol 43-53 interleukin 1 alpha Mus musculus 87-106 10465025-8 1994 These findings indicate that vitamin D3 analogues regulate cell proliferation by control of the transition of G1 and G2+M phases, reminiscent of the cdc2/CDK2 type of cell cycle control. Cholecalciferol 29-39 cyclin dependent kinase 1 Homo sapiens 149-153 10465025-8 1994 These findings indicate that vitamin D3 analogues regulate cell proliferation by control of the transition of G1 and G2+M phases, reminiscent of the cdc2/CDK2 type of cell cycle control. Cholecalciferol 29-39 cyclin dependent kinase 2 Homo sapiens 154-158 8227185-11 1993 Taken together, these findings raise the possibility that IL-4"s influence on mineral metabolism could be mediated by osteoblasts and that the effectiveness of this cytokine may be influenced by vitamin D3"s impact on IL-4R expression. Cholecalciferol 195-205 interleukin 4 receptor, alpha Mus musculus 218-223 8390565-6 1993 Our results indicate that insulin treatment of neuronal cells in primary culture increases PtdIns 3-kinase activity and the formation of the unique D-3-phosphorylated phosphoinositides, suggesting that growth factor-mediated neuronal growth may include the formation of novel phosphoinositide 3-phosphate phospholipids. Cholecalciferol 148-151 myotrophin Rattus norvegicus 202-215 8227185-6 1993 While parathyroid hormone (PTH) exposure did not influence IL-4R levels, vitamin D3 treatment augmented MC3T3 125I-IL-4 binding, in a time-dependent manner, up to threefold after a 24 h exposure with a metabolite specificity indicating the involvement of the vitamin D receptor. Cholecalciferol 73-83 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 259-277 8360493-0 1993 Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. Cholecalciferol 14-24 vitamin D binding protein Mus musculus 42-66 8360493-0 1993 Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. Cholecalciferol 14-24 galactosidase, beta 1 Mus musculus 128-146 8164209-1 1993 OBJECTIVE: To investigate the effects of vitamin D3 [1,25-(OH)2D3] metabolites on interleukin 1 beta (IL-1 beta) stimulated secretory activities and on the proliferation of human synovial fibroblasts in culture. Cholecalciferol 41-51 interleukin 1 beta Homo sapiens 82-100 8164209-1 1993 OBJECTIVE: To investigate the effects of vitamin D3 [1,25-(OH)2D3] metabolites on interleukin 1 beta (IL-1 beta) stimulated secretory activities and on the proliferation of human synovial fibroblasts in culture. Cholecalciferol 41-51 interleukin 1 beta Homo sapiens 102-111 8368339-0 1993 Vitamin D3 accelerates PTH-dependent calcium transport in distal convoluted tubule cells. Cholecalciferol 0-10 parathyroid hormone Mus musculus 23-26 8393784-6 1993 Accordingly, we show that PMLRAR can both prevent the binding of the vitamin D3 receptor (VDR) to a target sequence in vitro and inhibit vitamin D3-dependent activation of a VDR-responsive reporter gene in transfected cells. Cholecalciferol 69-79 PML-RARA regulated adaptor molecule 1 Homo sapiens 26-32 8393784-6 1993 Accordingly, we show that PMLRAR can both prevent the binding of the vitamin D3 receptor (VDR) to a target sequence in vitro and inhibit vitamin D3-dependent activation of a VDR-responsive reporter gene in transfected cells. Cholecalciferol 69-79 vitamin D receptor Homo sapiens 90-93 8390483-1 1993 Transport of vitamin D3 from its sites of cutaneous synthesis into the circulation has been assumed to be via the plasma vitamin D binding protein (DBP). Cholecalciferol 13-23 GC vitamin D binding protein Homo sapiens 121-146 8390483-1 1993 Transport of vitamin D3 from its sites of cutaneous synthesis into the circulation has been assumed to be via the plasma vitamin D binding protein (DBP). Cholecalciferol 13-23 D-box binding PAR bZIP transcription factor Homo sapiens 148-151 8390483-10 1993 These findings indicate that endogenously synthesized vitamin D3 travels in plasma almost exclusively on DBP, providing for a slower hepatic delivery of the vitamin D and the more sustained increase in plasma 25-hydroxycholecalciferol observed after depot, parenteral administration of vitamin D. Cholecalciferol 54-64 D-box binding PAR bZIP transcription factor Homo sapiens 105-108 8473513-5 1993 Vitamin D3 increases IL-1R expression dose- and metabolite-dependently, with 1,25-(OH)2D3 having the greatest potency, and also enhances IL-1"s capacity to stimulate IL-6 production at low IL-1 levels. Cholecalciferol 0-10 interleukin 1 complex Mus musculus 21-25 8103274-1 1993 The induction of epidermal ornithine decarboxylase (ODC) can be partially blocked by corticosteroids, retinoic acid or active vitamin D3. Cholecalciferol 126-136 ornithine decarboxylase 1 Homo sapiens 27-50 8103274-1 1993 The induction of epidermal ornithine decarboxylase (ODC) can be partially blocked by corticosteroids, retinoic acid or active vitamin D3. Cholecalciferol 126-136 ornithine decarboxylase 1 Homo sapiens 52-55 8386190-4 1993 Despite development of a macrophage morphology, < 5% of cytokine-stimulated U937 cells were adherent at 24 h. Addition of 1-10 nM urokinase-type plasminogen activator (uPA) induced adherence in the presence of transforming growth factor type beta-1, 1,25-(OH)2 vitamin D3, granulocyte macrophage colony-stimulating factor, or tumor necrosis factor alpha. Cholecalciferol 264-274 plasminogen activator, urokinase Homo sapiens 133-169 8224758-0 1993 Effect of estrogen in relation to dietary vitamin D3 and calcium on activity of intestinal alkaline phosphatase and Ca-ATPase in immature chicks. Cholecalciferol 42-52 alkaline phosphatase, intestinal Homo sapiens 80-111 8224760-9 1993 Vitamin D3 supplementation resulted in VDR upregulation in the intestine and kidney and induced renal 24-OHase but had no effects on VDRs in Harderian glands. Cholecalciferol 0-10 vitamin D3 receptor Heterocephalus glaber 39-42 7682243-0 1993 Functional antagonism between vitamin D3 and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells. Cholecalciferol 30-40 CD14 molecule Homo sapiens 80-84 7682243-0 1993 Functional antagonism between vitamin D3 and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells. Cholecalciferol 30-40 Fc epsilon receptor II Homo sapiens 89-93 8473513-5 1993 Vitamin D3 increases IL-1R expression dose- and metabolite-dependently, with 1,25-(OH)2D3 having the greatest potency, and also enhances IL-1"s capacity to stimulate IL-6 production at low IL-1 levels. Cholecalciferol 0-10 interleukin 6 Mus musculus 166-170 8473513-5 1993 Vitamin D3 increases IL-1R expression dose- and metabolite-dependently, with 1,25-(OH)2D3 having the greatest potency, and also enhances IL-1"s capacity to stimulate IL-6 production at low IL-1 levels. Cholecalciferol 0-10 interleukin 1 complex Mus musculus 137-141 8483269-4 1993 The complex of VDR and 1 alpha,25(OH)2D3 binds to vitamin D3-responsive elements (VDRE) present in the promoter region of target genes of 1 alpha,25(OH)2D3. Cholecalciferol 50-60 vitamin D receptor Homo sapiens 15-30 8502602-0 1993 [Oral pulsatile therapy with active vitamin D3 metabolites--an efficient method of parathyroid hormone synthesis suppression in uremic patients with severe hyperparathyroidism. Cholecalciferol 36-46 parathyroid hormone Homo sapiens 83-102 8470912-4 1993 The heterodimer formation between RXR and RAR or other members of the steroid/thyroid hormone receptor superfamily gave us a new aspect of hormonal gene control including retinoids, thyroid hormone, vitamin D3 and others. Cholecalciferol 199-209 retinoid X receptor alpha Homo sapiens 34-37 8470912-4 1993 The heterodimer formation between RXR and RAR or other members of the steroid/thyroid hormone receptor superfamily gave us a new aspect of hormonal gene control including retinoids, thyroid hormone, vitamin D3 and others. Cholecalciferol 199-209 retinoic acid receptor alpha Homo sapiens 42-45 8383719-0 1993 Transforming growth factor-beta potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines. Cholecalciferol 44-54 transforming growth factor beta 1 Homo sapiens 0-31 8516267-0 1993 Relationship between circulating vitamin D3 metabolites and prolactin or growth hormone levels in rat. Cholecalciferol 33-43 prolactin Rattus norvegicus 60-69 8516267-0 1993 Relationship between circulating vitamin D3 metabolites and prolactin or growth hormone levels in rat. Cholecalciferol 33-43 gonadotropin releasing hormone receptor Rattus norvegicus 73-87 8428788-8 1993 The results suggest that the enhanced pressor responses to norepinephrine and Ang II could be attributed to the direct effect of active vitamin D3 on vasculature rather than to hypercalcemia. Cholecalciferol 136-146 angiotensinogen Rattus norvegicus 78-84 8466756-0 1993 Vitamin D3 and calcipotriol enhance the secretion of transforming growth factor-beta 1 and -beta 2 in cultured murine keratinocytes. Cholecalciferol 0-10 transforming growth factor, beta 1 Mus musculus 53-98 8410379-1 1993 Messenger ribonucleic acid (mRNA) levels and activities of renal 25-hydroxyvitamin D3-24-hydroxylase (24-OHase) were determined in 3 groups of rats: vitamin D-deficient, normal, and 1 alpha-hydroxyvitamin D3 (1 alpha OHD3)-administered rats. Cholecalciferol 83-85 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 102-110 8105940-0 1993 Intermittent minibolus oral vitamin D3 in CAPD patients with resistant parathyroid hormone values. Cholecalciferol 28-38 parathyroid hormone Homo sapiens 71-90 8443002-1 1993 We have tested two new vitamin D3 derivatives, 22-oxa-1 alpha, 25-dihydroxyvitamin D3 (OCT) and 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3 (ED-71), for their effects on bone metabolism compared with 1 alpha, 25-dihydroxyvitamin D3 (1,25(OH)2D3) in two organ-culture systems. Cholecalciferol 23-33 plexin A2 Mus musculus 87-90 8466756-2 1993 Since TGF beta s are very potent inhibitors of keratinocyte growth we studied the effects of vitamin D3 and calcipotriol on the secretion of TGF beta in cultured murine keratinocytes. Cholecalciferol 93-103 transforming growth factor, beta 1 Mus musculus 141-149 8466756-6 1993 Heat treatment of the conditioned medium, which activates latent forms of TGF beta, revealed higher levels of growth inhibitory activity in the medium from vitamin D3 and calcipotriol treated than from control cultures indicating that a fraction of TGF beta was in a latent form. Cholecalciferol 156-166 transforming growth factor, beta 1 Mus musculus 74-82 8466756-6 1993 Heat treatment of the conditioned medium, which activates latent forms of TGF beta, revealed higher levels of growth inhibitory activity in the medium from vitamin D3 and calcipotriol treated than from control cultures indicating that a fraction of TGF beta was in a latent form. Cholecalciferol 156-166 transforming growth factor, beta 1 Mus musculus 249-257 8466756-7 1993 Active TGF beta was, however, detected considerably more in vitamin D3 and calcipotriol treated cultures than in control cultures. Cholecalciferol 60-70 transforming growth factor, beta 1 Mus musculus 7-15 8466756-9 1993 These results indicate that enhanced TGF beta 1 and TGF beta 2 secretion and activity is associated with vitamin D3-mediated growth inhibition of cultured keratinocytes. Cholecalciferol 105-115 transforming growth factor, beta 1 Mus musculus 37-47 8466756-9 1993 These results indicate that enhanced TGF beta 1 and TGF beta 2 secretion and activity is associated with vitamin D3-mediated growth inhibition of cultured keratinocytes. Cholecalciferol 105-115 transforming growth factor, beta 2 Mus musculus 52-62 8381250-3 1993 Gallium nitrate reduced both constitutive and vitamin D3-stimulated osteocalcin protein levels in culture medium by one-half and osteocalcin mRNA levels to one-third to one-tenth of control. Cholecalciferol 46-56 bone gamma-carboxyglutamate protein Rattus norvegicus 68-79 8396209-1 1993 The treatment of X-linked hypophosphatemia (XLH) consists of phosphate and vitamin D3 derivatives. Cholecalciferol 75-85 phosphate regulating endopeptidase homolog X-linked Homo sapiens 17-42 8399644-9 1993 In group 2, in order to avoid the further rise of serum PTH, the low-Ca PDS was supplemented with 2 micrograms/day of 1,25(OH)2D3 (vitamin D3); this was followed by a reduction in serum PTH with no increase in Ca2+ and PO4. Cholecalciferol 131-141 parathyroid hormone Homo sapiens 186-189 8394607-8 1993 Simultaneous influence of ecdysterone and vitamin D3 leads to the partial normalization of the biochemical indices studied (except for those which characterize LPO reactions) mainly in the active chromatin fraction. Cholecalciferol 42-52 lactoperoxidase Rattus norvegicus 160-163 1472030-0 1992 The effect of active vitamin D3 analogs and dexamethasone on the expression of osteocalcin gene in rat tibiae in vivo. Cholecalciferol 21-31 bone gamma-carboxyglutamate protein Rattus norvegicus 79-90 1337336-2 1992 GM-CSF or vitamin D3 enhanced the synthesis of the third component of complement (C3) by U937 cells, but had no stimulatory effect on the synthesis of the fourth component of complement (C4). Cholecalciferol 10-20 complement C3 Homo sapiens 70-84 1337336-5 1992 Vitamin D3 enhanced IFN-gamma-induced C4 synthesis by U937 cells. Cholecalciferol 0-10 interferon gamma Homo sapiens 20-29 8381250-4 1993 Gallium nitrate also inhibited vitamin D3 stimulation of osteocalcin and osteopontin mRNA levels but did not affect constitutive osteopontin mRNA levels. Cholecalciferol 31-41 bone gamma-carboxyglutamate protein Rattus norvegicus 57-68 8381250-4 1993 Gallium nitrate also inhibited vitamin D3 stimulation of osteocalcin and osteopontin mRNA levels but did not affect constitutive osteopontin mRNA levels. Cholecalciferol 31-41 secreted phosphoprotein 1 Rattus norvegicus 73-84 1459360-2 1992 Small amounts of calbindin mRNA detected in vitamin D3 deficient (D-deficient) chick intestine increased rapidly to maximal values 8 h after hormone injection. Cholecalciferol 44-54 calbindin 1 Gallus gallus 17-26 1395167-0 1992 Acute effect of dialysate calcium concentration and intravenous vitamin D3 on the secretion of parathyroid hormone in hemodialysis patients. Cholecalciferol 64-74 parathyroid hormone Homo sapiens 95-114 1445236-1 1992 A cytochrome P-450 which catalyses 25-hydroxylation of vitamin D3 has been purified to apparent homogeneity from pig liver microsomes. Cholecalciferol 55-65 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 2-18 1445236-8 1992 The vitamin D3 25-hydroxylase in pig liver microsomes exhibited a turnover and an apparent Km for 25-hydroxylation of vitamin D3 which were of the same order of magnitude as those of a well-characterized male-specific 25-hydroxylating cytochrome P-450 in rat liver microsomes. Cholecalciferol 4-14 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 235-251 1643114-10 1992 These results suggest that at least part of the direct effect of vitamin D3 metabolites on cell membranes may be related to changes in PA2 activity. Cholecalciferol 65-75 phospholipase A2 group IB Homo sapiens 135-138 1320952-3 1992 In the U937 cell line, recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) inhibits cell proliferation, 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits proliferation and induces the early differentiation antigen CD11b, and vitamin D3 inhibits proliferation and induces both CD11b and the late differentiation antigen CD14. Cholecalciferol 253-263 colony stimulating factor 2 Homo sapiens 41-89 1331703-1 1992 The mechanism for the transfer of fat-soluble vitamin D3 from the avascular basal cellular layers of the epidermis to dermal capillaries and peripheral circulation is unknown, although vitamin D-binding protein (DBP) is thought to mediate this process. Cholecalciferol 46-56 D-box binding PAR bZIP transcription factor Homo sapiens 212-215 1331703-6 1992 We conclude that vitamin D3 egress from the skin is not affected by elevated circulating vitamin D concentrations; thus, the cutaneous release of vitamin D is probably mediated by a protein such as DBP with a high carrying capacity for the vitamin. Cholecalciferol 17-27 D-box binding PAR bZIP transcription factor Homo sapiens 198-201 1361453-5 1992 Tumor necrosis factor and vitamin D3, which also induced ICAM-1 expression, increased HL-60 sensitivity to LAK lysis. Cholecalciferol 26-36 intercellular adhesion molecule 1 Homo sapiens 57-63 1328275-2 1992 Since UV-B mediates the cutaneous formation of vitamin D3, we examined the attenuation of that photosynthetic reaction by the commonly used fabrics cotton, wool, and polyester in black and white colors. Cholecalciferol 47-57 uncharacterized protein LOC107958776 Gossypium hirsutum 6-10 1328275-6 1992 Regular (seasonal) street clothing also prevented an elevation of the vitamin D3 in response to UV-B radiation. Cholecalciferol 70-80 uncharacterized protein LOC107958776 Gossypium hirsutum 96-100 1328275-7 1992 We conclude that clothing prevents or significantly impairs the formation of vitamin D3 after photostimulation with up to six MEDs of UV-B. Cholecalciferol 77-87 uncharacterized protein LOC107958776 Gossypium hirsutum 134-138 1320642-4 1992 In this study, neutrophils activated with C5a exhibited two distinct G protein-dependent signal pathways involving different phosphoinositides: 1) [32P]PI(4,5)P2 hydrolysis and [32P]PA production, and 2) the transient formation of D-3-phosphorylated phosphoinositides, [32P]PIP3 and [32P]PI(3,4)P2. Cholecalciferol 231-234 complement C5a receptor 1 Homo sapiens 42-45 1584805-9 1992 These results suggest that activation of the CAII gene occurs early in the differentiation events triggered by vitamin D3 in myelomonocytic cells. Cholecalciferol 111-121 carbonic anhydrase 2 Gallus gallus 45-49 1324161-6 1992 Binding of [3H]1,25(OH)2 vitamin D3 was increased to 130% of control in cytosolic extracts of UMR 106-06 cells pretreated for 3 days with 1 ng/ml TGF beta. Cholecalciferol 25-35 transforming growth factor, beta 1 Rattus norvegicus 146-154 1336906-1 1992 Dihydrotachysterol3, a reduced (or hydrogenated) analog of vitamin D3 in which the A ring has been rotate through 180 degrees , is, after hepatic 25-hydroxylation, converted in vivo to a dihydroxylated metabolite, termed peak H, which is at present unidentified but with good affinity for the vitamin D receptor. Cholecalciferol 59-69 vitamin D receptor Rattus norvegicus 293-311 1584219-1 1992 The high affinity calcium-binding protein calbindin-D28K is one of the known proteins transcriptionally up-regulated by the hormonally active form of vitamin D3, 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3]. Cholecalciferol 150-160 calbindin 1 Homo sapiens 42-51 1310351-0 1992 Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Cholecalciferol 91-101 retinoid X receptor alpha Homo sapiens 0-19 1310351-4 1992 RXR also interacts directly with and enhances the binding of nuclear receptors conferring responsiveness to vitamin D3 and thyroid hormone T3; the DNA-binding activities of these receptors are also stimulated by the presence of nuclear extracts. Cholecalciferol 108-118 retinoid X receptor alpha Homo sapiens 0-3 1350411-4 1992 Psoriatic lesions improving after 1-2 weeks" treatment with betamethasone or vitamin D3 analogue revealed PTH-rp reactivity just above the granular layer. Cholecalciferol 77-87 parathyroid hormone like hormone Homo sapiens 106-112 1309487-6 1992 The anti-p68 antibody synergizes with the active metabolite of vitamin D3, 1,25-dehydroxyvitamin D3, to induce monocyte to macrophage maturation and enhances the function of mature granulocytes stimulated with the granulocyte-macrophage colony-stimulating factor in vitro. Cholecalciferol 63-73 KH RNA binding domain containing, signal transduction associated 1 Homo sapiens 9-12 1667458-1 1991 We have developed an assay to measure the affinity of serum vitamin D binding protein for 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3, and vitamin D3, using uniform diameter (6.4 microns) polystyrene beads coated with phosphatidylcholine and vitamin D metabolites as the vitamin D donor. Cholecalciferol 100-110 GC vitamin D binding protein Homo sapiens 60-85 1723613-2 1991 One of the nutrients implicated as having an interaction with boron is cholecalciferol (Vit D3). Cholecalciferol 71-86 vitrin Gallus gallus 88-91 1800316-0 1991 The weak calcemic vitamin D3 analogue 22-oxacalcitriol suppresses the production of tumor necrosis factor-alpha by peripheral mononuclear cells. Cholecalciferol 18-28 tumor necrosis factor Homo sapiens 84-111 1843267-2 1991 The administration of active vitamin D3 gradually increased the serum BGP to more than 3 times the original level by the 8th week. Cholecalciferol 29-39 bone gamma-carboxyglutamate protein Homo sapiens 70-73 1843267-3 1991 At the 12th week after starting the active vitamin D3 therapy, mean BGP was about twice the original level, which was about half the maximum level at the 8th week. Cholecalciferol 43-53 bone gamma-carboxyglutamate protein Homo sapiens 68-71 1843267-7 1991 These data suggest that BGP was increased through direct stimulation of osteoblasts by the active vitamin D3, and the increase was not due to deterioration of secondary hyperparathyroidism. Cholecalciferol 98-108 bone gamma-carboxyglutamate protein Homo sapiens 24-27 1843267-8 1991 The reduction of the increase in the BGP level at the 12th week with insignificant biochemical changes suggest that activation of osteoblasts by vitamin D3 may be transient. Cholecalciferol 145-155 bone gamma-carboxyglutamate protein Homo sapiens 37-40 1843267-9 1991 In conclusion, intermittent active vitamin D3 increases serum BGP, without deterioration of major biochemical changes even in patients with moderate to severe secondary hyperparathyroidism, although the increase may be transient. Cholecalciferol 35-45 bone gamma-carboxyglutamate protein Homo sapiens 62-65 1843267-10 1991 These facts suggest that the serum BGP of hemodialysis patients is controlled at least in part by active vitamin D3. Cholecalciferol 105-115 bone gamma-carboxyglutamate protein Homo sapiens 35-38 1654998-1 1991 The effects of two anticonvulsant drugs, phenytoin and sodium valproate, on the bioactivation of vitamin D3 have been studied with respect to the microsomal and mitochondrial cytochrome P-450-linked monooxygenase systems that contribute to 25-hydroxylation of vitamin D3 in rabbit liver, and the mitochondrial cytochrome P-450-linked monooxygenase system that catalyzes 1 alpha-hydroxylation of 25-hydroxyvitamin D3 in rabbit kidney. Cholecalciferol 97-107 cytochrome P-450 Oryctolagus cuniculus 310-326 1654998-4 1991 It is possible that the inhibition of bioactivation of vitamin D3 by these anticonvulsant drugs causes rickets and osteomalacia, and the site of inhibition is expected to be the cytochrome P-450 mediated reactions in liver mitochondria. Cholecalciferol 55-65 cytochrome P-450 Oryctolagus cuniculus 178-194 1714931-0 1991 Expression of beta 4 integrins in human skin: comparison of epidermal distribution with beta 1-integrin epitopes, and modulation by calcium and vitamin D3 in cultured keratinocytes. Cholecalciferol 144-154 tubulin beta 3 class III Homo sapiens 14-20 1714931-7 1991 This Ca(++)-induced redistribution of beta 4 integrin epitopes could be counteracted by 10(-7) M vitamin D3. Cholecalciferol 97-107 tubulin beta 3 class III Homo sapiens 38-44 1669973-0 1991 Possible role of the hormonal form of vitamin D3 in the granuloma-associated angiotensin-converting enzyme activity. Cholecalciferol 38-48 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 77-106 1669973-1 1991 We studied effects of the hormonal form of vitamin D3 on the angiotensin-converting enzyme (ACE) activity of hepatic granulomas in mice infected with Schistosoma mansoni. Cholecalciferol 43-53 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 61-90 1669973-1 1991 We studied effects of the hormonal form of vitamin D3 on the angiotensin-converting enzyme (ACE) activity of hepatic granulomas in mice infected with Schistosoma mansoni. Cholecalciferol 43-53 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 92-95 1855478-0 1991 A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Cholecalciferol 8-18 OXA1L mitochondrial inner membrane protein Homo sapiens 30-35 1855478-2 1991 We have recently developed a novel vitamin D3 analog, 22-oxa-1,25-(OH)2D3 (OCT), that is capable of promoting differentiation and inhibiting proliferation without inducing hypercalcemia. Cholecalciferol 35-45 OXA1L mitochondrial inner membrane protein Homo sapiens 57-62 1855478-2 1991 We have recently developed a novel vitamin D3 analog, 22-oxa-1,25-(OH)2D3 (OCT), that is capable of promoting differentiation and inhibiting proliferation without inducing hypercalcemia. Cholecalciferol 35-45 plexin A2 Homo sapiens 75-78 1873206-0 1991 The induction of epidermal ornithine decarboxylase following tape stripping is inhibited by a topical vitamin D3 analogue (MC903). Cholecalciferol 102-112 ornithine decarboxylase 1 Homo sapiens 27-50 1659121-1 1991 This study used the ionophore, A23187, to examine the hypothesis that the regulation of alkaline phosphatase and phospholipase A2 activity by vitamin D3 metabolites in cartilage cells is mediated by changes in calcium influx. Cholecalciferol 142-152 phospholipase A2 group IB Homo sapiens 113-129 2049072-17 1991 The N-terminal amino acid sequence of cytochrome P-450(26) in kidney mitochondria resembled that of pig kidney microsomal 25-hydroxylase active in 25-hydroxylation of vitamin D3 and C27 steroids, whereas the sequence of pig liver mitochondrial cytochrome P-450(26) differed from those of rabbit and rat liver mitochondrial 26-hydroxylases as well as from those of other hitherto isolated mammalian cytochromes P-450. Cholecalciferol 167-177 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 38-54 1669973-6 1991 The present observation may have relevance to sarcoid granulomas characterized by an increased tissue ACE activity, since macrophages from patients with sarcoidosis synthesize a biologically active hormonal form of vitamin D3. Cholecalciferol 215-225 angiotensin I converting enzyme Homo sapiens 102-105 1669973-7 1991 Namely hormonal form of vitamin D3 locally produced by macrophages is involved not only in systemic Ca++ metabolism but also in the stimulation of macrophages themselves to produce ACE in the granulomas. Cholecalciferol 24-34 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 181-184 1709200-11 1991 IFN gamma treatment increased this binding by four-fold, PMA treatment resulted in a 50% increase in the number of IgG immune complexes bound, whereas vitamin D3 treated THP-1 cells bound half as many IgG immune complexes as control cells. Cholecalciferol 151-161 interferon gamma Homo sapiens 0-9 1709200-11 1991 IFN gamma treatment increased this binding by four-fold, PMA treatment resulted in a 50% increase in the number of IgG immune complexes bound, whereas vitamin D3 treated THP-1 cells bound half as many IgG immune complexes as control cells. Cholecalciferol 151-161 GLI family zinc finger 2 Homo sapiens 170-175 1709200-13 1991 Treatment of THP-1 cells with IFN gamma, TNF alpha, PMA, or vitamin D3 had no effect on Fc gamma RII expression. Cholecalciferol 60-70 GLI family zinc finger 2 Homo sapiens 13-18 1709200-16 1991 Fc gamma R expression may not be linked to differentiation of THP-1 cells since only 1,25 vitamin D3 was able to induce the expression of CD14, a marker of mature monocytic phenotype. Cholecalciferol 90-100 CD14 molecule Homo sapiens 138-142 2177986-3 1990 Other vitamin D3 metabolites had similar but weaker effects in increasing transferrin synthesis. Cholecalciferol 6-16 transferrin Rattus norvegicus 74-85 1656244-5 1991 Nuclear extracts from cells infected with the hVDR-expressing adenoviruses contain an activity that specifically binds an oligonucleotide with sequences from the rat osteocalcin vitamin D3 response element, as determined by gel mobility shift. Cholecalciferol 178-188 vitamin D receptor Homo sapiens 46-50 1656244-5 1991 Nuclear extracts from cells infected with the hVDR-expressing adenoviruses contain an activity that specifically binds an oligonucleotide with sequences from the rat osteocalcin vitamin D3 response element, as determined by gel mobility shift. Cholecalciferol 178-188 bone gamma-carboxyglutamate protein Rattus norvegicus 166-177 1769236-8 1991 These results suggest that vitamin D3 may be an important modulator of elastin expression. Cholecalciferol 27-37 elastin Bos taurus 71-78 1835629-7 1991 However, differences in the binding sites could be distinguished by competition experiments where vitamin D3, vitamin D2 or 7-dehydrocholesterol competed for the specific binding of 1.25-dihydroxyvitamin D3 to a greater extent by B700 than by vitamin D binding protein. Cholecalciferol 98-108 vitamin D binding protein Mus musculus 243-268 1835718-1 1991 Fibronectin release from cultured macrophages, derived from human blood monocytes, was measured during incubation of the cells with increasing concentrations of vitamin D3 metabolites or of aminobutane bisphosphonate (AHButBP) or dichloromethylene bisphosphonate (Cl2MBP), two powerful inhibitors of bone resorption. Cholecalciferol 161-171 fibronectin 1 Homo sapiens 0-11 1835718-3 1991 Opposite results were observed when the cells were incubated with vitamin D3 metabolites: the stimulation of fibronectin release was specific for 1,25-dihydroxyvitamin D3 relative to other vitamin D3 metabolites (1,25-dihydroxyvitamin D3 greater than 25-hydroxyvitamin D3 greater than 24,25-dihydroxyvitamin D3). Cholecalciferol 66-76 fibronectin 1 Homo sapiens 109-120 1835718-3 1991 Opposite results were observed when the cells were incubated with vitamin D3 metabolites: the stimulation of fibronectin release was specific for 1,25-dihydroxyvitamin D3 relative to other vitamin D3 metabolites (1,25-dihydroxyvitamin D3 greater than 25-hydroxyvitamin D3 greater than 24,25-dihydroxyvitamin D3). Cholecalciferol 160-170 fibronectin 1 Homo sapiens 109-120 1895752-0 1991 Inhibition by vitamin D3 of erythroid differentiation of human leukemia line cells induced by transforming growth factor beta or erythroid differentiation factor (activin A). Cholecalciferol 14-24 transforming growth factor beta 1 Homo sapiens 94-125 1895752-0 1991 Inhibition by vitamin D3 of erythroid differentiation of human leukemia line cells induced by transforming growth factor beta or erythroid differentiation factor (activin A). Cholecalciferol 14-24 inhibin subunit beta A Homo sapiens 129-161 27458673-2 1991 The present results show that stimulation of U-937 cells to macrophage differentiation by a phorbol ester or vitamin D3 induced a continuous high level expression of c-jun mRNA and protein. Cholecalciferol 109-119 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 166-171 1700829-8 1990 In contrast, both IFN-alpha and IFN-beta exerted some inhibitory effect on HIV production, which was more marked in vitamin D3-treated cultures than in untreated cultures. Cholecalciferol 116-126 interferon alpha 1 Homo sapiens 18-21 1700829-8 1990 In contrast, both IFN-alpha and IFN-beta exerted some inhibitory effect on HIV production, which was more marked in vitamin D3-treated cultures than in untreated cultures. Cholecalciferol 116-126 interferon alpha 1 Homo sapiens 32-35 1700829-9 1990 HIV production was significantly increased by antibodies to IFN-alpha in both untreated and vitamin D3-treated cultures. Cholecalciferol 92-102 interferon alpha 1 Homo sapiens 60-63 1700829-10 1990 Anti-IFN-beta antibody increased HIV production only in vitamin D3-treated cells. Cholecalciferol 56-66 interferon alpha 1 Homo sapiens 5-8 1700829-12 1990 Vitamin D3 treatment resulted in a higher expression of TNF receptors in differentiating cells than in control HIV-infected cells. Cholecalciferol 0-10 tumor necrosis factor Homo sapiens 56-59 1700829-13 1990 These data demonstrate a strong correlation between HIV production and macrophagelike differentiation in chronically infected U937 cells and suggest that endogenous IFN and TNF exert opposite effects in the regulation of virus production in both undifferentiated and vitamin D3-treated cell cultures. Cholecalciferol 267-277 interferon alpha 1 Homo sapiens 165-168 1700829-13 1990 These data demonstrate a strong correlation between HIV production and macrophagelike differentiation in chronically infected U937 cells and suggest that endogenous IFN and TNF exert opposite effects in the regulation of virus production in both undifferentiated and vitamin D3-treated cell cultures. Cholecalciferol 267-277 tumor necrosis factor Homo sapiens 173-176 2175918-9 1990 These results indicate that this 24-bp sequence containing two 9-bp motifs binds to the vitamin D receptor and mediates the vitamin D3 enhancement of murine Spp-1 gene expression. Cholecalciferol 124-134 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 88-106 2175918-9 1990 These results indicate that this 24-bp sequence containing two 9-bp motifs binds to the vitamin D receptor and mediates the vitamin D3 enhancement of murine Spp-1 gene expression. Cholecalciferol 124-134 secreted phosphoprotein 1 Mus musculus 157-162 2241170-5 1990 Following acute administration of vitamin D3, calbindin-D mRNA levels increased somewhat more rapidly than calbindin-D protein, but overall, the correlation was excellent. Cholecalciferol 34-44 calbindin 1 Gallus gallus 46-55 2241170-5 1990 Following acute administration of vitamin D3, calbindin-D mRNA levels increased somewhat more rapidly than calbindin-D protein, but overall, the correlation was excellent. Cholecalciferol 34-44 calbindin 1 Gallus gallus 107-116 2026586-1 1991 A cytochrome P-450 that catalyzes the 24-hydroxylation of 25-hydroxyvitamin D3 (P-450cc24: P-450cholecalciferol24) was purified to electrophoretic homogeneity from the kidney mitochondria of female rats treated with vitamin D3 (Ohyama, Y., Hayashi, S., and Okuda, K. (1989) FEBS Lett. Cholecalciferol 68-78 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 2-18 2026586-1 1991 A cytochrome P-450 that catalyzes the 24-hydroxylation of 25-hydroxyvitamin D3 (P-450cc24: P-450cholecalciferol24) was purified to electrophoretic homogeneity from the kidney mitochondria of female rats treated with vitamin D3 (Ohyama, Y., Hayashi, S., and Okuda, K. (1989) FEBS Lett. Cholecalciferol 68-78 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 80-89 2015403-0 1991 Two-step differentiation of AML-193 leukemic line: terminal maturation is induced by positive interaction of retinoic acid with granulocyte colony-stimulating factor (CSF) and vitamin D3 with monocyte CSF. Cholecalciferol 176-186 colony stimulating factor 2 Homo sapiens 201-204 2171663-1 1990 The rate of non-specific lipid transfer protein (nsLTP)-mediated exchange is independent of structure for dissimilar sterols: cholesterol, lanosterol, sitosterol and vitamin D-3. Cholecalciferol 166-177 sterol carrier protein 2 Homo sapiens 12-47 2171663-1 1990 The rate of non-specific lipid transfer protein (nsLTP)-mediated exchange is independent of structure for dissimilar sterols: cholesterol, lanosterol, sitosterol and vitamin D-3. Cholecalciferol 166-177 sterol carrier protein 2 Homo sapiens 49-54 2173501-2 1990 The vitamin D3 metabolism in 35 patients with primary Sjogren"s syndrome was investigated by measuring blood concentrations of 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25-(OH)2D3) and 25-hydroxyvitamin D3 (25-OHD3), as well as phenotypes and blood concentrations of Gc globulin, the main vitamin D3 binding protein in the blood. Cholecalciferol 4-14 GC vitamin D binding protein Homo sapiens 265-276 2169238-8 1990 After coupling to Sepharose, the antibody was able to bind to cytochrome P-450(25) from kidney as well as from pig liver microsomes, and to immunoprecipitate the activity for 25-hydroxylation of vitamin D3 and 5 beta-cholestane-3 alpha,7 alpha-diol when assayed in a reconstituted system. Cholecalciferol 195-205 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 62-78 2169238-11 1990 These results indicate a similar or the same species of cytochrome P-450 in pig kidney and liver microsomes catalysing 25-hydroxylation of vitamin D3 and C27 steroids. Cholecalciferol 139-149 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 56-72 2117528-2 1990 1,25-Dihydroxyvitamin D3 [1,25-(OH)2D3], a seco-steroid derived from vitamin D3, has previously been reported to enhance such expression alone or together with IFN gamma on a number of monocyte/macrophage tumorigenic lines. Cholecalciferol 14-24 interferon gamma Rattus norvegicus 160-169 2177015-0 1990 Modulation of chick intestinal and renal calbindin gene expression by dietary vitamin D3, 1,25-dihydroxyvitamin D3, calcium and phosphorus. Cholecalciferol 78-88 calbindin 1 Gallus gallus 41-50 2177015-4 1990 Renal calbindin and its mRNA were lower in the vitamin D-deficient than in vitamin D3- or 1,25-dihydroxyvitamin D3 (1,25(OH)2D3)-fed chicks. Cholecalciferol 75-85 calbindin 1 Gallus gallus 6-15 2119787-2 1990 In this study we investigated the effect of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the most active metabolite of vitamin D3, on the IFN-gamma-induced expression of MHC class II antigens on HEp-2 cells. Cholecalciferol 58-68 interferon gamma Homo sapiens 133-142 2375769-7 1990 In competition studies, MC 969 was able to inhibit 25-hydroxylation of tritiated vitamin D3 more effectively than 1 alpha-OH-D3 itself, indicating that the vitamin D3-25-hydroxylase may be responsible for generation of one or more of the metabolites observed. Cholecalciferol 81-91 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 156-181 2177015-9 1990 The results suggest that: (a) most of the changes in renal and intestinal calbindin could be attributed to the changes in the mRNA; (b) the adaptation to dietary Ca and P alterations requires vitamin D metabolites; (c) high dietary Ca affects intestinal and renal calbindin-mRNA and calbindin via mechanisms independent of kidney 1-hydroxylase; and (d) plasma Ca and renal calbindin or its mRNA tend to change together in vitamin D-deficient or vitamin D3-fed, but not in 1,25(OH)2D3-fed chicks. Cholecalciferol 445-455 calbindin 1 Gallus gallus 74-83 2169238-0 1990 Characterization of pig kidney microsomal cytochrome P-450 catalysing 25-hydroxylation of vitamin D3 and C27 steroids. Cholecalciferol 90-100 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 42-58 2169238-1 1990 The cytochrome P-450 enzyme which catalyses 25-hydroxylation of vitamin D3 (cytochrome P-450(25] from pig kidney microsomes [Postlind & Wikvall (1988) Biochem. Cholecalciferol 64-74 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 4-20 2169238-1 1990 The cytochrome P-450 enzyme which catalyses 25-hydroxylation of vitamin D3 (cytochrome P-450(25] from pig kidney microsomes [Postlind & Wikvall (1988) Biochem. Cholecalciferol 64-74 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 76-92 2169238-5 1990 The 25-hydroxylase activity towards vitamin D3 was 124 pmol.min-1.nmol of cytochrome P-450-1 and towards 1 alpha-hydroxyvitamin D3 it was 1375 pmol.min-1.nmol-1. Cholecalciferol 36-46 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 74-90 2159384-5 1990 Unexpectedly, cotransfection of Jun and Fos expression vectors suppresses basal level transcription of the osteocalcin gene and suppresses induction by both retinoic acid and vitamin D3. Cholecalciferol 175-185 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 40-43 2158960-1 1990 Calcitonin was used in conjunction with saline diuresis, furosemide, and prednisone in treatment of a dog that consumed a rodenticide that contained cholecalciferol and has been touted as safe for nontarget species. Cholecalciferol 149-164 calcitonin Canis lupus familiaris 0-10 2407190-0 1990 Novel vitamin D3 derivatives, 26-homo-delta 22-dehydro-1 alpha,25(S)-dihydroxyvitamin D3 and 26-homo-delta 22-dehydro-1 alpha,25(R)-dihydroxyvitamin D3: preferential activity in c-myc mRNA production and in induction of phenotypic differentiation of HL-60 cells. Cholecalciferol 6-16 MYC proto-oncogene, bHLH transcription factor Homo sapiens 178-183 2407190-1 1990 Novel vitamin D3 derivatives, 26-homo-delta 22-1 alpha,25(S)-dihydroxyvitamin D3 and 26-homo-delta 22-1 alpha,25(R)-dihydroxyvitamin D3 were compared with the native hormone, 1,25-dihydroxyvitamin D3, and with other vitamin D3 derivatives, in inhibition of cell growth, induction of phenotypic differentiation, and c-myc mRNA reduction of HL-60 cells. Cholecalciferol 6-16 MYC proto-oncogene, bHLH transcription factor Homo sapiens 315-320 2407190-7 1990 These results suggest that the novel vitamin D3 derivatives, 26-homo-delta 22-1 alpha,25(S)-(OH)2D3 and 26-homo-delta 22-1 alpha,25(R)-(OH)2D3, have preferential activity in inducing phenotypic differentiation and in inducing cell proliferation related c-myc mRNA activity. Cholecalciferol 37-47 MYC proto-oncogene, bHLH transcription factor Homo sapiens 253-258 1972874-4 1990 Peripheral lymphocyte subsets CD4/CD8 were higher in patients with senile osteoporosis than in the age-matched controls, and returned to normal after 1 month of 1 alpha(OH)vitamin D3 treatment. Cholecalciferol 172-182 CD4 molecule Homo sapiens 30-33 1972874-4 1990 Peripheral lymphocyte subsets CD4/CD8 were higher in patients with senile osteoporosis than in the age-matched controls, and returned to normal after 1 month of 1 alpha(OH)vitamin D3 treatment. Cholecalciferol 172-182 CD8a molecule Homo sapiens 34-37 2252808-7 1990 Controls showed a nearly linear secretion rate of osteocalcin, reaching 8-9 ng/10(6) cells by 8 h. Vitamin D3 (2.6 nM) maximally stimulated secretion nearly two-fold after 24 or 48 h of pretreatment in comparison to controls. Cholecalciferol 99-109 bone gamma-carboxyglutamate protein Rattus norvegicus 50-61 1693772-3 1990 In support of this hypothesis is the fact that the synthesis of osteopontin is stimulated by calcitriol (1,25-dihydroxy-vitamin(D3), a substance that induces bone resorption. Cholecalciferol 128-130 secreted phosphoprotein 1 Homo sapiens 64-75 2298449-11 1990 Competition assays with vitamin D3 and Gc in enzyme-linked immunosorbent assay indicate that the epitope of hDBP-1 on the Gc molecule may be related to the vitamin-D3-binding site. Cholecalciferol 24-34 DEAH-box helicase 15 Homo sapiens 108-114 2298449-11 1990 Competition assays with vitamin D3 and Gc in enzyme-linked immunosorbent assay indicate that the epitope of hDBP-1 on the Gc molecule may be related to the vitamin-D3-binding site. Cholecalciferol 156-166 DEAH-box helicase 15 Homo sapiens 108-114 33774074-17 2021 Another small trial showed that supplementation with cholecalciferol, 60,000 IU/d, decreased fibrinogen levels, but did not have an effect on D-dimer, procalcitonin and CRP levels, compared to placebo. Cholecalciferol 53-68 fibrinogen beta chain Homo sapiens 93-103 14236372-0 1963 [3 CASES OF LEPROMATOUS LEPROSY TREATED WITH LYSOZYME ASSOCIATED WITH CALCIFEROL (VITAMINS D2 AND D3)]. Cholecalciferol 98-100 lysozyme Homo sapiens 45-53 33775819-10 2021 Finally, energy intake influenced the vitamin D 25-hydroxylase through the 25-hydroxyvitamin D3/vitamin D3 ratio, which regulates the synthesis of the circulating form. Cholecalciferol 85-95 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 38-62 33939911-2 2021 We aimed in this study to investigate the safety and efficacy of ASCs + daily cholecalciferol (VIT D) for 6 months in patients with recent-onset T1D. Cholecalciferol 78-93 vitrin Homo sapiens 95-98 33806248-3 2021 The expression of Foxp3 in Tregs is regulated by the transcription factor GATA binding-protein 3 (GATA3) and vitamin D3. Cholecalciferol 109-119 forkhead box P3 Homo sapiens 18-23 33806248-4 2021 The aim of this retrospective case-control study was to investigate the potential association between FOXP3 and GATA3 genetic variants, Vitamin D3, and MS risk. Cholecalciferol 136-146 forkhead box P3 Homo sapiens 102-107 34802735-18 2022 Haptoglobin concentrations were significantly increased on 5 DIM in cows injected once with 12 x 106 IU of cholecalciferol. Cholecalciferol 107-122 haptoglobin Bos taurus 0-11 34894076-7 2022 Short-term vitamin D3 supplementation prevented Lipopolysaccharide-induced ALI by preventing pro-inflammatory cytokines including IL-1beta, IL-6, and TNF-alpha. Cholecalciferol 11-21 interleukin 1 alpha Mus musculus 130-138 34894076-7 2022 Short-term vitamin D3 supplementation prevented Lipopolysaccharide-induced ALI by preventing pro-inflammatory cytokines including IL-1beta, IL-6, and TNF-alpha. Cholecalciferol 11-21 interleukin 6 Mus musculus 140-144 34894076-7 2022 Short-term vitamin D3 supplementation prevented Lipopolysaccharide-induced ALI by preventing pro-inflammatory cytokines including IL-1beta, IL-6, and TNF-alpha. Cholecalciferol 11-21 tumor necrosis factor Mus musculus 150-159 34894076-9 2022 Short-term vitamin D3, but not long-term pretreatment significantly reduced the phosphorylation of STAT3 and SOCS3, but upregulated the phosphorylation of IkappaBalpha. Cholecalciferol 11-21 signal transducer and activator of transcription 3 Mus musculus 99-104 34894076-9 2022 Short-term vitamin D3, but not long-term pretreatment significantly reduced the phosphorylation of STAT3 and SOCS3, but upregulated the phosphorylation of IkappaBalpha. Cholecalciferol 11-21 suppressor of cytokine signaling 3 Mus musculus 109-114 34894076-9 2022 Short-term vitamin D3, but not long-term pretreatment significantly reduced the phosphorylation of STAT3 and SOCS3, but upregulated the phosphorylation of IkappaBalpha. Cholecalciferol 11-21 nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha Mus musculus 155-167 34657267-3 2022 We hypothesized that vitamin D3 supplementation affects OPG and RANKL activity in the aorta. Cholecalciferol 21-31 TNF receptor superfamily member 11B Rattus norvegicus 56-59 34657267-3 2022 We hypothesized that vitamin D3 supplementation affects OPG and RANKL activity in the aorta. Cholecalciferol 21-31 TNF superfamily member 11 Rattus norvegicus 64-69 34657267-7 2022 RESULTS: Opg and Il-1b expression levels were significantly associated with both diabetes and vitamin D3 supplementation in the aortas of the study groups (p <= 0.05). Cholecalciferol 94-104 TNF receptor superfamily member 11B Rattus norvegicus 9-12 34657267-7 2022 RESULTS: Opg and Il-1b expression levels were significantly associated with both diabetes and vitamin D3 supplementation in the aortas of the study groups (p <= 0.05). Cholecalciferol 94-104 interleukin 1 beta Rattus norvegicus 17-22 34657267-10 2022 CONCLUSIONS: It is concluded that vitamin D3 supplementation has a modulatory effect on OPG/RANKL activity in the vessel wall by ameliorating endothelial damage in diabetes. Cholecalciferol 34-44 TNF receptor superfamily member 11B Rattus norvegicus 88-91 34657267-10 2022 CONCLUSIONS: It is concluded that vitamin D3 supplementation has a modulatory effect on OPG/RANKL activity in the vessel wall by ameliorating endothelial damage in diabetes. Cholecalciferol 34-44 TNF superfamily member 11 Rattus norvegicus 92-97 33817577-0 2021 Vitamin D3 induces mesenchymal-to-endothelial transition and promotes a proangiogenic niche through IGF-1 signaling. Cholecalciferol 0-10 insulin like growth factor 1 Homo sapiens 100-105 32795167-8 2022 The units of Lispro, Aspart, and Glargine insulin were lower in the Vitamin D3 group at the end of the study (p = 0.031, p = 0.037, and p = 0.035, respectively) than in the placebo group. Cholecalciferol 68-78 insulin Homo sapiens 42-49 28398098-8 2018 RESULTS: ASC mineralization in dexamethasone or vitamin D3-induced ASCs correlated with both increased ERK1/2 and JNK1/2 activation. Cholecalciferol 48-58 mitogen-activated protein kinase 3 Homo sapiens 103-109 28398098-8 2018 RESULTS: ASC mineralization in dexamethasone or vitamin D3-induced ASCs correlated with both increased ERK1/2 and JNK1/2 activation. Cholecalciferol 48-58 mitogen-activated protein kinase 8 Homo sapiens 114-118 34844141-0 2022 Affinity-based protein profiling identifies vitamin D3 as a heat shock protein 70 antagonist that regulates hedgehog transduction in murine basal cell carcinoma. Cholecalciferol 44-54 heat shock protein 1B Mus musculus 60-81 34919352-8 2022 RESULTS: Vitamin D3 injection significantly affected the amounts of 25(OH) vitamin D, urea, insulin and insulin resistance index (p <= 0.05). Cholecalciferol 9-19 insulin Bos taurus 92-99 34504311-4 2022 Interestingly, the increased IgE responses correlated with stimulation of the vitamin D3-metabolizing enzymes CYP27B1 and CYP24A1 in the gut and increased luminal levels of oxidized vitamin D3 metabolites that are not ligands of the vitamin D receptor. Cholecalciferol 78-88 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 110-117 34504311-4 2022 Interestingly, the increased IgE responses correlated with stimulation of the vitamin D3-metabolizing enzymes CYP27B1 and CYP24A1 in the gut and increased luminal levels of oxidized vitamin D3 metabolites that are not ligands of the vitamin D receptor. Cholecalciferol 78-88 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 122-129 34919352-0 2022 Effects of vitamin D3 injection in close-up period on insulin resistance and energy balance in transition dairy cows. Cholecalciferol 11-21 insulin Bos taurus 54-61 34368951-9 2022 Klotho-deficient serum promoted BMP2/vitamin D3-induced protein expression of PIT2 and RUNX2, phosphorylation of SMAD1/5/8 and SMAD2/3, and extracellular matrix calcification. Cholecalciferol 37-47 klotho Mus musculus 0-6 34368951-9 2022 Klotho-deficient serum promoted BMP2/vitamin D3-induced protein expression of PIT2 and RUNX2, phosphorylation of SMAD1/5/8 and SMAD2/3, and extracellular matrix calcification. Cholecalciferol 37-47 bone morphogenetic protein 2 Mus musculus 32-36 34368951-9 2022 Klotho-deficient serum promoted BMP2/vitamin D3-induced protein expression of PIT2 and RUNX2, phosphorylation of SMAD1/5/8 and SMAD2/3, and extracellular matrix calcification. Cholecalciferol 37-47 solute carrier family 20, member 2 Mus musculus 78-82 34368951-9 2022 Klotho-deficient serum promoted BMP2/vitamin D3-induced protein expression of PIT2 and RUNX2, phosphorylation of SMAD1/5/8 and SMAD2/3, and extracellular matrix calcification. Cholecalciferol 37-47 runt related transcription factor 2 Mus musculus 87-92 34368951-9 2022 Klotho-deficient serum promoted BMP2/vitamin D3-induced protein expression of PIT2 and RUNX2, phosphorylation of SMAD1/5/8 and SMAD2/3, and extracellular matrix calcification. Cholecalciferol 37-47 SMAD family member 1 Mus musculus 113-122 34368951-9 2022 Klotho-deficient serum promoted BMP2/vitamin D3-induced protein expression of PIT2 and RUNX2, phosphorylation of SMAD1/5/8 and SMAD2/3, and extracellular matrix calcification. Cholecalciferol 37-47 SMAD family member 2 Mus musculus 127-134 34368951-10 2022 Interestingly, treatments with recombinant Klotho protein abolished BMP2/vitamin D3-induced osteoblastic transition and morphogenesis and calcification. Cholecalciferol 73-83 klotho Mus musculus 43-49 34368951-10 2022 Interestingly, treatments with recombinant Klotho protein abolished BMP2/vitamin D3-induced osteoblastic transition and morphogenesis and calcification. Cholecalciferol 73-83 bone morphogenetic protein 2 Mus musculus 68-72 34757179-0 2022 Vitamin D3 protects against nitrogen mustard-induced apoptosis of the bronchial epithelial cells via activating the VDR/Nrf2/Sirt3 pathway. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 116-119 34757179-0 2022 Vitamin D3 protects against nitrogen mustard-induced apoptosis of the bronchial epithelial cells via activating the VDR/Nrf2/Sirt3 pathway. Cholecalciferol 0-10 NFE2 like bZIP transcription factor 2 Homo sapiens 120-124 34757179-0 2022 Vitamin D3 protects against nitrogen mustard-induced apoptosis of the bronchial epithelial cells via activating the VDR/Nrf2/Sirt3 pathway. Cholecalciferol 0-10 sirtuin 3 Homo sapiens 125-130 34757179-9 2022 Inhibition of Nrf2 or Sirt3 could decrease the protective effects of vitamin D3 and enhance mitochondrial ROS production via modulating mitochondrial redox balance. Cholecalciferol 69-79 NFE2 like bZIP transcription factor 2 Homo sapiens 14-18 34757179-9 2022 Inhibition of Nrf2 or Sirt3 could decrease the protective effects of vitamin D3 and enhance mitochondrial ROS production via modulating mitochondrial redox balance. Cholecalciferol 69-79 sirtuin 3 Homo sapiens 22-27 34757179-10 2022 In conclusion, impaired VDR/Nrf2/Sirt3 axis contributed to NM-induced apoptosis, while vitamin D3 supplementation provides protective effects via the activation of VDR and the improvement of mitochondrial functions. Cholecalciferol 87-97 vitamin D receptor Homo sapiens 164-167 34919352-8 2022 RESULTS: Vitamin D3 injection significantly affected the amounts of 25(OH) vitamin D, urea, insulin and insulin resistance index (p <= 0.05). Cholecalciferol 9-19 insulin Bos taurus 104-111 34919352-12 2022 CONCLUSION: It seems that injection of vitamin D3 in close up period influenced lipolysis potentially modifying energy metabolism and resulted in reducing insulin resistance. Cholecalciferol 39-49 insulin Bos taurus 155-162 34710370-0 2021 Cholecalciferol and metformin protect against lipopolysaccharide-induced endothelial dysfunction and senescence by modulating sirtuin-1 and protein arginine methyltransferase-1. Cholecalciferol 0-15 sirtuin 1 Homo sapiens 126-135 34710370-0 2021 Cholecalciferol and metformin protect against lipopolysaccharide-induced endothelial dysfunction and senescence by modulating sirtuin-1 and protein arginine methyltransferase-1. Cholecalciferol 0-15 protein arginine methyltransferase 1 Homo sapiens 140-176 34710370-3 2021 In this study, we observed that a combination treatment with metformin (MET) and cholecalciferol (VD) blocked the LPS-induced S-adenosylmethionine (SAM)-dependent methyltransferase (SDM) activity in Eahy926 cells. Cholecalciferol 81-96 THUMP domain containing 2 Homo sapiens 126-180 34472641-0 2021 Sulindac and vitamin D3 synergically inhibit proliferation of MCF-7 breast cancer cell through AMPK/Akt/beta-catenin axis in vitro. Cholecalciferol 13-23 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 95-99 34472641-0 2021 Sulindac and vitamin D3 synergically inhibit proliferation of MCF-7 breast cancer cell through AMPK/Akt/beta-catenin axis in vitro. Cholecalciferol 13-23 AKT serine/threonine kinase 1 Homo sapiens 100-103 34472641-0 2021 Sulindac and vitamin D3 synergically inhibit proliferation of MCF-7 breast cancer cell through AMPK/Akt/beta-catenin axis in vitro. Cholecalciferol 13-23 catenin beta 1 Homo sapiens 104-116 34324049-0 2021 Increased integrity of cell-cell junctions accompanied by increased expression of claudin 4 in keratinocytes stimulated with vitamin D3. Cholecalciferol 125-135 claudin 4 Homo sapiens 82-91 34853015-9 2021 CONCLUSION: The results of our study show that the patients supplemented with a microencapsulated form of vitamin D3 achieved faster compensation of 25(OH)D levels, which in turn, under equal conditions, led to significant improvement in the metabolic profile, in particular insulin sensitivity. Cholecalciferol 106-116 insulin Homo sapiens 275-282 34656907-0 2021 Vitamin D3 alleviates pulmonary fibrosis by regulating the MAPK pathway via targeting PSAT1 expression in vivo and in vitro. Cholecalciferol 0-10 phosphoserine aminotransferase 1 Homo sapiens 86-91 34873873-5 2021 We previously identified a unique and specific transport mechanism for skin-generated vitamin D3 which requires vitamin D binding protein (DBP); a mechanism that differs from absorption and transport of oral vitamin D3 . Cholecalciferol 86-96 GC vitamin D binding protein Homo sapiens 112-137 34873873-5 2021 We previously identified a unique and specific transport mechanism for skin-generated vitamin D3 which requires vitamin D binding protein (DBP); a mechanism that differs from absorption and transport of oral vitamin D3 . Cholecalciferol 86-96 D-box binding PAR bZIP transcription factor Homo sapiens 139-142 34873873-8 2021 By examining the excretion of radiolabeled vitamin D3 injected unbound or pre-bound by DBP, we attributed the increased activity of skin-generated vitamin D3 to a significant reduction in biliary excretion of DBP-bound vitamin D relative to unbound vitamin D. Cholecalciferol 43-53 D-box binding PAR bZIP transcription factor Homo sapiens 87-90 34873873-8 2021 By examining the excretion of radiolabeled vitamin D3 injected unbound or pre-bound by DBP, we attributed the increased activity of skin-generated vitamin D3 to a significant reduction in biliary excretion of DBP-bound vitamin D relative to unbound vitamin D. Cholecalciferol 43-53 D-box binding PAR bZIP transcription factor Homo sapiens 209-212 34873873-8 2021 By examining the excretion of radiolabeled vitamin D3 injected unbound or pre-bound by DBP, we attributed the increased activity of skin-generated vitamin D3 to a significant reduction in biliary excretion of DBP-bound vitamin D relative to unbound vitamin D. Cholecalciferol 147-157 D-box binding PAR bZIP transcription factor Homo sapiens 87-90 34873873-8 2021 By examining the excretion of radiolabeled vitamin D3 injected unbound or pre-bound by DBP, we attributed the increased activity of skin-generated vitamin D3 to a significant reduction in biliary excretion of DBP-bound vitamin D relative to unbound vitamin D. Cholecalciferol 147-157 D-box binding PAR bZIP transcription factor Homo sapiens 209-212 34873873-9 2021 Thus, removal of vitamin D3 from the skin by the natural DBP system markedly improves biological activity compared to that given orally. Cholecalciferol 17-27 D-box binding PAR bZIP transcription factor Homo sapiens 57-60 34950832-1 2021 1,25(OH)2D3, the biologically active form of vitamin D3, is a major regulator of mineral and bone homeostasis and exerts its actions through binding to the vitamin D receptor (VDR), a ligand-activated transcription factor that can directly modulate gene expression in vitamin D-target tissues such as the intestine, kidney, and bone. Cholecalciferol 45-55 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 156-174 34849546-9 2022 With baseline 25(OH)D >=30 ng/mL as the reference, 25(OH)D <20 ng/mL was associated with a larger decline in PTH with vitamin D3 supplementation (-10 (95% CI: -15, -6) pg/mL) whereas 25(OH)D 20-30 ng/mL was not (-2 (95% CI: -6, 1) pg/mL). Cholecalciferol 118-128 parathyroid hormone Homo sapiens 109-112 34849546-7 2022 Mean (SD) change in PTH was -3 (16) pg/mL with vitamin D3 vs 2 (18) pg/mL with placebo (estimated mean difference, -5 (95% CI: -8, -2) pg/mL). Cholecalciferol 47-57 parathyroid hormone Homo sapiens 20-23 34849546-8 2022 Within the vitamin D3 group, lower baseline 25(OH)D was associated with a larger decline in PTH in a non-linear fashion. Cholecalciferol 11-21 parathyroid hormone Homo sapiens 92-95 34959623-0 2021 Vitamin D3 Prevents the Deleterious Effects of Testicular Torsion on Testis by Targeting miRNA-145 and ADAM17: In Silico and In Vivo Study. Cholecalciferol 0-10 microRNA 145 Homo sapiens 89-98 34959623-0 2021 Vitamin D3 Prevents the Deleterious Effects of Testicular Torsion on Testis by Targeting miRNA-145 and ADAM17: In Silico and In Vivo Study. Cholecalciferol 0-10 ADAM metallopeptidase domain 17 Homo sapiens 103-109 34959623-8 2021 Our results revealed that the protective effect of vitamin D3 treatment could be attributed to target miRNA145 and ADAM17 protein. Cholecalciferol 51-61 microRNA 145 Homo sapiens 102-110 34959623-8 2021 Our results revealed that the protective effect of vitamin D3 treatment could be attributed to target miRNA145 and ADAM17 protein. Cholecalciferol 51-61 ADAM metallopeptidase domain 17 Homo sapiens 115-121 34959623-9 2021 To further investigate these findings, we performed a detailed molecular modelling study in order to explore the binding affinity of vitamin D3 toward ADAM17 protein. Cholecalciferol 133-143 ADAM metallopeptidase domain 17 Homo sapiens 151-157 34959623-10 2021 Our results revealed that vitamin D3 has the ability to bind to the active site of ADAM17 protein via a set of hydrophobic and hydrophilic interactions with high docking score. Cholecalciferol 26-36 ADAM metallopeptidase domain 17 Homo sapiens 83-89 34959623-11 2021 In conclusion, this study highlights the protective pharmacological application of vitamin D3 to ameliorate the damages of testicular T/D on the testicular tissues via targeting miRNA145 and ADAM17 protein. Cholecalciferol 83-93 microRNA 145 Homo sapiens 178-186 34959623-11 2021 In conclusion, this study highlights the protective pharmacological application of vitamin D3 to ameliorate the damages of testicular T/D on the testicular tissues via targeting miRNA145 and ADAM17 protein. Cholecalciferol 83-93 ADAM metallopeptidase domain 17 Homo sapiens 191-197 34959778-1 2021 Several recent studies have demonstrated that the direct precursor of vitamin D3, the calcifediol (25(OH)D3), through the binding to the nuclear vitamin D receptor (VDR), is able to regulate the expression of many genes involved in several cellular processes. Cholecalciferol 70-80 vitamin D receptor Homo sapiens 145-163 34959778-1 2021 Several recent studies have demonstrated that the direct precursor of vitamin D3, the calcifediol (25(OH)D3), through the binding to the nuclear vitamin D receptor (VDR), is able to regulate the expression of many genes involved in several cellular processes. Cholecalciferol 70-80 vitamin D receptor Homo sapiens 165-168 34950832-1 2021 1,25(OH)2D3, the biologically active form of vitamin D3, is a major regulator of mineral and bone homeostasis and exerts its actions through binding to the vitamin D receptor (VDR), a ligand-activated transcription factor that can directly modulate gene expression in vitamin D-target tissues such as the intestine, kidney, and bone. Cholecalciferol 45-55 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 176-179 34867333-4 2021 Based on a network pharmacological analysis, N-acetyltransferase 2 (NAT2) was identified as a potential target of vitamin D3 against CRC. Cholecalciferol 114-124 N-acetyltransferase 2 Homo sapiens 45-66 34867333-4 2021 Based on a network pharmacological analysis, N-acetyltransferase 2 (NAT2) was identified as a potential target of vitamin D3 against CRC. Cholecalciferol 114-124 N-acetyltransferase 2 Homo sapiens 68-72 34867333-8 2021 These findings expand the potential uses of vitamin D3 against CRC and introduce VDR signaling via the enzyme NAT2 as a potential diagnostic and therapeutic target for CRC. Cholecalciferol 44-54 vitamin D receptor Homo sapiens 81-84 34297067-7 2021 CTX at 14 and 34 weeks" gestation were correlated in both placebo (r = 0.31) and cholecalciferol (r = 0.45) groups (P < 0.0001). Cholecalciferol 81-96 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 0-3 34836354-1 2021 Vitamin D3 is an essential micronutrient mediating pleiotropic effects in multiple tissues and cell types via its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), which activates the transcription factor vitamin D receptor. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 211-229 34782657-7 2021 All patients were fulfilling both old and new criteria of fibromyalgia syndrome, and not fulfilling any RA criteria, and had vitamin D3 deficiency or insufficiency. Cholecalciferol 125-135 3-hydroxyanthranilate 3,4-dioxygenase Homo sapiens 121-124 34824670-0 2021 Vitamin D3 Protects Mice from Diquat-Induced Oxidative Stress through the NF-kappaB/Nrf2/HO-1 Signaling Pathway. Cholecalciferol 0-10 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 74-83 34824670-0 2021 Vitamin D3 Protects Mice from Diquat-Induced Oxidative Stress through the NF-kappaB/Nrf2/HO-1 Signaling Pathway. Cholecalciferol 0-10 nuclear factor, erythroid derived 2, like 2 Mus musculus 84-88 34824670-0 2021 Vitamin D3 Protects Mice from Diquat-Induced Oxidative Stress through the NF-kappaB/Nrf2/HO-1 Signaling Pathway. Cholecalciferol 0-10 heme oxygenase 1 Mus musculus 89-93 34824670-3 2021 The results showed that oral gavage of vitamin D3 daily significantly improved the body weight gain and immune organ index and significantly reverted the abnormal changes of ALT, AST, SOD, GSH-Px, T-AOC, and MDA in the serum and jejunum induced by diquat. Cholecalciferol 39-49 glutamic pyruvic transaminase, soluble Mus musculus 174-177 34824670-4 2021 The addition of vitamin D3 also significantly reduced the concentration of DAO, D-LA, and certain proinflammatory cytokines in serum. Cholecalciferol 16-26 D-amino acid oxidase Mus musculus 75-78 34824670-7 2021 In addition, the results indicated that vitamin D3 could significantly reduce the phosphorylation level of NF-kappaB (p65) and enhance the expression of Nrf2 and HO-1 in the jejunum compared with the diquat-induced group. Cholecalciferol 40-50 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 107-116 34824670-7 2021 In addition, the results indicated that vitamin D3 could significantly reduce the phosphorylation level of NF-kappaB (p65) and enhance the expression of Nrf2 and HO-1 in the jejunum compared with the diquat-induced group. Cholecalciferol 40-50 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 118-121 34824670-7 2021 In addition, the results indicated that vitamin D3 could significantly reduce the phosphorylation level of NF-kappaB (p65) and enhance the expression of Nrf2 and HO-1 in the jejunum compared with the diquat-induced group. Cholecalciferol 40-50 nuclear factor, erythroid derived 2, like 2 Mus musculus 153-157 34824670-7 2021 In addition, the results indicated that vitamin D3 could significantly reduce the phosphorylation level of NF-kappaB (p65) and enhance the expression of Nrf2 and HO-1 in the jejunum compared with the diquat-induced group. Cholecalciferol 40-50 heme oxygenase 1 Mus musculus 162-166 34824670-8 2021 This study suggested that oral administration of vitamin D3 can protect mice against oxidative damage by inhibiting the phosphorylation level of NF-kappaB (p65) and activating Nrf2-related signaling pathways. Cholecalciferol 49-59 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 145-154 34824670-8 2021 This study suggested that oral administration of vitamin D3 can protect mice against oxidative damage by inhibiting the phosphorylation level of NF-kappaB (p65) and activating Nrf2-related signaling pathways. Cholecalciferol 49-59 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 156-159 34824670-8 2021 This study suggested that oral administration of vitamin D3 can protect mice against oxidative damage by inhibiting the phosphorylation level of NF-kappaB (p65) and activating Nrf2-related signaling pathways. Cholecalciferol 49-59 nuclear factor, erythroid derived 2, like 2 Mus musculus 176-180 34297067-8 2021 Median CTX(mug/mmol creatinine) increased from 14 to 34 weeks" gestation in both groups (n = 372 total) (placebo (n = 188) 223.6 to 449.7; cholecalciferol (n = 184) 222.3 to 419.3; P = 0.03 for placebo vs cholecalciferol difference in CTX at 34 weeks" gestation). Cholecalciferol 205-220 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 235-238 34297067-9 2021 The conditional increase in CTX(SD) from early to late pregnancy was greater in the placebo group (n = 188) than in the cholecalciferol group (n = 184) (placebo, mean(SD) 0.16(0.92); cholecalciferol, -0.16(1.06); p difference < 0.01). Cholecalciferol 120-135 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 28-31 34297067-9 2021 The conditional increase in CTX(SD) from early to late pregnancy was greater in the placebo group (n = 188) than in the cholecalciferol group (n = 184) (placebo, mean(SD) 0.16(0.92); cholecalciferol, -0.16(1.06); p difference < 0.01). Cholecalciferol 183-198 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 28-31 34297067-11 2021 CONCLUSIONS: Maternal urinary CTX, a bone resorption marker, rises through pregnancy, though to a lesser degree with gestational cholecalciferol supplementation, and is inversely associated with maternal bone mass post-partum.Clinical Trial Registry number and website: ISRCTN:82927713; EUDRACT:2007-001716-23. Cholecalciferol 129-144 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 30-33 34758235-8 2021 CONCLUSIONS: Some biological parameters such as low albumin, thrombocytosis, increased CRP, elevated levels of 25 OH vitamin D3, elevated levels of FGF23, elevated D-dimers, and elevated ferritin could be considered as laboratory negative predictive factors for CAL. Cholecalciferol 117-127 filamin binding LIM protein 1 Homo sapiens 262-265 34747516-7 2022 Compared with placebo, cholecalciferol significantly reduced whole PTH concentrations (between-group difference of -15% (95% confidence interval (CI), -25 to -3)), with greater treatment effects in subgroups with lower 25(OH)D, lower serum calcium, or higher estimated glomerular filtration rate (Pint < 0.05). Cholecalciferol 23-38 parathyroid hormone Homo sapiens 67-70 34747516-12 2022 In conclusion, 4000 IU/day cholecalciferol significantly reduced PTH levels and attenuated LS BMD loss after KTx. Cholecalciferol 27-42 parathyroid hormone Homo sapiens 65-68 34831233-3 2021 These ALP(+)-HUCPVCs were created from HUCPVCs in this study by culturing in the presence of activated vitamin D3, an inhibitor of bone morphogenetic protein signaling and transforming growth factor-beta1 (TGF-beta1). Cholecalciferol 103-113 alkaline phosphatase, placental Homo sapiens 6-9 34831233-3 2021 These ALP(+)-HUCPVCs were created from HUCPVCs in this study by culturing in the presence of activated vitamin D3, an inhibitor of bone morphogenetic protein signaling and transforming growth factor-beta1 (TGF-beta1). Cholecalciferol 103-113 transforming growth factor beta 1 Homo sapiens 206-215 34492244-0 2021 Vitamin D3/vitamin K2/magnesium-loaded polylactic acid/tricalcium phosphate/polycaprolactone composite nanofibers demonstrated osteoinductive effect by increasing Runx2 via Wnt/B-catenin pathway. Cholecalciferol 0-10 RUNX family transcription factor 2 Homo sapiens 163-168 34669255-12 2021 Pharmacological profile revealed that the treatment of DO and D3 inhibited the production of pro-inflammatory cytokines (TNF-alpha, IL-6) induced by lipopolysaccharide (LPS) in primary macrophages without any cytotoxic effect after administration of their effective concentrations. Cholecalciferol 62-64 tumor necrosis factor Homo sapiens 121-130 34669255-12 2021 Pharmacological profile revealed that the treatment of DO and D3 inhibited the production of pro-inflammatory cytokines (TNF-alpha, IL-6) induced by lipopolysaccharide (LPS) in primary macrophages without any cytotoxic effect after administration of their effective concentrations. Cholecalciferol 62-64 interleukin 6 Homo sapiens 132-136 34492244-0 2021 Vitamin D3/vitamin K2/magnesium-loaded polylactic acid/tricalcium phosphate/polycaprolactone composite nanofibers demonstrated osteoinductive effect by increasing Runx2 via Wnt/B-catenin pathway. Cholecalciferol 0-10 catenin beta 1 Homo sapiens 177-186 34492244-4 2021 Vitamin D3, vitamin K2, and magnesium demonstrated to support the osteogenic differentiation of mesenchymal stem cells by expressing Runx2, BMP2, and osteopontin and suppressing PPAR-gamma and Sox9. Cholecalciferol 0-10 RUNX family transcription factor 2 Homo sapiens 133-138 34492244-4 2021 Vitamin D3, vitamin K2, and magnesium demonstrated to support the osteogenic differentiation of mesenchymal stem cells by expressing Runx2, BMP2, and osteopontin and suppressing PPAR-gamma and Sox9. Cholecalciferol 0-10 bone morphogenetic protein 2 Homo sapiens 140-144 34492244-4 2021 Vitamin D3, vitamin K2, and magnesium demonstrated to support the osteogenic differentiation of mesenchymal stem cells by expressing Runx2, BMP2, and osteopontin and suppressing PPAR-gamma and Sox9. Cholecalciferol 0-10 secreted phosphoprotein 1 Homo sapiens 150-161 34492244-4 2021 Vitamin D3, vitamin K2, and magnesium demonstrated to support the osteogenic differentiation of mesenchymal stem cells by expressing Runx2, BMP2, and osteopontin and suppressing PPAR-gamma and Sox9. Cholecalciferol 0-10 peroxisome proliferator activated receptor gamma Homo sapiens 178-188 34492244-4 2021 Vitamin D3, vitamin K2, and magnesium demonstrated to support the osteogenic differentiation of mesenchymal stem cells by expressing Runx2, BMP2, and osteopontin and suppressing PPAR-gamma and Sox9. Cholecalciferol 0-10 SRY-box transcription factor 9 Homo sapiens 193-197 34721760-14 2021 The decreased ability of neutrophils to generate NETs, which can be achieved by vitamin D3/omega-3 PUFA supplementation, could have a positive effect on wound healing in T2DM patients and reduce the incidence and severity of complications. Cholecalciferol 80-90 pumilio RNA binding family member 3 Homo sapiens 99-103 34461573-0 2021 Vitamin D3 and estradiol alter PAD2 expression and activity levels in C6 glioma cells. Cholecalciferol 0-10 peptidyl arginine deiminase 2 Homo sapiens 31-35 34461573-3 2021 The aim of this study was to investigate the effects of vitamin D (25-hydroxy cholecalciferol (D3)) and estradiol on PAD2 gene expression level and its catalytic activity in rat C6 glioma cells. Cholecalciferol 95-97 peptidyl arginine deiminase 2 Homo sapiens 117-121 34827108-1 2021 The purpose of this study was to elucidate the effects of static electric field (SEF) treatment on vitamin D3 (Vit D3)-induced hypercalcemia and renal calcification in mice. Cholecalciferol 99-109 vitrin Mus musculus 111-114 34682898-9 2021 Serum calcium and 25-hydroxy vitamin D3 increased only in the DPP-4 inhibitor group, while other glycemic parameters did not show significant differences between the two groups. Cholecalciferol 29-39 dipeptidyl peptidase 4 Homo sapiens 62-67 34650431-11 2021 Our data further demonstrated that geniposide could inhibit the activation of p38 MAPK and then restrict the vitamin D receptor signaling stimulated by vitamin D3. Cholecalciferol 152-162 mitogen-activated protein kinase 14 Mus musculus 78-86 34255034-11 2021 CONCLUSIONS: Moderate supplementation of 15 ug/d cholecalciferol, in accordance with current recommendations, supports an adequate vitamin D status in adult women, irrespective of latitude, and might concomitantly prevent an increase in parathyroid hormone. Cholecalciferol 49-64 parathyroid hormone Homo sapiens 237-256 34669728-1 2021 Vitamin D3 (VD3) induces intestinal CYP3A that metabolizes orally administered anti-leukemic chemotherapeutic substrates dexamethasone (DEX) and dasatinib potentially causing a vitamin-drug interaction. Cholecalciferol 0-10 cytochrome P450, family 3, subfamily a, polypeptide 11 Mus musculus 36-41 34656640-9 2022 Serum 25-OH Vit D concentration increased by a mean of 17.2 nmol/L (standard deviation: 30.8 nmol/L) in the cholecalciferol group and declined by 8.2 nmol/L (+-24.3 nmol/L) in the placebo group (between group difference: 28.3 nmol/L (95% confidence interval 17.2, 39.4); p<0.001). Cholecalciferol 108-123 vitrin Homo sapiens 12-15 34684596-0 2021 COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng/mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis. Cholecalciferol 50-60 adaptor-related protein complex 2, alpha 2 subunit Mus musculus 145-156 34250710-0 2021 Chemical synthesis of side-chain-hydroxylated vitamin D3 derivatives and their metabolism by CYP27B1. Cholecalciferol 46-56 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 93-100 34250710-1 2021 1alpha,25-Dihydroxyvitamin D 3 (abbreviated here as 1,25D 3 ; other hydroxylated compounds are designated similarly) is a hormonally active form of vitamin D 3 (D 3 ), and is produced from D 3 by CYP27A1-mediated hydroxylation at C25, followed by CYP27B1-mediated hydroxylation at C1. Cholecalciferol 149-160 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 199-206 34250710-1 2021 1alpha,25-Dihydroxyvitamin D 3 (abbreviated here as 1,25D 3 ; other hydroxylated compounds are designated similarly) is a hormonally active form of vitamin D 3 (D 3 ), and is produced from D 3 by CYP27A1-mediated hydroxylation at C25, followed by CYP27B1-mediated hydroxylation at C1. Cholecalciferol 149-160 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 250-257 34780049-1 2021 As the active form of vitamin D3, 1alpha,25-(OH)2-D3 promotes receptor activator for nuclear factor-kappaB ligand (RANKL)-induced autophagy in osteoclast precursors (OCPs). Cholecalciferol 22-32 TNF superfamily member 11 Homo sapiens 115-120 34650431-11 2021 Our data further demonstrated that geniposide could inhibit the activation of p38 MAPK and then restrict the vitamin D receptor signaling stimulated by vitamin D3. Cholecalciferol 152-162 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 109-127 34339814-2 2021 In this light, vitamin D3 (vit.D3)-coated micelles were fabricated to encapsulate the cytotoxic drug; etoposide (ETP). Cholecalciferol 15-25 vitrin Homo sapiens 27-30 34570900-8 2021 However, MCs may use molecular mechanisms to exert immunosuppressive activity including releasing complement C3, lower expression of CD40L, and overexpression of enzymes with vitamin D3 metabolizing activity including CYP27A1 and CYP27B1. Cholecalciferol 175-185 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 218-225 34684328-3 2021 The current study aimed to evaluate the relative efficacy of ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) for raising the serum levels of vitamin D metabolites and functional indicators including serum parathyroid (PTH) levels, isometric muscle strength, hand grip strength and bone mineral density. Cholecalciferol 93-108 parathyroid hormone Homo sapiens 218-229 34684328-3 2021 The current study aimed to evaluate the relative efficacy of ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) for raising the serum levels of vitamin D metabolites and functional indicators including serum parathyroid (PTH) levels, isometric muscle strength, hand grip strength and bone mineral density. Cholecalciferol 93-108 parathyroid hormone Homo sapiens 231-234 34684328-3 2021 The current study aimed to evaluate the relative efficacy of ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) for raising the serum levels of vitamin D metabolites and functional indicators including serum parathyroid (PTH) levels, isometric muscle strength, hand grip strength and bone mineral density. Cholecalciferol 110-120 parathyroid hormone Homo sapiens 218-229 34684328-3 2021 The current study aimed to evaluate the relative efficacy of ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) for raising the serum levels of vitamin D metabolites and functional indicators including serum parathyroid (PTH) levels, isometric muscle strength, hand grip strength and bone mineral density. Cholecalciferol 110-120 parathyroid hormone Homo sapiens 231-234 34684328-9 2021 The quantitative analysis suggested higher efficacy of cholecalciferol than ergocalciferol in improving total 25(OH)D (mean difference: 15.69, 95%CI: 9.46 to 21.93 nmol/L) and reducing PTH levels, consistently across variable participant demographics, dosage and vehicle of supplementation. Cholecalciferol 55-70 parathyroid hormone Homo sapiens 185-188 34684328-12 2021 CONCLUSIONS: Compared to ergocalciferol, cholecalciferol intervention was more efficacious in improving vitamin D status (serum levels of total 25(OH)D and 25(OH)D3) and regulating PTH levels, irrespective of the participant demographics, dosage and vehicle of supplementation. Cholecalciferol 41-56 parathyroid hormone Homo sapiens 181-184 34587698-13 2021 After adjustments for triglycerides, BMI, uric acid, HbA1C, 25-OH vitamin D3, alcohol consumption, and anemia, the multiple logistic regression revealed that participants with low TTR levels had a significantly increased risk of BPPV (OR: 5.5; 95% CI, 2.55-11.9; p<0.001). Cholecalciferol 66-76 transthyretin Homo sapiens 180-183 34558256-8 2021 An increase in TGF-beta levels was noted among patients using vitamin D supplementation, which may suggest a mechanism by which cholecalciferol may improve MS prognosis. Cholecalciferol 128-143 transforming growth factor alpha Homo sapiens 15-23 34147475-9 2021 Vitamin D3 also downregulated the expression of vimentin, collagen I and alpha-smooth muscle actin and attenuated renal fibrosis and epithelial to mesenchymal transition in the kidney. Cholecalciferol 0-10 vimentin Rattus norvegicus 48-56 34147475-9 2021 Vitamin D3 also downregulated the expression of vimentin, collagen I and alpha-smooth muscle actin and attenuated renal fibrosis and epithelial to mesenchymal transition in the kidney. Cholecalciferol 0-10 actin gamma 2, smooth muscle Rattus norvegicus 73-98 34147475-10 2021 Importantly, vitamin D3 treatment increased the expression of the vitamin D receptor and inhibited Transforming growth factor-beta1 (TGF-beta1)/Smad3 signaling pathway in rats kidneys with chronic kidney disease. Cholecalciferol 13-23 vitamin D receptor Rattus norvegicus 66-84 34147475-10 2021 Importantly, vitamin D3 treatment increased the expression of the vitamin D receptor and inhibited Transforming growth factor-beta1 (TGF-beta1)/Smad3 signaling pathway in rats kidneys with chronic kidney disease. Cholecalciferol 13-23 transforming growth factor, beta 1 Rattus norvegicus 99-131 34147475-10 2021 Importantly, vitamin D3 treatment increased the expression of the vitamin D receptor and inhibited Transforming growth factor-beta1 (TGF-beta1)/Smad3 signaling pathway in rats kidneys with chronic kidney disease. Cholecalciferol 13-23 transforming growth factor, beta 1 Rattus norvegicus 133-142 34147475-10 2021 Importantly, vitamin D3 treatment increased the expression of the vitamin D receptor and inhibited Transforming growth factor-beta1 (TGF-beta1)/Smad3 signaling pathway in rats kidneys with chronic kidney disease. Cholecalciferol 13-23 SMAD family member 3 Rattus norvegicus 144-149 34147475-11 2021 Mechanistically, the upregulation of TGF-beta1 and phosphorylation of Smad3 induced by vitamin D3 was reversed by activation of the vitamin D receptor. Cholecalciferol 87-97 transforming growth factor, beta 1 Rattus norvegicus 37-46 34147475-11 2021 Mechanistically, the upregulation of TGF-beta1 and phosphorylation of Smad3 induced by vitamin D3 was reversed by activation of the vitamin D receptor. Cholecalciferol 87-97 SMAD family member 3 Rattus norvegicus 70-75 34147475-11 2021 Mechanistically, the upregulation of TGF-beta1 and phosphorylation of Smad3 induced by vitamin D3 was reversed by activation of the vitamin D receptor. Cholecalciferol 87-97 vitamin D receptor Rattus norvegicus 132-150 34147475-12 2021 Our findings indicated that vitamin D3 is a potential antifibrotic drug in chronic kidney disease via the vitmin D receptor and inhibiting TGF-beta1/Smad3 signaling pathway. Cholecalciferol 28-38 transforming growth factor, beta 1 Rattus norvegicus 139-148 34147475-12 2021 Our findings indicated that vitamin D3 is a potential antifibrotic drug in chronic kidney disease via the vitmin D receptor and inhibiting TGF-beta1/Smad3 signaling pathway. Cholecalciferol 28-38 SMAD family member 3 Rattus norvegicus 149-154 34506728-4 2022 Intriguingly, the interaction of lactone-vitamin D3 with HADHA does not affect the HADHA enzymatic activity but instead limits biosynthesis of carnitine, an endogenous metabolite required for the transport of fatty acids into the mitochondria for beta-oxidation. Cholecalciferol 41-51 hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha Homo sapiens 57-62 34506728-5 2022 Lactone-vitamin D3 dissociates the protein-protein interaction of HADHA with trimethyllysine dioxygenase (TMLD), thereby impairing the TMLD enzyme activity essential in carnitine biosynthesis. Cholecalciferol 8-18 hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha Homo sapiens 66-71 34506728-5 2022 Lactone-vitamin D3 dissociates the protein-protein interaction of HADHA with trimethyllysine dioxygenase (TMLD), thereby impairing the TMLD enzyme activity essential in carnitine biosynthesis. Cholecalciferol 8-18 trimethyllysine hydroxylase, epsilon Homo sapiens 77-104 34506728-5 2022 Lactone-vitamin D3 dissociates the protein-protein interaction of HADHA with trimethyllysine dioxygenase (TMLD), thereby impairing the TMLD enzyme activity essential in carnitine biosynthesis. Cholecalciferol 8-18 trimethyllysine hydroxylase, epsilon Homo sapiens 106-110 34506728-5 2022 Lactone-vitamin D3 dissociates the protein-protein interaction of HADHA with trimethyllysine dioxygenase (TMLD), thereby impairing the TMLD enzyme activity essential in carnitine biosynthesis. Cholecalciferol 8-18 trimethyllysine hydroxylase, epsilon Homo sapiens 135-139 34628889-8 2021 Following the addition of vitamin D3 treatment, serum Ca2+, FT3, FT4, and TRAb levels were significantly decreased relative to the ATD group, while the thyroid-stimulating hormone (TSH), PTH, and 25-OHVit D levels were normalized. Cholecalciferol 26-36 parathyroid hormone Homo sapiens 187-190 34502192-7 2021 Vitamin D3 was identified as responsible for the vitamin D receptor loss, for the increase in neutral sphingomyelinase content and sphingomyelin changes. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 49-67 34484626-15 2021 Conclusions: We found that vit D insufficient patients can be rapidly supplemented on the morning of surgery with a large dose of oral cholecalciferol 600,000 IU, and the effect was consistent over 2 weeks after surgery. Cholecalciferol 135-150 vitrin Homo sapiens 27-30 34302132-6 2021 RESULTS: Median C-reactive protein level was 10.8 mg/dL in the vitamin D3 group and 10.6 mg/dL in the control group (p = 0.465). Cholecalciferol 63-73 C-reactive protein Homo sapiens 16-34 34242778-20 2021 The proportion of women with the lowest cholecalciferol concentrations increased at V2 compared to the V1 (36.1 to 42.8 %; p = 0.02). Cholecalciferol 40-55 nibrin Homo sapiens 81-86 34502192-7 2021 Vitamin D3 was identified as responsible for the vitamin D receptor loss, for the increase in neutral sphingomyelinase content and sphingomyelin changes. Cholecalciferol 0-10 sphingomyelin phosphodiesterase 2 Homo sapiens 94-118 34512638-4 2021 We therefore aimed to investigate the effect of vitamin D3 treatment on viral-induced TLR3 responses in Bronchial Smooth Muscle Cells (BSMCs) as a mechanism contributing to pulmonary fibrosis in asthma and COPD. Cholecalciferol 48-58 toll like receptor 3 Homo sapiens 86-90 34512638-11 2021 Our findings suggest that vitamin D3 attenuates TLR3 agonist-induced inflammatory and fibrotic responses in BSMCs and support the clinical relevance of vitamin D3 supplementation in patients with viral infections having chronic respiratory diseases, such as asthma and COPD. Cholecalciferol 26-36 toll like receptor 3 Homo sapiens 48-52 34502192-9 2021 Incubation of the cells with neutral sphingomyelinase, or the same concentration of ceramide produced in exosomes was necessary and sufficient to stimulate embryonic hippocampal cell differentiation, as vitamin D3. Cholecalciferol 203-213 sphingomyelin phosphodiesterase 2 Homo sapiens 29-53 34576700-0 2021 The Cooperation of Bifidobacterium longum and Active Vitamin D3 on Innate Immunity in Salmonella Colitis Mice via Vitamin D Receptor. Cholecalciferol 53-63 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 114-132 34576700-8 2021 The in vivo study demonstrated the combination of probiotic Bifidobacterium longum and active vitamin D3 had the synergistic effects on reducing the severity of Salmonella colitis and body weight loss in C57BL/6 mice by reducing cecal inflammatory mIL-6, mIL-8, mTNF-alpha and mIL-1beta mRNA responses, blocking the translocation of bacteria while enhancing the antimicrobial peptide mhBD-3 mRNA in comparison to the infection only group. Cholecalciferol 94-104 interleukin 6 Mus musculus 248-253 34576700-8 2021 The in vivo study demonstrated the combination of probiotic Bifidobacterium longum and active vitamin D3 had the synergistic effects on reducing the severity of Salmonella colitis and body weight loss in C57BL/6 mice by reducing cecal inflammatory mIL-6, mIL-8, mTNF-alpha and mIL-1beta mRNA responses, blocking the translocation of bacteria while enhancing the antimicrobial peptide mhBD-3 mRNA in comparison to the infection only group. Cholecalciferol 94-104 chemokine (C-X-C motif) ligand 15 Mus musculus 255-260 34576700-8 2021 The in vivo study demonstrated the combination of probiotic Bifidobacterium longum and active vitamin D3 had the synergistic effects on reducing the severity of Salmonella colitis and body weight loss in C57BL/6 mice by reducing cecal inflammatory mIL-6, mIL-8, mTNF-alpha and mIL-1beta mRNA responses, blocking the translocation of bacteria while enhancing the antimicrobial peptide mhBD-3 mRNA in comparison to the infection only group. Cholecalciferol 94-104 tumor necrosis factor Mus musculus 262-272 34576700-8 2021 The in vivo study demonstrated the combination of probiotic Bifidobacterium longum and active vitamin D3 had the synergistic effects on reducing the severity of Salmonella colitis and body weight loss in C57BL/6 mice by reducing cecal inflammatory mIL-6, mIL-8, mTNF-alpha and mIL-1beta mRNA responses, blocking the translocation of bacteria while enhancing the antimicrobial peptide mhBD-3 mRNA in comparison to the infection only group. Cholecalciferol 94-104 interleukin 1 alpha Mus musculus 277-286 34445803-5 2021 Therefore, active forms of vitamin D3 including its canonical (1,25(OH)2D3) and noncanonical (CYP11A1-intitated) D3 derivatives as well as L3 derivatives are promising agents for the prevention, attenuation, or treatment of premature skin aging. Cholecalciferol 27-37 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 94-101 34174395-11 2021 Finally, Cel treatment reduced Vitamin D3-induced aortic calcification in mice and this effect was blocked by HMOX-1 inhibitor ZnPP9. Cholecalciferol 31-41 heme oxygenase 1 Mus musculus 110-116 34445803-5 2021 Therefore, active forms of vitamin D3 including its canonical (1,25(OH)2D3) and noncanonical (CYP11A1-intitated) D3 derivatives as well as L3 derivatives are promising agents for the prevention, attenuation, or treatment of premature skin aging. Cholecalciferol 113-115 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 94-101 34418235-5 2022 RESULTS: Ultraviolet radiation (UVR) and pigmentation genes interact to modify blood vitamin levels; Light skin IRF4-TT genotype has greatest folate loss while light skin HERC2-GG genotype has greatest vitamin D3 synthesis (reflected in both TOMS and seasonal data). Cholecalciferol 202-212 HECT and RLD domain containing E3 ubiquitin protein ligase 2 Homo sapiens 171-176 34418235-7 2022 Significant vitamin D3 photosynthesis only occurs within light skin HERC2-GG genotype, and is maximal at 305 nm. Cholecalciferol 12-22 HECT and RLD domain containing E3 ubiquitin protein ligase 2 Homo sapiens 68-73 34418235-11 2022 Lightest IRF4-TT/darkest HERC2-AA genotype combination (greatest folate loss/lowest vitamin D3 synthesis) has 0% occurrence. Cholecalciferol 84-94 HECT and RLD domain containing E3 ubiquitin protein ligase 2 Homo sapiens 25-30 34418235-12 2022 The opposing, commonest (39%) compound genotype (darkest IRF4-CC/lightest HERC2-GG) permits least folate loss and greatest synthesis of vitamin D3 . Cholecalciferol 136-146 interferon regulatory factor 4 Homo sapiens 57-61 34418235-12 2022 The opposing, commonest (39%) compound genotype (darkest IRF4-CC/lightest HERC2-GG) permits least folate loss and greatest synthesis of vitamin D3 . Cholecalciferol 136-146 HECT and RLD domain containing E3 ubiquitin protein ligase 2 Homo sapiens 74-79 34368851-9 2022 Daily consumption of soft plain cheese fortified with 2.5 microg of vitamin D3 and 302 mg of calcium for 4 weeks resulted in a mean increase of 0.8 ng/mL in 25(OH)D and 15.9 ng/mL in P1NP levels compared with baseline, and decreased CTX, TRAP5b, and PTH values. Cholecalciferol 68-78 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 233-236 34415218-2 2021 In this study, we used combined molecular docking, molecular dynamics simulations and binding free energy analyses to investigate the potentials of vitamin D3 and its hydroxyderivatives as TMPRSS2 inhibitor and to inhibit the SARS-CoV-2 receptor binding domain (RBD) binding to angiotensin-converting enzyme 2 (ACE2), as well as to unveil molecular and structural basis of 1,25(OH)2D3 capability to inhibit ACE2 and SARS-CoV-2 RBD interactions. Cholecalciferol 148-158 transmembrane serine protease 2 Homo sapiens 189-196 34415218-2 2021 In this study, we used combined molecular docking, molecular dynamics simulations and binding free energy analyses to investigate the potentials of vitamin D3 and its hydroxyderivatives as TMPRSS2 inhibitor and to inhibit the SARS-CoV-2 receptor binding domain (RBD) binding to angiotensin-converting enzyme 2 (ACE2), as well as to unveil molecular and structural basis of 1,25(OH)2D3 capability to inhibit ACE2 and SARS-CoV-2 RBD interactions. Cholecalciferol 148-158 angiotensin converting enzyme 2 Homo sapiens 278-309 34415218-2 2021 In this study, we used combined molecular docking, molecular dynamics simulations and binding free energy analyses to investigate the potentials of vitamin D3 and its hydroxyderivatives as TMPRSS2 inhibitor and to inhibit the SARS-CoV-2 receptor binding domain (RBD) binding to angiotensin-converting enzyme 2 (ACE2), as well as to unveil molecular and structural basis of 1,25(OH)2D3 capability to inhibit ACE2 and SARS-CoV-2 RBD interactions. Cholecalciferol 148-158 angiotensin converting enzyme 2 Homo sapiens 311-315 34415218-2 2021 In this study, we used combined molecular docking, molecular dynamics simulations and binding free energy analyses to investigate the potentials of vitamin D3 and its hydroxyderivatives as TMPRSS2 inhibitor and to inhibit the SARS-CoV-2 receptor binding domain (RBD) binding to angiotensin-converting enzyme 2 (ACE2), as well as to unveil molecular and structural basis of 1,25(OH)2D3 capability to inhibit ACE2 and SARS-CoV-2 RBD interactions. Cholecalciferol 148-158 angiotensin converting enzyme 2 Homo sapiens 407-411 34415218-3 2021 The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry. Cholecalciferol 22-32 transmembrane serine protease 2 Homo sapiens 97-104 34415218-3 2021 The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry. Cholecalciferol 22-32 angiotensin converting enzyme 2 Homo sapiens 137-141 34415218-3 2021 The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry. Cholecalciferol 22-32 transmembrane serine protease 2 Homo sapiens 252-259 34415218-3 2021 The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry. Cholecalciferol 22-32 angiotensin converting enzyme 2 Homo sapiens 286-290 34415218-3 2021 The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry. Cholecalciferol 181-191 transmembrane serine protease 2 Homo sapiens 97-104 34415218-3 2021 The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry. Cholecalciferol 181-191 angiotensin converting enzyme 2 Homo sapiens 137-141 34415218-3 2021 The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry. Cholecalciferol 181-191 transmembrane serine protease 2 Homo sapiens 252-259 34415218-3 2021 The results show that vitamin D3 and its hydroxyderivatives are favorable to bind active site of TMPRSS2 and the binding site(s) between ACE2 and SARS-CoV2-RBD, which indicate that vitamin D3 and its biologically active hydroxyderivatives can serve as TMPRSS2 inhibitor and can inhibit ACE2 binding of SARS-CoV-2 RBD to prevent SARS-CoV-2 entry. Cholecalciferol 181-191 angiotensin converting enzyme 2 Homo sapiens 286-290 34381124-1 2021 The present study aimed to investigate the effects of vitamin D3 (Vit D) administration on memory function, hippocampal level of amyloid-beta (Abeta), brain-derived neurotrophic factor (BDNF) and oxidative stress status in a rat model of unpredictable chronic mild stress (UCMS). Cholecalciferol 54-64 vitrin Rattus norvegicus 66-69 34368851-9 2022 Daily consumption of soft plain cheese fortified with 2.5 microg of vitamin D3 and 302 mg of calcium for 4 weeks resulted in a mean increase of 0.8 ng/mL in 25(OH)D and 15.9 ng/mL in P1NP levels compared with baseline, and decreased CTX, TRAP5b, and PTH values. Cholecalciferol 68-78 parathyroid hormone Homo sapiens 250-253 34368851-11 2022 Yogurt fortified with 10 microg of vitamin D3 and 800 mg of calcium did not change P1NP values after 8 weeks of intervention, but was associated with decreases of 0.0286 ng/mL and 1.06 U/L in PTH and TRAP5b, respectively. Cholecalciferol 35-45 parathyroid hormone Homo sapiens 192-195 34408754-7 2021 We show that in addition to the transcription factors AhR and RORgammat, the active form of vitamin D3 (1,25(OH)2D3) regulates IL-22 production in these cells. Cholecalciferol 92-102 interleukin 22 Homo sapiens 127-132 34358825-0 2021 Effect of supplementation with calcitriol versus cholecalciferol on insulin resistance in patients with nonalcoholic fatty liver disease: Several issues of concern. Cholecalciferol 49-64 insulin Homo sapiens 68-75 34268906-12 2021 Inhibition of SQLE reduced the levels of calcitriol (active form of vitamin D3) and CYP24A1, followed by an increase in intracellular Ca2+ concentration. Cholecalciferol 68-78 squalene epoxidase Homo sapiens 14-18 34132891-8 2021 There were positive significant correlations between levels of vitamin D3 and acute-phase reactants in serum, such as C-reactive protein (P = 0.0292). Cholecalciferol 63-73 C-reactive protein Homo sapiens 118-136 34143299-4 2021 The GH/IGF-1 system regulates glomerular hemodynamics, renal gluconeogenesis, tubular sodium and water, phosphate, and calcium handling, as well as renal synthesis of 1,25 (OH)2 vitamin D3 and the antiaging hormone Klotho. Cholecalciferol 178-188 insulin like growth factor 1 Homo sapiens 7-12 34294550-2 2022 This study aimed to assess the effects of cholecalciferol supplementation on FGF23 and alpha-klotho in patients with hypovitaminosis D requiring hemodialysis. Cholecalciferol 42-57 fibroblast growth factor 23 Homo sapiens 77-82 34362518-5 2021 Compared with the activated group, the platelet proliferation, proportion of CD41+/CD61+ and CD41+/CD62p+, content of PECAM-1 and RAGE expression in vitamin D3 groups were all decreased (P<0.05). Cholecalciferol 149-159 integrin alpha 2b Mus musculus 77-81 34362518-5 2021 Compared with the activated group, the platelet proliferation, proportion of CD41+/CD61+ and CD41+/CD62p+, content of PECAM-1 and RAGE expression in vitamin D3 groups were all decreased (P<0.05). Cholecalciferol 149-159 integrin beta 3 Mus musculus 83-87 34362518-5 2021 Compared with the activated group, the platelet proliferation, proportion of CD41+/CD61+ and CD41+/CD62p+, content of PECAM-1 and RAGE expression in vitamin D3 groups were all decreased (P<0.05). Cholecalciferol 149-159 integrin alpha 2b Mus musculus 93-97 34362518-5 2021 Compared with the activated group, the platelet proliferation, proportion of CD41+/CD61+ and CD41+/CD62p+, content of PECAM-1 and RAGE expression in vitamin D3 groups were all decreased (P<0.05). Cholecalciferol 149-159 selectin, platelet Mus musculus 99-104 34362518-5 2021 Compared with the activated group, the platelet proliferation, proportion of CD41+/CD61+ and CD41+/CD62p+, content of PECAM-1 and RAGE expression in vitamin D3 groups were all decreased (P<0.05). Cholecalciferol 149-159 platelet/endothelial cell adhesion molecule 1 Mus musculus 118-125 34362518-5 2021 Compared with the activated group, the platelet proliferation, proportion of CD41+/CD61+ and CD41+/CD62p+, content of PECAM-1 and RAGE expression in vitamin D3 groups were all decreased (P<0.05). Cholecalciferol 149-159 advanced glycosylation end product-specific receptor Mus musculus 130-134 34272637-2 2021 Tyrosine kinase inhibitor such as imatinib is reported to interfere with the activation of vitamin D3 by inhibiting CYP27B1 enzyme. Cholecalciferol 91-101 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 116-123 34294550-8 2022 However, the before-after differences between cholecalciferol supplement and placebo were significant only for alpha-klotho (P = .035). Cholecalciferol 46-61 klotho Homo sapiens 117-123 34294550-10 2022 CONCLUSION: Cholecalciferol supplementation of 50,000 IU for 12 weeks increases alpha-klotho levels in the serum of kidney failure patients undergoing hemodialysis. Cholecalciferol 12-27 klotho Homo sapiens 86-92 34255241-0 2021 Vitamin D3 decreases TNF-alpha-induced inflammation in lung epithelial cells through a reduction in mitochondrial fission and mitophagy. Cholecalciferol 0-10 tumor necrosis factor Homo sapiens 21-30 34298790-3 2021 GBM incidence has been negatively correlated with the serum levels of 25-hydroxy-vitamin D3, while the low pH within tumors has been shown to promote the expression of the vitamin D3-degrading enzyme 24-hydroxylase, encoded by the CYP24A1 gene. Cholecalciferol 172-182 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 231-238 34316406-17 2021 In addition, in THP-1 cells undergoing the combined stimulation, the gene expression patterns were influenced by vitamin D3, which also ablated the effect of the mechanical stimulus on PIEZO1 upregulation. Cholecalciferol 113-123 piezo type mechanosensitive ion channel component 1 Homo sapiens 185-191 34255241-5 2021 The purpose of this study was to examine the effects and mechanisms of action of vitamin D3 (Vit. Cholecalciferol 81-91 vitrin Homo sapiens 93-96 34238191-5 2022 They were stable (particle size and distribution) for 15 days when stored in a refrigerator and for 30 days at room temperature and 32 C. The nanoparticles decreased the drug cytotoxicity against fibroblasts, as shown by IC50 (nanoparticle: 32.48 mug mL-1; vitamin D3: 16.73 mug mL-1). Cholecalciferol 258-268 L1 cell adhesion molecule Mus musculus 280-284 34251424-8 2021 The qRT-PCR results were consistent with the transcriptome analyses, vitamin D3 appears to enhance CYP24A1, SHE, KRT16 but suppresses CILP expression in HTF. Cholecalciferol 69-79 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 99-106 34262557-0 2021 Low-Dose Vitamin D3 Supplementation Does Not Affect Natural Regulatory T Cell Population but Attenuates Seasonal Changes in T Cell-Produced IFN-gamma: Results From the D-SIRe2 Randomized Controlled Trial. Cholecalciferol 9-19 interferon gamma Homo sapiens 140-149 34163023-10 2022 Administration of BK channel activator BMS191011 (10 mg kg-1 d-1) in high-dosage vitamin D3-treated mice significantly ameliorated calcification. Cholecalciferol 83-93 potassium calcium-activated channel subfamily M alpha 1 Rattus norvegicus 18-28 34178387-0 2021 Vitamin D3 reduces hippocampal NR2A and anxiety in nicotine withdrawal mice. Cholecalciferol 0-10 glutamate receptor, ionotropic, NMDA2A (epsilon 1) Mus musculus 31-35 34178387-6 2021 Moreover, vitamin D3 supplementation attenuated the hippocampal NR2A expression on both protein and mRNA levels in nicotine and vitamin D3-treated mice. Cholecalciferol 10-20 glutamate receptor, ionotropic, NMDA2A (epsilon 1) Mus musculus 64-68 34178387-6 2021 Moreover, vitamin D3 supplementation attenuated the hippocampal NR2A expression on both protein and mRNA levels in nicotine and vitamin D3-treated mice. Cholecalciferol 128-138 glutamate receptor, ionotropic, NMDA2A (epsilon 1) Mus musculus 64-68 34178387-7 2021 Our data showed that dietary supplementation with vitamin D3 ameliorated nicotine withdrawal-induced anxiety, which may be related to downregulation of NR2A expression in hippocampus. Cholecalciferol 50-60 glutamate receptor, ionotropic, NMDA2A (epsilon 1) Mus musculus 152-156 34101754-0 2021 Vitamin D3 attenuates doxorubicin-induced senescence of human aortic endothelial cells by upregulation of IL-10 via the pAMPKalpha/Sirt1/Foxo3a signaling pathway. Cholecalciferol 0-10 interleukin 10 Homo sapiens 106-111 34101754-0 2021 Vitamin D3 attenuates doxorubicin-induced senescence of human aortic endothelial cells by upregulation of IL-10 via the pAMPKalpha/Sirt1/Foxo3a signaling pathway. Cholecalciferol 0-10 sirtuin 1 Homo sapiens 131-136 34101754-0 2021 Vitamin D3 attenuates doxorubicin-induced senescence of human aortic endothelial cells by upregulation of IL-10 via the pAMPKalpha/Sirt1/Foxo3a signaling pathway. Cholecalciferol 0-10 forkhead box O3 Homo sapiens 137-143 34101754-4 2021 We further show the protective effects of vitamin D3 are mediated by the upregulation of IL-10 and FOXO3a expression through fine modulation of pAMPKalpha/SIRT1/FOXO3a complex activity. Cholecalciferol 42-52 interleukin 10 Homo sapiens 89-94 34101754-4 2021 We further show the protective effects of vitamin D3 are mediated by the upregulation of IL-10 and FOXO3a expression through fine modulation of pAMPKalpha/SIRT1/FOXO3a complex activity. Cholecalciferol 42-52 forkhead box O3 Homo sapiens 99-105 34101754-4 2021 We further show the protective effects of vitamin D3 are mediated by the upregulation of IL-10 and FOXO3a expression through fine modulation of pAMPKalpha/SIRT1/FOXO3a complex activity. Cholecalciferol 42-52 sirtuin 1 Homo sapiens 155-160 34101754-4 2021 We further show the protective effects of vitamin D3 are mediated by the upregulation of IL-10 and FOXO3a expression through fine modulation of pAMPKalpha/SIRT1/FOXO3a complex activity. Cholecalciferol 42-52 forkhead box O3 Homo sapiens 161-167 34178862-8 2021 Vitamin D3 was applied via oral gavage once daily to the STZ + vit-D3 group for a total period of 14 days, starting from the 7th day of the experiment. Cholecalciferol 0-10 vitrin Rattus norvegicus 63-66 34531993-10 2021 Moreover, vitamin D3 treatment has increased the phosphorylation of cAMP-response element-binding protein and the expression of brain-derived neurotrophic factor and vitamin D receptor. Cholecalciferol 10-20 brain derived neurotrophic factor Mus musculus 128-161 34531993-10 2021 Moreover, vitamin D3 treatment has increased the phosphorylation of cAMP-response element-binding protein and the expression of brain-derived neurotrophic factor and vitamin D receptor. Cholecalciferol 10-20 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 166-184 34206371-0 2021 Knocking out the Vitamin D Receptor Enhances Malignancy and Decreases Responsiveness to Vitamin D3 Hydroxyderivatives in Human Melanoma Cells. Cholecalciferol 88-98 vitamin D receptor Homo sapiens 17-35 34071156-6 2021 The yield of milk (0.05 < p < 0.10), energy-corrected milk (p < 0.05), 3.5% fat-corrected milk (p < 0.05), and milk protein (p < 0.05) were significantly higher in 25-hydroxyvitamin D3-treated groups within 3 weeks of lactation than in vitamin D3-treated cows. Cholecalciferol 236-246 casein kappa Bos taurus 111-123 34071156-8 2021 Feeding 25-hydroxyvitamin D3 also showed a lower concentration of malondialdehyde (p < 0.05), interleukin 6 (p < 0.05), and tumor necrosis factor-alpha (TNF-alpha) (p < 0.05), as well as a higher concentration of alkaline phosphatase (p < 0.05), total antioxidant capacity (p < 0.05), and immunoglobulin G (p < 0.05) than vitamin D3. Cholecalciferol 322-332 interleukin 6 Bos taurus 94-107 34071156-8 2021 Feeding 25-hydroxyvitamin D3 also showed a lower concentration of malondialdehyde (p < 0.05), interleukin 6 (p < 0.05), and tumor necrosis factor-alpha (TNF-alpha) (p < 0.05), as well as a higher concentration of alkaline phosphatase (p < 0.05), total antioxidant capacity (p < 0.05), and immunoglobulin G (p < 0.05) than vitamin D3. Cholecalciferol 322-332 tumor necrosis factor Bos taurus 124-151 34109109-8 2021 Moreover, increased vitamin D3 levels by calcitriol supplementation or induction by UVB-radiation was associated with inhibited IL-6 signaling and increased the response to irradiation observed in animal models. Cholecalciferol 20-30 interleukin 6 Homo sapiens 128-132 34063823-8 2021 Possible molecular mechanisms of neuroprotective action of vitamin D3 can be associated with the increased expression level of transcription factor HIF-1alpha and maintaining the relationship between the levels of BDNF and TrkB expression in cells of primary neuronal cultures. Cholecalciferol 59-69 hypoxia inducible factor 1 subunit alpha Homo sapiens 148-158 34063823-8 2021 Possible molecular mechanisms of neuroprotective action of vitamin D3 can be associated with the increased expression level of transcription factor HIF-1alpha and maintaining the relationship between the levels of BDNF and TrkB expression in cells of primary neuronal cultures. Cholecalciferol 59-69 brain derived neurotrophic factor Homo sapiens 214-218 34063823-8 2021 Possible molecular mechanisms of neuroprotective action of vitamin D3 can be associated with the increased expression level of transcription factor HIF-1alpha and maintaining the relationship between the levels of BDNF and TrkB expression in cells of primary neuronal cultures. Cholecalciferol 59-69 neurotrophic receptor tyrosine kinase 2 Homo sapiens 223-227 34251424-8 2021 The qRT-PCR results were consistent with the transcriptome analyses, vitamin D3 appears to enhance CYP24A1, SHE, KRT16 but suppresses CILP expression in HTF. Cholecalciferol 69-79 Src homology 2 domain containing E Homo sapiens 108-111 34251424-8 2021 The qRT-PCR results were consistent with the transcriptome analyses, vitamin D3 appears to enhance CYP24A1, SHE, KRT16 but suppresses CILP expression in HTF. Cholecalciferol 69-79 keratin 16 Homo sapiens 113-118 34251424-8 2021 The qRT-PCR results were consistent with the transcriptome analyses, vitamin D3 appears to enhance CYP24A1, SHE, KRT16 but suppresses CILP expression in HTF. Cholecalciferol 69-79 cartilage intermediate layer protein Homo sapiens 134-138 34099581-5 2021 Noteworthy, recent studies suggested that supplementation with vitamin D3 may be an alternative therapy increasing insulin sensitivity and thereby improving reproductive parameters in PCOS women. Cholecalciferol 63-73 insulin Homo sapiens 115-122 34909713-4 2021 Furthermore, our results show that afatinib may interfere with vitamin D3 metabolism, acting via CYP27A1 and CYP24A1 to regulate calcium concentration through the phosphatidylinositol 3-kinase/protein kinase B pathway. Cholecalciferol 63-73 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 97-104 34909713-4 2021 Furthermore, our results show that afatinib may interfere with vitamin D3 metabolism, acting via CYP27A1 and CYP24A1 to regulate calcium concentration through the phosphatidylinositol 3-kinase/protein kinase B pathway. Cholecalciferol 63-73 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 109-116 34909713-4 2021 Furthermore, our results show that afatinib may interfere with vitamin D3 metabolism, acting via CYP27A1 and CYP24A1 to regulate calcium concentration through the phosphatidylinositol 3-kinase/protein kinase B pathway. Cholecalciferol 63-73 protein tyrosine kinase 2 beta Homo sapiens 193-209 34515192-7 2021 The mRNA and protein expression of CYP2R1 of hydroxylated vitamin D3 was significantly reduced; CYP11A1 and CYP11A2, which synthesize testosterone, were significantly reduced. Cholecalciferol 58-68 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 35-41 35183964-0 2022 pH-driven-assembled soy peptide nanoparticles as particulate emulsifier for oil-in-water Pickering emulsion and their potential for encapsulation of vitamin D3. Cholecalciferol 149-159 phenylalanine hydroxylase Homo sapiens 0-2 34725288-7 2021 The women, who received the course of the preventive therapy with metformin, vitamin D3 and corvitin, showed a decrease in the concentration of pro-inflammatory cytokines and an increase in anti-inflammatory cytokine IL-10, normalization of the balance between iNOS and arginase activity, and the normalization of the M1 / M2 macrophages ratio. Cholecalciferol 77-87 inositol-3-phosphate synthase 1 Homo sapiens 261-265 34725288-7 2021 The women, who received the course of the preventive therapy with metformin, vitamin D3 and corvitin, showed a decrease in the concentration of pro-inflammatory cytokines and an increase in anti-inflammatory cytokine IL-10, normalization of the balance between iNOS and arginase activity, and the normalization of the M1 / M2 macrophages ratio. Cholecalciferol 77-87 interleukin 10 Homo sapiens 217-222 35533917-0 2022 Vitamin D3 reverses the transcriptional profile of offspring CD4+ T lymphocytes exposed to intrauterine inflammation. Cholecalciferol 0-10 CD4 antigen Mus musculus 61-64 35364123-3 2022 Vitamin D3 is considered as a strong modulator of a number of transcription factors, including NF-kappaB. Cholecalciferol 0-10 nuclear factor kappa B subunit 1 Homo sapiens 95-104 35364123-13 2022 GENERAL SIGNIFICANCE: Vitamin D3 supplementation counteracts diabetes-induced kidney damage, most likely through VDR-mediated inhibition of NF-kappaB activation. Cholecalciferol 22-32 vitamin D receptor Homo sapiens 113-116 35364123-13 2022 GENERAL SIGNIFICANCE: Vitamin D3 supplementation counteracts diabetes-induced kidney damage, most likely through VDR-mediated inhibition of NF-kappaB activation. Cholecalciferol 22-32 nuclear factor kappa B subunit 1 Homo sapiens 140-149 35531910-6 2022 Our research provides the first evidence that exogenous FGF21 treatment can alleviate the vitamin D3 plus nicotine-induced VC at least in part via suppressing ATF4 mediated apoptosis and osteogenic transformation in rats. Cholecalciferol 90-100 fibroblast growth factor 21 Rattus norvegicus 56-61 35485195-6 2022 RESULTS: It was observed that vitamin D3 reduced expression of IFN-gamma, IL-4, IL-5, and IL-10 genes by 73, 50, 37, and 29%, respectively, and increased IL-2 gene expression by 31% (p <= 0.05). Cholecalciferol 30-40 interferon gamma Homo sapiens 63-72 35485195-6 2022 RESULTS: It was observed that vitamin D3 reduced expression of IFN-gamma, IL-4, IL-5, and IL-10 genes by 73, 50, 37, and 29%, respectively, and increased IL-2 gene expression by 31% (p <= 0.05). Cholecalciferol 30-40 interleukin 4 Homo sapiens 74-78 35485195-6 2022 RESULTS: It was observed that vitamin D3 reduced expression of IFN-gamma, IL-4, IL-5, and IL-10 genes by 73, 50, 37, and 29%, respectively, and increased IL-2 gene expression by 31% (p <= 0.05). Cholecalciferol 30-40 interleukin 5 Homo sapiens 80-84 35485195-6 2022 RESULTS: It was observed that vitamin D3 reduced expression of IFN-gamma, IL-4, IL-5, and IL-10 genes by 73, 50, 37, and 29%, respectively, and increased IL-2 gene expression by 31% (p <= 0.05). Cholecalciferol 30-40 interleukin 10 Homo sapiens 90-95 35485195-6 2022 RESULTS: It was observed that vitamin D3 reduced expression of IFN-gamma, IL-4, IL-5, and IL-10 genes by 73, 50, 37, and 29%, respectively, and increased IL-2 gene expression by 31% (p <= 0.05). Cholecalciferol 30-40 interleukin 2 Homo sapiens 154-158 35421413-0 2022 Molecular and structural basis of interactions of vitamin D3 hydroxyderivatives with aryl hydrocarbon receptor (AhR): An integrated experimental and computational study. Cholecalciferol 50-60 aryl hydrocarbon receptor Homo sapiens 85-110 35421413-0 2022 Molecular and structural basis of interactions of vitamin D3 hydroxyderivatives with aryl hydrocarbon receptor (AhR): An integrated experimental and computational study. Cholecalciferol 50-60 aryl hydrocarbon receptor Homo sapiens 112-115 35421413-1 2022 To better understand the molecular and structural basis underlying the interaction of vitamin D3 hydroxyderivatives with AhR, molecular simulation was used to probe the binding of 1,20(OH)2D3, 1,25(OH)2D3, 20,23(OH)2D3 and 20(OH)D3 to AhR. Cholecalciferol 86-96 aryl hydrocarbon receptor Homo sapiens 121-124 35421413-2 2022 qPCR showed that vitamin D3 derivatives stimulate expression of cyp1A1 and cyp1B1 genes that are downstream targets of AhR signaling. Cholecalciferol 17-27 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 64-70 35560516-2 2022 Vitamin D3 (VD3 ) through its receptor (VDR) plays an important immunomodulatory role in autoimmune misbalance, being capable of modulating immune responses. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 40-43 35421413-2 2022 qPCR showed that vitamin D3 derivatives stimulate expression of cyp1A1 and cyp1B1 genes that are downstream targets of AhR signaling. Cholecalciferol 17-27 cytochrome P450 family 1 subfamily B member 1 Homo sapiens 75-81 35421413-2 2022 qPCR showed that vitamin D3 derivatives stimulate expression of cyp1A1 and cyp1B1 genes that are downstream targets of AhR signaling. Cholecalciferol 17-27 aryl hydrocarbon receptor Homo sapiens 119-122 35421413-4 2022 Molecular dynamics simulations were used to model the binding of vitamin D3 derivatives to AhR to examine their influence on the structure, conformation and dynamics of the AhR ligand binding domain (LBD). Cholecalciferol 65-75 aryl hydrocarbon receptor Homo sapiens 91-94 35257869-7 2022 Although no difference in serum levels of 25(OH)D3, calcium or zonulin was observed in cholecalciferol-treated mice vs. healthy controls, a significant improvement in intestinal mucosa pathological features in mice administered cholecalciferol was observed by histological analysis. Cholecalciferol 87-102 haptoglobin Mus musculus 63-70 35257869-7 2022 Although no difference in serum levels of 25(OH)D3, calcium or zonulin was observed in cholecalciferol-treated mice vs. healthy controls, a significant improvement in intestinal mucosa pathological features in mice administered cholecalciferol was observed by histological analysis. Cholecalciferol 228-243 haptoglobin Mus musculus 63-70 35257869-9 2022 Immunohistochemical staining revealed increased expression of CD3 and ZO-1 in celiac mice compared to mice receiving high dose (130 mug/kg) cholecalciferol. Cholecalciferol 140-155 CD247 antigen Mus musculus 62-65 35257869-9 2022 Immunohistochemical staining revealed increased expression of CD3 and ZO-1 in celiac mice compared to mice receiving high dose (130 mug/kg) cholecalciferol. Cholecalciferol 140-155 tight junction protein 1 Mus musculus 70-74 35334282-0 2022 Cholecalciferol pretreatment ameliorates ischemia/reperfusion-induced acute kidney injury through inhibiting ROS production, NF-kappaB pathway and pyroptosis. Cholecalciferol 0-15 nuclear factor kappa B subunit 1 Homo sapiens 125-134 35603161-7 2022 We also observed epigenetic and genetic modulation of several of these T1D susceptibility genes in dendritic cells (DCs) treated with vitamin D3 and dexamethasone to acquire tolerogenic properties as compared to immune activating DCs (mDC) illustrating the interaction between genes and environment that collectively determines risk for T1D. Cholecalciferol 134-144 decorin Mus musculus 235-238 35334282-7 2022 Cholecalciferol reduced ROS production, suppressed activated NF-kappaB signaling, and inhibited gasdermin D (GSDMD, a pyroptosis execution protein)-mediated pyroptosis. Cholecalciferol 0-15 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 61-70 35334282-7 2022 Cholecalciferol reduced ROS production, suppressed activated NF-kappaB signaling, and inhibited gasdermin D (GSDMD, a pyroptosis execution protein)-mediated pyroptosis. Cholecalciferol 0-15 gasdermin D Homo sapiens 96-107 35334282-7 2022 Cholecalciferol reduced ROS production, suppressed activated NF-kappaB signaling, and inhibited gasdermin D (GSDMD, a pyroptosis execution protein)-mediated pyroptosis. Cholecalciferol 0-15 gasdermin D Homo sapiens 109-114 35334282-8 2022 Cholecalciferol therefore has potential, as a clinical drug, to protect renal function in I/R-induced AKI through reducing ROS production, NF-kappaB activation and GSDMD-mediated pyroptosis. Cholecalciferol 0-15 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 139-148 35334282-8 2022 Cholecalciferol therefore has potential, as a clinical drug, to protect renal function in I/R-induced AKI through reducing ROS production, NF-kappaB activation and GSDMD-mediated pyroptosis. Cholecalciferol 0-15 gasdermin D Homo sapiens 164-169 34995387-4 2022 However, it can be associated with the disturbances in transmembrane glycoprotein-LRP2/megalin, which is implicated in vitamin D3 transport to the cell, and defects in vitamin D-signalling through the nuclear receptors. Cholecalciferol 119-129 LDL receptor related protein 2 Homo sapiens 82-86 35547357-4 2022 By conducting this study, we wanted to emphasize the role of vitamin D3 in reducing the oxidative stress load on patients undergoing peritoneal dialysis (PD) via serum TRX level measurement. Cholecalciferol 61-71 thioredoxin Homo sapiens 168-171 35547357-10 2022 The serum TRX level was significantly higher (211,62 U/l +- 314,46) in the group receiving vitamin D3 compared to the group which is not using Vitamin D3 (101,63 U/l +- 215,03) (p < 0,006). Cholecalciferol 91-101 thioredoxin Homo sapiens 10-13 35547357-10 2022 The serum TRX level was significantly higher (211,62 U/l +- 314,46) in the group receiving vitamin D3 compared to the group which is not using Vitamin D3 (101,63 U/l +- 215,03) (p < 0,006). Cholecalciferol 143-153 thioredoxin Homo sapiens 10-13 35138562-8 2022 The acromegaly group showed an increase in DBP levels after cholecalciferol intake as opposed to the control group (p < 0.05) and had lower increase in free 25(OH)D levels (p < 0.05). Cholecalciferol 60-75 D-box binding PAR bZIP transcription factor Homo sapiens 43-46 34995387-4 2022 However, it can be associated with the disturbances in transmembrane glycoprotein-LRP2/megalin, which is implicated in vitamin D3 transport to the cell, and defects in vitamin D-signalling through the nuclear receptors. Cholecalciferol 119-129 LDL receptor related protein 2 Homo sapiens 87-94 35245520-0 2022 Enhanced in vitro tumoricidal effects of 5-Fluorouracil, thymoquinone, and active vitamin D3 triple therapy against colon cancer cells by attenuating the PI3K/AKT/mTOR pathway. Cholecalciferol 82-92 AKT serine/threonine kinase 1 Homo sapiens 159-162 35493433-0 2022 Vitamin D3 alleviates cigarette smoke extract-mediated epithelial-mesenchymal transition and fibrogenesis by upregulating CC16 expression in bronchial epithelial cells. Cholecalciferol 0-10 secretoglobin family 1A member 1 Homo sapiens 122-126 35493433-10 2022 The results of the present study found that vitamin D3 could increase the protein expression level of CC16 to inhibit the activation of the TGF-beta1/SMAD3 signaling pathway; thereby reducing the 20% increase in CSE-induced EMT- and fibrogenesis-related protein expression levels. Cholecalciferol 44-54 secretoglobin family 1A member 1 Homo sapiens 102-106 35493433-10 2022 The results of the present study found that vitamin D3 could increase the protein expression level of CC16 to inhibit the activation of the TGF-beta1/SMAD3 signaling pathway; thereby reducing the 20% increase in CSE-induced EMT- and fibrogenesis-related protein expression levels. Cholecalciferol 44-54 transforming growth factor beta 1 Homo sapiens 140-149 35493433-10 2022 The results of the present study found that vitamin D3 could increase the protein expression level of CC16 to inhibit the activation of the TGF-beta1/SMAD3 signaling pathway; thereby reducing the 20% increase in CSE-induced EMT- and fibrogenesis-related protein expression levels. Cholecalciferol 44-54 SMAD family member 3 Homo sapiens 150-155 35493433-11 2022 Following CC16 knockdown, the inhibitory effects of vitamin D3 on EMT- and fibrogenesis-related protein expression were partially reversed. Cholecalciferol 52-62 secretoglobin family 1A member 1 Homo sapiens 10-14 35493433-12 2022 To conclude, these results suggest that vitamin D3 can inhibit the protein expression levels of EMT- and fibrogenesis-related proteins induced by CSE, at least partially through the function of CC16. Cholecalciferol 40-50 secretoglobin family 1A member 1 Homo sapiens 194-198 35183675-12 2022 Mechanistically, our results demonstrated that vitamin D3 can activate AMPK, inhibiting the mTOR pathway, thus inhibiting NLRP3 inflammasome activation and alleviating pyroptosis in beta-cell dysfunction. Cholecalciferol 47-57 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 71-75 35183675-12 2022 Mechanistically, our results demonstrated that vitamin D3 can activate AMPK, inhibiting the mTOR pathway, thus inhibiting NLRP3 inflammasome activation and alleviating pyroptosis in beta-cell dysfunction. Cholecalciferol 47-57 mechanistic target of rapamycin kinase Rattus norvegicus 92-96 35183675-12 2022 Mechanistically, our results demonstrated that vitamin D3 can activate AMPK, inhibiting the mTOR pathway, thus inhibiting NLRP3 inflammasome activation and alleviating pyroptosis in beta-cell dysfunction. Cholecalciferol 47-57 NLR family, pyrin domain containing 3 Rattus norvegicus 122-127 35245520-0 2022 Enhanced in vitro tumoricidal effects of 5-Fluorouracil, thymoquinone, and active vitamin D3 triple therapy against colon cancer cells by attenuating the PI3K/AKT/mTOR pathway. Cholecalciferol 82-92 mechanistic target of rapamycin kinase Homo sapiens 163-167 35157949-10 2022 In addition, Vitamin D3 significantly alleviated anxiety- and depressive-like behaviors in TST and EPM test, decreased GFAP expression level, modified hippocampal astrocyte activation pattern, and advanced brain-derived neurotrophic factor (BDNF) distribution and expression in CA1 and CA3 of the hippocampus. Cholecalciferol 13-23 glial fibrillary acidic protein Mus musculus 119-123 35488267-0 2022 Cholecalciferol supplementation lowers leptin and TMAO but increases NO and VEGF-A levels in obese vitamin D deficient patients: Is it one of the potential cardioprotective mechanisms of vitamin D? Cholecalciferol 0-15 leptin Homo sapiens 39-45 35488267-0 2022 Cholecalciferol supplementation lowers leptin and TMAO but increases NO and VEGF-A levels in obese vitamin D deficient patients: Is it one of the potential cardioprotective mechanisms of vitamin D? Cholecalciferol 0-15 vascular endothelial growth factor A Homo sapiens 76-82 35445563-4 2022 We consider the likely biological determinants of cancer outcome, the reported effects of vitamin D3 on these in both cancerous and non-cancerous settings, and how the effect of vitamin D3 might change depending on the integrity of tumour vitamin D receptor (VDR) signalling. Cholecalciferol 178-188 vitamin D receptor Homo sapiens 239-257 35445563-6 2022 In animal models, having defective VDR signalling, vitamin D3 administration decreased survival and increased metastases. Cholecalciferol 51-61 vitamin D receptor Homo sapiens 35-38 35436103-1 2022 Overexpression of the vitamin D3-inactivating enzyme CYP24A1 (cytochrome P450 family 24 subfamily and hereafter referred to as CYP24) can cause chronic kidney diseases, osteoporosis, and several types of cancers. Cholecalciferol 22-32 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 53-60 35436103-1 2022 Overexpression of the vitamin D3-inactivating enzyme CYP24A1 (cytochrome P450 family 24 subfamily and hereafter referred to as CYP24) can cause chronic kidney diseases, osteoporosis, and several types of cancers. Cholecalciferol 22-32 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 127-132 35436103-4 2022 We have identified a novel 70-nt DNA aptamer-based inhibitor of CYP24 by utilizing the competition-based aptamer selection strategy, taking CYP24 as the positive target protein and CYP27B1 (the enzyme catalyzing active vitamin D3 production) as the countertarget protein. Cholecalciferol 219-229 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 64-69 35436103-4 2022 We have identified a novel 70-nt DNA aptamer-based inhibitor of CYP24 by utilizing the competition-based aptamer selection strategy, taking CYP24 as the positive target protein and CYP27B1 (the enzyme catalyzing active vitamin D3 production) as the countertarget protein. Cholecalciferol 219-229 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 140-145 35436103-4 2022 We have identified a novel 70-nt DNA aptamer-based inhibitor of CYP24 by utilizing the competition-based aptamer selection strategy, taking CYP24 as the positive target protein and CYP27B1 (the enzyme catalyzing active vitamin D3 production) as the countertarget protein. Cholecalciferol 219-229 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 181-188 35443806-9 2022 Conclusions: Study findings supported that CBD interacts with CYP2R1, CYP27B1, CYP24A1, and vitamin D receptors, resulting in increased vitamin D3 metabolites, which improved memory, pain tolerance, reduced inflammation, and aging through modulating antioxidative enzymes, cytokines, and neurotransmitters in VDD-induced rats. Cholecalciferol 136-146 cytochrome P450, family 2, subfamily r, polypeptide 1 Rattus norvegicus 62-68 35443806-9 2022 Conclusions: Study findings supported that CBD interacts with CYP2R1, CYP27B1, CYP24A1, and vitamin D receptors, resulting in increased vitamin D3 metabolites, which improved memory, pain tolerance, reduced inflammation, and aging through modulating antioxidative enzymes, cytokines, and neurotransmitters in VDD-induced rats. Cholecalciferol 136-146 cytochrome P450, family 27, subfamily b, polypeptide 1 Rattus norvegicus 70-77 35443806-9 2022 Conclusions: Study findings supported that CBD interacts with CYP2R1, CYP27B1, CYP24A1, and vitamin D receptors, resulting in increased vitamin D3 metabolites, which improved memory, pain tolerance, reduced inflammation, and aging through modulating antioxidative enzymes, cytokines, and neurotransmitters in VDD-induced rats. Cholecalciferol 136-146 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 79-86 35157949-10 2022 In addition, Vitamin D3 significantly alleviated anxiety- and depressive-like behaviors in TST and EPM test, decreased GFAP expression level, modified hippocampal astrocyte activation pattern, and advanced brain-derived neurotrophic factor (BDNF) distribution and expression in CA1 and CA3 of the hippocampus. Cholecalciferol 13-23 brain derived neurotrophic factor Mus musculus 206-239 35157949-10 2022 In addition, Vitamin D3 significantly alleviated anxiety- and depressive-like behaviors in TST and EPM test, decreased GFAP expression level, modified hippocampal astrocyte activation pattern, and advanced brain-derived neurotrophic factor (BDNF) distribution and expression in CA1 and CA3 of the hippocampus. Cholecalciferol 13-23 brain derived neurotrophic factor Mus musculus 241-245 35157949-10 2022 In addition, Vitamin D3 significantly alleviated anxiety- and depressive-like behaviors in TST and EPM test, decreased GFAP expression level, modified hippocampal astrocyte activation pattern, and advanced brain-derived neurotrophic factor (BDNF) distribution and expression in CA1 and CA3 of the hippocampus. Cholecalciferol 13-23 carbonic anhydrase 1 Mus musculus 278-281 35157949-10 2022 In addition, Vitamin D3 significantly alleviated anxiety- and depressive-like behaviors in TST and EPM test, decreased GFAP expression level, modified hippocampal astrocyte activation pattern, and advanced brain-derived neurotrophic factor (BDNF) distribution and expression in CA1 and CA3 of the hippocampus. Cholecalciferol 13-23 carbonic anhydrase 3 Mus musculus 286-289 35409330-2 2022 This study aimed to examine vitamin D3 metabolic enzymes, i.e., CYP27B1 and CYP24A1, mRNA transcript and protein abundance, and protein localization in the uterus of pigs on days 2-5, 10-12, 15-16 and 18-20 of the estrous cycle. Cholecalciferol 28-38 cytochrome P450 family 27 subfamily B member 1 Sus scrofa 64-71 35359726-0 2022 Vitamin D3 Suppresses Human Cytomegalovirus-Induced Vascular Endothelial Apoptosis via Rectification of Paradoxical m6A Modification of Mitochondrial Calcium Uniporter mRNA, Which Is Regulated by METTL3 and YTHDF3. Cholecalciferol 0-10 methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit Homo sapiens 196-202 35063658-0 2022 Vitamin D3 and zinc synergistically induce regulatory T cells and suppress interferon-gamma production in mixed lymphocyte culture. Cholecalciferol 0-10 interferon gamma Homo sapiens 75-91 35063658-2 2022 This work contributes to understanding the combined action of zinc and vitamin D3 in different in vitro models for immune reactions.Zinc and vitamin D3 in combination boosted the differentiation into Foxp3+CD4+ T cells (Treg). Cholecalciferol 71-81 forkhead box P3 Homo sapiens 200-205 35063658-2 2022 This work contributes to understanding the combined action of zinc and vitamin D3 in different in vitro models for immune reactions.Zinc and vitamin D3 in combination boosted the differentiation into Foxp3+CD4+ T cells (Treg). Cholecalciferol 71-81 CD4 molecule Homo sapiens 206-209 35063658-2 2022 This work contributes to understanding the combined action of zinc and vitamin D3 in different in vitro models for immune reactions.Zinc and vitamin D3 in combination boosted the differentiation into Foxp3+CD4+ T cells (Treg). Cholecalciferol 141-151 forkhead box P3 Homo sapiens 200-205 35063658-2 2022 This work contributes to understanding the combined action of zinc and vitamin D3 in different in vitro models for immune reactions.Zinc and vitamin D3 in combination boosted the differentiation into Foxp3+CD4+ T cells (Treg). Cholecalciferol 141-151 CD4 molecule Homo sapiens 206-209 35063658-3 2022 Vitamin D3 alone reduced the percentage of CD4+T-bet+ T cells (TH1). Cholecalciferol 0-10 CD4 molecule Homo sapiens 43-46 35063658-3 2022 Vitamin D3 alone reduced the percentage of CD4+T-bet+ T cells (TH1). Cholecalciferol 0-10 T-box transcription factor 21 Homo sapiens 47-52 35063658-4 2022 In mixed lymphocyte culture (MLC), therapeutic concentrations of vitamin D3 and zinc in combination suppressed interferon-gamma (IFN-gamma) secretion more strongly than the single agent treatment. Cholecalciferol 65-75 interferon gamma Homo sapiens 111-127 35063658-4 2022 In mixed lymphocyte culture (MLC), therapeutic concentrations of vitamin D3 and zinc in combination suppressed interferon-gamma (IFN-gamma) secretion more strongly than the single agent treatment. Cholecalciferol 65-75 interferon gamma Homo sapiens 129-138 35063658-9 2022 In summary, this study shows, for the first time, a vitamin D3-induced upregulation of CD4+Foxp3+ T cells in MLC. Cholecalciferol 52-62 CD4 molecule Homo sapiens 87-90 35063658-9 2022 In summary, this study shows, for the first time, a vitamin D3-induced upregulation of CD4+Foxp3+ T cells in MLC. Cholecalciferol 52-62 forkhead box P3 Homo sapiens 91-96 35338345-8 2022 We identified the Vitamin D response element (VDRE) binding sites in a reporter system showed that VDRE in the Claudin-5 promoter is required for vitamin D3-induced Claudin-5 expression. Cholecalciferol 146-156 claudin 5 Mus musculus 111-120 35338345-8 2022 We identified the Vitamin D response element (VDRE) binding sites in a reporter system showed that VDRE in the Claudin-5 promoter is required for vitamin D3-induced Claudin-5 expression. Cholecalciferol 146-156 claudin 5 Mus musculus 165-174 35326689-0 2022 In Vivo and In Vitro Enhanced Tumoricidal Effects of Metformin, Active Vitamin D3, and 5-Fluorouracil Triple Therapy against Colon Cancer by Modulating the PI3K/Akt/PTEN/mTOR Network. Cholecalciferol 71-81 AKT serine/threonine kinase 1 Homo sapiens 161-164 35326689-0 2022 In Vivo and In Vitro Enhanced Tumoricidal Effects of Metformin, Active Vitamin D3, and 5-Fluorouracil Triple Therapy against Colon Cancer by Modulating the PI3K/Akt/PTEN/mTOR Network. Cholecalciferol 71-81 phosphatase and tensin homolog Homo sapiens 165-169 35326689-0 2022 In Vivo and In Vitro Enhanced Tumoricidal Effects of Metformin, Active Vitamin D3, and 5-Fluorouracil Triple Therapy against Colon Cancer by Modulating the PI3K/Akt/PTEN/mTOR Network. Cholecalciferol 71-81 mechanistic target of rapamycin kinase Homo sapiens 170-174 35359726-0 2022 Vitamin D3 Suppresses Human Cytomegalovirus-Induced Vascular Endothelial Apoptosis via Rectification of Paradoxical m6A Modification of Mitochondrial Calcium Uniporter mRNA, Which Is Regulated by METTL3 and YTHDF3. Cholecalciferol 0-10 YTH N6-methyladenosine RNA binding protein 3 Homo sapiens 207-213 35359726-7 2022 Conversely, vitamin D3 downregulated the METTL3 by inhibiting the activation of AMPK, thereby inhibiting the m6A modification of MCU and cell apoptosis. Cholecalciferol 12-22 methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit Homo sapiens 41-47 35359726-7 2022 Conversely, vitamin D3 downregulated the METTL3 by inhibiting the activation of AMPK, thereby inhibiting the m6A modification of MCU and cell apoptosis. Cholecalciferol 12-22 protein kinase AMP-activated catalytic subunit alpha 2 Homo sapiens 80-84 35359726-7 2022 Conversely, vitamin D3 downregulated the METTL3 by inhibiting the activation of AMPK, thereby inhibiting the m6A modification of MCU and cell apoptosis. Cholecalciferol 12-22 mitochondrial calcium uniporter Homo sapiens 129-132 35221151-0 2022 Epidermal CD8+CD103+ skin resident memory T cells in psoriasis plaques are reduced in number but remain in the basement membrane zone after topical application of corticosteroid and vitamin D3. Cholecalciferol 182-192 CD8a molecule Homo sapiens 10-13 35221151-0 2022 Epidermal CD8+CD103+ skin resident memory T cells in psoriasis plaques are reduced in number but remain in the basement membrane zone after topical application of corticosteroid and vitamin D3. Cholecalciferol 182-192 integrin subunit alpha E Homo sapiens 14-19 35220479-11 2022 Highest AMH concentrations were found between August and October and this quartile was associated with highest D3 concentrations. Cholecalciferol 111-113 anti-Mullerian hormone Homo sapiens 8-11 35196318-4 2022 The current study investigated the effect of TGF-beta1 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in stromal cells induced by 1alpha,25(OH)2D3 (D3) and dexamethasone (Dex). Cholecalciferol 175-177 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 58-109 35196318-4 2022 The current study investigated the effect of TGF-beta1 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in stromal cells induced by 1alpha,25(OH)2D3 (D3) and dexamethasone (Dex). Cholecalciferol 175-177 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 111-116 35196318-5 2022 TGF-beta1 downregulated the expression of RANKL induced by D3 and Dex in mouse bone marrow stromal lineage, ST2 cells. Cholecalciferol 59-61 transforming growth factor, beta 1 Mus musculus 0-9 35196318-5 2022 TGF-beta1 downregulated the expression of RANKL induced by D3 and Dex in mouse bone marrow stromal lineage, ST2 cells. Cholecalciferol 59-61 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 42-47 35196318-11 2022 These results indicated that TGF-beta1 downregulates RANKL expression and the osteoclast-supporting activity of osteoblasts/stromal cells induced by D3 and Dex through the degradation of the RXR-alpha protein mediated by ubiquitin-proteasome system. Cholecalciferol 149-151 transforming growth factor, beta 1 Mus musculus 29-38 35196318-11 2022 These results indicated that TGF-beta1 downregulates RANKL expression and the osteoclast-supporting activity of osteoblasts/stromal cells induced by D3 and Dex through the degradation of the RXR-alpha protein mediated by ubiquitin-proteasome system. Cholecalciferol 149-151 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 53-58 35196318-11 2022 These results indicated that TGF-beta1 downregulates RANKL expression and the osteoclast-supporting activity of osteoblasts/stromal cells induced by D3 and Dex through the degradation of the RXR-alpha protein mediated by ubiquitin-proteasome system. Cholecalciferol 149-151 retinoid X receptor alpha Mus musculus 191-200 35126351-5 2021 Cells were stimulated or not with 100 ng/ml tumor necrosis factor alpha (TNF-alpha) or/and 1 nM or/and 0.01 nM vitamin D3 for 72 h. The expression levels of NLRP1, NLRP3, TLR1, TLR2, TLR4, and VDR in all examined SFs were analyzed by quantitative real-time PCR (RT-qPCR). Cholecalciferol 111-121 toll like receptor 1 Homo sapiens 171-175 35204824-0 2022 Vitamin D3 Stimulates Proliferation Capacity, Expression of Pluripotency Markers, and Osteogenesis of Human Bone Marrow Mesenchymal Stromal/Stem Cells, Partly through SIRT1 Signaling. Cholecalciferol 0-10 sirtuin 1 Homo sapiens 167-172 35126351-5 2021 Cells were stimulated or not with 100 ng/ml tumor necrosis factor alpha (TNF-alpha) or/and 1 nM or/and 0.01 nM vitamin D3 for 72 h. The expression levels of NLRP1, NLRP3, TLR1, TLR2, TLR4, and VDR in all examined SFs were analyzed by quantitative real-time PCR (RT-qPCR). Cholecalciferol 111-121 toll like receptor 2 Homo sapiens 177-181 35126351-5 2021 Cells were stimulated or not with 100 ng/ml tumor necrosis factor alpha (TNF-alpha) or/and 1 nM or/and 0.01 nM vitamin D3 for 72 h. The expression levels of NLRP1, NLRP3, TLR1, TLR2, TLR4, and VDR in all examined SFs were analyzed by quantitative real-time PCR (RT-qPCR). Cholecalciferol 111-121 toll like receptor 4 Homo sapiens 183-187 35126351-5 2021 Cells were stimulated or not with 100 ng/ml tumor necrosis factor alpha (TNF-alpha) or/and 1 nM or/and 0.01 nM vitamin D3 for 72 h. The expression levels of NLRP1, NLRP3, TLR1, TLR2, TLR4, and VDR in all examined SFs were analyzed by quantitative real-time PCR (RT-qPCR). Cholecalciferol 111-121 vitamin D receptor Homo sapiens 193-196 35053278-1 2022 1alpha,25-Dihydroxyvitamin D3 (1alpha,25(OH)2D3, 1) is an active form of vitamin D3 and regulates various biological phenomena, including calcium and phosphate homeostasis, bone metabolism, and immune response via binding to and activation of vitamin D receptor (VDR). Cholecalciferol 73-83 vitamin D receptor Homo sapiens 263-266 34989311-13 2022 Vitamin D3 and carbamazepine protect against CDI by restoring MITF expression and lysosomal function in mice. Cholecalciferol 0-10 melanogenesis associated transcription factor Mus musculus 62-66 35053278-1 2022 1alpha,25-Dihydroxyvitamin D3 (1alpha,25(OH)2D3, 1) is an active form of vitamin D3 and regulates various biological phenomena, including calcium and phosphate homeostasis, bone metabolism, and immune response via binding to and activation of vitamin D receptor (VDR). Cholecalciferol 73-83 vitamin D receptor Homo sapiens 243-261 35053549-1 2022 The active forms of vitamin D3 (calcitriol and tacalcitol) coupled to the vitamin D receptor (VDR) are known to exhibit anti-cancer properties. Cholecalciferol 20-30 vitamin D receptor Homo sapiens 74-92 35053549-1 2022 The active forms of vitamin D3 (calcitriol and tacalcitol) coupled to the vitamin D receptor (VDR) are known to exhibit anti-cancer properties. Cholecalciferol 20-30 vitamin D receptor Homo sapiens 94-97 35083032-2 2022 We evaluated the effect of a high dose of vitamin D3 on the Neuron-Specific Enolase (NSE) level, National Institute of Health Stroke Scale (NIHSS), and Barthel Index (BI) scoring system in moderate ischemic stroke patients. Cholecalciferol 42-52 enolase 2 Homo sapiens 60-83 35083032-2 2022 We evaluated the effect of a high dose of vitamin D3 on the Neuron-Specific Enolase (NSE) level, National Institute of Health Stroke Scale (NIHSS), and Barthel Index (BI) scoring system in moderate ischemic stroke patients. Cholecalciferol 42-52 enolase 2 Homo sapiens 85-88 35083032-12 2022 Conclusions: Administration of a single 600000 IU of vitamin D3 could have neuroprotective effects in patients with moderate ischemic stroke, according to its significantly positive effects on functional clinical outcomes (NIHSS and BI), but this effect on the biomarker related to neural damage (NSE) was not significant. Cholecalciferol 53-63 enolase 2 Homo sapiens 297-300 34997087-0 2022 Association between vitamin D3 levels and insulin resistance: a large sample cross-sectional study. Cholecalciferol 20-30 insulin Homo sapiens 42-49 34997087-1 2022 Previous studies have shown that vitamin D3 may be a potential factor in insulin resistance, but the relationship between vitamin D3 and insulin resistance still remains controversial. Cholecalciferol 33-43 insulin Homo sapiens 73-80 34997087-1 2022 Previous studies have shown that vitamin D3 may be a potential factor in insulin resistance, but the relationship between vitamin D3 and insulin resistance still remains controversial. Cholecalciferol 122-132 insulin Homo sapiens 137-144 34997087-2 2022 At present, more research is needed to explore the relationship between vitamin D3 and insulin resistance. Cholecalciferol 72-82 insulin Homo sapiens 87-94 34997087-5 2022 Finally, 9298 participants were selected through strict inclusion and exclusion criteria, Multivariate logistic regression analysis and curve fitting were conducted to explore the relationship between vitamin D3 level and insulin resistance. Cholecalciferol 201-211 insulin Homo sapiens 222-229 34997087-7 2022 The results revealed that there was a strong association between vitamin D3 and insulin resistance (OR 0.82, 95% CI 0.72-0.93). Cholecalciferol 65-75 insulin Homo sapiens 80-87 34997087-9 2022 There was a negative correlation between vitamin D3 level and insulin resistance, which provides a new proof for exploring the influencing factors of insulin resistance. Cholecalciferol 41-51 insulin Homo sapiens 62-69 35181615-8 2022 CONCLUSION: By targeting the Sirt1, EZH2 and CXCR4 pathways using relatively non-toxic adjuvant therapeutic agents such as metformin, melatonin, curcumin, sulforaphane, vitamin D3 and plerixafor, we should be able to target the biology of DLBCL. Cholecalciferol 169-179 sirtuin 1 Homo sapiens 29-34 34997087-9 2022 There was a negative correlation between vitamin D3 level and insulin resistance, which provides a new proof for exploring the influencing factors of insulin resistance. Cholecalciferol 41-51 insulin Homo sapiens 150-157 35181615-8 2022 CONCLUSION: By targeting the Sirt1, EZH2 and CXCR4 pathways using relatively non-toxic adjuvant therapeutic agents such as metformin, melatonin, curcumin, sulforaphane, vitamin D3 and plerixafor, we should be able to target the biology of DLBCL. Cholecalciferol 169-179 C-X-C motif chemokine receptor 4 Homo sapiens 45-50 34975341-4 2022 The present study found PolGD257A/D257A mice presented more severe calcification of aortas than wild type (WT) mice with vitamin D3 (Vit D3) treatment, and this phenomenon was also confirmed in vitro. Cholecalciferol 121-131 vitrin Mus musculus 133-136 35145896-1 2022 Objective: The purpose of this study was to evaluate the effects of ATRA (all trans retinoic acid), vitamin D3, and their combination on circulating levels of miR (MicroRNA) -125a-5p, miR-126, and miR-34ain diabetic rats. Cholecalciferol 100-110 microRNA 126b Rattus norvegicus 184-191 35145896-8 2022 In addition, vitamin D3+ATRA supplementation increased miR-126 expression (p=0.014). Cholecalciferol 13-23 microRNA 126b Rattus norvegicus 55-62 35145896-11 2022 Also, vitamin D3+ATRA can be considered a new therapeutic agent that can elevate miR-126 expression and prevent diabetes-related cardiovascular complications. Cholecalciferol 6-16 microRNA 126b Rattus norvegicus 81-88 2509030-2 1989 In idiopathic hypoparathyroidism (IHP), 100 Units of human PTH (1-34) increased urinary excretion of NAG from 0.029 +/- 0.027 to 0.173 +/- 0.035 U/lGF (p less than 0.05) in two patients before treatment and from 0.025 +/- 0.004 to 0.189 +/- 0.092U/lGF (p less than 0.02) in four patients during treatment with active vitamin D3 (1,25(OH)2D3 or 1 alpha OHD3). Cholecalciferol 317-327 parathyroid hormone Homo sapiens 59-62 35475214-6 2022 The computational analysis demonstrated that vitamin B12 resulted in depicting suitable significant binding with furin, RNA dependent RNA polymerase (RdRp), Main proteases (Mpro), ORF3a and ORF7a and Vitamin D3 with spike protein and vitamin B9 with non structural protein 3 (NSP3). Cholecalciferol 200-210 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 216-221 34473295-2 2022 OBJECTIVE: To investigate the effects of vitamin D3 supplementation on insulin sensitivity and beta-cell function. Cholecalciferol 41-51 insulin Homo sapiens 71-78 2509030-2 1989 In idiopathic hypoparathyroidism (IHP), 100 Units of human PTH (1-34) increased urinary excretion of NAG from 0.029 +/- 0.027 to 0.173 +/- 0.035 U/lGF (p less than 0.05) in two patients before treatment and from 0.025 +/- 0.004 to 0.189 +/- 0.092U/lGF (p less than 0.02) in four patients during treatment with active vitamin D3 (1,25(OH)2D3 or 1 alpha OHD3). Cholecalciferol 317-327 O-GlcNAcase Homo sapiens 101-104 2804448-5 1989 After vitamin D3 treatment, increased immunoreactivity of 28K calbindin was observed in the cytoplasm and, even more pronounced, in the nuclei. Cholecalciferol 6-16 hippocalcin Rattus norvegicus 62-71 2559250-0 1989 Effect of vitamin D3 administration on serum 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3 and osteocalcin in vitamin D-deficient elderly people. Cholecalciferol 10-20 bone gamma-carboxyglutamate protein Homo sapiens 96-107 2575735-1 1989 The present study was undertaken to investigate the in vitro effects of two cholecalciferol metabolites 1,25(OH)2CC and 24,25(OH)2CC on the renal cortex alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT) and acid phosphatase (ACP) activities in hypophysectomized rats. Cholecalciferol 76-91 gamma-glutamyltransferase 1 Rattus norvegicus 181-206 2550427-7 1989 This apparent reduction in the affinity of VDR for 1,25-(OH)2D3 was due to degradation of free 1,25-(OH)2[3H]D3 which occurred during whole cell saturation assay. Cholecalciferol 61-63 vitamin D receptor Homo sapiens 43-46 2548278-0 1989 Inhibition of human natural killer cell and lymphokine-activated killer cell cytotoxicity and differentiation by vitamin D3. Cholecalciferol 113-123 interleukin 2 Homo sapiens 44-54 2546501-3 1989 In cells treated with both 1,25-[3H]D3 and ketoconazole, up-regulation of VDR was increased by 40% over that observed with cells receiving 1,25-[3H]D3 alone. Cholecalciferol 36-38 vitamin D receptor Rattus norvegicus 74-77 2548278-2 1989 The effect of vitamin D3 and 1,25(OH)2D3 on human natural killer (NK) cells and their activation by interferon (IFN) and interleukin 2 (IL-2) was investigated. Cholecalciferol 14-24 interleukin 2 Homo sapiens 121-134 2548278-7 1989 Vitamin D3 inhibited both IFN and IL-2 activation of NK activity. Cholecalciferol 0-10 interferon alpha 1 Homo sapiens 26-29 2548278-7 1989 Vitamin D3 inhibited both IFN and IL-2 activation of NK activity. Cholecalciferol 0-10 interleukin 2 Homo sapiens 34-38 2548278-8 1989 However, increasing doses of IL-2 were able to abrogate the inhibition caused by vitamin D3. Cholecalciferol 81-91 interleukin 2 Homo sapiens 29-33 2548278-9 1989 Vitamin D3 was able to inhibit NK activity of phytohaemagglutinin and IL-2-activated cells, and also inhibit the proliferation and lymphokine-activated killer activity induced by IL-2. Cholecalciferol 0-10 interleukin 2 Homo sapiens 70-74 2786759-7 1989 Vitamin D3 inhibited TdR and IL-2 production in a dose-dependent manner but had no significant (P greater than 0.1) effect on IL-2R expression. Cholecalciferol 0-10 interleukin 2 Mus musculus 29-33 2548278-9 1989 Vitamin D3 was able to inhibit NK activity of phytohaemagglutinin and IL-2-activated cells, and also inhibit the proliferation and lymphokine-activated killer activity induced by IL-2. Cholecalciferol 0-10 interleukin 2 Homo sapiens 131-141 2786759-8 1989 Recombinant IL-2 had no effect on CsA-induced inhibition of TdR, whereas rIL-2 completely reversed the vitamin D3-induced inhibition of TdR. Cholecalciferol 103-113 interleukin 2 Rattus norvegicus 73-78 2548278-9 1989 Vitamin D3 was able to inhibit NK activity of phytohaemagglutinin and IL-2-activated cells, and also inhibit the proliferation and lymphokine-activated killer activity induced by IL-2. Cholecalciferol 0-10 interleukin 2 Homo sapiens 179-183 2548278-11 1989 NA cells pretreated with low doses of IL-2 were sensitive to inhibition by vitamin D3 while those pretreated with high doses of IL-2 were not. Cholecalciferol 75-85 interleukin 2 Homo sapiens 38-42 2786759-10 1989 A consistent synergism was observed between all concentrations of CsA used and vitamin D3 (10(-8) and 10(-7) M). Cholecalciferol 79-89 excision repaiross-complementing rodent repair deficiency, complementation group 8 Mus musculus 66-69 2786759-11 1989 This study shows that the potentiation of immunosuppressive effects of CsA by vitamin D3 could be used as an approach to reduce the dosage of CsA in clinical use without compromising immunosuppression, thus preventing or minimizing the dose-related toxic effects of CsA. Cholecalciferol 78-88 excision repaiross-complementing rodent repair deficiency, complementation group 8 Mus musculus 71-74 2548278-12 1989 The data presented suggest that vitamin D3 and 1,25(OH)2D3 inhibit NK activity and LAK cellular differentiation. Cholecalciferol 32-42 alpha kinase 1 Homo sapiens 83-86 2786759-11 1989 This study shows that the potentiation of immunosuppressive effects of CsA by vitamin D3 could be used as an approach to reduce the dosage of CsA in clinical use without compromising immunosuppression, thus preventing or minimizing the dose-related toxic effects of CsA. Cholecalciferol 78-88 excision repaiross-complementing rodent repair deficiency, complementation group 8 Mus musculus 142-145 2786759-11 1989 This study shows that the potentiation of immunosuppressive effects of CsA by vitamin D3 could be used as an approach to reduce the dosage of CsA in clinical use without compromising immunosuppression, thus preventing or minimizing the dose-related toxic effects of CsA. Cholecalciferol 78-88 excision repaiross-complementing rodent repair deficiency, complementation group 8 Mus musculus 142-145 2656246-7 1989 Taken together, these results indicate that 1,25-(OH)2D3, the most physiologically active form of vitamin D3, is the predominant regulator of PKI, but serum calcium, indirectly through the regulation of PTH secretion, is also involved. Cholecalciferol 98-108 tyrosine kinase 2 Gallus gallus 142-145 2521453-5 1989 Thus, in the presence of the vitamin D3 metabolite, only one-hundredth the concentration of CsA was required to produce the same effect on IL-2 production as that produced by CsA alone. Cholecalciferol 29-39 interleukin 2 Homo sapiens 139-143 2542952-1 1989 The influence of chronic vitamin D3 application on the concentration of the four calcium-binding proteins parvalbumin, the 28-kDa calbindin-D, calmodulin, and S-100 was studied in various brain regions and in the kidney. Cholecalciferol 25-35 parvalbumin Rattus norvegicus 106-117 2752207-4 1989 Although the mean intestinal level of calbindin-D28K was as low as 118.23 +/- 20.08 (SD) ng/mg protein in vitamin D-deficient mice (-D), the level of this protein was markedly increased to the control level (198.68 +/- 9.98 vs. 198.49 +/- 14.29 ng/mg protein of control) (P less than 0.001) in response to the administration of vitamin D3 (1000 I.U. Cholecalciferol 328-338 calbindin 1 Mus musculus 38-42 2492049-6 1989 IL-4 also stimulated C2 production by HL-60 cells that had been pre-treated with vitamin D3 to induce monocytic differentiation. Cholecalciferol 81-91 interleukin 4 Homo sapiens 0-4 2786632-0 1989 Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3. Cholecalciferol 107-117 bone gamma-carboxyglutamate protein Homo sapiens 31-42 2572101-1 1989 Skin biopsies from 5 patients with chronic plaque psoriasis were examined to test the effect of topical treatment with a new synthetic vitamin D3 analogue, MC 903, on epidermal interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF alpha). Cholecalciferol 135-145 interleukin 6 Homo sapiens 177-190 2851923-1 1988 The response to vitamin D3 (D3) was studied in a model of micronodular cirrhosis induced by CCl4. Cholecalciferol 16-26 C-C motif chemokine ligand 4 Rattus norvegicus 92-96 2612149-4 1989 Messenger RNAs for osteonectin and osteopontin were present in RCT-3 cells and osteopontin mRNA was enhanced by 1,25 (OH)2 vitamin D3 treatment. Cholecalciferol 123-133 secreted phosphoprotein 1 Rattus norvegicus 79-90 2843573-0 1988 Effects of active vitamin D3 and parathyroid hormone on the serum osteocalcin in idiopathic hypoparathyroidism and pseudohypoparathyroidism. Cholecalciferol 18-28 bone gamma-carboxyglutamate protein Homo sapiens 66-77 2843573-7 1988 In idiopathic hypoparathyroidism, the active vitamin D3 increased serum osteocalcin without PTH. Cholecalciferol 45-55 bone gamma-carboxyglutamate protein Homo sapiens 72-83 2843573-8 1988 In pseudohypoparathyroidism, PTH may increase serum osteocalcin or modulate the effect of active vitamin D3 on serum osteocalcin. Cholecalciferol 97-107 parathyroid hormone Homo sapiens 29-32 2843573-8 1988 In pseudohypoparathyroidism, PTH may increase serum osteocalcin or modulate the effect of active vitamin D3 on serum osteocalcin. Cholecalciferol 97-107 bone gamma-carboxyglutamate protein Homo sapiens 117-128 2553083-0 1989 The glyoxylate cycle in rat epiphyseal cartilage: the effect of vitamin-D3 on the activity of the enzymes isocitrate lyase and malate synthase. Cholecalciferol 64-74 citramalyl-CoA lyase Rattus norvegicus 127-142 2466090-4 1988 The presence of vitamin D3 reduced IFN-gamma titers when PHA and IL-2 were used to induce IFN, but not when ionomycin was used as the inducer. Cholecalciferol 16-26 interferon gamma Homo sapiens 35-44 2466090-4 1988 The presence of vitamin D3 reduced IFN-gamma titers when PHA and IL-2 were used to induce IFN, but not when ionomycin was used as the inducer. Cholecalciferol 16-26 interleukin 2 Homo sapiens 65-69 3196340-3 1988 The preparation also catalyzed 25-hydroxylation of vitamin D3 at a rate of 350 pmol/nmol of cytochrome P-450 x min-1. Cholecalciferol 51-61 cytochrome P-450 Oryctolagus cuniculus 92-108 3196340-8 1988 The results indicate that there are different species of cytochrome P-450 in rabbit liver mitochondria catalyzing 26-hydroxylation of 5 beta-cholestane-3 alpha, 7 alpha, 12 alpha-triol and 25-hydroxylation of vitamin D3. Cholecalciferol 209-219 cytochrome P-450 Oryctolagus cuniculus 57-73 2844763-8 1988 The liver mitochondrial cytochrome P-450 hydroxylates vitamin D3 and 1 alpha-hydroxyvitamin D3 at position 25, but did not show any activity toward xenobiotics such as benzphetamine, 7-ethoxycoumarin, and benzo[a]pyrene. Cholecalciferol 54-64 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 24-40 2837492-10 1988 Furthermore, P-450mt1, P-450mt2, as well as partially purified P-450 from control liver, but not P-450c, showed varying activities for 25- and 26-hydroxylation of cholesterol and 25-hydroxylation of vitamin D3. Cholecalciferol 199-209 cytochrome P450, family 1, subfamily a, polypeptide 1 Rattus norvegicus 23-31 2845922-0 1988 Purification of a cytochrome P-450 from pig kidney microsomes catalysing the 25-hydroxylation of vitamin D3. Cholecalciferol 97-107 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 18-34 2845922-1 1988 Cytochrome P-450 catalysing 25-hydroxylation of vitamin D3 was purified from pig kidney microsomes. Cholecalciferol 48-58 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 0-16 2845922-3 1988 The purified cytochrome P-450 catalysed 25-hydroxylation of vitamin D3 up to 1,000 times more efficiently, and 25-hydroxylation of 1 alpha-hydroxyvitamin D3 up to 4000 times more efficiently, than the microsomes. Cholecalciferol 60-70 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 13-29 2845922-9 1988 The possible role of the kidney microsomal cytochrome P-450 in the metabolism of vitamin D3 is discussed. Cholecalciferol 81-91 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 43-59 2844144-0 1988 25-Hydroxylation of vitamin D3 by a cytochrome P-450 from rabbit liver mitochondria. Cholecalciferol 20-30 cytochrome P-450 Oryctolagus cuniculus 36-52 2838261-6 1988 After iv administration of tracer amounts of vitamin D3 to fasting rats, gradient gel electrophoretic analyses of plasma revealed most of the [3H] associated with the vitamin D-binding protein, and smaller amounts associated with LDL and high density lipoprotein. Cholecalciferol 45-55 GC, vitamin D binding protein Rattus norvegicus 167-192 2844144-1 1988 A cytochrome P-450 catalysing 25-hydroxylation of vitamin D3 was purified from liver mitochondria of untreated rabbits. Cholecalciferol 50-60 cytochrome P-450 Oryctolagus cuniculus 2-18 2844144-5 1988 The purified cytochrome P-450 catalysed 25-hydroxylation of vitamin D3 up to 5000 times more efficiently than did the mitochondria. Cholecalciferol 60-70 cytochrome P-450 Oryctolagus cuniculus 13-29 2844144-8 1988 The cytochrome P-450 catalysed, in addition to 25-hydroxylation of vitamin D3, the 25-hydroxylation of 1 alpha-hydroxyvitamin D3 and the 26-hydroxylation of 5 beta-cholestane-3 alpha, 7 alpha, 12 alpha-triol. Cholecalciferol 67-77 cytochrome P-450 Oryctolagus cuniculus 4-20 2844144-10 1988 The results raise the possibility that the 25-hydroxylation of vitamin D3 and the 26-hydroxylation of C27 steroids are catalysed by the same species of cytochrome P-450 in liver mitochondria. Cholecalciferol 63-73 cytochrome P-450 Oryctolagus cuniculus 152-168 2844144-11 1988 The possible role of the liver mitochondrial cytochrome P-450 in the metabolism of vitamin D3 is discussed. Cholecalciferol 83-93 cytochrome P-450 Oryctolagus cuniculus 45-61 2840181-0 1988 Suppression of rat hepatic vitamin D-25-hydroxylase by cholecalciferol, but not by 25-hydroxy- or 1,25-dihydroxymetabolites. Cholecalciferol 55-70 cytochrome P450, family 2, subfamily r, polypeptide 1 Rattus norvegicus 27-51 2836517-1 1988 We found an increased amount of immunoreactive tyrosinase in human melanocytes after 6-d culturing with vitamin D3 (cholecalciferol). Cholecalciferol 104-114 tyrosinase Homo sapiens 47-57 2836517-1 1988 We found an increased amount of immunoreactive tyrosinase in human melanocytes after 6-d culturing with vitamin D3 (cholecalciferol). Cholecalciferol 116-131 tyrosinase Homo sapiens 47-57 2834451-7 1988 Pretreatment with vitamin D3 followed by IFN-gamma stimulation resulted in a 147% increase in C2 mRNA content compared with IFN-gamma stimulation alone. Cholecalciferol 18-28 interferon gamma Homo sapiens 124-133 2829737-0 1988 Differential effects of 1,25-dihydroxyvitamin D3 upon intestinal vitamin D3-dependent calbindin (a 28,000-dalton calcium binding protein) and its mRNA in D-replete and D-deficient chickens. Cholecalciferol 38-48 calbindin 1 Gallus gallus 86-95 3259542-2 1988 Since its production is dependent upon interleukin 1 (IL-1) produced by antigen-presenting cells, we tested five vitamin D3 analogues for effects on the production and function of human natural and recombinant IL-1. Cholecalciferol 113-123 interleukin 1 alpha Homo sapiens 54-58 2460437-0 1988 Immunochemical evidence for the catalysis of vitamin D3 25-hydroxylation and testosterone 16 alpha-hydroxylation by homologous forms of cytochrome P-450 in rat liver microsomes. Cholecalciferol 45-55 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 136-152 2829737-13 1988 Dietary withdrawal of vitamin D3 led to a gradual decline in ambient intestinal calbindin levels, while intestinal sensitivity to 1,25(OH)2D3 was restored. Cholecalciferol 22-32 calbindin 1 Gallus gallus 80-89 3621189-1 1987 Topical application of 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2D3], an active form of vitamin D3, was previously shown to inhibit the induction of ornithine decarboxylase (ODC) and tumor promotion by tumor promoters in mouse skin. Cholecalciferol 43-53 ornithine decarboxylase, structural 1 Mus musculus 154-177 3339128-1 1988 The hypophosphatemic (Hyp) mouse, a murine homologue of human X-linked hypophosphatemic rickets, is characterized by renal defects in brush border membrane phosphate transport and vitamin D3 metabolism. Cholecalciferol 180-190 phosphate regulating endopeptidase homolog, X-linked Mus musculus 22-25 3257676-0 1988 Biological activity of 26,26,26,27,27,27-hexafluorinated analogs of vitamin D3 in inhibiting interleukin-2 production by peripheral blood mononuclear cells stimulated by phytohemagglutinin. Cholecalciferol 68-78 interleukin 2 Homo sapiens 93-106 3266311-4 1988 This fact suggests that 1 alpha-OHD3 therapy may be useful for the restoration of IL-2 production in hemodialysis patients, and that the vitamin D3 deficiency may be responsible for the impairment of cellular immunity associated with IL-2 production disorder in hemodialysis patients. Cholecalciferol 137-147 interleukin 2 Homo sapiens 234-238 2850724-1 1988 With the development of a sensitive bioassay for the skeletal effects of parathyroid hormone (PTH), it has become possible to investigate the possible interaction between PTH and vitamin D3 metabolites. Cholecalciferol 179-189 parathyroid hormone Rattus norvegicus 73-92 2831435-1 1988 Biological assays were performed to evaluate 10-oxo-19-nor-vitamin D3 (10-oxo-D3) and 5(E) 25-hydroxy-10-oxo-19-nor-vitamin D3 (25-OH-10-oxo-D3) two bacterial products of vitamin D3 (D3) and 25-hydroxyvitamin D3 (25-OHD3) metabolism, respectively. Cholecalciferol 59-69 iodothyronine deiodinase 3 Homo sapiens 78-80 2831435-1 1988 Biological assays were performed to evaluate 10-oxo-19-nor-vitamin D3 (10-oxo-D3) and 5(E) 25-hydroxy-10-oxo-19-nor-vitamin D3 (25-OH-10-oxo-D3) two bacterial products of vitamin D3 (D3) and 25-hydroxyvitamin D3 (25-OHD3) metabolism, respectively. Cholecalciferol 59-69 iodothyronine deiodinase 3 Homo sapiens 78-80 3257676-6 1988 Suppression of PBMC proliferation by vitamin D3 analogs seemed to be a secondary effect of their inhibition of IL-2 production. Cholecalciferol 37-47 interleukin 2 Homo sapiens 111-115 2844707-0 1988 Pyloric gastrin-producing cells and pyloric sphincter muscle cells are nuclear targets for 3H 1,25(OH)2 vitamin D3. Cholecalciferol 104-114 gastrin Rattus norvegicus 8-15 2845200-0 1988 Effect of prostaglandin E2 on gamma-interferon and 1,25(OH)2D3 vitamin D3-induced c-myc reduction during HL-60 cell differentiation. Cholecalciferol 63-73 MYC proto-oncogene, bHLH transcription factor Homo sapiens 82-87 3119653-2 1987 The sarcoid cells, all collected from patients with normal calcium metabolism, synthesized 1,25-(OH)2-[3H]D3 from the substrate 25-hydroxyvitamin [3H]D3 (25OH-[3H]D3), whereas in vitro incubation with recombinant human interferon-gamma (IFN gamma) or lipopolysaccharide (LPS) was required for induction of synthesis of the hormone by normal PAM. Cholecalciferol 106-108 interferon gamma Homo sapiens 219-235 3119653-2 1987 The sarcoid cells, all collected from patients with normal calcium metabolism, synthesized 1,25-(OH)2-[3H]D3 from the substrate 25-hydroxyvitamin [3H]D3 (25OH-[3H]D3), whereas in vitro incubation with recombinant human interferon-gamma (IFN gamma) or lipopolysaccharide (LPS) was required for induction of synthesis of the hormone by normal PAM. Cholecalciferol 106-108 interferon gamma Homo sapiens 237-246 3621189-1 1987 Topical application of 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2D3], an active form of vitamin D3, was previously shown to inhibit the induction of ornithine decarboxylase (ODC) and tumor promotion by tumor promoters in mouse skin. Cholecalciferol 43-53 ornithine decarboxylase, structural 1 Mus musculus 179-182 3621189-7 1987 These results suggest that an active form of vitamin D3 has a systemic inhibitory effect on induction of ODC activity by tumor promoters. Cholecalciferol 45-55 ornithine decarboxylase, structural 1 Mus musculus 105-108 3034980-2 1987 We show that 1,25-dihydroxyvitamin D3 (1,25[OH]2D3), the most hormonally active metabolite of vitamin D3, modulates sensitively and specifically both the protein and messenger RNA accumulation of the multilineage growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF). Cholecalciferol 27-37 colony stimulating factor 2 Homo sapiens 227-275 3117462-11 1987 These data suggest that vitamin D3 inhibits Ig production by inhibiting IL-2 receptor expression on B cells and via its effect on adherent macrophages. Cholecalciferol 24-34 interleukin 2 receptor subunit beta Homo sapiens 72-85 2820580-0 1987 The involvement of intracellular calcium ion concentration and calmodulin in the 25-hydroxylation of cholecalciferol in ovine and rat liver. Cholecalciferol 101-116 calmodulin 1 Rattus norvegicus 63-73 2820580-7 1987 The calmodulin antagonists; W7, compound 48/80, trifluoperazine (TFP) and calmidazolium (R24571) were all found to effect a dose response inhibition of the 25 hydroxylation of cholecalciferol by homogenates of ovine liver. Cholecalciferol 176-191 calmodulin 1 Rattus norvegicus 4-14 3034980-2 1987 We show that 1,25-dihydroxyvitamin D3 (1,25[OH]2D3), the most hormonally active metabolite of vitamin D3, modulates sensitively and specifically both the protein and messenger RNA accumulation of the multilineage growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF). Cholecalciferol 27-37 colony stimulating factor 2 Homo sapiens 277-283 3026790-8 1987 25-Hydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 were effective but somewhat less potent inducers of CaBP, whereas vitamin D3 was without significant effect. Cholecalciferol 10-20 calcium-binding protein Gallus gallus 103-107 3033646-1 1987 1 alpha,25-Dihydroxyvitamin D3 [1,25-(OH)2D3], the biologically active metabolite of vitamin D3, inhibited synthesis of gamma-interferon (IFN-gamma) by phytohemagglutinin-activated peripheral blood lymphocytes (PBLs). Cholecalciferol 20-30 interferon gamma Homo sapiens 138-147 3491621-6 1986 Induction of CSF response appeared linked to differentiation, since KG1 cells differentiated with TPA and developed CSF-induced proliferative responses, but showed no differentiation or CSF induced proliferation after treatment with vitamin D3. Cholecalciferol 233-243 colony stimulating factor 2 Homo sapiens 13-16 3827911-1 1987 A mitochondrial cytochrome P-450 fraction, which catalyzed 25-hydroxylation of vitamin D3 much more efficiently than intact mitochondria was isolated from livers of male and female rats. Cholecalciferol 79-89 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 16-32 3828767-1 1986 The 28,000-Da vitamin D-dependent calcium-binding protein, CaBP, which is induced by one hormonally active form of vitamin D3, 1,25-dihydroxyvitamin D3, was localized by immunocytochemistry in the human brainstem, cerebellum and cervical segment of the spinal cord. Cholecalciferol 115-125 S100 calcium binding protein G Homo sapiens 59-63 3022423-1 1986 An increase in the amount of tyrosinase was demonstrated in the cultured human melanocyte after 6-day culturing with cholecalciferol (vitamin D3) by increased intensity of the immunofluorescent staining using monoclonal antibody against tyrosinase. Cholecalciferol 117-132 tyrosinase Homo sapiens 29-39 3018359-0 1986 Expression of monocyte-specific oncogenes c-fos and c-fms in HL60 cells treated with vitamin D3 analogs correlates with inhibition of DNA synthesis and reduced calmodulin concentration. Cholecalciferol 85-95 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 42-47 3018359-0 1986 Expression of monocyte-specific oncogenes c-fos and c-fms in HL60 cells treated with vitamin D3 analogs correlates with inhibition of DNA synthesis and reduced calmodulin concentration. Cholecalciferol 85-95 colony stimulating factor 1 receptor Homo sapiens 52-57 3018359-0 1986 Expression of monocyte-specific oncogenes c-fos and c-fms in HL60 cells treated with vitamin D3 analogs correlates with inhibition of DNA synthesis and reduced calmodulin concentration. Cholecalciferol 85-95 calmodulin 1 Homo sapiens 160-170 3787230-4 1986 HL60 cells induced to differentiate by DMSO or vitamin D3 decreased TfR but increased Fer. Cholecalciferol 47-57 transferrin receptor Homo sapiens 68-71 3787230-5 1986 Expression of TfR with fresh leukemia and normal marrow cells was less clear than in HL60 cells; DMSO or vitamin D3 induced differentiation was associated with a 10-fold Fer increase in leukemia cells and greater than 100-fold increase in marrow cells. Cholecalciferol 105-115 transferrin receptor Homo sapiens 14-17 3022423-1 1986 An increase in the amount of tyrosinase was demonstrated in the cultured human melanocyte after 6-day culturing with cholecalciferol (vitamin D3) by increased intensity of the immunofluorescent staining using monoclonal antibody against tyrosinase. Cholecalciferol 117-132 tyrosinase Homo sapiens 237-247 3022423-1 1986 An increase in the amount of tyrosinase was demonstrated in the cultured human melanocyte after 6-day culturing with cholecalciferol (vitamin D3) by increased intensity of the immunofluorescent staining using monoclonal antibody against tyrosinase. Cholecalciferol 134-144 tyrosinase Homo sapiens 29-39 3022423-1 1986 An increase in the amount of tyrosinase was demonstrated in the cultured human melanocyte after 6-day culturing with cholecalciferol (vitamin D3) by increased intensity of the immunofluorescent staining using monoclonal antibody against tyrosinase. Cholecalciferol 134-144 tyrosinase Homo sapiens 237-247 3745145-0 1986 Isolation of a cytochrome P-450 that catalyzes the 25-hydroxylation of vitamin D3 from rat liver microsomes. Cholecalciferol 71-81 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 15-31 3091093-1 1986 Cholecalciferol (calcitriol) the active hormonal form of vitamin D induces the synthesis of at least two intracellular calcium-binding proteins (Ka = 10(6) M-1), the cholecalcins (CaBP) in mammals. Cholecalciferol 0-15 S100 calcium binding protein G Rattus norvegicus 180-184 2821660-11 1986 22-Fluorovitamin D3 7 bound to the rat plasma vitamin D binding protein less avidly than vitamin D3. Cholecalciferol 9-19 GC, vitamin D binding protein Rattus norvegicus 46-71 3745145-1 1986 A molecular species of cytochrome P-450 that catalyzes the 25-hydroxylation of cholecalciferol (P-450cc25) was purified from rat liver microsomes on the basis of its catalytic activity. Cholecalciferol 79-94 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 23-39 3745145-10 1986 The antibody elicited against the purified enzyme in a rabbit inhibited the cholecalciferol 25-hydroxylation activity by more than 90% with a concentration of 2 mg of immunoglobulin per nmol of cytochrome P-450. Cholecalciferol 76-91 cytochrome P-450 Oryctolagus cuniculus 194-210 3028082-16 1986 Bradykinin (0.02 microgram/kg/min) also caused to kallikrein-like changes of vitamin D3. Cholecalciferol 77-87 kininogen 1 Canis lupus familiaris 0-10 3002968-4 1986 Because dihydroxy vitamin D3 (1,25-(OH)2 D3) can cause phenotypic differentiation of immature leukemic lines into macrophage-like cells, we have explored the possibility that exposure to cholecalciferol metabolites in vitro might increase the ability of monocytes to control proliferation of M. tuberculosis, or cause monocytes to mature into cells able to respond appropriately to IFN-gamma. Cholecalciferol 187-202 interferon gamma Homo sapiens 382-391 3933491-0 1985 Purification, immunological and biochemical characterization of rat 28 kDa cholecalcin (cholecalciferol-induced calcium-binding proteins). Cholecalciferol 88-103 S100 calcium binding protein G Rattus norvegicus 75-86 3002965-0 1985 Influence of vitamin D3 metabolites on the production of interleukins 1,2 and 3. Cholecalciferol 13-23 interleukin 2 Mus musculus 57-79 3002965-1 1985 We investigated the effect of vitamin D3 metabolites on the release of the three interleukins (IL) IL 1, IL 2 and IL 3 by mononuclear cells. Cholecalciferol 30-40 interleukin 1 complex Mus musculus 99-103 3002965-1 1985 We investigated the effect of vitamin D3 metabolites on the release of the three interleukins (IL) IL 1, IL 2 and IL 3 by mononuclear cells. Cholecalciferol 30-40 interleukin 2 Mus musculus 105-109 3002965-1 1985 We investigated the effect of vitamin D3 metabolites on the release of the three interleukins (IL) IL 1, IL 2 and IL 3 by mononuclear cells. Cholecalciferol 30-40 interleukin 3 Mus musculus 114-118 2999689-11 1985 When the amount of [3H]-25-hydroxyvitamin D3 formed was expressed in relation to the amount of enzyme present in the reaction medium, a constant C-25 hydroxylation capacity in all age groups was observed suggesting that the cytochrome P-450 isoenzyme responsible for the C-25 hydroxylation of vitamin D3 may be constitutionally determined and that its appearance originates during fetal life. Cholecalciferol 34-44 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 224-240 2998336-4 1985 The relative potencies of other vitamin D3 compounds correlated closely with their relative affinities for the 1,25-dihydroxyvitamin D3 receptor and their biological activities in other systems. Cholecalciferol 32-42 vitamin D receptor Rattus norvegicus 111-144 2990344-0 1985 Changes of intestinal alkaline phosphatase produced by cholecalciferol or 1,25-dihydroxyvitamin D3 in vitamin D-deficient chicks. Cholecalciferol 55-70 alkaline phosphatase, intestinal Homo sapiens 11-42 2990230-14 1985 The radioactive vitamin D3 recovered in the lymph fraction with d greater than 1.006 (free of chylomicrons) coeluted with purified rat serum binding protein for vitamin D and its metabolites (DBP) from an antirat DBP column. Cholecalciferol 16-26 D-box binding PAR bZIP transcription factor Rattus norvegicus 192-195 2990230-14 1985 The radioactive vitamin D3 recovered in the lymph fraction with d greater than 1.006 (free of chylomicrons) coeluted with purified rat serum binding protein for vitamin D and its metabolites (DBP) from an antirat DBP column. Cholecalciferol 16-26 D-box binding PAR bZIP transcription factor Rattus norvegicus 213-216 3838511-2 1985 The rat possesses two cholecalciferol-induced calcium-binding proteins, the cholecalcins (CaBP). Cholecalciferol 22-37 S100 calcium binding protein G Rattus norvegicus 90-94 3887031-7 1985 Elevation of the serum calcium concentration following vitamin D3 treatment resulted in reduced release of parathyroid hormone by exocytosis and enhanced retrieval of plasma membranes by endocytosis. Cholecalciferol 55-65 parathyroid hormone Rattus norvegicus 107-126 2987615-6 1985 With regard to in vitro activity in displacing radiolabeled 25-hydroxyvitamin D3 from vitamin D binding protein and radiolabelled 1,25-dihydroxyvitamin D3 from a chick intestinal cytosol receptor, 3 beta-fluorovitamin D3 and 3 beta-deoxyvitamin D3 both showed very poor binding efficiencies when compared with vitamin D3. Cholecalciferol 70-80 GC vitamin D binding protein Gallus gallus 86-111 3874829-1 1985 The pharmacological effects of prolonged administration of a corticosteroid, betamethasone, and active vitamin D3 [1,24R-(OH)2D3] on lymphoproliferation and autoimmune disease of MRL/MP-lpr/lpr (MRL/1) mice were examined. Cholecalciferol 103-115 Fas (TNF receptor superfamily member 6) Mus musculus 179-193 3001619-3 1985 vitamin D3-drops for 18 days) of vitamin D-deficiency rickets (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 63-66 6089793-1 1984 The amount of skin calcium-binding protein, evaluated using a sensitive radioimmunoassay and indirect immunofluorescence, was decreased in vitamin-D deficient rats and increased after one week vitamin D3 or 1 alpha-hydroxyvitamin D3 treatment. Cholecalciferol 193-203 hippocalcin Rattus norvegicus 19-42 6489266-4 1984 By transferring proteins separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis to nitrocellulose blots electrophoretically, CaBP was immunologically detected in brush borders from vitamin D3-treated chicks, but not in those from vitamin D3-deficient chicks. Cholecalciferol 197-207 centrin 1 Homo sapiens 141-145 6489266-4 1984 By transferring proteins separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis to nitrocellulose blots electrophoretically, CaBP was immunologically detected in brush borders from vitamin D3-treated chicks, but not in those from vitamin D3-deficient chicks. Cholecalciferol 246-256 centrin 1 Homo sapiens 141-145 6546486-6 1984 These results indicate that when the lactonization at C-23 and C-26 positions of various vitamin D3 derivatives occurred the stereochemical configuration at their C-23 and/or C-25 positions was not changed and the difference of the stereochemical configurations determined the rate of lactonization. Cholecalciferol 89-99 nucleolin Homo sapiens 54-58 6363517-1 1984 Vitamin D-dependent calcium-binding protein (CaBP) was localized in intestinal tissue sections obtained from rats raised under three different nutritional conditions: a normal vitamin D-replete diet, a vitamin D-free diet followed by supplementation with vitamin D3, or a vitamin D-free diet without additional supplementation. Cholecalciferol 255-265 hippocalcin Rattus norvegicus 20-43 6363517-1 1984 Vitamin D-dependent calcium-binding protein (CaBP) was localized in intestinal tissue sections obtained from rats raised under three different nutritional conditions: a normal vitamin D-replete diet, a vitamin D-free diet followed by supplementation with vitamin D3, or a vitamin D-free diet without additional supplementation. Cholecalciferol 255-265 hippocalcin Rattus norvegicus 45-49 6363517-6 1984 In rats raised on a vitamin D-deficient diet then supplemented with vitamin D3, CaBP was present in cells at the full depth of the crypts and in absorptive cells along the total villus length in the duodenum. Cholecalciferol 68-78 hippocalcin Rattus norvegicus 80-84 6331517-3 1984 Microsomal cytochrome P-450 catalyzed an efficient 25-hydroxylation of vitamin D3, but no 25-hydroxylation of vitamin D2 could be detected. Cholecalciferol 71-81 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 11-27 6427926-1 1984 The hormonal form of vitamin D3, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], at picomolar concentrations, inhibited the growth-promoting lymphokine interleukin-2, which is produced by human T lymphocytes activated in vitro by the mitogen phytohemagglutinin. Cholecalciferol 21-31 interleukin 2 Homo sapiens 144-157 6427926-2 1984 Other metabolites of vitamin D3 were less effective than 1,25(OH)2D3 in suppressing interleukin-2; their order of potency corresponded to their respective affinity for the 1,25(OH)2D3 receptor, suggesting that the effect on interleukin-2 was mediated by this specific receptor. Cholecalciferol 21-31 interleukin 2 Homo sapiens 84-97 6427926-2 1984 Other metabolites of vitamin D3 were less effective than 1,25(OH)2D3 in suppressing interleukin-2; their order of potency corresponded to their respective affinity for the 1,25(OH)2D3 receptor, suggesting that the effect on interleukin-2 was mediated by this specific receptor. Cholecalciferol 21-31 interleukin 2 Homo sapiens 224-237 6325646-5 1984 Low dietary intake of phosphorus resulted in an increase in 47Ca and 203Pb absorption and in CaBP synthesis when the animals were treated with cholecalciferol. Cholecalciferol 143-158 centrin 1 Homo sapiens 93-97 6546486-6 1984 These results indicate that when the lactonization at C-23 and C-26 positions of various vitamin D3 derivatives occurred the stereochemical configuration at their C-23 and/or C-25 positions was not changed and the difference of the stereochemical configurations determined the rate of lactonization. Cholecalciferol 89-99 nucleolin Homo sapiens 163-167 6311881-2 1983 Milk from cows kept indoors contained barely detectable vitamin (less than 2 IU/100 ml) predominantly in the form of vitamin D3. Cholecalciferol 117-127 Weaning weight-maternal milk Bos taurus 0-4 6687257-1 1983 The effects of cholecalciferol (vitamin D3)-binding proteins and anti-cytochrome b5 immunoglobulin were studied on vitamin D3 25-hydroxylase activities of microsomes and mitochondria under various experimental conditions. Cholecalciferol 15-30 sterol 26-hydroxylase, mitochondrial Oryctolagus cuniculus 115-140 6687257-1 1983 The effects of cholecalciferol (vitamin D3)-binding proteins and anti-cytochrome b5 immunoglobulin were studied on vitamin D3 25-hydroxylase activities of microsomes and mitochondria under various experimental conditions. Cholecalciferol 32-42 sterol 26-hydroxylase, mitochondrial Oryctolagus cuniculus 115-140 6687257-2 1983 The vitamin D3-binding protein in serum as well as in the liver postmicrosomal supernatant (cellular vitamin D3-binding protein), but not serum albumin and ovalbumin, stimulated vitamin D3 25-hydroxylase activities of microsomes and mitochondria. Cholecalciferol 4-14 sterol 26-hydroxylase, mitochondrial Oryctolagus cuniculus 178-203 6315669-8 1983 Treatment with 500 mg of vitamin D3, but not 50 mg of dihydrotachysterol, significantly increased serum Ca and CaBP concentrations in Holstein heifers after a lag period of 7 to 10 d. Serum Ca and CaBP concentrations began to increase in serum at approximately the same time and both exhibited parallel responses to treatment with vitamin D3. Cholecalciferol 25-35 S100 calcium binding protein G Bos taurus 111-115 6315669-8 1983 Treatment with 500 mg of vitamin D3, but not 50 mg of dihydrotachysterol, significantly increased serum Ca and CaBP concentrations in Holstein heifers after a lag period of 7 to 10 d. Serum Ca and CaBP concentrations began to increase in serum at approximately the same time and both exhibited parallel responses to treatment with vitamin D3. Cholecalciferol 25-35 S100 calcium binding protein G Bos taurus 197-201 6315669-10 1983 Serum Ca and CaBP concentrations were still elevated in heifers 75 d after initial treatment with vitamin D3. Cholecalciferol 98-108 S100 calcium binding protein G Bos taurus 13-17 6689055-10 1983 In addition, we demonstrate that removal of vitamin D3, after the onset of maturational change, results in the reappearance of elevated myc mRNA levels. Cholecalciferol 44-54 MYC proto-oncogene, bHLH transcription factor Homo sapiens 136-139 6688877-1 1983 Previous studies from this laboratory have demonstrated that the acute infusion of the vitamin D3 derivative, 1,25-dihydroxy vitamin D3 (1,25(OH)2D3) is antiphosphaturic when administered with small "permissive" amounts of parathyroid hormone (PTH). Cholecalciferol 87-97 parathyroid hormone Rattus norvegicus 223-242 6688877-1 1983 Previous studies from this laboratory have demonstrated that the acute infusion of the vitamin D3 derivative, 1,25-dihydroxy vitamin D3 (1,25(OH)2D3) is antiphosphaturic when administered with small "permissive" amounts of parathyroid hormone (PTH). Cholecalciferol 87-97 parathyroid hormone Rattus norvegicus 244-247 6311881-3 1983 When cows were given 5 or 10 million IU vitamin D3, maximums were in milk 3 to 7 days after oral doses and up to 10 days after intravenous injections. Cholecalciferol 40-50 Weaning weight-maternal milk Bos taurus 69-73 6897035-9 1982 Daily administration of vitamin D3 or 1 alpha,25-(OH)2D3 for 2 weeks resulted in a marked increase in CaBP levels mainly in the mid- and upper villus regions. Cholecalciferol 24-34 centrin 1 Homo sapiens 102-106 6297543-6 1983 This new vitamin D3 metabolite, however, had greater affinity than 25-hydroxyvitamin D3 to both the rat plasma vitamin D binding protein and the 1,25-dihydroxyvitamin D specific cytosol receptor. Cholecalciferol 9-19 GC, vitamin D binding protein Rattus norvegicus 111-136 6308609-1 1983 We have constructed a recombinant cDNA library to facilitate study of the genomic actions of vitamin D3 and its hormonally active metabolite 1,25-dihydroxyvitamin D3 in initiation of the de novo biosynthesis of a 28,000-dalton vitamin D-dependent calcium binding protein (CaBP) present in chick intestine. Cholecalciferol 93-103 calcium-binding protein Gallus gallus 247-270 6308609-1 1983 We have constructed a recombinant cDNA library to facilitate study of the genomic actions of vitamin D3 and its hormonally active metabolite 1,25-dihydroxyvitamin D3 in initiation of the de novo biosynthesis of a 28,000-dalton vitamin D-dependent calcium binding protein (CaBP) present in chick intestine. Cholecalciferol 93-103 calcium-binding protein Gallus gallus 272-276 6304056-0 1983 25-hydroxylation of C27-steroids and vitamin D3 by a constitutive cytochrome P-450 from rat liver microsomes. Cholecalciferol 37-47 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 66-82 6304056-1 1983 A constitutive cytochrome P-450 catalyzing 25-hydroxylation of C27-steroids and vitamin D3 was purified from rat liver microsomes. Cholecalciferol 80-90 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 15-31 6304056-3 1983 The purified cytochrome P-450 catalyzed 25-hydroxylation of 5 beta-cholestane-3 alpha, 7 alpha-diol, 5 beta-cholestane-3 alpha, 7 alpha, 12 alpha-triol, and 1 alpha-hydroxyvitamin D3 up to 50 times more efficiently, and 25-hydroxylation of vitamin D3 about 150 times more efficiently than the microsomes. Cholecalciferol 172-182 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 13-29 6304056-6 1983 The 25-hydroxylation of 5 beta-cholestane-3 alpha, 7 alpha, 12 alpha-triol and vitamin D3 with the purified cytochrome P-450 was not stimulated by addition of phospholipid or cytochrome b5 to the reconstituted system. Cholecalciferol 79-89 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 108-124 6304056-8 1983 The possibility that 25-hydroxylation of C27-steroids and vitamin D3 is catalyzed by the same species of cytochrome P-450 is discussed. Cholecalciferol 58-68 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 105-121 6847206-2 1983 Addition of papain to brush borders isolated from vitamin D3-treated and deficient chicks resulted in a differential solubilization of leucine aminopeptidase, maltase, and sucrase activities (114, 195, and 79%, respectively, of appropriate control levels) but not alkaline phosphatase activity. Cholecalciferol 50-60 carboxypeptidase Q Homo sapiens 143-157 6299329-2 1983 The plasma disappearance of 3H-labelled 25-hydroxyvitamin D3 (25(OH)D3) was studied in healthy volunteers on normal and high-fibre diets, using 3H-labelled tracer doses given intravenously. Cholecalciferol 68-70 iodothyronine deiodinase 3 Homo sapiens 58-60 6830145-4 1983 The results indicate that CaBP is not biosynthesised in response to raising the extracellular calcium ion concentration, and only appears if the chickens had received cholecalciferol. Cholecalciferol 167-182 calcium-binding protein Gallus gallus 26-30 6884003-1 1983 Cholecalciferol (vitamin D3) 25-hydroxylase activity and its tissue and subcellular distributions were studied using rabbit, rat, bovine, chick, duck, guinea-pig and yellowtail. Cholecalciferol 0-15 sterol 26-hydroxylase, mitochondrial Oryctolagus cuniculus 17-43 6981502-1 1982 In young rats, PTH markedly stimulates the renal conversion of 25-hydroxyvitamin D3 (25OHD3) to 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], the biologically active form of vitamin D3. Cholecalciferol 73-83 parathyroid hormone Rattus norvegicus 15-18 6263587-12 1981 It app]ears that 1 alpha-hydroxylase activities of the fetoplacental unit (placenta and fetal kidney) are blunted in TPTX animals and that CaBP synthesis in the fetus depends on the presence of 1 alpha-hydroxylated vitamin D3 metabolites in the mother. Cholecalciferol 215-225 hippocalcin Rattus norvegicus 139-143 6290291-0 1982 Effects of vitamin D3 metabolites on production of prolactin and growth hormone in rat pituitary cells. Cholecalciferol 11-21 prolactin Rattus norvegicus 51-60 6291527-0 1982 23-keto-25-hydroxyvitamin D3 and 23-keto-1,25-dihydroxyvitamin D3: two new vitamin D3 metabolites with high affinity for the 1,25-dihydroxyvitamin D3 receptor. Cholecalciferol 18-28 vitamin D receptor Homo sapiens 125-158 6278948-8 1982 Vitamin D3, in a single dose of 250 micrograms, partially restored serum calcium of vitamin D-deficient birds toward normal by 72 h and also partly restored renal cyclic AMP responsiveness to PTH and the PTH receptor number toward control values. Cholecalciferol 0-10 parathyroid hormone Gallus gallus 192-195 6278948-8 1982 Vitamin D3, in a single dose of 250 micrograms, partially restored serum calcium of vitamin D-deficient birds toward normal by 72 h and also partly restored renal cyclic AMP responsiveness to PTH and the PTH receptor number toward control values. Cholecalciferol 0-10 parathyroid hormone Gallus gallus 204-207 6274987-0 1981 Side chain hydroxylation of C27-steroids and vitamin D3 by a cytochrome P-450 enzyme system isolated from human liver mitochondria. Cholecalciferol 45-55 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 61-77 6274987-7 1981 The cytochrome P-450 preparation catalyzed 26-hydroxylation of C27-steroids and 25-hydroxylation of vitamin D3 when reconstructed with NADPH, the ferredoxin and the ferredoxin reductase. Cholecalciferol 100-110 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 4-20 6274987-7 1981 The cytochrome P-450 preparation catalyzed 26-hydroxylation of C27-steroids and 25-hydroxylation of vitamin D3 when reconstructed with NADPH, the ferredoxin and the ferredoxin reductase. Cholecalciferol 100-110 ferredoxin reductase Homo sapiens 165-185 6274987-11 1981 It is concluded that human liver mitochondria contain cytochrome P-450 involved in the oxidation of the side chain of C27-steroids and vitamin D3. Cholecalciferol 135-145 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 54-70 6141291-0 1982 Calcitonin secretion during postnatal development in the rat: beta-adrenergic agents and vitamin D3 metabolites. Cholecalciferol 89-99 calcitonin-related polypeptide alpha Rattus norvegicus 0-10 6141291-2 1982 So, in vivo and in vitro (using a perifusion system) effects of beta-adrenergic agents and vitamin D3 metabolites on CT release were studied in the rat during the postnatal development. Cholecalciferol 91-101 calcitonin-related polypeptide alpha Rattus norvegicus 117-119 6895593-1 1981 The effect of cholecalciferol and its metabolites on ornithine decarboxylase activity was investigated in the duodenal mucosa of vitamin D-deficient chicks. Cholecalciferol 14-29 ornithine decarboxylase Gallus gallus 53-76 6265564-4 1981 The plasma vitamin-D binding protein preferentially translocates vitamin D3 from the skin into the circulation. Cholecalciferol 65-75 GC vitamin D binding protein Homo sapiens 11-36 6895593-2 1981 The duodenal ornithine decarboxylase activity decreased in animals fed a vitamin D-deficient diet and its retarded activity was increased dose-dependently by a single injection of cholecalciferol. Cholecalciferol 180-195 ornithine decarboxylase Gallus gallus 13-36 734693-1 1978 Since intestinal calcium-binding protein (CaBP) can be regarded as an expression of the hormone-like action of 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) on the duodenal enterocyte we have investigated the potential biological activity of 25R and 25S,26-(OH)2D3 (two recently synthesized epimers of vitamin D3 metabolite) to promote intestinal CaBP production as compared to bone calcium mobilization in vitamin D and calcium-deficient rats. Cholecalciferol 125-135 S100 calcium binding protein G Rattus norvegicus 42-46 443376-2 1979 The relation between CaBP and calcium absorption was dependent on a) source of vitamin D activity (either vitamin D3 or 1,25-dihydroxycholecalciferol); b) dosage of vitamin D3; c) time after administration of vitamin D3 to rachitic animals. Cholecalciferol 106-116 centrin 1 Homo sapiens 21-25 443376-2 1979 The relation between CaBP and calcium absorption was dependent on a) source of vitamin D activity (either vitamin D3 or 1,25-dihydroxycholecalciferol); b) dosage of vitamin D3; c) time after administration of vitamin D3 to rachitic animals. Cholecalciferol 165-175 centrin 1 Homo sapiens 21-25 443376-2 1979 The relation between CaBP and calcium absorption was dependent on a) source of vitamin D activity (either vitamin D3 or 1,25-dihydroxycholecalciferol); b) dosage of vitamin D3; c) time after administration of vitamin D3 to rachitic animals. Cholecalciferol 165-175 centrin 1 Homo sapiens 21-25 221183-1 1979 Vitamin D3 in rachitic chicks stimulates calcium absorption and induces the synthesis of two pools of intestinal calcium-binding protein (CaBP), one soluble and the other membrane bound. Cholecalciferol 0-10 S100 calcium binding protein G Homo sapiens 138-142 221183-5 1979 It was further observed that the slope of the Ca absorption vs. soluble CaBP regression line was greater in chicks given 1,25-dihyroxyvitamin D3 compared to those given vitamin D3, and this is interpreted to mean that another factor or condition, in addition to assayed concentrations of soluble CaBP, determines the degree of calcium absorption. Cholecalciferol 134-144 S100 calcium binding protein G Homo sapiens 72-76 7453803-2 1980 However, it has long been known that a soluble, calcium-binding protein (CaBP), is produced in large amounts in the cytoplasm of the intestinal cells of animals after in vivo administration of vitamin D3 or 1,25-(OH)2D3 (refs 1,2). Cholecalciferol 193-203 calcium-binding protein Gallus gallus 48-71 7453803-2 1980 However, it has long been known that a soluble, calcium-binding protein (CaBP), is produced in large amounts in the cytoplasm of the intestinal cells of animals after in vivo administration of vitamin D3 or 1,25-(OH)2D3 (refs 1,2). Cholecalciferol 193-203 calcium-binding protein Gallus gallus 73-77 90502-0 1979 Quantitative studies of the interaction of cholecalciferol ((vitamin D3) and its metabolites with different genetic variants of the serum binding protein for these sterols. Cholecalciferol 43-58 growth hormone receptor Homo sapiens 132-153 90502-0 1979 Quantitative studies of the interaction of cholecalciferol ((vitamin D3) and its metabolites with different genetic variants of the serum binding protein for these sterols. Cholecalciferol 61-71 growth hormone receptor Homo sapiens 132-153 90502-1 1979 Cholecalciferol (vitamin D3) and its 25-hydroxy metabolite are transported in plasma bound to a specific protein, the binding protein for cholecalciferol and its metabolites (DBP). Cholecalciferol 0-15 D-box binding PAR bZIP transcription factor Homo sapiens 175-178 90502-1 1979 Cholecalciferol (vitamin D3) and its 25-hydroxy metabolite are transported in plasma bound to a specific protein, the binding protein for cholecalciferol and its metabolites (DBP). Cholecalciferol 17-27 D-box binding PAR bZIP transcription factor Homo sapiens 175-178 90502-1 1979 Cholecalciferol (vitamin D3) and its 25-hydroxy metabolite are transported in plasma bound to a specific protein, the binding protein for cholecalciferol and its metabolites (DBP). Cholecalciferol 138-153 D-box binding PAR bZIP transcription factor Homo sapiens 175-178 90502-8 1979 More extensive studies were then conducted to compare the binding of four cholecalciferol-related sterols to each of three genetic variants of DBP, by using sera from homozygous persons with the Gc 1-1, Gc 2-2 and Gc Ab-Ab phenotypes. Cholecalciferol 74-89 D-box binding PAR bZIP transcription factor Homo sapiens 143-146 90502-10 1979 The affinities of the three genetic types of DBP/Gc protein were found to be similar for each of the four cholecalciferol-related sterols. Cholecalciferol 106-121 GC vitamin D binding protein Homo sapiens 45-51 90502-15 1979 Thus the common genetic variants of DBP/Gc protein, and the uncommon genetic variants studied here, all appear to have similar binding properties for cholecalciferol and its several metabolites. Cholecalciferol 150-165 GC vitamin D binding protein Homo sapiens 36-42 211584-0 1978 Vitamin D3-induced calcium binding protein in bone tissue. Cholecalciferol 0-10 calcium-binding protein Gallus gallus 19-42 211584-1 1978 As detected by radioimmunoassay with antiserums against chick intestinal calcium binding protein (CaBP), administration of vitamin D3 to rachitic chicks causes a 25- to 100-fold increase in immunoreactive CaBP in chick bone. Cholecalciferol 123-133 calcium-binding protein Gallus gallus 73-96 211584-1 1978 As detected by radioimmunoassay with antiserums against chick intestinal calcium binding protein (CaBP), administration of vitamin D3 to rachitic chicks causes a 25- to 100-fold increase in immunoreactive CaBP in chick bone. Cholecalciferol 123-133 calcium-binding protein Gallus gallus 98-102 211584-1 1978 As detected by radioimmunoassay with antiserums against chick intestinal calcium binding protein (CaBP), administration of vitamin D3 to rachitic chicks causes a 25- to 100-fold increase in immunoreactive CaBP in chick bone. Cholecalciferol 123-133 calcium-binding protein Gallus gallus 205-209 204359-3 1978 The accumulation of cholecalciferol metabolites in the parotid gland was shown to be functional, as a calcium-binding protein was found to be present in the gland, possessing similar properties to the renal vitamin D-dependent calcium-binding protein. Cholecalciferol 20-35 hippocalcin Rattus norvegicus 102-125 357647-1 1978 Calcium binding protein (CaBP) was localized by the indirect peroxidase-labeled antibody method in chick duodenum 72 hr after administering 32.5 nmol of cholecalciferol to vitamin D-deficient chicks. Cholecalciferol 153-168 calcium-binding protein Gallus gallus 0-23 357647-1 1978 Calcium binding protein (CaBP) was localized by the indirect peroxidase-labeled antibody method in chick duodenum 72 hr after administering 32.5 nmol of cholecalciferol to vitamin D-deficient chicks. Cholecalciferol 153-168 calcium-binding protein Gallus gallus 25-29 204359-3 1978 The accumulation of cholecalciferol metabolites in the parotid gland was shown to be functional, as a calcium-binding protein was found to be present in the gland, possessing similar properties to the renal vitamin D-dependent calcium-binding protein. Cholecalciferol 20-35 hippocalcin Rattus norvegicus 227-250 402471-10 1977 Since EHDP inhibits formation of 1,25-(OH)2D3 the effect of PTH on Ca absorption is likely to be mediated through this vitamin D3 metabolite. Cholecalciferol 119-129 parathyroid hormone Rattus norvegicus 60-63 564862-2 1978 PTH potentiated CaBP synthesis in the presence of vitamin D3, 25-OH-D3, 1 alpha-OH-D3, DHT, and 1,25(OH)2D3. Cholecalciferol 50-60 parathyroid hormone Gallus gallus 0-3 204303-11 1978 Rachitic chicks require the presence of dietary calcium for maximum stimulation of calcium-binding protein production by cholecalciferol. Cholecalciferol 121-136 calcium-binding protein Gallus gallus 83-106 201067-3 1977 In the group of rabbits which were fed on the mixture of carbostimulin and vitamin D3 the phosphofructokinase activity is 7-2 times as high. Cholecalciferol 75-85 ATP-dependent 6-phosphofructokinase, muscle type Oryctolagus cuniculus 90-109 233823-11 1977 These studies in both the chick and rat indicate that dietary vitamin D3 excess enhances circulating 25-OHD3, probably because the vitamin D3-25-hydroxylase enzyme is not strigently controlled. Cholecalciferol 62-72 cytochrome P450, family 27, subfamily a, polypeptide 1 Rattus norvegicus 131-156 180950-0 1975 The role of calcium binding protein in the mechanism of action of cholecalciferol (vitamin D3). Cholecalciferol 66-81 centrin 1 Homo sapiens 12-35 195023-0 1977 Characterization of sterol carrier protein binding with 7-dehydrocholesterol and vitamin D3. Cholecalciferol 81-91 fatty acid binding protein 1 Rattus norvegicus 20-42 195023-9 1977 From these results, it was clearly demonstrated that SCP was involved in the transformation of 7-dehydrocholesterol to cholesterol and could also bind vitamin D3. Cholecalciferol 151-161 fatty acid binding protein 1 Rattus norvegicus 53-56 189757-9 1976 It is postulated that cholecalciferol forms part of a complex with its specific binding protein, Ca2+ and the yolk phosphoprotein, phosvitin. Cholecalciferol 22-37 carbonic anhydrase 2 Gallus gallus 97-100 189757-9 1976 It is postulated that cholecalciferol forms part of a complex with its specific binding protein, Ca2+ and the yolk phosphoprotein, phosvitin. Cholecalciferol 22-37 Casein kinase II subunit beta Gallus gallus 131-140 821943-6 1976 Sucrose gradient ultracentrifugation of Cal-BP and ligand incubations indicated that there was apparently one binding site for either cholecalciferol, calcifidiol or 1,25-dihydroxycholecalciferol per molecule of human Cal-BP. Cholecalciferol 134-149 calreticulin Rattus norvegicus 40-46 821943-9 1976 Specific binding of vitamin D3,25-OH-D3, and 1,25-(OH)2D3 by human serum was completely neutralized after immunoprecipitation of the serum with the gamma globulin fraction of anti-Cal-BP antiserum, indicating a common transport protein for these sterols in human plasma. Cholecalciferol 20-30 calreticulin Rattus norvegicus 180-186 180950-0 1975 The role of calcium binding protein in the mechanism of action of cholecalciferol (vitamin D3). Cholecalciferol 83-93 centrin 1 Homo sapiens 12-35 180950-1 1975 A role has been sought for the calcium binding protein (CaBP) which is synthesised de novo after giving cholecalciferol (CC, vitamin D3) to rachitic chicks. Cholecalciferol 104-119 centrin 1 Homo sapiens 31-54 180950-1 1975 A role has been sought for the calcium binding protein (CaBP) which is synthesised de novo after giving cholecalciferol (CC, vitamin D3) to rachitic chicks. Cholecalciferol 104-119 centrin 1 Homo sapiens 56-60 180950-1 1975 A role has been sought for the calcium binding protein (CaBP) which is synthesised de novo after giving cholecalciferol (CC, vitamin D3) to rachitic chicks. Cholecalciferol 125-135 centrin 1 Homo sapiens 31-54 180950-1 1975 A role has been sought for the calcium binding protein (CaBP) which is synthesised de novo after giving cholecalciferol (CC, vitamin D3) to rachitic chicks. Cholecalciferol 125-135 centrin 1 Homo sapiens 56-60 165031-17 1975 The data suggest that the production of 1,25-(OH)2D3 from a pulse dose of cholecalciferol is normally regulated, directly or indirectly, by the parathyroid hormone. Cholecalciferol 74-89 parathyroid hormone Homo sapiens 144-163 178845-1 1975 It was confirmed that delta 5,7-sterol delta 7-reductase activity was suppressed by cholecalciferol (vitamin D3) in the enzyme system consisted of microsomes and sterol carrier protein (SCP). Cholecalciferol 84-99 fatty acid binding protein 1 Rattus norvegicus 162-184 178845-1 1975 It was confirmed that delta 5,7-sterol delta 7-reductase activity was suppressed by cholecalciferol (vitamin D3) in the enzyme system consisted of microsomes and sterol carrier protein (SCP). Cholecalciferol 84-99 fatty acid binding protein 1 Rattus norvegicus 186-189 178845-1 1975 It was confirmed that delta 5,7-sterol delta 7-reductase activity was suppressed by cholecalciferol (vitamin D3) in the enzyme system consisted of microsomes and sterol carrier protein (SCP). Cholecalciferol 101-111 fatty acid binding protein 1 Rattus norvegicus 162-184 178845-1 1975 It was confirmed that delta 5,7-sterol delta 7-reductase activity was suppressed by cholecalciferol (vitamin D3) in the enzyme system consisted of microsomes and sterol carrier protein (SCP). Cholecalciferol 101-111 fatty acid binding protein 1 Rattus norvegicus 186-189 178845-2 1975 The enzyme activity was significantly decreased in the combination with microsomes obtained from either vitamin D-deficient or vitamin D3-treated rat liver and with SCP obtained from vitamin D3-treated rat. Cholecalciferol 127-137 fatty acid binding protein 1 Rattus norvegicus 165-168 178845-2 1975 The enzyme activity was significantly decreased in the combination with microsomes obtained from either vitamin D-deficient or vitamin D3-treated rat liver and with SCP obtained from vitamin D3-treated rat. Cholecalciferol 183-193 fatty acid binding protein 1 Rattus norvegicus 165-168 178845-3 1975 It was also demonstrated by the binding assay of the dextran-charcoal technique that 7-dehydrocholesterol binding to SCP could be specifically displaced by vitamin D3. Cholecalciferol 156-166 fatty acid binding protein 1 Rattus norvegicus 117-120 178845-4 1975 The inhibition of cholecalciferol on 7-dehydrocholesterol binding to liver SCP was confirmed to be non-competitive inhibition. Cholecalciferol 18-33 fatty acid binding protein 1 Rattus norvegicus 75-78 33043722-6 2021 Vitamin D3 (700-800IU/d) plus calcium showed statistical significance in reducing the incidence of total, hip and non-vertebral fractures in the pairwise meta-analysis. Cholecalciferol 0-10 hedgehog interacting protein Homo sapiens 106-109 31842709-2 2021 We aimed to investigate the effect of the calcitriol or active form of Vitamin D3 (1, 25(OH) 2D3) on serum Cholesteryl ester transfer protein (CETP) levels in a rabbit model of atherosclerosis. Cholecalciferol 71-81 cholesteryl ester transfer protein Oryctolagus cuniculus 107-141 31842709-2 2021 We aimed to investigate the effect of the calcitriol or active form of Vitamin D3 (1, 25(OH) 2D3) on serum Cholesteryl ester transfer protein (CETP) levels in a rabbit model of atherosclerosis. Cholecalciferol 71-81 cholesteryl ester transfer protein Oryctolagus cuniculus 143-147 33400182-0 2021 Protective Effect of Vitamin D3 Against Pb-Induced Neurotoxicity by Regulating the Nrf2 and NF-kappaB Pathways. Cholecalciferol 21-31 NFE2 like bZIP transcription factor 2 Rattus norvegicus 83-87 34032540-0 2022 Vitamin D Receptor (VDR) Allelic Variants Correlating with Response to Vitamin D3 Supplementation in Breast Cancer Survivors. Cholecalciferol 71-81 vitamin D receptor Homo sapiens 0-18 33592299-12 2021 CONCLUSION: Vitamin D3 efficiently protected allografts from memory T-cell allo-responses when combined with anti-CD40L/anti-LFA-1 antibodies therapy. Cholecalciferol 12-22 CD40 ligand Mus musculus 114-119 34051273-0 2021 Vitamin D3 protects against lead-induced testicular toxicity by modulating Nrf2 and NF-kappaB genes expression in rat. Cholecalciferol 0-10 NFE2 like bZIP transcription factor 2 Rattus norvegicus 75-79 34051273-3 2021 This study was conducted to evaluate the effects of vitamin D3 (VD) on the prevention of testicular damages of Pb and its association with Nrf2 and NF-kappaB gene expression levels and their downstream molecules. Cholecalciferol 52-62 NFE2 like bZIP transcription factor 2 Rattus norvegicus 139-143 34032540-0 2022 Vitamin D Receptor (VDR) Allelic Variants Correlating with Response to Vitamin D3 Supplementation in Breast Cancer Survivors. Cholecalciferol 71-81 vitamin D receptor Homo sapiens 20-23 34032540-1 2022 We investigated how vitamin D receptor (VDR) allelic variants affect breast cancer survivors" responses to vitamin D3 supplementation to increase circulating 25-hydroxy vitamin D (25(OH)D) levels. Cholecalciferol 107-117 vitamin D receptor Homo sapiens 20-38 34032540-4 2022 The TaqI and BsmI VDR sequence variants modified the effect of vitamin D3 treatment on the plasma 25(OH)D changes (P value = 0.008 for TaqI and P value = 0.0005 for BsmI). Cholecalciferol 63-73 vitamin D receptor Homo sapiens 18-21 34032540-7 2022 VDR allelic variants modulate vitamin D3 supplementation to increase plasma 25(OH) levels in breast cancer survivors. Cholecalciferol 30-40 vitamin D receptor Homo sapiens 0-3 33899473-1 2021 Vitamin D3 metabolites inhibit the expression of lipogenic genes by impairing sterol regulatory element-binding protein (SREBP), a master transcription factor of lipogenesis, independent of their canonical activity through a vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 225-243 34020532-11 2021 In diabetic hearts, the mRNA expression level of parp-1 gene was 2.8-fold higher compared to control rats and partially decreased by vitamin D3 treatment. Cholecalciferol 133-143 poly (ADP-ribose) polymerase 1 Rattus norvegicus 49-55 34011380-0 2021 Association of vitamin D-binding protein and vitamin D3 with insulin and homeostatic model assessment (HOMA-IR) in overweight and obese females. Cholecalciferol 45-55 insulin Homo sapiens 61-68 33899473-1 2021 Vitamin D3 metabolites inhibit the expression of lipogenic genes by impairing sterol regulatory element-binding protein (SREBP), a master transcription factor of lipogenesis, independent of their canonical activity through a vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 245-248 33548476-11 2021 Ki67-positive cells, a marker of placental proliferation, were reduced in mice administered with high-dose cholecalciferol. Cholecalciferol 107-122 antigen identified by monoclonal antibody Ki 67 Mus musculus 0-4 33964955-0 2021 Combined effect of vitamin C and vitamin D3 on intestinal epithelial barrier by regulating Notch signaling pathway. Cholecalciferol 33-43 notch receptor 1 Homo sapiens 91-96 33964955-3 2021 This study was performed to investigate whether vitamin C combined with vitamin D3 affects intestinal mucosal barrier stability via the Notch signaling pathway. Cholecalciferol 72-82 notch receptor 1 Homo sapiens 136-141 33964955-11 2021 In SW480 cell experiments, compared with the control group, cell migration and repair following treatment with different concentrations of vitamin C combined with vitamin D3 were significantly improved and the protein expression of Notch-1 was increased, whereas the protein expression of claudin-2 was significantly decreased. Cholecalciferol 163-173 claudin 2 Homo sapiens 289-298 33964955-12 2021 Thus, our results demonstrate that an appropriate amount of vitamin C combined with vitamin D3 can regulate the expression of claudin-2 by regulating Notch-1, relieve destruction of the intestinal mucosal barrier, and promote the repair of damage to the cell mucosal barrier. Cholecalciferol 84-94 claudin 2 Homo sapiens 126-135 33964955-12 2021 Thus, our results demonstrate that an appropriate amount of vitamin C combined with vitamin D3 can regulate the expression of claudin-2 by regulating Notch-1, relieve destruction of the intestinal mucosal barrier, and promote the repair of damage to the cell mucosal barrier. Cholecalciferol 84-94 notch receptor 1 Homo sapiens 150-157 33541129-0 2021 Effect of vitamin D3 supplementation on hepatic lipid dysregulation associated with autophagy regulatory AMPK/Akt-mTOR signaling in type 2 diabetic mice. Cholecalciferol 10-20 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 105-109 33541129-0 2021 Effect of vitamin D3 supplementation on hepatic lipid dysregulation associated with autophagy regulatory AMPK/Akt-mTOR signaling in type 2 diabetic mice. Cholecalciferol 10-20 thymoma viral proto-oncogene 1 Mus musculus 110-113 33541129-0 2021 Effect of vitamin D3 supplementation on hepatic lipid dysregulation associated with autophagy regulatory AMPK/Akt-mTOR signaling in type 2 diabetic mice. Cholecalciferol 10-20 mechanistic target of rapamycin kinase Mus musculus 114-118 33541129-8 2021 Importantly, vitamin D3 treatment induced autophagy by activating AMP-activated protein kinase (AMPK), inactivating Akt and ultimately blocking mammalian target of rapamycin (mTOR) activation in the T2DM mice. Cholecalciferol 13-23 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 66-94 33541129-8 2021 Importantly, vitamin D3 treatment induced autophagy by activating AMP-activated protein kinase (AMPK), inactivating Akt and ultimately blocking mammalian target of rapamycin (mTOR) activation in the T2DM mice. Cholecalciferol 13-23 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 96-100 33541129-8 2021 Importantly, vitamin D3 treatment induced autophagy by activating AMP-activated protein kinase (AMPK), inactivating Akt and ultimately blocking mammalian target of rapamycin (mTOR) activation in the T2DM mice. Cholecalciferol 13-23 AKT serine/threonine kinase 1 Homo sapiens 116-119 33541129-8 2021 Importantly, vitamin D3 treatment induced autophagy by activating AMP-activated protein kinase (AMPK), inactivating Akt and ultimately blocking mammalian target of rapamycin (mTOR) activation in the T2DM mice. Cholecalciferol 13-23 mechanistic target of rapamycin kinase Homo sapiens 144-173 33541129-8 2021 Importantly, vitamin D3 treatment induced autophagy by activating AMP-activated protein kinase (AMPK), inactivating Akt and ultimately blocking mammalian target of rapamycin (mTOR) activation in the T2DM mice. Cholecalciferol 13-23 mechanistic target of rapamycin kinase Homo sapiens 175-179 33541129-10 2021 The results suggested that vitamin D3 may ameliorate hepatic lipid dysregulation by activating autophagy regulatory AMPK/Akt-mTOR signaling in T2DM, providing insights into its beneficial effects on NAFLD in type 2 diabetic patients. Cholecalciferol 27-37 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 116-120 33541129-10 2021 The results suggested that vitamin D3 may ameliorate hepatic lipid dysregulation by activating autophagy regulatory AMPK/Akt-mTOR signaling in T2DM, providing insights into its beneficial effects on NAFLD in type 2 diabetic patients. Cholecalciferol 27-37 AKT serine/threonine kinase 1 Homo sapiens 121-124 33541129-10 2021 The results suggested that vitamin D3 may ameliorate hepatic lipid dysregulation by activating autophagy regulatory AMPK/Akt-mTOR signaling in T2DM, providing insights into its beneficial effects on NAFLD in type 2 diabetic patients. Cholecalciferol 27-37 mechanistic target of rapamycin kinase Homo sapiens 125-129 33548476-13 2021 MMP-2 and MMP-9, two matrix metalloproteinases, were downregulated in cholecalciferol-treated mouse placentae and calcitriol-treated human trophoblast cells. Cholecalciferol 70-85 matrix metallopeptidase 2 Mus musculus 0-5 33548476-13 2021 MMP-2 and MMP-9, two matrix metalloproteinases, were downregulated in cholecalciferol-treated mouse placentae and calcitriol-treated human trophoblast cells. Cholecalciferol 70-85 matrix metallopeptidase 9 Mus musculus 10-15 33985576-6 2021 Decreased expression levels of leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) and the presence of several LGR5-green fluorescent protein (GFP)-positive cells were observed in vitamin D3-treated organoids derived from LGR5-GFP mice. Cholecalciferol 195-205 leucine rich repeat containing G protein coupled receptor 5 Mus musculus 31-90 33985576-6 2021 Decreased expression levels of leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) and the presence of several LGR5-green fluorescent protein (GFP)-positive cells were observed in vitamin D3-treated organoids derived from LGR5-GFP mice. Cholecalciferol 195-205 leucine rich repeat containing G protein coupled receptor 5 Mus musculus 92-96 33985576-6 2021 Decreased expression levels of leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) and the presence of several LGR5-green fluorescent protein (GFP)-positive cells were observed in vitamin D3-treated organoids derived from LGR5-GFP mice. Cholecalciferol 195-205 leucine rich repeat containing G protein coupled receptor 5 Mus musculus 126-130 33985576-6 2021 Decreased expression levels of leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) and the presence of several LGR5-green fluorescent protein (GFP)-positive cells were observed in vitamin D3-treated organoids derived from LGR5-GFP mice. Cholecalciferol 195-205 leucine rich repeat containing G protein coupled receptor 5 Mus musculus 126-130 33985576-8 2021 Furthermore, the expression levels of unfolded protein response genes, C/EBP homologous protein (CHOP), and activating transcription factor 6 (ATF6) were upregulated in vitamin D3-treated organoids. Cholecalciferol 169-179 DNA-damage inducible transcript 3 Mus musculus 71-95 33985576-8 2021 Furthermore, the expression levels of unfolded protein response genes, C/EBP homologous protein (CHOP), and activating transcription factor 6 (ATF6) were upregulated in vitamin D3-treated organoids. Cholecalciferol 169-179 DNA-damage inducible transcript 3 Mus musculus 97-101 33985576-8 2021 Furthermore, the expression levels of unfolded protein response genes, C/EBP homologous protein (CHOP), and activating transcription factor 6 (ATF6) were upregulated in vitamin D3-treated organoids. Cholecalciferol 169-179 activating transcription factor 6 Mus musculus 108-141 33985576-8 2021 Furthermore, the expression levels of unfolded protein response genes, C/EBP homologous protein (CHOP), and activating transcription factor 6 (ATF6) were upregulated in vitamin D3-treated organoids. Cholecalciferol 169-179 activating transcription factor 6 Mus musculus 143-147 33548476-12 2021 N-cadherin and vimentin, two mesenchymal markers, were decreased in cholecalciferol-treated mouse placentae and calcitriol-treated human trophoblast cells. Cholecalciferol 68-83 cadherin 2 Mus musculus 0-10 33548476-12 2021 N-cadherin and vimentin, two mesenchymal markers, were decreased in cholecalciferol-treated mouse placentae and calcitriol-treated human trophoblast cells. Cholecalciferol 68-83 vimentin Mus musculus 15-23 33981701-5 2021 Sirtuin 3 upregulation was detected in high-fat diet-fed mice receiving vitamin D3 compared with that in high-fat diet-fed mice. Cholecalciferol 72-82 sirtuin 3 Mus musculus 0-9 33933463-7 2021 Here we investigated the caspase-9 and 3/7 activity during 1,25-dihydroxycholecalciferol (D3)-mediated differentiation of SH-SY5Y cells and took advantage of the inducible caspase-9 system in putting out the differentiation of the neuroblastoma cells. Cholecalciferol 90-92 caspase 9 Homo sapiens 25-42 33933463-7 2021 Here we investigated the caspase-9 and 3/7 activity during 1,25-dihydroxycholecalciferol (D3)-mediated differentiation of SH-SY5Y cells and took advantage of the inducible caspase-9 system in putting out the differentiation of the neuroblastoma cells. Cholecalciferol 90-92 caspase 9 Homo sapiens 25-34 33838712-4 2021 This study aims to investigate the effect of CPS on expression of CYP27A1, CYP27B1 and CYP24A1, the enzymes involved in synthesis and metabolism of vitamin D3, in human keratinocytes HaCaT and human fibroblasts BJ. Cholecalciferol 148-158 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 66-73 33838712-4 2021 This study aims to investigate the effect of CPS on expression of CYP27A1, CYP27B1 and CYP24A1, the enzymes involved in synthesis and metabolism of vitamin D3, in human keratinocytes HaCaT and human fibroblasts BJ. Cholecalciferol 148-158 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 75-82 33838712-4 2021 This study aims to investigate the effect of CPS on expression of CYP27A1, CYP27B1 and CYP24A1, the enzymes involved in synthesis and metabolism of vitamin D3, in human keratinocytes HaCaT and human fibroblasts BJ. Cholecalciferol 148-158 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 87-94 33753848-1 2021 The transcription factor vitamin D receptor (VDR) is the high affinity nuclear target of the biologically active form of vitamin D3 (1,25(OH)2D3). Cholecalciferol 121-131 vitamin D receptor Homo sapiens 25-43 33718825-5 2021 Using genetic and pharmacological inhibition, we show that the induction of mature IL-1beta is through a non-classical pathway dependent upon caspase-1, caspase-8, the NLRP3 inflammasome, potassium efflux, and autophagy while being independent of TRIF (TICAM1), vitamin D3, and pyroptosis. Cholecalciferol 262-272 interleukin 1 alpha Homo sapiens 83-91 33877707-10 2021 Compared to the control group, high-dose vitamin D3 supplementation resulted in a decreased trabecular number (regression coefficient B: -0.22; p < 0.01) and lower compression stiffness (B: -3.63; p < 0.05, together with an increase in the bone resorption marker CTX (B: 0.062; p < 0.05). Cholecalciferol 41-51 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 263-266 33516786-0 2021 Analysis of vitamin D3 metabolites in survivors of infantile idiopathic hypercalcemia caused by CYP24A1 mutation or SLC34A1 mutation. Cholecalciferol 12-22 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 96-103 33516786-0 2021 Analysis of vitamin D3 metabolites in survivors of infantile idiopathic hypercalcemia caused by CYP24A1 mutation or SLC34A1 mutation. Cholecalciferol 12-22 solute carrier family 34 member 1 Homo sapiens 116-123 33749990-7 2021 The changes in duodenal calcium and phosphate absorption in the iron deficient animals were associated with increased claudin 2 and 3 mRNA and protein levels, while levels of parathyroid hormone, fibroblast growth factor-23 and 1,25-dihydroxy vitamin D3 were unchanged. Cholecalciferol 243-253 fibroblast growth factor 23 Rattus norvegicus 196-229 33878208-8 2021 RESULTS: Treatment with vitamin D3 increased serum 25OHD and upregulated VDR in lung tissues with or without hyperoxia. Cholecalciferol 24-34 vitamin D receptor Rattus norvegicus 73-76 33878208-9 2021 In addition, treatment with vitamin D3 attenuated alveolar simplification, increased VEGF and VEGFR2, and protected alveolar simplification induced by hyperoxia. Cholecalciferol 28-38 vascular endothelial growth factor A Rattus norvegicus 85-89 33878208-9 2021 In addition, treatment with vitamin D3 attenuated alveolar simplification, increased VEGF and VEGFR2, and protected alveolar simplification induced by hyperoxia. Cholecalciferol 28-38 kinase insert domain receptor Rattus norvegicus 94-100 33878208-10 2021 Furthermore, treatment with vitamin D3 resulted in a decrease of IL-1beta and IFN-gamma and an increase of HIF-1alpha in lung tissues under hyperoxia conditions. Cholecalciferol 28-38 interleukin 1 alpha Rattus norvegicus 65-73 33878208-10 2021 Furthermore, treatment with vitamin D3 resulted in a decrease of IL-1beta and IFN-gamma and an increase of HIF-1alpha in lung tissues under hyperoxia conditions. Cholecalciferol 28-38 interferon gamma Rattus norvegicus 78-87 33878208-10 2021 Furthermore, treatment with vitamin D3 resulted in a decrease of IL-1beta and IFN-gamma and an increase of HIF-1alpha in lung tissues under hyperoxia conditions. Cholecalciferol 28-38 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 107-117 33848909-8 2021 In addition to the mentioned formulations, the combination of protein with Vitamin D3 also resulted in significantly higher serum IgA and IFN-gamma levels as compared to the fusion protein alone. Cholecalciferol 75-85 interferon gamma Mus musculus 138-147 32804345-9 2021 CONCLUSION: One-year cholecalciferol supplementation, able to restore D status, significantly improves FG, HbA1c, SBP and HDL-cholesterol levels in patients with poor-controlled type 2 diabetes mellitus and D deficiency. Cholecalciferol 21-36 selenium binding protein 1 Homo sapiens 114-117 33753848-1 2021 The transcription factor vitamin D receptor (VDR) is the high affinity nuclear target of the biologically active form of vitamin D3 (1,25(OH)2D3). Cholecalciferol 121-131 vitamin D receptor Homo sapiens 45-48 32243494-9 2021 In vivo, AAV-mediated overexpression of uromodulin ameliorated vascular calcification in mice with cholecalciferol overload. Cholecalciferol 99-114 uromodulin Homo sapiens 40-50 33618332-0 2021 Cholecalciferol (vitamin D3) has a direct protective activity against interleukin 6-induced atrophy in C2C12 myotubes. Cholecalciferol 0-15 interleukin 6 Mus musculus 70-83 33618332-0 2021 Cholecalciferol (vitamin D3) has a direct protective activity against interleukin 6-induced atrophy in C2C12 myotubes. Cholecalciferol 17-27 interleukin 6 Mus musculus 70-83 32243494-10 2021 Conversely, cholecalciferol overload-induced vascular calcification was aggravated in uromodulin-deficient mice. Cholecalciferol 12-27 uromodulin Mus musculus 86-96 32243494-18 2021 Uromodulin ameliorated vascular calcification in vitro and in mice with cholecalciferol overload, but not during renal failure in mice. Cholecalciferol 72-87 uromodulin Homo sapiens 0-10 33594986-9 2021 Cholecalciferol significantly increased serum levels of 25(OH)D and fetuin-A in the treatment group (p-value < 0.001), while no significant difference was observed in the placebo group. Cholecalciferol 0-15 alpha 2-HS glycoprotein Homo sapiens 68-76 33565715-6 2021 Changes in eGFR were 1.2 mL/min/1.73 m2 (95% CI; -0.7 to 3.1) in the cholecalciferol group and 1.8 mL/min/1.73 m2 (95% CI; -0.02 to 3.7) in the placebo group, with no significant between-group difference (-0.7 mL/min/1.73 m2 [95% CI; -3.3 to 2.0], P = 0.63). Cholecalciferol 69-84 epidermal growth factor receptor Homo sapiens 11-15 33565715-7 2021 Subgroup analyses showed detrimental effects of cholecalciferol in patients with eGFR <45 mL/min/1.73m2 (Pinteraction <0.05, between-group difference; -4.3 mL/min/1.73 m2 [95% CI; -7.3 to -1.3]). Cholecalciferol 48-63 epidermal growth factor receptor Homo sapiens 81-85 33572224-8 2021 Moreover, we found that the extent of CNP uptake by hCMEC/D3 was +43% higher in the presence of Abeta. Cholecalciferol 58-60 amyloid beta precursor protein Homo sapiens 96-101 33594986-12 2021 CONCLUSION: Cholecalciferol was shown to be an effective, tolerable, inexpensive pharmacotherapeutic option to overcome vitamin D deficiency, with a possible modulating effect on fetuin-A, among hemodialysis patients. Cholecalciferol 12-27 alpha 2-HS glycoprotein Homo sapiens 179-187 33597896-11 2021 The evidence of vitamin D3 metabolite retention was assessed by measuring CYP24A1 expression. Cholecalciferol 16-26 cytochrome P450 family 24 subfamily A member 1 Gallus gallus 74-81 33634989-0 2021 Vitamin D3 ameliorates nitrogen mustard-induced cutaneous inflammation by inactivating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway. Cholecalciferol 0-10 NLR family, pyrin domain containing 3 Mus musculus 91-96 33634989-0 2021 Vitamin D3 ameliorates nitrogen mustard-induced cutaneous inflammation by inactivating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway. Cholecalciferol 0-10 sirtuin 3 Mus musculus 122-127 33634989-0 2021 Vitamin D3 ameliorates nitrogen mustard-induced cutaneous inflammation by inactivating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway. Cholecalciferol 0-10 superoxide dismutase 2, mitochondrial Mus musculus 128-132 33709028-12 2021 Pathway enrichment analysis showed that the DEGs were significantly enriched in the retinoate biosynthesis II, signaling pathways regulating pluripotency of stem cells, ALK2 signaling events, vitamin D3 biosynthesis, cell cycle and aurora B signaling. Cholecalciferol 192-202 delta 4-desaturase, sphingolipid 1 Homo sapiens 44-48 33709028-12 2021 Pathway enrichment analysis showed that the DEGs were significantly enriched in the retinoate biosynthesis II, signaling pathways regulating pluripotency of stem cells, ALK2 signaling events, vitamin D3 biosynthesis, cell cycle and aurora B signaling. Cholecalciferol 192-202 aurora kinase B Homo sapiens 232-240 33191899-5 2021 Increased FGF23 secretion leads to hypophosphatemia by (1) reduced phosphate reabsorption via activation of the proximal renal tubular epithelial cells to internalize sodium phosphate cotransporters and (2) reduced activation of vitamin D3 via inhibition of the renal enzyme 1-alpha hydroxylase. Cholecalciferol 229-239 fibroblast growth factor 23 Homo sapiens 10-15 32844292-10 2021 CONCLUSION: Alfacalcidol and native vitamin D3 were equally effective in decreasing PTH levels and increasing serum 25(OH)D3 in pre-dialysis CKD patients. Cholecalciferol 36-46 parathyroid hormone Homo sapiens 84-87 30905309-9 2021 Functional DAF-16 proved to be crucial for the effects of cholecalciferol and DAF-16 nuclear translocation was increased by cholecalciferol and also RNAi versus nhr-8, daf-36, daf-9 or daf-12 with no additive or synergistic effects. Cholecalciferol 58-73 Fork-head domain-containing protein;Forkhead box protein O Caenorhabditis elegans 11-17 30905309-9 2021 Functional DAF-16 proved to be crucial for the effects of cholecalciferol and DAF-16 nuclear translocation was increased by cholecalciferol and also RNAi versus nhr-8, daf-36, daf-9 or daf-12 with no additive or synergistic effects. Cholecalciferol 124-139 Fork-head domain-containing protein;Forkhead box protein O Caenorhabditis elegans 11-17 30905309-9 2021 Functional DAF-16 proved to be crucial for the effects of cholecalciferol and DAF-16 nuclear translocation was increased by cholecalciferol and also RNAi versus nhr-8, daf-36, daf-9 or daf-12 with no additive or synergistic effects. Cholecalciferol 124-139 Fork-head domain-containing protein;Forkhead box protein O Caenorhabditis elegans 78-84 30905309-10 2021 CONCLUSIONS: Our results suggest, that cholecalciferol inhibits Abeta-induced paralysis in C. elegans through inhibition of steroid-signaling and the concomitant nuclear translocation of DAF-16. Cholecalciferol 39-54 Fork-head domain-containing protein;Forkhead box protein O Caenorhabditis elegans 187-193 33443066-0 2021 Vitamin D3-Induced Promotor Dissociation of PU.1 and YY1 Results in FcepsilonRI Reduction on Dendritic Cells in Atopic Dermatitis. Cholecalciferol 0-10 YY1 transcription factor Homo sapiens 53-56 33200827-4 2021 However, it is remains unknown whether NaPi-IIb is the only target for hormonal regulation by 1,25(OH)2 vitamin D3 . Cholecalciferol 104-114 solute carrier family 34 (sodium phosphate), member 2 Mus musculus 39-47 33200827-8 2021 In both groups, 1,25(OH)2 vitamin D3 elicited the expected increase of plasma FGF23 and reduction of PTH. Cholecalciferol 26-36 fibroblast growth factor 23 Mus musculus 78-83 33200827-8 2021 In both groups, 1,25(OH)2 vitamin D3 elicited the expected increase of plasma FGF23 and reduction of PTH. Cholecalciferol 26-36 parathyroid hormone Mus musculus 101-104 33200827-16 2021 In both genotypes, 1,25(OH)2 vitamin D3 induced similar hyperphosphaturic responses and changes in FGF23 and PTH. Cholecalciferol 29-39 fibroblast growth factor 23 Mus musculus 99-104 33200827-16 2021 In both genotypes, 1,25(OH)2 vitamin D3 induced similar hyperphosphaturic responses and changes in FGF23 and PTH. Cholecalciferol 29-39 parathyroid hormone Mus musculus 109-112 32475360-7 2021 In conclusion, vitamin D3 intervention with a treatment dose of 50,000 IU per week for at least 2 months may help in lowering homocysteine and CRP levels and may improve liver function tests, which in turn might help in minimizing the risk of CVD and liver diseases among overweight women but negatively affect kidney function. Cholecalciferol 15-25 C-reactive protein Homo sapiens 143-146 33721248-6 2021 Median of photoconversion to vitamin D3 through the year was higher in LAT3 S [median (IQR): LAT 3 S 4.1% (6.0); LAT 23 S 2.9% (4.5); p value = 0.020]. Cholecalciferol 29-39 solute carrier family 43 member 1 Homo sapiens 71-75 33721248-7 2021 Vitamin D3 production strongly correlated with UV-B (LAT3 S, r = 0.917; p < 0.0001 and at LAT23 S, r = 0.879; p < 0.0001) and SZA (LAT3 S, r = - 0.924; p < 0.0001 and in LAT23 S, r = - 0.808; p < 0.0001). Cholecalciferol 0-10 solute carrier family 43 member 1 Homo sapiens 53-57 33721248-7 2021 Vitamin D3 production strongly correlated with UV-B (LAT3 S, r = 0.917; p < 0.0001 and at LAT23 S, r = 0.879; p < 0.0001) and SZA (LAT3 S, r = - 0.924; p < 0.0001 and in LAT23 S, r = - 0.808; p < 0.0001). Cholecalciferol 0-10 solute carrier family 43 member 1 Homo sapiens 133-137 33188595-9 2021 In fully adjusted models, each 1% higher VDBP was associated with a 0.92%[95% CI(0.37,1.49%)], 0.76% (0.39, 1.13%), and 0.57% (0.29, 0.85%), higher 24,25(OH)2D3, 25(OH)D3, and 1,25(OH)2D3. Cholecalciferol 158-160 GC vitamin D binding protein Homo sapiens 41-45 33107570-1 2021 Previous studies showed that non-calcemic 20(OH)D3, a product of CYP11A1 action on vitamin D3, has antifibrotic activity in human dermal fibroblasts and in a bleomycin mouse model of scleroderma. Cholecalciferol 83-93 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 65-72 33552054-0 2020 Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4+ Cells Towards a Functional Hyporesponsiveness. Cholecalciferol 0-10 CD4 molecule Homo sapiens 88-91 32195696-0 2021 CCL20 mediates the anti-tumor effect of vitamin D3 in p38MAPK/NF-kappaB signaling in colitis-associated carcinogenesis. Cholecalciferol 40-50 chemokine (C-C motif) ligand 20 Mus musculus 0-5 32195696-0 2021 CCL20 mediates the anti-tumor effect of vitamin D3 in p38MAPK/NF-kappaB signaling in colitis-associated carcinogenesis. Cholecalciferol 40-50 mitogen-activated protein kinase 14 Mus musculus 54-61 32195696-3 2021 Here we aim to evaluate whether vitamin D3 plays a protective role in colitis-associated colorectal cancer (CAC) by affecting CCL20 and the molecular mechanism. Cholecalciferol 32-42 chemokine (C-C motif) ligand 20 Mus musculus 126-131 32195696-7 2021 In-vivo and -vitro, vitamin D3 reduced the levels of CCL20, phospho-p38 MAPK (p-p38) and phospho-NF-kappaB p65 (p-p65), and the transcriptional activity of NF-kappaB. Cholecalciferol 20-30 chemokine (C-C motif) ligand 20 Mus musculus 53-58 32195696-7 2021 In-vivo and -vitro, vitamin D3 reduced the levels of CCL20, phospho-p38 MAPK (p-p38) and phospho-NF-kappaB p65 (p-p65), and the transcriptional activity of NF-kappaB. Cholecalciferol 20-30 lymphocyte cytosolic protein 1 Mus musculus 89-110 32195696-7 2021 In-vivo and -vitro, vitamin D3 reduced the levels of CCL20, phospho-p38 MAPK (p-p38) and phospho-NF-kappaB p65 (p-p65), and the transcriptional activity of NF-kappaB. Cholecalciferol 20-30 lymphocyte cytosolic protein 1 Mus musculus 112-117 32195696-8 2021 Further studies showed that CCL20 mediated the inhibition of vitamin D3 in p38MAPK-mediated NF-kappaB signaling in vitro. Cholecalciferol 61-71 chemokine (C-C motif) ligand 20 Mus musculus 28-33 32195696-8 2021 Further studies showed that CCL20 mediated the inhibition of vitamin D3 in p38MAPK-mediated NF-kappaB signaling in vitro. Cholecalciferol 61-71 mitogen-activated protein kinase 14 Mus musculus 75-82 32195696-10 2021 Downregulation of CCL20 may contribute to the preventive effect of vitamin D3 on NF-kappaB activity. Cholecalciferol 67-77 chemokine (C-C motif) ligand 20 Mus musculus 18-23 32965596-14 2021 Low serum vitamin D3 level negatively associated with increased IL-9 and TLR2 expression and disease severity in RA patients. Cholecalciferol 10-20 interleukin 9 Homo sapiens 64-68 33540416-0 2021 Vitamin D3 Controls TLR4- and TLR2-Mediated Inflammatory Responses of Endometrial Cells. Cholecalciferol 0-10 toll like receptor 4 Homo sapiens 20-24 33540416-0 2021 Vitamin D3 Controls TLR4- and TLR2-Mediated Inflammatory Responses of Endometrial Cells. Cholecalciferol 0-10 toll like receptor 2 Homo sapiens 30-34 33162070-1 2021 Objectives of the experiment were to determine the length of exposure to an acidogenic diet that would elicit changes in acid-base balance, mineral digestion, and response to parathyroid hormone (PTH)-induced changes in blood Ca and vitamin D3 in prepartum dairy cows. Cholecalciferol 233-243 parathyroid hormone Bos taurus 175-194 33162070-1 2021 Objectives of the experiment were to determine the length of exposure to an acidogenic diet that would elicit changes in acid-base balance, mineral digestion, and response to parathyroid hormone (PTH)-induced changes in blood Ca and vitamin D3 in prepartum dairy cows. Cholecalciferol 233-243 parathyroid hormone Bos taurus 196-199 32474936-8 2021 RESULTS: The vitamin D3 -induced increase of osteocalcin and osteopontin expression was significantly decreased in the presence of standard PgLPS and Pam3CSK4, which was not observed by ultrapure PgLPS. Cholecalciferol 13-23 bone gamma-carboxyglutamate protein Homo sapiens 45-56 32474936-8 2021 RESULTS: The vitamin D3 -induced increase of osteocalcin and osteopontin expression was significantly decreased in the presence of standard PgLPS and Pam3CSK4, which was not observed by ultrapure PgLPS. Cholecalciferol 13-23 secreted phosphoprotein 1 Homo sapiens 61-72 32474936-11 2021 Standard PgLPS and Pam3CSK4 increased VDR expression in the presence of vitamin D3 . Cholecalciferol 72-82 vitamin D receptor Homo sapiens 38-41 32474936-13 2021 CONCLUSIONS: This study indicates that the transcriptional activity of VDR is diminished under inflammatory conditions, which might mitigate the effectiveness of vitamin D3 supplementation during periodontal treatment. Cholecalciferol 162-172 vitamin D receptor Homo sapiens 71-74 33210462-6 2021 Compared with wild-type mice, miR155-/- mice showed significant resistance to vitamin D3 induced vascular calcification. Cholecalciferol 78-88 microRNA 155 Mus musculus 30-36 33210462-7 2021 Protein analysis showed that miR155 deficiency alleviated the reduction of Rictor, increased phosphorylation of Akt at S473 and accelerated phosphorylation and degradation of FOXO3a in cultured VSMCs and in the aortas of vitamin D3-treated mice. Cholecalciferol 221-231 microRNA 155 Mus musculus 29-35 33210462-7 2021 Protein analysis showed that miR155 deficiency alleviated the reduction of Rictor, increased phosphorylation of Akt at S473 and accelerated phosphorylation and degradation of FOXO3a in cultured VSMCs and in the aortas of vitamin D3-treated mice. Cholecalciferol 221-231 forkhead box O3 Mus musculus 175-181 32965596-14 2021 Low serum vitamin D3 level negatively associated with increased IL-9 and TLR2 expression and disease severity in RA patients. Cholecalciferol 10-20 toll like receptor 2 Homo sapiens 73-77 32829183-1 2020 Vitamin D3 is the precursor of the steroid hormone calcitriol (1alpha,25-dihydroxyvitamin D3), a potent agonist of the transcription factor vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 140-158 33626316-4 2021 Overall, CYP2R1 structure adopts a closed conformation with the B" helix serving as a gate covering the substrate access channel, with the substrate vitamin D3 occupying a position with the side chain pointing toward the heme group. Cholecalciferol 149-159 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 9-15 33069738-9 2020 Female T1D mice treated with vitamin D3, insulin, or vitamin D3 plus insulin presented an increased expression of insulin growth factor-1 (IGF-1) mRNA. Cholecalciferol 29-39 insulin-like growth factor 1 Mus musculus 114-137 33069738-9 2020 Female T1D mice treated with vitamin D3, insulin, or vitamin D3 plus insulin presented an increased expression of insulin growth factor-1 (IGF-1) mRNA. Cholecalciferol 29-39 insulin-like growth factor 1 Mus musculus 139-144 33069738-9 2020 Female T1D mice treated with vitamin D3, insulin, or vitamin D3 plus insulin presented an increased expression of insulin growth factor-1 (IGF-1) mRNA. Cholecalciferol 53-63 insulin-like growth factor 1 Mus musculus 114-137 33069738-9 2020 Female T1D mice treated with vitamin D3, insulin, or vitamin D3 plus insulin presented an increased expression of insulin growth factor-1 (IGF-1) mRNA. Cholecalciferol 53-63 insulin-like growth factor 1 Mus musculus 139-144 33457118-0 2020 Effect of Vitamin D3 Supplementation on Insulin Sensitivity in Prediabetes With Hypovitaminosis D: A Randomized Placebo-Controlled Trial. Cholecalciferol 10-20 insulin Homo sapiens 40-47 33341312-0 2021 A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease. Cholecalciferol 67-82 insulin Homo sapiens 109-116 33288743-1 2020 The bioactive vitamin D3, 1alpha,25(OH)2D3, plays a central role in calcium homeostasis by controlling the activity of the vitamin D receptor (VDR) in various tissues. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 123-141 33288743-1 2020 The bioactive vitamin D3, 1alpha,25(OH)2D3, plays a central role in calcium homeostasis by controlling the activity of the vitamin D receptor (VDR) in various tissues. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 143-146 32906066-7 2021 Moreover, both MUB and UB exhibited improved encapsulation functionality to protect cholecalciferol (vitamin D3) from UV degradation compared to the original pectin. Cholecalciferol 84-99 ubiquitin like 3 Homo sapiens 15-18 32906066-7 2021 Moreover, both MUB and UB exhibited improved encapsulation functionality to protect cholecalciferol (vitamin D3) from UV degradation compared to the original pectin. Cholecalciferol 101-111 ubiquitin like 3 Homo sapiens 15-18 33368331-0 2021 Vitamin D3-elicited CD14+ human skin dendritic cells promote thymic stromal lymphopoietin-independent type 2 T-helper responses. Cholecalciferol 0-10 CD14 molecule Homo sapiens 20-24 33368331-0 2021 Vitamin D3-elicited CD14+ human skin dendritic cells promote thymic stromal lymphopoietin-independent type 2 T-helper responses. Cholecalciferol 0-10 thymic stromal lymphopoietin Mus musculus 61-89 33368331-8 2021 RESULTS: Vitamin D3 induced skin DCs to differentiate Th2 cells producing IL-4 and IL-13. Cholecalciferol 9-19 interleukin 4 Homo sapiens 74-78 33368331-8 2021 RESULTS: Vitamin D3 induced skin DCs to differentiate Th2 cells producing IL-4 and IL-13. Cholecalciferol 9-19 interleukin 13 Homo sapiens 83-88 33368331-9 2021 Vitamin D3 triggered TSLP release in ~30% of skin explants, correlating with IL-13 detection in Th2 cells. Cholecalciferol 0-10 thymic stromal lymphopoietin Homo sapiens 21-25 33368331-9 2021 Vitamin D3 triggered TSLP release in ~30% of skin explants, correlating with IL-13 detection in Th2 cells. Cholecalciferol 0-10 interleukin 13 Homo sapiens 77-82 33368331-11 2021 Among skin DCs emerged CD14+ cells that had responded directly to vitamin D3 and differed from classical CD14+ dermal emigrants. Cholecalciferol 66-76 CD14 molecule Homo sapiens 23-27 33368331-12 2021 Vitamin D3-elicited CD14+ DCs sufficed to promote IL-4+ Th2 cells in a TSLP-independent manner. Cholecalciferol 0-10 CD14 molecule Homo sapiens 20-24 33368331-12 2021 Vitamin D3-elicited CD14+ DCs sufficed to promote IL-4+ Th2 cells in a TSLP-independent manner. Cholecalciferol 0-10 interleukin 4 Homo sapiens 50-54 33368331-12 2021 Vitamin D3-elicited CD14+ DCs sufficed to promote IL-4+ Th2 cells in a TSLP-independent manner. Cholecalciferol 0-10 thymic stromal lymphopoietin Homo sapiens 71-75 33368331-13 2021 CONCLUSION: Vitamin D3, despite inducing TSLP in some donors, had a direct influence on skin DCs, affecting their phenotype and ability to drive Th2 responses independently of TSLP. Cholecalciferol 12-22 thymic stromal lymphopoietin Homo sapiens 41-45 32829183-1 2020 Vitamin D3 is the precursor of the steroid hormone calcitriol (1alpha,25-dihydroxyvitamin D3), a potent agonist of the transcription factor vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 160-163 33147594-1 2021 INTRODUCTION: This study was conducted to evaluate the effect of short-term sunlight exposure on blood pressure (BP) and pulse rate (PR) in vitamin D3-insufficient, prehypertensive patients. Cholecalciferol 140-150 transmembrane protein 37 Homo sapiens 133-135 33262439-3 2020 We investigated the effects of vitamin D3 (Vit D) and erythropoietin (EPO) on microRNA-21(miR-21) expression in renal IR. Cholecalciferol 31-41 microRNA 21 Rattus norvegicus 78-89 33262439-9 2020 Treatment with vitamin D3 and EPO significantly decreased the BUN-Cr levels and hsp70 and caspase-3 expression. Cholecalciferol 15-25 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 80-85 33262439-9 2020 Treatment with vitamin D3 and EPO significantly decreased the BUN-Cr levels and hsp70 and caspase-3 expression. Cholecalciferol 15-25 caspase 3 Rattus norvegicus 90-99 33246442-5 2020 It has also been reported that vitamin D3 treatment enhances dysferlin expression. Cholecalciferol 31-41 dysferlin Mus musculus 61-70 33238436-1 2020 The compound 1alpha,25-Dihydroxyvitamin D3 (1,25(OH)2D3) is the active form of vitamin D3 and a representative ligand of the vitamin D receptor (VDR). Cholecalciferol 32-42 vitamin D receptor Rattus norvegicus 125-143 33238436-1 2020 The compound 1alpha,25-Dihydroxyvitamin D3 (1,25(OH)2D3) is the active form of vitamin D3 and a representative ligand of the vitamin D receptor (VDR). Cholecalciferol 32-42 vitamin D receptor Rattus norvegicus 145-148 33198232-1 2020 Background and objective: The aim of the present study was to establish a new differentiation protocol using cannabidiol (CBD) and vitamin D3 (Vit. Cholecalciferol 131-141 vitrin Homo sapiens 143-146 33262439-0 2020 Vitamin D3 and erythropoietin protect against renal ischemia-reperfusion injury via heat shock protein 70 and microRNA-21 expression. Cholecalciferol 0-10 heat shock protein family A (Hsp70) member 1B Rattus norvegicus 84-105 33262439-0 2020 Vitamin D3 and erythropoietin protect against renal ischemia-reperfusion injury via heat shock protein 70 and microRNA-21 expression. Cholecalciferol 0-10 microRNA 21 Rattus norvegicus 110-121 33184146-14 2022 Fibrinogen levels significantly decreased with cholecalciferol supplementation (intergroup difference 0.70 ng/ml; P=0.007) unlike other inflammatory biomarkers. Cholecalciferol 47-62 fibrinogen beta chain Homo sapiens 0-10 33184146-15 2022 CONCLUSION: Greater proportion of vitamin D-deficient individuals with SARS-CoV-2 infection turned SARS-CoV-2 RNA negative with a significant decrease in fibrinogen on high-dose cholecalciferol supplementation. Cholecalciferol 178-193 fibrinogen beta chain Homo sapiens 154-164 33126474-6 2020 We demonstrated that 1alpha,25(OH)2 vitamin D3 acts via vitamin D receptor in GL15 cells and via neutral sphingomyelinase1, with an enrichment of ceramide pool, in U251 and LN18 cells. Cholecalciferol 36-46 vitamin D receptor Homo sapiens 56-74 33305262-11 2020 In contrast, altered transcription of genes from cholinergic, monoaminergic, and peptidergic neurotransmission, steroid sulfation and production as well as vitamin D3 activation was the main CYP46A1-independent efavirenz effect. Cholecalciferol 156-166 cytochrome P450, family 46, subfamily a, polypeptide 1 Mus musculus 191-198 32883565-0 2020 Immunomodulatory effects of vitamin D3 on gene expression of MDGF, EGF and PDGFB in endometriosis. Cholecalciferol 28-38 pro-platelet basic protein Homo sapiens 61-65 32883565-0 2020 Immunomodulatory effects of vitamin D3 on gene expression of MDGF, EGF and PDGFB in endometriosis. Cholecalciferol 28-38 epidermal growth factor Homo sapiens 67-70 32883565-0 2020 Immunomodulatory effects of vitamin D3 on gene expression of MDGF, EGF and PDGFB in endometriosis. Cholecalciferol 28-38 platelet derived growth factor subunit B Homo sapiens 75-80 32883565-2 2020 Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis. Cholecalciferol 47-57 platelet derived growth factor subunit B Homo sapiens 188-220 32883565-2 2020 Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis. Cholecalciferol 47-57 platelet derived growth factor subunit B Homo sapiens 222-227 32883565-2 2020 Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis. Cholecalciferol 47-57 pro-platelet basic protein Homo sapiens 230-271 32883565-2 2020 Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis. Cholecalciferol 47-57 pro-platelet basic protein Homo sapiens 273-277 32883565-2 2020 Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis. Cholecalciferol 47-57 pro-platelet basic protein Homo sapiens 293-297 32883565-2 2020 Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis. Cholecalciferol 47-57 epidermal growth factor Homo sapiens 303-326 32883565-2 2020 Based on the emerging immunomodulatory role of vitamin D3 in different inflammatory conditions, this study aimed to examine its modulatory effect on the expression levels of the genes for platelet-derived growth factor-B (PDGFB), monocyte/macrophage-derived growth factor (MDGF, also known as PPBP) and epidermal growth factor (EGF) in peritoneal fluid mononuclear cells (PFMC) in women with and without endometriosis. Cholecalciferol 47-57 epidermal growth factor Homo sapiens 328-331 32883565-6 2020 Vitamin D3 significantly decreased EGF expression at 6, 24 and 48 h (P < 0.001, P < 0.001 and P = 0.007, respectively), MDGF at 24 and 48 h (P < 0.001 and P = 0.009, respectively) and PDGFB at 6 h (P = 0.047) in the endometriosis group. Cholecalciferol 0-10 epidermal growth factor Homo sapiens 35-38 32883565-6 2020 Vitamin D3 significantly decreased EGF expression at 6, 24 and 48 h (P < 0.001, P < 0.001 and P = 0.007, respectively), MDGF at 24 and 48 h (P < 0.001 and P = 0.009, respectively) and PDGFB at 6 h (P = 0.047) in the endometriosis group. Cholecalciferol 0-10 pro-platelet basic protein Homo sapiens 120-124 32883565-6 2020 Vitamin D3 significantly decreased EGF expression at 6, 24 and 48 h (P < 0.001, P < 0.001 and P = 0.007, respectively), MDGF at 24 and 48 h (P < 0.001 and P = 0.009, respectively) and PDGFB at 6 h (P = 0.047) in the endometriosis group. Cholecalciferol 0-10 platelet derived growth factor subunit B Homo sapiens 184-189 33108744-0 2021 Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: Role of AMPK/SIRT1 activation and DPP-4 inhibition. Cholecalciferol 0-10 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 111-115 33108744-0 2021 Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: Role of AMPK/SIRT1 activation and DPP-4 inhibition. Cholecalciferol 0-10 sirtuin 1 Rattus norvegicus 116-121 33009959-7 2020 Oral over-the-counter (OTC) vitamin D3 and calcium citrate were prescribed to increase subjects" serum 25(OH)D to levels between 40 and 50 ng/ml, serum calcium levels above 9.2 mg/dl, and PTH levels below 60 pg/ml, which were confirmed at 6 and 12 weeks. Cholecalciferol 28-38 parathyroid hormone Homo sapiens 188-191 33107041-9 2021 RESULTS: Vitamin D3 significantly enhanced the generation of hCAP-18/LL-37. Cholecalciferol 9-19 cathelicidin antimicrobial peptide Homo sapiens 61-68 33107041-9 2021 RESULTS: Vitamin D3 significantly enhanced the generation of hCAP-18/LL-37. Cholecalciferol 9-19 cathelicidin antimicrobial peptide Homo sapiens 69-74 33107041-10 2021 A combination of Pg-LPS and vitamin D3 significantly promoted hCAP-18/LL-37 expression. Cholecalciferol 28-38 cathelicidin antimicrobial peptide Homo sapiens 62-69 33107041-10 2021 A combination of Pg-LPS and vitamin D3 significantly promoted hCAP-18/LL-37 expression. Cholecalciferol 28-38 cathelicidin antimicrobial peptide Homo sapiens 70-75 33107041-13 2021 CONCLUSION: The vitamin D pathway from vitamin D3 to hCAP-18/LL-37 exists in hPDLCs, and CYP27A1 might be involved in periodontal immune defense. Cholecalciferol 39-49 cathelicidin antimicrobial peptide Homo sapiens 53-60 33107041-13 2021 CONCLUSION: The vitamin D pathway from vitamin D3 to hCAP-18/LL-37 exists in hPDLCs, and CYP27A1 might be involved in periodontal immune defense. Cholecalciferol 39-49 cathelicidin antimicrobial peptide Homo sapiens 61-66 33194806-0 2020 Vitamin D3 Inhibits Helicobacter pylori Infection by Activating the VitD3/VDR-CAMP Pathway in Mice. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 74-77 31971486-3 2020 We found that the major enzyme responsible for 1,25-Vitamin D3 synthesis, the 1-hydoxylase CYP27B1 (3,6-fold for OVA IP and 2,7-fold for OVA IP + EC), the vitamin D receptor (not altered) and the sensitive Vitamin D-mediated signalling target gene CYP24A1 (65-fold in OVA IP and 726-fold in OVA IP + EC) are upregulated after systemic and systemic plus topical allergic sensitization (OVA IP + EC). Cholecalciferol 47-62 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 91-98 32564464-0 2020 Intestinal epithelial ablation of Pit-2/Slc20a2 in mice leads to sustained elevation of vitamin D3 upon dietary restriction of phosphate. Cholecalciferol 88-98 solute carrier family 20, member 2 Mus musculus 34-39 32564464-0 2020 Intestinal epithelial ablation of Pit-2/Slc20a2 in mice leads to sustained elevation of vitamin D3 upon dietary restriction of phosphate. Cholecalciferol 88-98 solute carrier family 20, member 2 Mus musculus 40-47 32564464-11 2020 However, in response to dietary phosphate restriction, Pit-2 deficient mice showed exacerbated hypercalciuria and sustained elevation of 1,25(OH)2 vitamin D3 . Cholecalciferol 147-157 solute carrier family 20, member 2 Mus musculus 55-60 31971486-3 2020 We found that the major enzyme responsible for 1,25-Vitamin D3 synthesis, the 1-hydoxylase CYP27B1 (3,6-fold for OVA IP and 2,7-fold for OVA IP + EC), the vitamin D receptor (not altered) and the sensitive Vitamin D-mediated signalling target gene CYP24A1 (65-fold in OVA IP and 726-fold in OVA IP + EC) are upregulated after systemic and systemic plus topical allergic sensitization (OVA IP + EC). Cholecalciferol 47-62 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 155-173 32784046-4 2020 Cyp27b1+/- mice were generated to develop a model of active vitamin D3 deficiency. Cholecalciferol 60-70 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 0-7 33585324-8 2020 However, serum PTH was high with slightly decreased Vitamin D3. Cholecalciferol 52-62 parathyroid hormone Homo sapiens 15-18 32936248-2 2020 The aim of this study was to investigate the effect of vitamin D deficiency on AAA development and examine if administering cholecalciferol (CCF) could limit growth of established AAA within the angiotensin-II (AngII) infused apolipoprotein E-deficient mouse model. Cholecalciferol 124-139 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 195-209 32593863-7 2020 The concentrations of pro-inflammatory cytokines (i.e., IL-1beta, IL-6, and TNF-alpha) and the chemokine (IL-8) showed a significant decrease in the treatment group while the concentration of IL-10 increased in the treatment groups following the vitamin D3 injection (P = .001). Cholecalciferol 246-256 interleukin-10 Bos taurus 192-197 32593863-8 2020 The evidence from the current study suggests that vitamin D3 exert the immunomodulatory effects in infectious diseases through the regulation of cytokines and activation of VDR pathways to produce antimicrobial peptides. Cholecalciferol 50-60 vitamin D receptor Bos taurus 173-176 32936248-2 2020 The aim of this study was to investigate the effect of vitamin D deficiency on AAA development and examine if administering cholecalciferol (CCF) could limit growth of established AAA within the angiotensin-II (AngII) infused apolipoprotein E-deficient mouse model. Cholecalciferol 124-139 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 211-216 32936248-2 2020 The aim of this study was to investigate the effect of vitamin D deficiency on AAA development and examine if administering cholecalciferol (CCF) could limit growth of established AAA within the angiotensin-II (AngII) infused apolipoprotein E-deficient mouse model. Cholecalciferol 141-144 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 195-209 32936248-2 2020 The aim of this study was to investigate the effect of vitamin D deficiency on AAA development and examine if administering cholecalciferol (CCF) could limit growth of established AAA within the angiotensin-II (AngII) infused apolipoprotein E-deficient mouse model. Cholecalciferol 141-144 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 211-216 32968158-0 2020 Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial. Cholecalciferol 10-25 hepcidin antimicrobial peptide Homo sapiens 35-43 32968158-1 2020 In this multicentre double-blind randomized clinical trial, we investigated the effects of oral cholecalciferol supplementation on serum hepcidin and parameters related to anaemia and CKD-MBD among haemodialysis patients. Cholecalciferol 96-111 hepcidin antimicrobial peptide Homo sapiens 137-145 32968158-5 2020 After adjustment for baseline values, serum hepcidin levels were higher at Day 3 in the combined cholecalciferol (vs. placebo) group, but were lower at Month 6 with increased erythropoietin resistance. Cholecalciferol 97-112 hepcidin antimicrobial peptide Homo sapiens 44-52 32968158-7 2020 Cholecalciferol also suppressed intact PTH only among patients with severe vitamin D deficiency. Cholecalciferol 0-15 parathyroid hormone Homo sapiens 39-42 32968158-8 2020 In conclusion, cholecalciferol supplementation increases serum hepcidin-25 levels in the short term and may increase erythropoietin resistance in the long term among haemodialysis patients. Cholecalciferol 15-30 erythropoietin Homo sapiens 117-131 32468622-7 2020 Instrumental limits of detection are 30 ng L-1 for testosterone using ESI and 1 mug L-1 for vitamin D3 using APCI. Cholecalciferol 92-102 L1 cell adhesion molecule Homo sapiens 84-87 33066859-8 2020 CONCLUSION: The intake of vitamin D3 did not change the quality and quantity of spermograms and serum levels of LH, FSH, TT, and FAI but affected FT and SHBG. Cholecalciferol 26-36 sex hormone binding globulin Homo sapiens 153-157 32768933-0 2020 Ziziphora clinopodioides flavonoids based on network pharmacology attenuates atherosclerosis in rats induced by high-fat emulsion combined with vitamin D3 by down-regulating VEGF/AKT/NF-kappaB signaling pathway. Cholecalciferol 144-154 vascular endothelial growth factor A Rattus norvegicus 174-178 32768933-0 2020 Ziziphora clinopodioides flavonoids based on network pharmacology attenuates atherosclerosis in rats induced by high-fat emulsion combined with vitamin D3 by down-regulating VEGF/AKT/NF-kappaB signaling pathway. Cholecalciferol 144-154 AKT serine/threonine kinase 1 Rattus norvegicus 179-182 32622071-12 2020 In conclusion, twelve months supplementation of vitamin D3 increased serum DLK1. Cholecalciferol 48-58 delta like non-canonical Notch ligand 1 Homo sapiens 75-79 32740169-3 2020 Linear regression was used to analyze whether the effect of vitamin D3 supplementation on response variables was associated with the selected VDR single nucleotide polymorphisms executing by "association" function in the R package "SNPassoc". Cholecalciferol 60-70 vitamin D receptor Homo sapiens 142-145 32344004-1 2020 Mutations in CYP2R1 and CYP27A1 involved in the conversion of Cholecalciferol into Calcidiol were associated with the impaired 25-hydroxylase activity therefore affecting the Vitamin D metabolism. Cholecalciferol 62-77 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 13-19 32344004-1 2020 Mutations in CYP2R1 and CYP27A1 involved in the conversion of Cholecalciferol into Calcidiol were associated with the impaired 25-hydroxylase activity therefore affecting the Vitamin D metabolism. Cholecalciferol 62-77 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 24-31 32048305-4 2020 Vitamin D3 applies its effect via the mitogen-activated pathway kinase-extracellular signal-regulated kinases (MAPK-ERK1/2) pathway. Cholecalciferol 0-10 mitogen-activated protein kinase 3 Mus musculus 116-122 33000618-0 2020 Vitamin D3 deficiency is associated with more severe insulin resistance and metformin use in patients with type 2 diabetes. Cholecalciferol 0-10 insulin Homo sapiens 53-60 32936063-1 2020 Background: Significant inverse correlations between circulating vitamin D3 and the presence and strength of common clinical entities influenced by insulin resistance (IR) have been reported. Cholecalciferol 65-75 insulin Homo sapiens 148-155 33000618-1 2020 BACKGROUND: Vitamin D3 (vit. Cholecalciferol 12-22 vitrin Homo sapiens 24-27 32585162-0 2020 Cholecalciferol abolishes depressive-like behavior and hippocampal glucocorticoid receptor impairment induced by chronic corticosterone administration in mice. Cholecalciferol 0-15 nuclear receptor subfamily 3, group C, member 1 Mus musculus 67-90 32585162-10 2020 Additionally, cholecalciferol treatment per se reduced the immunocontent of NLRP3 inflammasome-related proteins ASC, caspase-1, and TXNIP in the hippocampus of mice. Cholecalciferol 14-29 NLR family, pyrin domain containing 3 Mus musculus 76-81 32585162-10 2020 Additionally, cholecalciferol treatment per se reduced the immunocontent of NLRP3 inflammasome-related proteins ASC, caspase-1, and TXNIP in the hippocampus of mice. Cholecalciferol 14-29 steroid sulfatase Mus musculus 112-115 32585162-10 2020 Additionally, cholecalciferol treatment per se reduced the immunocontent of NLRP3 inflammasome-related proteins ASC, caspase-1, and TXNIP in the hippocampus of mice. Cholecalciferol 14-29 caspase 1 Mus musculus 117-126 32585162-10 2020 Additionally, cholecalciferol treatment per se reduced the immunocontent of NLRP3 inflammasome-related proteins ASC, caspase-1, and TXNIP in the hippocampus of mice. Cholecalciferol 14-29 thioredoxin interacting protein Mus musculus 132-137 32905226-0 2020 Erratum to: Pharmaceutic application of vitamin D3 on particle-induced fibrotic effects through induction of Nrf2 signals. Cholecalciferol 40-50 NFE2 like bZIP transcription factor 2 Homo sapiens 109-113 32878208-2 2020 To investigate the role of mast cells (MCs) and MC-specific proteases on the immunopathogenesis of AD, a vitamin D3-analog (MC903) was used to induce clinical AD-like symptoms in c-kit-dependent MC-deficient Wsh-/- and the MC protease-deficient mMCP-4-/-, mMCP-6-/-, and CPA3-/- mouse strains. Cholecalciferol 105-115 KIT proto-oncogene receptor tyrosine kinase Mus musculus 179-184 32702412-5 2020 RESULTS: Hdac9 expression was significantly down-regulated during high phosphate-induced vascular smooth muscle cell (VSMC) calcification and MAC in mice administered with vitamin D3 (vD). Cholecalciferol 172-182 histone deacetylase 9 Mus musculus 9-14 32831908-0 2020 Effect of supplementation with vitamins D3 and K2 on undercarboxylated osteocalcin and insulin serum levels in patients with type 2 diabetes mellitus: a randomized, double-blind, clinical trial. Cholecalciferol 40-42 bone gamma-carboxyglutamate protein Homo sapiens 71-82 32831908-0 2020 Effect of supplementation with vitamins D3 and K2 on undercarboxylated osteocalcin and insulin serum levels in patients with type 2 diabetes mellitus: a randomized, double-blind, clinical trial. Cholecalciferol 40-42 insulin Homo sapiens 87-94 32831908-2 2020 The objective of this study was to evaluate the effect of vitamin D3 and vitamin K2 supplements alone or in combination on osteocalcin levels and metabolic parameters in patients with T2DM. Cholecalciferol 58-68 bone gamma-carboxyglutamate protein Homo sapiens 123-134 32831908-10 2020 Only in the group with vitamin D3 supplementation, it was observed a reduction in undercarboxylated osteocalcin while vitamin K2 increased the carboxylated osteocalcin levels.Trial registration NCT04041492. Cholecalciferol 23-33 bone gamma-carboxyglutamate protein Homo sapiens 100-111 32831908-10 2020 Only in the group with vitamin D3 supplementation, it was observed a reduction in undercarboxylated osteocalcin while vitamin K2 increased the carboxylated osteocalcin levels.Trial registration NCT04041492. Cholecalciferol 23-33 bone gamma-carboxyglutamate protein Homo sapiens 156-167 32809289-3 2020 We herein report our experience on the impact of cholecalciferol supplementation on PTH and 25(OH)D levels in a group of RTRs with 25(OH)D <30 ng/mL and SHPT. Cholecalciferol 49-64 parathyroid hormone Homo sapiens 84-87 32447000-0 2020 CYP11A1-derived vitamin D3 products protect against UVB-induced inflammation and promote keratinocytes differentiation. Cholecalciferol 16-26 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 0-7 32742408-0 2020 Vitamin D3 protects articular cartilage by inhibiting the Wnt/beta-catenin signaling pathway. Cholecalciferol 0-10 Wnt family member 3A Homo sapiens 58-61 32742408-0 2020 Vitamin D3 protects articular cartilage by inhibiting the Wnt/beta-catenin signaling pathway. Cholecalciferol 0-10 catenin beta 1 Homo sapiens 62-74 32742408-7 2020 Furthermore, vitamin D3 and PNU-74654 were observed to partially attenuate the effects induced by TNF-alpha. Cholecalciferol 13-23 tumor necrosis factor Homo sapiens 98-107 32742408-9 2020 Western blotting data revealed that TNF-alpha increased Wnt-3a and beta-catenin protein levels in chondrocytes, while Vitamin D3 and PNU-74654 decreased the expression levels of Wnt-3a and nuclear beta-catenin. Cholecalciferol 118-128 Wnt family member 3A Homo sapiens 178-184 32742408-9 2020 Western blotting data revealed that TNF-alpha increased Wnt-3a and beta-catenin protein levels in chondrocytes, while Vitamin D3 and PNU-74654 decreased the expression levels of Wnt-3a and nuclear beta-catenin. Cholecalciferol 118-128 catenin beta 1 Homo sapiens 197-209 32742408-10 2020 In conclusion, the findings of the present study provided evidence to suggest that vitamin D3 may prevent articular cartilage degeneration and osteoarthritic disease progression by inhibiting the expression levels of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 through suppressing the Wnt/beta-catenin signaling pathway. Cholecalciferol 83-93 matrix metallopeptidase 3 Homo sapiens 217-222 32742408-10 2020 In conclusion, the findings of the present study provided evidence to suggest that vitamin D3 may prevent articular cartilage degeneration and osteoarthritic disease progression by inhibiting the expression levels of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 through suppressing the Wnt/beta-catenin signaling pathway. Cholecalciferol 83-93 matrix metallopeptidase 13 Homo sapiens 224-230 32742408-10 2020 In conclusion, the findings of the present study provided evidence to suggest that vitamin D3 may prevent articular cartilage degeneration and osteoarthritic disease progression by inhibiting the expression levels of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 through suppressing the Wnt/beta-catenin signaling pathway. Cholecalciferol 83-93 ADAM metallopeptidase with thrombospondin type 1 motif 4 Homo sapiens 232-240 32742408-10 2020 In conclusion, the findings of the present study provided evidence to suggest that vitamin D3 may prevent articular cartilage degeneration and osteoarthritic disease progression by inhibiting the expression levels of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 through suppressing the Wnt/beta-catenin signaling pathway. Cholecalciferol 83-93 ADAM metallopeptidase with thrombospondin type 1 motif 5 Homo sapiens 245-253 32742408-10 2020 In conclusion, the findings of the present study provided evidence to suggest that vitamin D3 may prevent articular cartilage degeneration and osteoarthritic disease progression by inhibiting the expression levels of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 through suppressing the Wnt/beta-catenin signaling pathway. Cholecalciferol 83-93 Wnt family member 3A Homo sapiens 278-281 32742408-10 2020 In conclusion, the findings of the present study provided evidence to suggest that vitamin D3 may prevent articular cartilage degeneration and osteoarthritic disease progression by inhibiting the expression levels of MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 through suppressing the Wnt/beta-catenin signaling pathway. Cholecalciferol 83-93 catenin beta 1 Homo sapiens 282-294 32447000-4 2020 Since the protective effect of 1,25(OH)2D3 against UVB-induced skin damage and inflammation is recognized, CYP11A1-derived vitamin D3-hydroxyderivatives including 20(OH)D3, 1,20(OH)2D3, 20,23(OH)2D3 and 1,20,23(OH)3D3 were tested for their anti-inflammatory and skin protection properties in UVB-irradiated human epidermal keratinocytes (HEKn). Cholecalciferol 123-133 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 107-114 32722164-9 2020 Therefore, this hypothesis paper describes the use of flavonoid supplements combined with vitamin D3 to activate Nrf2, which may be a potential target to prevent and/or decrease SARS-CoV-2 infection severity, reducing oxidative stress and inflammation, enhancing innate immunity, and downregulating ACE2 receptors. Cholecalciferol 90-100 NFE2 like bZIP transcription factor 2 Homo sapiens 113-117 32583974-9 2020 CONCLUSION: In conclusion, SR-B1 plays a critical role in vitamin D3 biology, paving the way for novel therapeutic interventions. Cholecalciferol 58-68 scavenger receptor class B member 1 Homo sapiens 27-32 32760818-7 2020 Combination of Vitamin D3 and MitoQ10 significantly reduced levels of estradiol, progesterone, FSH, LH, LH/FSH, SOD and MDA. Cholecalciferol 15-25 follicle stimulating hormone beta Mus musculus 95-98 32760818-7 2020 Combination of Vitamin D3 and MitoQ10 significantly reduced levels of estradiol, progesterone, FSH, LH, LH/FSH, SOD and MDA. Cholecalciferol 15-25 follicle stimulating hormone beta Mus musculus 107-110 32722164-9 2020 Therefore, this hypothesis paper describes the use of flavonoid supplements combined with vitamin D3 to activate Nrf2, which may be a potential target to prevent and/or decrease SARS-CoV-2 infection severity, reducing oxidative stress and inflammation, enhancing innate immunity, and downregulating ACE2 receptors. Cholecalciferol 90-100 angiotensin converting enzyme 2 Homo sapiens 299-303 32434409-8 2020 Significantly, in response to hyperphosphatemia induced by vitamin D3, medial VC was attenuated in TDAG51-/- mice. Cholecalciferol 59-69 pleckstrin homology like domain, family A, member 1 Mus musculus 99-105 32334010-9 2020 In addition, vitamin D3 decreased IL-6 and MDA levels, whereas the activities of CAT, SOD, and total thiol content in the hippocampus tissue were significantly increased. Cholecalciferol 13-23 interleukin 6 Rattus norvegicus 34-38 32154912-1 2020 BACKGROUND AND PURPOSE: The synthetic vitamin D3 analog paricalcitol acts as a selective activator of vitamin D receptor (VDR). Cholecalciferol 38-48 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 102-120 32154912-1 2020 BACKGROUND AND PURPOSE: The synthetic vitamin D3 analog paricalcitol acts as a selective activator of vitamin D receptor (VDR). Cholecalciferol 38-48 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 122-125 32360127-13 2020 SIGNIFICANCE: Overall, the present study shows that vitamin D3 had an impact on resistance to different chemotherapeutic agents which could be due to the inhibition of ALDH-1, suggesting its use as an adjuvant therapy to cancer patients receiving chemotherapy. Cholecalciferol 52-62 aldehyde dehydrogenase 1 family member A1 Homo sapiens 168-174 32542627-3 2020 In addition 65 patients receiving either cholecalciferol or placebo were analyzed during 6 months intervention and 6 months follow-up.T2D risk alleles are VDR rs7975232 "G" (pc=0.031), rs1544410 "G" (pc=0.027) and CYP2R1 rs10741657 "A" (pc=0.016). Cholecalciferol 41-56 vitamin D receptor Homo sapiens 155-158 32043288-0 2020 Adding Vitamin D3 to the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin Has the Potential to Protect beta-Cell Function in LADA Patients: A One-Year Pilot Study. Cholecalciferol 7-17 ladinin 1 Homo sapiens 121-125 32043288-1 2020 AIMS: This trial was conducted to explore the protective effect on beta-cell function of adding vitamin D3 to DPP-4 inhibitors to treat patients with LADA. Cholecalciferol 96-106 ladinin 1 Homo sapiens 150-154 32043288-7 2020 CONCLUSIONS: The data suggested that adding 2000 IU per day vitamin D3 to saxagliptin might preserve beta-cell function in patients with LADA. Cholecalciferol 60-70 ladinin 1 Homo sapiens 137-141 32542627-8 2020 The response to cholecalciferol supplementation can be measured as 25(OH)D3 increment and PTH suppression. Cholecalciferol 16-31 parathyroid hormone Homo sapiens 90-93 32530156-2 2020 We herein report our experience on the impact of cholecalciferol supplementation on PTH levels in a group of HD patients. Cholecalciferol 49-64 parathyroid hormone Homo sapiens 84-87 32663289-7 2020 We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs). Cholecalciferol 34-49 C-C motif chemokine ligand 2 Homo sapiens 73-78 32663289-7 2020 We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs). Cholecalciferol 34-49 vitamin D receptor Homo sapiens 163-182 32663289-7 2020 We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs). Cholecalciferol 34-49 vitamin D receptor Homo sapiens 184-187 32663289-7 2020 We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs). Cholecalciferol 51-61 C-C motif chemokine ligand 2 Homo sapiens 73-78 32663289-7 2020 We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs). Cholecalciferol 51-61 vitamin D receptor Homo sapiens 163-182 32663289-7 2020 We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs). Cholecalciferol 51-61 vitamin D receptor Homo sapiens 184-187 32565955-0 2020 Vitamin D3 mediates miR-15a-5p inhibition of liver cancer cell proliferation via targeting E2F3. Cholecalciferol 0-10 E2F transcription factor 3 S homeolog Xenopus laevis 91-95 32565955-8 2020 Therefore, Vitamin D3 suppressed cell proliferation by miR-15a-5p-mediated silencing of E2F3 gene expression. Cholecalciferol 11-21 E2F transcription factor 3 S homeolog Xenopus laevis 88-92 32154933-1 2020 FGF-23 has arisen as an early biomarker of renal dysfunction, but at the onset of chronic kidney disease (CKD) data suggest that FGF-23 may be produced independently of the parathyroid hormone (PTH), 1,25(OH)2 -Vitamin D3 signaling axis. Cholecalciferol 211-221 fibroblast growth factor 23 Mus musculus 129-135 32530156-12 2020 Cholecalciferol treatment significantly increased serum 25(OH)D levels, significantly decreased PTH levels and paricalcitol doses, concurrently entailing a better control of anemia. Cholecalciferol 0-15 parathyroid hormone Homo sapiens 96-99 31907922-0 2020 Ezh2-dependent H3K27me3 modification dynamically regulates vitamin D3-dependent epigenetic control of CYP24A1 gene expression in osteoblastic cells. Cholecalciferol 59-69 enhancer of zeste 2 polycomb repressive complex 2 subunit Homo sapiens 0-4 32348877-3 2020 Recently, for a clinical application, a few potent (highly cell-permeable and water-soluble) PAK1 blockers have been developed from natural or synthetic PAK1 blockers (triptolide, vitamin D3 and ketorolac) via a series of "chemical evolutions" that boost pharmacological activities >500 times. Cholecalciferol 180-190 p21 (RAC1) activated kinase 1 Homo sapiens 93-97 32348877-3 2020 Recently, for a clinical application, a few potent (highly cell-permeable and water-soluble) PAK1 blockers have been developed from natural or synthetic PAK1 blockers (triptolide, vitamin D3 and ketorolac) via a series of "chemical evolutions" that boost pharmacological activities >500 times. Cholecalciferol 180-190 p21 (RAC1) activated kinase 1 Homo sapiens 153-157 31868234-0 2020 Switches in histone modifications epigenetically control vitamin D3-dependent transcriptional upregulation of the CYP24A1 gene in osteoblastic cells. Cholecalciferol 57-67 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 114-121 32498437-1 2020 20(S)-Hydroxyvitamin D3 (20(OH)D3) is an endogenous metabolite produced by the action of CYP11A1 on the side chain of vitamin D3 (D3). Cholecalciferol 13-23 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 89-96 32498437-1 2020 20(S)-Hydroxyvitamin D3 (20(OH)D3) is an endogenous metabolite produced by the action of CYP11A1 on the side chain of vitamin D3 (D3). Cholecalciferol 21-23 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 89-96 32441029-1 2020 We have previously described new pathways of vitamin D3 activation by CYP11A1 to produce a variety of metabolites including 20(OH)D3 and 20,23(OH)2D3. Cholecalciferol 45-55 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 70-77 31907922-0 2020 Ezh2-dependent H3K27me3 modification dynamically regulates vitamin D3-dependent epigenetic control of CYP24A1 gene expression in osteoblastic cells. Cholecalciferol 59-69 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 102-109 31907922-4 2020 Treatment of cells with the active vitamin D metabolite 1,25(OH)2 D3 , results in transcriptional activation of the CYP24A1 gene, which encodes a 24-hydroxylase enzyme, that is, essential for physiological control of vitamin D3 levels. Cholecalciferol 217-227 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 116-123 32119872-0 2020 Differential effects of the 1,25D3-MARRS receptor (ERp57/PDIA3) on murine mammary gland development depend on the vitamin D3 dose. Cholecalciferol 114-124 protein disulfide isomerase associated 3 Mus musculus 51-56 32160330-0 2020 Pleiotropic effects of vitamin D3 on CD4+ T lymphocytes mediated by human periodontal ligament cells and inflammatory environment. Cholecalciferol 23-33 CD4 molecule Homo sapiens 37-40 32160330-2 2020 Here we analyzed the impact of vitamin D3 on the immunosuppressive properties of hPDLCs towards CD4+ T-lymphocytes. Cholecalciferol 31-41 CD4 molecule Homo sapiens 96-99 32160330-10 2020 CONCLUSION: Effects of vitamin D3 on CD4+ T-lymphocyte are modified by hPDLCs depending on the microenvironment. Cholecalciferol 23-33 CD4 molecule Homo sapiens 37-40 32119872-0 2020 Differential effects of the 1,25D3-MARRS receptor (ERp57/PDIA3) on murine mammary gland development depend on the vitamin D3 dose. Cholecalciferol 114-124 protein disulfide isomerase associated 3 Mus musculus 57-62 32234325-7 2020 Vitamin D3 restores the autophagic flux inhibited by IAV by upregulating the expression of Syntaxin-17 (STX17) and V-type proton ATPase subunit (ATP6V0A2) thereby causing a concomitant decrease in cellular apoptosis via a Vitamin D3 receptor (VDR) dependent mechanism. Cholecalciferol 0-10 syntaxin 17 Homo sapiens 91-102 32234325-7 2020 Vitamin D3 restores the autophagic flux inhibited by IAV by upregulating the expression of Syntaxin-17 (STX17) and V-type proton ATPase subunit (ATP6V0A2) thereby causing a concomitant decrease in cellular apoptosis via a Vitamin D3 receptor (VDR) dependent mechanism. Cholecalciferol 0-10 syntaxin 17 Homo sapiens 104-109 32234325-7 2020 Vitamin D3 restores the autophagic flux inhibited by IAV by upregulating the expression of Syntaxin-17 (STX17) and V-type proton ATPase subunit (ATP6V0A2) thereby causing a concomitant decrease in cellular apoptosis via a Vitamin D3 receptor (VDR) dependent mechanism. Cholecalciferol 0-10 ATPase H+ transporting V0 subunit a2 Homo sapiens 145-153 32234325-7 2020 Vitamin D3 restores the autophagic flux inhibited by IAV by upregulating the expression of Syntaxin-17 (STX17) and V-type proton ATPase subunit (ATP6V0A2) thereby causing a concomitant decrease in cellular apoptosis via a Vitamin D3 receptor (VDR) dependent mechanism. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 222-241 32234325-7 2020 Vitamin D3 restores the autophagic flux inhibited by IAV by upregulating the expression of Syntaxin-17 (STX17) and V-type proton ATPase subunit (ATP6V0A2) thereby causing a concomitant decrease in cellular apoptosis via a Vitamin D3 receptor (VDR) dependent mechanism. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 243-246 31593637-0 2020 The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial. Cholecalciferol 28-38 insulin Homo sapiens 61-68 32508805-8 2020 Some nTreg variation could be attributed to vitamin D status where normal linear regression estimated that an absolute increase in nTreg/CD4+ by 0.11% could be expected with 10 nmol increase in serum 25 (OH) vitamin D3 (p = 0.005, 95% CI: 0.03-0.19). Cholecalciferol 208-218 CD4 molecule Homo sapiens 137-140 32508805-13 2020 Important for cellular therapies requiring isolation of Tregs, the absolute number of beta7+CD4+CD25+FOXP3+Tregs was positively associated with 25(OH)vitamin D3 (R 2 = 0.0208, r = 0.184, p = 0.021) whereas the absolute numbers of CLA+CD4+CD25+FOXP3+Tregs in the periphery were not influenced by vitamin D status. Cholecalciferol 150-160 immunoglobulin kappa variable 2D-24 (non-functional) Homo sapiens 86-91 32508805-13 2020 Important for cellular therapies requiring isolation of Tregs, the absolute number of beta7+CD4+CD25+FOXP3+Tregs was positively associated with 25(OH)vitamin D3 (R 2 = 0.0208, r = 0.184, p = 0.021) whereas the absolute numbers of CLA+CD4+CD25+FOXP3+Tregs in the periphery were not influenced by vitamin D status. Cholecalciferol 150-160 CD4 molecule Homo sapiens 92-95 32508805-13 2020 Important for cellular therapies requiring isolation of Tregs, the absolute number of beta7+CD4+CD25+FOXP3+Tregs was positively associated with 25(OH)vitamin D3 (R 2 = 0.0208, r = 0.184, p = 0.021) whereas the absolute numbers of CLA+CD4+CD25+FOXP3+Tregs in the periphery were not influenced by vitamin D status. Cholecalciferol 150-160 interleukin 2 receptor subunit alpha Homo sapiens 96-100 32508805-13 2020 Important for cellular therapies requiring isolation of Tregs, the absolute number of beta7+CD4+CD25+FOXP3+Tregs was positively associated with 25(OH)vitamin D3 (R 2 = 0.0208, r = 0.184, p = 0.021) whereas the absolute numbers of CLA+CD4+CD25+FOXP3+Tregs in the periphery were not influenced by vitamin D status. Cholecalciferol 150-160 forkhead box P3 Homo sapiens 101-106 32528227-11 2020 Both enzymatic (GST, catalase, and SOD) and nonenzymatic antioxidants (reduced GSH) were raised significantly in the presence of vitamin D3 and curcumin, which resulted in the better recovery of neuronal cells from Abeta1-42 treatment. Cholecalciferol 129-139 glutathione S-transferase kappa 1 Homo sapiens 16-19 32528227-11 2020 Both enzymatic (GST, catalase, and SOD) and nonenzymatic antioxidants (reduced GSH) were raised significantly in the presence of vitamin D3 and curcumin, which resulted in the better recovery of neuronal cells from Abeta1-42 treatment. Cholecalciferol 129-139 catalase Homo sapiens 21-29 32528227-11 2020 Both enzymatic (GST, catalase, and SOD) and nonenzymatic antioxidants (reduced GSH) were raised significantly in the presence of vitamin D3 and curcumin, which resulted in the better recovery of neuronal cells from Abeta1-42 treatment. Cholecalciferol 129-139 superoxide dismutase 1 Homo sapiens 35-38 32374278-0 2020 Efficacy of weekly administration of cholecalciferol on parathyroid hormone in stable kidney-transplanted patients with CKD stage 1-3. Cholecalciferol 37-52 parathyroid hormone Homo sapiens 56-75 32374278-3 2020 We evaluated the efficacy of weekly cholecalciferol administration on parathyroid hormone (PTH) levels in stable KTx patients with chronic kidney disease stage 1-3. Cholecalciferol 36-51 parathyroid hormone Homo sapiens 70-89 32374278-3 2020 We evaluated the efficacy of weekly cholecalciferol administration on parathyroid hormone (PTH) levels in stable KTx patients with chronic kidney disease stage 1-3. Cholecalciferol 36-51 parathyroid hormone Homo sapiens 91-94 32374278-10 2020 Conclusions Weekly administration of cholecalciferol can significantly and stably reduce PTH levels, without any adverse effects on serum calcium and renal function. Cholecalciferol 37-52 parathyroid hormone Homo sapiens 89-92 32375246-3 2020 Restriction Fragment Length Polymorphism was completed for the detection of vitamin D receptor (VDR) gene polymorphism; Results: Serum 25-hydroxy vitamin D3 (vitamin D) levels were found to be 1.6 times elevated in severe dengue cases as compared to healthy controls. Cholecalciferol 76-85 vitamin D receptor Homo sapiens 96-99 31593637-0 2020 The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial. Cholecalciferol 28-38 tumor necrosis factor Homo sapiens 84-111 31593637-8 2020 It seems that chromium and vitamin D3 co-supplementation are probably effective in controlling HOMA-IR by decreasing TNF-alpha in T2DM. Cholecalciferol 27-37 tumor necrosis factor Homo sapiens 117-126 31593637-10 2020 Chromium and vitamin D3 alone and/or in simultaneous pretreatment decrease TNF-alpha in T2DM. Cholecalciferol 13-23 tumor necrosis factor Homo sapiens 75-84 32268148-8 2020 Smooth muscle-specific deletion of LGL1 increased HMGB1 level and aggravated vitamin D3-induced vascular calcification, which was attenuated by an HMGB1 inhibitor. Cholecalciferol 77-87 LLGL1 scribble cell polarity complex component Mus musculus 35-39 31899206-7 2020 Steatotic IL-17RA-deficient hepatocytes downregulated expression of Cxcl1 and other chemokines, exhibited a striking defect in TNF-TNFR1-dependent Caspase-2-SREBP-1/2-DHCR7-mediated cholesterol synthesis, and upregulated production of anti-oxidant Vitamin D3. Cholecalciferol 248-258 interleukin 17 receptor A Mus musculus 10-17 31899206-7 2020 Steatotic IL-17RA-deficient hepatocytes downregulated expression of Cxcl1 and other chemokines, exhibited a striking defect in TNF-TNFR1-dependent Caspase-2-SREBP-1/2-DHCR7-mediated cholesterol synthesis, and upregulated production of anti-oxidant Vitamin D3. Cholecalciferol 248-258 tumor necrosis factor Mus musculus 127-130 31899206-7 2020 Steatotic IL-17RA-deficient hepatocytes downregulated expression of Cxcl1 and other chemokines, exhibited a striking defect in TNF-TNFR1-dependent Caspase-2-SREBP-1/2-DHCR7-mediated cholesterol synthesis, and upregulated production of anti-oxidant Vitamin D3. Cholecalciferol 248-258 tumor necrosis factor receptor superfamily, member 1a Mus musculus 131-136 31899206-7 2020 Steatotic IL-17RA-deficient hepatocytes downregulated expression of Cxcl1 and other chemokines, exhibited a striking defect in TNF-TNFR1-dependent Caspase-2-SREBP-1/2-DHCR7-mediated cholesterol synthesis, and upregulated production of anti-oxidant Vitamin D3. Cholecalciferol 248-258 caspase 2 Mus musculus 147-156 32268148-8 2020 Smooth muscle-specific deletion of LGL1 increased HMGB1 level and aggravated vitamin D3-induced vascular calcification, which was attenuated by an HMGB1 inhibitor. Cholecalciferol 77-87 high mobility group box 1 Mus musculus 147-152 32357579-0 2020 Are Vitamin D3 Tablets and Oil Drops Equally Effective in Raising S-25-Hydroxyvitamin D Concentrations? Cholecalciferol 4-14 ribosomal protein S25 Homo sapiens 66-70 32483423-0 2020 Small-molecule activating SIRT6 elicits therapeutic effects and synergistically promotes anti-tumor activity of vitamin D3 in colorectal cancer. Cholecalciferol 112-122 sirtuin 6 Homo sapiens 26-31 31897949-6 2020 Also, the patients receiving vitamin D3 yielded a marginally significant lower IL-6 serum concentration (76.43 ng/L) compared to placebo (93.10 ng/L) (P value:0.055). Cholecalciferol 29-39 interleukin 6 Homo sapiens 79-83 32237947-5 2022 Significant increase in LL37 intensity of expression was observed after intralesional injection of vitamin D3 (p = 0.003) and in verrucae showing complete clinical response (p = 0.022).Conclusions: Intralesional injection of vitamin D is effective and safe treatment for verruca vulgaris and causes increase in LL37 expression. Cholecalciferol 99-109 cathelicidin antimicrobial peptide Homo sapiens 24-28 32344650-0 2020 The Effect of Vitamin D3 Supplementation on Hepcidin, Iron, and IL-6 Responses after a 100 km Ultra-Marathon. Cholecalciferol 14-24 hepcidin antimicrobial peptide Homo sapiens 44-52 32344650-0 2020 The Effect of Vitamin D3 Supplementation on Hepcidin, Iron, and IL-6 Responses after a 100 km Ultra-Marathon. Cholecalciferol 14-24 interleukin 6 Homo sapiens 64-68 32227012-6 2020 When three achiral fluorescent molecules, pyrene-1-carboxylic acid (D2), rhodamine 110 (D3) and rhodamine B (D4), were incorporated into the helical structures formed by bola-1, the nanohelix could be retained and the CPL from the dye molecules could be induced. Cholecalciferol 88-90 bolA family member 1 Homo sapiens 170-176 32325790-1 2020 The biologically active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), modulates innate and adaptive immunity via genes regulated by the transcription factor vitamin D receptor (VDR). Cholecalciferol 32-42 vitamin D receptor Homo sapiens 176-194 32325790-1 2020 The biologically active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), modulates innate and adaptive immunity via genes regulated by the transcription factor vitamin D receptor (VDR). Cholecalciferol 32-42 vitamin D receptor Homo sapiens 196-199 32316365-19 2020 In the immune tolerance phase of HBeAg-negative chronic HBV infection, vitamin D3 may be a modulator of immune function via CD8, CD19, and HBV DNA. Cholecalciferol 71-81 CD8a molecule Homo sapiens 124-127 31809868-14 2020 Furthermore, co-treatment with leptin and vitamin D3 metabolites promoted ALP activity compared with either alone. Cholecalciferol 42-52 ATHS Homo sapiens 74-77 32052217-2 2020 As suppression of parathyroid hormone (PTH) is one indicator of vitamin D efficacy, we examined to what extent doses of vitamin D3 supplementation suppress PTH levels in individuals with and without obesity. Cholecalciferol 120-130 parathyroid hormone Homo sapiens 156-159 32052217-5 2020 Obese individuals (n = 141) experienced a steep reduction of 3-month PTH from placebo to 1,000 IU/day of vitamin D3 supplementation, but no further reduction at 2,000 or 4,000 IU/day. Cholecalciferol 105-115 parathyroid hormone Homo sapiens 69-72 32052217-6 2020 For non-obese individuals (n = 109), the reduction of 3-month PTH was approximately linear for increasing vitamin D3 doses. Cholecalciferol 106-116 parathyroid hormone Homo sapiens 62-65 31986066-8 2020 Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs. Cholecalciferol 13-23 TNF superfamily member 11 Homo sapiens 50-55 31901710-6 2020 For premenopausal women, cholecalciferol supplementation resulted in a significant decrease in serum levels of Ang-2 and VEGF-A after 8 wk of treatment (P < 0.05). Cholecalciferol 25-40 angiopoietin 2 Homo sapiens 111-116 31901710-6 2020 For premenopausal women, cholecalciferol supplementation resulted in a significant decrease in serum levels of Ang-2 and VEGF-A after 8 wk of treatment (P < 0.05). Cholecalciferol 25-40 vascular endothelial growth factor A Homo sapiens 121-127 32742635-0 2020 Pharmaceutic application of vitamin D3 on particle-induced fibrotic effects through induction of Nrf2 signals. Cholecalciferol 28-38 NFE2 like bZIP transcription factor 2 Homo sapiens 97-101 32742635-6 2020 In vivo studies showed that vitamin D3 significantly attenuated fibrosis effects by decreasing alpha-smooth muscle actin-regulated extracellular matrix deposition and restoring expressions of E-cadherin and N-cadherin. Cholecalciferol 28-38 cadherin 1 Homo sapiens 192-202 32742635-6 2020 In vivo studies showed that vitamin D3 significantly attenuated fibrosis effects by decreasing alpha-smooth muscle actin-regulated extracellular matrix deposition and restoring expressions of E-cadherin and N-cadherin. Cholecalciferol 28-38 cadherin 2 Homo sapiens 207-217 32742635-9 2020 In addition, our results indicated that the therapeutic effects of vitamin D3 were through Nrf2 signals. Cholecalciferol 67-77 NFE2 like bZIP transcription factor 2 Homo sapiens 91-95 32127613-2 2020 Reabsorption of vitamin D3 occurs in the proximal tubule after being endocytosed in combination with DBP (vitamin D binding protein) by the megalin/cubilin receptor. Cholecalciferol 16-26 GC vitamin D binding protein Homo sapiens 106-131 32127613-2 2020 Reabsorption of vitamin D3 occurs in the proximal tubule after being endocytosed in combination with DBP (vitamin D binding protein) by the megalin/cubilin receptor. Cholecalciferol 16-26 LDL receptor related protein 2 Homo sapiens 140-147 32122449-10 2020 Results: The median level of serum IgE was increased in patients with vitamin D3 deficiency compared with other groups. Cholecalciferol 70-80 immunoglobulin heavy constant epsilon Homo sapiens 35-38 32122449-13 2020 Conclusion: Vitamin D3 deficiency is associated with exacerbation severity and serum IgE levels in patients with pediatric asthma; hence, it can have an important role in pediatric asthma pathogenesis, possibly through IgE. Cholecalciferol 12-22 immunoglobulin heavy constant epsilon Homo sapiens 85-88 32122449-13 2020 Conclusion: Vitamin D3 deficiency is associated with exacerbation severity and serum IgE levels in patients with pediatric asthma; hence, it can have an important role in pediatric asthma pathogenesis, possibly through IgE. Cholecalciferol 12-22 immunoglobulin heavy constant epsilon Homo sapiens 219-222 31053513-9 2020 CONCLUSION: In the DALI vitamin D trial, supplementation with 1600 IU vitamin D3/day achieved vitamin D sufficiency in virtually all pregnant women and a small effect in FPG at 35-37 weeks. Cholecalciferol 70-80 DNMT1-associated long intergenic non-coding RNA Homo sapiens 19-23 31544572-0 2020 Vitamin D3 favorable outcome on recognition memory and prefrontal cortex expression of choline acetyltransferase and acetylcholinesterase in experimental model of chronic high-fat feeding. Cholecalciferol 0-10 choline O-acetyltransferase Rattus norvegicus 87-112 31544572-0 2020 Vitamin D3 favorable outcome on recognition memory and prefrontal cortex expression of choline acetyltransferase and acetylcholinesterase in experimental model of chronic high-fat feeding. Cholecalciferol 0-10 acetylcholinesterase Rattus norvegicus 117-137 31544572-5 2020 Vitamin D3 supplementation with HFD significantly increased the exploration of the novel object and the discrimination index and attenuated the alterations in the prefrontal cortex CAT and Achase expression.Conclusions: The present findings support the potential effect of vitamin D on recognition memory and cholinergic transmission in the prefrontal cortex and add to the pathophysiology of HFD consumption. Cholecalciferol 0-10 choline O-acetyltransferase Rattus norvegicus 181-184 31544572-5 2020 Vitamin D3 supplementation with HFD significantly increased the exploration of the novel object and the discrimination index and attenuated the alterations in the prefrontal cortex CAT and Achase expression.Conclusions: The present findings support the potential effect of vitamin D on recognition memory and cholinergic transmission in the prefrontal cortex and add to the pathophysiology of HFD consumption. Cholecalciferol 0-10 acetylcholinesterase Rattus norvegicus 189-195 32251441-1 2020 BACKGROUND & AIMS: In our previous study, a Seesaw model was proposed for the fluctuation of crucial anti- (IL-10) and pro-inflammatory (Il-6 & IL-17A) cytokines through vitamin D3. Cholecalciferol 170-180 interleukin 10 Homo sapiens 108-113 32251441-1 2020 BACKGROUND & AIMS: In our previous study, a Seesaw model was proposed for the fluctuation of crucial anti- (IL-10) and pro-inflammatory (Il-6 & IL-17A) cytokines through vitamin D3. Cholecalciferol 170-180 interleukin 6 Homo sapiens 137-141 32251441-1 2020 BACKGROUND & AIMS: In our previous study, a Seesaw model was proposed for the fluctuation of crucial anti- (IL-10) and pro-inflammatory (Il-6 & IL-17A) cytokines through vitamin D3. Cholecalciferol 170-180 interleukin 17A Homo sapiens 144-150 32251441-7 2020 In addition, the plasma levels of IL-27, TGF-beta1, IL-10, IL-17A, and IL-6 significantly changed following the administration of vitamin D3. Cholecalciferol 130-140 interleukin 27 Homo sapiens 34-39 32251441-7 2020 In addition, the plasma levels of IL-27, TGF-beta1, IL-10, IL-17A, and IL-6 significantly changed following the administration of vitamin D3. Cholecalciferol 130-140 transforming growth factor beta 1 Homo sapiens 41-50 32251441-7 2020 In addition, the plasma levels of IL-27, TGF-beta1, IL-10, IL-17A, and IL-6 significantly changed following the administration of vitamin D3. Cholecalciferol 130-140 interleukin 10 Homo sapiens 52-57 32251441-7 2020 In addition, the plasma levels of IL-27, TGF-beta1, IL-10, IL-17A, and IL-6 significantly changed following the administration of vitamin D3. Cholecalciferol 130-140 interleukin 17A Homo sapiens 59-65 32251441-7 2020 In addition, the plasma levels of IL-27, TGF-beta1, IL-10, IL-17A, and IL-6 significantly changed following the administration of vitamin D3. Cholecalciferol 130-140 interleukin 6 Homo sapiens 71-75 31783155-6 2020 There is a key impact of the lower vitamin D3 in NWD1 and its signaling through the Vdr. Cholecalciferol 35-45 NACHT and WD repeat domain containing 1 Mus musculus 49-53 31783155-6 2020 There is a key impact of the lower vitamin D3 in NWD1 and its signaling through the Vdr. Cholecalciferol 35-45 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 84-87 31410630-0 2020 Oxytetracycline reduces inflammation and treponeme burden whereas vitamin D3 promotes beta-defensin expression in bovine infectious digital dermatitis. Cholecalciferol 66-76 LOC100296173 Bos taurus 86-99 31701851-0 2020 A single injection of vitamin D3 improves insulin sensitivity and beta-cell function but not muscle damage or the inflammatory and cardiovascular responses to an acute bout of resistance exercise in vitamin D-deficient resistance-trained males. Cholecalciferol 22-32 insulin Homo sapiens 42-49 31701851-9 2020 A single injection of vitamin D3 improved insulin resistance and beta-cell function following RE in previously vitamin D-deficient resistance-trained males. Cholecalciferol 22-32 insulin Homo sapiens 42-49 32031576-2 2020 Cholecalciferol (VIT-D) is a known modulator of oxidative stress and angiogenesis. Cholecalciferol 0-15 vitrin Homo sapiens 17-20 31879032-6 2020 The results showed that vitamin D3 treatment increases PR mRNA and protein level and phospho-Ser294 PR protein level in the isolated eSC of both RIF patients and the control group. Cholecalciferol 24-34 progesterone receptor Homo sapiens 55-57 31879032-6 2020 The results showed that vitamin D3 treatment increases PR mRNA and protein level and phospho-Ser294 PR protein level in the isolated eSC of both RIF patients and the control group. Cholecalciferol 24-34 progesterone receptor Homo sapiens 100-102 31879032-7 2020 These results suggest that vitamin D3 may possibly play a key role during the embryo implantation process by affecting the expression pattern and regulatory modifications of the PR in the eSC. Cholecalciferol 27-37 progesterone receptor Homo sapiens 178-180 31410630-9 2020 Vitamin D3 did not modify expression of cytokines or Tlrs, or bacterial loads, but enhanced transcription of tracheal antimicrobial peptide (Tap), a key bovine beta-defensin. Cholecalciferol 0-10 tracheal antimicrobial peptide Bos taurus 109-139 31410630-9 2020 Vitamin D3 did not modify expression of cytokines or Tlrs, or bacterial loads, but enhanced transcription of tracheal antimicrobial peptide (Tap), a key bovine beta-defensin. Cholecalciferol 0-10 tracheal antimicrobial peptide Bos taurus 141-144 31410630-9 2020 Vitamin D3 did not modify expression of cytokines or Tlrs, or bacterial loads, but enhanced transcription of tracheal antimicrobial peptide (Tap), a key bovine beta-defensin. Cholecalciferol 0-10 LOC100296173 Bos taurus 160-173 31628941-0 2020 Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer. Cholecalciferol 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 43-57 31820026-11 2020 Exposure of human intestinal Caco-2 cells to 10-100 nM PCB 126 in the presence of vitamin D3 resulted in inhibition of mRNAs for the calcium transporters TRPV6 and PMCA1b (P < 0.05). Cholecalciferol 82-92 transient receptor potential cation channel subfamily V member 6 Homo sapiens 154-159 31978964-6 2020 Results: While we found no differences in Th17 cells between vitamin D3 groups, vitamin D3 restriction specifically promoted memory B cell development, accompanied by elevated levels of serum IgM, IgG1, IgG3, and anti-dsDNA IgG. Cholecalciferol 80-90 immunoglobulin heavy constant mu Mus musculus 192-195 31978964-6 2020 Results: While we found no differences in Th17 cells between vitamin D3 groups, vitamin D3 restriction specifically promoted memory B cell development, accompanied by elevated levels of serum IgM, IgG1, IgG3, and anti-dsDNA IgG. Cholecalciferol 80-90 LOC105243590 Mus musculus 197-201 31978964-6 2020 Results: While we found no differences in Th17 cells between vitamin D3 groups, vitamin D3 restriction specifically promoted memory B cell development, accompanied by elevated levels of serum IgM, IgG1, IgG3, and anti-dsDNA IgG. Cholecalciferol 80-90 Immunoglobulin heavy constant gamma 3 Mus musculus 203-207 31731231-0 2020 Vitamin D3-mediated resistance to a multiple sclerosis model disease depends on myeloid cell 1,25-dihydroxyvitamin D3 synthesis and correlates with increased CD4+ T cell CTLA-4 expression. Cholecalciferol 0-10 CD4 molecule Homo sapiens 158-161 31731231-0 2020 Vitamin D3-mediated resistance to a multiple sclerosis model disease depends on myeloid cell 1,25-dihydroxyvitamin D3 synthesis and correlates with increased CD4+ T cell CTLA-4 expression. Cholecalciferol 0-10 cytotoxic T-lymphocyte associated protein 4 Homo sapiens 170-176 31731231-6 2020 These new data provide solid support for the view that vitamin D3 reduces MS risk in part through a mechanism involving myeloid cell 1,25-(OH)2D3 production and CTLA-4 upregulation in CNS-infiltrating CD4+ T cells. Cholecalciferol 55-65 cytotoxic T-lymphocyte associated protein 4 Homo sapiens 161-167 31731231-6 2020 These new data provide solid support for the view that vitamin D3 reduces MS risk in part through a mechanism involving myeloid cell 1,25-(OH)2D3 production and CTLA-4 upregulation in CNS-infiltrating CD4+ T cells. Cholecalciferol 55-65 CD4 molecule Homo sapiens 201-204 31731231-7 2020 We suggest that CTLA-4 serves as a vitamin D3-regulated immunological checkpoint in multiple sclerosis prevention. Cholecalciferol 35-45 cytotoxic T-lymphocyte associated protein 4 Homo sapiens 16-22 31820026-7 2020 Hyperparathyroidism was accompanied by increased expression of mRNAs of vitamin D3 metabolizing cytochrome P450 enzymes CYP27B1 and CYP24 in the kidney (P < 0.05). Cholecalciferol 72-82 cytochrome P450, family 27, subfamily b, polypeptide 1 Rattus norvegicus 120-127 31820026-7 2020 Hyperparathyroidism was accompanied by increased expression of mRNAs of vitamin D3 metabolizing cytochrome P450 enzymes CYP27B1 and CYP24 in the kidney (P < 0.05). Cholecalciferol 72-82 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 132-137 31628941-4 2020 The present study, therefore, aimed at investigating the effect of both curcumin (CUR) and vitamin D3 (D3) on MDR-1 and ALDH-1 expression and consequently the resistance to PAX both in vitro and in vivo. Cholecalciferol 91-101 ATP binding cassette subfamily B member 1 Homo sapiens 110-115 31628941-4 2020 The present study, therefore, aimed at investigating the effect of both curcumin (CUR) and vitamin D3 (D3) on MDR-1 and ALDH-1 expression and consequently the resistance to PAX both in vitro and in vivo. Cholecalciferol 91-101 aldehyde dehydrogenase 1 family member A1 Homo sapiens 120-126 31628941-4 2020 The present study, therefore, aimed at investigating the effect of both curcumin (CUR) and vitamin D3 (D3) on MDR-1 and ALDH-1 expression and consequently the resistance to PAX both in vitro and in vivo. Cholecalciferol 99-101 ATP binding cassette subfamily B member 1 Homo sapiens 110-115 31628941-4 2020 The present study, therefore, aimed at investigating the effect of both curcumin (CUR) and vitamin D3 (D3) on MDR-1 and ALDH-1 expression and consequently the resistance to PAX both in vitro and in vivo. Cholecalciferol 99-101 aldehyde dehydrogenase 1 family member A1 Homo sapiens 120-126 32918223-5 2020 Vitamin D3 itself and its canonical (1,25(OH)2D3) and noncanonical (CYP11A1-intitated) D3 hydroxyderivatives show photoprotective functions in the skin. Cholecalciferol 0-10 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 68-75 32203968-0 2020 Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 - A Randomized Clinical Trial. Cholecalciferol 0-10 corticotropin releasing hormone Homo sapiens 129-160 32918226-2 2020 The active form of vitamin D, vitamin D3 or calcitriol, binds to the ligand-activated transcription factor vitamin D receptor (VDR) for genomic and non-genomic effects. Cholecalciferol 30-40 vitamin D receptor Homo sapiens 107-125 32918226-2 2020 The active form of vitamin D, vitamin D3 or calcitriol, binds to the ligand-activated transcription factor vitamin D receptor (VDR) for genomic and non-genomic effects. Cholecalciferol 30-40 vitamin D receptor Homo sapiens 127-130 32013343-7 2020 Most of the negative changes were negligible but PTH level dramatically decreased after 48 hours in 2 - 8 C. In addition, although a clear increase in the concentration of triglycerides, Cr, Urea, T4, and 25-OH vitamin D3 was observed, it was not significant. Cholecalciferol 211-221 parathyroid hormone Homo sapiens 49-52 31657006-4 2020 We explored whether 48-week high-dose vitamin D3 supplements were associated with lower circulating NfL levels. Cholecalciferol 38-48 neurofilament light chain Homo sapiens 100-103 32203968-0 2020 Vitamin D3 Supplementation in Diarrhea-Predominant Irritable Bowel Syndrome Patients: The Effects on Symptoms Improvement, Serum Corticotropin-Releasing Hormone, and Interleukin-6 - A Randomized Clinical Trial. Cholecalciferol 0-10 interleukin 6 Homo sapiens 166-179 32203968-12 2020 CONCLUSION: Our findings indicate that vitamin D3 supplementation can modulate the serum level of CRH and IL-6 and can improve symptoms in IBS-D patients. Cholecalciferol 39-49 corticotropin releasing hormone Homo sapiens 98-101 32203968-12 2020 CONCLUSION: Our findings indicate that vitamin D3 supplementation can modulate the serum level of CRH and IL-6 and can improve symptoms in IBS-D patients. Cholecalciferol 39-49 interleukin 6 Homo sapiens 106-110 32009088-6 2020 Results In a multivariable linear regression analysis, FGF19 was associated with ALT, a history of cardiovascular disease, and medication with active vitamin D3. Cholecalciferol 150-160 fibroblast growth factor 19 Homo sapiens 55-60 32863311-1 2020 The vitamin D receptor (VDR) is a nuclear receptor for the active form of vitamin D3 and also for the secondary bile acid lithocholic acid (LCA). Cholecalciferol 74-84 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 4-22 31668442-10 2020 Abundance of mRNA transcripts for interleukin-1beta (IL1B) and inducible nitric oxide synthase (iNOS) in milk somatic cells before S. uberis challenge were increased in cows fed 25(OH)D3 compared with cows fed vitamin D3. Cholecalciferol 210-220 nitric oxide synthase 2 Bos taurus 96-100 31106659-4 2020 After 8 weeks of intervention, patients who received combined vitamin D3 and omega-3 fatty acids supplements compared with omega-3, vitamin D3, and placebo groups had significantly decreased CRP and TNF-alpha. Cholecalciferol 62-72 C-reactive protein Homo sapiens 191-194 31106659-4 2020 After 8 weeks of intervention, patients who received combined vitamin D3 and omega-3 fatty acids supplements compared with omega-3, vitamin D3, and placebo groups had significantly decreased CRP and TNF-alpha. Cholecalciferol 62-72 tumor necrosis factor Homo sapiens 199-208 31106659-4 2020 After 8 weeks of intervention, patients who received combined vitamin D3 and omega-3 fatty acids supplements compared with omega-3, vitamin D3, and placebo groups had significantly decreased CRP and TNF-alpha. Cholecalciferol 132-142 C-reactive protein Homo sapiens 191-194 31106659-4 2020 After 8 weeks of intervention, patients who received combined vitamin D3 and omega-3 fatty acids supplements compared with omega-3, vitamin D3, and placebo groups had significantly decreased CRP and TNF-alpha. Cholecalciferol 132-142 tumor necrosis factor Homo sapiens 199-208 31106659-5 2020 In addition, serum level of IL-6 was decreased significantly in omega-3, vitamin D3, and cosupplementation groups compared with baseline. Cholecalciferol 73-83 interleukin 6 Homo sapiens 28-32 31124381-11 2020 However, treatment initiation significantly improved plasma IL-10 levels after 2 months in both placebo and cholecalciferol groups. Cholecalciferol 108-123 interleukin 10 Homo sapiens 60-65 32863311-1 2020 The vitamin D receptor (VDR) is a nuclear receptor for the active form of vitamin D3 and also for the secondary bile acid lithocholic acid (LCA). Cholecalciferol 74-84 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 24-27 31618573-2 2019 In the present study, we dissect the complex biological activity of vitamin D by designing synthetic vitamin D3 analogs specific for VDR or SREBP pathway, i.e., a VDR activator that lacks SREBP inhibitory activity, or an SREBP inhibitor devoid of VDR activity. Cholecalciferol 101-111 vitamin D receptor Homo sapiens 133-136 32877827-1 2020 Vitamin D3 is a fat-soluble essential nutrient that affects multiple biologic functions in the organism through calcitriol and the vitamin D3 receptor. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 131-150 32877827-3 2020 The mechanisms of vitamin D3 action involve, among others, polymorphism of vitamin D3 receptor, cell cycle, caspases, and cancer stem cells. Cholecalciferol 18-28 vitamin D receptor Homo sapiens 75-94 31618573-1 2019 Vitamin D3 metabolites are capable of controlling gene expression in mammalian cells through two independent pathways: vitamin D receptor (VDR) and sterol regulatory element-binding protein (SREBP) pathways. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 119-137 31618573-1 2019 Vitamin D3 metabolites are capable of controlling gene expression in mammalian cells through two independent pathways: vitamin D receptor (VDR) and sterol regulatory element-binding protein (SREBP) pathways. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 139-142 31667917-9 2020 In addition, the hypermethylation of cg07873128 at the baseline, which is located in the imprinted gene OSBPL5, might reduce the serum 25(OH)D response to vitamin D3 supplementation. Cholecalciferol 155-165 oxysterol binding protein like 5 Homo sapiens 104-110 33271562-0 2020 Correlation of Vitamin D3 with the Expression of RORgammat and Foxp3 mRNAs in the Peripheral Blood of Myasthenia Gravis Patients. Cholecalciferol 15-25 forkhead box P3 Homo sapiens 63-68 32597823-8 2020 Although therapies selectively down-regulating both AhR and IDO1 are currently lacking, medications in clinical use such as dexamethasone may down-regulate both AhR and IDO1 genes, as calcitriol/vitamin D3 may down-regulate the AhR gene, and tocopherol/vitamin E may down-regulate the IDO1 gene. Cholecalciferol 195-205 aryl hydrocarbon receptor Homo sapiens 161-164 32597823-8 2020 Although therapies selectively down-regulating both AhR and IDO1 are currently lacking, medications in clinical use such as dexamethasone may down-regulate both AhR and IDO1 genes, as calcitriol/vitamin D3 may down-regulate the AhR gene, and tocopherol/vitamin E may down-regulate the IDO1 gene. Cholecalciferol 195-205 aryl hydrocarbon receptor Homo sapiens 161-164 31769776-0 2019 Synthesis and vitamin D receptor affinity of 16-oxa vitamin D3 analogues. Cholecalciferol 45-62 vitamin D receptor Homo sapiens 14-32 31618573-2 2019 In the present study, we dissect the complex biological activity of vitamin D by designing synthetic vitamin D3 analogs specific for VDR or SREBP pathway, i.e., a VDR activator that lacks SREBP inhibitory activity, or an SREBP inhibitor devoid of VDR activity. Cholecalciferol 101-111 CCHC-type zinc finger nucleic acid binding protein Homo sapiens 140-145 31618573-1 2019 Vitamin D3 metabolites are capable of controlling gene expression in mammalian cells through two independent pathways: vitamin D receptor (VDR) and sterol regulatory element-binding protein (SREBP) pathways. Cholecalciferol 0-10 CCHC-type zinc finger nucleic acid binding protein Homo sapiens 148-189 31618573-1 2019 Vitamin D3 metabolites are capable of controlling gene expression in mammalian cells through two independent pathways: vitamin D receptor (VDR) and sterol regulatory element-binding protein (SREBP) pathways. Cholecalciferol 0-10 CCHC-type zinc finger nucleic acid binding protein Homo sapiens 191-196 31618573-2 2019 In the present study, we dissect the complex biological activity of vitamin D by designing synthetic vitamin D3 analogs specific for VDR or SREBP pathway, i.e., a VDR activator that lacks SREBP inhibitory activity, or an SREBP inhibitor devoid of VDR activity. Cholecalciferol 101-111 vitamin D receptor Homo sapiens 163-166 31618573-2 2019 In the present study, we dissect the complex biological activity of vitamin D by designing synthetic vitamin D3 analogs specific for VDR or SREBP pathway, i.e., a VDR activator that lacks SREBP inhibitory activity, or an SREBP inhibitor devoid of VDR activity. Cholecalciferol 101-111 vitamin D receptor Homo sapiens 163-166 31675485-0 2019 Glucocorticoids employ the monomeric glucocorticoid receptor to potentiate vitamin D3 and parathyroid hormone-induced osteoclastogenesis. Cholecalciferol 75-85 nuclear receptor subfamily 3, group C, member 1 Mus musculus 37-60 31822280-1 2019 BACKGROUND: The deficiency of vitamin D receptor (VDR) or its ligand, vitamin D3, is linked to the development of renal diseases. Cholecalciferol 70-80 vitamin D receptor Homo sapiens 30-48 31822280-1 2019 BACKGROUND: The deficiency of vitamin D receptor (VDR) or its ligand, vitamin D3, is linked to the development of renal diseases. Cholecalciferol 70-80 vitamin D receptor Homo sapiens 50-53 31787743-0 2019 Vitamin D3 Is Transformed into 1,25(OH)2D3 by Triggering CYP3A11(CYP3A4) Activity and Hydrolyzing Midazolam. Cholecalciferol 0-10 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 57-64 31787743-3 2019 This study aimed to investigate effects of vitamin D3 (VD3) on CYP3A11 activity. Cholecalciferol 43-53 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 63-70 31787743-10 2019 Expressions of hepatic CYP3A11 were more than 10-fold higher in rats treated with vitamin D3 compared to Control rats (p<0.05). Cholecalciferol 82-92 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 23-30 31787743-12 2019 CYP3A11 expressions in vitamin D3-treated groups were significantly higher compared to the Control group (p<0.05). Cholecalciferol 23-33 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 0-7 31787743-15 2019 CONCLUSIONS Vitamin D3 was transformed into 1,25(OH)2D3 by triggering CYP3A11 and CYP3A11 activity and by hydrolyzing MDZ. Cholecalciferol 12-22 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 70-77 31787743-15 2019 CONCLUSIONS Vitamin D3 was transformed into 1,25(OH)2D3 by triggering CYP3A11 and CYP3A11 activity and by hydrolyzing MDZ. Cholecalciferol 12-22 cytochrome P450, family 3, subfamily a, polypeptide 2 Rattus norvegicus 82-89 31675485-7 2019 These data demonstrate that the GR cooperates with D3 and PTH signaling, causing massive osteoclastogenesis, which may explain the rapid bone loss observed with high dosages of GC treatment.-Conaway, H. H., Henning, P., Lie, A., Tuckermann, J., Lerner, U. H. Glucocorticoids employ the monomeric glucocorticoid receptor to potentiate vitamin D3 and parathyroid hormone-induced osteoclastogenesis. Cholecalciferol 334-344 nuclear receptor subfamily 3, group C, member 1 Mus musculus 32-34 31847491-8 2019 The additional gene network analysis revealed 43 new genes and 127 new interactions, so in the whole 222 out of 281 (79%) high scored genes from SFARI Gene database were connected with mTOR signaling activity and/or dependent on vitamin D3 availability directly or indirectly. Cholecalciferol 229-239 mechanistic target of rapamycin kinase Homo sapiens 185-189 31794287-5 2022 After vitamin D3 supplementation with HFD, cardiac apoptotic, inflammatory and oxidative markers were mitigated and expression of UCP3 was downregulated and UCP2 was upregulated. Cholecalciferol 6-16 uncoupling protein 3 Rattus norvegicus 130-134 31794287-5 2022 After vitamin D3 supplementation with HFD, cardiac apoptotic, inflammatory and oxidative markers were mitigated and expression of UCP3 was downregulated and UCP2 was upregulated. Cholecalciferol 6-16 uncoupling protein 2 Rattus norvegicus 157-161 31794287-6 2022 This work highlights the novel cardioprotective effect of vitamin D3 in the experimental model of HFD feeding through the downregulation of UCP3. Cholecalciferol 58-68 uncoupling protein 3 Rattus norvegicus 140-144 31541729-1 2019 During our ongoing studies of vitamin D, we focused on the vitamin D3 side-chain 24-position, which is the major metabolic site of human CYP24A1. Cholecalciferol 59-69 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 137-144 31100998-1 2019 OBJECTIVE: Investigate Vitamin D3 (VD3) effect on the Acetylcholinesterase (AChE), oxidative damage and behavioral tests in animals subjected to Intracerebroventicular injection of Streptozotocin (ICV-STZ) simulating a Sporadic Dementia of Alzheimer"s Type (SDAT) and treated with VD3 (21 days). Cholecalciferol 23-33 acetylcholinesterase Rattus norvegicus 54-74 31805709-2 2019 The aim of this study was to determine whether omega-3 FA and cholecalciferol have effects on vitamin D metabolism related to CYP27B1 and 24-hydroxylase (CYP24) activities in the kidney and liver of 5/6 nephrectomy (Nx) rats. Cholecalciferol 62-77 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 126-152 31805709-2 2019 The aim of this study was to determine whether omega-3 FA and cholecalciferol have effects on vitamin D metabolism related to CYP27B1 and 24-hydroxylase (CYP24) activities in the kidney and liver of 5/6 nephrectomy (Nx) rats. Cholecalciferol 62-77 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 154-159 31805709-7 2019 CYP24 expression was increased in the kidney of the 5/6 Nx rat model, which was found to be reversed by omega-3 FA or cholecalciferol/omega-3 FA supplementation. Cholecalciferol 118-133 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 0-5 31805709-8 2019 Decreased CYP27B1 expression was observed in the liver of the 5/6 Nx rats and its expression was recovered by supplementation with cholecalciferol/omega-3 FA. Cholecalciferol 131-146 cytochrome P450, family 27, subfamily b, polypeptide 1 Rattus norvegicus 10-17 31805709-9 2019 In conclusion, omega-3 FA and cholecalciferol may synergistically increase 1,25(OH)2D levels by inhibiting CYP24 expression in the kidney and liver and activating CYP27B1 expression in the liver of 5/6 Nx rats. Cholecalciferol 30-45 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 107-112 31805709-9 2019 In conclusion, omega-3 FA and cholecalciferol may synergistically increase 1,25(OH)2D levels by inhibiting CYP24 expression in the kidney and liver and activating CYP27B1 expression in the liver of 5/6 Nx rats. Cholecalciferol 30-45 cytochrome P450, family 27, subfamily b, polypeptide 1 Rattus norvegicus 163-170 31100998-1 2019 OBJECTIVE: Investigate Vitamin D3 (VD3) effect on the Acetylcholinesterase (AChE), oxidative damage and behavioral tests in animals subjected to Intracerebroventicular injection of Streptozotocin (ICV-STZ) simulating a Sporadic Dementia of Alzheimer"s Type (SDAT) and treated with VD3 (21 days). Cholecalciferol 23-33 acetylcholinesterase Rattus norvegicus 76-80 31619537-3 2019 We show that deletion of LprE Mtb results in reduction of M. tuberculosis virulence in human and mouse macrophages due to upregulation of vitamin D3-responsive cathelicidin expression through the TLR2-dependent p38-MAPK-CYP27B1-VDR signaling pathway. Cholecalciferol 138-148 toll-like receptor 2 Mus musculus 196-200 31703120-10 2019 Mean change in eGFR from baseline to year 5 was -12.3 (95% CI, -13.4 to -11.2) mL/min/1.73 m2 with vitamin D3 vs -13.1 (95% CI, -14.2 to -11.9) mL/min/1.73 m2 with placebo (difference, 0.9 [95% CI, -0.7 to 2.5] mL/min/1.73 m2). Cholecalciferol 99-109 epidermal growth factor receptor Homo sapiens 15-19 31566824-5 2019 The treatment of vitamin D3 at lower doses to aged rats showed increased expression of BAX and active caspase-3 in the sperm, this finding suggests that increased apoptosis may be responsible for removal of poor quality sperm during aging. Cholecalciferol 17-27 BCL2 associated X, apoptosis regulator Rattus norvegicus 87-90 31566824-5 2019 The treatment of vitamin D3 at lower doses to aged rats showed increased expression of BAX and active caspase-3 in the sperm, this finding suggests that increased apoptosis may be responsible for removal of poor quality sperm during aging. Cholecalciferol 17-27 caspase 3 Rattus norvegicus 102-111 31566824-8 2019 It has been found that expression of AGER, visfatin, and HSPA1A increased in the sperm aged rats and vitamin D3 treatments at both doses decreased its expression. Cholecalciferol 101-111 advanced glycosylation end product-specific receptor Rattus norvegicus 37-41 31566824-9 2019 Thus, it might be suggested that during aging vitamin D3 treatment would be important for managing the sperm quality by regulating the apoptosis, antioxidant system and DNA integrity via modulation of visfatin and HSPA1A. Cholecalciferol 46-56 nicotinamide phosphoribosyltransferase Rattus norvegicus 201-209 31566824-9 2019 Thus, it might be suggested that during aging vitamin D3 treatment would be important for managing the sperm quality by regulating the apoptosis, antioxidant system and DNA integrity via modulation of visfatin and HSPA1A. Cholecalciferol 46-56 heat shock protein family A (Hsp70) member 1A Rattus norvegicus 214-220 31775746-18 2019 Additional experiment showed that Cyp27b1 gene knockout, leading to active vitamin D3 deficiency, exacerbated BLM-induced pulmonary fibrosis. Cholecalciferol 75-85 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 34-41 31619537-3 2019 We show that deletion of LprE Mtb results in reduction of M. tuberculosis virulence in human and mouse macrophages due to upregulation of vitamin D3-responsive cathelicidin expression through the TLR2-dependent p38-MAPK-CYP27B1-VDR signaling pathway. Cholecalciferol 138-148 mitogen-activated protein kinase 14 Mus musculus 211-219 31619537-3 2019 We show that deletion of LprE Mtb results in reduction of M. tuberculosis virulence in human and mouse macrophages due to upregulation of vitamin D3-responsive cathelicidin expression through the TLR2-dependent p38-MAPK-CYP27B1-VDR signaling pathway. Cholecalciferol 138-148 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 220-227 31619537-3 2019 We show that deletion of LprE Mtb results in reduction of M. tuberculosis virulence in human and mouse macrophages due to upregulation of vitamin D3-responsive cathelicidin expression through the TLR2-dependent p38-MAPK-CYP27B1-VDR signaling pathway. Cholecalciferol 138-148 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 228-231 31325498-1 2019 A phase inversion based cold water dilution method was developed to encapsulate Vitamin D3 (Vit D) in nano-structured lipid carrier (NLC) by blending caprylic-/capric triglyceride, Leciva S70 and Kolliphor HS 15, Vit D and sodium chloride. Cholecalciferol 80-90 vitrin Homo sapiens 92-95 31867158-3 2019 VD3 is converted to the active form, 1alpha,25-dihydroxyvitamin D3 (1,25-D3), by cytochrome P450 2R1 (CYP2R1)/CYP27A1 and CYP27B1 sequentially, and deactivated by multiple enzymes including CYP3A4. Cholecalciferol 0-3 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 81-100 31867158-3 2019 VD3 is converted to the active form, 1alpha,25-dihydroxyvitamin D3 (1,25-D3), by cytochrome P450 2R1 (CYP2R1)/CYP27A1 and CYP27B1 sequentially, and deactivated by multiple enzymes including CYP3A4. Cholecalciferol 0-3 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 102-108 31867158-3 2019 VD3 is converted to the active form, 1alpha,25-dihydroxyvitamin D3 (1,25-D3), by cytochrome P450 2R1 (CYP2R1)/CYP27A1 and CYP27B1 sequentially, and deactivated by multiple enzymes including CYP3A4. Cholecalciferol 0-3 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 110-117 31867158-3 2019 VD3 is converted to the active form, 1alpha,25-dihydroxyvitamin D3 (1,25-D3), by cytochrome P450 2R1 (CYP2R1)/CYP27A1 and CYP27B1 sequentially, and deactivated by multiple enzymes including CYP3A4. Cholecalciferol 0-3 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 122-129 31867158-3 2019 VD3 is converted to the active form, 1alpha,25-dihydroxyvitamin D3 (1,25-D3), by cytochrome P450 2R1 (CYP2R1)/CYP27A1 and CYP27B1 sequentially, and deactivated by multiple enzymes including CYP3A4. Cholecalciferol 0-3 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 190-196 31361973-12 2019 In the organoids and colitis IL-10-/- mice, vitamin D3 treatment increased VDR and ATG16L1 protein expression levels, which activated autophagic responses. Cholecalciferol 44-54 interleukin 10 Mus musculus 29-34 31361973-12 2019 In the organoids and colitis IL-10-/- mice, vitamin D3 treatment increased VDR and ATG16L1 protein expression levels, which activated autophagic responses. Cholecalciferol 44-54 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 75-78 31361973-12 2019 In the organoids and colitis IL-10-/- mice, vitamin D3 treatment increased VDR and ATG16L1 protein expression levels, which activated autophagic responses. Cholecalciferol 44-54 autophagy related 16-like 1 (S. cerevisiae) Mus musculus 83-90 31616008-3 2019 Mechanistically, we also found a gender-specific correlation of the CYP2C9rs1799853T/T genotype with serum vitamin D3 levels (P = 0.00085) and a modest effect on IL1beta levels after stimulation of PBMCs or blood with LPS and PHA (P = 0.0057 and P = 0.0058). Cholecalciferol 107-117 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 68-74 31798578-2 2019 Although there are only a few reports on interdependency of their actions, the interplay between IFN-gamma and vit D3 has been clearly demonstrated in certain aspects of immune reactivity. Cholecalciferol 111-117 interferon gamma Homo sapiens 97-106 31798578-4 2019 Combined treatment with vit D3 and IFN-gamma caused an extensive expression of immunoglobulin-like transcript (ILT)-3 and programmed death ligand (PDL)-1 on gamma/D3DCs, significantly greater than that caused by vit D3 alone. Cholecalciferol 24-30 leukocyte immunoglobulin like receptor B4 Homo sapiens 79-117 31798578-4 2019 Combined treatment with vit D3 and IFN-gamma caused an extensive expression of immunoglobulin-like transcript (ILT)-3 and programmed death ligand (PDL)-1 on gamma/D3DCs, significantly greater than that caused by vit D3 alone. Cholecalciferol 24-30 CD274 molecule Homo sapiens 133-153 31798578-4 2019 Combined treatment with vit D3 and IFN-gamma caused an extensive expression of immunoglobulin-like transcript (ILT)-3 and programmed death ligand (PDL)-1 on gamma/D3DCs, significantly greater than that caused by vit D3 alone. Cholecalciferol 212-218 interferon gamma Homo sapiens 35-44 31798578-4 2019 Combined treatment with vit D3 and IFN-gamma caused an extensive expression of immunoglobulin-like transcript (ILT)-3 and programmed death ligand (PDL)-1 on gamma/D3DCs, significantly greater than that caused by vit D3 alone. Cholecalciferol 212-218 leukocyte immunoglobulin like receptor B4 Homo sapiens 79-117 31798578-10 2019 The percentage of FoxP3-positive cells in co-cultures with naive CD4+ T cells was significantly higher where gamma/D3DCs were used as stimulators compared to DCs treated with vit D3 alone and it could be partially reversed by PDL-1 blockade. Cholecalciferol 175-181 forkhead box P3 Homo sapiens 18-23 31798578-10 2019 The percentage of FoxP3-positive cells in co-cultures with naive CD4+ T cells was significantly higher where gamma/D3DCs were used as stimulators compared to DCs treated with vit D3 alone and it could be partially reversed by PDL-1 blockade. Cholecalciferol 175-181 CD274 molecule Homo sapiens 226-231 31737787-2 2019 The present study investigated vitamin D3 on over-expression of CXCR3 and CXCL10 in mice induced by cigarette smoking. Cholecalciferol 31-41 chemokine (C-X-C motif) receptor 3 Mus musculus 64-69 31737787-2 2019 The present study investigated vitamin D3 on over-expression of CXCR3 and CXCL10 in mice induced by cigarette smoking. Cholecalciferol 31-41 chemokine (C-X-C motif) ligand 10 Mus musculus 74-80 31559433-0 2019 Effect of vitamin D3 supplementation on insulin resistance and beta-cell function in prediabetes: a double-blind, randomized, placebo-controlled trial. Cholecalciferol 10-20 insulin Homo sapiens 40-47 31559433-3 2019 OBJECTIVE: The purpose of this double-blind randomized placebo-controlled trial was to investigate the effect of vitamin D3 supplementation on insulin resistance (IR) and beta-cell function in people with prediabetes and suboptimal vitamin D status (<50 nmol/L). Cholecalciferol 113-123 insulin Homo sapiens 143-150 31614338-11 2019 CONCLUSIONS: In severe vitamin D deficiency, a high-dose cholecalciferol supplementation was associated with a reduction in thrombin generation and an average decreased number of fibrin protofibrils per fibers and fibrin fiber size measured by turbidimetry. Cholecalciferol 57-72 coagulation factor II, thrombin Homo sapiens 124-132 31365099-10 2019 CONCLUSIONS: In infants, vitamin D binding protein genotype affects 25OHD concentration and efficiency of high-dose vitamin D3 supplementation. Cholecalciferol 116-126 GC vitamin D binding protein Homo sapiens 25-50 31372708-0 2019 Oral vitamin D3 supplementation increases serum fibroblast growth factor 23 concentration in vitamin D-deficient patients: a systematic review and meta-analysis. Cholecalciferol 5-15 fibroblast growth factor 23 Homo sapiens 48-75 31372708-8 2019 The meta-analyses found that serum intact FGF23 increased significantly after oral vitamin D3 supplementation in vitamin D-deficient participants with the pooled SMD of 0.36 (95%CI, 0.14, 0.57; p = 0.001; I2 of 36%). Cholecalciferol 83-93 fibroblast growth factor 23 Homo sapiens 42-47 31372708-9 2019 Serum C-terminal FGF23 also increased after vitamin D3 supplementation in vitamin D-deficient participants with the pooled SMD of 0.28 although without reaching statistical significance (95%CI, - 0.08, 0.65; p = 0.13; I2 of 0%). Cholecalciferol 44-54 fibroblast growth factor 23 Homo sapiens 17-22 31372708-13 2019 The present systematic review and meta-analysis revealed that serum intact FGF23 concentration increased significantly after oral vitamin D3 supplementation in vitamin D-deficient participants. Cholecalciferol 130-140 fibroblast growth factor 23 Homo sapiens 75-80 31582399-1 2019 OBJECTIVE: To determine the effect of vitamin D3 on interferon-beta (IFN-beta) response and immune regulation in MS mononuclear cells (MNCs). Cholecalciferol 38-48 interferon beta 1 Homo sapiens 52-67 31582399-1 2019 OBJECTIVE: To determine the effect of vitamin D3 on interferon-beta (IFN-beta) response and immune regulation in MS mononuclear cells (MNCs). Cholecalciferol 38-48 interferon beta 1 Homo sapiens 69-77 31465769-9 2019 Vitamin D3 effects on epithelial intracellular Ca++ (Ca++i) were determined using the dye Cal-520. Cholecalciferol 0-10 carbonic anhydrase 1 Mus musculus 53-58 31561249-14 2019 Thus, vitamin D3 is involved in desmosome and hemidesmosome junction formation/regulation, and their decreased expression likely contributes to the loosely adherent corneal epithelium in VDR KO mice. Cholecalciferol 6-16 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 187-190 31250540-10 2019 Supplementation with 2,000-IU/d vitamin D3 is more effective than 1,000 IU/d in pregnant women in terms of increasing circulating 25(OH)D, ameliorating pro-inflammatory markers notably TNF-alpha in mother and IL-6 in cord blood, and improving neonatal outcomes including the birth sizes. Cholecalciferol 32-42 tumor necrosis factor Homo sapiens 185-194 31250540-10 2019 Supplementation with 2,000-IU/d vitamin D3 is more effective than 1,000 IU/d in pregnant women in terms of increasing circulating 25(OH)D, ameliorating pro-inflammatory markers notably TNF-alpha in mother and IL-6 in cord blood, and improving neonatal outcomes including the birth sizes. Cholecalciferol 32-42 interleukin 6 Homo sapiens 209-213 31326626-2 2019 Calcitriol (1,25D3), the most active form of vitamin D3, acts mainly through the vitamin D receptor, regulating the expression of target genes. Cholecalciferol 45-55 vitamin D receptor Homo sapiens 81-99 31001801-9 2019 Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation. Cholecalciferol 164-174 oxytocin/neurophysin I prepropeptide Rattus norvegicus 23-26 31539353-4 2019 Materials and methods We evaluated the effect of in vitro treatment with a precursor of VitD, cholecalciferol, on the activation/maturation phenotype of differentiated monocyte-derived DCs and their ability to transfer HIV-1 to autologous CD4+ T cells. Cholecalciferol 94-109 CD4 molecule Homo sapiens 239-242 31001801-9 2019 Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation. Cholecalciferol 164-174 prodynorphin Rattus norvegicus 28-32 31001801-9 2019 Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation. Cholecalciferol 164-174 proenkephalin Rattus norvegicus 34-38 31001801-9 2019 Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation. Cholecalciferol 164-174 proopiomelanocortin Rattus norvegicus 40-44 31001801-9 2019 Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation. Cholecalciferol 164-174 parathyroid hormone Rattus norvegicus 46-49 31001801-9 2019 Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation. Cholecalciferol 164-174 tachykinin, precursor 1 Rattus norvegicus 51-55 31001801-9 2019 Overall, several genes-Oxt, Pdyn, Penk, Pomc, Pth, Tac1, and Tgfb1-encoding for peptides/hormones stand out as top candidates to explain the therapeutic benefit of vitamin D3 supplementation. Cholecalciferol 164-174 transforming growth factor, beta 1 Rattus norvegicus 61-66 31352041-0 2019 Effects of glucocorticoids on vitamin D3-metabolizing 24-hydroxylase (CYP24A1) in Saos-2 cells and primary human osteoblasts. Cholecalciferol 30-40 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 70-77 31352041-4 2019 In the current study, human osteosarcoma Saos-2 cells and primary human osteoblasts were found to express mRNA for the vitamin D receptor as well as activating and deactivating enzymes in vitamin D3 metabolism. Cholecalciferol 188-198 vitamin D receptor Homo sapiens 119-137 31402771-8 2019 Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed. Cholecalciferol 96-106 interleukin 4 Mus musculus 135-139 31402771-8 2019 Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed. Cholecalciferol 96-106 interleukin 10 Mus musculus 141-146 31402771-8 2019 Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed. Cholecalciferol 96-106 transforming growth factor, beta 1 Mus musculus 152-160 31402771-8 2019 Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed. Cholecalciferol 96-106 interferon gamma Mus musculus 213-222 31402771-8 2019 Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed. Cholecalciferol 96-106 interleukin 6 Mus musculus 224-228 31402771-8 2019 Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed. Cholecalciferol 96-106 tumor necrosis factor Mus musculus 230-239 31402771-8 2019 Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed. Cholecalciferol 96-106 interleukin 17A Mus musculus 245-250 31402771-10 2019 Real-time PCR results indicated that middle and high dose vitamin D3 treatment reduced T-bet and ROR-gammat expression, but enhanced GATA3 and Foxp3 expression. Cholecalciferol 58-68 GATA binding protein 3 Mus musculus 133-138 31402771-10 2019 Real-time PCR results indicated that middle and high dose vitamin D3 treatment reduced T-bet and ROR-gammat expression, but enhanced GATA3 and Foxp3 expression. Cholecalciferol 58-68 forkhead box P3 Mus musculus 143-148 31402771-12 2019 This study indicated that middle and high doses of vitamin D3 deviate the balance between Th1/Th2 and Th17/Treg to Th2 and Treg. Cholecalciferol 51-61 negative elongation factor complex member C/D, Th1l Mus musculus 90-93 31402771-12 2019 This study indicated that middle and high doses of vitamin D3 deviate the balance between Th1/Th2 and Th17/Treg to Th2 and Treg. Cholecalciferol 51-61 heart and neural crest derivatives expressed 2 Mus musculus 94-97 31402771-12 2019 This study indicated that middle and high doses of vitamin D3 deviate the balance between Th1/Th2 and Th17/Treg to Th2 and Treg. Cholecalciferol 51-61 heart and neural crest derivatives expressed 2 Mus musculus 115-118 31575929-8 2019 The expression of AGER was down-regulated by vitamin D3 treatment in aged testis. Cholecalciferol 45-55 advanced glycosylation end product-specific receptor Rattus norvegicus 18-22 31575929-10 2019 The immunolocalization of VDR showed increased immunostaining in the testis by vitamin D3 treatment. Cholecalciferol 79-89 vitamin D receptor Rattus norvegicus 26-29 31527804-10 2019 Moreover, the expression levels of hsa-miR146b-5p in CD14+ monocytes were significantly increased after achieving SVR and 1(OH)Vitamin D3 treatment. Cholecalciferol 127-137 CD14 molecule Homo sapiens 53-57 31427443-13 2019 In vitro experiments showed that active vitamin D3 inhibits TGF-beta-induced Smad2/3 phosphorylation in MRC-5 cells. Cholecalciferol 40-50 transforming growth factor alpha Homo sapiens 60-68 31427443-13 2019 In vitro experiments showed that active vitamin D3 inhibits TGF-beta-induced Smad2/3 phosphorylation in MRC-5 cells. Cholecalciferol 40-50 SMAD family member 2 Homo sapiens 77-84 31572402-1 2019 The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) activates at sub-nanomolar concentrations the transcription factor vitamin D receptor (VDR). Cholecalciferol 4-14 vitamin D receptor Homo sapiens 137-155 31521173-0 2019 Correction to: Vitamin D receptor gene polymorphisms affecting changes in visceral fat, waist circumference and lipid profile in breast cancer survivors supplemented with vitamin D3. Cholecalciferol 171-181 vitamin D receptor Homo sapiens 15-33 31572402-1 2019 The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) activates at sub-nanomolar concentrations the transcription factor vitamin D receptor (VDR). Cholecalciferol 4-14 vitamin D receptor Homo sapiens 157-160 31519581-6 2019 CONCLUSION: Antioxidant regulation via TXNIP is an important cell death mechanism in human endometrial cancer, and occurs via induction by vitamin D3. Cholecalciferol 139-149 thioredoxin interacting protein Homo sapiens 39-44 31583252-10 2019 Conclusion: The serum 25(OH)D level in patients with diabetes mellitus after long-term vitamin D3 supplementation is associated with CYP27B1 polymorphism. Cholecalciferol 87-97 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 133-140 31508781-3 2019 Immunomodulation mediated by vitamin D3, especially the production of antimicrobial peptides such as cathelicidin LL-37, might be related to the severity and symptoms of CD. Cholecalciferol 29-39 cathelicidin antimicrobial peptide Homo sapiens 114-119 30696977-8 2019 RESULTS: Results of this study showed that cholecalciferol supplementation caused a significant decrease in Th17/Tr1 ratio. Cholecalciferol 43-58 thioredoxin reductase 1 Homo sapiens 113-116 30696977-12 2019 CONCLUSIONS: In this novel preliminary clinical trial study, supplementation with cholecalciferol in HT patients for 3 months changed the balance of CD4+ T-cell subsets to improve the disease control. Cholecalciferol 82-97 CD4 molecule Homo sapiens 149-152 31313056-11 2019 The rs10766197 variant, near the CYP2R1 gene locus, significantly modified the efficacy of high-dose vitamin D3 supplementation for its effects on improving cognitive abilities indicate that some subjects might require a higher dose to benefit from in terms of cognitive performance. Cholecalciferol 101-111 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 33-39 31344685-1 2019 OBJECTIVE: To determine whether vitamin D3 supplementation improves insulin sensitivity, using the hyperinsulinemic-euglycemic clamp. Cholecalciferol 32-42 insulin Homo sapiens 68-75 31265936-5 2019 In this work, best binding modes of vitamin D3 and E on insulin obtained from AutoDock Vina were selected for Molecular Dynamic, MD, study. Cholecalciferol 36-46 insulin Homo sapiens 56-63 31496777-4 2019 As an affordable natural agent, vitamin D3 can be used to counteract obesity-induced inflammation, block early adipogenesis, enhance glucose uptake, counteract hyperleptinemia, ameliorate insulin resistance, and reduce hypertension. Cholecalciferol 32-42 insulin Homo sapiens 188-195 30712064-0 2019 Novel bisphosphonate compound FYB-931 preferentially inhibits aortic calcification in vitamin D3-treated rats. Cholecalciferol 86-96 FYN binding protein 1 Rattus norvegicus 30-33 31169292-6 2019 Furthermore, the DNA mismatch repair pathway is elevated in Lgr5hi cells by lower vitamin D3 and/or calcium in NWD1, paralleled by reduced accumulation of relevant somatic mutations detected by single-cell exome sequencing. Cholecalciferol 82-92 leucine rich repeat containing G protein coupled receptor 5 Mus musculus 60-64 30916559-2 2019 Vitamin D3 acts via its metabolite 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] as potent agonist of the transcription factor vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 125-143 31395070-0 2019 Vitamin D receptor gene polymorphisms affecting changes in visceral fat, waist circumference and lipid profile in breast cancer survivors supplemented with vitamin D3. Cholecalciferol 156-166 vitamin D receptor Homo sapiens 0-18 31395070-5 2019 Multivariate multiple linear regression analyses were used to determine the association between the VDR single-nucleotide polymorphisms (SNPs) and changes in metabolic and anthropometric measures in response to vitamin D3 supplementation. Cholecalciferol 211-221 vitamin D receptor Homo sapiens 100-103 31395070-8 2019 In addition, the heterozygous genotype (Bb) of the BsmI VDR was associated with higher increase in WC following vitamin D3 supplementation, compared to BB [2.7(0.1,5.3)]. Cholecalciferol 112-122 vitamin D receptor Homo sapiens 56-59 31395070-10 2019 CONCLUSIONS: Findings of this study showed that genetic variation in the VDR gene was associated with changes in cardio-metabolic parameters in breast cancer survivors, supplemented with vitamin D3, results could provide a novel insight into better understanding of which subset of individuals benefit most from normalization of vitamin D status. Cholecalciferol 187-197 vitamin D receptor Homo sapiens 73-76 31176774-0 2019 Vitamin D3 increases the Caspase-3 p12, MTHFR, and P-glycoprotein reducing amyloid-beta42 in the kidney of a mouse model for Down syndrome. Cholecalciferol 0-10 caspase 3 Mus musculus 25-34 31176774-0 2019 Vitamin D3 increases the Caspase-3 p12, MTHFR, and P-glycoprotein reducing amyloid-beta42 in the kidney of a mouse model for Down syndrome. Cholecalciferol 0-10 CDK2 (cyclin-dependent kinase 2)-associated protein 1 Mus musculus 35-38 31176774-0 2019 Vitamin D3 increases the Caspase-3 p12, MTHFR, and P-glycoprotein reducing amyloid-beta42 in the kidney of a mouse model for Down syndrome. Cholecalciferol 0-10 methylenetetrahydrofolate reductase Mus musculus 40-45 31176774-0 2019 Vitamin D3 increases the Caspase-3 p12, MTHFR, and P-glycoprotein reducing amyloid-beta42 in the kidney of a mouse model for Down syndrome. Cholecalciferol 0-10 phosphoglycolate phosphatase Mus musculus 51-65 30916559-2 2019 Vitamin D3 acts via its metabolite 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] as potent agonist of the transcription factor vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 145-148 31460469-1 2019 The multimolecular complexes formed between 2,4,6,8,10,12-hexanitro-2,4,6,6,8,10,12-hexaazaisowurtzitane (CL-20) and nitropyrazole compounds were investigated using B3LYP-D3/6-311G(d,p) and B97-3c methods. Cholecalciferol 170-173 epithelial membrane protein 1 Homo sapiens 106-111 31387633-0 2019 Regulation of somatostatin expression by vitamin D3 and valproic acid in human adipose-derived mesenchymal stem cells. Cholecalciferol 41-51 somatostatin Homo sapiens 14-26 31387633-6 2019 Furthermore, the reprogramming effect of vitamin D3 and VPA was evaluated on somatostatin expression in pancreatic lineage differentiation. Cholecalciferol 41-51 somatostatin Homo sapiens 77-89 31387633-12 2019 Upon stimulation with vitamin D3, nuclear translocation of vitamin D receptor (VDR) was observed. Cholecalciferol 22-32 vitamin D receptor Homo sapiens 59-77 31387633-12 2019 Upon stimulation with vitamin D3, nuclear translocation of vitamin D receptor (VDR) was observed. Cholecalciferol 22-32 vitamin D receptor Homo sapiens 79-82 31450894-0 2019 IL-6 Impairs the Activity of Vitamin D3 in the Regulation of Epithelial-Mesenchymal Transition in Triple Negative Breast Cancer. Cholecalciferol 29-39 interleukin 6 Homo sapiens 0-4 31387633-13 2019 Interestingly, the presence of vitamin D3 reduced the transcription of the somatostatin gene. Cholecalciferol 31-41 somatostatin Homo sapiens 75-87 31387633-18 2019 Moreover, our results demonstrate that somatostatin expression in ADMSC is constitutive, partially secreted and regulated by vitamin D3 and VPA. Cholecalciferol 125-135 somatostatin Homo sapiens 39-51 31450894-12 2019 Conclusion: The presence of IL-6 in the breast tumor microenvironment may impair theactivity of vitamin D3 signaling, limiting its anti-tumor effects in TNBC. Cholecalciferol 96-106 interleukin 6 Homo sapiens 28-32 30597013-9 2019 Moreover, ChemR23-deficient mice were protected against vitamin D3-induced vascular calcification. Cholecalciferol 56-66 chemokine-like receptor 1 Mus musculus 10-17 30888584-0 2019 Cholecalciferol supplementation increases FGF23 in peritoneal dialysis patients with hypovitaminosis D: a randomized clinical trial. Cholecalciferol 0-15 fibroblast growth factor 23 Homo sapiens 42-47 31043390-1 2019 PURPOSE: The biologically active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 (vit D), has immunoregulatory properties via binding vitamin D receptor (VDR). Cholecalciferol 47-57 vitamin D receptor Homo sapiens 137-155 31043390-1 2019 PURPOSE: The biologically active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 (vit D), has immunoregulatory properties via binding vitamin D receptor (VDR). Cholecalciferol 47-57 vitamin D receptor Homo sapiens 157-160 30802957-11 2019 Topical application of both vitamin D3 and 1,25(OH)2 D3 to the gingiva of mice led to rapid inhibition of IL-1alpha expression, a prominent pro-inflammatory cytokine associated with inflammation, which also exhibited more than a 2-fold decrease from basal levels in OKF6/TERT1 cells upon 1,25(OH)2 D3 treatment, as determined by RNA-seq. Cholecalciferol 28-38 interleukin 1 alpha Mus musculus 106-115 31357443-4 2019 The results showed that vitamin D3 (5.0 mg/kg), as well as fluoxetine treatment, considerably reversed the depression-like state in the SPT and FST, decreased serum corticosterone/ACTH levels, and increased BDNF and NT-3/NT-4 levels in the hippocampus of long-term OVX rats compared to OVX rats with CUMS (p < 0.05). Cholecalciferol 24-34 brain-derived neurotrophic factor Rattus norvegicus 207-211 30825201-3 2019 In this study, we show that 1,25-dihydroxyvitamin D3 (the active form of vitamin D3) induces senescence of glioma cells and increases the expression of senescence markers, INK4A and cyclin-dependent kinase inhibitor 1A (CDKN1A). Cholecalciferol 42-52 cyclin dependent kinase inhibitor 2A Homo sapiens 172-177 30825201-3 2019 In this study, we show that 1,25-dihydroxyvitamin D3 (the active form of vitamin D3) induces senescence of glioma cells and increases the expression of senescence markers, INK4A and cyclin-dependent kinase inhibitor 1A (CDKN1A). Cholecalciferol 42-52 cyclin dependent kinase inhibitor 1A Homo sapiens 182-218 30825201-3 2019 In this study, we show that 1,25-dihydroxyvitamin D3 (the active form of vitamin D3) induces senescence of glioma cells and increases the expression of senescence markers, INK4A and cyclin-dependent kinase inhibitor 1A (CDKN1A). Cholecalciferol 42-52 cyclin dependent kinase inhibitor 1A Homo sapiens 220-226 31357443-5 2019 Thus, a high dose of vitamin D3 (5.0 mg/kg sc) could improve the depression-like profile in long-term OVX adult female rats subjected to the CUMS procedure, which might be mediated by the regulation of BDNF and the NT-3/NT-4 signaling pathways in the hippocampus, as well as the corticosterone/ACTH levels of the blood serum. Cholecalciferol 21-31 brain-derived neurotrophic factor Rattus norvegicus 202-206 31044263-9 2019 Furthermore, using a multiple linear regression model, we confirmed FGF23 as a predictor for reduced trabecular parameters even when adjusting for confounding factors such as age, BMI, phosphate, bone-specific alkaline phosphatase, vitamin D3, and PTH. Cholecalciferol 232-242 fibroblast growth factor 23 Homo sapiens 68-73 31592277-24 2019 Vitamin D3 level (1,25(OH)2D) was negatively associated with serum TNF-alpha concentration and airway obstruction level and severity of COPD. Cholecalciferol 0-10 tumor necrosis factor Homo sapiens 67-76 31357443-4 2019 The results showed that vitamin D3 (5.0 mg/kg), as well as fluoxetine treatment, considerably reversed the depression-like state in the SPT and FST, decreased serum corticosterone/ACTH levels, and increased BDNF and NT-3/NT-4 levels in the hippocampus of long-term OVX rats compared to OVX rats with CUMS (p < 0.05). Cholecalciferol 24-34 neurotrophin 3 Rattus norvegicus 216-220 31357443-5 2019 Thus, a high dose of vitamin D3 (5.0 mg/kg sc) could improve the depression-like profile in long-term OVX adult female rats subjected to the CUMS procedure, which might be mediated by the regulation of BDNF and the NT-3/NT-4 signaling pathways in the hippocampus, as well as the corticosterone/ACTH levels of the blood serum. Cholecalciferol 21-31 neurotrophin 3 Rattus norvegicus 215-219 31357443-4 2019 The results showed that vitamin D3 (5.0 mg/kg), as well as fluoxetine treatment, considerably reversed the depression-like state in the SPT and FST, decreased serum corticosterone/ACTH levels, and increased BDNF and NT-3/NT-4 levels in the hippocampus of long-term OVX rats compared to OVX rats with CUMS (p < 0.05). Cholecalciferol 24-34 neurotrophin 4 Rattus norvegicus 221-225 31357443-5 2019 Thus, a high dose of vitamin D3 (5.0 mg/kg sc) could improve the depression-like profile in long-term OVX adult female rats subjected to the CUMS procedure, which might be mediated by the regulation of BDNF and the NT-3/NT-4 signaling pathways in the hippocampus, as well as the corticosterone/ACTH levels of the blood serum. Cholecalciferol 21-31 neurotrophin 4 Rattus norvegicus 220-224 30478352-10 2019 Treatment of UF cells with Vitamin D3 (100 nM) significantly decreased DNA damage and restored DDR concomitant with VDR induction. Cholecalciferol 27-37 vitamin D receptor Homo sapiens 116-119 30827608-2 2019 In this study, the interactions of beta-casein with curcumin and vitamin D3 under the same physico-chemical conditions were investigated. Cholecalciferol 65-75 casein beta Bos taurus 35-46 30827608-5 2019 Conversely, the SPR responses obtained for vitamin D3 show that the interactions between this hydrophobic compound and the beta-casein immobilized on the sensor chip were below the sensitivity of the SPR apparatus. Cholecalciferol 43-53 casein beta Bos taurus 123-134 31287793-0 2019 miR-99b-3p is induced by vitamin D3 and contributes to its antiproliferative effects in gastric cancer cells by targeting HoxD3. Cholecalciferol 25-35 microRNA 99b Homo sapiens 0-7 31287793-0 2019 miR-99b-3p is induced by vitamin D3 and contributes to its antiproliferative effects in gastric cancer cells by targeting HoxD3. Cholecalciferol 25-35 homeobox D3 Homo sapiens 122-127 31287793-2 2019 miR-99b-3p, the tumor suppressor gene, is not only decreased in GC tissues, but is also induced by vitamin D3 through the vitamin D receptor (VDR) binding on the promoter domain of miR-99b. Cholecalciferol 99-109 microRNA 99b Homo sapiens 0-7 31287793-2 2019 miR-99b-3p, the tumor suppressor gene, is not only decreased in GC tissues, but is also induced by vitamin D3 through the vitamin D receptor (VDR) binding on the promoter domain of miR-99b. Cholecalciferol 99-109 vitamin D receptor Homo sapiens 122-140 31287793-2 2019 miR-99b-3p, the tumor suppressor gene, is not only decreased in GC tissues, but is also induced by vitamin D3 through the vitamin D receptor (VDR) binding on the promoter domain of miR-99b. Cholecalciferol 99-109 vitamin D receptor Homo sapiens 142-145 31287793-2 2019 miR-99b-3p, the tumor suppressor gene, is not only decreased in GC tissues, but is also induced by vitamin D3 through the vitamin D receptor (VDR) binding on the promoter domain of miR-99b. Cholecalciferol 99-109 microRNA 99b Homo sapiens 181-188 31287793-4 2019 Overall, our results show that miR-99b-3p mediates the antiproliferative of vitamin D3 in GC cells and might hold promise for prognosis and therapeutic strategies for GC treatment. Cholecalciferol 76-86 microRNA 99b Homo sapiens 31-38 30478352-11 2019 Notably, the PCR array demonstrated that among 75 downregulated genes after VDR KD, 67 (89.3%) were upregulated after vitamin D3 treatment. Cholecalciferol 118-128 vitamin D receptor Homo sapiens 76-79 31350967-0 2019 Genetic Variations in VDR could Modulate the Efficacy of Vitamin D3 Supplementation on Inflammatory Markers and Total Antioxidant Capacity among Breast Cancer Women: A Randomized Double Blind Controlled Trial. Cholecalciferol 57-67 vitamin D receptor Homo sapiens 22-25 31350967-4 2019 This study was aimed to assess the impact of vitamin D3 supplementation onthe serum concentration of inflammatory markers and antioxidant capacity with regard to VDR polymorphism in theVDR gene in breast cancer women. Cholecalciferol 45-55 vitamin D receptor Homo sapiens 162-165 31174403-0 2019 The Influence of Different Cholecalciferol Supplementation Regimes on 25(OH) Cholecalciferol, Calcium and Parathyroid Hormone after Bariatric Surgery. Cholecalciferol 27-42 parathyroid hormone Homo sapiens 106-125 30856341-8 2019 Vitamin D3 treatment significantly decreased ovariectomy-induced cardiac Fas and FasL apoptosis-related proteins, whole heart mass, body mass, C-reactive protein, and malondialdehyde accompanied by decreased inflammation and reduced collagen deposition between cardiac muscle fibres. Cholecalciferol 0-10 Fas ligand Rattus norvegicus 81-85 30856341-8 2019 Vitamin D3 treatment significantly decreased ovariectomy-induced cardiac Fas and FasL apoptosis-related proteins, whole heart mass, body mass, C-reactive protein, and malondialdehyde accompanied by decreased inflammation and reduced collagen deposition between cardiac muscle fibres. Cholecalciferol 0-10 C-reactive protein Rattus norvegicus 143-161 30959372-8 2019 RESULTS: Vitamin D3 significantly increased the expression of mPR alpha and mPR beta on the surface of CD4+ T cells (p <= 0.05). Cholecalciferol 9-19 S100 calcium binding protein A6 (calcyclin) Mus musculus 62-71 30959372-8 2019 RESULTS: Vitamin D3 significantly increased the expression of mPR alpha and mPR beta on the surface of CD4+ T cells (p <= 0.05). Cholecalciferol 9-19 progesterone receptor Mus musculus 76-84 31233568-7 2019 In young healthy mice acute or chronic treatment with D3 induces hyperactivation of TrkA-mediated signals in hippocampus, and causes a deficit in hippocampal-dependent memory consolidation proximal to drug exposure, without affecting learning or memory retrieval. Cholecalciferol 54-56 neurotrophic tyrosine kinase, receptor, type 1 Mus musculus 84-88 31140795-5 2019 Advantages of the stereodivergent nature of this reaction are seen in the synthesis of anti- and syn-1,3 amino alcohol vitamin D3 analogue intermediates in half the steps and higher overall yield relative to previous routes. Cholecalciferol 119-129 synapsin I Homo sapiens 97-102 31278070-2 2019 Deficiency in vitamin D3 (VD3), which regulates gene expression through binding to vitamin D receptor (VDR), is associated with high risks of COPD susceptibility. Cholecalciferol 14-24 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 83-101 31278070-2 2019 Deficiency in vitamin D3 (VD3), which regulates gene expression through binding to vitamin D receptor (VDR), is associated with high risks of COPD susceptibility. Cholecalciferol 14-24 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 103-106 31460236-0 2019 Synthesis and CYP24A1-Dependent Metabolism of 23-Fluorinated Vitamin D3 Analogues. Cholecalciferol 61-71 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 14-21 31293564-0 2019 MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients. Cholecalciferol 33-43 microtubule associated protein 7 Homo sapiens 0-4 31293564-0 2019 MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients. Cholecalciferol 33-43 mucin like 1 Homo sapiens 9-14 30790351-8 2019 Using linear regression we determined a curve with 25(OH)D3/cholecalciferol versus normalized Cyp2R1 mRNA abundance with an R2 value of 0.85. Cholecalciferol 60-75 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 94-100 31281852-0 2019 Vitamin D3 Activates Phosphatidylinositol-3-Kinase/Protein Kinase B via Insulin-Like Growth Factor-1 to Improve Testicular Function in Diabetic Rats. Cholecalciferol 0-10 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma Rattus norvegicus 21-50 31281852-0 2019 Vitamin D3 Activates Phosphatidylinositol-3-Kinase/Protein Kinase B via Insulin-Like Growth Factor-1 to Improve Testicular Function in Diabetic Rats. Cholecalciferol 0-10 insulin-like growth factor 1 Rattus norvegicus 72-100 31281852-7 2019 Results: Twelve weeks of vitamin D3 supplementation improved the testosterone levels, as shown by the increase in the level of serum IGF-1 in diabetic rats. Cholecalciferol 25-35 insulin-like growth factor 1 Rattus norvegicus 133-138 31281852-8 2019 Phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT), which was a downstream of the signaling pathway of IGF-1, was significantly increased after vitamin D3 treatment. Cholecalciferol 153-163 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma Rattus norvegicus 0-29 31281852-8 2019 Phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT), which was a downstream of the signaling pathway of IGF-1, was significantly increased after vitamin D3 treatment. Cholecalciferol 153-163 AKT serine/threonine kinase 1 Rattus norvegicus 55-58 31281852-8 2019 Phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT), which was a downstream of the signaling pathway of IGF-1, was significantly increased after vitamin D3 treatment. Cholecalciferol 153-163 insulin-like growth factor 1 Rattus norvegicus 112-117 31281852-9 2019 Conclusions: The study shows that vitamin D3 may promote the expression of testosterone and improve testicular function in diabetic rats by activating PI3K/AKT via IGF-1. Cholecalciferol 34-44 AKT serine/threonine kinase 1 Rattus norvegicus 156-159 31281852-9 2019 Conclusions: The study shows that vitamin D3 may promote the expression of testosterone and improve testicular function in diabetic rats by activating PI3K/AKT via IGF-1. Cholecalciferol 34-44 insulin-like growth factor 1 Rattus norvegicus 164-169 31167402-0 2019 Vitamin D Receptor Genetic Variation and Cancer Biomarkers among Breast Cancer Patients Supplemented with Vitamin D3: A Single-Arm Non-Randomized Before and After Trial. Cholecalciferol 106-116 vitamin D receptor Homo sapiens 0-18 31167402-5 2019 In addition, carriers of BsmI bb showed greater decrease in circulating TNFalpha levels after vitamin D3 supplementation [recessive model (bb compared to BB & Bb]. Cholecalciferol 94-104 tumor necrosis factor Homo sapiens 72-80 31167402-8 2019 Overall, our findings suggest that changes in certain inflammatory biomarkers in breast cancer survivors with low plasma 25(OH)D levels, supplemented with vitamin D3, may depend on VDR SNPs and haplotypes. Cholecalciferol 155-165 vitamin D receptor Homo sapiens 181-184 31086078-6 2019 Using the CRISPR-Cas9 editing technology to knockout the vitamin D receptor, we found that the antiviral activity of vitamin D3 and 25(OH)D3 was not impaired in the vitamin D receptor knockout cells. Cholecalciferol 117-127 vitamin D receptor Homo sapiens 57-75 30927227-4 2019 The proteins of FGF19 subfamily influence the enterohepatic circulation of bile, participate in glucose and lipid metabolism regulation, and maintenance of phosphorus and vitamin D3 homeostasis. Cholecalciferol 171-181 fibroblast growth factor 19 Homo sapiens 16-21 30923019-6 2019 Vitamin D3 treatment also increased CYP19A1 and decreased AR expression in the testes of d-gal-induced aged and normal rats. Cholecalciferol 0-10 cytochrome P450, family 19, subfamily a, polypeptide 1 Rattus norvegicus 36-43 30923019-6 2019 Vitamin D3 treatment also increased CYP19A1 and decreased AR expression in the testes of d-gal-induced aged and normal rats. Cholecalciferol 0-10 ferredoxin reductase Rattus norvegicus 58-60 31092845-1 2019 Vitamin D3 (vitD3) and its active metabolite, calcitriol (1,25-(OH)2D3), affect multiple tissue types by interacting with the vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 126-144 31092845-1 2019 Vitamin D3 (vitD3) and its active metabolite, calcitriol (1,25-(OH)2D3), affect multiple tissue types by interacting with the vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 146-149 30930221-3 2019 Hence, we assessed the role of sodium butyrate (NaB), sodium octanoate (NaO) and cholecalciferol on S. aureus adhesin expression and its internalization into bMECs. Cholecalciferol 81-96 AT695_RS03940 Staphylococcus aureus 110-117 31002352-7 2019 Furthermore, vitamin D3 delayed the onset of tumor formation derived from injection of ovarian CSCs to nude mice, by reducing CD44 and enhancing beta-catenin expressions in vivo. Cholecalciferol 13-23 CD44 antigen Mus musculus 126-130 31002352-7 2019 Furthermore, vitamin D3 delayed the onset of tumor formation derived from injection of ovarian CSCs to nude mice, by reducing CD44 and enhancing beta-catenin expressions in vivo. Cholecalciferol 13-23 catenin (cadherin associated protein), beta 1 Mus musculus 145-157 31039479-0 2019 Protective effects of novel derivatives of vitamin D3 and lumisterol against UVB-induced damage in human keratinocytes involve activation of Nrf2 and p53 defense mechanisms. Cholecalciferol 43-53 NFE2 like bZIP transcription factor 2 Homo sapiens 141-145 31039479-0 2019 Protective effects of novel derivatives of vitamin D3 and lumisterol against UVB-induced damage in human keratinocytes involve activation of Nrf2 and p53 defense mechanisms. Cholecalciferol 43-53 tumor protein p53 Homo sapiens 150-153 31039479-12 2019 In conclusion, pretreatment of keratinocytes with 1,25(OH)2D3 or CYP11A1-derived vitamin D3- or lumisterol hydroxy-derivatives, protected them against UVB-induced damage via activation of the Nrf2-dependent antioxidant response and p53-phosphorylation, as well as by the induction of the DNA repair system. Cholecalciferol 81-91 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 65-72 31039479-12 2019 In conclusion, pretreatment of keratinocytes with 1,25(OH)2D3 or CYP11A1-derived vitamin D3- or lumisterol hydroxy-derivatives, protected them against UVB-induced damage via activation of the Nrf2-dependent antioxidant response and p53-phosphorylation, as well as by the induction of the DNA repair system. Cholecalciferol 81-91 NFE2 like bZIP transcription factor 2 Homo sapiens 192-196 31039479-12 2019 In conclusion, pretreatment of keratinocytes with 1,25(OH)2D3 or CYP11A1-derived vitamin D3- or lumisterol hydroxy-derivatives, protected them against UVB-induced damage via activation of the Nrf2-dependent antioxidant response and p53-phosphorylation, as well as by the induction of the DNA repair system. Cholecalciferol 81-91 tumor protein p53 Homo sapiens 232-235 31086078-9 2019 Taken together, this study proposes a novel mode of action for the anti-hepatitis C virus activity of vitamin D3 that is mediated by 25(OH)D3 in a vitamin D receptor-independent mechanism. Cholecalciferol 102-112 vitamin D receptor Homo sapiens 147-165 30972950-0 2019 Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 72-75 30729713-1 2019 AIM: Vitamin D3 or 25(OH)D3 may have a potential role in rheumatoid arthritis (RA) pathogenesis by inhibiting the expression of pro-inflammatory cytokines including interleukin-6 (IL-6). Cholecalciferol 5-15 interleukin 6 Homo sapiens 165-178 30765133-4 2019 Tolerogenic DC (tolDC) obtained by vitamin D3 treatment were studied in parallel. Cholecalciferol 35-45 chemokine (C-C motif) ligand 22 Mus musculus 12-14 30729713-1 2019 AIM: Vitamin D3 or 25(OH)D3 may have a potential role in rheumatoid arthritis (RA) pathogenesis by inhibiting the expression of pro-inflammatory cytokines including interleukin-6 (IL-6). Cholecalciferol 5-15 interleukin 6 Homo sapiens 180-184 31060176-14 2019 (2) At PIH 6 and 24, expressions of ZO-1 and occludin of intestinal tissue of mice in vitamin D3 vehicle+ burn injury group were significantly lower than those of mice in vitamin D3 vehicle+ sham injury group, and expressions of ZO-1 and occludin of intestinal tissue of mice in vitamin D3+ burn injury group were close to those of mice in vitamin D3+ sham injury group. Cholecalciferol 86-96 occludin Mus musculus 45-53 31060176-15 2019 At PIH 6 and 24, expressions of ZO-1 and occludin of intestinal tissue of mice in vitamin D3+ burn injury group were significantly higher than those of mice in vitamin D3 vehicle+ burn injury group. Cholecalciferol 82-92 occludin Mus musculus 41-49 31060176-18 2019 (4) At PIH 6 and 24, expressions of occludin of intestinal tissue of mice in vitamin D3 vehicle+ burn injury group were 0.720+-0.003, 0.638+-0.052 respectively, significantly lower than 0.918+-0.003 of mice in vitamin D3 vehicle+ sham injury group (t=57.33, 5.36, P<0.05). Cholecalciferol 77-87 occludin Mus musculus 36-44 31060176-19 2019 At PIH 6 and 24, expressions of occludin of intestinal tissue of mice in vitamin D3+ burn injury group were 0.994+-0.058, 1.064+-0.060, close to 0.938+-0.023 of mice in vitamin D3+ sham injury group (t=0.91, 1.96, P>0.05). Cholecalciferol 73-83 occludin Mus musculus 32-40 31060176-20 2019 At PIH 6 and 24, expressions of occludin of intestinal tissue of mice in vitamin D3 vehicle+ burn injury group were significantly lower than those of mice in vitamin D3+ burn injury group (t=4.75, 5.35, P<0.05). Cholecalciferol 73-83 occludin Mus musculus 32-40 30978243-0 2019 25(OH)D3 and 1.25(OH)2D3 inhibits TNF-alpha expression in human monocyte derived macrophages. Cholecalciferol 6-8 tumor necrosis factor Homo sapiens 34-43 30477283-4 2019 Vitamin D3 was administered in patients with either vitamin D deficiency or insufficiency and CRP serum vitamin D levels and PMS were re-examined at 6 months of administration. Cholecalciferol 0-10 C-reactive protein Homo sapiens 94-97 30961641-1 2019 OBJECTIVE: Vitamin D receptor (VDR) activities have been noted for a number of B cell malignancies which showed varying sensitivities to vitamin D3 (1,25-dihydroxyvitamin D3, VD3, calcitriol) and its synthetic analogs. Cholecalciferol 137-147 vitamin D receptor Homo sapiens 11-29 30961641-1 2019 OBJECTIVE: Vitamin D receptor (VDR) activities have been noted for a number of B cell malignancies which showed varying sensitivities to vitamin D3 (1,25-dihydroxyvitamin D3, VD3, calcitriol) and its synthetic analogs. Cholecalciferol 137-147 vitamin D receptor Homo sapiens 31-34 30612517-7 2019 Vitamin D3 treatment caused a restored lysosomal degradation function by activating the PDIA3 receptor, thereby promoting the nuclear translocation of PDIA3-STAT3 protein complex and the subsequent upregulation of MCOLN3 channels, resulting in an enhanced Ca2+ release from lysosomes and normalized lysosomal acidification. Cholecalciferol 0-10 protein disulfide isomerase family A member 3 Homo sapiens 88-93 30612517-7 2019 Vitamin D3 treatment caused a restored lysosomal degradation function by activating the PDIA3 receptor, thereby promoting the nuclear translocation of PDIA3-STAT3 protein complex and the subsequent upregulation of MCOLN3 channels, resulting in an enhanced Ca2+ release from lysosomes and normalized lysosomal acidification. Cholecalciferol 0-10 signal transducer and activator of transcription 3 Homo sapiens 157-162 30612517-7 2019 Vitamin D3 treatment caused a restored lysosomal degradation function by activating the PDIA3 receptor, thereby promoting the nuclear translocation of PDIA3-STAT3 protein complex and the subsequent upregulation of MCOLN3 channels, resulting in an enhanced Ca2+ release from lysosomes and normalized lysosomal acidification. Cholecalciferol 0-10 mucolipin TRP cation channel 3 Homo sapiens 214-220 30430362-8 2019 Taken together, our findings provided novel experimental evidences supporting that vitamin D3 could reduce the predominantly oxidative stress-mediated inflammation induced by PM2.5via the p38/NF-kappaB/NLRP3 signaling pathway. Cholecalciferol 83-93 mitogen-activated protein kinase 14 Homo sapiens 188-191 30430362-8 2019 Taken together, our findings provided novel experimental evidences supporting that vitamin D3 could reduce the predominantly oxidative stress-mediated inflammation induced by PM2.5via the p38/NF-kappaB/NLRP3 signaling pathway. Cholecalciferol 83-93 nuclear factor kappa B subunit 1 Homo sapiens 192-201 30430362-8 2019 Taken together, our findings provided novel experimental evidences supporting that vitamin D3 could reduce the predominantly oxidative stress-mediated inflammation induced by PM2.5via the p38/NF-kappaB/NLRP3 signaling pathway. Cholecalciferol 83-93 NLR family pyrin domain containing 3 Homo sapiens 202-207 30070012-8 2019 CONCLUSIONS: Deficiency of vitamin D3 accompanied with higher IL-17 in an inverse pattern may have a possible role in active acne vulgaris. Cholecalciferol 27-37 interleukin 17A Homo sapiens 62-67 30678899-4 2019 The simultaneous presence of nHA and vitamin D3 led to the increased activity of ALP in the early stages (on the 14th day) and increased mineralization in the late stages (on the 21st day) in differentiated hADSCs. Cholecalciferol 37-47 ATHS Homo sapiens 81-84 30678899-5 2019 Further, it was found that the use of nHA and vitamin D3 resulted in increased expression of BGLAP and COLL I and reduced expression of ALP and RUNX2 in hADSCs for 21 days. Cholecalciferol 46-56 bone gamma-carboxyglutamate protein Homo sapiens 93-98 30678899-5 2019 Further, it was found that the use of nHA and vitamin D3 resulted in increased expression of BGLAP and COLL I and reduced expression of ALP and RUNX2 in hADSCs for 21 days. Cholecalciferol 46-56 ATHS Homo sapiens 136-139 30678899-5 2019 Further, it was found that the use of nHA and vitamin D3 resulted in increased expression of BGLAP and COLL I and reduced expression of ALP and RUNX2 in hADSCs for 21 days. Cholecalciferol 46-56 RUNX family transcription factor 2 Homo sapiens 144-149 31019650-8 2019 Additional experiment showed that I/R-induced upregulation of renal GRP78 and CHOP was inhibited by cholecalciferol. Cholecalciferol 100-115 heat shock protein 5 Mus musculus 68-73 30922377-10 2019 RESULTS: The level of Il-17A in EBC significantly decreased in calcitriol group from 0,475 pg/mL (+- SD 0,515 pg/mL) to 0,384 pg/mL (+- SD 0,429 pg/mL) (p = 0,008); there was no change in cholecalciferol group (p = 0,074). Cholecalciferol 188-203 interleukin 17A Homo sapiens 22-28 31019650-8 2019 Additional experiment showed that I/R-induced upregulation of renal GRP78 and CHOP was inhibited by cholecalciferol. Cholecalciferol 100-115 DNA-damage inducible transcript 3 Mus musculus 78-82 31019650-11 2019 I/R-induced upregulation of renal NADPH oxidases, such as p47phox, gp91phox, and nox4, was inhibited by cholecalciferol. Cholecalciferol 104-119 neutrophil cytosolic factor 1 Mus musculus 58-65 31019650-11 2019 I/R-induced upregulation of renal NADPH oxidases, such as p47phox, gp91phox, and nox4, was inhibited by cholecalciferol. Cholecalciferol 104-119 cytochrome b-245, beta polypeptide Mus musculus 67-75 31019650-11 2019 I/R-induced upregulation of renal NADPH oxidases, such as p47phox, gp91phox, and nox4, was inhibited by cholecalciferol. Cholecalciferol 104-119 NADPH oxidase 4 Mus musculus 81-85 31019650-12 2019 I/R-induced upregulation of heme oxygenase- (HO-) 1, gshpx and gshrd, was attenuated in mice pretreated with cholecalciferol. Cholecalciferol 109-124 heme oxygenase 1 Mus musculus 28-51 28825325-1 2019 The role of vitamin D3 (VitD3) in the upregulation of osteopontin (OPN) and eNOS in the endothelium of cerebral arteries after subarachnoid hemorrhage (SAH) is investigated. Cholecalciferol 12-22 secreted phosphoprotein 1 Rattus norvegicus 54-65 30792149-0 2019 Impact of high-fat diet and vitamin D3 supplementation on aortic stenosis establishment in waved-2 epidermal growth factor receptor mutant mice. Cholecalciferol 28-38 epidermal growth factor receptor Mus musculus 91-98 30792149-0 2019 Impact of high-fat diet and vitamin D3 supplementation on aortic stenosis establishment in waved-2 epidermal growth factor receptor mutant mice. Cholecalciferol 28-38 epidermal growth factor receptor Mus musculus 99-131 30792149-9 2019 HFD and vitamin D3 supplementation did result in improvements to the model, since AS was only detected in 6 (15.3%) mice (2 in the 3 groups) and AR was developed in the remaining animals. Cholecalciferol 8-18 ferredoxin reductase Mus musculus 145-147 30901909-2 2019 Vitamin D3 represents a master example of nutrigenomics, since via its metabolite 1alpha,25-dihydroxyvitamin D3, which binds with high-affinity to the vitamin D receptor, the secosteroid directly affects the epigenome and transcriptome at thousands of loci within the human genome. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 151-169 30890957-1 2019 The molecular basis of vitamin D signaling implies that the metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) of the secosteroid vitamin D3 activates the transcription factor vitamin D receptor (VDR), which in turn modulates the expression of hundreds of primary vitamin D target genes. Cholecalciferol 90-100 vitamin D receptor Homo sapiens 180-198 30890957-1 2019 The molecular basis of vitamin D signaling implies that the metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) of the secosteroid vitamin D3 activates the transcription factor vitamin D receptor (VDR), which in turn modulates the expression of hundreds of primary vitamin D target genes. Cholecalciferol 90-100 vitamin D receptor Homo sapiens 200-203 29602956-2 2019 Considering the high prevalence of vitamin D deficiency and the association of FGF23 with adverse outcomes, we investigated effects of vitamin D3 supplementation on FGF23 concentrations. Cholecalciferol 135-145 fibroblast growth factor 23 Homo sapiens 165-170 30389627-2 2019 An alternative pathway of vitamin D3 metabolism by cytochrome P450scc CYP11A1 was reported to afford 20-hydroxyvitamin D3 (3), functions of which remain to be explored. Cholecalciferol 26-36 cholesterol side-chain cleavage enzyme, mitochondrial Bos taurus 70-77 30387163-12 2019 Using a Cox regression model, the hazard ratio for hypocalcaemia in the cholecalciferol group was 0.56 (95%CI 0.32-0.98, P = 0.04) after stratification for Day 1 PTH. Cholecalciferol 72-87 parathyroid hormone Homo sapiens 162-165 30222077-3 2019 Both cholecalciferol (D3) and 25-hydroxycholecalciferol [25(OH)D3] apical effluxes were decreased by chemical inhibition of ABCB1 in Caco-2 cells and increased by ABCB1 overexpression in Griptites or Madin-Darby canine kidney type II cells. Cholecalciferol 5-20 ATP binding cassette subfamily B member 1 Homo sapiens 124-129 30222077-3 2019 Both cholecalciferol (D3) and 25-hydroxycholecalciferol [25(OH)D3] apical effluxes were decreased by chemical inhibition of ABCB1 in Caco-2 cells and increased by ABCB1 overexpression in Griptites or Madin-Darby canine kidney type II cells. Cholecalciferol 5-20 ATP binding cassette subfamily B member 1 Homo sapiens 163-168 28825325-1 2019 The role of vitamin D3 (VitD3) in the upregulation of osteopontin (OPN) and eNOS in the endothelium of cerebral arteries after subarachnoid hemorrhage (SAH) is investigated. Cholecalciferol 12-22 secreted phosphoprotein 1 Rattus norvegicus 67-70 28825325-1 2019 The role of vitamin D3 (VitD3) in the upregulation of osteopontin (OPN) and eNOS in the endothelium of cerebral arteries after subarachnoid hemorrhage (SAH) is investigated. Cholecalciferol 12-22 nitric oxide synthase 3 Rattus norvegicus 76-80 30367940-1 2019 Three 23-hydroxylated vitamin D3 derivatives, which are metabolites of 25-hydroxyvitamin D3 produced by CYP24A1 and a related diastereomer, were efficiently synthesized. Cholecalciferol 22-32 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 104-111 30967742-5 2019 VDDR2A is a rare autosomal recessive disorder caused by mutation in the Vitamin D receptor gene, leading to end-organ resistance to 1,25(OH)2 Vitamin D3. Cholecalciferol 142-152 vitamin D receptor Homo sapiens 72-90 30662354-4 2019 Therefore, in this research, we aimed to explore the roles and mechanisms of FGF21 in VC induced by vitamin D3 plus nicotine (VDN) treatment rats. Cholecalciferol 100-110 fibroblast growth factor 21 Rattus norvegicus 77-82 30382318-0 2019 Mutation update and long-term outcome after treatment with active vitamin D3 in Chinese patients with pseudovitamin D-deficiency rickets (PDDR). Cholecalciferol 66-76 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 138-142 30382318-14 2019 Our findings revealed after 1-year treatment of active vitamin D3, PTH and ALP significantly decreased. Cholecalciferol 55-65 ATHS Homo sapiens 75-78 30399506-1 2019 Vitamin D3 acting via its nuclear receptor (VDR) was shown to target many reproductive tissues and regulate their function. Cholecalciferol 0-10 vitamin D receptor Sus scrofa 44-47 30669280-2 2019 Our aim was to identify whether antenatal vitamin D3 supplementation affects iron status (via hepcidin suppression) and/or inflammation. Cholecalciferol 42-52 hepcidin antimicrobial peptide Homo sapiens 94-102 31061279-8 2019 Taken together, we suggest that administration of cholecalciferol might be useful to suppress symptomatic food allergy in association with the decrease of CD69+ CD4+ T cells. Cholecalciferol 50-65 CD4 antigen Mus musculus 161-164 30067874-10 2019 CONCLUSIONS: Asian compared with Caucasian males had a larger increment in measured free 25OHD following 150 000 units vitamin D3, possibly reflecting differences in DBP affinity for 25OHD. Cholecalciferol 119-129 D-box binding PAR bZIP transcription factor Homo sapiens 166-169 31269890-0 2019 The Effect of Vitamin D3 Supplementation on Serum BDNF, Dopamine and Serotonin in Children with Attention-Deficit/Hyperactivity Disorder. Cholecalciferol 14-24 brain derived neurotrophic factor Homo sapiens 50-54 30367913-0 2019 Vitamin D3 deficiency in puberty rats causes presynaptic malfunctioning through alterations in exocytotic release and uptake of glutamate/GABA and expression of EAAC-1/GAT-3 transporters. Cholecalciferol 0-10 solute carrier family 1 member 1 Rattus norvegicus 161-167 30367913-0 2019 Vitamin D3 deficiency in puberty rats causes presynaptic malfunctioning through alterations in exocytotic release and uptake of glutamate/GABA and expression of EAAC-1/GAT-3 transporters. Cholecalciferol 0-10 solute carrier family 6 member 11 Rattus norvegicus 168-173 31061279-0 2019 Effect of Cholecalciferol in Food Allergy Mouse Model Is Associated with Decrease of CD69+ CD4+ T Cells. Cholecalciferol 10-25 CD69 antigen Mus musculus 85-89 30253183-1 2019 Vitamin D3 (1,25-dihydroxyvitamin D3, VD3) in vitro attenuates the effect of the pro-inflammatory advanced glycation end products (AGEs) on steroidogenesis in human granulosa cells (GCs) by downregulating the receptor for AGEs (RAGE). Cholecalciferol 0-10 advanced glycosylation end-product specific receptor Homo sapiens 228-232 31602990-6 2019 Moreover, there was a significant inverse association between vitamin D3 levels and megalin levels in urine (OR=0.281, p=0.047). Cholecalciferol 62-72 LDL receptor related protein 2 Homo sapiens 84-91 31269890-5 2019 Therefore, this study aimed to investigate the effect of vitamin D3 supplementation on serum levels of brain-derived neurotrophic factor (BDNF), dopamine and serotonin in school-aged children with ADHD. Cholecalciferol 57-67 brain derived neurotrophic factor Homo sapiens 103-136 31269890-5 2019 Therefore, this study aimed to investigate the effect of vitamin D3 supplementation on serum levels of brain-derived neurotrophic factor (BDNF), dopamine and serotonin in school-aged children with ADHD. Cholecalciferol 57-67 brain derived neurotrophic factor Homo sapiens 138-142 31298160-2 2019 The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 acts as a nuclear hormone activating the transcription factor vitamin D receptor (VDR). Cholecalciferol 4-14 vitamin D receptor Homo sapiens 118-136 31298160-2 2019 The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 acts as a nuclear hormone activating the transcription factor vitamin D receptor (VDR). Cholecalciferol 4-14 vitamin D receptor Homo sapiens 138-141 31804923-1 2019 PURPOSE: The purpose of this retrospective cohort study was to measure the difference between cholecalciferol and ergocalciferol in their ability to effect vitamin D, parathyroid hormone (PTH), calcium, and phosphorous serum concentrations in patients with stage 3 or 4 chronic kidney disease. Cholecalciferol 94-109 parathyroid hormone Homo sapiens 167-186 31804923-1 2019 PURPOSE: The purpose of this retrospective cohort study was to measure the difference between cholecalciferol and ergocalciferol in their ability to effect vitamin D, parathyroid hormone (PTH), calcium, and phosphorous serum concentrations in patients with stage 3 or 4 chronic kidney disease. Cholecalciferol 94-109 parathyroid hormone Homo sapiens 188-191 29990544-7 2019 We also quantified an increase of 25(OH)D in adipose tissue that was inversely correlated to the free 25(OH)D. Interestingly, this accumulation of 25(OH)D in adipose tissue was highly correlated to the induction of Cyp2r1, which could actively participate in vitamin D3 trapping and subsequent conversion to 25(OH)D in adipose tissue. Cholecalciferol 259-269 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 215-221 31061279-0 2019 Effect of Cholecalciferol in Food Allergy Mouse Model Is Associated with Decrease of CD69+ CD4+ T Cells. Cholecalciferol 10-25 CD4 antigen Mus musculus 91-94 31061279-6 2019 Treatment of cholecalciferol reduced the allergic diarrhea (p<0.05) with the decreasing tendency of CD69+ CD4+ T cells, suggesting that the cell population might be associated with the attenuating effect of cholecalciferol on diarrhea occurrence, although immunoglobulin E levels and cytokine productions were not significantly altered by the treatment of cholecalciferol. Cholecalciferol 13-28 CD69 antigen Mus musculus 103-107 31061279-6 2019 Treatment of cholecalciferol reduced the allergic diarrhea (p<0.05) with the decreasing tendency of CD69+ CD4+ T cells, suggesting that the cell population might be associated with the attenuating effect of cholecalciferol on diarrhea occurrence, although immunoglobulin E levels and cytokine productions were not significantly altered by the treatment of cholecalciferol. Cholecalciferol 13-28 CD4 antigen Mus musculus 109-112 31061279-6 2019 Treatment of cholecalciferol reduced the allergic diarrhea (p<0.05) with the decreasing tendency of CD69+ CD4+ T cells, suggesting that the cell population might be associated with the attenuating effect of cholecalciferol on diarrhea occurrence, although immunoglobulin E levels and cytokine productions were not significantly altered by the treatment of cholecalciferol. Cholecalciferol 210-225 CD4 antigen Mus musculus 109-112 31061279-6 2019 Treatment of cholecalciferol reduced the allergic diarrhea (p<0.05) with the decreasing tendency of CD69+ CD4+ T cells, suggesting that the cell population might be associated with the attenuating effect of cholecalciferol on diarrhea occurrence, although immunoglobulin E levels and cytokine productions were not significantly altered by the treatment of cholecalciferol. Cholecalciferol 210-225 CD4 antigen Mus musculus 109-112 31061279-8 2019 Taken together, we suggest that administration of cholecalciferol might be useful to suppress symptomatic food allergy in association with the decrease of CD69+ CD4+ T cells. Cholecalciferol 50-65 CD69 antigen Mus musculus 155-159 30930376-4 2019 We found that activated vitamin D3 may be a candidate agent for modulating the Abeta clearance across the BBB. Cholecalciferol 24-34 amyloid beta precursor protein Homo sapiens 79-84 30618630-0 2018 1, 25-D3 Protects From Cerebral Ischemia by Maintaining BBB Permeability via PPAR-gamma Activation. Cholecalciferol 6-8 peroxisome proliferator-activated receptor gamma Rattus norvegicus 77-87 30545134-13 2018 CONCLUSION: Oral supplementation with 3000 IU/day of vitamin D3 during eight weeks showed to be sufficient to prevent a decline in hematological levels of hemoglobin and hematocrit, and improve transferrin of 25(OH)D levels. Cholecalciferol 53-63 transferrin Homo sapiens 194-205 30453584-4 2018 The mRNA levels of TG2 and TNF-alpha were higher in PBMC of subjects having hypovitaminosis D, namely plasma 25(OH)vitamin D3 levels lower than 50 nmol/L, than in those with normal vitamin D levels. Cholecalciferol 115-125 transglutaminase 2 Homo sapiens 19-22 30232176-3 2018 We report that the active metabolite of vitamin D3, calcitriol, and its analog calcipotriol are selectively cytotoxic to MRP1-overexpressing cells, besides inhibiting transport function of P-gp, MRP1, and BCRP. Cholecalciferol 40-50 ATP binding cassette subfamily C member 1 Homo sapiens 121-125 30232176-3 2018 We report that the active metabolite of vitamin D3, calcitriol, and its analog calcipotriol are selectively cytotoxic to MRP1-overexpressing cells, besides inhibiting transport function of P-gp, MRP1, and BCRP. Cholecalciferol 40-50 phosphoglycolate phosphatase Homo sapiens 189-193 30232176-3 2018 We report that the active metabolite of vitamin D3, calcitriol, and its analog calcipotriol are selectively cytotoxic to MRP1-overexpressing cells, besides inhibiting transport function of P-gp, MRP1, and BCRP. Cholecalciferol 40-50 ATP binding cassette subfamily C member 1 Homo sapiens 195-199 30232176-3 2018 We report that the active metabolite of vitamin D3, calcitriol, and its analog calcipotriol are selectively cytotoxic to MRP1-overexpressing cells, besides inhibiting transport function of P-gp, MRP1, and BCRP. Cholecalciferol 40-50 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 205-209 30232176-6 2018 Such collateral sensitivity, however, was not observed in HEK293/P-gp and HEK293/BCRP cells, although the vitamin D3 analogs inhibited calcein efflux in P-gp-overexpressing cells, and mitoxantrone efflux in BCRP-overexpressing cells. Cholecalciferol 106-116 phosphoglycolate phosphatase Homo sapiens 153-157 30232176-6 2018 Such collateral sensitivity, however, was not observed in HEK293/P-gp and HEK293/BCRP cells, although the vitamin D3 analogs inhibited calcein efflux in P-gp-overexpressing cells, and mitoxantrone efflux in BCRP-overexpressing cells. Cholecalciferol 106-116 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 207-211 30568875-1 2019 Objective: Through its receptor (VDR), vitamin D3 plays an important role in a wide variety of cellular processes. Cholecalciferol 39-49 vitamin D receptor Homo sapiens 33-36 30453584-4 2018 The mRNA levels of TG2 and TNF-alpha were higher in PBMC of subjects having hypovitaminosis D, namely plasma 25(OH)vitamin D3 levels lower than 50 nmol/L, than in those with normal vitamin D levels. Cholecalciferol 115-125 tumor necrosis factor Homo sapiens 27-36 29931459-2 2018 In a double-blinded, randomized placebo-controlled trial, we aimed to investigate effects of vitamin D3 supplementation on above-mentioned outcomes in healthy community-dwelling postmenopausal women with plasma levels of 25-hydroxyvitamin D (25(OH)D) below < 50 nmol/l and high parathyroid hormone (PTH) levels. Cholecalciferol 93-103 parathyroid hormone Homo sapiens 281-300 30532541-3 2018 Patients were randomly assigned to 8-week oral treatment with 100,000 IU/week cholecalciferol (Vit D group) or a matching placebo (control group). Cholecalciferol 78-93 vitrin Homo sapiens 95-98 30533524-5 2018 Results: Vitamin D3 affected the levels of IL-17A, IL-10, and IL-6 among the 3 groups (p < 0.001 for all). Cholecalciferol 9-19 interleukin 17A Homo sapiens 43-49 30533524-5 2018 Results: Vitamin D3 affected the levels of IL-17A, IL-10, and IL-6 among the 3 groups (p < 0.001 for all). Cholecalciferol 9-19 interleukin 10 Homo sapiens 51-56 30533524-5 2018 Results: Vitamin D3 affected the levels of IL-17A, IL-10, and IL-6 among the 3 groups (p < 0.001 for all). Cholecalciferol 9-19 interleukin 6 Homo sapiens 62-66 30533524-8 2018 Conclusions: Although supplementation with vitamin D3 reduced the mRNA expression levels of IL-17A and IL-6, it increased the mRNA expression level of IL-10 in all groups. Cholecalciferol 43-53 interleukin 17A Homo sapiens 92-98 30533524-8 2018 Conclusions: Although supplementation with vitamin D3 reduced the mRNA expression levels of IL-17A and IL-6, it increased the mRNA expression level of IL-10 in all groups. Cholecalciferol 43-53 interleukin 6 Homo sapiens 103-107 30533524-8 2018 Conclusions: Although supplementation with vitamin D3 reduced the mRNA expression levels of IL-17A and IL-6, it increased the mRNA expression level of IL-10 in all groups. Cholecalciferol 43-53 interleukin 10 Homo sapiens 151-156 30533524-10 2018 Of interest, in a deficiency state of serum vitamin D3, IL-17A expression had a positive feedback effect on the expression of IL-6. Cholecalciferol 44-54 interleukin 17A Homo sapiens 56-62 30533524-10 2018 Of interest, in a deficiency state of serum vitamin D3, IL-17A expression had a positive feedback effect on the expression of IL-6. Cholecalciferol 44-54 interleukin 6 Homo sapiens 126-130 29931459-2 2018 In a double-blinded, randomized placebo-controlled trial, we aimed to investigate effects of vitamin D3 supplementation on above-mentioned outcomes in healthy community-dwelling postmenopausal women with plasma levels of 25-hydroxyvitamin D (25(OH)D) below < 50 nmol/l and high parathyroid hormone (PTH) levels. Cholecalciferol 93-103 parathyroid hormone Homo sapiens 302-305 29931459-4 2018 Vitamin D3 supplementation increased levels of 25(OH)D and 1,25(OH)2D by 230% (95% CI 189 to 272)%, p < 0.001 and 58% (190 to 271%), p < 0.001, respectively, and reduced PTH by 17% (- 23 to - 11%), p < 0.001. Cholecalciferol 0-10 parathyroid hormone Homo sapiens 176-179 30166055-0 2018 The vitamin D3 analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production. Cholecalciferol 4-14 interleukin 23, alpha subunit p19 Mus musculus 126-131 30243072-2 2018 Vitamin D (Vit.D; cholecalciferol) has regulatory functions associated with both innate and adaptive immune responses. Cholecalciferol 18-33 vitrin Mus musculus 0-3 29733445-0 2018 Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial. Cholecalciferol 67-77 parathyroid hormone Homo sapiens 81-100 29733445-9 2018 Vitamin D3 supplementation reduced PTH by 3.4% (25th, 75th -9.0 to 8.7) compared to a 7.1% increase (25th, 75th -2.4 to 30.9) in the placebo group (P = .01), but did not affect blood pressure, cardiac conduction or concentrations of renin and aldosterone. Cholecalciferol 0-10 parathyroid hormone Homo sapiens 35-38 29733445-9 2018 Vitamin D3 supplementation reduced PTH by 3.4% (25th, 75th -9.0 to 8.7) compared to a 7.1% increase (25th, 75th -2.4 to 30.9) in the placebo group (P = .01), but did not affect blood pressure, cardiac conduction or concentrations of renin and aldosterone. Cholecalciferol 0-10 renin Homo sapiens 233-238 29733445-11 2018 Vitamin D3 reduced PTH but did not affect blood pressure, cardiac conduction or the RAAS. Cholecalciferol 0-10 parathyroid hormone Homo sapiens 19-22 30166055-0 2018 The vitamin D3 analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production. Cholecalciferol 4-14 interleukin 17A Mus musculus 136-141 30166055-1 2018 BACKGROUND: Psoriasis is a Th1/Th17-mediated inflammatory dermatosis treated with topical corticosteroids and vitamin D3 analogs (VD3 As). Cholecalciferol 110-120 negative elongation factor complex member C/D, Th1l Mus musculus 27-30 30043092-7 2018 Vitamin D3 treatment reduced PTH by 17% (11-23%), but did not reduce RAAS activity. Cholecalciferol 0-10 parathyroid hormone Homo sapiens 29-32 30297679-14 2018 Thus, our microarray, qPCR, functional studies and molecular modeling indicate that AhR is the major receptor target for 20,23(OH)2D3, opening an exciting area of investigation on the interaction of different vitamin D3-hydroxyderivatives with AhR and the subsequent downstream activation of signal transduction pathways in a cell-type-dependent manner. Cholecalciferol 209-219 aryl hydrocarbon receptor Homo sapiens 84-87 30356853-8 2018 The results of our study showed that vitamin D3 supplementation in patients with T1DM and T2DM reduced the concentrations of the inflammatory Th1-type cytokines and increased the levels of Th2-type cytokines. Cholecalciferol 37-47 negative elongation factor complex member C/D Homo sapiens 142-145 30043092-9 2018 CONCLUSIONS: Vitamin D3 supplementation normalized vitamin D levels and reduced PTH. Cholecalciferol 13-23 parathyroid hormone Homo sapiens 80-83 30233662-0 2018 CYP24A1 depletion facilitates the antitumor effect of vitamin D3 on thyroid cancer cells. Cholecalciferol 54-64 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 0-7 28913556-0 2018 High-dose vitamin D3 supplementation decreases the number of colonic CD103+ dendritic cells in healthy subjects. Cholecalciferol 10-20 integrin subunit alpha E Homo sapiens 69-74 30402875-0 2018 Vitamin D3 promotes cerebral angiogenesis after cerebral infarction in rats by activating Shh signaling pathway. Cholecalciferol 0-10 sonic hedgehog signaling molecule Rattus norvegicus 90-93 30445888-18 2018 CONCLUSION: The proposed protocol of cholecalciferol and dietary calcium supplementation is safe and valid for correcting vitamin D abnormalities in almost all patients as well as reducing PTH levels in a high percentage of patients; however, it is not sufficient for normalization, particularly in patients exposed to tenofovir or efavirenz. Cholecalciferol 37-52 parathyroid hormone Homo sapiens 189-192 29869004-9 2018 CONCLUSIONS: In BPD/DS patients, having hypovitaminosis D despite full oral supplementation, a single injection of 600,000 IU of cholecalciferol was effective in elevating vitamin D levels and normalizing levels of intact PTH. Cholecalciferol 129-144 parathyroid hormone Homo sapiens 222-225 30184235-5 2018 Treatment of WT-TE671 cells with vitamin D3 alone and cotreatment with U0126 also promoted dysferlin expression. Cholecalciferol 33-43 dysferlin Homo sapiens 91-100 29775620-7 2018 Levels of VDBP along with total 25OH vitamin D3 can be used to calculate free 25OH vitamin D3 levels and these compare well with consensus values determined independently. Cholecalciferol 83-93 GC vitamin D binding protein Homo sapiens 10-14 29310423-8 2018 To investigate the in vivo effects of Phloxine O, we induced TSLP expression in mouse ear skin by topically applying MC903, a vitamin D3 analogue that is a well-known inducer of atopic dermatitis-like symptoms. Cholecalciferol 126-136 thymic stromal lymphopoietin Mus musculus 61-65 29961920-11 2018 Our data demonstrate stimulation of FGF23 levels in mice which impacts mostly on 1,25 (OH)2 vitamin D3 levels and metabolism. Cholecalciferol 92-102 fibroblast growth factor 23 Mus musculus 36-41 30119888-0 2018 Role of PKB/SGK-dependent phosphorylation of GSK-3alpha/beta in vascular calcification during cholecalciferol overload in mice. Cholecalciferol 94-109 thymoma viral proto-oncogene 1 Mus musculus 8-11 30119888-0 2018 Role of PKB/SGK-dependent phosphorylation of GSK-3alpha/beta in vascular calcification during cholecalciferol overload in mice. Cholecalciferol 94-109 serum/glucocorticoid regulated kinase 1 Mus musculus 12-15 30119888-0 2018 Role of PKB/SGK-dependent phosphorylation of GSK-3alpha/beta in vascular calcification during cholecalciferol overload in mice. Cholecalciferol 94-109 glycogen synthase kinase 3 alpha Mus musculus 45-55 30119888-5 2018 In gsk-3WT mice, high-dosed cholecalciferol induced vascular calcification and aortic osteo-/chondrogenic signaling, shown by increased expression of osteogenic markers Msx2, Cbfa1 and tissue-nonspecific alkaline phosphatase (Alpl). Cholecalciferol 28-43 msh homeobox 2 Mus musculus 169-173 30119888-5 2018 In gsk-3WT mice, high-dosed cholecalciferol induced vascular calcification and aortic osteo-/chondrogenic signaling, shown by increased expression of osteogenic markers Msx2, Cbfa1 and tissue-nonspecific alkaline phosphatase (Alpl). Cholecalciferol 28-43 runt related transcription factor 2 Mus musculus 175-180 30119888-5 2018 In gsk-3WT mice, high-dosed cholecalciferol induced vascular calcification and aortic osteo-/chondrogenic signaling, shown by increased expression of osteogenic markers Msx2, Cbfa1 and tissue-nonspecific alkaline phosphatase (Alpl). Cholecalciferol 28-43 alkaline phosphatase, liver/bone/kidney Mus musculus 226-230 30119888-7 2018 Cholecalciferol decreased aortic Gsk-3alpha/beta phosphorylation (Ser21/9) in gsk-3WT mice, while no phosphorylation was observed in gsk-3KI mice. Cholecalciferol 0-15 glycogen synthase kinase 3 alpha Mus musculus 33-43 30119888-8 2018 Moreover, the mRNA expression of type III sodium-dependent phosphate transporter (Pit1) and plasminogen activator inhibitor 1 (Pai1) was increased following cholecalciferol treatment in aortic tissue of gsk-3WT mice, effects again blunted in gsk-3KI mice. Cholecalciferol 157-172 solute carrier family 20, member 1 Mus musculus 82-86 30119888-8 2018 Moreover, the mRNA expression of type III sodium-dependent phosphate transporter (Pit1) and plasminogen activator inhibitor 1 (Pai1) was increased following cholecalciferol treatment in aortic tissue of gsk-3WT mice, effects again blunted in gsk-3KI mice. Cholecalciferol 157-172 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 92-125 30119888-8 2018 Moreover, the mRNA expression of type III sodium-dependent phosphate transporter (Pit1) and plasminogen activator inhibitor 1 (Pai1) was increased following cholecalciferol treatment in aortic tissue of gsk-3WT mice, effects again blunted in gsk-3KI mice. Cholecalciferol 157-172 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 127-131 29436118-6 2018 RESULTS: In aorta from a rat vitamin D3 calcification model, CST abrogated calcium deposition and pathological damage, decreased the protein expression of OCN and beta-catenin and increased SM-alpha-actin expression. Cholecalciferol 29-39 cortistatin Rattus norvegicus 61-64 30246694-0 2018 Vitamin D3 Induced Decrease in IL-17 and Malondialdehyde, and Increase in IL-10 and Total Antioxidant Capacity Levels in Patients with Irritable Bowel Syndrome. Cholecalciferol 0-10 interleukin 17A Homo sapiens 31-36 30246694-0 2018 Vitamin D3 Induced Decrease in IL-17 and Malondialdehyde, and Increase in IL-10 and Total Antioxidant Capacity Levels in Patients with Irritable Bowel Syndrome. Cholecalciferol 0-10 interleukin 10 Homo sapiens 74-79 30246694-8 2018 CONCLUSION: Vitamin D3 supplementation reduces the serum IL-17 and MDA levels, and augments the serum IL-10 and TAC levels in IBS patients, particularly in IBS-D subtype. Cholecalciferol 12-22 interleukin 17A Homo sapiens 57-62 30246694-8 2018 CONCLUSION: Vitamin D3 supplementation reduces the serum IL-17 and MDA levels, and augments the serum IL-10 and TAC levels in IBS patients, particularly in IBS-D subtype. Cholecalciferol 12-22 interleukin 10 Homo sapiens 102-107 29955863-6 2018 A significant positive correlation was found between Cyp2r1 mRNA and 25(OH)D, and a stronger correlation was found between Cyp2r1 mRNA and the ratio of 25(OH)D3 to cholecalciferol. Cholecalciferol 164-179 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 123-129 29889103-7 2018 Aortic calcification, stiffness, and osteo-/chondrogenic transdifferentiation in mice following cholecalciferol overload were strongly reduced by genetic knockout or pharmacological inhibition of Sgk1 by EMD638683. Cholecalciferol 96-111 serum/glucocorticoid regulated kinase 1 Mus musculus 196-200 29981295-3 2018 The present study aimed to investigate the cholecalciferol capability to revert depressive-like behavior induced by chronic corticosterone (CORT) treatment in mice and its implication on the oxidative stress modulation. Cholecalciferol 43-58 cortistatin Mus musculus 140-144 29981295-8 2018 It was observed that corticosterone treatment resulted in depressive-like behavior with established oxidative stress in mice, while cholecalciferol ameliorated both, behavioral (immobility time and grooming latency) and biochemical (protein carbonyl and nitrite levels) changes induced by CORT model, suggesting that cholecalciferol has antidepressant-like effect with the involvement of the oxidative stress modulation. Cholecalciferol 132-147 cortistatin Mus musculus 289-293 29527916-8 2018 These results suggest that androgens regulate the response of follicular cells to vitamin D3 in pigs ovary via regulation of VDR transcriptional activity. Cholecalciferol 82-92 vitamin D receptor Sus scrofa 125-128 29655559-7 2018 The combination of negative DCAD and cholecalciferol reduced IGF1 concentrations prepartum. Cholecalciferol 37-52 insulin like growth factor 1 Bos taurus 61-65 29655559-11 2018 We found evidence of a feedback mechanism between vitamin D3 and IGF1, with positive effect size (ES) on the same day and 3 d later, and negative ES 9 d later, that was more evident in cholecalciferol-fed cows. Cholecalciferol 50-60 insulin like growth factor 1 Bos taurus 65-69 29655559-11 2018 We found evidence of a feedback mechanism between vitamin D3 and IGF1, with positive effect size (ES) on the same day and 3 d later, and negative ES 9 d later, that was more evident in cholecalciferol-fed cows. Cholecalciferol 185-200 insulin like growth factor 1 Bos taurus 65-69 29452159-0 2018 CYP27A1 acts on the pre-vitamin D3 photoproduct, lumisterol, producing biologically active hydroxy-metabolites. Cholecalciferol 24-34 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 0-7 29452159-3 2018 Recently, we reported that L3 is present in serum and that CYP11A1 can act on L3 producing monohydroxy- and dihydroxy-metabolites which inhibit skin cell proliferation similarly to 1alpha,25-dihydroxyvitamin D3. Cholecalciferol 208-210 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 59-66 29452159-8 2018 CYP27A1 displayed a high kcat for the metabolism of L3 (76 mol product/min/mol CYP27A1) and a catalytic efficiency (kcat/Km) that was 260-fold higher than that for vitamin D3. Cholecalciferol 164-174 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 0-7 29844206-4 2018 Activation of Vdr signaling by the vitamin D3 agonist calcitriol increased the outgrowth of EryD colonies from fetal liver and adult bone marrow, maintained progenitor potential, and delayed erythroid maturation, as revealed by clonogenic assays, suspension culture, cell surface phenotype, and gene expression analyses. Cholecalciferol 35-45 vitamin D receptor Homo sapiens 14-17 29719203-1 2018 The metabolites of vitamin D3 (VD3) mediated by different cytochrome P450 (CYP) enzymes, play fundamental roles in many physiological processes in relation to human health. Cholecalciferol 19-29 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 58-73 29719203-1 2018 The metabolites of vitamin D3 (VD3) mediated by different cytochrome P450 (CYP) enzymes, play fundamental roles in many physiological processes in relation to human health. Cholecalciferol 19-29 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 75-78 29930537-12 2018 Cholecalciferol prevented prednisolone-elicited disturbances of the RANKL/RANK/OPG, which correlated with improved bioavailability and vitamin D signaling through VDR. Cholecalciferol 0-15 TNF superfamily member 11 Rattus norvegicus 68-73 29751936-14 2018 We found a significant correlation of cholecalciferol with the variability of SBP during the day. Cholecalciferol 38-53 selenium binding protein 1 Homo sapiens 78-81 29930537-12 2018 Cholecalciferol prevented prednisolone-elicited disturbances of the RANKL/RANK/OPG, which correlated with improved bioavailability and vitamin D signaling through VDR. Cholecalciferol 0-15 TNF receptor superfamily member 11B Rattus norvegicus 79-82 29930537-12 2018 Cholecalciferol prevented prednisolone-elicited disturbances of the RANKL/RANK/OPG, which correlated with improved bioavailability and vitamin D signaling through VDR. Cholecalciferol 0-15 vitamin D receptor Rattus norvegicus 163-166 29930537-14 2018 Our findings suggest that prednisolone-induced abnormalities in GR and RANKL/RANK/OPG signaling pathways are associated with the impairments of vitamin D auto/paracrine system in BM cells and can be ameliorated by cholecalciferol supplementation. Cholecalciferol 214-229 TNF superfamily member 11 Rattus norvegicus 71-76 29930537-14 2018 Our findings suggest that prednisolone-induced abnormalities in GR and RANKL/RANK/OPG signaling pathways are associated with the impairments of vitamin D auto/paracrine system in BM cells and can be ameliorated by cholecalciferol supplementation. Cholecalciferol 214-229 TNF receptor superfamily member 11B Rattus norvegicus 82-85 29676471-7 2018 Vitamin D3 and 5-aminoimidazole-4-carboxamide-1-beta-D-riboside or Aicar (AMPK activator) not only reduced gene expression of steroidogenic enzymes (P450scc or Cyp11a1, StAR, Cyp19a1 and 3B-HSD), but also reduced production of progesterone and 17B-estradiol assessed by radioimmunoassay. Cholecalciferol 0-10 cytochrome P450, family 11, subfamily a, polypeptide 1 Mus musculus 149-156 29392742-0 2018 The Vitamin D3 analogue calcipotriol suppresses CpG-activated TLR9-MyD88 signalling in murine plasmacytoid dendritic cells. Cholecalciferol 4-14 toll-like receptor 9 Mus musculus 62-66 29392742-0 2018 The Vitamin D3 analogue calcipotriol suppresses CpG-activated TLR9-MyD88 signalling in murine plasmacytoid dendritic cells. Cholecalciferol 4-14 myeloid differentiation primary response gene 88 Mus musculus 67-72 29726119-9 2018 Vitamin D3 levels appeared to be modulated by genetic variation in CYP24A1 and VDR genes. Cholecalciferol 0-10 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 67-74 29726119-9 2018 Vitamin D3 levels appeared to be modulated by genetic variation in CYP24A1 and VDR genes. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 79-82 29676471-7 2018 Vitamin D3 and 5-aminoimidazole-4-carboxamide-1-beta-D-riboside or Aicar (AMPK activator) not only reduced gene expression of steroidogenic enzymes (P450scc or Cyp11a1, StAR, Cyp19a1 and 3B-HSD), but also reduced production of progesterone and 17B-estradiol assessed by radioimmunoassay. Cholecalciferol 0-10 cytochrome P450, family 11, subfamily a, polypeptide 1 Mus musculus 160-167 29676471-7 2018 Vitamin D3 and 5-aminoimidazole-4-carboxamide-1-beta-D-riboside or Aicar (AMPK activator) not only reduced gene expression of steroidogenic enzymes (P450scc or Cyp11a1, StAR, Cyp19a1 and 3B-HSD), but also reduced production of progesterone and 17B-estradiol assessed by radioimmunoassay. Cholecalciferol 0-10 steroidogenic acute regulatory protein Mus musculus 169-173 29676471-7 2018 Vitamin D3 and 5-aminoimidazole-4-carboxamide-1-beta-D-riboside or Aicar (AMPK activator) not only reduced gene expression of steroidogenic enzymes (P450scc or Cyp11a1, StAR, Cyp19a1 and 3B-HSD), but also reduced production of progesterone and 17B-estradiol assessed by radioimmunoassay. Cholecalciferol 0-10 cytochrome P450, family 19, subfamily a, polypeptide 1 Mus musculus 175-193 29677904-0 2018 Re: Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation. Cholecalciferol 4-14 transient receptor potential cation channel subfamily C member 6 Homo sapiens 100-105 28918929-4 2018 However, increased VDR following vitamin D3 (VD3) treatment improved insulin release of early-passage MIN6 and insulin index of db/- (heterozygous) islets to levels seen in normal functional islets. Cholecalciferol 33-43 vitamin D receptor Rattus norvegicus 19-22 29431349-3 2018 The aim of our study was to evaluate the effect of active vitamin D3 (VD) on the expression of pro-inflammatory and anti-inflammatory cytokines (IL-6, IL-8, IL-10 and IL-12) in human gingival fibroblasts (hGF) and human periodontal ligament cells (hPDLc) triggered by Porphyromonas gingivalis and Streptococcus pyogenes. Cholecalciferol 58-68 interleukin 6 Homo sapiens 145-149 29431349-3 2018 The aim of our study was to evaluate the effect of active vitamin D3 (VD) on the expression of pro-inflammatory and anti-inflammatory cytokines (IL-6, IL-8, IL-10 and IL-12) in human gingival fibroblasts (hGF) and human periodontal ligament cells (hPDLc) triggered by Porphyromonas gingivalis and Streptococcus pyogenes. Cholecalciferol 58-68 C-X-C motif chemokine ligand 8 Homo sapiens 151-155 29431349-3 2018 The aim of our study was to evaluate the effect of active vitamin D3 (VD) on the expression of pro-inflammatory and anti-inflammatory cytokines (IL-6, IL-8, IL-10 and IL-12) in human gingival fibroblasts (hGF) and human periodontal ligament cells (hPDLc) triggered by Porphyromonas gingivalis and Streptococcus pyogenes. Cholecalciferol 58-68 interleukin 10 Homo sapiens 157-162 29431349-3 2018 The aim of our study was to evaluate the effect of active vitamin D3 (VD) on the expression of pro-inflammatory and anti-inflammatory cytokines (IL-6, IL-8, IL-10 and IL-12) in human gingival fibroblasts (hGF) and human periodontal ligament cells (hPDLc) triggered by Porphyromonas gingivalis and Streptococcus pyogenes. Cholecalciferol 58-68 hepatocyte growth factor Homo sapiens 205-208 29875733-1 2018 The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] is the exclusive high-affinity ligand of the vitamin D receptor (VDR), a transcription factor with direct effects on gene expression. Cholecalciferol 4-14 vitamin D receptor Homo sapiens 115-133 29875733-1 2018 The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] is the exclusive high-affinity ligand of the vitamin D receptor (VDR), a transcription factor with direct effects on gene expression. Cholecalciferol 4-14 vitamin D receptor Homo sapiens 135-138 29522785-0 2018 Vitamin D3 inhibits the proliferation of T helper cells, downregulate CD4+ T cell cytokines and upregulate inhibitory markers. Cholecalciferol 0-10 CD4 molecule Homo sapiens 70-73 29467214-2 2018 25-Hydroxyvitamin D3 (25OHD3), the most abundant circulating metabolite of vitamin D3, is further transformed to the biologically active metabolite 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) by CYP27B1 in the kidney and extrarenal tissues, and to nonactive metabolites by other cytochrome P450 enzymes. Cholecalciferol 10-20 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 201-208 29528271-0 2018 Genetic polymorphisms of vitamin D3 metabolizing CYP24A1 and CYP2R1 enzymes in Turkish patients with ischemic stroke. Cholecalciferol 25-35 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 49-56 29528271-0 2018 Genetic polymorphisms of vitamin D3 metabolizing CYP24A1 and CYP2R1 enzymes in Turkish patients with ischemic stroke. Cholecalciferol 25-35 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 61-67 29849881-0 2018 Effects of Vitamin D3 on the NADPH Oxidase and Matrix Metalloproteinase 9 in an Animal Model of Global Cerebral Ischemia. Cholecalciferol 11-21 matrix metallopeptidase 9 Mus musculus 47-73 29849881-8 2018 Pretreatment with vitamin D3 was especially effective on NOX2 subunits, MMP9, and the level of malondialdehyde and superoxide anion. Cholecalciferol 18-28 cytochrome b-245, beta polypeptide Mus musculus 57-61 29849881-8 2018 Pretreatment with vitamin D3 was especially effective on NOX2 subunits, MMP9, and the level of malondialdehyde and superoxide anion. Cholecalciferol 18-28 matrix metallopeptidase 9 Mus musculus 72-76 29438722-3 2018 Mouse mammary glands express the critical enzymes responsible for 1,25(OH)2D synthesis (Cyp2r1 and Cyp27b1), degradation (Cyp24a1), as well as the vitamin D3 receptor (Vdr), and genetically modified mouse models have revealed a great deal about the role of vitamin D3 in cancer initiation and progression. Cholecalciferol 147-157 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 168-171 29438722-4 2018 Ablation of Vdr or Cyp27b1 in murine models of mammary cancer reduces the anti-tumor effects of vitamin D3, while elevation of Cyp24a1 levels increases degradation of 1,25(OH)2D, leading to diminished anti-tumor effects. Cholecalciferol 96-106 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 12-15 29438722-4 2018 Ablation of Vdr or Cyp27b1 in murine models of mammary cancer reduces the anti-tumor effects of vitamin D3, while elevation of Cyp24a1 levels increases degradation of 1,25(OH)2D, leading to diminished anti-tumor effects. Cholecalciferol 96-106 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 19-26 29766000-2 2018 This study aimed to elucidate the effect of vitamin D3 on gene expression of lectin-like oxidized LDL receptor-1 (LOX-1), scavenger receptor-A (SR-A), Cluster of Differentiation 36 (CD36), and Cluster of Differentiation 68 (CD68) as the main Ox-LDL receptors in streptozotocin (STZ)-induced diabetic rat aortas. Cholecalciferol 44-54 oxidized low density lipoprotein receptor 1 Rattus norvegicus 114-119 29766000-9 2018 CD68 and LOX-1 expression were greater in the vitamin D3/diabetic rats than in the diabetic control and healthy control rats, respectively. Cholecalciferol 46-56 oxidized low density lipoprotein receptor 1 Rattus norvegicus 9-14 29632537-4 2018 In contrast, pharmacological agents, such as vitamin D3 and adalimumab, were reported to induce the expansion of Tregs by promoting the interaction of transmembrane TNF (tmTNF) with TNFR2. Cholecalciferol 45-55 TNF receptor superfamily member 1B Homo sapiens 182-187 29504254-7 2018 CONCLUSIONS: Cholecalciferol supplementation, combined with a weight loss program, significantly improves insulin sensitivity in healthy subjects with obesity and might represent a personalized approach for insulin-resistant subjects with obesity. Cholecalciferol 13-28 insulin Homo sapiens 106-113 29504254-7 2018 CONCLUSIONS: Cholecalciferol supplementation, combined with a weight loss program, significantly improves insulin sensitivity in healthy subjects with obesity and might represent a personalized approach for insulin-resistant subjects with obesity. Cholecalciferol 13-28 insulin Homo sapiens 207-214 29633734-2 2018 Currently available treatments for HPT include high dose vitamin D (ergocalciferol, D2 and cholecalciferol, D3) or, the active metabolite dihydroxy vitamin D (calcitriol), in addition to calcium supplements.This regimen, if not well monitored, can lead to hypercalciuria, as PTH deficiency impairs renal calcium reabsorption. Cholecalciferol 91-106 HPT Homo sapiens 35-38 27988847-0 2018 Calcium and vitamin D3 combinations improve fatty liver disease through AMPK-independent mechanisms. Cholecalciferol 12-22 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 72-76 29534438-0 2018 Expression of TXNIP in Cancer Cells and Regulation by 1,25(OH)2D3: Is It Really the Vitamin D3 Upregulated Protein? Cholecalciferol 84-94 thioredoxin interacting protein Homo sapiens 14-19 29349624-2 2018 RESULTS: Compared to the untreated control or individual drug, the combinations of aspirin and vitamin D3 significantly decreased the rates of cell proliferation by CCK-8 assay, and caused higher rates of cell apoptosis in both CAL-27 and SCC-15 cells by Annexin V-FITC apoptosis assay and flow cytometry. Cholecalciferol 95-105 annexin A5 Homo sapiens 255-264 29349624-3 2018 Remarkably, the combined treatment with aspirin and vitamin D3 significantly suppressed the expression of Bcl-2 protein and p-Erk1/2 protein, examined by western blot analysis. Cholecalciferol 52-62 BCL2 apoptosis regulator Homo sapiens 106-111 29349624-3 2018 Remarkably, the combined treatment with aspirin and vitamin D3 significantly suppressed the expression of Bcl-2 protein and p-Erk1/2 protein, examined by western blot analysis. Cholecalciferol 52-62 mitogen-activated protein kinase 3 Homo sapiens 126-132 29439405-0 2018 Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients. Cholecalciferol 0-15 parathyroid hormone Homo sapiens 41-60 28795342-0 2018 Effect of Cholecalciferol therapy on serum FGF23 in vitamin D deficient patients: a randomized clinical trial. Cholecalciferol 10-25 fibroblast growth factor 23 Homo sapiens 43-48 28795342-2 2018 However, the effect of Cholecalciferol therapy on FGF23 serum level in patients with vitamin D deficiency has not been studied, yet. Cholecalciferol 23-38 fibroblast growth factor 23 Homo sapiens 50-55 28795342-5 2018 RESULTS: After Cholecalciferol therapy, delta of serum PTH in treatment group was less than the controls (P < 0.001). Cholecalciferol 15-30 parathyroid hormone Homo sapiens 55-58 29682582-0 2018 Vitamin D3 Protects against Diabetic Retinopathy by Inhibiting High-Glucose-Induced Activation of the ROS/TXNIP/NLRP3 Inflammasome Pathway. Cholecalciferol 0-10 thioredoxin interacting protein Homo sapiens 106-111 29682582-0 2018 Vitamin D3 Protects against Diabetic Retinopathy by Inhibiting High-Glucose-Induced Activation of the ROS/TXNIP/NLRP3 Inflammasome Pathway. Cholecalciferol 0-10 NLR family pyrin domain containing 3 Homo sapiens 112-117 29682582-7 2018 Results: Vitamin D3 significantly downregulated intracellular ROS and inhibited TRX-interacting protein (TXNIP)/NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome pathway activation. Cholecalciferol 9-19 thioredoxin interacting protein Homo sapiens 80-103 29682582-7 2018 Results: Vitamin D3 significantly downregulated intracellular ROS and inhibited TRX-interacting protein (TXNIP)/NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome pathway activation. Cholecalciferol 9-19 thioredoxin interacting protein Homo sapiens 105-110 29682582-7 2018 Results: Vitamin D3 significantly downregulated intracellular ROS and inhibited TRX-interacting protein (TXNIP)/NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome pathway activation. Cholecalciferol 9-19 NLR family pyrin domain containing 3 Homo sapiens 165-170 29682582-8 2018 Additionally, vitamin D3 reduced vascular endothelial growth factor (VEGF) expression and the Bax/Bcl-2 ratio. Cholecalciferol 14-24 vascular endothelial growth factor A Homo sapiens 33-67 29682582-8 2018 Additionally, vitamin D3 reduced vascular endothelial growth factor (VEGF) expression and the Bax/Bcl-2 ratio. Cholecalciferol 14-24 vascular endothelial growth factor A Homo sapiens 69-73 29682582-8 2018 Additionally, vitamin D3 reduced vascular endothelial growth factor (VEGF) expression and the Bax/Bcl-2 ratio. Cholecalciferol 14-24 BCL2 associated X, apoptosis regulator Homo sapiens 94-97 29682582-8 2018 Additionally, vitamin D3 reduced vascular endothelial growth factor (VEGF) expression and the Bax/Bcl-2 ratio. Cholecalciferol 14-24 BCL2 apoptosis regulator Homo sapiens 98-103 29682582-10 2018 Conclusions: Vitamin D3 decreases diabetes-induced ROS and exerts protective effects against retinal vascular damage and cell apoptosis in association with inhibition of the ROS/TXNIP/NLRP3 inflammasome pathway. Cholecalciferol 13-23 thioredoxin interacting protein Homo sapiens 178-183 29682582-10 2018 Conclusions: Vitamin D3 decreases diabetes-induced ROS and exerts protective effects against retinal vascular damage and cell apoptosis in association with inhibition of the ROS/TXNIP/NLRP3 inflammasome pathway. Cholecalciferol 13-23 NLR family pyrin domain containing 3 Homo sapiens 184-189 29462197-9 2018 The level of Let-7 in thymic B progenitors was up regulated by in vitro co-culture with IL15, Vitamin-D3, and retinoic acid, thus down-regulating Arid3a to promote B cell differentiation. Cholecalciferol 94-104 AT rich interactive domain 3A (BRIGHT-like) Mus musculus 146-152 29331461-0 2018 Stabilizing vitamin D3 using the molten globule state of alpha-lactalbumin. Cholecalciferol 12-22 lactalbumin alpha Bos taurus 57-74 29331461-3 2018 The MG state of alpha-LA exposes a significant number of hydrophobic patches that could be used to bind and stabilize small hydrophobic molecules such as vitamin D3 (vitD). Cholecalciferol 154-164 lactalbumin alpha Bos taurus 16-24 29273827-12 2018 CONCLUSION: These findings suggest that oral administration of vitamin D3 analogues (ALF and ELD) stimulates FCA but plain vitamin D3 does not. Cholecalciferol 63-73 general transcription factor IIA subunit 1 like Homo sapiens 85-88 29273827-12 2018 CONCLUSION: These findings suggest that oral administration of vitamin D3 analogues (ALF and ELD) stimulates FCA but plain vitamin D3 does not. Cholecalciferol 123-133 general transcription factor IIA subunit 1 like Homo sapiens 85-88 29273827-13 2018 Those effects of vitamin D3 compounds on FCA were independent of serum calcitriol concentration, suggesting that ALF and ELD may directly stimulate intestinal vitamin D receptors. Cholecalciferol 17-27 general transcription factor IIA subunit 1 like Homo sapiens 113-116 30511526-10 2018 mRNA expression of Arg-1 in vitamin D3 group was higher than that in AS-serum group (t=6.219, P<0.05), while mRNA expression of iNOS was lower than that in AS-serum group (t=5.876, P<0.05). Cholecalciferol 28-38 arginase 1 Homo sapiens 19-24 29483908-12 2018 Expression of the tissue homing-associated markers alpha4beta7 and CCR9 or CCR10 on lymphocytes can be influenced by vitamin A and vitamin D3, respectively. Cholecalciferol 131-141 C-C motif chemokine receptor 9 Bos taurus 67-71 29483908-12 2018 Expression of the tissue homing-associated markers alpha4beta7 and CCR9 or CCR10 on lymphocytes can be influenced by vitamin A and vitamin D3, respectively. Cholecalciferol 131-141 C-C motif chemokine receptor 10 Bos taurus 75-80 29243851-5 2018 Cholecalciferol treatment partially restored renal Oat3 mRNA/protein expression back to that of vitamin D-sufficient mice. Cholecalciferol 0-15 solute carrier family 22 (organic anion transporter), member 8 Mus musculus 51-55 30856079-0 2018 Vitamin D3 supplementation improves serum SFRP5 and Wnt5a levels in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Cholecalciferol 0-10 secreted frizzled related protein 5 Homo sapiens 42-47 29186386-0 2018 Gene Expression Pattern in Response to Cholecalciferol Supplementation Highlights Cubilin as a Major Protein of 25(OH)D Uptake in Adipocytes and Male Mice White Adipose Tissue. Cholecalciferol 39-54 cubilin (intrinsic factor-cobalamin receptor) Mus musculus 82-89 29186386-4 2018 Mice supplemented with cholecalciferol (15,000 IU/kg of body weight per day) for 4 days showed decreased messenger RNA (mRNA) levels of proteins involved in cholecalciferol metabolism (Cyp24a1, Cyp27a1) and decreased cubilin mRNA levels in WAT. Cholecalciferol 23-38 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 185-192 29186386-4 2018 Mice supplemented with cholecalciferol (15,000 IU/kg of body weight per day) for 4 days showed decreased messenger RNA (mRNA) levels of proteins involved in cholecalciferol metabolism (Cyp24a1, Cyp27a1) and decreased cubilin mRNA levels in WAT. Cholecalciferol 23-38 cytochrome P450, family 27, subfamily a, polypeptide 1 Mus musculus 194-201 29186386-4 2018 Mice supplemented with cholecalciferol (15,000 IU/kg of body weight per day) for 4 days showed decreased messenger RNA (mRNA) levels of proteins involved in cholecalciferol metabolism (Cyp24a1, Cyp27a1) and decreased cubilin mRNA levels in WAT. Cholecalciferol 23-38 cubilin (intrinsic factor-cobalamin receptor) Mus musculus 217-224 29186386-4 2018 Mice supplemented with cholecalciferol (15,000 IU/kg of body weight per day) for 4 days showed decreased messenger RNA (mRNA) levels of proteins involved in cholecalciferol metabolism (Cyp24a1, Cyp27a1) and decreased cubilin mRNA levels in WAT. Cholecalciferol 157-172 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 185-192 29186386-4 2018 Mice supplemented with cholecalciferol (15,000 IU/kg of body weight per day) for 4 days showed decreased messenger RNA (mRNA) levels of proteins involved in cholecalciferol metabolism (Cyp24a1, Cyp27a1) and decreased cubilin mRNA levels in WAT. Cholecalciferol 157-172 cytochrome P450, family 27, subfamily a, polypeptide 1 Mus musculus 194-201 29370073-3 2018 Studies with vitamin D3 plus phorbol ester transformed THP-1 macrophages demonstrated that functionalization, regardless of amount, corresponded with profoundly decreased NLRP3 inflammasome activation. Cholecalciferol 13-23 NLR family, pyrin domain containing 3 Mus musculus 171-176 30856079-0 2018 Vitamin D3 supplementation improves serum SFRP5 and Wnt5a levels in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Cholecalciferol 0-10 Wnt family member 5A Homo sapiens 52-57 30856079-1 2018 Objective: To explore the effect of vitamin D3 on novel serum adipokines, secreted frizzled-related protein 5 (SFRP5) and Wingless-Type MMTV Integration Site Family Member 5a (Wnt5a) levels in Type 2 Diabetes Mellitus (T2DM) patients. Cholecalciferol 36-46 Wnt family member 5A Homo sapiens 176-181 30856079-9 2018 Conclusion: 8 weeks of vitamin D3 supplementation for patients with type 2 diabetes may increase serum anti-inflammatory adipokine SFRP5 but decrease serum pro-inflammatory Wnt5a and TNF-alpha. Cholecalciferol 23-33 secreted frizzled related protein 5 Homo sapiens 131-136 30856079-9 2018 Conclusion: 8 weeks of vitamin D3 supplementation for patients with type 2 diabetes may increase serum anti-inflammatory adipokine SFRP5 but decrease serum pro-inflammatory Wnt5a and TNF-alpha. Cholecalciferol 23-33 Wnt family member 5A Homo sapiens 173-178 30856079-9 2018 Conclusion: 8 weeks of vitamin D3 supplementation for patients with type 2 diabetes may increase serum anti-inflammatory adipokine SFRP5 but decrease serum pro-inflammatory Wnt5a and TNF-alpha. Cholecalciferol 23-33 tumor necrosis factor Homo sapiens 183-192 29403473-5 2017 Only a minority of in vitro generated vitamin D3 (vitD3)-treated tolDCs expressed the inflammatory chemokine receptor CCR5. Cholecalciferol 38-48 C-C motif chemokine receptor 5 Homo sapiens 118-122 29153546-1 2018 Vitamin D3 upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4+ T cells in vitro. Cholecalciferol 0-10 interleukin 2 receptor subunit alpha Homo sapiens 23-42 29273504-0 2018 Fibroblast growth factor 21 ameliorates vascular calcification by inhibiting osteogenic transition in vitamin D3 plus nicotine-treated rats. Cholecalciferol 102-112 fibroblast growth factor 21 Rattus norvegicus 0-27 29273504-4 2018 Thus, in this study, we observed the effect and mechanism of FGF21 on VC induced by vitamin D3 plus nicotine (VDN) treated rats. Cholecalciferol 84-94 fibroblast growth factor 21 Rattus norvegicus 61-66 29416330-8 2018 Vitamin D3 restored uncoupled eNOS and endothelial function by increasing cytoprotective NO and decreasing the cytotoxic ONOO-. Cholecalciferol 0-10 nitric oxide synthase 3 Homo sapiens 30-34 29416330-9 2018 The beneficial effect of vitamin D3 is associated with a favorable rate of NO and ONOO- release, restoration of the [NO]/[ONOO-] and the overall decrease in the overexpression of eNOS, inducible nitric oxide synthase and NADPH oxidase. Cholecalciferol 25-35 nitric oxide synthase 3 Homo sapiens 179-183 29153546-5 2018 We speculate that vitamin D3 may promote the maintenance of CD25-related immune homeostasis in MS. Cholecalciferol 18-28 interleukin 2 receptor subunit alpha Homo sapiens 60-64 29153546-1 2018 Vitamin D3 upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4+ T cells in vitro. Cholecalciferol 0-10 interleukin 2 receptor subunit alpha Homo sapiens 44-49 29153546-1 2018 Vitamin D3 upregulates IL-2 receptor alpha (IL2RA, CD25)-expression on CD4+ T cells in vitro. Cholecalciferol 0-10 interleukin 2 receptor subunit alpha Homo sapiens 51-55 29153546-2 2018 We investigated effects of 48-weeks vitamin D3 supplements on CD25-expression by CD4+ T cells of patients with multiple sclerosis (MS). Cholecalciferol 36-46 interleukin 2 receptor subunit alpha Homo sapiens 62-66 30269120-3 2018 A combination of oral active vitamin D3 and phosphate salt is the current standard therapy for patients with FGF23-related hypophosphatemic rickets and osteomalacia. Cholecalciferol 29-39 fibroblast growth factor 23 Homo sapiens 109-114 28747359-5 2017 The model predicts that large perturbations in PTH or vitamin D3 synthesis have a greater impact on the plasma concentration of Ca2+ ([Ca2+]p) than on that of PO4 ([PO4]p); due to negative feedback loops, [PO4]p does not consistently increase when the production rate of PTH or vitamin D3 is decreased. Cholecalciferol 278-288 parathyroid hormone Rattus norvegicus 47-50 29257234-3 2018 The aim of the present study was to investigate the therapeutic effects and the underlying primary mechanism of FGF-21 on atherosclerosis in a rat model induced by vitamin D3 and a high fat diet. Cholecalciferol 164-174 fibroblast growth factor 21 Rattus norvegicus 112-118 29115640-9 2018 In conclusion, IMA and NIL interfere with the vitamin D3 cascade due to their metabolism by CYP27B1. Cholecalciferol 46-56 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 92-99 28747359-5 2017 The model predicts that large perturbations in PTH or vitamin D3 synthesis have a greater impact on the plasma concentration of Ca2+ ([Ca2+]p) than on that of PO4 ([PO4]p); due to negative feedback loops, [PO4]p does not consistently increase when the production rate of PTH or vitamin D3 is decreased. Cholecalciferol 54-64 parathyroid hormone Rattus norvegicus 271-274 28034764-4 2018 The concept is based on the fact that vitamin D3 activates via its metabolite 1alpha,25-dihydroxyvitamin D3 the transcription factor vitamin D receptor and thus has a direct effect on the epigenome and transcriptome of many human tissues and cell types. Cholecalciferol 38-48 vitamin D receptor Homo sapiens 133-151 30412176-0 2018 [The influence of the vitamin D3 level in the blood serum of lactase gene polymorphism on the development of chronic polypous rhinosinusitis]. Cholecalciferol 22-32 lactase Homo sapiens 61-68 30412176-1 2018 The objective of the present study was to elucidate the possible correlations between the vitamin D3 level in the blood serum and lactase gene polymorphism (LCT-13910 T>C) in the patients presenting with chronic polypous rhinosinusitis (CPRS). Cholecalciferol 90-100 lactase Homo sapiens 130-137 29021285-5 2017 Notably, in vitro experiments with trophoblasts showed increased production and secretion of 25(OH)D3 and higher CYP24A1 gene transcript abundance in response to cholecalciferol treatment.Conclusions: The numerous associations of many of the placental biomarkers of vitamin D metabolism with circulating vitamin D metabolites among pregnant women [including a CYP27B1-associated increase in 1,25(OH)2D3] and the evidence of trophoblast production and secretion of vitamin D metabolites, especially 25(OH)D3, suggest that the placenta may play an active role in modulating the vitamin D metabolite profile in maternal circulation in human pregnancy. Cholecalciferol 162-177 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 113-120 29021285-5 2017 Notably, in vitro experiments with trophoblasts showed increased production and secretion of 25(OH)D3 and higher CYP24A1 gene transcript abundance in response to cholecalciferol treatment.Conclusions: The numerous associations of many of the placental biomarkers of vitamin D metabolism with circulating vitamin D metabolites among pregnant women [including a CYP27B1-associated increase in 1,25(OH)2D3] and the evidence of trophoblast production and secretion of vitamin D metabolites, especially 25(OH)D3, suggest that the placenta may play an active role in modulating the vitamin D metabolite profile in maternal circulation in human pregnancy. Cholecalciferol 162-177 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 360-367 28544067-4 2017 The present study investigated the effects of vitamin D3 on the expression of TLR3, TLR7, and TLR9 in SLE patients. Cholecalciferol 46-56 toll like receptor 3 Homo sapiens 78-82 29165303-1 2017 In mouse skin models, mast cells have been shown to express vitamin D receptor (VDR) that can mediate the immunosuppressive effects of ultraviolet B radiation and vitamin D3. Cholecalciferol 163-173 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 60-78 29271617-0 2017 Effects of Single Vitamin D3 Injection (200,000 Units) on Serum Fibroblast Growth Factor 23 and Sclerostin Levels in Subjects with Vitamin D Deficiency. Cholecalciferol 18-28 fibroblast growth factor 23 Homo sapiens 64-91 29271617-0 2017 Effects of Single Vitamin D3 Injection (200,000 Units) on Serum Fibroblast Growth Factor 23 and Sclerostin Levels in Subjects with Vitamin D Deficiency. Cholecalciferol 18-28 sclerostin Homo sapiens 96-106 29271617-4 2017 The aim of this study was to evaluate the effects of vitamin D3 intramuscular injection therapy on serum fibroblast growth factor 23 concentrations, and several other parameters associated with bone metabolism such as sclerostin, dickkopf-1, and parathyroid hormone. Cholecalciferol 53-63 fibroblast growth factor 23 Homo sapiens 105-132 28484266-4 2017 Upon phorbol-myristate acetate or Vitamin D3/granulocyte macrophage colony-stimulating factor (GM-CSF)-driven differentiation, both ADAR1 and ADAR2 enzymes are upregulated, with a concomitant global increase of A-to-I RNA editing. Cholecalciferol 34-44 colony stimulating factor 2 Homo sapiens 95-101 28484266-4 2017 Upon phorbol-myristate acetate or Vitamin D3/granulocyte macrophage colony-stimulating factor (GM-CSF)-driven differentiation, both ADAR1 and ADAR2 enzymes are upregulated, with a concomitant global increase of A-to-I RNA editing. Cholecalciferol 34-44 adenosine deaminase RNA specific Homo sapiens 132-137 28484266-4 2017 Upon phorbol-myristate acetate or Vitamin D3/granulocyte macrophage colony-stimulating factor (GM-CSF)-driven differentiation, both ADAR1 and ADAR2 enzymes are upregulated, with a concomitant global increase of A-to-I RNA editing. Cholecalciferol 34-44 adenosine deaminase RNA specific B1 Homo sapiens 142-147 29165303-1 2017 In mouse skin models, mast cells have been shown to express vitamin D receptor (VDR) that can mediate the immunosuppressive effects of ultraviolet B radiation and vitamin D3. Cholecalciferol 163-173 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 80-83 29165303-2 2017 However, VDR activation leads to the expression of CYP24A1, a hydroxylase that can inactivate vitamin D3 metabolites. Cholecalciferol 94-104 vitamin D receptor Homo sapiens 9-12 28544067-4 2017 The present study investigated the effects of vitamin D3 on the expression of TLR3, TLR7, and TLR9 in SLE patients. Cholecalciferol 46-56 toll like receptor 7 Homo sapiens 84-88 29165303-2 2017 However, VDR activation leads to the expression of CYP24A1, a hydroxylase that can inactivate vitamin D3 metabolites. Cholecalciferol 94-104 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 51-58 28544067-4 2017 The present study investigated the effects of vitamin D3 on the expression of TLR3, TLR7, and TLR9 in SLE patients. Cholecalciferol 46-56 toll like receptor 9 Homo sapiens 94-98 29061804-4 2017 We aimed to investigate the effect of MART-10 [19-nor-2alpha-(3-hydroxypropyl)-1alpha,25(OH)2D3], a 1alpha,25-dihydroxy-vitamin D3 (1alpha,25(OH)2D3) analog, on PanNET cell metastasis after VEGF-A stimulation. Cholecalciferol 119-130 vascular endothelial growth factor A Homo sapiens 190-196 28808057-0 2017 A kidney-specific genetic control module in mice governs endocrine regulation of the cytochrome P450 gene Cyp27b1 essential for vitamin D3 activation. Cholecalciferol 128-138 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 106-113 29084522-3 2017 The objective of this study was to determine if vitamin D3 at a comparatively high dose would replete 25-hydroxyvitamin D (25(OH)D) stores, improve BNP, PTH, cardiopulmonary function, reduce inflammatory markers, and improve quality of life (QOL) in HF patients. Cholecalciferol 48-58 natriuretic peptide B Homo sapiens 148-151 29084522-3 2017 The objective of this study was to determine if vitamin D3 at a comparatively high dose would replete 25-hydroxyvitamin D (25(OH)D) stores, improve BNP, PTH, cardiopulmonary function, reduce inflammatory markers, and improve quality of life (QOL) in HF patients. Cholecalciferol 48-58 parathyroid hormone Homo sapiens 153-156 28808057-2 2017 Terminal activation of vitamin D3 to its hormonal form, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), occurs in the kidney via the cytochrome P450 enzyme CYP27B1. Cholecalciferol 23-33 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 153-160 29171448-11 2017 RESULTS: Supplementation of Vitamin D3 on the 2nd-line anti-TB therapy increases Vitamin D3 receptor, CRAMP, LC3B, caspase-3 (P = 0.026, P = 0.000, P= 0.001), presses MMP1, and the number of bacteria (P = 0.010 and P= 0.000, respectively). Cholecalciferol 28-38 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 81-100 28605609-4 2017 Therefore, we investigated the effects of postexercise supplementation with protein and carbohydrate (CHO) and vitamins D3 and K2 on the postexercise hepcidin response. Cholecalciferol 111-122 hepcidin antimicrobial peptide Homo sapiens 150-158 29171448-11 2017 RESULTS: Supplementation of Vitamin D3 on the 2nd-line anti-TB therapy increases Vitamin D3 receptor, CRAMP, LC3B, caspase-3 (P = 0.026, P = 0.000, P= 0.001), presses MMP1, and the number of bacteria (P = 0.010 and P= 0.000, respectively). Cholecalciferol 28-38 cathelicidin antimicrobial peptide Mus musculus 102-107 29171448-11 2017 RESULTS: Supplementation of Vitamin D3 on the 2nd-line anti-TB therapy increases Vitamin D3 receptor, CRAMP, LC3B, caspase-3 (P = 0.026, P = 0.000, P= 0.001), presses MMP1, and the number of bacteria (P = 0.010 and P= 0.000, respectively). Cholecalciferol 28-38 microtubule-associated protein 1 light chain 3 beta Mus musculus 109-113 29171448-11 2017 RESULTS: Supplementation of Vitamin D3 on the 2nd-line anti-TB therapy increases Vitamin D3 receptor, CRAMP, LC3B, caspase-3 (P = 0.026, P = 0.000, P= 0.001), presses MMP1, and the number of bacteria (P = 0.010 and P= 0.000, respectively). Cholecalciferol 28-38 caspase 3 Mus musculus 115-124 29171448-11 2017 RESULTS: Supplementation of Vitamin D3 on the 2nd-line anti-TB therapy increases Vitamin D3 receptor, CRAMP, LC3B, caspase-3 (P = 0.026, P = 0.000, P= 0.001), presses MMP1, and the number of bacteria (P = 0.010 and P= 0.000, respectively). Cholecalciferol 28-38 matrix metallopeptidase 13 Mus musculus 167-171 28130182-0 2017 Induction of CFTR gene expression by 1,25(OH)2 vitamin D3, 25OH vitamin D3, and vitamin D3 in cultured human airway epithelial cells and in mouse airways. Cholecalciferol 47-57 CF transmembrane conductance regulator Homo sapiens 13-17 28576736-5 2017 A blinded, unsupervised hierarchical clustering of participants based on global gene expression profiles revealed that participants with significantly higher serum vitamin D3 levels after treatment (P = 0.007) demonstrated increased skin expression of the anti-inflammatory mediator arginase-1 (P = 0.005), and a sustained reduction in skin redness (P = 0.02), correlating with significant expression of genes related to skin barrier repair. Cholecalciferol 164-174 arginase 1 Homo sapiens 283-293 28664547-0 2017 Vitamin D3 ameliorates podocyte injury through the nephrin signalling pathway. Cholecalciferol 0-10 NPHS1 adhesion molecule, nephrin Rattus norvegicus 51-58 28664547-4 2017 Vitamin D3 through its receptor, VDR, provides renal protection in DN but limited data exist about its effect on podocytes. Cholecalciferol 0-10 vitamin D receptor Rattus norvegicus 33-36 28130182-8 2017 Treatment of BEC with 10muM cholecalciferol led to increases in both CYP24A1 and CFTR mRNA levels, even when added to the apical surface of cells grown in an air-liquid interface, suggesting that topical administration of vitamin D could be used therapeutically. Cholecalciferol 28-43 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 69-76 27923594-2 2017 Although CYP24A1 catalyzes multi-step oxidations toward the CD-ring side chain of the active vitamin D3 [1alpha,25(OH)2D3], the CYP24A1-dependent metabolism of AH-1 tended to stop at the first step hydroxylation at the C24-position of AH-1. Cholecalciferol 93-103 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 9-16 28130182-8 2017 Treatment of BEC with 10muM cholecalciferol led to increases in both CYP24A1 and CFTR mRNA levels, even when added to the apical surface of cells grown in an air-liquid interface, suggesting that topical administration of vitamin D could be used therapeutically. Cholecalciferol 28-43 cystic fibrosis transmembrane conductance regulator Mus musculus 81-85 28931466-7 2017 After treatment with 1-alpha,25-dihydroxyvitamin D3, the biologically active form of vitamin D3, there were significant increases in the ALP activities of Caco-2 cells. Cholecalciferol 41-51 alkaline phosphatase, placental Homo sapiens 137-140 28686246-1 2017 DMY combined with the dietary vitamin D3 at lower concentrations exhibited a synergistic effect on the inhibition of tyrosinase. Cholecalciferol 30-40 tyrosinase Homo sapiens 117-127 28257826-5 2017 This review will present the structural information on recognition of the vitamin D3 and metabolites by CYP proteins and DBP as well as the structural basis of VDR activation by 1,25(OH)2D3 and metabolites. Cholecalciferol 74-84 D-box binding PAR bZIP transcription factor Homo sapiens 121-124 28315703-1 2017 The molecular endocrinology of vitamin D is based on the facts that i) its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) is the high affinity ligand of the nuclear receptor vitamin D receptor (VDR) and ii) the transcription factor VDR is the unique target of 1,25(OH)2D3 in the nucleus. Cholecalciferol 113-115 vitamin D receptor Homo sapiens 202-205 28315703-1 2017 The molecular endocrinology of vitamin D is based on the facts that i) its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) is the high affinity ligand of the nuclear receptor vitamin D receptor (VDR) and ii) the transcription factor VDR is the unique target of 1,25(OH)2D3 in the nucleus. Cholecalciferol 113-115 vitamin D receptor Homo sapiens 240-243 28780161-0 2017 Synthesis and evaluation of vitamin D3 analogues with C-11 modifications as inhibitors of Hedgehog signaling. Cholecalciferol 28-38 RNA polymerase III subunit K Homo sapiens 54-58 28662432-7 2017 RESULTS: Low vitamin D3 levels were accompanied with decreased expression of cathelicidin and VDR in PKDL-BT patients. Cholecalciferol 13-23 vitamin D receptor Homo sapiens 94-97 27402475-0 2017 High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults. Cholecalciferol 10-20 hepcidin antimicrobial peptide Homo sapiens 41-49 27402475-3 2017 We aimed to examine the effect of high-dose vitamin D3 on plasma hepcidin, inflammatory cytokine, and ferritin concentrations in healthy adults. Cholecalciferol 44-54 hepcidin antimicrobial peptide Homo sapiens 65-73 27402475-7 2017 After 1 week, plasma hepcidin concentrations decreased by 73% from baseline in those who received vitamin D3 (geometric mean ratio [GMR] = 0.27 (95% CI: 0.11-0.62); P = 0.005); there was no significant change in the placebo group (GMR = 0.73 (95% CI: 0.49-1.09); P = 0.11). Cholecalciferol 98-108 hepcidin antimicrobial peptide Homo sapiens 21-29 27402475-9 2017 CONCLUSIONS: High-dose vitamin D3 significantly reduced plasma hepcidin concentrations in healthy adults 1 week post-dosing, without a change in plasma pro-inflammatory cytokine or ferritin concentrations. Cholecalciferol 23-33 hepcidin antimicrobial peptide Homo sapiens 63-71 29041890-0 2017 [Effect of Cholecalciferol and Diuretics as Components of Combination Antihypertensive Therapy on Plasma Renin Activity and Endothelial Function in Patients With Arterial Hypertension]. Cholecalciferol 11-26 renin Homo sapiens 105-110 29041890-1 2017 AIM: To evaluate the effect of cholecalciferol and diuretics as components of combination antihypertensive therapy (CAHT) on plasma renin activity (PRA) and endothelial function in patients with arterial hypertension (AH). Cholecalciferol 31-46 renin Homo sapiens 132-137 28891930-3 2017 The active metabolite of vitamin D3 has an immunoregulatory role mediated by binding to the vitamin D receptor (VDR) in monocyte, macrophages, and lymphocytes. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 92-110 28891930-3 2017 The active metabolite of vitamin D3 has an immunoregulatory role mediated by binding to the vitamin D receptor (VDR) in monocyte, macrophages, and lymphocytes. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 112-115 28891930-9 2017 CONCLUSION: Genetic polymorphism in two SNP in VDR may be correlated with development of ASD symptoms by influencing functionality of vitamin D3 metabolism, while vitamin D3 levels were not significantly different between ASD and non-ASD children. Cholecalciferol 134-144 vitamin D receptor Homo sapiens 47-50 28692301-7 2017 Adjunctive vitamin D3 accelerated sputum culture conversion in patients with one or more minor alleles for SNPs in genes encoding the vitamin D receptor (rs4334089, rs11568820) and 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1: rs4646536) (adjusted hazard ratio >= 1.47; P for interaction <= 0.02). Cholecalciferol 11-21 vitamin D receptor Homo sapiens 134-152 28692301-7 2017 Adjunctive vitamin D3 accelerated sputum culture conversion in patients with one or more minor alleles for SNPs in genes encoding the vitamin D receptor (rs4334089, rs11568820) and 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1: rs4646536) (adjusted hazard ratio >= 1.47; P for interaction <= 0.02). Cholecalciferol 11-21 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 221-228 28795969-0 2017 E-cadherin Mediates the Preventive Effect of Vitamin D3 in Colitis-associated Carcinogenesis. Cholecalciferol 45-55 cadherin 1 Mus musculus 0-10 28795969-7 2017 Cell proliferation decreased in vitamin D3 groups compared with the control group after inhibition of expression of beta-catenin and its downstream target gene cyclin D1 in the colon. Cholecalciferol 32-42 catenin (cadherin associated protein), beta 1 Mus musculus 116-128 28795969-7 2017 Cell proliferation decreased in vitamin D3 groups compared with the control group after inhibition of expression of beta-catenin and its downstream target gene cyclin D1 in the colon. Cholecalciferol 32-42 cyclin D1 Mus musculus 160-169 28795969-8 2017 In vitro, vitamin D3 reduced the transcriptional activity and nuclear level of beta-catenin, and it also increased E-cadherin expression and its binding affinity for beta-catenin. Cholecalciferol 10-20 catenin (cadherin associated protein), beta 1 Mus musculus 79-91 28795969-8 2017 In vitro, vitamin D3 reduced the transcriptional activity and nuclear level of beta-catenin, and it also increased E-cadherin expression and its binding affinity for beta-catenin. Cholecalciferol 10-20 cadherin 1 Mus musculus 115-125 28795969-8 2017 In vitro, vitamin D3 reduced the transcriptional activity and nuclear level of beta-catenin, and it also increased E-cadherin expression and its binding affinity for beta-catenin. Cholecalciferol 10-20 catenin (cadherin associated protein), beta 1 Mus musculus 166-178 28795969-9 2017 Moreover, repression of E-cadherin was rescued by supplemental vitamin D3 in mouse colons. Cholecalciferol 63-73 cadherin 1 Mus musculus 24-34 28795969-11 2017 Our findings further suggest that upregulation of E-cadherin contributes to the preventive effect of vitamin D3 on beta-catenin activity. Cholecalciferol 101-111 cadherin 1 Mus musculus 50-60 28795969-11 2017 Our findings further suggest that upregulation of E-cadherin contributes to the preventive effect of vitamin D3 on beta-catenin activity. Cholecalciferol 101-111 catenin (cadherin associated protein), beta 1 Mus musculus 115-127 28746983-4 2017 Among the 13 human SULTs, SULT2A1 shows sulfating activity toward all vitamin D3 -related compounds, whereas SULT1A1 and SULT2B1a/SULT2B1b show sulfating activity exclusively for, respectively, calcitriol and 7-dehydrocholesterol. Cholecalciferol 70-80 sulfotransferase family 2A member 1 Homo sapiens 26-33 28532201-11 2017 Interestingly, vitamin D3 inhibits ex vivo NO production, iNOS and NF-kappaB expression in BD patients. Cholecalciferol 15-25 nitric oxide synthase 2 Homo sapiens 58-62 28575224-2 2017 Objective: To determine whether SNPs in DHCR7, CYP2R1, CYP24A1, and GC are associated with the response to gestational cholecalciferol supplementation. Cholecalciferol 119-134 7-dehydrocholesterol reductase Homo sapiens 40-45 28575224-2 2017 Objective: To determine whether SNPs in DHCR7, CYP2R1, CYP24A1, and GC are associated with the response to gestational cholecalciferol supplementation. Cholecalciferol 119-134 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 47-53 28575224-2 2017 Objective: To determine whether SNPs in DHCR7, CYP2R1, CYP24A1, and GC are associated with the response to gestational cholecalciferol supplementation. Cholecalciferol 119-134 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 55-62 28575224-12 2017 Conclusions: Genetic variation in DHCR7, which encodes 7-dehyrocholesterol reductase in the epidermal vitamin D biosynthesis pathway, appears to modify baseline 25(OH)D. In contrast, the response to antenatal cholecalciferol supplementation was associated with SNPs in CYP2R1, which may alter 25-hydroxylase activity, and GC, which may affect vitamin D binding protein synthesis or metabolite affinity. Cholecalciferol 209-224 7-dehydrocholesterol reductase Homo sapiens 34-39 27671249-1 2017 In this study, we investigated the role of vitamin D3 (VitD3) on endogenous osteopontin (OPN), a neuroprotective glycoprotein, after subarachnoid hemorrhage (SAH). Cholecalciferol 43-53 secreted phosphoprotein 1 Rattus norvegicus 76-87 27671249-1 2017 In this study, we investigated the role of vitamin D3 (VitD3) on endogenous osteopontin (OPN), a neuroprotective glycoprotein, after subarachnoid hemorrhage (SAH). Cholecalciferol 43-53 secreted phosphoprotein 1 Rattus norvegicus 89-92 27671249-3 2017 Vitamin D3 (30, 60, 120 ng/kg/day) increased more than one fold endogenous OPN expression in astrocytes and endothelial cells of rat brain. Cholecalciferol 0-10 secreted phosphoprotein 1 Rattus norvegicus 75-78 27671249-6 2017 These protective effects of vitamin D3 were completely attenuated by intracerebroventricular injection of transcription inhibitor Actinomycin D and significantly inhibited by small interfering ribonucleic acid (siRNA) for vitamin D receptor and OPN in Pre-SAH + VitD3 rats. Cholecalciferol 28-38 vitamin D receptor Rattus norvegicus 222-240 27671249-6 2017 These protective effects of vitamin D3 were completely attenuated by intracerebroventricular injection of transcription inhibitor Actinomycin D and significantly inhibited by small interfering ribonucleic acid (siRNA) for vitamin D receptor and OPN in Pre-SAH + VitD3 rats. Cholecalciferol 28-38 secreted phosphoprotein 1 Rattus norvegicus 245-248 27671249-8 2017 The results show that intranasal vitamin D3 attenuates blood-brain barrier (BBB) disruption through endogenous upregulation of OPN and subsequent CD44 and P-gp glycosylation signals in brain endothelial cells. Cholecalciferol 33-43 secreted phosphoprotein 1 Rattus norvegicus 127-130 27671249-8 2017 The results show that intranasal vitamin D3 attenuates blood-brain barrier (BBB) disruption through endogenous upregulation of OPN and subsequent CD44 and P-gp glycosylation signals in brain endothelial cells. Cholecalciferol 33-43 CD44 molecule (Indian blood group) Rattus norvegicus 146-150 27671249-8 2017 The results show that intranasal vitamin D3 attenuates blood-brain barrier (BBB) disruption through endogenous upregulation of OPN and subsequent CD44 and P-gp glycosylation signals in brain endothelial cells. Cholecalciferol 33-43 phosphoglycolate phosphatase Rattus norvegicus 155-159 28978056-3 2017 The 1alpha-Hydroxylase ["1alpha(OH)ase"] is a key enzyme for activate vitamin D3 synthesis. Cholecalciferol 70-80 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 25-38 29145536-5 2017 RESULTS: Significant positive effects on DID, FCP, and SCP levels were observed after supplementation with alphacalcidole and cholecalciferol, whereas supplementation with calcitriol showed no effect. Cholecalciferol 126-141 solute carrier family 50 member 1 Homo sapiens 55-58 28978056-4 2017 Here, we show that 1alpha(OH)ase stable knockdown by targeted shRNA led to vitamin D3 depletion in L02 hepatocytes. Cholecalciferol 75-85 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 19-32 28218743-2 2017 Vitamin D is activated through hydroxylation by 25-hydroxylases (CYP2R1 or CYP27A1) and 1alpha-hydroxylase (CYP27B1) to produce 1,25(OH)2D3, or through the action of CYP11A1 to produce mono-di- and trihydroxy-D3 products that can be further modified by CYP27B1, CYP27A1, and CYP24A1. Cholecalciferol 208-211 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 65-71 28665937-6 2017 We observed a reduction in the expression of TLR7, TLR9, INF-gamma and CYP24a1 and an increase in VDR and CYP27b1 expression in patients which were supplemented with cholecalciferol, whereas no differences were found in the placebo group. Cholecalciferol 166-181 toll like receptor 7 Homo sapiens 45-49 28665937-6 2017 We observed a reduction in the expression of TLR7, TLR9, INF-gamma and CYP24a1 and an increase in VDR and CYP27b1 expression in patients which were supplemented with cholecalciferol, whereas no differences were found in the placebo group. Cholecalciferol 166-181 toll like receptor 9 Homo sapiens 51-55 28665937-6 2017 We observed a reduction in the expression of TLR7, TLR9, INF-gamma and CYP24a1 and an increase in VDR and CYP27b1 expression in patients which were supplemented with cholecalciferol, whereas no differences were found in the placebo group. Cholecalciferol 166-181 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 71-78 28665937-6 2017 We observed a reduction in the expression of TLR7, TLR9, INF-gamma and CYP24a1 and an increase in VDR and CYP27b1 expression in patients which were supplemented with cholecalciferol, whereas no differences were found in the placebo group. Cholecalciferol 166-181 vitamin D receptor Homo sapiens 98-101 28665937-6 2017 We observed a reduction in the expression of TLR7, TLR9, INF-gamma and CYP24a1 and an increase in VDR and CYP27b1 expression in patients which were supplemented with cholecalciferol, whereas no differences were found in the placebo group. Cholecalciferol 166-181 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 106-113 28430709-4 2017 Here, we found that lipopolysaccharide stimulation in astrocytes could enhance the expression of vitamin D receptor and Cyp27B1, which encodes the enzyme for converting vitamin D3 into its active form. Cholecalciferol 169-179 vitamin D receptor Rattus norvegicus 97-115 28430709-4 2017 Here, we found that lipopolysaccharide stimulation in astrocytes could enhance the expression of vitamin D receptor and Cyp27B1, which encodes the enzyme for converting vitamin D3 into its active form. Cholecalciferol 169-179 cytochrome P450, family 27, subfamily b, polypeptide 1 Rattus norvegicus 120-127 28430709-5 2017 Vitamin D3 suppressed the expression of proinflammatory cytokines tumour necrosis factor-alpha, interleukin-1beta, vascular endothelial growth factor, and also TLR4 in activated astrocytes. Cholecalciferol 0-10 interleukin 1 beta Rattus norvegicus 96-113 28430709-5 2017 Vitamin D3 suppressed the expression of proinflammatory cytokines tumour necrosis factor-alpha, interleukin-1beta, vascular endothelial growth factor, and also TLR4 in activated astrocytes. Cholecalciferol 0-10 toll-like receptor 4 Rattus norvegicus 160-164 28592257-2 2017 Ointment containing 1,25-dihydroxy-22-oxavitamin D3 (maxacalcitol), a noncalcemic analog of the active form of vitamin D3, is applied for the treatment of hyperkeratotic cutaneous conditions such as psoriasis and ichtyosis because it suppresses the proliferation and promotes the differentiation of keratinocytes through interaction with the vitamin D receptor. Cholecalciferol 41-51 vitamin D receptor Homo sapiens 342-360 28474500-0 2017 Vitamin D3 supplementation of a high fat high sugar diet ameliorates prediabetic phenotype in female LDLR-/- and LDLR+/+ mice. Cholecalciferol 0-10 low density lipoprotein receptor Mus musculus 101-105 28474500-0 2017 Vitamin D3 supplementation of a high fat high sugar diet ameliorates prediabetic phenotype in female LDLR-/- and LDLR+/+ mice. Cholecalciferol 0-10 low density lipoprotein receptor Mus musculus 113-117 28474500-5 2017 Levels of non-esterified fatty acids and lipid peroxidation products were significantly lower in the group supplemented with additional Vitamin D3 , as were systemic markers of inflammation (serum endotoxin and IL-6). Cholecalciferol 136-146 interleukin 6 Mus musculus 211-215 28474500-8 2017 CONCLUSION: In summary, Vitamin D3 was a significantly beneficial dietary additive to blunt a prediabetic phenotype in diet-induced obesity of female LDLR-/- and LDLR+/+ mice. Cholecalciferol 24-34 low density lipoprotein receptor Mus musculus 150-154 28474500-8 2017 CONCLUSION: In summary, Vitamin D3 was a significantly beneficial dietary additive to blunt a prediabetic phenotype in diet-induced obesity of female LDLR-/- and LDLR+/+ mice. Cholecalciferol 24-34 low density lipoprotein receptor Mus musculus 162-166 28218743-2 2017 Vitamin D is activated through hydroxylation by 25-hydroxylases (CYP2R1 or CYP27A1) and 1alpha-hydroxylase (CYP27B1) to produce 1,25(OH)2D3, or through the action of CYP11A1 to produce mono-di- and trihydroxy-D3 products that can be further modified by CYP27B1, CYP27A1, and CYP24A1. Cholecalciferol 208-211 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 108-115 28475159-5 2017 Compared to the PL group, cholecalciferol administration increased 25(OH)Vit D levels (p < 0.001) and promoted a significant increase of HMW-A expression analyzed by WIB (p = 0.02). Cholecalciferol 26-41 cilia and flagella associated protein 97 Homo sapiens 140-143 28332200-3 2017 The direct actions of vitamin D3 on naive T cells result in the proliferation of more regulatory T cells and inhibitory cytokines such as IL-4, IL-10 and IL-5. Cholecalciferol 22-32 interleukin 4 Homo sapiens 138-142 28332200-3 2017 The direct actions of vitamin D3 on naive T cells result in the proliferation of more regulatory T cells and inhibitory cytokines such as IL-4, IL-10 and IL-5. Cholecalciferol 22-32 interleukin 10 Homo sapiens 144-149 28332200-3 2017 The direct actions of vitamin D3 on naive T cells result in the proliferation of more regulatory T cells and inhibitory cytokines such as IL-4, IL-10 and IL-5. Cholecalciferol 22-32 interleukin 5 Homo sapiens 154-158 28938596-0 2017 Vitamin D3 induces vitamin D receptor and HDAC11 binding to relieve the promoter of the tight junction proteins. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 19-37 28938596-0 2017 Vitamin D3 induces vitamin D receptor and HDAC11 binding to relieve the promoter of the tight junction proteins. Cholecalciferol 0-10 histone deacetylase 11 Homo sapiens 42-48 28475159-9 2017 Current findings suggest that acute cholecalciferol administration selectively modifies HMW-A and the leptin/HMW-A ratio. Cholecalciferol 36-51 cilia and flagella associated protein 97 Homo sapiens 88-91 28475159-9 2017 Current findings suggest that acute cholecalciferol administration selectively modifies HMW-A and the leptin/HMW-A ratio. Cholecalciferol 36-51 leptin Homo sapiens 102-108 28475159-9 2017 Current findings suggest that acute cholecalciferol administration selectively modifies HMW-A and the leptin/HMW-A ratio. Cholecalciferol 36-51 cilia and flagella associated protein 97 Homo sapiens 109-112 28095044-2 2017 Vitamin D3 undergoes conversion through a multitude of enzymatic reactions described within the paper, and vitamin D levels are dependent on many factors including the vitamin D binding protein (DBP). Cholecalciferol 0-10 D-box binding PAR bZIP transcription factor Homo sapiens 195-198 28476406-0 2017 Influence of Cdx2 and TaqI Gene Variants on Vitamin D3 Modulated Intracellular Chemokine Positive T-Cell Subsets in Pulmonary Tuberculosis. Cholecalciferol 44-54 caudal type homeobox 2 Homo sapiens 13-17 28476406-4 2017 FINDINGS: Vitamin D3 significantly suppressed monocyte chemoattractant protein 1, macrophage inhibitory protein (MIP)-1alpha, MIP-1beta, regulated on activation, normal T-cell expressed and secreted (RANTES), and interferon-gamma inducible protein 10 (IP-10)-positive T-cell subsets compared with culture filtrate antigen stimulated cells without vitamin D3 treatment. Cholecalciferol 10-20 C-C motif chemokine ligand 2 Homo sapiens 46-80 28476406-4 2017 FINDINGS: Vitamin D3 significantly suppressed monocyte chemoattractant protein 1, macrophage inhibitory protein (MIP)-1alpha, MIP-1beta, regulated on activation, normal T-cell expressed and secreted (RANTES), and interferon-gamma inducible protein 10 (IP-10)-positive T-cell subsets compared with culture filtrate antigen stimulated cells without vitamin D3 treatment. Cholecalciferol 10-20 C-C motif chemokine ligand 3 Homo sapiens 82-124 28476406-4 2017 FINDINGS: Vitamin D3 significantly suppressed monocyte chemoattractant protein 1, macrophage inhibitory protein (MIP)-1alpha, MIP-1beta, regulated on activation, normal T-cell expressed and secreted (RANTES), and interferon-gamma inducible protein 10 (IP-10)-positive T-cell subsets compared with culture filtrate antigen stimulated cells without vitamin D3 treatment. Cholecalciferol 10-20 C-C motif chemokine ligand 4 Homo sapiens 126-135 28476406-4 2017 FINDINGS: Vitamin D3 significantly suppressed monocyte chemoattractant protein 1, macrophage inhibitory protein (MIP)-1alpha, MIP-1beta, regulated on activation, normal T-cell expressed and secreted (RANTES), and interferon-gamma inducible protein 10 (IP-10)-positive T-cell subsets compared with culture filtrate antigen stimulated cells without vitamin D3 treatment. Cholecalciferol 10-20 C-C motif chemokine ligand 5 Homo sapiens 200-206 28476406-4 2017 FINDINGS: Vitamin D3 significantly suppressed monocyte chemoattractant protein 1, macrophage inhibitory protein (MIP)-1alpha, MIP-1beta, regulated on activation, normal T-cell expressed and secreted (RANTES), and interferon-gamma inducible protein 10 (IP-10)-positive T-cell subsets compared with culture filtrate antigen stimulated cells without vitamin D3 treatment. Cholecalciferol 10-20 C-X-C motif chemokine ligand 10 Homo sapiens 213-250 28476406-4 2017 FINDINGS: Vitamin D3 significantly suppressed monocyte chemoattractant protein 1, macrophage inhibitory protein (MIP)-1alpha, MIP-1beta, regulated on activation, normal T-cell expressed and secreted (RANTES), and interferon-gamma inducible protein 10 (IP-10)-positive T-cell subsets compared with culture filtrate antigen stimulated cells without vitamin D3 treatment. Cholecalciferol 10-20 C-X-C motif chemokine ligand 10 Homo sapiens 252-257 28476406-6 2017 Whereas in the TaqI tt genotype, decreased MIP-1beta and RANTES and increased IP-10-positive T cells were observed compared with the TT genotype in vitamin D3 treated cells (p < 0.05). Cholecalciferol 148-158 C-C motif chemokine ligand 4 Homo sapiens 43-52 28476406-6 2017 Whereas in the TaqI tt genotype, decreased MIP-1beta and RANTES and increased IP-10-positive T cells were observed compared with the TT genotype in vitamin D3 treated cells (p < 0.05). Cholecalciferol 148-158 C-C motif chemokine ligand 5 Homo sapiens 57-63 28476406-6 2017 Whereas in the TaqI tt genotype, decreased MIP-1beta and RANTES and increased IP-10-positive T cells were observed compared with the TT genotype in vitamin D3 treated cells (p < 0.05). Cholecalciferol 148-158 C-X-C motif chemokine ligand 10 Homo sapiens 78-83 28476406-7 2017 IMPLICATIONS: This study suggests that vitamin D3 may regulate the chemokine-positive T cells through the Cdx2 AA and TaqI tt genotypes. Cholecalciferol 39-49 caudal type homeobox 2 Homo sapiens 106-110 27978548-15 2017 Conclusions and Relevance: Our findings suggest that benefits from vitamin D3 supplementation for the prevention of advanced colorectal adenomas may vary according to vitamin D receptor genotype. Cholecalciferol 67-77 vitamin D receptor Homo sapiens 167-185 28004974-0 2017 Vitamin D3 protects against prednisolone-induced liver injury associated with the impairment of the hepatic NF-kappaB/iNOS/NO pathway. Cholecalciferol 0-10 nitric oxide synthase 2 Rattus norvegicus 118-122 27978548-2 2017 Objective: To investigate whether common variants in 7 vitamin D and calcium pathway genes (VDR, GC, DHCR7, CYP2R1, CYP27B1, CYP24A1, and CASR) modify the effects of vitamin D3 or calcium supplementation on colorectal adenoma recurrence. Cholecalciferol 166-176 7-dehydrocholesterol reductase Homo sapiens 101-106 27978548-2 2017 Objective: To investigate whether common variants in 7 vitamin D and calcium pathway genes (VDR, GC, DHCR7, CYP2R1, CYP27B1, CYP24A1, and CASR) modify the effects of vitamin D3 or calcium supplementation on colorectal adenoma recurrence. Cholecalciferol 166-176 calcium sensing receptor Homo sapiens 138-142 28383552-2 2017 Here we report that MyD88 signaling is crucial in the pathogenesis of experimental AD induced by vitamin D3 analog MC903. Cholecalciferol 97-107 myeloid differentiation primary response gene 88 Mus musculus 20-25 28421904-11 2017 which is an active metabolite of vitamin D3, induces Ishikawa endometrial cancer cell death in a concentration-dependent manner by activation of caspase-3 and -9, along with elevation of Bcl-2 and Bcl-xL. Cholecalciferol 33-43 caspase 3 Homo sapiens 145-161 28421904-11 2017 which is an active metabolite of vitamin D3, induces Ishikawa endometrial cancer cell death in a concentration-dependent manner by activation of caspase-3 and -9, along with elevation of Bcl-2 and Bcl-xL. Cholecalciferol 33-43 BCL2 apoptosis regulator Homo sapiens 187-192 28421904-11 2017 which is an active metabolite of vitamin D3, induces Ishikawa endometrial cancer cell death in a concentration-dependent manner by activation of caspase-3 and -9, along with elevation of Bcl-2 and Bcl-xL. Cholecalciferol 33-43 BCL2 like 1 Homo sapiens 197-203 28013381-0 2017 Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial. Cholecalciferol 29-44 hepcidin antimicrobial peptide Homo sapiens 64-72 28013381-3 2017 METHODS: A randomized controlled trial of daily vitamin D supplementation for 12 weeks was performed with the aim to test the effects of 4000 versus 400 IU of cholecalciferol on serum hepcidin levels in children with non-dialysis CKD recruited at a tertiary care children"s hospital. Cholecalciferol 159-174 hepcidin antimicrobial peptide Homo sapiens 184-192 28116494-1 2017 Vitamin D3 and its metabolites are lipophilic molecules with low aqueous solubility and must be transported bound to plasma carrier proteins, primarily to vitamin D binding protein (DBP). Cholecalciferol 0-10 GC vitamin D binding protein Homo sapiens 155-180 28116494-1 2017 Vitamin D3 and its metabolites are lipophilic molecules with low aqueous solubility and must be transported bound to plasma carrier proteins, primarily to vitamin D binding protein (DBP). Cholecalciferol 0-10 D-box binding PAR bZIP transcription factor Homo sapiens 182-185 28116494-2 2017 The biological functions of vitamin D3 metabolites are intimately dependent on the protein, hence the importance of determining their affinity for DBP. Cholecalciferol 28-38 D-box binding PAR bZIP transcription factor Homo sapiens 147-150 28116494-3 2017 In this study, we developed a novel procedure for measuring the kinetic and equilibrium constants of human-DBP with vitamin D3 and three metabolites: 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], 25-hydroxyvitamin D3 (25OHD3) and 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] by surface plasmon resonance (SPR). Cholecalciferol 116-126 D-box binding PAR bZIP transcription factor Homo sapiens 107-110 28004974-8 2017 In conclusion, prednisolone-induced liver disturbances were associated with the impairment of NF-kappaB/iNOS/NO responses that can be ameliorated by vitamin D3 treatment through VDR-mediated mechanisms. Cholecalciferol 149-159 nitric oxide synthase 2 Rattus norvegicus 104-111 28004974-8 2017 In conclusion, prednisolone-induced liver disturbances were associated with the impairment of NF-kappaB/iNOS/NO responses that can be ameliorated by vitamin D3 treatment through VDR-mediated mechanisms. Cholecalciferol 149-159 vitamin D receptor Rattus norvegicus 178-181 28338939-4 2017 Based on these observations, we have proposed that this latitude-dependent gradient of FLG mutations across Europe, Asia and Africa could have provided an evolutionary advantage for heterozygous FLG mutation carriers, residing at northern latitudes, depletion of the FLG downstream product, trans-urocanic acid, would facilitate the intracutaneous synthesis of vitamin D3 by allowing increased transcutaneous absorption of UVB photons. Cholecalciferol 361-371 filaggrin Homo sapiens 87-90 28338939-4 2017 Based on these observations, we have proposed that this latitude-dependent gradient of FLG mutations across Europe, Asia and Africa could have provided an evolutionary advantage for heterozygous FLG mutation carriers, residing at northern latitudes, depletion of the FLG downstream product, trans-urocanic acid, would facilitate the intracutaneous synthesis of vitamin D3 by allowing increased transcutaneous absorption of UVB photons. Cholecalciferol 361-371 filaggrin Homo sapiens 195-198 28338939-4 2017 Based on these observations, we have proposed that this latitude-dependent gradient of FLG mutations across Europe, Asia and Africa could have provided an evolutionary advantage for heterozygous FLG mutation carriers, residing at northern latitudes, depletion of the FLG downstream product, trans-urocanic acid, would facilitate the intracutaneous synthesis of vitamin D3 by allowing increased transcutaneous absorption of UVB photons. Cholecalciferol 361-371 filaggrin Homo sapiens 195-198 26054653-2 2017 In fact, it has been demonstrated that topical administration of vitamin D3 inhibits Langerhans cells migration from the central cornea, corneal neovascularization, and production of cytokines (i.e., interleukin-1-6-8) in experimental animals. Cholecalciferol 65-75 LOW QUALITY PROTEIN: pro-interleukin-16 Cavia porcellus 200-217 28077289-0 2017 Vitamin D3 protects against Abeta peptide cytotoxicity in differentiated human neuroblastoma SH- SY5Y cells: A role for S1P1/p38MAPK/ATF4 axis. Cholecalciferol 0-10 sphingosine-1-phosphate receptor 1 Homo sapiens 120-124 28077289-0 2017 Vitamin D3 protects against Abeta peptide cytotoxicity in differentiated human neuroblastoma SH- SY5Y cells: A role for S1P1/p38MAPK/ATF4 axis. Cholecalciferol 0-10 activating transcription factor 4 Homo sapiens 133-137 28054069-4 2017 Human keratinocytes contain the enzymatic machinery (CYP27B1) for the synthesis of the biologically most active natural vitamin D metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), representing an autonomous vitamin D3 pathway. Cholecalciferol 155-165 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 53-60 28383629-4 2017 Short-acting beta2-adrenoreceptor agonists, budesonide and formoterol (all important relievers in asthma exacerbation), such as vitamin D3, vitamin C, have been shown to inhibit airway cells inflammatory responses by modulating these chemokines. Cholecalciferol 128-138 adrenoceptor beta 2 Homo sapiens 13-33 28001444-4 2017 We demonstrated VDR protein expression in primary plasmablastic tumor cells and confirmed in cell lines expression of both VDR and the metabolic enzyme CYP27B1, which catalyzes active vitamin D3 production. Cholecalciferol 184-194 vitamin D receptor Homo sapiens 123-126 28001444-4 2017 We demonstrated VDR protein expression in primary plasmablastic tumor cells and confirmed in cell lines expression of both VDR and the metabolic enzyme CYP27B1, which catalyzes active vitamin D3 production. Cholecalciferol 184-194 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 152-159 28001444-6 2017 Positive autoregulation evidenced intact VDR function in all plasmablastic lines, and inhibition of growth by active vitamin D3 was both dependent on MYC protein inhibition and could be enhanced by cotreatment with a synthetic ROR ligand SR-1078. Cholecalciferol 117-127 MYC proto-oncogene, bHLH transcription factor Homo sapiens 150-153 28001444-6 2017 Positive autoregulation evidenced intact VDR function in all plasmablastic lines, and inhibition of growth by active vitamin D3 was both dependent on MYC protein inhibition and could be enhanced by cotreatment with a synthetic ROR ligand SR-1078. Cholecalciferol 117-127 RAR related orphan receptor A Homo sapiens 227-230 28001444-7 2017 Furthermore, a VDR polymorphism, FOK1, was associated with greater vitamin D3-dependent growth inhibition. Cholecalciferol 67-77 vitamin D receptor Homo sapiens 15-18 28222027-4 2017 RESULTS: Cholecalciferol at 10-7M increased the proportion of CD4+ CD38+ and CD8+ CD38+ cells, and decreased CD8+HLA-DR+ cells. Cholecalciferol 9-24 CD4 molecule Homo sapiens 62-65 28222027-4 2017 RESULTS: Cholecalciferol at 10-7M increased the proportion of CD4+ CD38+ and CD8+ CD38+ cells, and decreased CD8+HLA-DR+ cells. Cholecalciferol 9-24 CD38 molecule Homo sapiens 67-71 28222027-4 2017 RESULTS: Cholecalciferol at 10-7M increased the proportion of CD4+ CD38+ and CD8+ CD38+ cells, and decreased CD8+HLA-DR+ cells. Cholecalciferol 9-24 CD8a molecule Homo sapiens 77-80 28222027-4 2017 RESULTS: Cholecalciferol at 10-7M increased the proportion of CD4+ CD38+ and CD8+ CD38+ cells, and decreased CD8+HLA-DR+ cells. Cholecalciferol 9-24 CD38 molecule Homo sapiens 82-86 28222027-4 2017 RESULTS: Cholecalciferol at 10-7M increased the proportion of CD4+ CD38+ and CD8+ CD38+ cells, and decreased CD8+HLA-DR+ cells. Cholecalciferol 9-24 CD8a molecule Homo sapiens 109-112 27984337-9 2017 High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2. Cholecalciferol 11-26 msh homeobox 2 Mus musculus 110-114 27984337-9 2017 High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2. Cholecalciferol 11-26 runt related transcription factor 2 Mus musculus 116-121 27984337-9 2017 High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2. Cholecalciferol 11-26 alkaline phosphatase, liver/bone/kidney Mus musculus 126-130 27984337-9 2017 High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2. Cholecalciferol 11-26 collagen, type I, alpha 1 Mus musculus 152-158 27984337-9 2017 High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2. Cholecalciferol 11-26 collagen, type III, alpha 1 Mus musculus 180-186 27984337-9 2017 High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2. Cholecalciferol 11-26 fibronectin 1 Mus musculus 192-203 27984337-9 2017 High-dosed cholecalciferol treatment induced vascular calcification and upregulated aortic osteogenic markers Msx2, Cbfa1 and Alpl and collagen type I (Col1a1), collagen type III (Col3a1) and fibronectin (Fbn) mRNA expression in mice, effects reduced by additional treatment with MgCl2. Cholecalciferol 11-26 fibronectin 1 Mus musculus 205-208 27984337-10 2017 These effects were paralleled by increased aortic Casr mRNA expression in cholecalciferol-treated mice, which was further augmented by MgCl2. Cholecalciferol 74-89 calcium-sensing receptor Mus musculus 50-54 26826259-7 2017 Glutamine, arginine, and vitamin D3, but not ALA, significantly attenuated IL-8 production. Cholecalciferol 25-35 C-X-C motif chemokine ligand 8 Homo sapiens 75-79 28392936-9 2017 CONCLUSIONS: Following supplementation with 5,000 IU of vitamin D3, all subjects" 25(OH)D levels rose to a sufficient level (>=30 ng mL-1). Cholecalciferol 56-66 L1 cell adhesion molecule Mus musculus 136-140 27966575-8 2017 The combined group of vitamin D2 and D3 treated patients decreased plasma IL-8 (P<0.05). Cholecalciferol 37-39 C-X-C motif chemokine ligand 8 Homo sapiens 74-78 28039464-1 2017 A novel pathway of vitamin D3 (D3) metabolism, initiated by C20-hydroxylation of D3 by CYP11A1, has been confirmed to operate in vivo. Cholecalciferol 19-29 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 87-94 27852823-2 2017 We previously showed that hRXRalpha phosphorylation at serine 260 through the Ras-Raf-MAPK ERK1/2 activation is responsible for resistance to the growth inhibitory effects of 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the biologically active metabolite of vitamin D3 To further investigate the mechanism of this resistance, we studied intranuclear dynamics of hVDR and hRXRalpha-tagged constructs in living cells together with endogenous and tagged protein in fixed cells. Cholecalciferol 202-204 retinoid X receptor alpha Homo sapiens 26-35 27852823-2 2017 We previously showed that hRXRalpha phosphorylation at serine 260 through the Ras-Raf-MAPK ERK1/2 activation is responsible for resistance to the growth inhibitory effects of 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the biologically active metabolite of vitamin D3 To further investigate the mechanism of this resistance, we studied intranuclear dynamics of hVDR and hRXRalpha-tagged constructs in living cells together with endogenous and tagged protein in fixed cells. Cholecalciferol 194-204 retinoid X receptor alpha Homo sapiens 26-35 28079136-0 2017 SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial. Cholecalciferol 75-85 retinoid X receptor alpha Homo sapiens 18-22 27879271-0 2017 Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation. Cholecalciferol 0-10 transient receptor potential cation channel subfamily C member 6 Homo sapiens 96-101 28056993-0 2017 Effect of active vitamin D3 on VEGF-induced ADAM33 expression and proliferation in human airway smooth muscle cells: implications for asthma treatment. Cholecalciferol 17-27 vascular endothelial growth factor A Homo sapiens 31-35 28056993-0 2017 Effect of active vitamin D3 on VEGF-induced ADAM33 expression and proliferation in human airway smooth muscle cells: implications for asthma treatment. Cholecalciferol 17-27 ADAM metallopeptidase domain 33 Homo sapiens 44-50 27930980-11 2017 We concluded that vitamin D3 ameliorated insulin resistance and hyperinsulinemia in diabetic rat model received HFW through reduction of IDE and activation of insulin receptor phosphorylation. Cholecalciferol 18-28 insulin degrading enzyme Rattus norvegicus 137-140 27816791-7 2017 METHODS: M1- and M2-like Mphis were generated in vitro from the THP-1 monocyte cell line by differentiation with PMA and Vitamin D3, respectively. Cholecalciferol 121-131 GLI family zinc finger 2 Homo sapiens 64-69 27930980-0 2017 Vitamin D3 intake as regulator of insulin degrading enzyme and insulin receptor phosphorylation in diabetic rats. Cholecalciferol 0-10 insulin receptor Rattus norvegicus 63-79 27930980-11 2017 We concluded that vitamin D3 ameliorated insulin resistance and hyperinsulinemia in diabetic rat model received HFW through reduction of IDE and activation of insulin receptor phosphorylation. Cholecalciferol 18-28 insulin receptor Rattus norvegicus 159-175 28637951-9 2017 Maxacalcitol (22-oxacalcitriol: OCT) is a biologically active metabolite of vitamin D3 analog, and OCT increases hCAP-18/LL-37 production by human gingival epithelial cells. Cholecalciferol 76-86 plexin A2 Homo sapiens 32-35 28164126-7 2017 Western blotting showed that MMP2 expression was significantly increased in rats treated with cholecalciferol. Cholecalciferol 94-109 matrix metallopeptidase 2 Rattus norvegicus 29-33 29074830-3 2017 An active form of vitamin D3, 1alpha,25(OH)2D3, binds to vitamin D nuclear receptor(VDR, vitamin D receptor), and regulates expression of specific target genes. Cholecalciferol 18-28 vitamin D receptor Homo sapiens 84-87 27697285-0 2017 Vitamin D3 regulates LAMP3 expression in monocyte derived dendritic cells. Cholecalciferol 0-10 lysosomal associated membrane protein 3 Homo sapiens 21-26 27697285-4 2017 Here, we investigated the capacity of Vitamin D3 to modulate the expression of LAMP3 during the dendritic cells differentiation and maturation. Cholecalciferol 38-48 lysosomal associated membrane protein 3 Homo sapiens 79-84 27697285-5 2017 Our results demonstrated that the Vitamin D3 reduce the LAMP3 mRNA/protein expression during the dendritic cells differentiation and maturation, via NFkappaB pathways. Cholecalciferol 34-44 lysosomal associated membrane protein 3 Homo sapiens 56-61 27697285-6 2017 Furthermore, we demonstrated that the Vitamin D3 was able to modulate the expression of LAMP3 likewise to in vitro tolerogenic dendritic cells. Cholecalciferol 38-48 lysosomal associated membrane protein 3 Homo sapiens 88-93 29074830-3 2017 An active form of vitamin D3, 1alpha,25(OH)2D3, binds to vitamin D nuclear receptor(VDR, vitamin D receptor), and regulates expression of specific target genes. Cholecalciferol 18-28 vitamin D receptor Homo sapiens 89-107 27667787-0 2017 Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor-beta1. Cholecalciferol 61-71 transforming growth factor beta 1 Homo sapiens 126-158 27473187-3 2017 INTRODUCTION: This study evaluated the association between polymorphisms in four single nucleotide polymorphisms (SNPs) of the CYP2R1 gene and 25(OH)D levels before and 1 year after supplementation with two different doses of vitamin D3 (600 IU daily or a dose equivalent to 3750 IU daily), in a cohort of 218 (96 men and 122 women) Lebanese elderly overweight subjects. Cholecalciferol 226-236 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 127-133 29179169-4 2017 FGF23 inhibits Cyp27b1, an enzyme to produce an active vitamin D3, 1,25(OH)2D3, through FGF receptor/Klotho complex. Cholecalciferol 55-65 fibroblast growth factor 23 Homo sapiens 0-5 29179169-4 2017 FGF23 inhibits Cyp27b1, an enzyme to produce an active vitamin D3, 1,25(OH)2D3, through FGF receptor/Klotho complex. Cholecalciferol 55-65 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 15-22 29179169-4 2017 FGF23 inhibits Cyp27b1, an enzyme to produce an active vitamin D3, 1,25(OH)2D3, through FGF receptor/Klotho complex. Cholecalciferol 55-65 klotho Homo sapiens 101-107 28477201-3 2017 When treated in vitro with cholecalciferol or 1,25(OH)2 vitamin D3, cells polarized under Th9 conditions significantly downregulate production of IL-9. Cholecalciferol 27-42 interleukin 9 Homo sapiens 146-150 27998432-8 2016 Conclusions: Flushing dose of vitamin D3 and nicotine can induce the change of pathology and function of the kidney.Meanwhile, the expression of FGF21 in kidney up-regulated significantly, suggesting that FGF21 may be involved in the occurrence and development of vascular calcification and subsequent kidney injury. Cholecalciferol 30-40 fibroblast growth factor 21 Rattus norvegicus 145-150 28003019-12 2016 Transcriptome and pathway analyses revealed that ERbeta knockdown led to activation of TGFbeta signalling and induced expression of a network of genes with functions in extracellular matrix, tumor cell invasion and vitamin D3 metabolism. Cholecalciferol 215-225 estrogen receptor 2 Homo sapiens 49-55 27509245-4 2016 RESULTS: Cholecalciferol decreased the frequency of HIV-1-infected p24CD4 T cells and levels of p24 in supernatants in a dose-dependent manner. Cholecalciferol 9-24 transmembrane p24 trafficking protein 2 Homo sapiens 67-70 27998432-8 2016 Conclusions: Flushing dose of vitamin D3 and nicotine can induce the change of pathology and function of the kidney.Meanwhile, the expression of FGF21 in kidney up-regulated significantly, suggesting that FGF21 may be involved in the occurrence and development of vascular calcification and subsequent kidney injury. Cholecalciferol 30-40 fibroblast growth factor 21 Rattus norvegicus 205-210 27942020-12 2016 We hypothesize that the vitamin D receptor-lithocholic acid partnership evolved as a by-product of natural selection on the ligand-receptor partnership between the vitamin D receptor and the native VDR ligand: 1alpha,25-dihydroxyvitamin D3, the biologically active metabolite of vitamin D3. Cholecalciferol 229-239 vitamin D receptor Homo sapiens 24-42 27942020-12 2016 We hypothesize that the vitamin D receptor-lithocholic acid partnership evolved as a by-product of natural selection on the ligand-receptor partnership between the vitamin D receptor and the native VDR ligand: 1alpha,25-dihydroxyvitamin D3, the biologically active metabolite of vitamin D3. Cholecalciferol 229-239 vitamin D receptor Homo sapiens 164-182 27942020-12 2016 We hypothesize that the vitamin D receptor-lithocholic acid partnership evolved as a by-product of natural selection on the ligand-receptor partnership between the vitamin D receptor and the native VDR ligand: 1alpha,25-dihydroxyvitamin D3, the biologically active metabolite of vitamin D3. Cholecalciferol 229-239 vitamin D receptor Homo sapiens 198-201 27897272-1 2016 Calcitriol, the active form of vitamin D3, can regulate the gene expression through the binding to the nuclear receptor VDR, but it can also display nongenomic actions, acting through a membrane-associated receptor, which has been discovered as the disulfide isomerase ERp57. Cholecalciferol 31-41 vitamin D receptor Homo sapiens 120-123 27161894-9 2016 In monocytes, while CYP27B1 expression and VDR expression increased in the cholecalciferol group (p < 0.05), CYP27B1 expression did not change, and VDR expression decreased in the control group (p < 0.05). Cholecalciferol 75-90 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 20-27 27161894-9 2016 In monocytes, while CYP27B1 expression and VDR expression increased in the cholecalciferol group (p < 0.05), CYP27B1 expression did not change, and VDR expression decreased in the control group (p < 0.05). Cholecalciferol 75-90 vitamin D receptor Homo sapiens 43-46 27161894-11 2016 Serum concentration of IL-6 and CRP decreased from 8.1 +- 6.6 pg/mL to 4.6 +- 4.1 pg/mL (p < 0.05) and from 0.50 (0.10-1.27) mg/dL to 0.28 (0.09-0.62) mg/dL (p < 0.05), respectively only in the cholecalciferol group. Cholecalciferol 200-215 interleukin 6 Homo sapiens 23-27 27161894-11 2016 Serum concentration of IL-6 and CRP decreased from 8.1 +- 6.6 pg/mL to 4.6 +- 4.1 pg/mL (p < 0.05) and from 0.50 (0.10-1.27) mg/dL to 0.28 (0.09-0.62) mg/dL (p < 0.05), respectively only in the cholecalciferol group. Cholecalciferol 200-215 C-reactive protein Homo sapiens 32-35 27642128-8 2016 Molecular dynamic simulation results indicated that vitamin D3 decreases the helical and strand structural contents of human insulin, but vitamin E stabilizes more regular secondary structures such as helical and strand structural contents as shown by experimental results. Cholecalciferol 52-62 insulin Homo sapiens 125-132 27897272-1 2016 Calcitriol, the active form of vitamin D3, can regulate the gene expression through the binding to the nuclear receptor VDR, but it can also display nongenomic actions, acting through a membrane-associated receptor, which has been discovered as the disulfide isomerase ERp57. Cholecalciferol 31-41 protein disulfide isomerase family A member 3 Homo sapiens 269-274 26232635-1 2016 Recently, we found that 2alpha-[2-(tetrazol-2-yl)ethyl]-1alpha,25-dihydroxyvitamin D3 showed higher osteocalcin promoter transactivation activity in human osteosarcoma (HOS) cells and a greater therapeutic effect in ovariectomized (OVX) rats in vivo than those of active vitamin D3, 1alpha,25(OH)2D3. Cholecalciferol 75-85 bone gamma-carboxyglutamate protein Homo sapiens 100-111 27820818-0 2016 Increased Serum Levels of IL-17A and IL-23 Are Associated with Decreased Vitamin D3 and Increased Pain in Osteoarthritis. Cholecalciferol 73-83 interleukin 17A Homo sapiens 26-32 27820818-0 2016 Increased Serum Levels of IL-17A and IL-23 Are Associated with Decreased Vitamin D3 and Increased Pain in Osteoarthritis. Cholecalciferol 73-83 interleukin 23 subunit alpha Homo sapiens 37-42 27820818-5 2016 A significant positive correlation was found between the serum levels of IL-17A and IL-23 using WOMAC pain scores and vitamin D3 serum levels. Cholecalciferol 118-128 interleukin 17A Homo sapiens 73-79 27820818-5 2016 A significant positive correlation was found between the serum levels of IL-17A and IL-23 using WOMAC pain scores and vitamin D3 serum levels. Cholecalciferol 118-128 interleukin 23 subunit alpha Homo sapiens 84-89 27827962-0 2016 Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients. Cholecalciferol 0-15 parathyroid hormone Homo sapiens 41-60 27454349-1 2016 INTRODUCTION: Vitamin D3 activates via its hormonal form 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the transcription factor vitamin D receptor (VDR). Cholecalciferol 14-24 vitamin D receptor Homo sapiens 132-150 27454349-1 2016 INTRODUCTION: Vitamin D3 activates via its hormonal form 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the transcription factor vitamin D receptor (VDR). Cholecalciferol 14-24 vitamin D receptor Homo sapiens 152-155 27018098-9 2016 Interestingly, both myoblasts and myotubes expressed CYP27B1 and CYP24 mRNA which are required for vitamin D3 metabolism. Cholecalciferol 99-109 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 53-60 27018098-9 2016 Interestingly, both myoblasts and myotubes expressed CYP27B1 and CYP24 mRNA which are required for vitamin D3 metabolism. Cholecalciferol 99-109 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 65-70 28063949-7 2017 In addition, cholecalciferol supplementation significantly upregulated pAMPK, SIRT-1 and GLUT-4 levels in adipose tissue of mice fed with HFD. Cholecalciferol 13-28 sirtuin 1 Mus musculus 78-84 28063949-7 2017 In addition, cholecalciferol supplementation significantly upregulated pAMPK, SIRT-1 and GLUT-4 levels in adipose tissue of mice fed with HFD. Cholecalciferol 13-28 solute carrier family 2 (facilitated glucose transporter), member 4 Mus musculus 89-95 27648718-0 2016 Cholecalciferol treatment downregulates renin-angiotensin system and improves endothelial function in essential hypertensive patients with hypovitaminosid D. BACKGROUND: Vitamin D deficiency is related to an increased prevalence of cardiovascular disease. Cholecalciferol 0-15 renin Homo sapiens 40-45 27648718-11 2016 CONCLUSION: The restoration of normal vitamin D levels after 8-week cholecalciferol treatment is able to inhibit peripheral renin-angiotensin system and improve FMD in essential hypertensive patients with hypovitaminosis D. Cholecalciferol 68-83 renin Homo sapiens 124-129 26592177-4 2016 An increased intake of vitamin D3 in a high fat diet-induced obesity mouse model is associated with a decreased weight of white adipose tissue due to induction of apoptosis and the improved blood markers related to adiposity, diabetes, and vitamin D status (plasma concentrations of glucose, insulin, adiponectin, 25-hydroxyvitamin D, and 1,25(OH)2D3). Cholecalciferol 23-33 adiponectin, C1Q and collagen domain containing Mus musculus 301-312 27783938-4 2016 We found that vitamin-D3-induced lifespan extension requires the stress response pathway genes skn-1, ire-1, and xbp-1. Cholecalciferol 14-24 endoplasmic reticulum to nucleus signaling 1 Homo sapiens 102-107 27554639-0 2016 TAZ regulates cell proliferation and sensitivity to vitamin D3 in intrahepatic cholangiocarcinoma. Cholecalciferol 52-62 tafazzin, phospholipid-lysophospholipid transacylase Homo sapiens 0-3 27554639-6 2016 Vitamin D3 can also inhibit cell proliferation by promoting p53 expression in ICC cells. Cholecalciferol 0-10 tumor protein p53 Homo sapiens 60-63 27542236-4 2016 The main objective was to investigate if intake of vitamin D3 enriched salmon or vitamin D3 tablets decreased bone biomarkers (urinary N-telopeptides, deoxypyridinoline, serum bone-specific alkaline phosphatase, and osteocalcin) compared to a low vitamin D3 intake. Cholecalciferol 51-61 bone gamma-carboxyglutamate protein Homo sapiens 216-227 27783938-4 2016 We found that vitamin-D3-induced lifespan extension requires the stress response pathway genes skn-1, ire-1, and xbp-1. Cholecalciferol 14-24 X-box binding protein 1 Homo sapiens 113-118 27830027-9 2016 Cyp27a1 prevented Cca cell apoptosis induced by vitamin D3. Cholecalciferol 48-58 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 0-7 27705794-7 2016 Finally, gene expression and epistasis analysis indicated that CXCL8(IL-8) was a functional target of vitamin D3-mediated HSPC regulation. Cholecalciferol 102-112 C-X-C motif chemokine ligand 8 Homo sapiens 63-68 27705794-7 2016 Finally, gene expression and epistasis analysis indicated that CXCL8(IL-8) was a functional target of vitamin D3-mediated HSPC regulation. Cholecalciferol 102-112 C-X-C motif chemokine ligand 8 Homo sapiens 69-73 27259383-6 2016 CYP27A1 is involved in the metabolism of vitamin D3, which plays important roles in modulating immune function. Cholecalciferol 41-51 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 0-7 27616756-2 2016 The purpose of this study was to examine whether 25(OH)D levels and supplementation with oral cholecalciferol (Vitamin D3 (Vit D3)) are associated with morbidity and mortality among patients with significant CKD. Cholecalciferol 94-109 vitrin Homo sapiens 111-114 27107558-0 2016 Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. Cholecalciferol 0-10 solute carrier family 30 member 10 Homo sapiens 61-69 27107558-9 2016 In addition to increasing gene expression of SLC30A10 and the positive control TRPV6, vitamin D3 also increased ZnT10 protein expression, as indicated by Western blot and cytofluorescence. Cholecalciferol 86-96 solute carrier family 30 member 10 Homo sapiens 45-53 27107558-0 2016 Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 78-96 27107558-9 2016 In addition to increasing gene expression of SLC30A10 and the positive control TRPV6, vitamin D3 also increased ZnT10 protein expression, as indicated by Western blot and cytofluorescence. Cholecalciferol 86-96 transient receptor potential cation channel subfamily V member 6 Homo sapiens 79-84 27107558-9 2016 In addition to increasing gene expression of SLC30A10 and the positive control TRPV6, vitamin D3 also increased ZnT10 protein expression, as indicated by Western blot and cytofluorescence. Cholecalciferol 86-96 solute carrier family 30 member 10 Homo sapiens 112-117 27174720-7 2016 5000 IU/kg dietary vitamin D3 supplementation greatly up-regulated LC3-II/LC3-I ratios and PR-39 mRNA expression under the condition of RV challenged. Cholecalciferol 19-29 antibacterial protein PR-39 Sus scrofa 91-96 27174721-2 2016 Previous studies showed that stress-activated protein kinase JNKs (c-Jun NH2-terminal kinases) and p38 cooperated to activate VDR and increase vitamin D3-dependent growth inhibition in breast cancer cells. Cholecalciferol 143-153 mitogen-activated protein kinase 14 Homo sapiens 99-102 27595605-1 2016 BACKGROUND: The vitamin D receptor (VDR) mediates the immunological function of vitamin D3, which activates macrophages, and vitamin D deficiency has been linked to tuberculosis risk. Cholecalciferol 80-90 vitamin D receptor Homo sapiens 16-34 27798898-0 2016 Vitamin D3 Treatment Influences PGE2 and TGFbeta in Normal and Increased Breast Cancer Risk Women. Cholecalciferol 0-10 transforming growth factor beta 1 Homo sapiens 41-48 27798898-9 2016 CONCLUSION: Vitamin D3 influenced TGFbeta1 and -beta2 expression. Cholecalciferol 12-22 transforming growth factor beta 1 Homo sapiens 34-53 27595605-1 2016 BACKGROUND: The vitamin D receptor (VDR) mediates the immunological function of vitamin D3, which activates macrophages, and vitamin D deficiency has been linked to tuberculosis risk. Cholecalciferol 80-90 vitamin D receptor Homo sapiens 36-39 29767113-0 2016 Vitamin D3 increased intestinal Na/Pi-IIb and CYP27B1 mRNA level in rats fed low-phosphorus diets. Cholecalciferol 0-10 cytochrome P450, family 27, subfamily b, polypeptide 1 Rattus norvegicus 46-53 27369077-2 2016 The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores. Cholecalciferol 35-45 vitamin D receptor Homo sapiens 4-22 27369077-2 2016 The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores. Cholecalciferol 35-45 vitamin D receptor Homo sapiens 24-27 27369077-2 2016 The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores. Cholecalciferol 97-107 vitamin D receptor Homo sapiens 4-22 27369077-2 2016 The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores. Cholecalciferol 97-107 vitamin D receptor Homo sapiens 24-27 27369077-2 2016 The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores. Cholecalciferol 97-107 importin 4 Homo sapiens 69-79 27369077-2 2016 The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores. Cholecalciferol 97-107 vitamin D receptor Homo sapiens 93-96 27369077-8 2016 The PoreWalker algorithm indicates that, of the 427 residues in each VDR monomer, 91 line the largest channel, including two vitamin D3 binding sites and residues from both the TM helix and "half-helix". Cholecalciferol 125-135 vitamin D receptor Homo sapiens 69-72 27369077-10 2016 Programmed changes in bound cholesterol may regulate both membrane Ca(2+) response systems and vitamin D3 uptake as well as receptor internalization by the endomembrane system culminating in uptake of the vitamin D3-VDR-importin-4 complex into the nucleus. Cholecalciferol 205-215 vitamin D receptor Homo sapiens 216-219 27369077-10 2016 Programmed changes in bound cholesterol may regulate both membrane Ca(2+) response systems and vitamin D3 uptake as well as receptor internalization by the endomembrane system culminating in uptake of the vitamin D3-VDR-importin-4 complex into the nucleus. Cholecalciferol 205-215 importin 4 Homo sapiens 220-230 27575987-3 2016 In that first study the active vitamin D3 metabolite, 1,25-dihydroxycholecalciferol (1,25D), stimulated YKL-40 expression, thereby indicating that a vital factor for skeletal health promoted YKL-40 synthesis by bone forming cells. Cholecalciferol 31-41 chitinase 3 like 1 Homo sapiens 104-110 27575987-3 2016 In that first study the active vitamin D3 metabolite, 1,25-dihydroxycholecalciferol (1,25D), stimulated YKL-40 expression, thereby indicating that a vital factor for skeletal health promoted YKL-40 synthesis by bone forming cells. Cholecalciferol 31-41 chitinase 3 like 1 Homo sapiens 191-197 27500498-1 2016 The active metabolite of vitamin D3 , 1alpha,25-dihydroxyvitamin D3 , acts as a ligand for the vitamin D receptor (VDR) and activates VDR-mediated gene expression. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 95-113 27500498-1 2016 The active metabolite of vitamin D3 , 1alpha,25-dihydroxyvitamin D3 , acts as a ligand for the vitamin D receptor (VDR) and activates VDR-mediated gene expression. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 115-118 27500498-1 2016 The active metabolite of vitamin D3 , 1alpha,25-dihydroxyvitamin D3 , acts as a ligand for the vitamin D receptor (VDR) and activates VDR-mediated gene expression. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 134-137 27500498-2 2016 Recently, we characterized 1alpha,25-dihydroxyvitamin D3 -26,23-lactams (DLAMs), which mimic vitamin D3 metabolites, as noncalcemic VDR ligands that barely activate the receptor. Cholecalciferol 46-56 vitamin D receptor Homo sapiens 132-135 27107558-12 2016 In conclusion, we have shown that vitamin D3 transactivates the SLC30A10 gene in a VDR-dependent manner, resulting in increased ZnT10 protein expression. Cholecalciferol 34-44 solute carrier family 30 member 10 Homo sapiens 64-72 27107558-12 2016 In conclusion, we have shown that vitamin D3 transactivates the SLC30A10 gene in a VDR-dependent manner, resulting in increased ZnT10 protein expression. Cholecalciferol 34-44 vitamin D receptor Homo sapiens 83-86 27107558-12 2016 In conclusion, we have shown that vitamin D3 transactivates the SLC30A10 gene in a VDR-dependent manner, resulting in increased ZnT10 protein expression. Cholecalciferol 34-44 solute carrier family 30 member 10 Homo sapiens 128-133 27107558-13 2016 Because SLC30A10 is highly expressed in the small intestine, it is possible that the control of zinc and manganese systemic levels is regulated by vitamin D3 in the intestine. Cholecalciferol 147-157 solute carrier family 30 member 10 Homo sapiens 8-16 27642554-2 2016 In the present study, we examined the molecular mechanism of Npnt gene expression and found that vitamin D3 (1alpha,25-dihydroxyvitamin D3,VD 3) strongly enhanced Npnt mRNA expression in MC3T3-E1 cells from a mouse osteoblastic cell line. Cholecalciferol 97-107 nephronectin Mus musculus 61-65 26375627-1 2016 Through experimental and theoretical approaches, it has been shown that bovine beta-lactoglobulin (betalg) uses its hydrophobic cavity or calyx as the primary binding site for hydrophobic molecules, whereas the existence of a second ligand binding site at the dimeric interface has only been structurally identified for vitamin D3 (VD3). Cholecalciferol 320-330 beta-lactoglobulin Bos taurus 79-97 27506667-3 2016 PURPOSE: We aimed to investigate whether 16 weeks of daily vitamin D3 supplementation had an effect on serum ferritin, haemoglobin, serum iron and transferrin saturation. Cholecalciferol 59-69 transferrin Homo sapiens 147-158 27506771-0 2016 Prenatal high-dose vitamin D3 supplementation has balanced effects on cord blood Th1 and Th2 responses. Cholecalciferol 19-29 negative elongation factor complex member C/D Homo sapiens 81-84 27221206-9 2016 Vitamin D3 and calcium supplementation increased the concentrations of calcium, phosphorous and decreased the concentrations of parathyroid hormone and alkaline phosphatase. Cholecalciferol 0-10 parathyroid hormone Homo sapiens 128-147 27473111-0 2016 Vitamin D3/VDR resists diet-induced obesity by modulating UCP3 expression in muscles. Cholecalciferol 0-10 uncoupling protein 3 (mitochondrial, proton carrier) Mus musculus 58-62 27473111-8 2016 RESULTS: Mice consuming a high-fat diet treated with cholecalciferol had lower body weight and adipose tissue weight and higher expression of UCP3 compared to the other treatment groups. Cholecalciferol 53-68 uncoupling protein 3 (mitochondrial, proton carrier) Mus musculus 142-146 27484042-0 2016 The protective role of vitamin D3 in a murine model of asthma via the suppression of TGF-beta/Smad signaling and activation of the Nrf2/HO-1 pathway. Cholecalciferol 23-33 nuclear factor, erythroid derived 2, like 2 Mus musculus 131-135 27484042-0 2016 The protective role of vitamin D3 in a murine model of asthma via the suppression of TGF-beta/Smad signaling and activation of the Nrf2/HO-1 pathway. Cholecalciferol 23-33 heme oxygenase 1 Mus musculus 136-140 27484042-6 2016 In addition, treatment with vitamin D3 decreased alpha-SMA expression, collagen deposition and goblet cell hyperplasia, and inhibited TGF-beta/Smad signaling in the asthmatic airway. Cholecalciferol 28-38 actin alpha 2, smooth muscle, aorta Mus musculus 49-58 27484042-8 2016 Furthermore, treatment with vitamin D3 enhanced activation of the Nrf2/HO-1 pathway in the airways of asthmatic mice. Cholecalciferol 28-38 nuclear factor, erythroid derived 2, like 2 Mus musculus 66-70 27484042-8 2016 Furthermore, treatment with vitamin D3 enhanced activation of the Nrf2/HO-1 pathway in the airways of asthmatic mice. Cholecalciferol 28-38 heme oxygenase 1 Mus musculus 71-75 27484042-9 2016 In conclusion, these findings suggest that vitamin D3 may protect airways from asthmatic damage via the suppression of TGF-beta/Smad signaling and activation of the Nrf2/HO-1 pathway; however, these protective effects were shown to be accompanied by hypercalcemia. Cholecalciferol 43-53 nuclear factor, erythroid derived 2, like 2 Mus musculus 165-169 27484042-9 2016 In conclusion, these findings suggest that vitamin D3 may protect airways from asthmatic damage via the suppression of TGF-beta/Smad signaling and activation of the Nrf2/HO-1 pathway; however, these protective effects were shown to be accompanied by hypercalcemia. Cholecalciferol 43-53 heme oxygenase 1 Mus musculus 170-174 27447175-4 2016 It was shown that human keratinocytes possess the enzymatic machinery (CYP27B1) for the synthesis of the biologically most active natural vitamin D metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), representing an autonomous vitamin D3 pathway. Cholecalciferol 173-183 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 71-78 27345382-10 2016 However, when the genetic variants of the VDR gene were analyzed after adjusting for the serum 25-OH vitamin D3 level, the TaqI and BsmI minor allele increased the risk of PD. Cholecalciferol 101-111 vitamin D receptor Homo sapiens 42-45 27642554-2 2016 In the present study, we examined the molecular mechanism of Npnt gene expression and found that vitamin D3 (1alpha,25-dihydroxyvitamin D3,VD 3) strongly enhanced Npnt mRNA expression in MC3T3-E1 cells from a mouse osteoblastic cell line. Cholecalciferol 97-107 interferon activated gene 205 Mus musculus 136-143 27642554-2 2016 In the present study, we examined the molecular mechanism of Npnt gene expression and found that vitamin D3 (1alpha,25-dihydroxyvitamin D3,VD 3) strongly enhanced Npnt mRNA expression in MC3T3-E1 cells from a mouse osteoblastic cell line. Cholecalciferol 97-107 nephronectin Mus musculus 163-167 27424994-0 2016 Role of vitamin D3 in regulation of interleukin-6 and osteopontin expression in liver of diabetic mice. Cholecalciferol 8-18 interleukin 6 Mus musculus 36-49 25601896-0 2016 The Effect of High-Dose Vitamin D3 on Soluble P-Selectin and hs-CRP Level in Patients With Venous Thromboembolism: A Randomized Clinical Trial. Cholecalciferol 24-34 selectin P Homo sapiens 46-56 27424994-0 2016 Role of vitamin D3 in regulation of interleukin-6 and osteopontin expression in liver of diabetic mice. Cholecalciferol 8-18 secreted phosphoprotein 1 Mus musculus 54-65 27424994-1 2016 OBJECTIVE: To study the link between hepatic interleukin-6 (IL-6) and osteopontin (OPN) gene expression and vitamin D3 status associated with type 1 diabetes in mice; and to evaluate the effects of vitamin D3 treatment (800 IU/kg of body weight for 6 weeks) on diabetes-induced impairments. Cholecalciferol 108-118 interleukin 6 Mus musculus 45-58 27424994-1 2016 OBJECTIVE: To study the link between hepatic interleukin-6 (IL-6) and osteopontin (OPN) gene expression and vitamin D3 status associated with type 1 diabetes in mice; and to evaluate the effects of vitamin D3 treatment (800 IU/kg of body weight for 6 weeks) on diabetes-induced impairments. Cholecalciferol 108-118 interleukin 6 Mus musculus 60-64 27424994-6 2016 Vitamin D3 treatment restored 25OHD3 that led to a substantial reduction of OPN and IL-6 mRNA levels. Cholecalciferol 0-10 secreted phosphoprotein 1 Mus musculus 76-79 27424994-6 2016 Vitamin D3 treatment restored 25OHD3 that led to a substantial reduction of OPN and IL-6 mRNA levels. Cholecalciferol 0-10 interleukin 6 Mus musculus 84-88 27424994-7 2016 CONCLUSIONS: Diabetes-induced vitamin D3 deficiency was associated with increased hepatic levels of IL-6 and OPN mRNA and these changes were countered by vitamin D3 administration. Cholecalciferol 30-40 interleukin 6 Mus musculus 100-104 27424994-7 2016 CONCLUSIONS: Diabetes-induced vitamin D3 deficiency was associated with increased hepatic levels of IL-6 and OPN mRNA and these changes were countered by vitamin D3 administration. Cholecalciferol 30-40 secreted phosphoprotein 1 Mus musculus 109-112 27655488-7 2016 Ex vivo human osteoblasts cultured, for 3 weeks, with vitamin D3 and vitamin K2 were exposed to PENT, a well-known advanced glycoxidation end product for the last 72 hours. Cholecalciferol 54-64 phenylethanolamine N-methyltransferase Homo sapiens 96-100 27295094-0 2016 Vitamin D3 inhibits TNFalpha-induced latent HIV reactivation in J-LAT cells. Cholecalciferol 0-10 tumor necrosis factor Homo sapiens 20-28 27295094-0 2016 Vitamin D3 inhibits TNFalpha-induced latent HIV reactivation in J-LAT cells. Cholecalciferol 0-10 linker for activation of T cells Homo sapiens 66-69 26939683-1 2016 BACKGROUND: As 1,25(OH)2D3 vitamin D3 induces fibroblast growth factor-23 (FGF-23) production and suppresses the renin-angiotensin-aldosterone system (RAAS), its absence in vitamin-D-dependent rickets type I (VDDR-I) may have adverse health consequences. Cholecalciferol 27-37 fibroblast growth factor 23 Homo sapiens 46-73 26939683-1 2016 BACKGROUND: As 1,25(OH)2D3 vitamin D3 induces fibroblast growth factor-23 (FGF-23) production and suppresses the renin-angiotensin-aldosterone system (RAAS), its absence in vitamin-D-dependent rickets type I (VDDR-I) may have adverse health consequences. Cholecalciferol 27-37 fibroblast growth factor 23 Homo sapiens 75-81 26939683-1 2016 BACKGROUND: As 1,25(OH)2D3 vitamin D3 induces fibroblast growth factor-23 (FGF-23) production and suppresses the renin-angiotensin-aldosterone system (RAAS), its absence in vitamin-D-dependent rickets type I (VDDR-I) may have adverse health consequences. Cholecalciferol 27-37 renin Homo sapiens 113-118 26939683-1 2016 BACKGROUND: As 1,25(OH)2D3 vitamin D3 induces fibroblast growth factor-23 (FGF-23) production and suppresses the renin-angiotensin-aldosterone system (RAAS), its absence in vitamin-D-dependent rickets type I (VDDR-I) may have adverse health consequences. Cholecalciferol 27-37 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 173-216 30480416-7 2016 Prolonged vitamin D3 treatment (within 2 months) in a dose of 20 IU/animal leads to normalization of the proliferative activity and the ratio of T-cell subpopulations, reduces the formation of phosphorylated subunit of NF-kappaB - p65 and contributes to a balanced secretion of IgG against artificial antigen. Cholecalciferol 10-20 RELA proto-oncogene, NF-kB subunit Homo sapiens 231-234 27317433-8 2016 In addition a novel finding is represented by the demonstration that pre-treatment with vitamin D3 is also able to significantly counteract tumoral biomarkers activation, such as p53, pan-Ras, Ki67 and c-Myc, and consequently the catalytic iron-induced cellular injury. Cholecalciferol 88-98 tumor protein p53 Homo sapiens 179-182 27317433-8 2016 In addition a novel finding is represented by the demonstration that pre-treatment with vitamin D3 is also able to significantly counteract tumoral biomarkers activation, such as p53, pan-Ras, Ki67 and c-Myc, and consequently the catalytic iron-induced cellular injury. Cholecalciferol 88-98 MYC proto-oncogene, bHLH transcription factor Homo sapiens 202-207 27296673-9 2016 RESULTS: Cholecalciferol supplementation was associated with higher absolute numbers of Helios(+), CTLA-4(+), and total Tregs than calcitriol (p < 0.001, p = 0.004, p = 0.001 respectively). Cholecalciferol 9-24 cytotoxic T-lymphocyte associated protein 4 Homo sapiens 99-105 27154546-1 2016 The active form of vitamin D3 (1alpha,25(OH)2D3, also known as calcitriol) controls the expression of target genes via the vitamin D receptor (VDR). Cholecalciferol 19-29 vitamin D receptor Homo sapiens 123-141 27154546-1 2016 The active form of vitamin D3 (1alpha,25(OH)2D3, also known as calcitriol) controls the expression of target genes via the vitamin D receptor (VDR). Cholecalciferol 19-29 vitamin D receptor Homo sapiens 143-146 27314336-7 2016 Furthermore, our study confirms a deregulation of the vitamin D system: among the transcription factors that potentially regulate the deregulated genes, we find TCF3 and SP1 that are both involved in vitamin D3-induced p27Kip1 expression. Cholecalciferol 200-210 transcription factor 3 Homo sapiens 161-165 27314336-7 2016 Furthermore, our study confirms a deregulation of the vitamin D system: among the transcription factors that potentially regulate the deregulated genes, we find TCF3 and SP1 that are both involved in vitamin D3-induced p27Kip1 expression. Cholecalciferol 200-210 cyclin dependent kinase inhibitor 1B Homo sapiens 219-226 27622485-0 2016 Dendritic cells generated in the presence of vitamin D3 and stimulated with lipopolysaccharide secrete IL-8, IL-1beta, IL-10 and induce relatively low levels of CD4+CD25hiFoxp3+ T cells. Cholecalciferol 45-55 C-X-C motif chemokine ligand 8 Homo sapiens 103-107 27622485-0 2016 Dendritic cells generated in the presence of vitamin D3 and stimulated with lipopolysaccharide secrete IL-8, IL-1beta, IL-10 and induce relatively low levels of CD4+CD25hiFoxp3+ T cells. Cholecalciferol 45-55 interleukin 1 beta Homo sapiens 109-117 27622485-0 2016 Dendritic cells generated in the presence of vitamin D3 and stimulated with lipopolysaccharide secrete IL-8, IL-1beta, IL-10 and induce relatively low levels of CD4+CD25hiFoxp3+ T cells. Cholecalciferol 45-55 interleukin 10 Homo sapiens 119-124 27622485-0 2016 Dendritic cells generated in the presence of vitamin D3 and stimulated with lipopolysaccharide secrete IL-8, IL-1beta, IL-10 and induce relatively low levels of CD4+CD25hiFoxp3+ T cells. Cholecalciferol 45-55 CD4 molecule Homo sapiens 161-164 27333923-9 2016 Cholecalciferol supplementation (mean dose of 3384 +- 1211 IU) was followed by a significant increase in 25-OH-D3 concentration (from 17.3 +- 5.8 to 41.4 +- 17.5 ng/ml; p<0.05) and decrease in PTH (p<0.05). Cholecalciferol 0-15 parathyroid hormone Homo sapiens 196-199 27199286-6 2016 Focusing on the phosphatidylinositol 3-kinase (PI3K) signalling pathway, we found that the reduced expression of Pik3r1 mRNA was reversed by cholecalciferol supplementation in skeletal muscle, and that insulin-stimulated glucose uptake into C2C12 myotube was inhibited in the presence of quetiapine, which was reversed by concomitant calcitriol in a PI3K-dependent manner. Cholecalciferol 141-156 phosphoinositide-3-kinase regulatory subunit 1 Mus musculus 16-45 27199286-6 2016 Focusing on the phosphatidylinositol 3-kinase (PI3K) signalling pathway, we found that the reduced expression of Pik3r1 mRNA was reversed by cholecalciferol supplementation in skeletal muscle, and that insulin-stimulated glucose uptake into C2C12 myotube was inhibited in the presence of quetiapine, which was reversed by concomitant calcitriol in a PI3K-dependent manner. Cholecalciferol 141-156 phosphoinositide-3-kinase regulatory subunit 1 Mus musculus 113-119 26970587-1 2016 20S-Hydroxyvitamin D3 [20(OH)D3] is the biologically active major product of the action of CYP11A1 on vitamin D3 and is present in human plasma. Cholecalciferol 11-21 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 91-98 26902087-2 2016 The VDR binds to active vitamin D3 metabolites, which stimulates downstream transduction signaling involved in various physiological activities such as calcium homeostasis, bone mineralization, and cell differentiation. Cholecalciferol 24-34 vitamin D receptor Homo sapiens 4-7 27143932-10 2016 Moreover, we found the vitamin D3 increased the expression of E-cadherin and vitamin D receptor while it decreased the expression of beta-catenin. Cholecalciferol 23-33 cadherin 1 Mus musculus 62-72 27143932-10 2016 Moreover, we found the vitamin D3 increased the expression of E-cadherin and vitamin D receptor while it decreased the expression of beta-catenin. Cholecalciferol 23-33 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 77-95 27143932-10 2016 Moreover, we found the vitamin D3 increased the expression of E-cadherin and vitamin D receptor while it decreased the expression of beta-catenin. Cholecalciferol 23-33 catenin (cadherin associated protein), beta 1 Mus musculus 133-145 27091127-7 2016 CONCLUSIONS: We found that however all normal and malignant germ-line derived cells express functional VDR, Vitamin D3 differently affects their proliferation and migration. Cholecalciferol 108-118 vitamin D receptor Homo sapiens 103-106 27103796-8 2016 The plasma vitamin D3 level was lower in patients with the GC2 variant (estimated =-3.73 ng/mL) and higher in those with genotype 1F-1S (estimated =4.08 ng/mL). Cholecalciferol 11-21 solute carrier family 25 member 18 Homo sapiens 59-62 27058533-1 2016 Ultraviolet (UV) radiation is involved in almost all skin cancer cases, but on the other hand, it stimulates the production of pre-vitamin D3, whose active metabolite, 1,25-dihydroxyvitamin D3 (1,25VD3), plays important physiological functions on binding with its receptor (vitamin D receptor, VDR). Cholecalciferol 131-141 vitamin D receptor Homo sapiens 294-297 26820714-0 2016 Vitamin D3 Inhibits Wnt/beta-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells. Cholecalciferol 0-10 Wnt family member 4 Homo sapiens 20-23 26820714-0 2016 Vitamin D3 Inhibits Wnt/beta-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells. Cholecalciferol 0-10 catenin beta 1 Homo sapiens 24-36 26820714-0 2016 Vitamin D3 Inhibits Wnt/beta-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells. Cholecalciferol 0-10 mechanistic target of rapamycin kinase Homo sapiens 41-45 26820714-2 2016 OBJECTIVE: The objective of the study was to examine the role of vitamin D3 in the modulation of Wnt/beta-catenin and mammalian target of rapamycin (mTOR) signaling in human UF cells. Cholecalciferol 65-75 Wnt family member 4 Homo sapiens 97-100 26820714-2 2016 OBJECTIVE: The objective of the study was to examine the role of vitamin D3 in the modulation of Wnt/beta-catenin and mammalian target of rapamycin (mTOR) signaling in human UF cells. Cholecalciferol 65-75 catenin beta 1 Homo sapiens 101-113 26820714-2 2016 OBJECTIVE: The objective of the study was to examine the role of vitamin D3 in the modulation of Wnt/beta-catenin and mammalian target of rapamycin (mTOR) signaling in human UF cells. Cholecalciferol 65-75 mechanistic target of rapamycin kinase Homo sapiens 118-147 26820714-2 2016 OBJECTIVE: The objective of the study was to examine the role of vitamin D3 in the modulation of Wnt/beta-catenin and mammalian target of rapamycin (mTOR) signaling in human UF cells. Cholecalciferol 65-75 mechanistic target of rapamycin kinase Homo sapiens 149-153 26820714-6 2016 Vitamin D3 administration reduced the levels of Wnt4 and beta-catenin in both HuLM and PUF cells. Cholecalciferol 0-10 Wnt family member 4 Homo sapiens 48-52 26820714-6 2016 Vitamin D3 administration reduced the levels of Wnt4 and beta-catenin in both HuLM and PUF cells. Cholecalciferol 0-10 catenin beta 1 Homo sapiens 57-69 26820714-7 2016 Vitamin D3 also reduced the expression/activation of mTOR signaling in both cell types. Cholecalciferol 0-10 mechanistic target of rapamycin kinase Homo sapiens 53-57 26820714-8 2016 In contrast, vitamin D3 induced the expression of DNA damaged-induced transcription 4 (an inhibitor of mTOR) and tuberous sclerosis genes (TSC1/2) in a concentration-dependent manner in HuLM cells. Cholecalciferol 13-23 mechanistic target of rapamycin kinase Homo sapiens 103-107 26820714-8 2016 In contrast, vitamin D3 induced the expression of DNA damaged-induced transcription 4 (an inhibitor of mTOR) and tuberous sclerosis genes (TSC1/2) in a concentration-dependent manner in HuLM cells. Cholecalciferol 13-23 TSC complex subunit 1 Homo sapiens 139-145 26820714-11 2016 Together these results suggest that vitamin D3 functions as an inhibitor of Wnt4/beta-catenin and mTOR signaling pathways, which may play major roles in fibroid pathogenesis. Cholecalciferol 36-46 Wnt family member 4 Homo sapiens 76-80 26820714-11 2016 Together these results suggest that vitamin D3 functions as an inhibitor of Wnt4/beta-catenin and mTOR signaling pathways, which may play major roles in fibroid pathogenesis. Cholecalciferol 36-46 catenin beta 1 Homo sapiens 81-93 26820714-11 2016 Together these results suggest that vitamin D3 functions as an inhibitor of Wnt4/beta-catenin and mTOR signaling pathways, which may play major roles in fibroid pathogenesis. Cholecalciferol 36-46 mechanistic target of rapamycin kinase Homo sapiens 98-102 26893158-9 2016 These observations were supported in vivo whereby Cftr(-/-) mice fed large amounts of vitamin D3 for 2 mo led to a reduction in the number of eosinophils and apoptotic cells in the duodenal mucosa of females but not males. Cholecalciferol 86-96 cystic fibrosis transmembrane conductance regulator Mus musculus 50-54 26691009-6 2016 In addition, vitamin D3 treatment reduced VEGF-A gene expression by EESCs (P = 0.046-0.009). Cholecalciferol 13-23 vascular endothelial growth factor A Homo sapiens 42-48 27279980-4 2016 In the present experiment, the effect of vitamin D3 on the expression of IL-17, IL-23, IL-4 and IFN-gamma were assessed in activated chromatin-induced mouse model for SLE. Cholecalciferol 41-51 interleukin 17A Mus musculus 73-78 27279980-4 2016 In the present experiment, the effect of vitamin D3 on the expression of IL-17, IL-23, IL-4 and IFN-gamma were assessed in activated chromatin-induced mouse model for SLE. Cholecalciferol 41-51 interleukin 23, alpha subunit p19 Mus musculus 80-85 27279980-4 2016 In the present experiment, the effect of vitamin D3 on the expression of IL-17, IL-23, IL-4 and IFN-gamma were assessed in activated chromatin-induced mouse model for SLE. Cholecalciferol 41-51 interleukin 4 Mus musculus 87-91 27279980-4 2016 In the present experiment, the effect of vitamin D3 on the expression of IL-17, IL-23, IL-4 and IFN-gamma were assessed in activated chromatin-induced mouse model for SLE. Cholecalciferol 41-51 interferon gamma Mus musculus 96-105 27279980-8 2016 RESULTS: The results showed that IL-17, IL-23, and IFN-gamma mRNA expression, and IL-17 titers were decreased remarkably and that of IL-4 increased in mice which received vitamin D3 before SLE induction. Cholecalciferol 171-181 interleukin 17A Mus musculus 33-38 27279980-8 2016 RESULTS: The results showed that IL-17, IL-23, and IFN-gamma mRNA expression, and IL-17 titers were decreased remarkably and that of IL-4 increased in mice which received vitamin D3 before SLE induction. Cholecalciferol 171-181 interleukin 23, alpha subunit p19 Mus musculus 40-45 27279980-8 2016 RESULTS: The results showed that IL-17, IL-23, and IFN-gamma mRNA expression, and IL-17 titers were decreased remarkably and that of IL-4 increased in mice which received vitamin D3 before SLE induction. Cholecalciferol 171-181 interferon gamma Mus musculus 51-60 27279980-8 2016 RESULTS: The results showed that IL-17, IL-23, and IFN-gamma mRNA expression, and IL-17 titers were decreased remarkably and that of IL-4 increased in mice which received vitamin D3 before SLE induction. Cholecalciferol 171-181 interleukin 17A Mus musculus 82-87 27279980-8 2016 RESULTS: The results showed that IL-17, IL-23, and IFN-gamma mRNA expression, and IL-17 titers were decreased remarkably and that of IL-4 increased in mice which received vitamin D3 before SLE induction. Cholecalciferol 171-181 interleukin 4 Mus musculus 133-137 26694996-7 2016 Vitamin D3 was protective against vitamin D deficiency-induced cholesterol increase by maintaining the transcriptional activity of VDR and Insig-2 expression. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 131-134 26694996-7 2016 Vitamin D3 was protective against vitamin D deficiency-induced cholesterol increase by maintaining the transcriptional activity of VDR and Insig-2 expression. Cholecalciferol 0-10 insulin induced gene 2 Homo sapiens 139-146 26943970-0 2016 Vitamin D3 alters microglia immune activation by an IL-10 dependent SOCS3 mechanism. Cholecalciferol 0-10 interleukin 10 Homo sapiens 52-57 26943970-0 2016 Vitamin D3 alters microglia immune activation by an IL-10 dependent SOCS3 mechanism. Cholecalciferol 0-10 suppressor of cytokine signaling 3 Homo sapiens 68-73 26943970-7 2016 In this study, activated microglia increased the expression of the vitamin D receptor and Cyp27b1, which encodes the enzyme for converting vitamin D3 into its active form, thereby enhancing their responsiveness to vitamin D3. Cholecalciferol 139-149 vitamin D receptor Homo sapiens 67-85 26943970-7 2016 In this study, activated microglia increased the expression of the vitamin D receptor and Cyp27b1, which encodes the enzyme for converting vitamin D3 into its active form, thereby enhancing their responsiveness to vitamin D3. Cholecalciferol 139-149 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 90-97 26943970-7 2016 In this study, activated microglia increased the expression of the vitamin D receptor and Cyp27b1, which encodes the enzyme for converting vitamin D3 into its active form, thereby enhancing their responsiveness to vitamin D3. Cholecalciferol 214-224 vitamin D receptor Homo sapiens 67-85 26943970-7 2016 In this study, activated microglia increased the expression of the vitamin D receptor and Cyp27b1, which encodes the enzyme for converting vitamin D3 into its active form, thereby enhancing their responsiveness to vitamin D3. Cholecalciferol 214-224 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 90-97 26943970-8 2016 Most importantly, the activated microglia exposed to vitamin D3 had reduced expression of pro-inflammatory cytokines, IL-6, IL-12, and TNFalpha, and increased expression of IL-10. Cholecalciferol 53-63 interleukin 6 Homo sapiens 118-122 26943970-8 2016 Most importantly, the activated microglia exposed to vitamin D3 had reduced expression of pro-inflammatory cytokines, IL-6, IL-12, and TNFalpha, and increased expression of IL-10. Cholecalciferol 53-63 tumor necrosis factor Homo sapiens 135-143 26943970-8 2016 Most importantly, the activated microglia exposed to vitamin D3 had reduced expression of pro-inflammatory cytokines, IL-6, IL-12, and TNFalpha, and increased expression of IL-10. Cholecalciferol 53-63 interleukin 10 Homo sapiens 173-178 26943970-10 2016 Therefore, vitamin D3 increases the expression of IL-10 creating a feedback loop via SOCS3 that downregulates the pro-inflammatory immune response by activated microglia which would likewise prevent immune mediated damage in the CNS. Cholecalciferol 11-21 interleukin 10 Homo sapiens 50-55 26943970-10 2016 Therefore, vitamin D3 increases the expression of IL-10 creating a feedback loop via SOCS3 that downregulates the pro-inflammatory immune response by activated microglia which would likewise prevent immune mediated damage in the CNS. Cholecalciferol 11-21 suppressor of cytokine signaling 3 Homo sapiens 85-90 26762804-3 2016 We recently described the therapeutic activity of the association between myelin oligodendrocyte glycoprotein peptide (MOG) and active vitamin D3 (VitD) against experimental autoimmune encephalomyelitis (EAE). Cholecalciferol 135-145 myelin oligodendrocyte glycoprotein Mus musculus 74-117 26976974-1 2016 Vitamin D3 (D3) can be metabolized by cytochrome P450scc (CYP11A1) into 20S-hydroxyvitamin D3 (20D3) as a major metabolite. Cholecalciferol 0-10 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 58-65 26786573-2 2016 This study was designed to investigate the effect of high-dose vitamin D3 treatment on beta-cell function, insulin sensitivity, and glucose tolerance in subjects with prediabetes or diet-treated type 2 diabetes. Cholecalciferol 63-73 insulin Homo sapiens 107-114 26813503-2 2016 A combination of oral active vitamin D3 and phosphate is the current standard therapy for FGF23-related hypophosphatemia. Cholecalciferol 29-39 fibroblast growth factor 23 Homo sapiens 90-95 26744303-0 2016 Inhibition of alpha-glucosidase by vitamin D3 and the effect of vitamins B1 and B2. Cholecalciferol 35-45 sucrase-isomaltase Homo sapiens 14-31 26744303-3 2016 The inhibitory effect of vitamin D3 on alpha-glucosidase as well as its mechanism of action was investigated in this work. Cholecalciferol 25-35 sucrase-isomaltase Homo sapiens 39-56 26744303-4 2016 The results showed that vitamin D3 exhibited stronger inhibition on alpha-glucosidase than acarbose with the IC50 value of 1.28 x 10(-4) mol L(-1), and the inhibition was a mixed-type mechanism through a multiphase kinetic process. Cholecalciferol 24-34 sucrase-isomaltase Homo sapiens 68-85 26744303-6 2016 Vitamin D3 interacted with alpha-glucosidase by hydrophobic interactions, and molecular docking further verified that the inhibitor inserted into the active site pocket of alpha-glucosidase and interacted with the amino residues, which induced the rearrangement and conformational changes of alpha-glucosidase, and might move to cover the active pocket, hindering the binding of the substrate leading to the inhibition of the enzyme activity. Cholecalciferol 0-10 sucrase-isomaltase Homo sapiens 27-44 26744303-6 2016 Vitamin D3 interacted with alpha-glucosidase by hydrophobic interactions, and molecular docking further verified that the inhibitor inserted into the active site pocket of alpha-glucosidase and interacted with the amino residues, which induced the rearrangement and conformational changes of alpha-glucosidase, and might move to cover the active pocket, hindering the binding of the substrate leading to the inhibition of the enzyme activity. Cholecalciferol 0-10 sucrase-isomaltase Homo sapiens 172-189 26744303-6 2016 Vitamin D3 interacted with alpha-glucosidase by hydrophobic interactions, and molecular docking further verified that the inhibitor inserted into the active site pocket of alpha-glucosidase and interacted with the amino residues, which induced the rearrangement and conformational changes of alpha-glucosidase, and might move to cover the active pocket, hindering the binding of the substrate leading to the inhibition of the enzyme activity. Cholecalciferol 0-10 sucrase-isomaltase Homo sapiens 172-189 26744303-7 2016 Moreover, it was found that vitamin D3 combined with vitamin B1 or vitamin B2 exhibited significant synergistic effects on inhibition of alpha-glucosidase. Cholecalciferol 28-38 sucrase-isomaltase Homo sapiens 137-154 26744303-8 2016 This study has provided new insights into the role of vitamin D3 in inhibiting alpha-glucosidase catalysis and offered useful information on the dietary recommendation of vitamin D3 for the treatment of type 2 diabetes. Cholecalciferol 54-64 sucrase-isomaltase Homo sapiens 79-96 26977043-1 2016 BACKGROUND: Vitamin D3 can be metabolized in the skin to 25(OH)D and 1,25(OH)2D because the skin expresses vitamin D-25-hydroxylase, 25(OH)D-1-alpha-hydroxylase, and the vitamin D receptor. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 170-188 26358366-6 2016 Furthermore, pre-treatment with Dex inhibits vitamin D3 induced cathelicidin expression in THP-1 monocytes, primary monocytes and in the human bronchial epithelial cell line BCi NS 1.1. Cholecalciferol 45-55 GLI family zinc finger 2 Homo sapiens 91-96 26358366-7 2016 We also demonstrate that treatment with the glucocorticoid receptor (GR) inhibitor RU486 counteracts Dex mediated down-regulation of basal and vitamin D3 induced cathelicidin expression in THP-1 monocytes. Cholecalciferol 143-153 nuclear receptor subfamily 3 group C member 1 Homo sapiens 44-67 26358366-7 2016 We also demonstrate that treatment with the glucocorticoid receptor (GR) inhibitor RU486 counteracts Dex mediated down-regulation of basal and vitamin D3 induced cathelicidin expression in THP-1 monocytes. Cholecalciferol 143-153 nuclear receptor subfamily 3 group C member 1 Homo sapiens 69-71 26358366-7 2016 We also demonstrate that treatment with the glucocorticoid receptor (GR) inhibitor RU486 counteracts Dex mediated down-regulation of basal and vitamin D3 induced cathelicidin expression in THP-1 monocytes. Cholecalciferol 143-153 GLI family zinc finger 2 Homo sapiens 189-194 26828994-3 2016 Although agents such as omega-3 (omega3) and vitamin D3 (Vit D3) are known to contribute to the success of islet allo-transplantation (ITX), in this study we aimed to experimentally determine their effects on glycemia and TNF-alpha production. Cholecalciferol 45-55 tumor necrosis factor Rattus norvegicus 222-231 26499096-9 2016 Plasma samples collected from patients after the administration of activated vitamin D3 caused significantly increased ALP activity in SMC compared to the samples drawn prior to activated vitamin D3 and here, again induction of ferritin diminished the osteoblastic transformation. Cholecalciferol 77-87 alkaline phosphatase, placental Homo sapiens 119-122 26653112-9 2016 RESULTS: Treatment with 4000 IU of vitamin D3 decreased intracellular CD4+ ATP release by 95.5 ng/ml (interquartile range, -219.5 to 105.8). Cholecalciferol 35-45 CD4 molecule Homo sapiens 70-73 26653112-10 2016 In contrast, 400 IU of vitamin D3 decreased intracellular CD4+ ATP release by 0.5 ng/ml (interquartile range, -69.2 to 148.5). Cholecalciferol 23-33 CD4 molecule Homo sapiens 58-61 26653112-11 2016 In a proportional odds model, high-dose vitamin D3 was more likely than low-dose vitamin D3 to decrease CD4+ ATP release (odds ratio, 3.43; 95% confidence interval, 1.06-1.11). Cholecalciferol 40-50 CD4 molecule Homo sapiens 104-107 26653112-11 2016 In a proportional odds model, high-dose vitamin D3 was more likely than low-dose vitamin D3 to decrease CD4+ ATP release (odds ratio, 3.43; 95% confidence interval, 1.06-1.11). Cholecalciferol 81-91 CD4 molecule Homo sapiens 104-107 26653112-12 2016 CONCLUSIONS: In this ancillary study of a randomized controlled trial, we found that high-dose vitamin D3 significantly reduced CD4+ T-cell activation compared to low-dose vitamin D3, providing human evidence that vitamin D can influence cell-mediated immunity. Cholecalciferol 95-105 CD4 molecule Homo sapiens 128-131 26718578-9 2016 CONCLUSIONS: Cholecalciferol supplementation with 10,400 IU daily is safe and tolerable in patients with MS and exhibits in vivo pleiotropic immunomodulatory effects in MS, which include reduction of interleukin-17 production by CD4(+) T cells and decreased proportion of effector memory CD4(+) T cells with concomitant increase in central memory CD4(+) T cells and naive CD4(+) T cells. Cholecalciferol 13-28 CD4 molecule Homo sapiens 229-232 26718578-9 2016 CONCLUSIONS: Cholecalciferol supplementation with 10,400 IU daily is safe and tolerable in patients with MS and exhibits in vivo pleiotropic immunomodulatory effects in MS, which include reduction of interleukin-17 production by CD4(+) T cells and decreased proportion of effector memory CD4(+) T cells with concomitant increase in central memory CD4(+) T cells and naive CD4(+) T cells. Cholecalciferol 13-28 CD4 molecule Homo sapiens 288-291 26718578-9 2016 CONCLUSIONS: Cholecalciferol supplementation with 10,400 IU daily is safe and tolerable in patients with MS and exhibits in vivo pleiotropic immunomodulatory effects in MS, which include reduction of interleukin-17 production by CD4(+) T cells and decreased proportion of effector memory CD4(+) T cells with concomitant increase in central memory CD4(+) T cells and naive CD4(+) T cells. Cholecalciferol 13-28 CD4 molecule Homo sapiens 288-291 26718578-9 2016 CONCLUSIONS: Cholecalciferol supplementation with 10,400 IU daily is safe and tolerable in patients with MS and exhibits in vivo pleiotropic immunomodulatory effects in MS, which include reduction of interleukin-17 production by CD4(+) T cells and decreased proportion of effector memory CD4(+) T cells with concomitant increase in central memory CD4(+) T cells and naive CD4(+) T cells. Cholecalciferol 13-28 CD4 molecule Homo sapiens 288-291 27356607-0 2016 Vitamin D3 analog maxacalcitol (OCT) induces hCAP-18/LL-37 production in human oral epithelial cells. Cholecalciferol 0-10 plexin A2 Homo sapiens 32-35 26638999-0 2016 Expression of human CYP27A1 in B. megaterium for the efficient hydroxylation of cholesterol, vitamin D3 and 7-dehydrocholesterol. Cholecalciferol 93-103 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 20-27 26638999-4 2016 The resulting whole cell system allowed the efficient biotechnological conversion of the CYP27A1 substrates cholesterol, 7-dehydrocholesterol (7-DHC) and vitamin D3. Cholecalciferol 154-164 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 89-96 26238339-11 2016 Irrespective of the dietary vitamin D3, dietary soy is able to increase tumour volume when tumours overexpress CYP24A1, suggesting that combination of vitamin D3 and soy could have an anti-tumourigenic effect only if CYP24A1 levels are normal. Cholecalciferol 151-161 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 111-118 26238339-11 2016 Irrespective of the dietary vitamin D3, dietary soy is able to increase tumour volume when tumours overexpress CYP24A1, suggesting that combination of vitamin D3 and soy could have an anti-tumourigenic effect only if CYP24A1 levels are normal. Cholecalciferol 151-161 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 217-224 26750596-3 2016 Here, we show that addition of 1,25D3, the active form of vitamin D3, during CD8(+) T-cell differentiation prevents IL-4-induced conversion to IL-13-producers. Cholecalciferol 58-68 CD8a molecule Homo sapiens 77-80 26750596-3 2016 Here, we show that addition of 1,25D3, the active form of vitamin D3, during CD8(+) T-cell differentiation prevents IL-4-induced conversion to IL-13-producers. Cholecalciferol 58-68 interleukin 4 Homo sapiens 116-120 26750596-3 2016 Here, we show that addition of 1,25D3, the active form of vitamin D3, during CD8(+) T-cell differentiation prevents IL-4-induced conversion to IL-13-producers. Cholecalciferol 58-68 interleukin 13 Homo sapiens 143-148 27336154-0 2016 Vitamin D3-Supplemented Yogurt Drink Improves Insulin Resistance and Lipid Profiles in Women with Gestational Diabetes Mellitus: A Randomized Double Blinded Clinical Trial. Cholecalciferol 0-10 insulin Homo sapiens 46-53 27336154-1 2016 BACKGROUND: Our study aimed to examine the effects of daily consumption of vitamin D3-supplemented yogurt (VDY) drink on insulin resistance and lipid profiles in pregnant gestational diabetes mellitus (GDM) patients. Cholecalciferol 75-85 insulin Homo sapiens 121-128 27356607-0 2016 Vitamin D3 analog maxacalcitol (OCT) induces hCAP-18/LL-37 production in human oral epithelial cells. Cholecalciferol 0-10 cathelicidin antimicrobial peptide Homo sapiens 45-52 27356607-0 2016 Vitamin D3 analog maxacalcitol (OCT) induces hCAP-18/LL-37 production in human oral epithelial cells. Cholecalciferol 0-10 cathelicidin antimicrobial peptide Homo sapiens 53-58 27356607-1 2016 Maxacalcitol (22-oxacalcitriol: OCT) is a synthetic vitamin D3 analog with a limited calcemic effect. Cholecalciferol 52-62 plexin A2 Homo sapiens 32-35 27252860-2 2016 Herein, we report a case of a young male, diagnosed with LADA based on both clinical presentation and positive anti-glutamic acid decarboxylase antibodies (GAD-abs), which were normalized after combined treatment with a dipeptidyl peptidase-4 inhibitor (DPP-4) (sitagliptin) and cholecalciferol. Cholecalciferol 279-294 dipeptidyl peptidase 4 Homo sapiens 220-242 26607259-11 2016 CONCLUSION: Although exploratory, this study indicates rs8176345 in CYP27B1 gene as significantly correlated with erlotinib-induced SR in aNSCLC patients probably through a mechanism mediated by vitamin D3 and inflammation at skin level. Cholecalciferol 195-205 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 68-75 27777388-2 2016 Active vitamin D3 and its derivatives have their own feature of pharmacokinetics, due to differences in binding affinity for carrier protein such as vitamin D binding protein and in metabolism. Cholecalciferol 7-17 GC vitamin D binding protein Homo sapiens 149-174 28035286-11 2016 Vitamin D3 also activates CD4+CD25+FoxP3+ regulatory T-cells, and these medications combined can improve the immune response in patients with new-onset T1DM and probably promote sustained clinical remission. Cholecalciferol 0-10 forkhead box P3 Homo sapiens 35-40 28035286-12 2016 LEARNING POINTS: The use of sitagliptin and vitamin D3 in patients with new-onset type 1 diabetes mellitus (T1DM) may help decrease the daily insulin requirement by delaying beta cell loss and improving endogenous insulin production.The use of sitagliptin and vitamin D3 in new-onset T1DM could help regulate the imbalance between Th17 and Treg cells.Age 14 years or above, absence of ketoacidosis and positive C-peptide levels in patients with T1DM are good criteria to predict prolonged T1DM remission.The determination of anti-GAD antibodies and C-peptide levels could be helpful in the follow-up of patients in use of sitagliptin and vitamin D3, which could be associated with prolonged T1DM clinical remission. Cholecalciferol 44-54 insulin Homo sapiens 142-149 28035286-12 2016 LEARNING POINTS: The use of sitagliptin and vitamin D3 in patients with new-onset type 1 diabetes mellitus (T1DM) may help decrease the daily insulin requirement by delaying beta cell loss and improving endogenous insulin production.The use of sitagliptin and vitamin D3 in new-onset T1DM could help regulate the imbalance between Th17 and Treg cells.Age 14 years or above, absence of ketoacidosis and positive C-peptide levels in patients with T1DM are good criteria to predict prolonged T1DM remission.The determination of anti-GAD antibodies and C-peptide levels could be helpful in the follow-up of patients in use of sitagliptin and vitamin D3, which could be associated with prolonged T1DM clinical remission. Cholecalciferol 44-54 insulin Homo sapiens 214-221 28035286-12 2016 LEARNING POINTS: The use of sitagliptin and vitamin D3 in patients with new-onset type 1 diabetes mellitus (T1DM) may help decrease the daily insulin requirement by delaying beta cell loss and improving endogenous insulin production.The use of sitagliptin and vitamin D3 in new-onset T1DM could help regulate the imbalance between Th17 and Treg cells.Age 14 years or above, absence of ketoacidosis and positive C-peptide levels in patients with T1DM are good criteria to predict prolonged T1DM remission.The determination of anti-GAD antibodies and C-peptide levels could be helpful in the follow-up of patients in use of sitagliptin and vitamin D3, which could be associated with prolonged T1DM clinical remission. Cholecalciferol 44-54 glutamate decarboxylase 1 Homo sapiens 530-533 27764518-0 2016 Administration of vitamin D3 induces CNPase and myelin oligodendrocyte glycoprotein expression in the cerebral cortex of the murine model of cuprizone-induced demyelination. Cholecalciferol 18-28 2',3'-cyclic nucleotide 3' phosphodiesterase Mus musculus 37-43 27764518-0 2016 Administration of vitamin D3 induces CNPase and myelin oligodendrocyte glycoprotein expression in the cerebral cortex of the murine model of cuprizone-induced demyelination. Cholecalciferol 18-28 myelin oligodendrocyte glycoprotein Mus musculus 48-83 26433491-0 2016 Vitamin D3 modulates the innate immune response through regulation of the hCAP-18/LL-37 gene expression and cytokine production. Cholecalciferol 0-10 cathelicidin antimicrobial peptide Homo sapiens 74-81 26433491-0 2016 Vitamin D3 modulates the innate immune response through regulation of the hCAP-18/LL-37 gene expression and cytokine production. Cholecalciferol 0-10 cathelicidin antimicrobial peptide Homo sapiens 82-87 27096068-10 2016 Also, results indicated that vitamin D3 caused a decrease in lipid peroxidation levels and an increase in CAT activities. Cholecalciferol 29-39 catalase Homo sapiens 106-109 27313879-0 2016 Vitamin D3 Suppresses Class II Invariant Chain Peptide Expression on Activated B-Lymphocytes: A Plausible Mechanism for Downregulation of Acute Inflammatory Conditions. Cholecalciferol 0-10 proopiomelanocortin Homo sapiens 22-54 26385608-2 2016 In this study, we examined the potencies of other vitamin D3 and D2 analogs to stimulate the ectodomain shedding of TNFR1 in HASMCs. Cholecalciferol 50-60 TNF receptor superfamily member 1A Homo sapiens 116-121 27505422-0 2016 Vitamin D3 Partly Antagonizes Advanced-Glycation Endproducts-Induced NFkappaB Activation in Mouse Podocytes. Cholecalciferol 0-10 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 69-77 27505422-13 2016 CONCLUSION: Vitamin D3 or its analog paricalcitol partly prevented AGE-mediated NFkappaB activation, an important feature of diabetic nephropathy (DN). Cholecalciferol 12-22 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 80-88 25777538-5 2016 We hypothesized that 1,25-dihydroyvitamin D3 (1,25-D3), the active form of vitamin D3, promotes differentiation by modulating beta-catenin/T-cell factor (TCF) 4-mediated gene transcription. Cholecalciferol 34-44 catenin (cadherin associated protein), beta 1 Mus musculus 126-138 27701167-7 2016 Patients with mGFR below the median shown significantly higher PTH and lower vitamin D3. Cholecalciferol 77-87 Rap guanine nucleotide exchange factor (GEF) 5 Mus musculus 14-18 27313879-3 2016 We hypothesized that activated vitamin D3 suppresses CLIP expression on activated B-cells after nonspecific activation or priming of C57BL/6 mice with CpG. Cholecalciferol 31-41 CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) Mus musculus 53-57 27313879-4 2016 This study showed activated vitamin D3 actively reduced CLIP expression and decreased the number of CLIP(+) B-lymphocytes in a dose and formulation dependent fashion. Cholecalciferol 28-38 proopiomelanocortin Homo sapiens 56-60 27313879-4 2016 This study showed activated vitamin D3 actively reduced CLIP expression and decreased the number of CLIP(+) B-lymphocytes in a dose and formulation dependent fashion. Cholecalciferol 28-38 proopiomelanocortin Homo sapiens 100-104 27313879-5 2016 Flow cytometry was used to analyze changes in mean fluorescent intensity (MFI) based on changes in concentration of CLIP on activated B-lymphocytes after treatment with the various formulations of vitamin D3. Cholecalciferol 197-207 proopiomelanocortin Homo sapiens 116-120 26827960-1 2016 The Arg274 residue of the ligand binding domain of human vitamin D receptor (hVDR) is important for 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) binding as a specific ligand through forming a hydrogen bond with the 1alpha-OH group of the active vitamin D3, 1alpha,25(OH)2D3. Cholecalciferol 119-129 vitamin D receptor Homo sapiens 57-75 26440923-9 2016 Compared with the control group, patients treated with vitamin D3 also had greater decreases in high sensitivity C-reactive protein and renin-angiotensin system activity (p < 0.05). Cholecalciferol 55-65 C-reactive protein Homo sapiens 113-131 26440923-9 2016 Compared with the control group, patients treated with vitamin D3 also had greater decreases in high sensitivity C-reactive protein and renin-angiotensin system activity (p < 0.05). Cholecalciferol 55-65 renin Homo sapiens 136-141 26827949-1 2016 The vitamin D nuclear receptor (VDR) and its natural ligand, 1alpha,25-dihydroxyvitamin D3 hormone (1,25(OH)2D3, or calcitriol), classically regulate mineral homeostasis and metabolism but also much broader range of biological functions, such as cell growth, differentiation, antiproliferation, apoptosis, adaptive/innate immune responses. Cholecalciferol 88-90 vitamin D receptor Homo sapiens 4-30 26827949-1 2016 The vitamin D nuclear receptor (VDR) and its natural ligand, 1alpha,25-dihydroxyvitamin D3 hormone (1,25(OH)2D3, or calcitriol), classically regulate mineral homeostasis and metabolism but also much broader range of biological functions, such as cell growth, differentiation, antiproliferation, apoptosis, adaptive/innate immune responses. Cholecalciferol 88-90 vitamin D receptor Homo sapiens 32-35 26827960-1 2016 The Arg274 residue of the ligand binding domain of human vitamin D receptor (hVDR) is important for 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) binding as a specific ligand through forming a hydrogen bond with the 1alpha-OH group of the active vitamin D3, 1alpha,25(OH)2D3. Cholecalciferol 119-129 vitamin D receptor Homo sapiens 77-81 26314252-2 2015 Herein, we presented evidence indicating that DDX5 is transcriptionally upregulated by calcitriol, the hormonal form of vitamin D3. Cholecalciferol 120-130 DEAD-box helicase 5 Homo sapiens 46-50 26664810-4 2015 We show that treatment of VA10 cells with vitamin D3 and/or 4-phenyl butyric acid counteracted cyclic stretch mediated down-regulation of CAMP mRNA and protein expression (LL-37). Cholecalciferol 42-52 cathelicidin antimicrobial peptide Homo sapiens 138-142 26206289-7 2015 In contrast, peptide delivered intradermally on the surface of vitamin D3-modulated (tolerogenic) dendritic cells, controls autoimmunity in association with proinsulin-specific IL-10 production, but no change in regulatory CD4 T cells. Cholecalciferol 63-73 insulin II Mus musculus 157-167 29391997-6 2015 There was a positive correlation between IFN-gamma and vitamin D levels (p<0.05) in the study group, whereas IgE, IL-4, and IL-10 levels showed a negative correlation with vitamin D3 levels (p<0.05). Cholecalciferol 175-185 immunoglobulin heavy constant epsilon Homo sapiens 112-115 29391997-6 2015 There was a positive correlation between IFN-gamma and vitamin D levels (p<0.05) in the study group, whereas IgE, IL-4, and IL-10 levels showed a negative correlation with vitamin D3 levels (p<0.05). Cholecalciferol 175-185 interleukin 10 Homo sapiens 127-132 26560812-3 2015 Both genetic and pharmacological inhibition of PDK4 ameliorated the calcification in phosphate-treated VSMCs and aortic rings and in vitamin D3-treated mice. Cholecalciferol 133-143 pyruvate dehydrogenase kinase, isoenzyme 4 Mus musculus 47-51 26640388-9 2015 Twelve-month oral cholecalciferol administration increased 25-hydroxyvitamin D and reduced PTH serum levels. Cholecalciferol 18-33 parathyroid hormone Homo sapiens 91-94 26640388-12 2015 Oral cholecalciferol administration increased 25-hydroxyvitamin D and mildly reduced PTH serum levels. Cholecalciferol 5-20 parathyroid hormone Homo sapiens 85-88 26399683-6 2015 Bropirimine partially suppressed the expression of RANKL mRNA in UAMS-32 cells induced by activated vitamin D3. Cholecalciferol 100-110 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 51-56 26501255-1 2015 Vitamin D3 shows tumoristatic and anticancer effects by acting through the vitamin D receptor (VDR), while hydroxylation of 25-hydroxyvitamin D3 at position 1alpha by CYP27B1 is an essential step in its activation. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 75-93 26336925-6 2015 Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma. Cholecalciferol 31-41 tumor necrosis factor Mus musculus 188-197 26336925-6 2015 Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma. Cholecalciferol 31-41 interleukin 1 beta Mus musculus 199-207 26336925-6 2015 Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma. Cholecalciferol 31-41 interleukin 6 Mus musculus 209-213 26336925-6 2015 Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma. Cholecalciferol 31-41 interleukin 17A Mus musculus 225-231 26336925-6 2015 Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma. Cholecalciferol 31-41 interleukin 17F Mus musculus 237-243 26336925-6 2015 Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma. Cholecalciferol 31-41 regenerating islet-derived 3 gamma Mus musculus 281-290 26397033-0 2015 Evaluation of the lipopolysaccharide-induced transcription of the human TREM-1 gene in vitamin D3-matured THP-1 macrophage-like cells. Cholecalciferol 87-97 triggering receptor expressed on myeloid cells 1 Homo sapiens 72-78 26397033-4 2015 Reverse transcription-polymerase chain reaction (RT-PCR) revealed that TREM-1 mRNA was constitutively expressed at a low level in resting cells, and that its expression was upregulated by treatment with vitamin D3 (VitD3), but not by LPS. Cholecalciferol 203-213 triggering receptor expressed on myeloid cells 1 Homo sapiens 71-77 26463745-3 2015 OBJECTIVES: To study vitamin D3 metabolizing enzymes, CYP27A1 and CYP27B1, in mast cells in epithelial skin cancers and psoriasis. Cholecalciferol 21-31 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 54-61 25938886-10 2015 Totally, the administration of cholecalciferol supplements among pregnant women at risk for pre-eclampsia for 12 weeks had favorable effects on insulin metabolism parameters, serum HDL-cholesterol, and plasma TAC concentrations. Cholecalciferol 31-46 insulin Homo sapiens 144-151 26501255-1 2015 Vitamin D3 shows tumoristatic and anticancer effects by acting through the vitamin D receptor (VDR), while hydroxylation of 25-hydroxyvitamin D3 at position 1alpha by CYP27B1 is an essential step in its activation. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 95-98 26408720-9 2015 CONCLUSION: This observation indicates that a combination of high-dose vitamin D3 and ketogenic diet leads to changes in some biological markers of breast cancer, i.e. negativization of HER2 expression and increased expression of PgR. Cholecalciferol 71-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 186-190 26770399-0 2015 Vitamin D3 alters Toll-like receptor 4 signaling in monocytes of pregnant women at risk for preeclampsia. Cholecalciferol 0-10 toll like receptor 4 Homo sapiens 18-38 26770399-4 2015 Because vitamin D3 supplementation can induce anti-inflammatory cytokine signaling, peripheral blood monocytes were investigated by flow cytometry for expression of toll-like receptor 4 (TLR4), an important mediator of innate immune response. Cholecalciferol 8-18 toll like receptor 4 Homo sapiens 187-191 26770399-9 2015 Based on these results, we conclude that vitamin D3 supplementation for patients at risk of preeclampsia leads to a decrease in the expression of peripheral blood monocytes TLR4 and a subsequent decrease in pro-inflammatory cytokine secretion. Cholecalciferol 41-51 toll like receptor 4 Homo sapiens 173-177 26770399-10 2015 Therefore, inhibiting the expression of monocytes TLR4 through vitamin D3 supplement may be a new approach to preeclampsia prevention. Cholecalciferol 63-73 toll like receptor 4 Homo sapiens 50-54 26445902-1 2015 To investigate whether novel pathways of vitamin D3 (D3) and 7-dehydrocholesterol (7DHC) metabolism initiated by CYP11A1 and previously characterized in vitro, occur in vivo, we analyzed samples of human serum and epidermis, and pig adrenals for the presence of intermediates and products of these pathways. Cholecalciferol 41-51 cytochrome P450 family 11 subfamily A member 1 Sus scrofa 113-120 26408720-9 2015 CONCLUSION: This observation indicates that a combination of high-dose vitamin D3 and ketogenic diet leads to changes in some biological markers of breast cancer, i.e. negativization of HER2 expression and increased expression of PgR. Cholecalciferol 71-81 progesterone receptor Homo sapiens 230-233 25495336-10 2015 CONCLUSIONS: Vitamin D3 promotes osteogenic differentiation but also downregulates inflammation promoter-induced IL-6 cytokine and CXCL1 chemokine expression in human PDL cells, suggesting that vitamin D3 both stimulates bone regeneration and antagonizes inflammation in human periodontal tissue. Cholecalciferol 13-23 interleukin 6 Homo sapiens 113-117 26054778-8 2015 Vitamin D3 supplementation restored the alteration in vitamin D receptor expression, AMPA receptor density and AMPA and IP3 receptor expression in the pancreatic islets that helps to restore the calcium-mediated insulin secretion. Cholecalciferol 0-10 inositol 1,4,5-trisphosphate receptor, type 3 Rattus norvegicus 120-132 25495336-10 2015 CONCLUSIONS: Vitamin D3 promotes osteogenic differentiation but also downregulates inflammation promoter-induced IL-6 cytokine and CXCL1 chemokine expression in human PDL cells, suggesting that vitamin D3 both stimulates bone regeneration and antagonizes inflammation in human periodontal tissue. Cholecalciferol 13-23 C-X-C motif chemokine ligand 1 Homo sapiens 131-136 25495336-10 2015 CONCLUSIONS: Vitamin D3 promotes osteogenic differentiation but also downregulates inflammation promoter-induced IL-6 cytokine and CXCL1 chemokine expression in human PDL cells, suggesting that vitamin D3 both stimulates bone regeneration and antagonizes inflammation in human periodontal tissue. Cholecalciferol 194-204 interleukin 6 Homo sapiens 113-117 25495336-10 2015 CONCLUSIONS: Vitamin D3 promotes osteogenic differentiation but also downregulates inflammation promoter-induced IL-6 cytokine and CXCL1 chemokine expression in human PDL cells, suggesting that vitamin D3 both stimulates bone regeneration and antagonizes inflammation in human periodontal tissue. Cholecalciferol 194-204 C-X-C motif chemokine ligand 1 Homo sapiens 131-136 26394045-2 2015 Previous results have shown that vitamin D3 (vitD3) and 4-phenyl butyrate (PBA) are potent inducers of the host defense peptide LL-37 that possess anti-mycobacterial effects. Cholecalciferol 33-43 cathelicidin antimicrobial peptide Homo sapiens 128-133 26904855-3 2015 Vitamin D metabolic enzymes synthesize and degrade active vitamin D3 and its metabolic intermediates, and active vitamin D3 exerts its biological effects through binding to vitamin D receptor (VDR). Cholecalciferol 58-68 vitamin D receptor Homo sapiens 193-196 26904855-3 2015 Vitamin D metabolic enzymes synthesize and degrade active vitamin D3 and its metabolic intermediates, and active vitamin D3 exerts its biological effects through binding to vitamin D receptor (VDR). Cholecalciferol 113-123 vitamin D receptor Homo sapiens 173-191 26904855-3 2015 Vitamin D metabolic enzymes synthesize and degrade active vitamin D3 and its metabolic intermediates, and active vitamin D3 exerts its biological effects through binding to vitamin D receptor (VDR). Cholecalciferol 113-123 vitamin D receptor Homo sapiens 193-196 26904855-4 2015 VDR and vitamin D metabolic enzymes expressed in male reproductive system, it suggest that vitamin D3 plays a pivotal role in male reproductive biology. Cholecalciferol 91-101 vitamin D receptor Homo sapiens 0-3 25495336-5 2015 RESULTS: Treatment with 30 ng/mL of vitamin D3, corresponding to an optimal plasma concentration of vitamin D, for 24 h had no effect on PDL cell number and morphology but increased PDL cell osteopontin and osteocalcin mRNA expression by about 70 and 40%, respectively, and, moreover, treatment with vitamin D3 for 48 h enhanced PDL cell alkaline phosphatase activity by about two times showing that vitamin D3 exerts pro-osteogenic effects in human PDL cells. Cholecalciferol 36-46 secreted phosphoprotein 1 Homo sapiens 191-202 25495336-5 2015 RESULTS: Treatment with 30 ng/mL of vitamin D3, corresponding to an optimal plasma concentration of vitamin D, for 24 h had no effect on PDL cell number and morphology but increased PDL cell osteopontin and osteocalcin mRNA expression by about 70 and 40%, respectively, and, moreover, treatment with vitamin D3 for 48 h enhanced PDL cell alkaline phosphatase activity by about two times showing that vitamin D3 exerts pro-osteogenic effects in human PDL cells. Cholecalciferol 36-46 bone gamma-carboxyglutamate protein Homo sapiens 207-218 25495336-7 2015 The LPS-induced increase in IL-6 and CXCL1 transcripts was attenuated by vitamin D3 (30 ng/mL). Cholecalciferol 73-83 interleukin 6 Homo sapiens 28-32 25495336-7 2015 The LPS-induced increase in IL-6 and CXCL1 transcripts was attenuated by vitamin D3 (30 ng/mL). Cholecalciferol 73-83 C-X-C motif chemokine ligand 1 Homo sapiens 37-42 25495336-8 2015 Treatment with vitamin D3 (3-300 ng/mL) for 24 h reduced the LPS-evoked increase in PDL cell IL-6 protein by about 50%. Cholecalciferol 15-25 interleukin 6 Homo sapiens 93-97 26007153-2 2015 The aim of this study was to investigate the effects of vitamin D3 treatment on serum sclerostin levels in young adult females with severe vitamin D deficiency. Cholecalciferol 56-66 sclerostin Homo sapiens 86-96 26007153-7 2015 We conclude that serum sclerostin level is decreased following vitamin D3 treatment in patients with vitamin D deficiency. Cholecalciferol 63-73 sclerostin Homo sapiens 23-33 25931412-1 2015 Several compounds are produced along the complex pathways of vitamin D3 metabolism, and synthetic analogs have been generated to improve kinetics and/or vitamin D receptor activation. Cholecalciferol 61-71 vitamin D receptor Homo sapiens 153-171 26562280-3 2015 The advent of new treatment options for NF1 such as topical vitamin D3 analogues, lovastatin, rapamycin (or sirolimus), and imatinib mesylate has added new dimensions that require further investigation to provide the greatest benefit to patients. Cholecalciferol 60-70 neurofibromin 1 Homo sapiens 40-43 26184408-3 2015 The discovery that almost all tissues and cells in the body express the VDR and that several tissues possess the enzymatic capability to convert 25-hydroxyvitamin D (25(OH)-D3; cholecalciferol) to the active form, suggests that vitamin D fulfills various extra-osseous functions (Bouillon et al., Endocr Rev 29(6):726-776, 2008; Holick, N Engl J Med 357(3):266-281, 2007). Cholecalciferol 177-192 vitamin D receptor Homo sapiens 72-75 26350811-3 2015 OBJECTIVE: To examine the effect of sunlight exposure and serum DHCR7 levels on cholecalciferol and cholesterol levels and studying any interrelationship. Cholecalciferol 80-95 7-dehydrocholesterol reductase Homo sapiens 64-69 26232426-4 2015 RegDC generated from monocyte-derived DC treated either with LPS and dexamethasone, vitamin D3, or vitamin D3 and dexamethasone instructed NK cells to secrete lower amounts of IFN-gamma than NK cells exposed to mDC. Cholecalciferol 84-94 chemokine (C-C motif) ligand 22 Mus musculus 3-5 26232426-4 2015 RegDC generated from monocyte-derived DC treated either with LPS and dexamethasone, vitamin D3, or vitamin D3 and dexamethasone instructed NK cells to secrete lower amounts of IFN-gamma than NK cells exposed to mDC. Cholecalciferol 99-109 chemokine (C-C motif) ligand 22 Mus musculus 3-5 26232426-4 2015 RegDC generated from monocyte-derived DC treated either with LPS and dexamethasone, vitamin D3, or vitamin D3 and dexamethasone instructed NK cells to secrete lower amounts of IFN-gamma than NK cells exposed to mDC. Cholecalciferol 99-109 interferon gamma Homo sapiens 176-185 26198928-12 2015 The multiple linear regression analysis indicated that the consumption of vitamin D3 was positively and significantly associated with the logarithm of IL-17 measures (beta=1.719; p=0.002 and R2=0.91), adjusted by EDSS scores. Cholecalciferol 74-84 interleukin 17A Homo sapiens 151-156 26198928-13 2015 CONCLUSION: IL-17 levels showed significant change in RRMS patients after receiving high dose vitamin D3 for 12weeks. Cholecalciferol 94-104 interleukin 17A Homo sapiens 12-17 26126827-3 2015 Here, we demonstrate that calcitriol, the hormonally active form of vitamin D3, is an excellent candidate for transmission of Ptch/Smo interaction. Cholecalciferol 68-78 patched 1 Homo sapiens 126-130 26126827-3 2015 Here, we demonstrate that calcitriol, the hormonally active form of vitamin D3, is an excellent candidate for transmission of Ptch/Smo interaction. Cholecalciferol 68-78 smoothened, frizzled class receptor Homo sapiens 131-134 26205949-11 2015 Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P < 0.05), in comparison with their corresponding monotherapy groups. Cholecalciferol 17-27 catenin beta 1 Rattus norvegicus 91-103 26205949-11 2015 Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P < 0.05), in comparison with their corresponding monotherapy groups. Cholecalciferol 17-27 nitric oxide synthase 2 Rattus norvegicus 105-109 26205949-12 2015 CONCLUSIONS: Vitamin D3 and 5-FU synergise together and exhibit better anticancer effects by modulating Wnt/beta-catenin pathway, TGF-beta1 signals, iNOS, COX-2 and HSP-90. Cholecalciferol 13-23 catenin beta 1 Rattus norvegicus 108-120 26205949-12 2015 CONCLUSIONS: Vitamin D3 and 5-FU synergise together and exhibit better anticancer effects by modulating Wnt/beta-catenin pathway, TGF-beta1 signals, iNOS, COX-2 and HSP-90. Cholecalciferol 13-23 transforming growth factor, beta 1 Rattus norvegicus 130-139 26205949-12 2015 CONCLUSIONS: Vitamin D3 and 5-FU synergise together and exhibit better anticancer effects by modulating Wnt/beta-catenin pathway, TGF-beta1 signals, iNOS, COX-2 and HSP-90. Cholecalciferol 13-23 nitric oxide synthase 2 Rattus norvegicus 149-153 26205949-12 2015 CONCLUSIONS: Vitamin D3 and 5-FU synergise together and exhibit better anticancer effects by modulating Wnt/beta-catenin pathway, TGF-beta1 signals, iNOS, COX-2 and HSP-90. Cholecalciferol 13-23 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 155-160 26205949-11 2015 Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P < 0.05), in comparison with their corresponding monotherapy groups. Cholecalciferol 17-27 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 111-116 26205949-11 2015 Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P < 0.05), in comparison with their corresponding monotherapy groups. Cholecalciferol 17-27 heat shock protein 90 alpha family class A member 1 Rattus norvegicus 121-127 26205949-12 2015 CONCLUSIONS: Vitamin D3 and 5-FU synergise together and exhibit better anticancer effects by modulating Wnt/beta-catenin pathway, TGF-beta1 signals, iNOS, COX-2 and HSP-90. Cholecalciferol 13-23 heat shock protein 90 alpha family class A member 1 Rattus norvegicus 165-171 26205949-11 2015 Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P < 0.05), in comparison with their corresponding monotherapy groups. Cholecalciferol 17-27 dickkopf WNT signaling pathway inhibitor 1 Rattus norvegicus 174-179 26205949-11 2015 Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P < 0.05), in comparison with their corresponding monotherapy groups. Cholecalciferol 17-27 transforming growth factor, beta 1 Rattus norvegicus 181-190 26205949-11 2015 Mechanistically, vitamin D3/5-FU co-therapy significantly decreased the expression of Wnt, beta-catenin, iNOS, COX-2 and HSP-90 and significantly increased the expression of DKK-1, TGF-beta1, TGF-betaR2, smad4 (P < 0.05), in comparison with their corresponding monotherapy groups. Cholecalciferol 17-27 SMAD family member 4 Rattus norvegicus 204-209 25576857-2 2015 In this randomized controlled double blind trial, we examined whether vitamin D3 supplementation at 2500 IU/d (D) or placebo has differential effects on markers of insulin sensitivity and bone turnover in overweight/obese postmenopausal women during 6 weeks of caloric restriction (weight loss; WL, n = 39) compared to weight maintenance (WM, n = 37). Cholecalciferol 70-80 insulin Homo sapiens 164-171 25908506-7 2015 In stratified analyses, participants randomized to vitamin D3 who lost 5% to 10% of baseline weight, versus participants who gained weight/had no weight-loss, had significantly greater decreases in levels of IL6 compared with those randomized to placebo: absolute change -0.75 pg/mL (-17.2%), placebo versus -1.77 pg/mL (-37.3%), vitamin D, P = 0.004. Cholecalciferol 51-61 interleukin 6 Homo sapiens 208-211 25998127-4 2015 We found that de-differentiated Schwann cells could be re-differentiated in vitro into mature cells by treatment with an aldose reductase inhibitor, to reduce sorbitol levels, or with vitamin D3, to elevate Igf1 expression. Cholecalciferol 184-194 insulin like growth factor 1 Homo sapiens 207-211 25908506-9 2015 Effects of vitamin D3 supplementation on levels of IL1beta were inconsistent when stratified by weight loss. Cholecalciferol 11-21 interleukin 1 beta Homo sapiens 51-58 25908506-11 2015 In conclusion, vitamin D3 supplementation in combination with weight-loss of at least 5% of baseline weight was associated with significant reductions in levels of IL6. Cholecalciferol 15-25 interleukin 6 Homo sapiens 164-167 26002980-3 2015 In this study, we show that the CCR8-inducing factors are heat stable and protease resistant and include the vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 and PGE2. Cholecalciferol 109-119 C-C motif chemokine receptor 8 Homo sapiens 32-36 25707738-6 2015 The protocol was evaluated in anti-CD3/CD28-stimulated peripheral blood mononuclear cells (PBMCs) from vitamin D3- (n = 9) and placebo-treated (n = 9) CD patients. Cholecalciferol 103-113 CD28 molecule Homo sapiens 39-43 26002980-8 2015 Epidermal-derived vitamin D3 metabolites and PGs provide an essential cue for the localization of CCR8(+) immune surveillance T cells within healthy human skin. Cholecalciferol 18-28 C-C motif chemokine receptor 8 Homo sapiens 98-102 26158294-0 2015 p53 directly activates cystatin D/CST5 to mediate mesenchymal-epithelial transition: a possible link to tumor suppression by vitamin D3. Cholecalciferol 125-135 tumor protein p53 Homo sapiens 0-3 26158294-0 2015 p53 directly activates cystatin D/CST5 to mediate mesenchymal-epithelial transition: a possible link to tumor suppression by vitamin D3. Cholecalciferol 125-135 cystatin D Homo sapiens 23-33 26158294-11 2015 In addition, treatment with calcitriol, the active vitamin D3 metabolite, and simultaneous activation of p53 resulted in enhanced CST5 induction and increased repression of SNAIL, an epithelial-mesenchymal transition (EMT) inducing transcription factor. Cholecalciferol 51-61 cystatin D Homo sapiens 130-134 26158294-0 2015 p53 directly activates cystatin D/CST5 to mediate mesenchymal-epithelial transition: a possible link to tumor suppression by vitamin D3. Cholecalciferol 125-135 cystatin D Homo sapiens 34-38 26158294-11 2015 In addition, treatment with calcitriol, the active vitamin D3 metabolite, and simultaneous activation of p53 resulted in enhanced CST5 induction and increased repression of SNAIL, an epithelial-mesenchymal transition (EMT) inducing transcription factor. Cholecalciferol 51-61 snail family transcriptional repressor 1 Homo sapiens 173-178 26098102-2 2015 In this study, 7-dehydrocholesterol (7-DHC, a crucial precursor of vitamin D3) biosynthesis pathway was constructed in Saccharomyces cerevisiae BY4742 with endogenous ergosterol synthesis pathway blocked by knocking out the erg5 gene (encoding C-22 desaturase). Cholecalciferol 67-77 C-22 sterol desaturase Saccharomyces cerevisiae S288C 224-228 26158294-15 2015 In addition, they suggest that a combined treatment activating p53 and the vitamin D3 pathway may function via induction of CST5. Cholecalciferol 75-85 cystatin D Homo sapiens 124-128 25762594-7 2015 Vitamin D3 significantly promoted RANKL expression in ABCs and OPG in DPCs. Cholecalciferol 0-10 TNF superfamily member 11 Rattus norvegicus 34-39 26065916-0 2015 Vitamin D3 inhibits lipopolysaccharide-induced placental inflammation through reinforcing interaction between vitamin D receptor and nuclear factor kappa B p65 subunit. Cholecalciferol 0-10 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 110-128 26065916-0 2015 Vitamin D3 inhibits lipopolysaccharide-induced placental inflammation through reinforcing interaction between vitamin D receptor and nuclear factor kappa B p65 subunit. Cholecalciferol 0-10 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 133-155 26068234-4 2015 As placental cytochrome P450scc pleiotropic activity is implicated in the metabolism of free radical mediated arachidonic acid derivatives as well as multiple Vitamin D3 hydroxylations and progesterone synthesis, we propose that Vitamin D3 might act as a competitive inhibitor of placental cytochrome P450scc preventing the production of lipid peroxides or excess progesterone synthesis, both of which may contribute to the etiopathogenesis of preeclampsia. Cholecalciferol 159-169 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 13-31 25835512-3 2015 We conducted a clinical study to determine whether oral cholecalciferol supplementation would exert direct bioactivity in human skin through modulation of the VD receptor (VDR). Cholecalciferol 56-71 vitamin D receptor Homo sapiens 159-170 25835512-3 2015 We conducted a clinical study to determine whether oral cholecalciferol supplementation would exert direct bioactivity in human skin through modulation of the VD receptor (VDR). Cholecalciferol 56-71 vitamin D receptor Homo sapiens 172-175 25835512-11 2015 High-dose cholecalciferol supplementation raised serum VD metabolite levels concurrently with CYP24 mRNA and caspase-14 levels in the skin. Cholecalciferol 10-25 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 94-99 25835512-11 2015 High-dose cholecalciferol supplementation raised serum VD metabolite levels concurrently with CYP24 mRNA and caspase-14 levels in the skin. Cholecalciferol 10-25 caspase 14 Homo sapiens 109-119 25903858-0 2015 Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway. Cholecalciferol 0-10 mechanistic target of rapamycin kinase Homo sapiens 120-124 25827670-0 2015 Effect of vitamin D3 supplementation and influence of BsmI polymorphism of the VDR gene of the inflammatory profile and oxidative stress in elderly women with vitamin D insufficiency: Vitamin D3 megadose reduces inflammatory markers. Cholecalciferol 184-194 vitamin D receptor Homo sapiens 79-82 25777546-0 2015 Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Cholecalciferol 68-78 interferon alpha 1 Homo sapiens 86-96 25762594-7 2015 Vitamin D3 significantly promoted RANKL expression in ABCs and OPG in DPCs. Cholecalciferol 0-10 TNF receptor superfamily member 11B Rattus norvegicus 63-66 25814176-7 2015 Treatment of cells with 1,25(OH)2D3 increased the ability of macrophages to respond to stimuli and produce NO, but vitamin D3 alone did not activate macrophages and resulted in the down-regulation of CD86, MHC-II, CXCL8 and IL-1beta. Cholecalciferol 115-125 CD86 molecule Gallus gallus 200-204 25929726-11 2015 Based on these findings, it was concluded that the administration of cholecalciferol markedly attenuated the development of ISO-induced cardiac hypertrophy likely through downregulation of TNF-alpha /NF-kb/p65 signaling pathways. Cholecalciferol 69-84 tumor necrosis factor Rattus norvegicus 189-198 25929726-11 2015 Based on these findings, it was concluded that the administration of cholecalciferol markedly attenuated the development of ISO-induced cardiac hypertrophy likely through downregulation of TNF-alpha /NF-kb/p65 signaling pathways. Cholecalciferol 69-84 RELA proto-oncogene, NF-kB subunit Rattus norvegicus 200-205 25929726-11 2015 Based on these findings, it was concluded that the administration of cholecalciferol markedly attenuated the development of ISO-induced cardiac hypertrophy likely through downregulation of TNF-alpha /NF-kb/p65 signaling pathways. Cholecalciferol 69-84 synaptotagmin 1 Rattus norvegicus 206-209 25814176-7 2015 Treatment of cells with 1,25(OH)2D3 increased the ability of macrophages to respond to stimuli and produce NO, but vitamin D3 alone did not activate macrophages and resulted in the down-regulation of CD86, MHC-II, CXCL8 and IL-1beta. Cholecalciferol 115-125 interleukin 8-like 2 Gallus gallus 214-219 25639477-0 2015 Vitamin D3 metabolites enhance the NLRP3-dependent secretion of IL-1beta from human THP-1 monocytic cells. Cholecalciferol 0-10 NLR family pyrin domain containing 3 Homo sapiens 35-40 25869067-7 2015 Our results suggest that orally ingested dietary vitamin D3 in aged mice improves glucose metabolism as a GLP-1 enhancer. Cholecalciferol 49-59 glucagon Mus musculus 106-111 28377958-0 2015 Effect of vitamin D3-supplementation on bone markers (serum P1NP and CTX): A randomized, double blinded, placebo controlled trial among healthy immigrants living in Norway. Cholecalciferol 10-20 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 60-72 28377958-12 2015 The plasma PTH had decreased by a mean of - 1.97 pmol/L (95% CI: - 2.7, - 1.3, P < 0.0001) in the vitamin D3 group compared to placebo. Cholecalciferol 101-111 parathyroid hormone Homo sapiens 11-14 25741777-1 2015 Vitamin D3 is one of the few natural compounds that has, via its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) and the transcription factor vitamin D receptor (VDR), a direct effect on gene regulation. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 149-167 25741777-1 2015 Vitamin D3 is one of the few natural compounds that has, via its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) and the transcription factor vitamin D receptor (VDR), a direct effect on gene regulation. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 169-172 25639477-0 2015 Vitamin D3 metabolites enhance the NLRP3-dependent secretion of IL-1beta from human THP-1 monocytic cells. Cholecalciferol 0-10 interleukin 1 beta Homo sapiens 64-72 25639477-0 2015 Vitamin D3 metabolites enhance the NLRP3-dependent secretion of IL-1beta from human THP-1 monocytic cells. Cholecalciferol 0-10 GLI family zinc finger 2 Homo sapiens 84-89 25639477-2 2015 With metabolic enzymes for vitamin D3 activation and vitamin D receptors (VDR) now identified in a variety of immune cells, the active vitamin D3 metabolite 1,25(OH)2D3, is thought to possess immunomodulatory properties. Cholecalciferol 135-145 vitamin D receptor Homo sapiens 53-72 25639477-2 2015 With metabolic enzymes for vitamin D3 activation and vitamin D receptors (VDR) now identified in a variety of immune cells, the active vitamin D3 metabolite 1,25(OH)2D3, is thought to possess immunomodulatory properties. Cholecalciferol 135-145 vitamin D receptor Homo sapiens 74-77 25788584-14 2015 In line with the in vivo data, in vitro functional studies showed that cells treated with 25(OH)D3 for 24 h had increased VDR expression, and activated the mechanistic target of rapamycin (mTOR)/S6 kinase (S6K) pathway, enhanced Ki67 protein concentrations, and induced QM7 cell proliferation compared with untreated or cholecalciferol-treated cells. Cholecalciferol 320-335 serine/threonine-protein kinase mTOR Coturnix japonica 189-193 25569194-2 2015 This study evaluates the effects of vitamin D3 and vitamin K2 supplementation in conjunction with conventional periodontal therapy (scaling and root planing [SRP]) on gingival interleukin (IL)-1beta and IL-10, serum bone alkaline phosphatase (B-ALP) and tartrate-resistant acid phosphatase 5b (TRAP-5b), and calcium and alveolar bone levels in rats with experimentally induced periodontitis. Cholecalciferol 36-46 interleukin 10 Rattus norvegicus 203-208 25875760-2 2015 Using samples from a 5-month vitamin D3 intervention study (VitDmet), we recently reported that the expression of 12 VDR target genes in peripheral blood mononuclear cells (PBMCs) as well as 12 biochemical and clinical parameters of the study participants are significantly triggered by vitamin D3. Cholecalciferol 287-297 vitamin D receptor Homo sapiens 117-120 25727742-1 2015 CYP11A1 hydroxylates vitamin D3 producing 20S-hydroxyvitamin D3 [20(OH)D3] and 20S,23-dihydroxyvitamin D3 [20,23(OH)2D3] as the major and most characterized metabolites. Cholecalciferol 21-31 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 0-7 25466013-6 2015 Vitamin D3, used as a model nutraceutical, was successfully entrapped in the betalg/Lyso microspheres with an encapsulation efficiency of 90.8+-4.8%. Cholecalciferol 0-10 lysozyme Homo sapiens 84-88 25875760-1 2015 Vitamin D3 has transcriptome- and genome-wide effects and activates, via the binding of its metabolite 1alpha,25-dihydroxyvitamin D3 to the transcription factor vitamin D receptor (VDR), several hundred target genes. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 161-179 25875760-1 2015 Vitamin D3 has transcriptome- and genome-wide effects and activates, via the binding of its metabolite 1alpha,25-dihydroxyvitamin D3 to the transcription factor vitamin D receptor (VDR), several hundred target genes. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 181-184 25875760-2 2015 Using samples from a 5-month vitamin D3 intervention study (VitDmet), we recently reported that the expression of 12 VDR target genes in peripheral blood mononuclear cells (PBMCs) as well as 12 biochemical and clinical parameters of the study participants are significantly triggered by vitamin D3. Cholecalciferol 29-39 vitamin D receptor Homo sapiens 117-120 25849854-11 2015 These novel findings demonstrate for the first time that p63 variants are differentially expressed in naive hMSC (TAp63alpha,beta), are important during the osteoblastic differentiation of hMSC (TAp63gamma and DeltaNp63beta), and are differentially regulated by the vitamin D3 metabolites, 1alpha,25(OH)2D3 and 24R,25(OH)2D3. Cholecalciferol 266-276 tumor protein p63 Homo sapiens 57-60 25762621-0 2015 miR-145 mediates the antiproliferative and gene regulatory effects of vitamin D3 by directly targeting E2F3 in gastric cancer cells. Cholecalciferol 70-80 E2F transcription factor 3 S homeolog Xenopus laevis 103-107 25849854-11 2015 These novel findings demonstrate for the first time that p63 variants are differentially expressed in naive hMSC (TAp63alpha,beta), are important during the osteoblastic differentiation of hMSC (TAp63gamma and DeltaNp63beta), and are differentially regulated by the vitamin D3 metabolites, 1alpha,25(OH)2D3 and 24R,25(OH)2D3. Cholecalciferol 266-276 musculin Homo sapiens 108-112 25849854-11 2015 These novel findings demonstrate for the first time that p63 variants are differentially expressed in naive hMSC (TAp63alpha,beta), are important during the osteoblastic differentiation of hMSC (TAp63gamma and DeltaNp63beta), and are differentially regulated by the vitamin D3 metabolites, 1alpha,25(OH)2D3 and 24R,25(OH)2D3. Cholecalciferol 266-276 musculin Homo sapiens 189-193 25835492-1 2015 PURPOSE: To investigate the effect of vitamin D3 on hepatic Cytochrome P450 enzyme (CYP) 3A4 in patients with abnormal glucose regulation using the endogenous marker 4beta-hydroxycholesterol (4beta-OHC):cholesterol ratio. Cholecalciferol 38-48 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 60-92 25448738-1 2015 Vitamin D3 is a pleiotropic signaling molecule that has via activation of the transcription factor vitamin D receptor (VDR) a direct effect on the expression of more than 100 genes. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 99-117 25448738-1 2015 Vitamin D3 is a pleiotropic signaling molecule that has via activation of the transcription factor vitamin D receptor (VDR) a direct effect on the expression of more than 100 genes. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 119-122 25448743-4 2015 The cholesterol side chain cleavage enzyme CYP11A1 is expressed in skin and produces 20-hydroxyvitamin D3 (20OHD) as a major product of vitamin D3. Cholecalciferol 95-105 cytochrome P450, family 11, subfamily a, polypeptide 1 Mus musculus 43-50 25500071-3 2015 Treatment of adult human epidermal keratinocytes (HEKa) with 10muM cholecalciferol resulted in a rapid decrease in DHCR7 activity (19% of control activity at 2h). Cholecalciferol 67-82 7-dehydrocholesterol reductase Homo sapiens 115-120 25500068-0 2015 Synthesis and biological activities of vitamin D3 derivatives with cyanoalkyl side chain at C-2 position. Cholecalciferol 39-49 complement C2 Homo sapiens 92-95 25500068-1 2015 We synthesized and evaluated novel vitamin D3 derivatives with cyanoalkyl side chain at C-2 position on the basis of our previous research for 2alpha side chain which bears nitrogen atom-containing functional group. Cholecalciferol 35-45 complement C2 Homo sapiens 88-91 24166893-6 2015 These preliminary results, although not statistically significant, suggest that supplemental calcium and vitamin D3 may increase TGFbeta1 expression and shift TGFalpha expression downward from the differentiation to the proliferation zone in the crypts in the normal-appearing colorectal mucosa of sporadic colorectal adenoma patients, and support further investigation in a larger clinical trial. Cholecalciferol 105-115 transforming growth factor beta 1 Homo sapiens 129-137 25617667-1 2015 CYP11A1 hydroxylates the side chain of vitamin D3 (D3) in a sequential fashion [D3 20S(OH)D3 20,23(OH)2D3 17,20,23(OH)3D3], in an alternative to the classical pathway of activation [D3 25(OH)D3 1,25(OH)2D3]. Cholecalciferol 39-49 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 0-7 25501030-6 2015 Based on interaction studies of imatinib with the cytochrome P450 (CYP450) inhibitors VID400 and ketoconazole, it is proposed that imatinib may interfere with the vitamin D3 cascade due to its metabolism by CYP27B1, which is involved in vitamin D3 metabolism. Cholecalciferol 163-173 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 207-214 24166893-6 2015 These preliminary results, although not statistically significant, suggest that supplemental calcium and vitamin D3 may increase TGFbeta1 expression and shift TGFalpha expression downward from the differentiation to the proliferation zone in the crypts in the normal-appearing colorectal mucosa of sporadic colorectal adenoma patients, and support further investigation in a larger clinical trial. Cholecalciferol 105-115 transforming growth factor alpha Homo sapiens 159-167 25799416-1 2015 BACKGROUND: Vitamin D3 is a secoster oid that exerts its effect by binding to its nuclear receptor called vitamin D receptor (VDR), inducing apoptosis and thereby inhibiting cell proliferation in cancer cells. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 106-124 25799416-1 2015 BACKGROUND: Vitamin D3 is a secoster oid that exerts its effect by binding to its nuclear receptor called vitamin D receptor (VDR), inducing apoptosis and thereby inhibiting cell proliferation in cancer cells. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 126-129 25667505-2 2015 This important medical problem leads to the question, whether an insight into the genome-wide actions of the transcription factor vitamin D receptor (VDR) and its high affinity ligand 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) can help in a more global appreciation of the physiological impact of vitamin D3. Cholecalciferol 203-213 vitamin D receptor Homo sapiens 130-148 25479835-0 2015 Effects of 1,25-dihydroxyvitamin D3 and vitamin D3 on the expression of the vitamin d receptor in human skeletal muscle cells. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 76-94 25479835-2 2015 We conducted a series of studies to examine the (1) effect of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on VDR gene expression in human primary myoblasts, (2) effect of 16-week supplementation with vitamin D3 on intramuscular VDR gene expression in older women, and (3) association between serum 25-hydroxyvitamin D (25OHD) and intramuscular VDR protein concentration in older adults. Cholecalciferol 76-86 vitamin D receptor Homo sapiens 104-107 25479835-5 2015 Intramuscular VDR mRNA was significantly different from placebo after 16 weeks of vitamin D3 (1.2+-0.99; -3.2+-1.7, respectively; P=0.04). Cholecalciferol 82-92 vitamin D receptor Homo sapiens 14-17 25479835-9 2015 25OHD is associated with VDR protein and 16 weeks of supplementation with vitamin D3 resulted in a persistent increase in VDR gene expression of vitamin D3 in muscle tissue biopsies. Cholecalciferol 74-84 vitamin D receptor Homo sapiens 122-125 25479835-9 2015 25OHD is associated with VDR protein and 16 weeks of supplementation with vitamin D3 resulted in a persistent increase in VDR gene expression of vitamin D3 in muscle tissue biopsies. Cholecalciferol 145-155 vitamin D receptor Homo sapiens 122-125 25716812-2 2015 To express its biological action, active vitamin D3 (1alpha,25-dihydroxyvitamin D3) interacts with three proteins : vitamin D binding protein (DBP), vitamin D receptor (VDR), and CYP24A1. Cholecalciferol 41-51 GC vitamin D binding protein Homo sapiens 116-141 25716812-2 2015 To express its biological action, active vitamin D3 (1alpha,25-dihydroxyvitamin D3) interacts with three proteins : vitamin D binding protein (DBP), vitamin D receptor (VDR), and CYP24A1. Cholecalciferol 41-51 D-box binding PAR bZIP transcription factor Homo sapiens 143-146 25716812-2 2015 To express its biological action, active vitamin D3 (1alpha,25-dihydroxyvitamin D3) interacts with three proteins : vitamin D binding protein (DBP), vitamin D receptor (VDR), and CYP24A1. Cholecalciferol 41-51 vitamin D receptor Homo sapiens 149-167 25716812-2 2015 To express its biological action, active vitamin D3 (1alpha,25-dihydroxyvitamin D3) interacts with three proteins : vitamin D binding protein (DBP), vitamin D receptor (VDR), and CYP24A1. Cholecalciferol 41-51 vitamin D receptor Homo sapiens 169-172 25716812-2 2015 To express its biological action, active vitamin D3 (1alpha,25-dihydroxyvitamin D3) interacts with three proteins : vitamin D binding protein (DBP), vitamin D receptor (VDR), and CYP24A1. Cholecalciferol 41-51 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 179-186 25716813-3 2015 Meanwhile, the active form of vitamin D3, 1alpha, 25-dihydroxyvitamin D3 [1alpha, 25 (OH) 2D3], upregulates expression of receptor activator of nuclear factor-kappaB ligand (RANKL) in osteoblastic cells. Cholecalciferol 30-40 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 122-172 25716813-3 2015 Meanwhile, the active form of vitamin D3, 1alpha, 25-dihydroxyvitamin D3 [1alpha, 25 (OH) 2D3], upregulates expression of receptor activator of nuclear factor-kappaB ligand (RANKL) in osteoblastic cells. Cholecalciferol 30-40 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 174-179 25716813-8 2015 However, daily administration of an active vitamin D3 analog (eldecalcitol, an osteoporotic therapeutic drug) for a month suppressed RANKL expression in osteoblasts, resulting in suppression of bone resorption. Cholecalciferol 43-53 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 133-138 25866638-0 2015 TSLP is differentially regulated by vitamin D3 and cytokines in human skin. Cholecalciferol 36-46 thymic stromal lymphopoietin Homo sapiens 0-4 25201000-9 2015 CONCLUSIONS: A definite alteration was seen in vitamin D3-inactivating CYP24A1 gene activity in PTC compared to their normal tissues on a relatively large patient population. Cholecalciferol 47-57 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 71-78 26005829-13 2015 A cholecalciferol load was administered, with significant descent of PTH. Cholecalciferol 2-17 parathyroid hormone Homo sapiens 69-72 25773149-0 2015 Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta. Cholecalciferol 0-10 LAP Homo sapiens 103-106 25773149-0 2015 Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta. Cholecalciferol 0-10 transforming growth factor beta 1 Homo sapiens 111-119 25773149-9 2015 CONCLUSIONS: We showed increased serum latency activated peptide (LAP) of TGF-beta levels in MS patients treated with vitamin D3. Cholecalciferol 118-128 LAP Homo sapiens 66-69 25773149-9 2015 CONCLUSIONS: We showed increased serum latency activated peptide (LAP) of TGF-beta levels in MS patients treated with vitamin D3. Cholecalciferol 118-128 transforming growth factor beta 1 Homo sapiens 74-82 25561293-0 2015 Vitamin D3 as a novel regulator of basic fibroblast growth factor in chronic rhinosinusitis with nasal polyposis. Cholecalciferol 0-10 fibroblast growth factor 2 Homo sapiens 35-65 25441291-5 2015 Atopic dermatitis and increased serum TSLP concentrations were induced by topical application of the vitamin D3 analog MC903. Cholecalciferol 101-111 thymic stromal lymphopoietin Homo sapiens 38-42 25187428-1 2015 BACKGROUND AND AIM: Vitamin D3 improves portal hypertension (PH) through the activation of vitamin D receptor (VDR) and calcium-sensing receptor (CaSR) in cirrhotic rats. Cholecalciferol 20-30 vitamin D receptor Rattus norvegicus 91-109 25187428-1 2015 BACKGROUND AND AIM: Vitamin D3 improves portal hypertension (PH) through the activation of vitamin D receptor (VDR) and calcium-sensing receptor (CaSR) in cirrhotic rats. Cholecalciferol 20-30 vitamin D receptor Rattus norvegicus 111-114 25187428-1 2015 BACKGROUND AND AIM: Vitamin D3 improves portal hypertension (PH) through the activation of vitamin D receptor (VDR) and calcium-sensing receptor (CaSR) in cirrhotic rats. Cholecalciferol 20-30 calcium-sensing receptor Rattus norvegicus 120-144 25187428-1 2015 BACKGROUND AND AIM: Vitamin D3 improves portal hypertension (PH) through the activation of vitamin D receptor (VDR) and calcium-sensing receptor (CaSR) in cirrhotic rats. Cholecalciferol 20-30 calcium-sensing receptor Rattus norvegicus 146-150 25187428-8 2015 In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions. Cholecalciferol 19-29 renin Rattus norvegicus 78-83 25187428-8 2015 In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions. Cholecalciferol 19-29 angiotensinogen Rattus norvegicus 153-167 25187428-8 2015 In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions. Cholecalciferol 19-29 angiotensinogen Rattus norvegicus 169-174 25187428-8 2015 In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions. Cholecalciferol 19-29 calcium-sensing receptor Rattus norvegicus 188-192 25187428-8 2015 In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions. Cholecalciferol 19-29 angiotensinogen Rattus norvegicus 202-207 25187428-8 2015 In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions. Cholecalciferol 19-29 angiotensinogen Rattus norvegicus 202-207 25187428-8 2015 In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions. Cholecalciferol 19-29 vitamin D receptor Rattus norvegicus 358-361 25187428-8 2015 In cirrhotic rats, vitamin D3 administration decreasing IHR by inhibiting the renin-angiotensin system, hepatic oxidative stress, inflammation/fibrosis, angiotensin II (ANGII) production, CaSR-mediated ANGII hyperresponsiveness, ANGII-induced hepatic stellate cells contraction, and correcting hepatic endothelial dysfunction through upregulation of hepatic VDR, CaSR, and endothelial nitric oxide synthase expressions. Cholecalciferol 19-29 calcium-sensing receptor Rattus norvegicus 363-367 26038696-8 2015 Furthermore, we evaluated the metabolism of ED-71 by recombinant CYP24A1, which plays an important role in the metabolism of the active form of vitamin D3 (1alpha,25(OH)2D3) and its analogs. Cholecalciferol 144-154 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 65-72 25667505-2 2015 This important medical problem leads to the question, whether an insight into the genome-wide actions of the transcription factor vitamin D receptor (VDR) and its high affinity ligand 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) can help in a more global appreciation of the physiological impact of vitamin D3. Cholecalciferol 203-213 vitamin D receptor Homo sapiens 150-153 25416412-6 2015 Furthermore, our results showed that enhancement of metformin"s chemopreventive effects by vitamin D3 was associated with downregulation of S6P expression, via the AMPK (IGFI)/mTOR pathway. Cholecalciferol 91-101 mechanistic target of rapamycin kinase Rattus norvegicus 176-180 25416412-7 2015 In addition, enhancement of vitamin D3"s chemopreventive effects by metformin was associated with inhibition of the protein expressions of c-Myc and Cyclin D1, via the vitamin D receptor/beta-catenin pathway. Cholecalciferol 28-38 MYC proto-oncogene, bHLH transcription factor Rattus norvegicus 139-144 25416412-7 2015 In addition, enhancement of vitamin D3"s chemopreventive effects by metformin was associated with inhibition of the protein expressions of c-Myc and Cyclin D1, via the vitamin D receptor/beta-catenin pathway. Cholecalciferol 28-38 cyclin D1 Rattus norvegicus 149-158 25563481-8 2015 The release of proinflammatory interleukin (IL)-6 was decreased and the release of anti-inflammatory IL-10 was increased in mice fed a diet with high vitamin D3 supplementation. Cholecalciferol 150-160 interleukin 10 Mus musculus 101-106 25644349-2 2015 OBJECTIVE: The objective of the study was to determine the effect of 2 doses of cholecalciferol (vitamin D3) supplementation on insulin action (Si) and pancreatic beta-cell function in obese adolescents. Cholecalciferol 80-95 insulin Homo sapiens 128-135 25644349-2 2015 OBJECTIVE: The objective of the study was to determine the effect of 2 doses of cholecalciferol (vitamin D3) supplementation on insulin action (Si) and pancreatic beta-cell function in obese adolescents. Cholecalciferol 97-107 insulin Homo sapiens 128-135 25458314-6 2015 PBA also increases mRNA expression of the vitamin D3 regulated genes CYP24A1 and CD14. Cholecalciferol 42-52 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 69-76 25458314-6 2015 PBA also increases mRNA expression of the vitamin D3 regulated genes CYP24A1 and CD14. Cholecalciferol 42-52 CD14 molecule Homo sapiens 81-85 25530010-10 2015 High vitamin D3 and calcium intakes significantly increased bone Ca and P content and relative bone weight in DIO mice, which was accompanied by an increase in 1,25(OH)2D3 and a decrease in PTH and osteocalcin concentrations in blood. Cholecalciferol 5-15 parathyroid hormone Mus musculus 190-193 25530010-10 2015 High vitamin D3 and calcium intakes significantly increased bone Ca and P content and relative bone weight in DIO mice, which was accompanied by an increase in 1,25(OH)2D3 and a decrease in PTH and osteocalcin concentrations in blood. Cholecalciferol 5-15 bone gamma-carboxyglutamate protein 2 Mus musculus 198-209 26413188-6 2015 Moreover, we uncovered yet another paradox; the increasing CMM incidences significantly correlate with decreasing personal annual UV dose, a proxy for low vitamin D3 levels. Cholecalciferol 155-165 dysplastic nevus syndrome Homo sapiens 59-62 26413188-9 2015 Thus, we propose the 2 major risk factors for getting CMM are intermittent UV exposures that result in low cutaneous levels of vitamin D3 and possibly viral infection. Cholecalciferol 127-137 dysplastic nevus syndrome Homo sapiens 54-57 25271011-2 2015 This study investigated whether high-dose vitamin D3 given once to healthy adults before winter will (1) prevent the wintertime decline in vitamin D status, (2) promote vitamin D sufficiency 1 year following the dose and (3) prevent the rise of parathyroid hormone (PTH) concentrations. Cholecalciferol 42-52 parathyroid hormone Homo sapiens 245-264 25997252-0 2015 Synergistic antitumor activity of vitamin D3 combined with metformin in human breast carcinoma MDA-MB-231 cells involves m-TOR related signaling pathways. Cholecalciferol 34-44 RAR related orphan receptor C Homo sapiens 123-126 25527766-0 2015 Common variants in CYP2R1 and GC genes are both determinants of serum 25-hydroxyvitamin D concentrations after UVB irradiation and after consumption of vitamin D3-fortified bread and milk during winter in Denmark. Cholecalciferol 152-162 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 19-25 25527766-2 2015 In the Food with vitamin D (VitmaD) study, we showed that common genetic variants rs10741657 and rs10766197 in 25-hydroxylase (CYP2R1) and rs842999 and rs4588 in vitamin D binding protein (GC) predict 25(OH)D concentrations at late summer and after 6-mo consumption of cholecalciferol (vitamin D3)-fortified bread and milk. Cholecalciferol 269-284 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 127-133 25527766-2 2015 In the Food with vitamin D (VitmaD) study, we showed that common genetic variants rs10741657 and rs10766197 in 25-hydroxylase (CYP2R1) and rs842999 and rs4588 in vitamin D binding protein (GC) predict 25(OH)D concentrations at late summer and after 6-mo consumption of cholecalciferol (vitamin D3)-fortified bread and milk. Cholecalciferol 286-296 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 127-133 25527766-9 2015 CONCLUSION: Common genetic variants in the CYP2R1 and GC genes modify 25(OH)D concentrations in the same manner after artificial UVB-induced vitamin D and consumption of vitamin D3-fortified bread and milk. Cholecalciferol 170-180 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 43-49 25538061-0 2015 Identification of two populations of osteoarthritic osteoblasts according to the 1,25[OH]2 vitamin D3 potency to stimulate osteocalcin. Cholecalciferol 91-101 bone gamma-carboxyglutamate protein Homo sapiens 123-134 26218841-6 2015 PBA and the active form of vitamin D3 (1,25[OH]2D3), separately or particularly in combination, were able to overcome Mtb-induced suppression of LL-37 expression. Cholecalciferol 27-37 cathelicidin antimicrobial peptide Homo sapiens 145-150 26064953-7 2015 Vitamin D3 supplementation decreased the calcium entry through calcium release activated calcium (CRAC) channels and purinergic P2X7 channels. Cholecalciferol 0-10 purinergic receptor P2X 7 Homo sapiens 128-132 26064953-10 2015 Vitamin D3 supplementation had a beneficial effect on [Ca(2+)]i decreasing calcium entry via CRAC and P2X7 channels and reducing P2X7 receptors expression. Cholecalciferol 0-10 purinergic receptor P2X 7 Homo sapiens 102-106 26064953-10 2015 Vitamin D3 supplementation had a beneficial effect on [Ca(2+)]i decreasing calcium entry via CRAC and P2X7 channels and reducing P2X7 receptors expression. Cholecalciferol 0-10 purinergic receptor P2X 7 Homo sapiens 129-133 25429711-5 2015 Cholecalciferol, the precursor of active vitamin D3, is a strong inhibitor of Shh-Gli signaling and may have growth inhibitory effects in renal cancer. Cholecalciferol 0-15 sonic hedgehog signaling molecule Homo sapiens 78-81 25429711-5 2015 Cholecalciferol, the precursor of active vitamin D3, is a strong inhibitor of Shh-Gli signaling and may have growth inhibitory effects in renal cancer. Cholecalciferol 0-15 GLI family zinc finger 1 Homo sapiens 82-85 25429711-5 2015 Cholecalciferol, the precursor of active vitamin D3, is a strong inhibitor of Shh-Gli signaling and may have growth inhibitory effects in renal cancer. Cholecalciferol 41-51 sonic hedgehog signaling molecule Homo sapiens 78-81 25429711-5 2015 Cholecalciferol, the precursor of active vitamin D3, is a strong inhibitor of Shh-Gli signaling and may have growth inhibitory effects in renal cancer. Cholecalciferol 41-51 GLI family zinc finger 1 Homo sapiens 82-85 25872112-0 2015 Vitamin D3 Treatment Decreases Frequencies of CD16-Positive and TNF-alpha-Secreting Monocytes in Asthmatic Patients. Cholecalciferol 0-10 Fc gamma receptor IIIa Homo sapiens 46-50 25584176-0 2015 Effect of vitamin D3 supplementation on TNF-alpha serum level and disease activity index in Iranian IBD patients. Cholecalciferol 10-20 tumor necrosis factor Homo sapiens 40-49 25584176-1 2015 AIM: The aim of the study was to assess the effectiveness of vitamin D3 [1, 25(OH)2D3] treatment in IBD with regard to tumor necrosis factor-alpha (TNF-alpha) serum level and clinical disease activity index (CDAI). Cholecalciferol 61-71 tumor necrosis factor Homo sapiens 119-146 25584176-1 2015 AIM: The aim of the study was to assess the effectiveness of vitamin D3 [1, 25(OH)2D3] treatment in IBD with regard to tumor necrosis factor-alpha (TNF-alpha) serum level and clinical disease activity index (CDAI). Cholecalciferol 61-71 tumor necrosis factor Homo sapiens 148-157 25584176-12 2015 CONCLUSION: Oral supplementation vitamin D3 significantly increased serum vitamin D levels and insignificantly reduced serum TNF-alpha level. Cholecalciferol 33-43 tumor necrosis factor Homo sapiens 125-134 25872112-0 2015 Vitamin D3 Treatment Decreases Frequencies of CD16-Positive and TNF-alpha-Secreting Monocytes in Asthmatic Patients. Cholecalciferol 0-10 tumor necrosis factor Homo sapiens 64-73 25872112-2 2015 Here, we wished to analyze whether the active form of vitamin D, i.e. vitamin D3, referred to as 1alpha,25-dihydroxyvitamin D3 [1,25-(OH)2D3] can exert GC-like proapoptotic effects on CD16-positive monocytes and thus decrease the proinflammatory potential of these cells. Cholecalciferol 70-80 Fc gamma receptor IIIa Homo sapiens 184-188 26401986-11 2015 CONCLUSION: IL-10 levels increased significantly in RRMS patients after taking high-dose vitamin D3 for 3 months. Cholecalciferol 89-99 interleukin 10 Homo sapiens 12-17 25628655-0 2015 The Associations of Novel Vitamin D3 Metabolic Gene CYP27A1 Polymorphism, Adiponectin/Leptin Ratio, and Metabolic Syndrome in Middle-Aged Taiwanese Males. Cholecalciferol 26-36 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 52-59 25628655-2 2015 Both vitamin D3 and adipocytokines (especially adiponectin and leptin) have a great impact on CVD and MetS. Cholecalciferol 5-15 adiponectin, C1Q and collagen domain containing Homo sapiens 47-58 25628655-2 2015 Both vitamin D3 and adipocytokines (especially adiponectin and leptin) have a great impact on CVD and MetS. Cholecalciferol 5-15 leptin Homo sapiens 63-69 25628655-3 2015 In vitamin D3 metabolism, the vitamin D3 25-hydroxylase (CYP27A1) and 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) are two key enzymes. Cholecalciferol 3-13 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 30-55 25628655-3 2015 In vitamin D3 metabolism, the vitamin D3 25-hydroxylase (CYP27A1) and 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) are two key enzymes. Cholecalciferol 3-13 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 57-64 25628655-3 2015 In vitamin D3 metabolism, the vitamin D3 25-hydroxylase (CYP27A1) and 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) are two key enzymes. Cholecalciferol 3-13 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 70-110 25628655-3 2015 In vitamin D3 metabolism, the vitamin D3 25-hydroxylase (CYP27A1) and 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) are two key enzymes. Cholecalciferol 3-13 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 112-119 25236689-4 2015 Pups maintained on milk from lactating heterozygous (GALC(twi/+) ) mothers that were fed a vitamin D3-supplemented diet until weaning and then fed a vitamin D3-supplemented diet demonstrated delayed body weight loss and development of disease in twi mice. Cholecalciferol 91-101 galactosylceramidase Mus musculus 53-57 25236689-4 2015 Pups maintained on milk from lactating heterozygous (GALC(twi/+) ) mothers that were fed a vitamin D3-supplemented diet until weaning and then fed a vitamin D3-supplemented diet demonstrated delayed body weight loss and development of disease in twi mice. Cholecalciferol 91-101 galactosylceramidase Mus musculus 58-61 25236689-4 2015 Pups maintained on milk from lactating heterozygous (GALC(twi/+) ) mothers that were fed a vitamin D3-supplemented diet until weaning and then fed a vitamin D3-supplemented diet demonstrated delayed body weight loss and development of disease in twi mice. Cholecalciferol 149-159 galactosylceramidase Mus musculus 53-57 25236689-4 2015 Pups maintained on milk from lactating heterozygous (GALC(twi/+) ) mothers that were fed a vitamin D3-supplemented diet until weaning and then fed a vitamin D3-supplemented diet demonstrated delayed body weight loss and development of disease in twi mice. Cholecalciferol 149-159 galactosylceramidase Mus musculus 246-249 25015343-5 2014 METHODS AND RESULTS: In healthy volunteers, supplementation of vitamin D3 (4000 IU cholecalciferol per day) increased the number of circulating CD45-CD117+Sca1+Flk1+ angiogenic myeloid cells, which are thought to promote vascular regeneration. Cholecalciferol 63-73 protein tyrosine phosphatase, receptor type, C Mus musculus 144-148 25460500-9 2014 Thus, BRCA1 expression is critical for mediating the biological impact of vitamin D3 in breast tumor cells. Cholecalciferol 74-84 BRCA1 DNA repair associated Homo sapiens 6-11 24451003-0 2014 Effects of vitamin D3 stimulation of thioredoxin-interacting protein in hepatocellular carcinoma. Cholecalciferol 11-21 thioredoxin interacting protein Homo sapiens 37-68 24451003-4 2014 In addition, we wanted to determine the effects of vitamin D3-induced TXNIP stimulation in HCC-derived cell lines. Cholecalciferol 51-61 thioredoxin interacting protein Homo sapiens 70-75 24451003-8 2014 RESULTS: TXNIP expression levels were low in HCC cell lines, and vitamin D3 stimulated TXNIP expression in vitro. Cholecalciferol 65-75 thioredoxin interacting protein Homo sapiens 87-92 24451003-9 2014 In HCC cells transfected with a TXNIP expression vector or treated with exogenous vitamin D3, there was a reduction in cell proliferation and an increase in apoptosis. Cholecalciferol 82-92 thioredoxin interacting protein Homo sapiens 32-37 24451003-13 2014 Vitamin D3 stimulates TXNIP expression, resulting in diminished proliferation and enhanced apoptosis. Cholecalciferol 0-10 thioredoxin interacting protein Homo sapiens 22-27 24451003-15 2014 These findings suggest that stimulation of TXNIP expression, by factors such as vitamin D3, may attenuate carcinogenesis in patients with chronic liver disease. Cholecalciferol 80-90 thioredoxin interacting protein Homo sapiens 43-48 24777663-0 2014 The paracrine feedback loop between vitamin D3 (1,25(OH)2D3) and PTHrP in prehypertrophic chondrocytes. Cholecalciferol 36-46 parathyroid hormone-like peptide Mus musculus 65-70 24777663-1 2014 The endocrine feedback loop between vitamin D3(1,25(OH)2D3) and parathyroid hormone (PTH) plays a central role in skeletal development. Cholecalciferol 36-46 parathyroid hormone Mus musculus 64-83 24777663-1 2014 The endocrine feedback loop between vitamin D3(1,25(OH)2D3) and parathyroid hormone (PTH) plays a central role in skeletal development. Cholecalciferol 36-46 parathyroid hormone Mus musculus 85-88 25376735-8 2014 DISCUSSION: We previously reported that the intensive cholecalciferol treatment (100 000 IU every 2 weeks for 2 months) was safe in RTR. Cholecalciferol 54-69 nuclear receptor subfamily 6 group A member 1 Homo sapiens 132-135 25236584-0 2014 Vitamin D3 metabolite calcidiol primes human dendritic cells to promote the development of immunomodulatory IL-10-producing T cells. Cholecalciferol 0-10 interleukin 10 Homo sapiens 108-113 25297969-8 2014 A vitamin D3-deficient diet normalized the serum 1,25 (OH)2 vitamin D3 level in kl/kl mice and enhanced UUO-induced RTF and TGF-beta/Smad3 signaling. Cholecalciferol 2-12 transforming growth factor, beta 1 Mus musculus 124-132 25297969-8 2014 A vitamin D3-deficient diet normalized the serum 1,25 (OH)2 vitamin D3 level in kl/kl mice and enhanced UUO-induced RTF and TGF-beta/Smad3 signaling. Cholecalciferol 2-12 SMAD family member 3 Mus musculus 133-138 25130438-6 2014 The catalytic efficiency of bovine CYP11A1 for metabolism of L3 dissolved in 2-hydroxypropyl-beta-cyclodextrin was approximately 20% of that reported for vitamin D3 and cholesterol. Cholecalciferol 154-164 cholesterol side-chain cleavage enzyme, mitochondrial Bos taurus 35-42 24269662-10 2014 In summary, our results suggest that abiraterone inhibits the CYP3A4-mediated inactivation of active vitamin D3 in human liver and intestine, potentially providing additional anti-cancer benefits to prostate cancer patients. Cholecalciferol 101-111 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 62-68 25138634-1 2014 20-Hydroxyvitamin D3 [20(OH)D3], the major product of CYP11A1 action on vitamin D3, is biologically active and like 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] can inhibit proliferation and promote differentiation of a range of cells, and has anti-inflammatory properties. Cholecalciferol 10-20 cytochrome P450, family 11, subfamily a, polypeptide 1 Mus musculus 54-61 24975273-4 2014 Using adipose tissue biopsy samples from 47 participants of a 5-month vitamin D3 intervention study, we demonstrated that all four primary VDR target genes can serve as biomarkers for the vitamin D3 responsiveness of human individuals. Cholecalciferol 70-80 vitamin D receptor Homo sapiens 139-142 24975273-4 2014 Using adipose tissue biopsy samples from 47 participants of a 5-month vitamin D3 intervention study, we demonstrated that all four primary VDR target genes can serve as biomarkers for the vitamin D3 responsiveness of human individuals. Cholecalciferol 188-198 vitamin D receptor Homo sapiens 139-142 24975273-7 2014 Using human adipocytes as examples, we show that such ubiquitous VDR target genes can be used as markers for the individual"s response to a supplementation with vitamin D3. Cholecalciferol 161-171 vitamin D receptor Homo sapiens 65-68 25089537-0 2014 Prenatal vitamin D3 supplementation suppresses LL-37 peptide expression in ex vivo activated neonatal macrophages but not their killing capacity. Cholecalciferol 9-19 cathelicidin antimicrobial peptide Homo sapiens 47-52 25230725-1 2014 BACKGROUND: In vitro studies have shown that the active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), can regulate differentiation of CD4+ T cells by inhibiting Th1 and Th17 cell differentiation and promoting Th2 and Treg cell differentiation. Cholecalciferol 64-74 negative elongation factor complex member C/D Homo sapiens 180-183 25380286-8 2014 Vitamin D3 inhibited LPS-induced ROS and DNA damage and were associated with a decline in TNF-alpha and NFkappaB in epithelial cells. Cholecalciferol 0-10 tumor necrosis factor Homo sapiens 90-99 25380286-8 2014 Vitamin D3 inhibited LPS-induced ROS and DNA damage and were associated with a decline in TNF-alpha and NFkappaB in epithelial cells. Cholecalciferol 0-10 nuclear factor kappa B subunit 1 Homo sapiens 104-112 25139050-8 2014 In examining cellular cross-talk ex vivo, we show that ligand-dependent VDR signaling in adipocytes significantly inhibits mammary epithelial cell growth in part through the vitamin D3-dependent production of the cytokine IL-6. Cholecalciferol 174-184 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 72-75 25139050-8 2014 In examining cellular cross-talk ex vivo, we show that ligand-dependent VDR signaling in adipocytes significantly inhibits mammary epithelial cell growth in part through the vitamin D3-dependent production of the cytokine IL-6. Cholecalciferol 174-184 interleukin 6 Mus musculus 222-226 25139050-9 2014 Collectively, these studies delineate independent roles for vitamin D3-dependent VDR signaling in mammary adipocytes and epithelial cells in controlling pubertal mammary gland development. Cholecalciferol 60-70 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 81-84 25729548-0 2014 Vitamin D3 influence the Th1/Th2 ratio in C57BL/6 induced model of experimental autoimmune encephalomyelitis. Cholecalciferol 0-10 negative elongation factor complex member C/D Homo sapiens 25-28 25729548-12 2014 The level of TNF-alpha but not IL-10 significantly decreased following vitamin D3 administration. Cholecalciferol 71-81 tumor necrosis factor Homo sapiens 13-22 24960544-0 2014 Activation of FGF-23 mediated vitamin D degradative pathways by cholecalciferol. Cholecalciferol 64-79 fibroblast growth factor 23 Homo sapiens 14-20 24960544-2 2014 OBJECTIVE: The aim was to investigate if FGF-23 and 24,25(OH)2D can guide cholecalciferol replacement. Cholecalciferol 74-89 fibroblast growth factor 23 Homo sapiens 41-47 24960544-3 2014 DESIGN: Oral cholecalciferol (10,000 IU weekly) administered to subjects with 25(OH)D levels < 20 etag/mL and eGFR > 60 mL/min/1.73 m(2) (n = 25), chronic kidney disease (CKD) (n = 27), or end stage renal disease (ESRD) (n = 14). Cholecalciferol 13-28 CD59 molecule (CD59 blood group) Homo sapiens 129-134 24960544-7 2014 Cholecalciferol increased serum FGF-23 levels only in normal subjects (44 +- 57 etag/mL, P = .01). Cholecalciferol 0-15 fibroblast growth factor 23 Homo sapiens 32-38 24960544-11 2014 In addition, catabolism of 25(OH)D may also contribute to the low circulating vitamin D levels in CKD, since elevations of FGF-23 in CKD are associated with increased 24,25(OH)2D after cholecalciferol administration. Cholecalciferol 185-200 fibroblast growth factor 23 Homo sapiens 123-129 25070320-0 2014 Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial. Cholecalciferol 68-78 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 20-26 25070320-0 2014 Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial. Cholecalciferol 68-78 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 28-35 25070320-0 2014 Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial. Cholecalciferol 68-78 vitamin D receptor Homo sapiens 41-44 25070320-10 2014 The increase in [25(OH)D] due to vitamin D3 supplementation was modified by genotypes at rs10766197 near CYP2R1, rs6013897 near CYP24A1, and rs7968585 near VDR. Cholecalciferol 33-43 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 105-111 25070320-10 2014 The increase in [25(OH)D] due to vitamin D3 supplementation was modified by genotypes at rs10766197 near CYP2R1, rs6013897 near CYP24A1, and rs7968585 near VDR. Cholecalciferol 33-43 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 128-135 25070320-10 2014 The increase in [25(OH)D] due to vitamin D3 supplementation was modified by genotypes at rs10766197 near CYP2R1, rs6013897 near CYP24A1, and rs7968585 near VDR. Cholecalciferol 33-43 vitamin D receptor Homo sapiens 156-159 25070320-11 2014 CONCLUSIONS: The increase in [25(OH)D] attributable to vitamin D3 supplementation may vary according to common genetic differences in vitamin D 25-hydroxylase (CYP2R1), 24-hydroxylase (CYP24A1), and the vitamin D receptor (VDR) genes. Cholecalciferol 55-65 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 134-158 25070320-11 2014 CONCLUSIONS: The increase in [25(OH)D] attributable to vitamin D3 supplementation may vary according to common genetic differences in vitamin D 25-hydroxylase (CYP2R1), 24-hydroxylase (CYP24A1), and the vitamin D receptor (VDR) genes. Cholecalciferol 55-65 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 160-166 25070320-11 2014 CONCLUSIONS: The increase in [25(OH)D] attributable to vitamin D3 supplementation may vary according to common genetic differences in vitamin D 25-hydroxylase (CYP2R1), 24-hydroxylase (CYP24A1), and the vitamin D receptor (VDR) genes. Cholecalciferol 55-65 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 185-192 25070320-11 2014 CONCLUSIONS: The increase in [25(OH)D] attributable to vitamin D3 supplementation may vary according to common genetic differences in vitamin D 25-hydroxylase (CYP2R1), 24-hydroxylase (CYP24A1), and the vitamin D receptor (VDR) genes. Cholecalciferol 55-65 vitamin D receptor Homo sapiens 203-221 25070320-11 2014 CONCLUSIONS: The increase in [25(OH)D] attributable to vitamin D3 supplementation may vary according to common genetic differences in vitamin D 25-hydroxylase (CYP2R1), 24-hydroxylase (CYP24A1), and the vitamin D receptor (VDR) genes. Cholecalciferol 55-65 vitamin D receptor Homo sapiens 223-226 24176765-1 2014 Research over the last decade has revealed that CYP11A1 can hydroxylate the side chain of vitamin D3 at carbons 17, 20, 22 and 23 to produce at least 10 metabolites, with 20(OH)D3, 20,23(OH)2D3, 20,22(OH)2D3, 17,20(OH)2D3 and 17,20,23(OH)3D3 being the main products. Cholecalciferol 90-100 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 48-55 24176765-3 2014 The placenta, adrenal glands and epidermal keratinocytes have been shown to metabolize vitamin D3 via this CYP11A1-mediated pathway that is modified by the activity of CYP27B1, with 20(OH)D3 (the major metabolite), 20,23(OH)2D3, 1,20(OH)2D3, 1,20,23(OH)3D3 and 17,20,23(OH)3D3 being detected, defining these secosteroids as endogenous regulators/natural products. Cholecalciferol 87-97 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 107-114 24176765-3 2014 The placenta, adrenal glands and epidermal keratinocytes have been shown to metabolize vitamin D3 via this CYP11A1-mediated pathway that is modified by the activity of CYP27B1, with 20(OH)D3 (the major metabolite), 20,23(OH)2D3, 1,20(OH)2D3, 1,20,23(OH)3D3 and 17,20,23(OH)3D3 being detected, defining these secosteroids as endogenous regulators/natural products. Cholecalciferol 87-97 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 168-175 25109309-3 2014 The present study investigated the effect of derivatives of vitamin D3 on GGT activity in LLC-PK1 porcine renal tubular epithelial cells in order to analyze the biochemical basis of bone metabolism-associated alterations in GGT activity in the kidney. Cholecalciferol 60-70 glutathione hydrolase 1 proenzyme Sus scrofa 74-77 25135648-7 2014 In conclusion, our data support that DMF stimulates Nrf2 activity to attenuate hyperphosphatamia in vitro or Vitamin D3-induced in vivo vascular calcification, which would be a beneficial effect on vascular diseases induced by oxidative stress such as vascular calcification. Cholecalciferol 109-119 nuclear factor, erythroid derived 2, like 2 Mus musculus 52-56 25247786-8 2014 Male offspring exposed to continuous 25 IU vitamin D3/kg diet had lower (p < 0.001) colonic VDR expression and those exposed only to low vitamin D3 until weaning had higher serum IL-6. Cholecalciferol 43-53 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 95-98 25247786-8 2014 Male offspring exposed to continuous 25 IU vitamin D3/kg diet had lower (p < 0.001) colonic VDR expression and those exposed only to low vitamin D3 until weaning had higher serum IL-6. Cholecalciferol 140-150 interleukin 6 Mus musculus 182-186 25356124-1 2014 OBJECTIVES: To measure the effect of vitamin D3 (VitD) supplementation on erythrocyte indices, serum and kidney erythropoietin (EPO) in normal rats treated with Pegylated interferon-alpha (Peg-INF-alpha) and ribavirin (RBV). Cholecalciferol 37-47 erythropoietin Rattus norvegicus 112-126 25386886-5 2014 This changes were accompanied by the impairments of vitamin D3 25-hydroxylase isoforms (CYP27A1 and CYP2R1) expression, which are the main enzymes of cholecalciferol biotransformation to 25(OH)D3 - precursor of hormonally active form of vitamin D3. Cholecalciferol 150-165 cytochrome P450, family 27, subfamily a, polypeptide 1 Mus musculus 52-77 25386886-5 2014 This changes were accompanied by the impairments of vitamin D3 25-hydroxylase isoforms (CYP27A1 and CYP2R1) expression, which are the main enzymes of cholecalciferol biotransformation to 25(OH)D3 - precursor of hormonally active form of vitamin D3. Cholecalciferol 150-165 cytochrome P450, family 27, subfamily a, polypeptide 1 Mus musculus 88-95 25386886-5 2014 This changes were accompanied by the impairments of vitamin D3 25-hydroxylase isoforms (CYP27A1 and CYP2R1) expression, which are the main enzymes of cholecalciferol biotransformation to 25(OH)D3 - precursor of hormonally active form of vitamin D3. Cholecalciferol 150-165 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 100-106 25386886-5 2014 This changes were accompanied by the impairments of vitamin D3 25-hydroxylase isoforms (CYP27A1 and CYP2R1) expression, which are the main enzymes of cholecalciferol biotransformation to 25(OH)D3 - precursor of hormonally active form of vitamin D3. Cholecalciferol 52-62 cytochrome P450, family 27, subfamily a, polypeptide 1 Mus musculus 88-95 25386886-5 2014 This changes were accompanied by the impairments of vitamin D3 25-hydroxylase isoforms (CYP27A1 and CYP2R1) expression, which are the main enzymes of cholecalciferol biotransformation to 25(OH)D3 - precursor of hormonally active form of vitamin D3. Cholecalciferol 52-62 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 100-106 25317290-2 2014 This study was conducted to represent the effect of supplemental vitamin D3 on serum leptin, TNF-alpha and adiposity in type 2 diabetic patients. Cholecalciferol 65-75 leptin Homo sapiens 85-91 25317290-2 2014 This study was conducted to represent the effect of supplemental vitamin D3 on serum leptin, TNF-alpha and adiposity in type 2 diabetic patients. Cholecalciferol 65-75 tumor necrosis factor Homo sapiens 93-102 24974387-2 2014 There are few data about the effect of vitamin D3 (cholecalciferol) supplementation on prostate-specific antigen (PSA) in healthy Black men. Cholecalciferol 51-66 kallikrein related peptidase 3 Homo sapiens 87-118 25506102-0 2014 Evidence That Loss-of-Function Filaggrin Gene Mutations Evolved in Northern Europeans to Favor Intracutaneous Vitamin D3 Production. Cholecalciferol 110-120 filaggrin Homo sapiens 31-40 25044176-0 2014 Effects of 12 weeks high dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency - a double-blind, randomized, placebo-controlled trial. Cholecalciferol 30-40 insulin Homo sapiens 54-61 25165875-0 2014 Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK. Cholecalciferol 33-43 BCL2 interacting killer Homo sapiens 107-110 24854954-0 2014 Primary vitamin D receptor target genes as biomarkers for the vitamin D3 status in the hematopoietic system. Cholecalciferol 62-72 vitamin D receptor Homo sapiens 8-26 24931970-7 2014 Birds fed 25-hydroxycholecalciferol at 25 and 50 microg/kg and injected with LPS had approximately 7-fold and 3-fold less (P = 0.010) IL-1beta mRNA in the liver compared with those birds fed 6.25 microg/kg of 25-hydroxycholecalciferol and the cholecalciferol (250 IU/kg) group. Cholecalciferol 20-35 interleukin 1, beta Gallus gallus 134-142 24931970-9 2014 At 28 d of age, birds were fed 25-hydroxycholecalciferol and injected with LPS had 1.1-fold less (P < 0.01) IL-1beta mRNA in the liver than the cholecalciferol-fed group. Cholecalciferol 41-56 interleukin 1, beta Gallus gallus 111-119 25015343-5 2014 METHODS AND RESULTS: In healthy volunteers, supplementation of vitamin D3 (4000 IU cholecalciferol per day) increased the number of circulating CD45-CD117+Sca1+Flk1+ angiogenic myeloid cells, which are thought to promote vascular regeneration. Cholecalciferol 63-73 kinase insert domain protein receptor Mus musculus 160-164 25015343-5 2014 METHODS AND RESULTS: In healthy volunteers, supplementation of vitamin D3 (4000 IU cholecalciferol per day) increased the number of circulating CD45-CD117+Sca1+Flk1+ angiogenic myeloid cells, which are thought to promote vascular regeneration. Cholecalciferol 83-98 protein tyrosine phosphatase, receptor type, C Mus musculus 144-148 25015343-5 2014 METHODS AND RESULTS: In healthy volunteers, supplementation of vitamin D3 (4000 IU cholecalciferol per day) increased the number of circulating CD45-CD117+Sca1+Flk1+ angiogenic myeloid cells, which are thought to promote vascular regeneration. Cholecalciferol 83-98 kinase insert domain protein receptor Mus musculus 160-164 25015343-15 2014 CONCLUSIONS: By inducing SDF1, vitamin D3 is a novel approach to promote vascular repair. Cholecalciferol 31-41 chemokine (C-X-C motif) ligand 12 Mus musculus 25-29 24332699-9 2014 In those with CD, a lower p:t Akt ratio (<0.97) was associated with lower serum vitamin D3, lower physical activity indices (49 vs 64 mmol/L, 1.7 vs 2.2x10(6) accelerometer counts respectively, each p<0.05) and a trend towards lower serum ferritin levels (128 vs 322mg/L, p=0.07), compared with CD subjects with normal/high p:t Akt ratios. Cholecalciferol 83-93 AKT serine/threonine kinase 1 Homo sapiens 30-33 24911063-7 2014 These cells responded to treatment with activated vitamin D3 by upregulating OCN. Cholecalciferol 50-60 bone gamma-carboxyglutamate protein Homo sapiens 77-80 24657655-5 2014 Finally, the pro-hormone cholecalciferol reduced RUNX2 transcriptional activity and decreased migration of melanoma cells, further suggesting a role of RUNX2 in melanoma cell migration. Cholecalciferol 25-40 RUNX family transcription factor 2 Homo sapiens 49-54 24657655-5 2014 Finally, the pro-hormone cholecalciferol reduced RUNX2 transcriptional activity and decreased migration of melanoma cells, further suggesting a role of RUNX2 in melanoma cell migration. Cholecalciferol 25-40 RUNX family transcription factor 2 Homo sapiens 152-157 24892558-12 2014 VDR- or VEGF blockade reduced tubule formation, partially restorable by vitamin D3. Cholecalciferol 72-82 vitamin D receptor Homo sapiens 0-3 24892558-12 2014 VDR- or VEGF blockade reduced tubule formation, partially restorable by vitamin D3. Cholecalciferol 72-82 vascular endothelial growth factor A Homo sapiens 8-12 23999998-0 2014 High-dose cholecalciferol supplementation significantly increases peripheral CD4+ Tregs in healthy adults without negatively affecting the frequency of other immune cells. Cholecalciferol 10-25 CD4 molecule Homo sapiens 77-80 24922634-1 2014 BACKGROUND: Vitamin D3, acting via vitamin D receptor (VDR) affects a wide range of biological activities, including inhibition of proliferation and angiogenesis, with net antitumor effects. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 35-53 24922634-1 2014 BACKGROUND: Vitamin D3, acting via vitamin D receptor (VDR) affects a wide range of biological activities, including inhibition of proliferation and angiogenesis, with net antitumor effects. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 55-58 24646031-3 2014 In many cases, downregulation of CDK activity by ATRA and vitamin D3 is a result of elevated p21- and p27-bound CDKs. Cholecalciferol 58-68 H3 histone pseudogene 16 Homo sapiens 93-96 24646031-3 2014 In many cases, downregulation of CDK activity by ATRA and vitamin D3 is a result of elevated p21- and p27-bound CDKs. Cholecalciferol 58-68 interferon alpha inducible protein 27 Homo sapiens 102-105 24646031-3 2014 In many cases, downregulation of CDK activity by ATRA and vitamin D3 is a result of elevated p21- and p27-bound CDKs. Cholecalciferol 58-68 cyclin dependent kinase 2 Homo sapiens 112-116 24646031-6 2014 ATRA and vitamin D3 can also downregulate expression of G1 CDKs, especially CDK2 and CDK6. Cholecalciferol 9-19 cyclin dependent kinase 2 Homo sapiens 59-63 24646031-6 2014 ATRA and vitamin D3 can also downregulate expression of G1 CDKs, especially CDK2 and CDK6. Cholecalciferol 9-19 cyclin dependent kinase 2 Homo sapiens 76-80 24646031-6 2014 ATRA and vitamin D3 can also downregulate expression of G1 CDKs, especially CDK2 and CDK6. Cholecalciferol 9-19 cyclin dependent kinase 6 Homo sapiens 85-89 24646031-8 2014 In vitro, not only dephosphorylation of pRb but also elevation of total pRb is required for ATRA and vitamin D3 to suppress growth and trigger their differentiation. Cholecalciferol 101-111 RB transcriptional corepressor 1 Homo sapiens 40-43 24646031-8 2014 In vitro, not only dephosphorylation of pRb but also elevation of total pRb is required for ATRA and vitamin D3 to suppress growth and trigger their differentiation. Cholecalciferol 101-111 RB transcriptional corepressor 1 Homo sapiens 72-75 24550187-6 2014 Moreover, vitamin D3 treatment decreased interferon-gamma-positive CD8(+) T cells and increased CD4(+)(CD25(+))FoxP3(+) T cells in pancreatic draining lymph nodes. Cholecalciferol 10-20 CD4 antigen Mus musculus 96-99 24727236-11 2014 Cholecalciferol supplementation decreased the latency period of passively avoiding tasks in rats with hepatosteatosis, and also significantly reduced brain TNF-alpha and plasma MDA levels. Cholecalciferol 0-15 tumor necrosis factor Rattus norvegicus 156-165 24622804-2 2014 OBJECTIVE: We compared 12 mo of vitamin D3 supplementation with placebo on weight, body composition, insulin, and C-reactive protein (CRP) in postmenopausal women in a weight-loss intervention. Cholecalciferol 32-42 C-reactive protein Homo sapiens 114-132 24613576-3 2014 We investigated 25-hydroxyvitamin D3 levels in children and adults with neurofibromatosis type 1 in winter and summer and compared them to healthy controls to get more pathogenic insights in vitamin D3 metabolism in NF1 patients. Cholecalciferol 26-36 neurofibromin 1 Homo sapiens 72-96 24619107-9 2014 After vitamin D3, exclusively in women a reduction in the area under the postprandial curve for monocytes CD11b and CD35 by 10.5% (P=0.016) and 12.5% (P=0.04) and neutrophil CD11b by 17.0% (P=0.014) was observed. Cholecalciferol 6-16 integrin subunit alpha M Homo sapiens 106-111 24619107-9 2014 After vitamin D3, exclusively in women a reduction in the area under the postprandial curve for monocytes CD11b and CD35 by 10.5% (P=0.016) and 12.5% (P=0.04) and neutrophil CD11b by 17.0% (P=0.014) was observed. Cholecalciferol 6-16 complement C3b/C4b receptor 1 (Knops blood group) Homo sapiens 116-120 24619107-9 2014 After vitamin D3, exclusively in women a reduction in the area under the postprandial curve for monocytes CD11b and CD35 by 10.5% (P=0.016) and 12.5% (P=0.04) and neutrophil CD11b by 17.0% (P=0.014) was observed. Cholecalciferol 6-16 integrin subunit alpha M Homo sapiens 174-179 24461581-3 2014 OBJECTIVE: We sought to assess whether the vitamin D3 metabolites 25OHD3 and 1alpha,25(OH)2D3 can repress IgE-dependent mast cell activation through mast cell-25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) and mast cell-VDR activity. Cholecalciferol 43-53 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 199-206 24461581-3 2014 OBJECTIVE: We sought to assess whether the vitamin D3 metabolites 25OHD3 and 1alpha,25(OH)2D3 can repress IgE-dependent mast cell activation through mast cell-25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) and mast cell-VDR activity. Cholecalciferol 43-53 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 222-225 24461581-5 2014 RESULTS: Here we show that mouse and human mast cells can convert 25OHD3 to 1alpha,25(OH)2D3 through CYP27B1 activity and that both of these vitamin D3 metabolites suppressed IgE-induced mast cell-derived proinflammatory and vasodilatory mediator production in a VDR-dependent manner in vitro. Cholecalciferol 141-151 vitamin D receptor Homo sapiens 263-266 24461581-6 2014 Furthermore, epicutaneously applied vitamin D3 metabolites significantly reduced the magnitude of skin swelling associated with IgE-mediated PCA reactions in vivo; a response that required functional mast cell-VDRs and mast cell-CYP27B1. Cholecalciferol 36-46 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 229-236 24486455-13 2014 In summary, our results suggest that ginsenosides, specifically aPPD and aPPT, inhibit the CYP3A4-mediated catabolism of active vitamin D3 in human liver and intestine, potentially providing additional vitamin D-related benefits to patients with cancer, neurodegenerative and metabolic diseases. Cholecalciferol 128-138 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 91-97 24597546-9 2014 Upon inhibition of the vitamin D3-metabolizing enzymes (cytochrome P450s), 25(OH)D3 increased ROS production, potentially due to its known (low) affinity for VDR. Cholecalciferol 23-33 vitamin D receptor Homo sapiens 158-161 24855833-4 2014 On postnatal day (PND) 21, plasma IL-4 levels were elevated by 10.43% (p < 0.01) in the offspring from the high dose vitamin D3 group compared with the control group. Cholecalciferol 120-130 interleukin 4 Rattus norvegicus 34-38 23612780-0 2014 The in vitro treatment with vitamin D3 is ineffective on the expression of PKC isoenzymes, but decreases further the impaired production of IL-2 in the T lymphocytes of SLE patients. Cholecalciferol 28-38 interleukin 2 Homo sapiens 140-144 23612780-1 2014 The objective of the study was to investigate the possibility whether the in vitro treatment with vitamin D3 can restore the impaired expression of protein kinase C (PKC) isoenzymes and IL-2 production in the lymphocytes of patients with systemic lupus erythematosus (SLE). Cholecalciferol 98-108 interleukin 2 Homo sapiens 186-190 23612780-5 2014 However, 100 nM of vitamin D3 significantly increased the release of IL-10, but suppressed the production of IL-2, IL-6, interferon gamma and TNF alpha in the culture supernatants of both groups. Cholecalciferol 19-29 interleukin 10 Homo sapiens 69-74 23612780-5 2014 However, 100 nM of vitamin D3 significantly increased the release of IL-10, but suppressed the production of IL-2, IL-6, interferon gamma and TNF alpha in the culture supernatants of both groups. Cholecalciferol 19-29 interleukin 2 Homo sapiens 109-113 23612780-5 2014 However, 100 nM of vitamin D3 significantly increased the release of IL-10, but suppressed the production of IL-2, IL-6, interferon gamma and TNF alpha in the culture supernatants of both groups. Cholecalciferol 19-29 interleukin 6 Homo sapiens 115-119 23612780-5 2014 However, 100 nM of vitamin D3 significantly increased the release of IL-10, but suppressed the production of IL-2, IL-6, interferon gamma and TNF alpha in the culture supernatants of both groups. Cholecalciferol 19-29 interferon gamma Homo sapiens 121-137 23612780-5 2014 However, 100 nM of vitamin D3 significantly increased the release of IL-10, but suppressed the production of IL-2, IL-6, interferon gamma and TNF alpha in the culture supernatants of both groups. Cholecalciferol 19-29 tumor necrosis factor Homo sapiens 142-151 23612780-6 2014 As the low production of IL-2 is one of the main pathologic features of SLE, we recommend to avoid the use of high doses of vitamin D3 for treatment of lupus patients with vitamin D3 deficiency. Cholecalciferol 124-134 interleukin 2 Homo sapiens 25-29 23612780-6 2014 As the low production of IL-2 is one of the main pathologic features of SLE, we recommend to avoid the use of high doses of vitamin D3 for treatment of lupus patients with vitamin D3 deficiency. Cholecalciferol 172-182 interleukin 2 Homo sapiens 25-29 24246341-11 2014 Vitamin D3 doses >=300,000 IU provided optimal changes in serum/plasma 25(OH)D and parathyroid hormone (PTH) concentrations. Cholecalciferol 0-10 parathyroid hormone Homo sapiens 86-105 25505940-5 2014 METHOD: In a double blind randomized placebo controlled study we evaluated the effect of a monthly dose of 100,000IU of vitamin D3 for three months on the level of serum 25(OH)D, intact parathyroid hormone (PTH), urinary isoprostane, adipocyte cytokine expression and arterial stiffness among 130 overweight and obese (BMI > 25) African Americans with elevated blood pressure (130 - 150/85 - 100 mmHg) and low serum vitamin D level (10 - 25 ng/ml). Cholecalciferol 120-130 parathyroid hormone Homo sapiens 186-205 24792400-1 2014 The active form of vitamin D3, 1,25(OH)2D3, has significant immunomodulatory properties and is an important determinant in the differentiation of CD4+ effector T cells. Cholecalciferol 19-29 CD4 molecule Homo sapiens 146-149 23999998-3 2014 METHODS: In a double-blind, placebo controlled study in 60 healthy volunteers, we assessed the effect of a 12-week high-dose oral cholecalciferol supplementation (140,000 IU/month) on the number and function of CD4(pos)CD25(high)FoxP3(pos)CD127(dim) Tregs. Cholecalciferol 130-145 CD4 molecule Homo sapiens 211-214 24670704-2 2014 CXCL10 gene expression is downregulated in monocytes by metabolically active vitamin D3 (1,25dihydroxy vitamin D). Cholecalciferol 77-87 C-X-C motif chemokine ligand 10 Homo sapiens 0-6 24576880-5 2014 RESULTS: The HSF, HCEC-12, ODM-2, and ARPE-19 express mRNA and protein for all vitamin D3 synthesizing and metabolizing components. Cholecalciferol 79-89 interleukin 6 Homo sapiens 13-16 24374976-9 2014 RESULTS: Compared with baseline values, LPS-matured mo-DC exhibited reduced expression of CD80 and reduced production of the cytokines IL-10, IL-1beta, and IL-6 following 26 weeks of oral vitamin D3 supplementation. Cholecalciferol 188-198 interleukin 10 Homo sapiens 135-140 24374976-9 2014 RESULTS: Compared with baseline values, LPS-matured mo-DC exhibited reduced expression of CD80 and reduced production of the cytokines IL-10, IL-1beta, and IL-6 following 26 weeks of oral vitamin D3 supplementation. Cholecalciferol 188-198 interleukin 6 Homo sapiens 156-160 24398649-1 2014 OBJECTIVES: We assessed the effect of cholecalciferol and calcium supplementation on mRNA expression of cathelicidin (LL-37), Th1 and Th2 cytokines and their transcription factors in the peripheral blood mononuclear cells (PBMCs) in healthy females with vitamin D deficiency (VDD). Cholecalciferol 38-53 cathelicidin antimicrobial peptide Homo sapiens 118-123 27122781-0 2014 Effect of Vitamin D3 on Monocyte Chemoattractant Protein 1 Production in Monocytes and Macrophages. Cholecalciferol 10-20 C-C motif chemokine ligand 2 Homo sapiens 24-58 24398649-1 2014 OBJECTIVES: We assessed the effect of cholecalciferol and calcium supplementation on mRNA expression of cathelicidin (LL-37), Th1 and Th2 cytokines and their transcription factors in the peripheral blood mononuclear cells (PBMCs) in healthy females with vitamin D deficiency (VDD). Cholecalciferol 38-53 negative elongation factor complex member C/D Homo sapiens 126-129 24398649-6 2014 Despite significant increase in mean serum 25(OH)D in the cholecalciferol-supplemented groups, their mean mRNA transcripts of LL-37, IFN-gamma, IL-4, transcription factors and their IFN-gamma/IL-4 and T-bet/GATA-3 ratios were similar to that of calcium and placebo groups. Cholecalciferol 58-73 cathelicidin antimicrobial peptide Homo sapiens 126-131 23283825-0 2014 Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D. INTRODUCTION: Vitamin D plasma levels are negatively associated with blood pressure and cardiovascular mortality, and vitamin D supplementation reduces cardiovascular events. Cholecalciferol 0-15 renin Homo sapiens 51-56 24327720-10 2014 Future studies of longer supplemental vitamin D3 duration are necessary to examine the complex influence of vitamin D3 on CRP and other chronic inflammatory cytokines for possible reduction of cancer health disparities in African Americans. Cholecalciferol 108-118 C-reactive protein Homo sapiens 122-125 24423366-12 2014 Postoperatively, PTH remained lower in the cholecalciferol group compared with the placebo group (P = .04). Cholecalciferol 43-58 parathyroid hormone Homo sapiens 17-20 25568836-0 2014 Genetic evidence for a pathogenic role for the vitamin D3 metabolizing enzyme CYP24A1 in multiple sclerosis. Cholecalciferol 47-57 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 78-85 25568836-12 2014 INTERPRETATION: The known MS risk allele rs2248359-C increases CYP24A1 expression in human brain providing a genetic link between MS and vitamin D metabolism, and predicting that the physiologically active form of vitamin D3 is protective. Cholecalciferol 214-224 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 63-70 24868917-1 2014 The study was devoted to identifying the relation between vitamin D3 availability (assessed by the level of circulatory 25OHD3), content of vitamin D3 25-hydroxylase isozymes CYP27A1 and CYP2R1 in hepatic tissue and functional activity of peripheral blood phagocytes in mice with experimental type 1 diabetes. Cholecalciferol 58-68 cytochrome P450, family 27, subfamily a, polypeptide 1 Mus musculus 140-165 24868917-1 2014 The study was devoted to identifying the relation between vitamin D3 availability (assessed by the level of circulatory 25OHD3), content of vitamin D3 25-hydroxylase isozymes CYP27A1 and CYP2R1 in hepatic tissue and functional activity of peripheral blood phagocytes in mice with experimental type 1 diabetes. Cholecalciferol 58-68 cytochrome P450, family 27, subfamily a, polypeptide 1 Mus musculus 175-182 24868917-1 2014 The study was devoted to identifying the relation between vitamin D3 availability (assessed by the level of circulatory 25OHD3), content of vitamin D3 25-hydroxylase isozymes CYP27A1 and CYP2R1 in hepatic tissue and functional activity of peripheral blood phagocytes in mice with experimental type 1 diabetes. Cholecalciferol 58-68 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 187-193 24868917-4 2014 Cholecalciferol administration resulted in normalization of tissue levels of both isoforms of vitamin D3 25-hydroxylase and blood serum 25OHD3 content. Cholecalciferol 0-15 cytochrome P450, family 27, subfamily a, polypeptide 1 Mus musculus 94-119 24393028-14 2014 The change of the electronic configuration of the metal atom from d(3) (Tc(IV)) to d(5) (Tc(II)) is accompanied by the formation of metal-metal bonds in the coordination polyhedra. Cholecalciferol 66-70 transcobalamin 2 Homo sapiens 89-95 24277747-14 2014 TNF-alpha/IL-10 expressing CD3(+)/4(+) cell ratios were significantly decreased with 100 nM of vitamin D3 (31.3 +- 9.4, P < 0.05) when compared with controls (40.4 +- 11.3) in vitro. Cholecalciferol 95-105 tumor necrosis factor Homo sapiens 0-9 24313624-7 2014 Following cholecalciferol intake, the frequencies of circulating CD38 expressing B cells were significantly increased and IFN-gamma+ , and/or IL-17+ CD4+ T helper cells were decreased. Cholecalciferol 10-25 CD38 molecule Homo sapiens 65-69 24313624-7 2014 Following cholecalciferol intake, the frequencies of circulating CD38 expressing B cells were significantly increased and IFN-gamma+ , and/or IL-17+ CD4+ T helper cells were decreased. Cholecalciferol 10-25 interferon gamma Homo sapiens 122-131 24313624-7 2014 Following cholecalciferol intake, the frequencies of circulating CD38 expressing B cells were significantly increased and IFN-gamma+ , and/or IL-17+ CD4+ T helper cells were decreased. Cholecalciferol 10-25 interleukin 17A Homo sapiens 142-147 24313624-7 2014 Following cholecalciferol intake, the frequencies of circulating CD38 expressing B cells were significantly increased and IFN-gamma+ , and/or IL-17+ CD4+ T helper cells were decreased. Cholecalciferol 10-25 CD4 molecule Homo sapiens 149-152 24277747-14 2014 TNF-alpha/IL-10 expressing CD3(+)/4(+) cell ratios were significantly decreased with 100 nM of vitamin D3 (31.3 +- 9.4, P < 0.05) when compared with controls (40.4 +- 11.3) in vitro. Cholecalciferol 95-105 interleukin 10 Homo sapiens 10-15 24277747-15 2014 Additionally, INF-gamma/IL-10 expressing CD3(+)/4(+) cell ratio was significantly decreased with 100 nM of vitamin D3 (12.1 +- 4.0, P < 0.05) when compared with controls (14.8 +- 4.6). Cholecalciferol 107-117 interleukin 10 Homo sapiens 24-29 24277747-16 2014 IFN-gamma and TNF-alpha secretion from NK cells were significantly decreased (P < 0.01 each), and IL-10, IL-1beta, vascular endothelial growth factor and granulocyte colony stimulating factor levels were significantly increased (P < 0.01 each) with vitamin D3 100 nM when compared with those of controls. Cholecalciferol 255-265 tumor necrosis factor Homo sapiens 14-23 24445291-17 2014 CONCLUSIONS: Oral vitamin D3 raised prostate calcitriol levels (level 1 evidence) and modestly lowered both PSA and PTH. Cholecalciferol 18-28 kallikrein related peptidase 3 Homo sapiens 108-111 24445291-17 2014 CONCLUSIONS: Oral vitamin D3 raised prostate calcitriol levels (level 1 evidence) and modestly lowered both PSA and PTH. Cholecalciferol 18-28 parathyroid hormone Homo sapiens 116-119 24404137-8 2014 Western Immunoblot (WIB) analyses of 2D-gels demonstrated a downregulation of adiponectin in VDD subjects, which was confirmed in the plasma from VDD with respect to NVD subjects (p<0.035) and increased following 12mo vitamin D3 supplementation in VDD subjects (p<0.02). Cholecalciferol 221-231 adiponectin, C1Q and collagen domain containing Homo sapiens 78-89 24466013-1 2014 Renal alpha-Klotho (alpha-KL) plays a fundamental role as a co-receptor for fibroblast growth factor 23 (FGF23), a phosphaturic hormone and regulator of 1,25(OH)2 vitamin D3 (1,25VitD3). Cholecalciferol 163-173 fibroblast growth factor 23 Homo sapiens 76-103 24466013-1 2014 Renal alpha-Klotho (alpha-KL) plays a fundamental role as a co-receptor for fibroblast growth factor 23 (FGF23), a phosphaturic hormone and regulator of 1,25(OH)2 vitamin D3 (1,25VitD3). Cholecalciferol 163-173 fibroblast growth factor 23 Homo sapiens 105-110 24466411-2 2014 A full vitamin D (refers to vitamin D2 and D3) endocrine system, characterized by a specific VDR (vitamin D receptor, member of the nuclear receptor family), specific vitamin D metabolizing CYP450 enzymes regulated by calciotropic hormones and a dedicated plasma transport-protein is only found in vertebrates. Cholecalciferol 43-45 vitamin D receptor Homo sapiens 93-96 24466411-2 2014 A full vitamin D (refers to vitamin D2 and D3) endocrine system, characterized by a specific VDR (vitamin D receptor, member of the nuclear receptor family), specific vitamin D metabolizing CYP450 enzymes regulated by calciotropic hormones and a dedicated plasma transport-protein is only found in vertebrates. Cholecalciferol 43-45 vitamin D receptor Homo sapiens 98-116 24404137-9 2014 High molecular weight (HMW) adiponectin, a surrogate indicator of insulin sensitivity, was significantly lower in VDD subjects (p<0.02) and improved with vitamin D3 supplementation (p<0.042). Cholecalciferol 157-167 adiponectin, C1Q and collagen domain containing Homo sapiens 28-39 24356952-8 2014 Vitamin D3 supplementation significantly increased serum leptin and OPG levels. Cholecalciferol 0-10 leptin Homo sapiens 57-63 24356952-8 2014 Vitamin D3 supplementation significantly increased serum leptin and OPG levels. Cholecalciferol 0-10 TNF receptor superfamily member 11b Homo sapiens 68-71 25486939-1 2014 The hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1a), has a wide variety of biological activities and its major molecular target is considered to be the vitamin D receptor (VDR). Cholecalciferol 30-40 vitamin D receptor Homo sapiens 177-195 25207374-4 2014 This has been demonstrated in BCC-bearing Ptch mutant mice and BCC cell lines, in which both vitamin D3 and its active metabolite calcitriol (1alpha-25(OH)2D3) exert antitumor effects. Cholecalciferol 93-103 patched 1 Mus musculus 42-46 25486939-1 2014 The hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1a), has a wide variety of biological activities and its major molecular target is considered to be the vitamin D receptor (VDR). Cholecalciferol 30-40 vitamin D receptor Homo sapiens 197-200 25669690-0 2014 The effect of vitamin D3 supplementation on intracellular calcium and plasma membrane calcium ATPase activity in early stages of chronic kidney disease. Cholecalciferol 14-24 ATPase plasma membrane Ca2+ transporting 3 Homo sapiens 70-100 24081904-0 2014 Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies. Cholecalciferol 111-121 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 24-31 24081904-6 2014 The use of CYP24A1 RNAi enhanced the cytostatic effects of vitamin D3 in human prostate cancer cells. Cholecalciferol 59-69 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 11-18 24081904-7 2014 Remarkably, subcutaneous and orthotopic xenografts of prostate cancer cells harboring CYP24A1 shRNA resulted in a drastic reduction in tumor volume when mice were subjected to vitamin D3 supplementation. Cholecalciferol 176-186 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 86-93 24081904-8 2014 CYP24A1 may be a predictive marker of vitamin D3 clinical efficacy in patients with advanced prostate cancer. Cholecalciferol 38-48 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 0-7 24081904-9 2014 For those with up-regulated CYP24A1, combination therapy with RNAi targeting CYP24A1 could be considered to improve clinical responsiveness to vitamin D3. Cholecalciferol 143-153 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 28-35 24081904-9 2014 For those with up-regulated CYP24A1, combination therapy with RNAi targeting CYP24A1 could be considered to improve clinical responsiveness to vitamin D3. Cholecalciferol 143-153 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 77-84 25034315-0 2014 Effect of vitamin D3 supplementation on serum 25(OH)D, lipids and markers of insulin resistance in obese adolescents: a prospective, randomized, placebo-controlled pilot trial. Cholecalciferol 10-20 insulin Homo sapiens 77-84 25034315-7 2014 CONCLUSIONS: 12 weeks of vitamin D3 supplementation in obese adolescents with 2,000 IU once daily resulted in a modest increase in 25(OH)D concentration in obese adolescents, but did not affect the lipid profile and markers of insulin resistance and inflammation. Cholecalciferol 25-35 insulin Homo sapiens 227-234 25034315-8 2014 Further studies with higher doses of vitamin D3 and/or longer duration of supplementation are needed to understand if vitamin D3 supplementation can impact lipid profiles and markers of insulin resistance and inflammation in obese children. Cholecalciferol 118-128 insulin Homo sapiens 186-193 23775785-9 2014 Administration of vitamin D3 compounds to these mice resulted in substantial levels of CAMP in the systemic circulation. Cholecalciferol 18-28 cathelicidin antimicrobial peptide Mus musculus 87-91 23761326-2 2014 The main objective of this trial was to measure the effect of different doses of vitamin D3 on serum 25OHD and serum parathyroid hormone (PTH) in young women with vitamin D insufficiency (serum 25OHD <= 20 ng/mL (50 nmol/L). Cholecalciferol 81-91 parathyroid hormone Homo sapiens 117-136 23761326-2 2014 The main objective of this trial was to measure the effect of different doses of vitamin D3 on serum 25OHD and serum parathyroid hormone (PTH) in young women with vitamin D insufficiency (serum 25OHD <= 20 ng/mL (50 nmol/L). Cholecalciferol 81-91 parathyroid hormone Homo sapiens 138-141 23564710-1 2014 The vitamin D signal transduction system involves a series of cytochrome P450-containing sterol hydroxylases to generate and degrade the active hormone, 1alpha,25-dihydroxyvitamin D3, which serves as a ligand for the vitamin D receptor-mediated transcriptional gene expression described in companion articles in this review series. Cholecalciferol 180-182 vitamin D receptor Homo sapiens 217-235 24918275-3 2014 Nowadays, growing attention is focused on the study of the interactions of the active form of vitamin D3 with its receptor and inhibitory effect of vitamin D3 receptor polymorphisms on multiple signaling pathways involved in proliferative and metastatic processes. Cholecalciferol 94-104 vitamin D receptor Homo sapiens 148-167 24918275-5 2014 It summarizes current knowledge of malignant melanoma in regard to the role of the active form of vitamin D3 binding to vitamin D3 receptor (VDR), as well as it describes the influence of polymorphisms of VDR on the inhibition of HH. Cholecalciferol 98-108 vitamin D receptor Homo sapiens 120-139 24918275-5 2014 It summarizes current knowledge of malignant melanoma in regard to the role of the active form of vitamin D3 binding to vitamin D3 receptor (VDR), as well as it describes the influence of polymorphisms of VDR on the inhibition of HH. Cholecalciferol 98-108 vitamin D receptor Homo sapiens 141-144 24192346-3 2014 The aim of our study is to elucidate the impact of 25(OH) vitamin D3 on amyloid precursor protein processing in mice and N2A cells utilizing very moderate and physiological vitamin D hypovitaminosis in the range of 20-30% compared to wild-type mice. Cholecalciferol 58-68 amyloid beta (A4) precursor protein Mus musculus 72-97 25669690-2 2014 The aim of our study was to investigate the impact of 6 months vitamin D(3) supplementation (14 000 IU/week) on free cytosolic calcium concentration ([Ca(2+)](i)) and on the plasma membrane calcium ATPase (PMCA) activity of patients with CKD stage 2-3. Cholecalciferol 63-75 ATPase plasma membrane Ca2+ transporting 3 Homo sapiens 206-210 24349534-2 2013 We investigated the roles of vitamin D receptor (Vdr) and runt-related transcription factor 2 (Runx2) in the osteoblastic differentiation of VSMCs in response to vitamin D3 using in vitro VSMCs cultures and in vivo in Vdr knockout (Vdr(-/-)) and Runx2 carboxy-terminus truncated heterozygous (Runx2(+/DeltaC)) mice. Cholecalciferol 162-172 runt related transcription factor 2 Mus musculus 58-93 24379907-3 2013 The principal aim of this study was to investigate if the phosphodiesterase inhibitor Ibudilast (Ibu) and 1alpha,25-dihydroxyvitamin D3 (Vit D3) could interfere with NO release from trigeminal SGCs. Cholecalciferol 133-135 vitrin Rattus norvegicus 137-140 24349534-2 2013 We investigated the roles of vitamin D receptor (Vdr) and runt-related transcription factor 2 (Runx2) in the osteoblastic differentiation of VSMCs in response to vitamin D3 using in vitro VSMCs cultures and in vivo in Vdr knockout (Vdr(-/-)) and Runx2 carboxy-terminus truncated heterozygous (Runx2(+/DeltaC)) mice. Cholecalciferol 162-172 runt related transcription factor 2 Mus musculus 95-100 24349534-3 2013 Treatment of VSMCs with active vitamin D3 promoted matrix mineral deposition, and increased the expressions of Vdr, Runx2, and of osteoblastic genes but decreased the expression of smooth muscle myosin heavy chain in primary VSMCs cultures. Cholecalciferol 31-41 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 111-114 24349534-3 2013 Treatment of VSMCs with active vitamin D3 promoted matrix mineral deposition, and increased the expressions of Vdr, Runx2, and of osteoblastic genes but decreased the expression of smooth muscle myosin heavy chain in primary VSMCs cultures. Cholecalciferol 31-41 runt related transcription factor 2 Mus musculus 116-121 24349534-5 2013 Furthermore, silencing Vdr or Runx2 attenuated the procalcific effects of vitamin D3. Cholecalciferol 74-84 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 23-26 23973664-2 2013 The present study was designed to identify a possible correlation between ORM1 and Vitamin D3 (1,25(OH)2D3), a hormone exerting a widespread effect on cell proliferation, differentiation and regulation of the immune system. Cholecalciferol 83-93 orosomucoid 1 Homo sapiens 74-78 24349534-5 2013 Furthermore, silencing Vdr or Runx2 attenuated the procalcific effects of vitamin D3. Cholecalciferol 74-84 runt related transcription factor 2 Mus musculus 30-35 24349534-7 2013 Vascular calcification induced by high-dose vitamin D3 was completely inhibited in Vdr(-/-) or Runx2(+/DeltaC) mice, despite elevated levels of serum calcium or alkaline phosphatase. Cholecalciferol 44-54 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 83-86 24349534-7 2013 Vascular calcification induced by high-dose vitamin D3 was completely inhibited in Vdr(-/-) or Runx2(+/DeltaC) mice, despite elevated levels of serum calcium or alkaline phosphatase. Cholecalciferol 44-54 runt related transcription factor 2 Mus musculus 95-100 24349534-8 2013 Collectively, these findings suggest that functional cooperation between Vdr and Runx2 is necessary for vascular calcification in response to vitamin D3. Cholecalciferol 142-152 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 73-76 24349534-8 2013 Collectively, these findings suggest that functional cooperation between Vdr and Runx2 is necessary for vascular calcification in response to vitamin D3. Cholecalciferol 142-152 runt related transcription factor 2 Mus musculus 81-86 24304609-9 2013 PTH levels correlate negatively with serum 25-OH-Vitamin D3 levels, and neither calcium nor vitamin D intake exert a strong influence on either of the two parameters. Cholecalciferol 49-59 parathyroid hormone Homo sapiens 0-3 24060240-8 2013 IL-8 production stimulated with LPS was diminished by vitamin D3 derivatives. Cholecalciferol 54-64 C-X-C motif chemokine ligand 8 Homo sapiens 0-4 24060240-10 2013 The anti-inflammatory effect of vitamin D3 derivatives was thus associated with diminution of IL-8 production due to increased release of sCD14. Cholecalciferol 32-42 C-X-C motif chemokine ligand 8 Homo sapiens 94-98 24060240-0 2013 Vitamin D3 derivatives increase soluble CD14 release through ERK1/2 activation and decrease IL-8 production in intestinal epithelial cells. Cholecalciferol 0-10 CD14 molecule Homo sapiens 40-44 24060240-0 2013 Vitamin D3 derivatives increase soluble CD14 release through ERK1/2 activation and decrease IL-8 production in intestinal epithelial cells. Cholecalciferol 0-10 mitogen-activated protein kinase 3 Homo sapiens 61-67 24060240-0 2013 Vitamin D3 derivatives increase soluble CD14 release through ERK1/2 activation and decrease IL-8 production in intestinal epithelial cells. Cholecalciferol 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 92-96 24060240-4 2013 Among the innate immune-related receptors such as Toll-like receptor (TLR) 1, 2, 4, 6, and CD14 examined by flow cytometry, only CD14 was up-regulated by vitamin D3 derivatives. Cholecalciferol 154-164 CD14 molecule Homo sapiens 91-95 24060240-4 2013 Among the innate immune-related receptors such as Toll-like receptor (TLR) 1, 2, 4, 6, and CD14 examined by flow cytometry, only CD14 was up-regulated by vitamin D3 derivatives. Cholecalciferol 154-164 CD14 molecule Homo sapiens 129-133 24060240-5 2013 Release of soluble form CD14 (sCD14) was also increased by vitamin D3 derivatives. Cholecalciferol 59-69 CD14 molecule Homo sapiens 24-28 24392366-5 2013 In this study, we tried to find out the probable association of Vitamin D3, calcium and magnesium with reference to insulin resistance in type 2 diabetes mellitus (T2DM) cases. Cholecalciferol 64-74 insulin Homo sapiens 116-123 24304198-5 2013 It was hypothesized that vitamin D3 supplementation would increase the lifespan of C. elegans in a DAF-12-dependent manner. Cholecalciferol 25-35 Nuclear hormone receptor family member daf-12 Caenorhabditis elegans 99-105 24304198-7 2013 The daf-12 mutants exposed to 1,000 microg/ml vitamin D3 lived significantly longer than daf-12 controls exposed to 0 microg/ml (p<0.001), but among worms exposed to 1,000 microg/ml vitamin D3, wild type lived significantly longer than daf-12 (p<0.01). Cholecalciferol 46-56 Nuclear hormone receptor family member daf-12 Caenorhabditis elegans 4-10 24304198-7 2013 The daf-12 mutants exposed to 1,000 microg/ml vitamin D3 lived significantly longer than daf-12 controls exposed to 0 microg/ml (p<0.001), but among worms exposed to 1,000 microg/ml vitamin D3, wild type lived significantly longer than daf-12 (p<0.01). Cholecalciferol 185-195 Nuclear hormone receptor family member daf-12 Caenorhabditis elegans 4-10 24304198-8 2013 The data suggest that vitamin D3 can interact with multiple receptors, possibly implicating the NHR family of nuclear hormone receptors related to DAF-12. Cholecalciferol 22-32 Nuclear hormone receptor family member daf-12 Caenorhabditis elegans 147-153 24183235-4 2013 U937 subclones expressing the NPM-RAR mutants showed significantly less inhibition of vitamin D3/TGFbeta-induced differentiation, compared with NPM-RAR. Cholecalciferol 86-96 retinoic acid receptor alpha Homo sapiens 34-37 24183235-4 2013 U937 subclones expressing the NPM-RAR mutants showed significantly less inhibition of vitamin D3/TGFbeta-induced differentiation, compared with NPM-RAR. Cholecalciferol 86-96 transforming growth factor beta 1 Homo sapiens 97-104 24108316-0 2013 A randomized study on the effect of vitamin D3 supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. Cholecalciferol 36-46 vitamin D receptor Homo sapiens 97-115 24108316-10 2013 CONCLUSION: Vitamin D3 supplementation increased intramyonuclear VDR concentration by 30% and increased muscle fiber size by 10% in older, mobility-limited, vitamin D-insufficient women. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 65-68 24183235-4 2013 U937 subclones expressing the NPM-RAR mutants showed significantly less inhibition of vitamin D3/TGFbeta-induced differentiation, compared with NPM-RAR. Cholecalciferol 86-96 nucleophosmin 1 Homo sapiens 30-33 23961975-0 2013 Narrowband ultraviolet B irradiation increases the serum level of vitamin D3 in patients with neurofibromatosis 1. Cholecalciferol 66-76 neurofibromin 1 Homo sapiens 94-113 24169587-2 2013 Our results indicate that 1,25(OH)2D3, the biologically active metabolite of vitamin D3, calcipotriol and FTY720 augment IL-2-activated NK cell lysis of K562 and RAJI tumor cell lines as well as immature (i) and mature (m) DCs, with variable efficacies. Cholecalciferol 77-87 interleukin 2 Homo sapiens 121-125 24169587-5 2013 The three drugs down-regulate the expression of CCR6 on the surface of iDCs, whereas vitamin D3 and calcipotriol tend to up-regulate the expression of CCR7 on mDCs, suggesting that they may influence the migration of DCs into the lymph nodes. Cholecalciferol 85-95 C-C motif chemokine receptor 7 Homo sapiens 151-155 23792937-14 2013 These findings may explain why cholecalciferol and ergocalciferol supplementation result in similar magnitudes of PTH reduction, but implicate potential differences in other vitamin D metabolites, such as 24,25(OH)2D, that could explain their different effects on ionized calcium. Cholecalciferol 31-46 parathyroid hormone Homo sapiens 114-117 23792937-1 2013 We previously showed that oral cholecalciferol and ergocalciferol have comparable effects in decreasing circulating parathyroid hormone (PTH), despite a greater increase in total serum 25-hydroxyvitamin D (25OHD) concentration with cholecalciferol supplementation. Cholecalciferol 31-46 parathyroid hormone Homo sapiens 116-135 23792937-1 2013 We previously showed that oral cholecalciferol and ergocalciferol have comparable effects in decreasing circulating parathyroid hormone (PTH), despite a greater increase in total serum 25-hydroxyvitamin D (25OHD) concentration with cholecalciferol supplementation. Cholecalciferol 31-46 parathyroid hormone Homo sapiens 137-140 23961975-1 2013 The serum vitamin D3 levels in patients with neurofibromatosis 1 has been reported to be significantly lower than that in control subjects, and the level of vitamin D3 reversely correlates with the severity of neurofibroma formation. Cholecalciferol 10-20 neurofibromin 1 Homo sapiens 45-64 23961975-1 2013 The serum vitamin D3 levels in patients with neurofibromatosis 1 has been reported to be significantly lower than that in control subjects, and the level of vitamin D3 reversely correlates with the severity of neurofibroma formation. Cholecalciferol 157-167 neurofibromin 1 Homo sapiens 45-64 23961975-2 2013 We found that narrowband ultraviolet B (NB-UVB) irradiation increased the serum level of 1,25(OH)2 vitamin D3 in patients with neurofibromatosis 1. Cholecalciferol 99-109 neurofibromin 1 Homo sapiens 127-146 23961975-5 2013 It is suggested that NB-UVB irradiation is effective for increasing the serum level of vitamin D3 in patients with neurofibromatosis 1, which may be of benefit for skin symptoms such as pigmented macules or neurofibromas. Cholecalciferol 87-97 neurofibromin 1 Homo sapiens 115-134 23966631-0 2013 Human CD1c+ myeloid dendritic cells acquire a high level of retinoic acid-producing capacity in response to vitamin D3. Cholecalciferol 108-118 CD1c molecule Homo sapiens 6-10 23974111-0 2013 EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells. Cholecalciferol 94-104 epidermal growth factor receptor Homo sapiens 0-4 23899497-3 2013 The vitamin D receptor (VDR) is a nuclear receptor for the active form of vitamin D3 that regulates numerous physiological processes. Cholecalciferol 74-84 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 4-22 23899497-3 2013 The vitamin D receptor (VDR) is a nuclear receptor for the active form of vitamin D3 that regulates numerous physiological processes. Cholecalciferol 74-84 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 24-27 23869208-7 2013 CD14(hi) and CD14(lo) M1- and M2-like MPhis were generated in vitro from the THP-1 monocyte cell line by differentiation with PMA and vitamin D3, respectively. Cholecalciferol 134-144 CD14 molecule Homo sapiens 0-4 23814095-0 2013 Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Cholecalciferol 0-10 matrix metallopeptidase 2 Homo sapiens 49-82 23924389-2 2013 The objective of this study was to determine the effect of vitamin D3 supplementation in a cohort of Saudi DMT2 population on diet, insulin and/or different oral hypoglycemic agents and compare them with a non-DMT2 control cohort. Cholecalciferol 59-69 insulin Homo sapiens 132-139 24023320-9 2013 CONCLUSION: Vitamin D-3 reduces the PG cascade and increases TGFbeta2 in a dose-dependent fashion. Cholecalciferol 12-23 transforming growth factor beta 2 Homo sapiens 61-69 24009820-9 2013 Additionally, cell culture experiments proved that Vitamin D3 could prevent the degradation of mutant LXR-alpha and restore its functional activity to some extent. Cholecalciferol 51-61 nuclear receptor subfamily 1 group H member 3 Homo sapiens 102-111 24009820-10 2013 CONCLUSION: Mutant LXR-alpha protein in CHD subjects is degraded by BARD1/BRCA1 complex and Vitamin D3 can rescue and restore its function. Cholecalciferol 92-102 nuclear receptor subfamily 1 group H member 3 Homo sapiens 19-28 23895820-0 2013 Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). Cholecalciferol 11-21 renin Homo sapiens 52-57 23456391-6 2013 In the 50 patients receiving D(3) supplementation, serum levels of 25(OH)D(3) increased (p = 0.008), PTH decreased (p = 0.036) and 24,25(OH)(2)D(3), 1,25(OH)(2)D(3), VDBP levels and PBMC 24-OHase activity were unchanged. Cholecalciferol 29-33 parathyroid hormone Homo sapiens 101-104 23456391-6 2013 In the 50 patients receiving D(3) supplementation, serum levels of 25(OH)D(3) increased (p = 0.008), PTH decreased (p = 0.036) and 24,25(OH)(2)D(3), 1,25(OH)(2)D(3), VDBP levels and PBMC 24-OHase activity were unchanged. Cholecalciferol 29-33 GC vitamin D binding protein Homo sapiens 166-170 23456391-6 2013 In the 50 patients receiving D(3) supplementation, serum levels of 25(OH)D(3) increased (p = 0.008), PTH decreased (p = 0.036) and 24,25(OH)(2)D(3), 1,25(OH)(2)D(3), VDBP levels and PBMC 24-OHase activity were unchanged. Cholecalciferol 29-33 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 187-195 23639807-10 2013 Bone vitamin D receptor expression was increased in mice with chronic colitis, especially in the high vitamin D3 group. Cholecalciferol 102-112 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 5-23 23837623-6 2013 RESULTS: We find evidence of positive selection for DHCR7, which governs availability of 7-dehydrocholesterol for conversion to vitamin D3 by the action of sunlight on the skin. Cholecalciferol 128-138 7-dehydrocholesterol reductase Homo sapiens 52-57 23220095-4 2013 The active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3], is known to be a hormone which enhances RANKL expression in vitro. Cholecalciferol 19-29 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 121-126 23591713-8 2013 The bone resorption marker C-terminal telopetide of type 1 collagen (CTX) decreased borderline significantly in the cholecalciferol group compared with the placebo group (p = 0.07). Cholecalciferol 116-131 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 52-73 23026510-1 2013 We previously demonstrated that non-small cell lung cancer (NSCLC) cells and primary human lung tumors aberrantly express the vitamin D3-catabolizing enzyme, CYP24, and that CYP24 restricts transcriptional regulation and growth control by 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) in NSCLC cells. Cholecalciferol 126-136 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 158-163 23500833-3 2013 The present study was aimed to evaluate in vitro differences in VEGF production and expression of cultured human osteoblastic cells derived from healthy donors and from subjects affected by osteoarthritis and osteoporosis, under basal conditions than after vitamin D3, and to investigate the angiogenic activity of culture media obtained by these cells in chick embryo chorioallantoic membrane (CAM) assay. Cholecalciferol 257-267 vascular endothelial growth factor A Homo sapiens 64-68 23026510-1 2013 We previously demonstrated that non-small cell lung cancer (NSCLC) cells and primary human lung tumors aberrantly express the vitamin D3-catabolizing enzyme, CYP24, and that CYP24 restricts transcriptional regulation and growth control by 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) in NSCLC cells. Cholecalciferol 126-136 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 174-179 22939886-5 2013 We found elevations in circulating calcitriol as well as increased CYP27B1 expression in the tumor and the intestine in tumor-bearing mice ingesting a vitamin D3-supplemented diet. Cholecalciferol 151-161 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 67-74 23378417-10 2013 The PTH levels tended to increase over the study period under placebo and to decrease in the cholecalciferol group. Cholecalciferol 93-108 parathyroid hormone Homo sapiens 4-7 23853726-1 2013 The hormonally active form of vitamin D3, 1,25(OH)2D3 (calcitriol), exerts actions through VDR receptor, which acts as a transcriptional factor. Cholecalciferol 30-40 vitamin D receptor Homo sapiens 91-94 23339019-14 2013 When DBP was upregulated, however, the benefits from the vitamin D3 supplements were lost. Cholecalciferol 57-67 D-box binding PAR bZIP transcription factor Homo sapiens 5-8 23467424-5 2013 Moreover, CIDHPs lacking VDR displayed enhanced ANG II production, and treatment of HIV/CIDHPs with EB1089 (vitamin D3; VD) attenuated ANG II production. Cholecalciferol 108-118 angiogenin Homo sapiens 135-138 23065434-9 2013 CONCLUSIONS: Cholecalciferol replacement therapy significantly decreases PTH levels and insulin resistance. Cholecalciferol 13-28 insulin Homo sapiens 88-95 23674869-0 2013 CYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells. Cholecalciferol 56-66 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 0-7 23737310-0 2013 Comparison of vitamin D3 serum levels in new diagnosed patients with multiple sclerosis versus their healthy relatives. Cholecalciferol 14-24 MS Homo sapiens 69-87 23717463-10 2013 RESULTS: 1(OH) vitamin D3/Peg-IFN/RBV treatment could induce rapid viral reduction, especially in IL28B T/T polymorphism. Cholecalciferol 15-25 interferon lambda 3 Homo sapiens 98-103 23717463-11 2013 Several kinds of cytokines including IP-10 were significantly decreased after 4 weeks of 1(OH) vitamin D3 treatment (p<0.05). Cholecalciferol 95-105 C-X-C motif chemokine ligand 10 Homo sapiens 37-42 23674869-2 2013 25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), the enzyme that inactivates the active vitamin D3 metabolite 1,25-dihydroxyvitamin D3 (1,25-D3), is considered to be the main enzyme determining the biological half-life of 1,25-D3. Cholecalciferol 86-96 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 37-44 23674869-4 2013 The aim of this study was to investigate the anti-tumor effects of vitamin D3 on the human CRC cell line Caco-2 after inhibition of the cytochrome P450 component of CYP24A1 activity. Cholecalciferol 67-77 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 165-172 23485413-6 2013 Interaction analyses showed that VDR FokI genotypes modified the effect of vitamin D3 on changes in the HY stage (P-interaction = 0.045), UPDRS total (P-interaction = 0.039), and UPDRS part II (P-interaction = 0.021). Cholecalciferol 75-85 vitamin D receptor Homo sapiens 33-36 23548573-4 2013 When vitamin D3 or vitamin D2 was added to the cell suspension of CYP2R1-expressing yeast cells in a buffer containing glucose and beta-cyclodextrin, the vitamins were converted into their 25-hydroxylated products. Cholecalciferol 5-15 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 66-72 24327998-6 2013 After one-year use, the median % changes of BMD at three sites were similar among the three groups; however, the median values were highest in alendronate + cholecalciferol group (L1-4: 4.48%, 6.74%, and 4.50%; FT: 2.09%, 3.70%, and 2.31%; FN: 3.05%, 3.79%, and 2.03%). Cholecalciferol 157-172 immunoglobulin kappa variable 1D-17 Homo sapiens 180-184 23971693-9 2013 We predict that cholecalciferol will attenuate hypertension, proteinuria and reduce the urinary excretion of a biomarker, monocyte chemoattractant protein-1 (MCP-1, a surrogate inflammatory marker of progression in ADPKD). Cholecalciferol 16-31 C-C motif chemokine ligand 2 Homo sapiens 122-156 23971693-9 2013 We predict that cholecalciferol will attenuate hypertension, proteinuria and reduce the urinary excretion of a biomarker, monocyte chemoattractant protein-1 (MCP-1, a surrogate inflammatory marker of progression in ADPKD). Cholecalciferol 16-31 C-C motif chemokine ligand 2 Homo sapiens 158-163 23457386-6 2013 Treatment with vitamin D3 increased the RANKL/OPG ratio and DKK-2 expression and reduced DKK-1 expression in each cell population, but did not affect beta-catenin levels. Cholecalciferol 15-25 TNF superfamily member 11 Homo sapiens 40-45 23457386-6 2013 Treatment with vitamin D3 increased the RANKL/OPG ratio and DKK-2 expression and reduced DKK-1 expression in each cell population, but did not affect beta-catenin levels. Cholecalciferol 15-25 TNF receptor superfamily member 11b Homo sapiens 46-49 23457386-6 2013 Treatment with vitamin D3 increased the RANKL/OPG ratio and DKK-2 expression and reduced DKK-1 expression in each cell population, but did not affect beta-catenin levels. Cholecalciferol 15-25 dickkopf WNT signaling pathway inhibitor 2 Homo sapiens 60-65 23457386-6 2013 Treatment with vitamin D3 increased the RANKL/OPG ratio and DKK-2 expression and reduced DKK-1 expression in each cell population, but did not affect beta-catenin levels. Cholecalciferol 15-25 dickkopf WNT signaling pathway inhibitor 1 Homo sapiens 89-94 23454830-0 2013 Hydroxylation of CYP11A1-derived products of vitamin D3 metabolism by human and mouse CYP27B1. Cholecalciferol 45-55 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 17-24 23454830-0 2013 Hydroxylation of CYP11A1-derived products of vitamin D3 metabolism by human and mouse CYP27B1. Cholecalciferol 45-55 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 86-93 23454830-1 2013 CYP11A1 can hydroxylate vitamin D3 at carbons 17, 20, 22, and 23, producing a range of secosteroids which are biologically active with respect to their ability to inhibit proliferation and stimulate differentiation of various cell types, including cancer cells. Cholecalciferol 24-34 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 0-7 23021159-0 2013 Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients: a retrospective clinical study. Cholecalciferol 10-20 neurofibromin 1 Homo sapiens 50-69 23021159-3 2013 This study investigates the therapeutic potential of oral vitamin D3 on bone mineral density (BMD) in NF1 patients with vitamin D3 deficiency. Cholecalciferol 58-68 neurofibromin 1 Homo sapiens 102-105 23021159-3 2013 This study investigates the therapeutic potential of oral vitamin D3 on bone mineral density (BMD) in NF1 patients with vitamin D3 deficiency. Cholecalciferol 120-130 neurofibromin 1 Homo sapiens 102-105 23021159-10 2013 CONCLUSIONS: Vitamin D3 supplementation improves BMD in adult NF1 patients. Cholecalciferol 13-23 neurofibromin 1 Homo sapiens 62-65 23556437-0 2013 Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D3 or D2supplementation. Cholecalciferol 98-108 GC vitamin D binding protein Homo sapiens 56-81 23940873-4 2013 The study has shown that prednisolone action causes impairment of cholecalciferol metabolism in hepatocytes due to inhibiting vitamin D3 25-hydroxylase activity. Cholecalciferol 66-81 cytochrome P450, family 27, subfamily a, polypeptide 1 Rattus norvegicus 126-151 23556437-13 2013 CONCLUSION: Genetic variation in DBP (rs4588 SNP) influences responsiveness to vitamin D3 but not vitamin D2. Cholecalciferol 79-89 D-box binding PAR bZIP transcription factor Homo sapiens 33-36 23199009-9 2013 In patients receiving calcitriol and cholecalciferol, the mean levels of P1NP (p<0.001) and CTx (p= 0.002) declined significantly compared to our placebo group. Cholecalciferol 37-52 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 95-98 23521914-0 2013 Vitamin D3 induces IDO+ tolerogenic DCs and enhances Treg, reducing the severity of EAE. Cholecalciferol 0-10 indoleamine 2,3-dioxygenase 1 Rattus norvegicus 19-22 23593176-3 2013 Recent studies implicate that hormones including glucocorticoids (ligand for glucocorticoid receptor) and vitamin D3 (ligand for vitamin D receptor) protect or promote repair of podocytes from injury. Cholecalciferol 106-116 vitamin D receptor Homo sapiens 129-147 23375797-3 2013 Vitamin D3 is synthesized by the enzyme, CYP27B1, and signals via the nuclear vitamin D3 receptor. Cholecalciferol 0-10 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 41-48 23375797-3 2013 Vitamin D3 is synthesized by the enzyme, CYP27B1, and signals via the nuclear vitamin D3 receptor. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 78-97 23375797-4 2013 The enzyme, CYP24A1, degrades vitamin D3. Cholecalciferol 30-40 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 12-19 23375797-10 2013 Vitamin D3 receptor, CYP24A1 and CYP27B1 expression was measured in cholangiocarcinoma cells stimulated with vehicle or vitamin D3. Cholecalciferol 120-130 vitamin D receptor Homo sapiens 0-19 23375797-10 2013 Vitamin D3 receptor, CYP24A1 and CYP27B1 expression was measured in cholangiocarcinoma cells stimulated with vehicle or vitamin D3. Cholecalciferol 120-130 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 33-40 23375797-12 2013 Vitamin D3 induced nuclear translocation of vitamin D3 receptor in cholangiocarcinoma and decreased cholangiocarcinoma growth. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 44-63 23375797-13 2013 CONCLUSION: Treatment with vitamin D3 decreased CYP24A1, whereas CYP27B1 expression increased. Cholecalciferol 27-37 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 48-55 23521914-4 2013 RESULTS: This study provides evidence that the in vivo administration of vitamin D3, as well as the adoptive transfer of vitamin D3 -induced IDO(+) immature/tolerogenic dendritic cells, leads to a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) regulatory T cells in the lymph nodes in a rat model of MS, experimental autoimmune EAE. Cholecalciferol 73-83 Cd4 molecule Rattus norvegicus 239-242 23521914-4 2013 RESULTS: This study provides evidence that the in vivo administration of vitamin D3, as well as the adoptive transfer of vitamin D3 -induced IDO(+) immature/tolerogenic dendritic cells, leads to a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) regulatory T cells in the lymph nodes in a rat model of MS, experimental autoimmune EAE. Cholecalciferol 73-83 forkhead box P3 Rattus norvegicus 254-259 23521914-4 2013 RESULTS: This study provides evidence that the in vivo administration of vitamin D3, as well as the adoptive transfer of vitamin D3 -induced IDO(+) immature/tolerogenic dendritic cells, leads to a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) regulatory T cells in the lymph nodes in a rat model of MS, experimental autoimmune EAE. Cholecalciferol 121-131 indoleamine 2,3-dioxygenase 1 Rattus norvegicus 141-144 23521914-4 2013 RESULTS: This study provides evidence that the in vivo administration of vitamin D3, as well as the adoptive transfer of vitamin D3 -induced IDO(+) immature/tolerogenic dendritic cells, leads to a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) regulatory T cells in the lymph nodes in a rat model of MS, experimental autoimmune EAE. Cholecalciferol 121-131 Cd4 molecule Rattus norvegicus 239-242 23521914-4 2013 RESULTS: This study provides evidence that the in vivo administration of vitamin D3, as well as the adoptive transfer of vitamin D3 -induced IDO(+) immature/tolerogenic dendritic cells, leads to a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) regulatory T cells in the lymph nodes in a rat model of MS, experimental autoimmune EAE. Cholecalciferol 121-131 forkhead box P3 Rattus norvegicus 254-259 23521914-6 2013 Bone marrow-derived DCs cultivated in the presence of vitamin D3 present a tolerogenic profile with high IL-10, TNFalpha, and IDO expression and decreased MHC-II and CD80 expression. Cholecalciferol 54-64 interleukin 10 Rattus norvegicus 105-110 23521914-6 2013 Bone marrow-derived DCs cultivated in the presence of vitamin D3 present a tolerogenic profile with high IL-10, TNFalpha, and IDO expression and decreased MHC-II and CD80 expression. Cholecalciferol 54-64 tumor necrosis factor Rattus norvegicus 112-120 23521914-6 2013 Bone marrow-derived DCs cultivated in the presence of vitamin D3 present a tolerogenic profile with high IL-10, TNFalpha, and IDO expression and decreased MHC-II and CD80 expression. Cholecalciferol 54-64 indoleamine 2,3-dioxygenase 1 Rattus norvegicus 126-129 23521914-6 2013 Bone marrow-derived DCs cultivated in the presence of vitamin D3 present a tolerogenic profile with high IL-10, TNFalpha, and IDO expression and decreased MHC-II and CD80 expression. Cholecalciferol 54-64 Cd80 molecule Rattus norvegicus 166-170 23521914-7 2013 The adoptive transfer of IDO (+) DCs induces a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) T cells in the lymph nodes, comparable with vitamin D3 treatment. Cholecalciferol 157-167 indoleamine 2,3-dioxygenase 1 Rattus norvegicus 25-28 23458303-6 2013 To our knowledge, this is the first time, albeit using a simple model, a description of the complete passage of D(3) through the cell membrane, the cytoplasm, into the cell nucleus, and finally the production of RANKL with its passage to the exterior of the cell, has been modeled. Cholecalciferol 112-116 TNF superfamily member 11 Homo sapiens 212-217 22661288-0 2013 Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies. Cholecalciferol 103-113 CEA cell adhesion molecule 1 Homo sapiens 58-61 22661288-0 2013 Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies. Cholecalciferol 103-113 CEA cell adhesion molecule 1 Homo sapiens 69-72 23489420-5 2013 Based on the induction of a transcriptional activator consisting of the vitamin D receptor fused to the Gal4 DNA-binding domain, the vitamin D3-responsive sensor facilitates non-invasive and rapid assessment of permeability and functional properties of vitamin D3 analogues. Cholecalciferol 133-143 vitamin D receptor Homo sapiens 72-90 23142162-7 2013 RESULTS: Vitamin D3 therapy significantly raised 25(OH)D and 1,25(OH)2D concentrations, and lowered parathyroid hormone, but had no effect on concentrations of adiponectin, resistin, leptin, IL-6, PAI-1, urinary TGFbeta1, or HOMA-IR. Cholecalciferol 9-19 serpin family E member 1 Homo sapiens 197-202 23142162-7 2013 RESULTS: Vitamin D3 therapy significantly raised 25(OH)D and 1,25(OH)2D concentrations, and lowered parathyroid hormone, but had no effect on concentrations of adiponectin, resistin, leptin, IL-6, PAI-1, urinary TGFbeta1, or HOMA-IR. Cholecalciferol 9-19 transforming growth factor beta 1 Homo sapiens 212-220 23361158-7 2013 RESULTS: By 12 weeks, serum MCP-1 decreased in the cholecalciferol group (66.2+-2.5 to 60.8+-2.6 pg/ml, group-by-time interaction P=0.02) but was not different from baseline at 1 year. Cholecalciferol 51-66 C-C motif chemokine ligand 2 Homo sapiens 28-33 23361158-10 2013 CONCLUSIONS: High-dose cholecalciferol decreased serum MCP-1 concentrations by 12 weeks in patients with early CKD, although the decrease was not maintained for the remainder of the year. Cholecalciferol 23-38 C-C motif chemokine ligand 2 Homo sapiens 55-60 23463655-15 2013 CONCLUSIONS: Oral vitamin D3 raised prostate calcitriol levels (level 1 evidence) and modestly lowered both PSA and PTH. Cholecalciferol 18-28 kallikrein related peptidase 3 Homo sapiens 108-111 23463655-15 2013 CONCLUSIONS: Oral vitamin D3 raised prostate calcitriol levels (level 1 evidence) and modestly lowered both PSA and PTH. Cholecalciferol 18-28 parathyroid hormone Homo sapiens 116-119 23489420-5 2013 Based on the induction of a transcriptional activator consisting of the vitamin D receptor fused to the Gal4 DNA-binding domain, the vitamin D3-responsive sensor facilitates non-invasive and rapid assessment of permeability and functional properties of vitamin D3 analogues. Cholecalciferol 253-263 vitamin D receptor Homo sapiens 72-90 25382938-2 2013 Presented here is a study on the effects of the local delivery of cholecalciferol (D3) using nanoparticulate carriers composed of hydroxyapatite (HAp) and poly(D,L-lactide-co-glycolide) (PLGA). Cholecalciferol 66-81 scaffold attachment factor B Mus musculus 146-149 23611825-6 2013 Cholecalciferol supplementation produced an early (3 months) decrease in PTH, a concomitant increase in 25(OH)D, and a later (6 months) increase in 1,25(OH)2D levels, all persisting at 12 months. Cholecalciferol 0-15 parathyroid hormone Homo sapiens 73-76 23611825-9 2013 CONCLUSIONS: In our cohort of HIV-infected youth, a 12-month cholecalciferol supplementation increased 25(OH)D and 1-25(OH)2D and decreased PTH levels but had no effect on CD4+ T-cells. Cholecalciferol 61-76 parathyroid hormone Homo sapiens 140-143 23386641-3 2013 OBJECTIVES: The objective of the study was to measure the effect of vitamin D3 on serum 25OHD and serum PTH in older African American women with vitamin D insufficiency and the serum 25OHD 20 ng/mL or less (<50 nmol/L). Cholecalciferol 68-78 parathyroid hormone Homo sapiens 104-107 25382938-3 2013 Multifunctional nanoparticulate HAp-based powders were prepared for the purpose of: (a) either fast or sustained, local delivery of cholecalciferol, and (b) the secondary, osteoconductive and defect-filling effect of the carrier itself. Cholecalciferol 132-147 scaffold attachment factor B Mus musculus 32-35 25382938-6 2013 In contrast, an extensively fast release of cholecalciferol from the system comprising HAp nanoparticles coated with cholecalciferol (HAp/D3) triggered necrosis of the osteoblastic cells in vitro. Cholecalciferol 44-59 scaffold attachment factor B Mus musculus 87-90 25382938-6 2013 In contrast, an extensively fast release of cholecalciferol from the system comprising HAp nanoparticles coated with cholecalciferol (HAp/D3) triggered necrosis of the osteoblastic cells in vitro. Cholecalciferol 44-59 scaffold attachment factor B Mus musculus 134-137 25382938-6 2013 In contrast, an extensively fast release of cholecalciferol from the system comprising HAp nanoparticles coated with cholecalciferol (HAp/D3) triggered necrosis of the osteoblastic cells in vitro. Cholecalciferol 117-132 scaffold attachment factor B Mus musculus 134-137 25382938-7 2013 Artificial defects induced in the osteoporotic bone of the rat mandible were successfully reconstructed following implantation of cholecalciferol-coated HAp nanoparticles as well as those comprising HAp nanoparticles coated with cholecalciferol-loaded PLGA (HAp/D3/PLGA). Cholecalciferol 130-145 scaffold attachment factor B Mus musculus 153-156 23465499-5 2013 Klotho participates in mineral homeostasis via interplay with other calciophosphoregulatory hormones (parathyroid hormone, fibroblast growth factor-23, and 1,25-[OH]2 vitamin D3) in kidney, bone, intestine, and parathyroid gland. Cholecalciferol 167-177 klotho Homo sapiens 0-6 23348932-4 2013 Thanks, in fact, to its considerable functional versatility, MLT can exert both direct and indirect anticancer effects in factorial synergy with other differentiating, antiproliferative, immunomodulating and trophic molecules that form part of the anticancer treatment formulated by Luigi Di Bella (Di Bella Method, DBM: somatostatin, retinoids, ascorbic acid, vitamin D3, prolactin inhibitors, chondroitin-sulfate). Cholecalciferol 361-371 MALT1 paracaspase Homo sapiens 61-64 22720723-7 2013 High-dose cholecalciferol supplementation differentially influenced skin-homing markers on Treg with an increased level of CCR10 expression and while a reduction in CCR4 expression level was observed together with a lower percentage of Treg expressing CCR4. Cholecalciferol 10-25 C-C motif chemokine receptor 10 Homo sapiens 123-128 22720723-7 2013 High-dose cholecalciferol supplementation differentially influenced skin-homing markers on Treg with an increased level of CCR10 expression and while a reduction in CCR4 expression level was observed together with a lower percentage of Treg expressing CCR4. Cholecalciferol 10-25 C-C motif chemokine receptor 4 Homo sapiens 165-169 22720723-7 2013 High-dose cholecalciferol supplementation differentially influenced skin-homing markers on Treg with an increased level of CCR10 expression and while a reduction in CCR4 expression level was observed together with a lower percentage of Treg expressing CCR4. Cholecalciferol 10-25 C-C motif chemokine receptor 4 Homo sapiens 252-256 22124604-5 2013 Osteoarthritic osteoblasts showed a significantly higher VEGF expression compared to the normal and OP osteoblasts, both under basal conditions than in the presence of vitamin D3, whereas no difference was found between osteoporotic and normal osteoblast. Cholecalciferol 168-178 vascular endothelial growth factor A Homo sapiens 57-61 22124604-6 2013 Vitamin D3 significantly enhanced VEGF expression in normal and pathological osteoblasts. Cholecalciferol 0-10 vascular endothelial growth factor A Homo sapiens 34-38 22124604-7 2013 This preliminary study supports the hypothesis that VEGF is involved in the pathogenic mechanisms underlying the bone alterations typical of osteoarthritis and confirms the crucial role of vitamin D3 supplementation in metabolic bone diseases. Cholecalciferol 189-199 vascular endothelial growth factor A Homo sapiens 52-56 23295467-0 2013 20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo. Cholecalciferol 11-21 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 46-53 23291929-0 2013 Intradermal application of vitamin D3 increases migration of CD14+ dermal dendritic cells and promotes the development of Foxp3+ regulatory T cells. Cholecalciferol 27-37 CD14 molecule Homo sapiens 61-65 23291929-0 2013 Intradermal application of vitamin D3 increases migration of CD14+ dermal dendritic cells and promotes the development of Foxp3+ regulatory T cells. Cholecalciferol 27-37 forkhead box P3 Homo sapiens 122-127 24494038-4 2013 Action of CYP11A1 on vitamin D3 and D2 produces novel hydroxyderivatives with OH added at positions C17, C20, C22, C23 and C24, some of which can be hydroxylated by CYP27B1 and/or by CYP27A1 and/ or by CYP24A1.The main products of these pathways are biologically active with a potency related to their chemical structure and the target cell type. Cholecalciferol 21-31 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 10-17 23710204-2 2013 Vitamin D3 inhibits the maturation of human DC measured by changes in surface expression of HLA-DR, CD14, CD40, CD80, CD83, and CD86. Cholecalciferol 0-10 CD14 molecule Homo sapiens 100-104 23710204-2 2013 Vitamin D3 inhibits the maturation of human DC measured by changes in surface expression of HLA-DR, CD14, CD40, CD80, CD83, and CD86. Cholecalciferol 0-10 CD40 molecule Homo sapiens 106-110 23710204-2 2013 Vitamin D3 inhibits the maturation of human DC measured by changes in surface expression of HLA-DR, CD14, CD40, CD80, CD83, and CD86. Cholecalciferol 0-10 CD80 molecule Homo sapiens 112-116 23710204-2 2013 Vitamin D3 inhibits the maturation of human DC measured by changes in surface expression of HLA-DR, CD14, CD40, CD80, CD83, and CD86. Cholecalciferol 0-10 CD83 molecule Homo sapiens 118-122 23710204-2 2013 Vitamin D3 inhibits the maturation of human DC measured by changes in surface expression of HLA-DR, CD14, CD40, CD80, CD83, and CD86. Cholecalciferol 0-10 CD86 molecule Homo sapiens 128-132 23710204-5 2013 Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation. Cholecalciferol 0-10 CD40 molecule Homo sapiens 59-63 23710204-5 2013 Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation. Cholecalciferol 0-10 CD80 molecule Homo sapiens 65-69 23710204-5 2013 Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation. Cholecalciferol 0-10 CD83 molecule Homo sapiens 71-75 23710204-5 2013 Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation. Cholecalciferol 0-10 CD86 molecule Homo sapiens 81-85 23710204-5 2013 Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation. Cholecalciferol 0-10 CD14 molecule Homo sapiens 120-124 23710204-5 2013 Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation. Cholecalciferol 166-176 CD40 molecule Homo sapiens 59-63 23710204-5 2013 Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation. Cholecalciferol 166-176 CD80 molecule Homo sapiens 65-69 23710204-5 2013 Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation. Cholecalciferol 166-176 CD83 molecule Homo sapiens 71-75 23710204-5 2013 Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation. Cholecalciferol 166-176 CD86 molecule Homo sapiens 81-85 23710204-5 2013 Vitamin D3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D3-induced inhibition of dendritic cell differentiation. Cholecalciferol 166-176 CD14 molecule Homo sapiens 120-124 23710204-6 2013 Vitamin D3 acted in synergy with the TLR agonists LPS and peptidoglycan (PGN) in inducing IL-6, IL-8, and IL-10, whereas vitamin D3 completely inhibited LPS-induced secretion of IL-12. Cholecalciferol 0-10 interleukin 6 Homo sapiens 90-94 23710204-6 2013 Vitamin D3 acted in synergy with the TLR agonists LPS and peptidoglycan (PGN) in inducing IL-6, IL-8, and IL-10, whereas vitamin D3 completely inhibited LPS-induced secretion of IL-12. Cholecalciferol 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 96-100 23710204-6 2013 Vitamin D3 acted in synergy with the TLR agonists LPS and peptidoglycan (PGN) in inducing IL-6, IL-8, and IL-10, whereas vitamin D3 completely inhibited LPS-induced secretion of IL-12. Cholecalciferol 0-10 interleukin 10 Homo sapiens 106-111 24494038-4 2013 Action of CYP11A1 on vitamin D3 and D2 produces novel hydroxyderivatives with OH added at positions C17, C20, C22, C23 and C24, some of which can be hydroxylated by CYP27B1 and/or by CYP27A1 and/ or by CYP24A1.The main products of these pathways are biologically active with a potency related to their chemical structure and the target cell type. Cholecalciferol 21-31 cytokine like 1 Homo sapiens 100-103 24494038-4 2013 Action of CYP11A1 on vitamin D3 and D2 produces novel hydroxyderivatives with OH added at positions C17, C20, C22, C23 and C24, some of which can be hydroxylated by CYP27B1 and/or by CYP27A1 and/ or by CYP24A1.The main products of these pathways are biologically active with a potency related to their chemical structure and the target cell type. Cholecalciferol 21-31 nucleolin Homo sapiens 115-118 24494038-4 2013 Action of CYP11A1 on vitamin D3 and D2 produces novel hydroxyderivatives with OH added at positions C17, C20, C22, C23 and C24, some of which can be hydroxylated by CYP27B1 and/or by CYP27A1 and/ or by CYP24A1.The main products of these pathways are biologically active with a potency related to their chemical structure and the target cell type. Cholecalciferol 21-31 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 165-172 24494038-4 2013 Action of CYP11A1 on vitamin D3 and D2 produces novel hydroxyderivatives with OH added at positions C17, C20, C22, C23 and C24, some of which can be hydroxylated by CYP27B1 and/or by CYP27A1 and/ or by CYP24A1.The main products of these pathways are biologically active with a potency related to their chemical structure and the target cell type. Cholecalciferol 21-31 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 183-190 24494038-4 2013 Action of CYP11A1 on vitamin D3 and D2 produces novel hydroxyderivatives with OH added at positions C17, C20, C22, C23 and C24, some of which can be hydroxylated by CYP27B1 and/or by CYP27A1 and/ or by CYP24A1.The main products of these pathways are biologically active with a potency related to their chemical structure and the target cell type. Cholecalciferol 21-31 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 202-209 23042025-2 2013 Vitamin D3 and dexamethasone-modulated dendritic cells (Combi-DCs) loaded with islet antigens inducing islet-specific regulatory CD4(+) T cells may offer a tissue-specific intervention therapy. Cholecalciferol 0-10 CD4 molecule Homo sapiens 129-132 23159604-0 2013 A vitamin D3 analog augmented interleukin-8 production by human monocytic cells in response to various microbe-related synthetic ligands, especially NOD2 agonistic muramyldipeptide. Cholecalciferol 2-12 C-X-C motif chemokine ligand 8 Homo sapiens 30-43 23159604-0 2013 A vitamin D3 analog augmented interleukin-8 production by human monocytic cells in response to various microbe-related synthetic ligands, especially NOD2 agonistic muramyldipeptide. Cholecalciferol 2-12 nucleotide binding oligomerization domain containing 2 Homo sapiens 149-153 22832486-5 2013 Furthermore, using TSLP(over) mice in which overexpression of keratinocytic TSLP is induced by skin topical application of MC903 (a vitamin D3 analog) in a dose-dependent manner, we show that keratinocytic TSLP levels are correlated with skin sensitization strength and asthma severity. Cholecalciferol 132-142 thymic stromal lymphopoietin Mus musculus 19-23 22832486-5 2013 Furthermore, using TSLP(over) mice in which overexpression of keratinocytic TSLP is induced by skin topical application of MC903 (a vitamin D3 analog) in a dose-dependent manner, we show that keratinocytic TSLP levels are correlated with skin sensitization strength and asthma severity. Cholecalciferol 132-142 thymic stromal lymphopoietin Mus musculus 76-80 22832486-5 2013 Furthermore, using TSLP(over) mice in which overexpression of keratinocytic TSLP is induced by skin topical application of MC903 (a vitamin D3 analog) in a dose-dependent manner, we show that keratinocytic TSLP levels are correlated with skin sensitization strength and asthma severity. Cholecalciferol 132-142 thymic stromal lymphopoietin Mus musculus 76-80 23043683-1 2013 AIM: To assess the impact of vitamin D supplementation (cholecalciferol) on the insulin sensitivity and metabolic health of patients with chronic kidney disease (CKD). Cholecalciferol 56-71 insulin Homo sapiens 80-87 22858193-6 2013 SIE treatment was more effective than vitamin D3 or 17beta-estradiol in inhibiting increases in serum tumor necrosis factor-alpha levels and osteoblast osteoprotegerin expression. Cholecalciferol 38-48 tumor necrosis factor Rattus norvegicus 102-129 22858193-7 2013 SIE plus vitamin D3 was more effective in increasing osterix expression than each alone. Cholecalciferol 9-19 Sp7 transcription factor Rattus norvegicus 53-60 22858193-12 2013 In addition, there are further effects on increasing transcription factor osterix expression and preosteoblast proliferation when these were combined with vitamin D3. Cholecalciferol 155-165 Sp7 transcription factor Rattus norvegicus 74-81 23673970-0 2013 Cholecalciferol supplementation reduces soluble Klotho concentration in hemodialysis patients. Cholecalciferol 0-15 klotho Homo sapiens 48-54 23424670-11 2013 Furthermore, either the TLR2 or TLR6 antibody reduced vitamin D3 signaling and tumor cell progression in vitro. Cholecalciferol 54-64 toll like receptor 2 Homo sapiens 24-28 23424670-11 2013 Furthermore, either the TLR2 or TLR6 antibody reduced vitamin D3 signaling and tumor cell progression in vitro. Cholecalciferol 54-64 toll like receptor 6 Homo sapiens 32-36 23673970-3 2013 OBJECTIVES: The aim of the study was to evaluate the effect of cholecalciferol supplementation on soluble Klotho levels in HD patients. Cholecalciferol 63-78 klotho Homo sapiens 106-112 23673970-8 2013 Cholecalciferol treatment reduced the median concentration of soluble Klotho (from 438.73 pg/ml; interquartile range, 257.99-865.51 pg/ml; to 370.94 pg/ml; 181.72-710.91 pg/ml; P <0.05). Cholecalciferol 0-15 klotho Homo sapiens 70-76 23673970-10 2013 CONCLUSIONS: Supplementation with cholecalciferol in HD patients decreases soluble Klotho levels without affecting the FGF-23 concentration. Cholecalciferol 34-49 klotho Homo sapiens 83-89 22925537-0 2012 Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects. Cholecalciferol 41-56 interleukin 6 Homo sapiens 60-73 22925537-0 2012 Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects. Cholecalciferol 41-56 tumor necrosis factor Homo sapiens 75-102 22925537-0 2012 Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects. Cholecalciferol 41-56 insulin Homo sapiens 107-114 22925537-6 2012 We also proposed that the intervention with high dose of cholecalciferol may have effect on the cytokine levels and result in corresponding changes in the measures of insulin resistance (HOMA-IR and QUICKI). Cholecalciferol 57-72 insulin Homo sapiens 167-174 22871591-7 2012 In vivo overexpression of miR-204 by injection of miR-204 agomirs in Kunming mice attenuated vitamin D3-induced medial artery calcification. Cholecalciferol 93-103 microRNA 204 Mus musculus 26-33 22317756-12 2012 The findings showed that supplementation with vitamin D3 can significantly improve HDL-cholesterol, apoA-I concentrations and LDL-cholesterol:apoB-100 ratio, which remained significant in the multivariate model including anthropometric, dietary and physical activity measures. Cholecalciferol 46-56 apolipoprotein A1 Homo sapiens 100-106 22317756-12 2012 The findings showed that supplementation with vitamin D3 can significantly improve HDL-cholesterol, apoA-I concentrations and LDL-cholesterol:apoB-100 ratio, which remained significant in the multivariate model including anthropometric, dietary and physical activity measures. Cholecalciferol 46-56 apolipoprotein B Homo sapiens 142-150 22843547-3 2012 Interestingly, the precursor of active vitamin D3 (VD3), cholecalciferol, has been demonstrated to be a strong inhibitor of SHH-Gli signaling. Cholecalciferol 39-49 sonic hedgehog signaling molecule Homo sapiens 124-127 22843547-3 2012 Interestingly, the precursor of active vitamin D3 (VD3), cholecalciferol, has been demonstrated to be a strong inhibitor of SHH-Gli signaling. Cholecalciferol 39-49 GLI family zinc finger 1 Homo sapiens 128-131 22843547-3 2012 Interestingly, the precursor of active vitamin D3 (VD3), cholecalciferol, has been demonstrated to be a strong inhibitor of SHH-Gli signaling. Cholecalciferol 57-72 sonic hedgehog signaling molecule Homo sapiens 124-127 22843547-3 2012 Interestingly, the precursor of active vitamin D3 (VD3), cholecalciferol, has been demonstrated to be a strong inhibitor of SHH-Gli signaling. Cholecalciferol 57-72 GLI family zinc finger 1 Homo sapiens 128-131 22843547-8 2012 Cholecalciferol decreases cell proliferation and increases cell death by inhibition of the SHH-Gli pathway. Cholecalciferol 0-15 sonic hedgehog signaling molecule Homo sapiens 91-94 22843547-8 2012 Cholecalciferol decreases cell proliferation and increases cell death by inhibition of the SHH-Gli pathway. Cholecalciferol 0-15 GLI family zinc finger 1 Homo sapiens 95-98 22843547-11 2012 These findings establish that, although VD3 receptors and metabolizing enzymes are absent in CCC, cholecalciferol supplementation is a strong tool to block the reactivation of SHH-Gli pathway in this pathology, leading ultimately to tumor regression. Cholecalciferol 98-113 sonic hedgehog signaling molecule Homo sapiens 176-179 22843547-11 2012 These findings establish that, although VD3 receptors and metabolizing enzymes are absent in CCC, cholecalciferol supplementation is a strong tool to block the reactivation of SHH-Gli pathway in this pathology, leading ultimately to tumor regression. Cholecalciferol 98-113 GLI family zinc finger 1 Homo sapiens 180-183 22753133-0 2012 Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Cholecalciferol 96-106 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 38-45 22655972-5 2012 Cholecalciferol alone or together with bacteria diminished tracheal antimicrobial peptide (TAP) and bovine neutrophil beta-defensin (BNBD) 5 mRNA expression; while alone induced the expression of lingual antimicrobial peptide (LAP), bovine beta-defensin 1 (DEFB1) and bovine psoriasin (S100A7), which was inhibited in the presence of S. aureus. Cholecalciferol 0-15 beta-defensin 5 Bos taurus 100-140 22655972-5 2012 Cholecalciferol alone or together with bacteria diminished tracheal antimicrobial peptide (TAP) and bovine neutrophil beta-defensin (BNBD) 5 mRNA expression; while alone induced the expression of lingual antimicrobial peptide (LAP), bovine beta-defensin 1 (DEFB1) and bovine psoriasin (S100A7), which was inhibited in the presence of S. aureus. Cholecalciferol 0-15 lingual antimicrobial peptide Bos taurus 196-225 22655972-5 2012 Cholecalciferol alone or together with bacteria diminished tracheal antimicrobial peptide (TAP) and bovine neutrophil beta-defensin (BNBD) 5 mRNA expression; while alone induced the expression of lingual antimicrobial peptide (LAP), bovine beta-defensin 1 (DEFB1) and bovine psoriasin (S100A7), which was inhibited in the presence of S. aureus. Cholecalciferol 0-15 lingual antimicrobial peptide Bos taurus 227-230 22655972-5 2012 Cholecalciferol alone or together with bacteria diminished tracheal antimicrobial peptide (TAP) and bovine neutrophil beta-defensin (BNBD) 5 mRNA expression; while alone induced the expression of lingual antimicrobial peptide (LAP), bovine beta-defensin 1 (DEFB1) and bovine psoriasin (S100A7), which was inhibited in the presence of S. aureus. Cholecalciferol 0-15 beta-defensin 1 Bos taurus 240-255 22655972-5 2012 Cholecalciferol alone or together with bacteria diminished tracheal antimicrobial peptide (TAP) and bovine neutrophil beta-defensin (BNBD) 5 mRNA expression; while alone induced the expression of lingual antimicrobial peptide (LAP), bovine beta-defensin 1 (DEFB1) and bovine psoriasin (S100A7), which was inhibited in the presence of S. aureus. Cholecalciferol 0-15 beta-defensin 1 Bos taurus 257-262 23246829-1 2012 Vitamin-D3 upregulated protein-1 (VDUP1) is a stress response protein. Cholecalciferol 0-10 thioredoxin interacting protein Mus musculus 34-39 22871591-7 2012 In vivo overexpression of miR-204 by injection of miR-204 agomirs in Kunming mice attenuated vitamin D3-induced medial artery calcification. Cholecalciferol 93-103 microRNA 204 Mus musculus 50-57 22989379-5 2012 All new vitamin D3 analogues bound less strongly to the VDR than 1alpha,25-dihydroxyvitamin D3 but had similar antiproliferative, pro-differentiating, and transcriptional activity as the native hormone. Cholecalciferol 8-18 vitamin D receptor Homo sapiens 56-59 23076256-1 2012 Vitamin D(3) is a neurosteroid that mediates its effects via the vitamin D receptor (VDR). Cholecalciferol 0-12 vitamin D receptor Homo sapiens 65-83 23076256-1 2012 Vitamin D(3) is a neurosteroid that mediates its effects via the vitamin D receptor (VDR). Cholecalciferol 0-12 vitamin D receptor Homo sapiens 85-88 22930071-0 2012 Synthesis of vitamin D3 derivatives with nitrogen-linked substituents at A-ring C-2 and evaluation of their vitamin D receptor-mediated transcriptional activity. Cholecalciferol 13-23 complement C2 Homo sapiens 80-83 22930071-0 2012 Synthesis of vitamin D3 derivatives with nitrogen-linked substituents at A-ring C-2 and evaluation of their vitamin D receptor-mediated transcriptional activity. Cholecalciferol 13-23 vitamin D receptor Homo sapiens 108-126 22964475-0 2012 A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on the APC/beta-catenin pathway in the normal mucosa of colorectal adenoma patients. Cholecalciferol 71-81 catenin beta 1 Homo sapiens 93-105 22212646-9 2012 We conclude that both 1500 mug and two doses of 3000 mug vitamin D3 had a beneficial effect on infant anthropometry, the larger dose also improving CB ALP and maternal 25(OH)D. Cholecalciferol 57-67 alkaline phosphatase, placental Homo sapiens 151-154 22862690-1 2012 CYP27B1 is a mitochondrial cytochrome P450 that catalyses the hydroxylation of 25-hydroxyvitamin D3 at the C1alpha-position to give the hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3. Cholecalciferol 89-99 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 0-7 22862690-1 2012 CYP27B1 is a mitochondrial cytochrome P450 that catalyses the hydroxylation of 25-hydroxyvitamin D3 at the C1alpha-position to give the hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3. Cholecalciferol 89-99 endogenous retrovirus group K member 1 Homo sapiens 107-114 23097629-9 2012 During NTera2 tumor formation, down-regulation of VDR was observed, resulting in limited responsiveness to cholecalciferol and 1,25(OH)(2)D(3) treatment in vivo. Cholecalciferol 107-122 vitamin D receptor Homo sapiens 50-53 22910291-4 2012 We analyzed the effect of vitamin D3 on dysferlin expression in vitro using HL60 cells, monocytes and myotubes from controls and carriers of a single mutation in DYSF. Cholecalciferol 26-36 dysferlin Homo sapiens 40-49 22910291-7 2012 Treatment with vitamin D3 increased expression of dysferlin in vitro. Cholecalciferol 15-25 dysferlin Homo sapiens 50-59 22910291-8 2012 The effect of vitamin D3 was mediated by both a nongenomic pathway through MEK/ERK and a genomic pathway involving binding of vitamin D3 receptor to the dysferlin promoter. Cholecalciferol 14-24 mitogen-activated protein kinase kinase 7 Homo sapiens 75-78 22910291-8 2012 The effect of vitamin D3 was mediated by both a nongenomic pathway through MEK/ERK and a genomic pathway involving binding of vitamin D3 receptor to the dysferlin promoter. Cholecalciferol 14-24 mitogen-activated protein kinase 1 Homo sapiens 79-82 22910291-8 2012 The effect of vitamin D3 was mediated by both a nongenomic pathway through MEK/ERK and a genomic pathway involving binding of vitamin D3 receptor to the dysferlin promoter. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 126-145 22910291-8 2012 The effect of vitamin D3 was mediated by both a nongenomic pathway through MEK/ERK and a genomic pathway involving binding of vitamin D3 receptor to the dysferlin promoter. Cholecalciferol 14-24 dysferlin Homo sapiens 153-162 22910291-9 2012 Carriers treated with vitamin D3 had significantly increased expression of dysferlin in monocytes compared with nontreated carriers (P < 0.05). Cholecalciferol 22-32 dysferlin Homo sapiens 75-84 22910291-10 2012 These findings will have important therapeutic implications since a combination of different molecular strategies together with vitamin D3 uptake could increase dysferlin expression to nonpathological protein levels. Cholecalciferol 128-138 dysferlin Homo sapiens 161-170 22572998-9 2012 Estrous cycles were restored when vitamin D(3)-deficient Cyp27b1 null young adult females were transferred to a vitamin D(3)-replete diet. Cholecalciferol 34-46 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 57-64 22854402-0 2012 High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Cholecalciferol 10-25 parathyroid hormone Homo sapiens 34-53 22854402-11 2012 Furthermore, serum PTH improved after cholecalciferol treatment, particularly in patients who had secondary hyperparathyroidism. Cholecalciferol 38-53 parathyroid hormone Homo sapiens 19-22 22683847-0 2012 In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1. Cholecalciferol 40-50 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 75-82 22683847-0 2012 In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1. Cholecalciferol 40-50 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 99-106 22822092-8 2012 Cholecalciferol supplementation led to a significant increase to a median of 155 nmol/L 25-OHD (interquartile range 137-173 nmol/L) in treated patients (n = 25, P < 0.001). Cholecalciferol 0-15 immunoglobulin kappa variable 3D-7 Homo sapiens 86-94 22822092-11 2012 Cholecalciferol supplementation caused a significant increase in serum calcium and FGF-23. Cholecalciferol 0-15 fibroblast growth factor 23 Homo sapiens 83-89 22896638-0 2012 The Ifng gene is essential for Vdr gene expression and vitamin D3-mediated reduction of the pathogenic T cell burden in the central nervous system in experimental autoimmune encephalomyelitis, a multiple sclerosis model. Cholecalciferol 55-65 interferon gamma Mus musculus 4-8 22896638-5 2012 Sardinian MS patients frequently carry a low Ifng expresser allele, suggesting that inadequate IFN-gamma may undermine vitamin D3-mediated inhibition of demyelinating disease. Cholecalciferol 119-129 interferon gamma Homo sapiens 45-49 22896638-5 2012 Sardinian MS patients frequently carry a low Ifng expresser allele, suggesting that inadequate IFN-gamma may undermine vitamin D3-mediated inhibition of demyelinating disease. Cholecalciferol 119-129 interferon gamma Homo sapiens 95-104 22896638-12 2012 Thus, the Ifng gene was needed for CNS Vdr gene expression and vitamin D3-dependent mechanisms that inhibit EAE. Cholecalciferol 63-73 interferon gamma Mus musculus 10-14 22770938-6 2012 However, the activity of these enzymes returned to near control values with hexokinase activity reaching 0.717 +- 0.003 mug/mg/ml on vitamin D3 supplementation. Cholecalciferol 133-143 hexokinase 1 Homo sapiens 76-86 22677528-0 2012 Systematic SAR study of the side chain of nonsecosteroidal vitamin D3 analogs. Cholecalciferol 59-69 sarcosine dehydrogenase Homo sapiens 11-14 21477267-4 2012 Vitamin D3 exerts its actions through the vitamin D receptor, which is known to be an important regulator of P-glycoprotein (P-gp). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 42-60 21477267-4 2012 Vitamin D3 exerts its actions through the vitamin D receptor, which is known to be an important regulator of P-glycoprotein (P-gp). Cholecalciferol 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 109-123 21477267-4 2012 Vitamin D3 exerts its actions through the vitamin D receptor, which is known to be an important regulator of P-glycoprotein (P-gp). Cholecalciferol 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 125-129 21477267-5 2012 As P-gp plays a significant role in limiting drug bioavailability, we undertook a study to compare single-dose digoxin (a P-gp substrate) pharmacokinetics in eight healthy male subjects before and after vitamin D3 supplementation (1000 IU per day). Cholecalciferol 203-213 ATP binding cassette subfamily B member 1 Homo sapiens 3-7 22579915-0 2012 beta2-adrenoceptor and insulin receptor expression in the skeletal muscle of streptozotocin induced diabetic rats: antagonism by vitamin D3 and curcumin. Cholecalciferol 129-139 adrenoceptor beta 2 Rattus norvegicus 0-18 22579915-0 2012 beta2-adrenoceptor and insulin receptor expression in the skeletal muscle of streptozotocin induced diabetic rats: antagonism by vitamin D3 and curcumin. Cholecalciferol 129-139 insulin receptor Rattus norvegicus 23-39 22751874-5 2012 RESULTS: Mean (SD) chemokine ligand 2 (monocyte chemoattractant protein 1) levels were significantly higher (184.6 [101.1] vs 121.4 [55.8] pg/mL) at 12 months, as well as the increase in regulatory T-cell percentage (4.55% [1.5%] vs 3.34% [1.8%]) with cholecalciferol vs placebo. Cholecalciferol 252-267 C-C motif chemokine ligand 2 Homo sapiens 39-73 22751874-8 2012 CONCLUSIONS: Cholecalciferol used as adjunctive therapy with insulin is safe and associated with a protective immunologic effect and slow decline of residual beta-cell function in patients with new-onset T1DM. Cholecalciferol 13-28 insulin Homo sapiens 61-68 22508710-2 2012 OBJECTIVES: The objective of the study was to determine whether vitamin D(3) supplementation at 4000 IU/d for 1 yr is safe and would result in a decrease in serum levels of prostate-specific antigen (PSA) or in the rate of progression. Cholecalciferol 64-76 kallikrein related peptidase 3 Homo sapiens 200-203 22539586-0 2012 Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study. Cholecalciferol 0-10 angiotensinogen Homo sapiens 54-68 22508713-12 2012 Cholecalciferol supplementation prevented seasonal AMH change. Cholecalciferol 0-15 anti-Mullerian hormone Homo sapiens 51-54 22539586-2 2012 OBJECTIVE: The objective of the study was to evaluate whether vitamin D(3) therapy in obesity reduces tissue-RAS activity, as indicated by an increase in tissue sensitivity to angiotensin II (AngII). Cholecalciferol 62-74 angiotensinogen Homo sapiens 176-190 22539586-2 2012 OBJECTIVE: The objective of the study was to evaluate whether vitamin D(3) therapy in obesity reduces tissue-RAS activity, as indicated by an increase in tissue sensitivity to angiotensin II (AngII). Cholecalciferol 62-74 angiotensinogen Homo sapiens 192-197 22211698-0 2012 Interleukin-17- and protease-activated receptor 2-mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 and glucocorticoids in human keratinocytes. Cholecalciferol 118-128 F2R like trypsin receptor 1 Homo sapiens 0-49 22211698-0 2012 Interleukin-17- and protease-activated receptor 2-mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 and glucocorticoids in human keratinocytes. Cholecalciferol 118-128 C-X-C motif chemokine ligand 1 Homo sapiens 73-78 22211698-0 2012 Interleukin-17- and protease-activated receptor 2-mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 and glucocorticoids in human keratinocytes. Cholecalciferol 118-128 C-X-C motif chemokine ligand 8 Homo sapiens 83-88 26105278-15 2012 mRNA expression analysis showed a 1.8 times higher expression of VEGF-A mRNA in ECFCs treated with 10nM vitamin D3 compared to controls (1.82+-0.43, p<0.0001, n=18). Cholecalciferol 104-114 vascular endothelial growth factor A Homo sapiens 65-71 26105278-17 2012 This effect is mediated by an up-regulation of VEGF-mRNA in ECFCs by Vitamin D3. Cholecalciferol 69-79 vascular endothelial growth factor A Homo sapiens 47-51 26105278-6 2012 OBJECTIVES: Therefore we investigated the influence of vitamin D3 on the differentiation of endothelial progenitor cells (ECFCs) in a placental angiogenesis model and hypothesized that vitamin D3 stimulates the expression of vascular endothelial growth factor (VEGF) in ECFCs. Cholecalciferol 55-65 vascular endothelial growth factor A Homo sapiens 225-259 26105278-6 2012 OBJECTIVES: Therefore we investigated the influence of vitamin D3 on the differentiation of endothelial progenitor cells (ECFCs) in a placental angiogenesis model and hypothesized that vitamin D3 stimulates the expression of vascular endothelial growth factor (VEGF) in ECFCs. Cholecalciferol 185-195 vascular endothelial growth factor A Homo sapiens 225-259 22419730-4 2012 RESULTS: Only vigorous treatment with im cholecalciferol led to a significant improvement of serum calcium, a decrease in PTH levels, and histological improvement of osteomalacic bone disease. Cholecalciferol 41-56 parathyroid hormone Homo sapiens 122-125 26105278-6 2012 OBJECTIVES: Therefore we investigated the influence of vitamin D3 on the differentiation of endothelial progenitor cells (ECFCs) in a placental angiogenesis model and hypothesized that vitamin D3 stimulates the expression of vascular endothelial growth factor (VEGF) in ECFCs. Cholecalciferol 185-195 vascular endothelial growth factor A Homo sapiens 261-265 25386318-3 2012 Vitamin D3 analog is also reported to suppress T-cell mediated immunity, T-cell skin recruitment, and skin infiltration via down-regulating cutaneous lymphocyte antigen expression. Cholecalciferol 0-10 major histocompatibility complex, class II, DO alpha Homo sapiens 150-168 22486751-2 2012 Vitamin D3 enhances LL-37 production in keratinocytes. Cholecalciferol 0-10 cathelicidin antimicrobial peptide Homo sapiens 20-25 22486751-12 2012 CONCLUSIONS: Systemic vitamin D3 levels are reduced in patients with AD, which may contribute to decreased systemic LL-37 levels. Cholecalciferol 22-32 cathelicidin antimicrobial peptide Homo sapiens 116-121 22350110-3 2012 The aim of this prospective study was to test the effect of vitamin D (cholecalciferol) on the incidence of APR and intensity of pain in women undergoing infusion of zoledronic acid for postmenopausal osteoporosis. Cholecalciferol 71-86 phorbol-12-myristate-13-acetate-induced protein 1 Homo sapiens 108-111 22387385-6 2012 Moreover, vitamin D3 significantly reduced the levels of proinflammatory cytokines (TNF-alpha, IL-6, IL-12p70 and IL-1beta) produced by infected U937 cells. Cholecalciferol 10-20 tumor necrosis factor Homo sapiens 84-93 22387385-6 2012 Moreover, vitamin D3 significantly reduced the levels of proinflammatory cytokines (TNF-alpha, IL-6, IL-12p70 and IL-1beta) produced by infected U937 cells. Cholecalciferol 10-20 interleukin 6 Homo sapiens 95-99 22387385-6 2012 Moreover, vitamin D3 significantly reduced the levels of proinflammatory cytokines (TNF-alpha, IL-6, IL-12p70 and IL-1beta) produced by infected U937 cells. Cholecalciferol 10-20 interleukin 1 beta Homo sapiens 114-122 22492477-2 2012 Calcitriol, the biologically active form of vitamin D3, affects not only bone metabolism but also acts on the renal renin secretion, the pancreatic insulin production in the beta cells, growth and proliferation of smooth and cardiac muscle cells and the function of lymphocytes and macrophages. Cholecalciferol 44-54 renin Homo sapiens 116-121 26069623-0 2012 Influence of Tumor Necrosis Factor alpha, Parathyroid Hormone, and Vitamin D3 on Modulation of the RANKL2 Isoform: A Pilot Study. Cholecalciferol 67-77 TNF superfamily member 11 Homo sapiens 99-105 22210453-0 2012 Metabolism of cholesterol, vitamin D3 and 20-hydroxyvitamin D3 incorporated into phospholipid vesicles by human CYP27A1. Cholecalciferol 27-37 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 112-119 22210453-1 2012 CYP27A1 is a mitochondrial cytochrome P450 which can hydroxylate vitamin D3 and cholesterol at carbons 25 and 26, respectively. Cholecalciferol 65-75 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 0-7 22210453-5 2012 We also examined the ability of CYP27A1 to metabolize 20-hydroxyvitamin D3 (20(OH)D3), a novel non-calcemic form of vitamin D derived from CYP11A1 action on vitamin D3 which has anti-proliferative activity on keratinocytes, leukemic and myeloid cells. Cholecalciferol 64-74 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 32-39 22210453-5 2012 We also examined the ability of CYP27A1 to metabolize 20-hydroxyvitamin D3 (20(OH)D3), a novel non-calcemic form of vitamin D derived from CYP11A1 action on vitamin D3 which has anti-proliferative activity on keratinocytes, leukemic and myeloid cells. Cholecalciferol 64-74 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 139-146 22210453-8 2012 20(OH)D3 was metabolized by CYP27A1 to two major products with a k(cat)/K(m) that was 2.5-fold higher than that for vitamin D3, suggesting that 20(OH)D3 could effectively compete with vitamin D3 for catalysis. Cholecalciferol 116-126 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 28-35 22210453-8 2012 20(OH)D3 was metabolized by CYP27A1 to two major products with a k(cat)/K(m) that was 2.5-fold higher than that for vitamin D3, suggesting that 20(OH)D3 could effectively compete with vitamin D3 for catalysis. Cholecalciferol 184-194 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 28-35 22210453-11 2012 Our study reports the highest k(cat) for the 25-hydroxylation of vitamin D3 by any human cytochrome P450 suggesting that CYP27A1 might be an important contributor to the synthesis of 25-hydroxyvitamin D3, particularly in tissues where it is highly expressed. Cholecalciferol 65-75 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 121-128 21994003-3 2012 Our results demonstrated that vitamin D3-mediated prevention of clinical signs, CNS cellular lesions and demyelination observed in WT mice was abrogated in GPR30-KO mice with EAE. Cholecalciferol 30-40 G protein-coupled estrogen receptor 1 Mus musculus 156-161 21994003-4 2012 Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 & CCR3 in spleen tissue. Cholecalciferol 22-32 G protein-coupled estrogen receptor 1 Mus musculus 53-56 21994003-4 2012 Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 & CCR3 in spleen tissue. Cholecalciferol 22-32 interleukin 10 Mus musculus 96-101 21994003-4 2012 Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 & CCR3 in spleen tissue. Cholecalciferol 22-32 interleukin 6 Mus musculus 106-110 21994003-4 2012 Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 & CCR3 in spleen tissue. Cholecalciferol 22-32 myelin oligodendrocyte glycoprotein Mus musculus 123-126 21994003-4 2012 Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 & CCR3 in spleen tissue. Cholecalciferol 22-32 chemokine (C-C motif) ligand 5 Mus musculus 184-188 21994003-4 2012 Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 & CCR3 in spleen tissue. Cholecalciferol 22-32 chemokine (C-C motif) receptor 1 Mus musculus 190-194 21994003-4 2012 Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 & CCR3 in spleen tissue. Cholecalciferol 22-32 chemokine (C-C motif) receptor 3 Mus musculus 201-205 21994003-5 2012 These results demonstrate for the first time that the MER is a key contributor to the E2-dependent effects of vitamin D3-mediated protection in EAE. Cholecalciferol 110-120 G protein-coupled estrogen receptor 1 Mus musculus 54-57 25520983-5 2012 Vitamin D3 increased the gene expressions of pro-inflammatory cytokines and peroxisome proliferator-activated receptor gamma, but decreased interleukin-15 in adipose tissue through nuclear vitamin D receptor and uncoupling protein-2 signals. Cholecalciferol 0-10 peroxisome proliferator activated receptor gamma Mus musculus 76-124 25520983-5 2012 Vitamin D3 increased the gene expressions of pro-inflammatory cytokines and peroxisome proliferator-activated receptor gamma, but decreased interleukin-15 in adipose tissue through nuclear vitamin D receptor and uncoupling protein-2 signals. Cholecalciferol 0-10 interleukin 15 Mus musculus 140-154 25520983-8 2012 Vitamin D3 amplified muscle u- and m-calpain protein content and suppressed muscle calpastatin protein content. Cholecalciferol 0-10 calpain 2 Mus musculus 35-44 22293363-10 2012 CONCLUSIONS: Among HIV-infected individuals with vitamin D deficiency, supplementation with 4,000 IU vitamin D3 daily for 12 weeks modestly improved vitamin D status and cholesterol but worsened insulin resistance without change in endothelial function. Cholecalciferol 101-111 insulin Homo sapiens 195-202 22283867-1 2012 INTRODUCTION: Therapy with vitamin D3 analogs suppress the parathyroid hormone (PTH) secretion in chronic kidney disease (CKD) patients suffering from secondary hyperparathyroidism (sHPT). Cholecalciferol 27-37 parathyroid hormone Homo sapiens 59-78 21801466-3 2012 The present results showed that in non-invasive MCF-7 cells, ATRA, vitamin D3 and resveratrol possess high efficacy in the reduction of PTEN promoter methylation. Cholecalciferol 67-77 phosphatase and tensin homolog Homo sapiens 136-140 21801466-4 2012 It was associated with PTEN induction as well as DNA methyltransferase down-regulation and p21 up-regulation after treatments with vitamin D3 and resveratrol, suggesting a complex regulation of the DNA methylation machinery. Cholecalciferol 131-141 H3 histone pseudogene 16 Homo sapiens 91-94 21801466-5 2012 Vitamin D3 and resveratrol improved the inhibitory effects of 2CdA and F-ara-A on PTEN methylation in MCF-7 cells; however, only the combined action of vitamin D3 and 2CdA boosted the induction of PTEN expression, suggesting a cooperation of these compounds in additional processes driving changes in PTEN expression. Cholecalciferol 0-10 phosphatase and tensin homolog Homo sapiens 82-86 21801466-5 2012 Vitamin D3 and resveratrol improved the inhibitory effects of 2CdA and F-ara-A on PTEN methylation in MCF-7 cells; however, only the combined action of vitamin D3 and 2CdA boosted the induction of PTEN expression, suggesting a cooperation of these compounds in additional processes driving changes in PTEN expression. Cholecalciferol 0-10 phosphatase and tensin homolog Homo sapiens 197-201 21801466-5 2012 Vitamin D3 and resveratrol improved the inhibitory effects of 2CdA and F-ara-A on PTEN methylation in MCF-7 cells; however, only the combined action of vitamin D3 and 2CdA boosted the induction of PTEN expression, suggesting a cooperation of these compounds in additional processes driving changes in PTEN expression. Cholecalciferol 0-10 phosphatase and tensin homolog Homo sapiens 197-201 21801466-5 2012 Vitamin D3 and resveratrol improved the inhibitory effects of 2CdA and F-ara-A on PTEN methylation in MCF-7 cells; however, only the combined action of vitamin D3 and 2CdA boosted the induction of PTEN expression, suggesting a cooperation of these compounds in additional processes driving changes in PTEN expression. Cholecalciferol 152-162 phosphatase and tensin homolog Homo sapiens 197-201 21801466-5 2012 Vitamin D3 and resveratrol improved the inhibitory effects of 2CdA and F-ara-A on PTEN methylation in MCF-7 cells; however, only the combined action of vitamin D3 and 2CdA boosted the induction of PTEN expression, suggesting a cooperation of these compounds in additional processes driving changes in PTEN expression. Cholecalciferol 152-162 phosphatase and tensin homolog Homo sapiens 197-201 21801466-6 2012 In contrast, in highly invasive MDA-MB-231 cells, only vitamin D3 reduced PTEN methylation and induced its expression without notable effects in combined treatments. Cholecalciferol 55-65 phosphatase and tensin homolog Homo sapiens 74-78 22251138-0 2012 Effects of vitamin D3 on the expression of growth-related oncogene-alpha in THP-1 cells and human primary monocytes. Cholecalciferol 11-21 GLI family zinc finger 2 Homo sapiens 76-81 22251138-10 2012 Moreover, vitamin D3 may have potentiality in treating GRO-alpha-related chronic inflammatory diseases, like asthma and autoimmune diseases. Cholecalciferol 10-20 C-X-C motif chemokine ligand 1 Homo sapiens 55-64 22889840-0 2012 Cholecalciferol supplementation in chronic kidney disease: restoration of vitamin D status and impact on parathyroid hormone. Cholecalciferol 0-15 parathyroid hormone Homo sapiens 105-124 26069623-3 2012 Here, we investigated through a mechanistic model, human 293 cells stably transfected with the RANKL2cDNA, the production and modulation of RANKL2 protein stability upon treatment with TNF-alpha, vitamin D3, and PTH. Cholecalciferol 196-206 TNF superfamily member 11 Homo sapiens 140-146 21930443-5 2012 Similarly, FACS analysis and ELISA testing demonstrated that Vitamin D3 significantly decreased the response frequency and the response intensity of IFN-gamma and TNF-alpha production in the whole CD3-positive T lymphocyte population as well as in "naive" CD4+ CD45RA+ and "memory" CD4+ CD45RO+ T lymphocyte subsets. Cholecalciferol 61-71 interferon gamma Homo sapiens 149-158 21977923-11 2012 CONCLUSIONS: A single injection of 300,000 IU of vitamin D3 achieves a 3-month serum 25-hydroxyvitamin D range of 50-80 nmol/l and is an efficient, effective and safe procedure for improving the vitamin status and indices of insulin resistance in mothers with gestational diabetes after delivery. Cholecalciferol 49-59 insulin Homo sapiens 225-232 21930443-5 2012 Similarly, FACS analysis and ELISA testing demonstrated that Vitamin D3 significantly decreased the response frequency and the response intensity of IFN-gamma and TNF-alpha production in the whole CD3-positive T lymphocyte population as well as in "naive" CD4+ CD45RA+ and "memory" CD4+ CD45RO+ T lymphocyte subsets. Cholecalciferol 61-71 tumor necrosis factor Homo sapiens 163-172 21930443-5 2012 Similarly, FACS analysis and ELISA testing demonstrated that Vitamin D3 significantly decreased the response frequency and the response intensity of IFN-gamma and TNF-alpha production in the whole CD3-positive T lymphocyte population as well as in "naive" CD4+ CD45RA+ and "memory" CD4+ CD45RO+ T lymphocyte subsets. Cholecalciferol 61-71 CD4 molecule Homo sapiens 256-259 21930443-5 2012 Similarly, FACS analysis and ELISA testing demonstrated that Vitamin D3 significantly decreased the response frequency and the response intensity of IFN-gamma and TNF-alpha production in the whole CD3-positive T lymphocyte population as well as in "naive" CD4+ CD45RA+ and "memory" CD4+ CD45RO+ T lymphocyte subsets. Cholecalciferol 61-71 CD4 molecule Homo sapiens 261-264 23152895-1 2012 The vitamin D3 system imposes immunosuppressive effects on monocytic cells, in part, by inhibiting NF-kappaB-dependent expression of proinflammatory mediators. Cholecalciferol 4-14 nuclear factor kappa B subunit 1 Homo sapiens 99-108 21966879-8 2012 Cultures treated with Dex (100 nM), Vit-D3 (10/50 nM), and BMP-2 (500 ng/mL) demonstrated maximal calcification and up-regulation of ALP and bone sialoprotein expression. Cholecalciferol 36-42 alkaline phosphatase, placental Homo sapiens 133-136 22992568-8 2012 Overall, both cancerous and N-thy cell lines express CYP27A1 and CYP2R1 in addition to CYP27B1, establishing the potential to metabolize D(3) to 1,25(OH)(2)D(3). Cholecalciferol 137-141 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 53-60 22992568-8 2012 Overall, both cancerous and N-thy cell lines express CYP27A1 and CYP2R1 in addition to CYP27B1, establishing the potential to metabolize D(3) to 1,25(OH)(2)D(3). Cholecalciferol 137-141 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 65-71 22992568-8 2012 Overall, both cancerous and N-thy cell lines express CYP27A1 and CYP2R1 in addition to CYP27B1, establishing the potential to metabolize D(3) to 1,25(OH)(2)D(3). Cholecalciferol 137-141 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 87-94 23152895-4 2012 We examined the influence of vitamin D3 signaling on LPS-induced expression of CD55 in human monocytic THP-1 cells using quantitative PCR, immunoblot, immunohistochemistry, and NF-kappaB activation pathway inhibitors. Cholecalciferol 29-39 CD55 molecule (Cromer blood group) Homo sapiens 79-83 23152895-8 2012 Our results unexpectedly suggest that vitamin D3 signaling may promote an anti-inflammatory response through an NF-kappaB-dependent increase in CD55 expression. Cholecalciferol 38-48 nuclear factor kappa B subunit 1 Homo sapiens 112-121 22085420-4 2011 PTH levels were restored to normal by the fourth postoperative week, allowing us to wean the patients off calcium and vitamin D3 supplementation, which was attributed to full autograft function. Cholecalciferol 118-128 parathyroid hormone Homo sapiens 0-3 23152895-8 2012 Our results unexpectedly suggest that vitamin D3 signaling may promote an anti-inflammatory response through an NF-kappaB-dependent increase in CD55 expression. Cholecalciferol 38-48 CD55 molecule (Cromer blood group) Homo sapiens 144-148 22095230-0 2011 High basal NF-kappaB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives. Cholecalciferol 107-117 nuclear factor kappa B subunit 1 Homo sapiens 11-20 22095230-7 2011 Treatment of nonpigmented cells with vitamin D3 derivatives inhibited NF-kappaB DNA binding and NF-kappaB-dependent reporter assays, as well as inhibited the nuclear translocation of the p65 NF-kappaB subunit and its accumulation in the cytoplasm. Cholecalciferol 37-47 nuclear factor kappa B subunit 1 Homo sapiens 70-79 22095230-7 2011 Treatment of nonpigmented cells with vitamin D3 derivatives inhibited NF-kappaB DNA binding and NF-kappaB-dependent reporter assays, as well as inhibited the nuclear translocation of the p65 NF-kappaB subunit and its accumulation in the cytoplasm. Cholecalciferol 37-47 nuclear factor kappa B subunit 1 Homo sapiens 96-105 22095230-7 2011 Treatment of nonpigmented cells with vitamin D3 derivatives inhibited NF-kappaB DNA binding and NF-kappaB-dependent reporter assays, as well as inhibited the nuclear translocation of the p65 NF-kappaB subunit and its accumulation in the cytoplasm. Cholecalciferol 37-47 RELA proto-oncogene, NF-kB subunit Homo sapiens 187-190 22095230-7 2011 Treatment of nonpigmented cells with vitamin D3 derivatives inhibited NF-kappaB DNA binding and NF-kappaB-dependent reporter assays, as well as inhibited the nuclear translocation of the p65 NF-kappaB subunit and its accumulation in the cytoplasm. Cholecalciferol 37-47 nuclear factor kappa B subunit 1 Homo sapiens 96-105 22095230-9 2011 CONCLUSION: Classical 1,25(OH)(2)D(3) and novel 20(OH)D(3) hydroxyderivatives of vitamin D3 can target NF-kappaB and regulate melanoma progression in nonpigmented melanoma cells. Cholecalciferol 81-91 nuclear factor kappa B subunit 1 Homo sapiens 103-112 22242193-1 2012 1,25-dihydroxyvitamin D3 (1,25D3) was reported to induce premature organismal aging in fibroblast growth factor-23 (Fgf23) and klotho deficient mice, which is of main interest as 1,25D3 supplementation of its precursor cholecalciferol is used in basic osteoporosis treatment. Cholecalciferol 219-234 fibroblast growth factor 23 Mus musculus 87-114 21964212-1 2011 TXNIP (also named as VDUP-1 or TBP-2) was originally isolated in HL60 cells treated with Vitamin D3. Cholecalciferol 89-99 thioredoxin interacting protein Homo sapiens 0-5 21964212-1 2011 TXNIP (also named as VDUP-1 or TBP-2) was originally isolated in HL60 cells treated with Vitamin D3. Cholecalciferol 89-99 thioredoxin interacting protein Homo sapiens 21-27 21964212-1 2011 TXNIP (also named as VDUP-1 or TBP-2) was originally isolated in HL60 cells treated with Vitamin D3. Cholecalciferol 89-99 TATA-box binding protein like 2 Homo sapiens 31-36 21878656-2 2011 Recent reports provided evidence of Ptch-dependent secretion of vitamin D(3)-related compound, which functions as an endogenous inhibitor of Hh signaling by repressing the activity of the signal transduction partner of Ptch, Smoothened (Smo). Cholecalciferol 64-76 patched 1 Homo sapiens 36-40 21843606-4 2011 Using PET analysis, reduction in [18F]2-fluoro-2-deoxy-d-glucose (FDG) uptake or tumor volume in tumors chemopreventively treated with vitamin D3 were detected in MNU-induced tumors, vitamin D3 reduced expression of 25-hydroxylase (25OHase) (p<0.01) and 24-hydroxylase (24OHase) (p<0.01) and Seocalcitol 24OHase. Cholecalciferol 135-145 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 273-280 21843606-4 2011 Using PET analysis, reduction in [18F]2-fluoro-2-deoxy-d-glucose (FDG) uptake or tumor volume in tumors chemopreventively treated with vitamin D3 were detected in MNU-induced tumors, vitamin D3 reduced expression of 25-hydroxylase (25OHase) (p<0.01) and 24-hydroxylase (24OHase) (p<0.01) and Seocalcitol 24OHase. Cholecalciferol 135-145 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 310-317 21843606-5 2011 Positive regulation of 25OHase mRNA level after the treatment with vitamin D3 was observed in liver, while in kidney, vitamin D3 and Seocalcitol induced expression of 24OHase was significant. Cholecalciferol 118-128 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 167-174 20462603-8 2011 RESULTS: Compared with the saline + sham group, there was a significant increase in plasma IL-6 level in both saline + I/R and vitamin D3 + I/R groups and muscle, lung wet/dry weight ratio in the saline + I/R group (P < 0.05). Cholecalciferol 127-137 interleukin 6 Rattus norvegicus 91-95 20462603-10 2011 Compared with the vitamin D3 + sham group, there was a significant increase in plasma IL-6 levels in the vitamin D3 + I/R group, and leukocyte HO-1 expression in vitamin D3 + sham group (P < 0.05). Cholecalciferol 105-115 interleukin 6 Rattus norvegicus 86-90 20462603-10 2011 Compared with the vitamin D3 + sham group, there was a significant increase in plasma IL-6 levels in the vitamin D3 + I/R group, and leukocyte HO-1 expression in vitamin D3 + sham group (P < 0.05). Cholecalciferol 105-115 interleukin 6 Rattus norvegicus 86-90 20462603-12 2011 CONCLUSIONS: Pretreatment of vitamin D3 ameliorates the systemic IL-6 levels, lung and muscle injury induced by ischemia followed by reperfusion of bilateral occluded vessels in a rat model. Cholecalciferol 29-39 interleukin 6 Rattus norvegicus 65-69 21878656-2 2011 Recent reports provided evidence of Ptch-dependent secretion of vitamin D(3)-related compound, which functions as an endogenous inhibitor of Hh signaling by repressing the activity of the signal transduction partner of Ptch, Smoothened (Smo). Cholecalciferol 64-76 patched 1 Homo sapiens 219-223 21878656-2 2011 Recent reports provided evidence of Ptch-dependent secretion of vitamin D(3)-related compound, which functions as an endogenous inhibitor of Hh signaling by repressing the activity of the signal transduction partner of Ptch, Smoothened (Smo). Cholecalciferol 64-76 smoothened, frizzled class receptor Homo sapiens 225-235 22118750-9 2011 Human studies evaluating the relationship between vitamin D3 and apo A-I and HDLc have yielded conflicting results, but most suggest a positive link between increasing vitamin D3 levels and plasma apo A-I and HDLc. Cholecalciferol 50-60 apolipoprotein A1 Homo sapiens 65-72 21878656-2 2011 Recent reports provided evidence of Ptch-dependent secretion of vitamin D(3)-related compound, which functions as an endogenous inhibitor of Hh signaling by repressing the activity of the signal transduction partner of Ptch, Smoothened (Smo). Cholecalciferol 64-76 smoothened, frizzled class receptor Homo sapiens 225-228 22118750-9 2011 Human studies evaluating the relationship between vitamin D3 and apo A-I and HDLc have yielded conflicting results, but most suggest a positive link between increasing vitamin D3 levels and plasma apo A-I and HDLc. Cholecalciferol 168-178 apolipoprotein A1 Homo sapiens 197-204 21832985-0 2011 Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Cholecalciferol 5-20 transforming growth factor beta 1 Homo sapiens 55-64 21896008-2 2011 Vitamin D3 inhibits parathyroid hormone secretion, adaptive immunity and cell proliferation, and at the same time promotes insulin secretion, innate immunity and stimulates cellular differentiation. Cholecalciferol 0-10 insulin Homo sapiens 123-130 21617846-6 2011 Compared with the control group, ghrelin mRNA expression was up-regulated and the myocardium calcium content was significantly increased in vitamin D3 and nicotine-treated rats. Cholecalciferol 140-150 ghrelin and obestatin prepropeptide Rattus norvegicus 33-40 21617846-11 2011 These results indicate that exogenous administration with ghrelin attenuates myocardial calcification induced by nicotine and vitamin D3, and that the possible mechanism is via the ghrelin-induced increase in the OPN mRNA levels and decrease in the ET-1 mRNA expression in the myocardium. Cholecalciferol 126-136 ghrelin and obestatin prepropeptide Rattus norvegicus 58-65 21617846-11 2011 These results indicate that exogenous administration with ghrelin attenuates myocardial calcification induced by nicotine and vitamin D3, and that the possible mechanism is via the ghrelin-induced increase in the OPN mRNA levels and decrease in the ET-1 mRNA expression in the myocardium. Cholecalciferol 126-136 ghrelin and obestatin prepropeptide Rattus norvegicus 181-188 21832985-0 2011 Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Cholecalciferol 5-20 renin Homo sapiens 125-130 21832985-8 2011 Thus, in the short term, dietary vitamin D repletion with cholecalciferol had a beneficial effect in delaying the progression of diabetic nephropathy above that due to established renin-angiotensin-aldosterone system inhibition. Cholecalciferol 58-73 renin Homo sapiens 180-185 21640145-7 2011 Liposome uptake by THP-1 vitamin D3 stimulated macrophage-like cells did not show a liposome size-dependent pattern of uptake. Cholecalciferol 25-35 GLI family zinc finger 2 Homo sapiens 19-24 21382175-0 2011 The effect of vitamin D3 and ketoconazole combination on VDR-mediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 57-60 21677063-0 2011 Production of 22-hydroxy metabolites of vitamin d3 by cytochrome p450scc (CYP11A1) and analysis of their biological activities on skin cells. Cholecalciferol 40-50 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 54-72 21677063-0 2011 Production of 22-hydroxy metabolites of vitamin d3 by cytochrome p450scc (CYP11A1) and analysis of their biological activities on skin cells. Cholecalciferol 40-50 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 74-81 20671418-1 2011 OBJECTIVE: The aim of the study was to evaluate whether vitamin D [25-(OH) D3] status affects serum IGFI concentrations in healthy subjects. Cholecalciferol 75-77 insulin like growth factor 1 Homo sapiens 100-104 22025972-6 2011 Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling. Cholecalciferol 0-10 patched 1 Homo sapiens 63-71 22025972-6 2011 Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling. Cholecalciferol 0-10 GLI family zinc finger 1 Homo sapiens 73-77 22025972-6 2011 Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling. Cholecalciferol 0-10 cyclin D1 Homo sapiens 79-88 22025972-6 2011 Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling. Cholecalciferol 0-10 BCL2 apoptosis regulator Homo sapiens 94-98 22025972-6 2011 Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling. Cholecalciferol 132-142 patched 1 Homo sapiens 63-71 22025972-6 2011 Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling. Cholecalciferol 132-142 GLI family zinc finger 1 Homo sapiens 73-77 22025972-6 2011 Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling. Cholecalciferol 132-142 cyclin D1 Homo sapiens 79-88 22025972-6 2011 Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling. Cholecalciferol 132-142 BCL2 apoptosis regulator Homo sapiens 94-98 21382175-0 2011 The effect of vitamin D3 and ketoconazole combination on VDR-mediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance. Cholecalciferol 14-24 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 21766921-6 2011 The C-C and C-S stretching mode of 1599 cm(-1) and the C-S-C and C-C-S bending mode of 472 cm(-1) strongly couple to the b(3)u highest occupied molecular orbital (HOMO) in TTF molecule. Cholecalciferol 65-70 ras homolog family member H Homo sapiens 172-175 21653679-3 2011 Microarray analyses of control- and vitamin D(3)-treated PrP/SCs revealed global gene expression signatures consistent with induction of differentiation. Cholecalciferol 36-48 complement component 4 binding protein alpha Homo sapiens 57-60 21455565-6 2011 In MCF-7 cells, silencing of the icb-1 gene inhibited the ATRA- and the vitamin D3-induced up-regulation of lactoferrin and estrogen receptor beta expression. Cholecalciferol 72-82 thymocyte selection associated family member 2 Homo sapiens 33-38 21635154-1 2011 OBJECTIVE: The objective of this study is to investigate the effect of a newly developed calcium carbonate-vitamin D3 chewable tablet formulation (600 mg of calcium + 400 IU of vitamin D3) on serum/urine calcium and serum parathyroid hormone (PTH) as measures of intestinal calcium absorption compared to a placebo. Cholecalciferol 107-117 parathyroid hormone Homo sapiens 222-241 21635154-1 2011 OBJECTIVE: The objective of this study is to investigate the effect of a newly developed calcium carbonate-vitamin D3 chewable tablet formulation (600 mg of calcium + 400 IU of vitamin D3) on serum/urine calcium and serum parathyroid hormone (PTH) as measures of intestinal calcium absorption compared to a placebo. Cholecalciferol 107-117 parathyroid hormone Homo sapiens 243-246 21455565-6 2011 In MCF-7 cells, silencing of the icb-1 gene inhibited the ATRA- and the vitamin D3-induced up-regulation of lactoferrin and estrogen receptor beta expression. Cholecalciferol 72-82 estrogen receptor 2 Homo sapiens 124-146 21455565-0 2011 Silencing of the icb-1 gene inhibits the induction of differentiation-associated genes by vitamin D3 and all-trans retinoic acid in gynecological cancer cells. Cholecalciferol 90-100 thymocyte selection associated family member 2 Homo sapiens 17-22 21455565-3 2011 Knockdown of icb-1 inhibited the vitamin D3-induced up-regulation of E-cadherin expression in both MCF-7 and HEC-1B cells. Cholecalciferol 33-43 thymocyte selection associated family member 2 Homo sapiens 13-18 21455565-7 2011 The data of our knockdown study suggest that icb-1 may act as a mediator of differentiation signals in breast cancer cells induced by ATRA or vitamin D3. Cholecalciferol 142-152 thymocyte selection associated family member 2 Homo sapiens 45-50 21539305-0 2011 New C15-substituted active vitamin D3. Cholecalciferol 27-37 placenta associated 8 Homo sapiens 4-7 21455565-3 2011 Knockdown of icb-1 inhibited the vitamin D3-induced up-regulation of E-cadherin expression in both MCF-7 and HEC-1B cells. Cholecalciferol 33-43 cadherin 1 Homo sapiens 69-79 21397016-0 2011 A human vitamin D receptor mutant activated by cholecalciferol. Cholecalciferol 47-62 vitamin D receptor Homo sapiens 8-26 21397016-6 2011 Furthermore, via random mutagenesis, a hVDR mutant, H305F/H397Y, was discovered to bind a novel small molecule, cholecalciferol, a precursor in the 1alpha,25-dihydroxyvitamin D(3) biosynthetic pathway, which does not activate wild-type hVDR. Cholecalciferol 112-127 vitamin D receptor Homo sapiens 39-43 21397016-6 2011 Furthermore, via random mutagenesis, a hVDR mutant, H305F/H397Y, was discovered to bind a novel small molecule, cholecalciferol, a precursor in the 1alpha,25-dihydroxyvitamin D(3) biosynthetic pathway, which does not activate wild-type hVDR. Cholecalciferol 112-127 vitamin D receptor Homo sapiens 236-240 21397016-8 2011 In silico docking analysis of the variant displays a dramatic conformational shift of cholecalciferol in the ligand binding pocket in comparison to the docked analysis of cholecalciferol with wild-type hVDR. Cholecalciferol 86-101 vitamin D receptor Homo sapiens 202-206 21397016-8 2011 In silico docking analysis of the variant displays a dramatic conformational shift of cholecalciferol in the ligand binding pocket in comparison to the docked analysis of cholecalciferol with wild-type hVDR. Cholecalciferol 171-186 vitamin D receptor Homo sapiens 202-206 21459125-0 2011 PKC and PTPalpha participate in Src activation by 1alpha,25OH2 vitamin D3 in C2C12 skeletal muscle cells. Cholecalciferol 63-73 protein phosphatase 2 protein activator Mus musculus 8-16 21459125-0 2011 PKC and PTPalpha participate in Src activation by 1alpha,25OH2 vitamin D3 in C2C12 skeletal muscle cells. Cholecalciferol 63-73 Rous sarcoma oncogene Mus musculus 32-35 21498585-4 2011 Stimulating the expression of mCD14 with vitamin D3 enhanced the response to ExoS and LPS. Cholecalciferol 41-51 CD14 antigen Mus musculus 30-35 21696575-0 2011 Efficacy of vitamin D3-fortified-yogurt drink on anthropometric, metabolic, inflammatory and oxidative stress biomarkers according to vitamin D receptor gene polymorphisms in type 2 diabetic patients: a study protocol for a randomized controlled clinical trial. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 134-152 21458526-0 2011 A novel interaction between insulin-like growth factor binding protein-6 and the vitamin D receptor inhibits the role of vitamin D3 in osteoblast differentiation. Cholecalciferol 121-131 insulin like growth factor binding protein 6 Homo sapiens 28-72 21458526-0 2011 A novel interaction between insulin-like growth factor binding protein-6 and the vitamin D receptor inhibits the role of vitamin D3 in osteoblast differentiation. Cholecalciferol 121-131 vitamin D receptor Homo sapiens 81-99 21436386-4 2011 We find that indeed in BCC cells, vitamin D3 blocks both proliferation and HH signaling as assessed by mRNA expression of the HH target gene Gli1. Cholecalciferol 34-44 GLI-Kruppel family member GLI1 Mus musculus 141-145 21458410-4 2011 NCX activity was decreased by -D diet, returning to normal values after 50 IU daily of cholecalciferol/10 days or a dose of 1mug calcitriol/kg of b.w. Cholecalciferol 87-102 T cell leukemia homeobox 2 Homo sapiens 0-3 21436386-5 2011 These effects of vitamin D3 on Gli1 expression and on BCC cell proliferation are comparable to the effects of cyclopamine, a known inhibitor of the HH pathway. Cholecalciferol 17-27 GLI-Kruppel family member GLI1 Mus musculus 31-35 21436386-6 2011 These results are specific for vitamin D3, because the precursor 7-dehydrocholesterol and the downstream products 25-hydroxy vitamin D3 [25(OH)D] and 1,25-dihydroxy vitamin D3 [1,25(OH)(2)D] are considerably less effective in reducing either Gli1 mRNA or cellular proliferation. Cholecalciferol 31-41 GLI-Kruppel family member GLI1 Mus musculus 242-246 21436386-8 2011 Finally, topical vitamin D3 treatment of existing murine BCC tumors significantly decreases Gli1 and Ki67 staining. Cholecalciferol 17-27 GLI-Kruppel family member GLI1 Mus musculus 92-96 21436386-8 2011 Finally, topical vitamin D3 treatment of existing murine BCC tumors significantly decreases Gli1 and Ki67 staining. Cholecalciferol 17-27 antigen identified by monoclonal antibody Ki 67 Mus musculus 101-105 20655720-0 2011 Vitamin D3 restores altered cholinergic and insulin receptor expression in the cerebral cortex and muscarinic M3 receptor expression in pancreatic islets of streptozotocin induced diabetic rats. Cholecalciferol 0-10 insulin receptor Rattus norvegicus 44-60 21280209-9 2011 In vivo, cholecalciferol uptake in proximal intestinal fragments was 60% higher in mice overexpressing SR-BI than in wild-type mice (p<0.05), while ezetimibe effect remained non-significant. Cholecalciferol 9-24 scavenger receptor class B, member 1 Mus musculus 103-108 21280209-6 2011 Moreover Block Lipid Transport-1 (SR-BI inhibitor) and ezetimibe glucuronide (Niemann-Pick C1 Like 1 inhibitor) significantly decreased cholecalciferol transport. Cholecalciferol 136-151 scavenger receptor class B, member 1 Mus musculus 34-39 21300513-1 2011 A reliable, accurate and reproducible method to quantify vitamin D3 (Vit. Cholecalciferol 57-67 vitrin Homo sapiens 69-72 21722813-9 2011 However, hBD-2 concentrations were below the limit of detection in NL fluids at baseline and after the administration of cholecalciferol or the sham-challenge. Cholecalciferol 121-136 defensin beta 4A Homo sapiens 9-14 21167785-0 2011 1alpha,25-dihydroxyvitamin D3 (vitamin D3) catalyzes suppressive activity on human natural regulatory T cells, uniquely modulates cell cycle progression, and augments FOXP3. Cholecalciferol 19-29 forkhead box P3 Homo sapiens 167-172 21483824-1 2011 BACKGROUND: The 1alpha,25-dihydroxy-3-epi-vitamin-D3 (1alpha,25(OH)2-3-epi-D3), a natural metabolite of the seco-steroid vitamin D3, exerts its biological activity through binding to its cognate vitamin D nuclear receptor (VDR), a ligand dependent transcription regulator. Cholecalciferol 121-131 vitamin D receptor Homo sapiens 195-221 21483824-1 2011 BACKGROUND: The 1alpha,25-dihydroxy-3-epi-vitamin-D3 (1alpha,25(OH)2-3-epi-D3), a natural metabolite of the seco-steroid vitamin D3, exerts its biological activity through binding to its cognate vitamin D nuclear receptor (VDR), a ligand dependent transcription regulator. Cholecalciferol 121-131 vitamin D receptor Homo sapiens 223-226 21134350-1 2011 CYP27A1, an enzyme with several important roles in cholesterol homeostasis and vitamin D3 metabolism, has been ascribed anti-atherogenic properties. Cholecalciferol 79-89 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 0-7 21091766-0 2011 Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFbeta-1-dependent growth inhibition of breast cancer cells. Cholecalciferol 14-24 AKT serine/threonine kinase 1 Homo sapiens 55-58 21091766-0 2011 Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFbeta-1-dependent growth inhibition of breast cancer cells. Cholecalciferol 14-24 MDM2 proto-oncogene Homo sapiens 63-67 21091766-0 2011 Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFbeta-1-dependent growth inhibition of breast cancer cells. Cholecalciferol 14-24 transforming growth factor beta 1 Homo sapiens 79-88 21352586-0 2011 Supplementing alpha-tocopherol (vitamin E) and vitamin D3 in high fat diet decrease IL-6 production in murine epididymal adipose tissue and 3T3-L1 adipocytes following LPS stimulation. Cholecalciferol 47-57 interleukin 6 Mus musculus 84-88 21352586-4 2011 We examined the effects of vitamin D3 and vitamin E supplementation on levels of IL-6 and IL-10 (as a marker of anti-inflammatory cytokines since, a balance between pro- and anti-inflammatory cytokines is maintained) protein expression in adipose tissue of mice provided with an HFD. Cholecalciferol 27-37 interleukin 6 Mus musculus 81-85 21352586-4 2011 We examined the effects of vitamin D3 and vitamin E supplementation on levels of IL-6 and IL-10 (as a marker of anti-inflammatory cytokines since, a balance between pro- and anti-inflammatory cytokines is maintained) protein expression in adipose tissue of mice provided with an HFD. Cholecalciferol 27-37 interleukin 10 Mus musculus 90-95 21352586-5 2011 Additionally, we measured the effects of vitamin E and vitamin D3 treatment on LPS-stimulated 3T3-L1 adipocytes IL-6 and IL-10 secretion. Cholecalciferol 55-65 interleukin 6 Mus musculus 112-116 21352586-5 2011 Additionally, we measured the effects of vitamin E and vitamin D3 treatment on LPS-stimulated 3T3-L1 adipocytes IL-6 and IL-10 secretion. Cholecalciferol 55-65 interleukin 10 Mus musculus 121-126 21352586-7 2011 A 24-hour treatment of vitamin D3 and vitamin E significantly reduced the IL-6 levels in the adipocytes culture medium without affecting IL-10 levels. Cholecalciferol 23-33 interleukin 6 Mus musculus 74-78 21352586-8 2011 CONCLUSIONS: Vitamin D3 and vitamin E supplementation in an HFD had an anti-inflammatory effect by decreasing IL-6 production in epididymal adipose tissue in mice and in 3T3-L1 adipocytes stimulated with LPS. Cholecalciferol 13-23 interleukin 6 Mus musculus 110-114 21347289-0 2011 TRPV6 determines the effect of vitamin D3 on prostate cancer cell growth. Cholecalciferol 31-41 transient receptor potential cation channel subfamily V member 6 Homo sapiens 0-5 21115105-0 2011 Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia? Cholecalciferol 73-83 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 64-69 21115105-2 2011 In the current paper we propose a possible mechanism of VPA-induced osteomalacia involving accelerated catabolism of 1alpha,25(OH)(2)-vitamin D3 (VD3) due to increased expression of CYP24. Cholecalciferol 134-144 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 182-187 21395540-3 2011 These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR). Cholecalciferol 43-53 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 128-138 21167785-7 2011 The enhanced suppressive capacity is likely due to vitamin D3"s ability to uniquely modulate cell cycle progression and elevate FOXP3 expression. Cholecalciferol 51-61 forkhead box P3 Homo sapiens 128-133 21395540-3 2011 These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR). Cholecalciferol 43-53 nuclear receptor subfamily 1 group I member 2 Homo sapiens 146-165 21395540-3 2011 These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR). Cholecalciferol 43-53 nuclear receptor subfamily 1 group I member 2 Homo sapiens 167-170 21084270-7 2011 In the vitamin D3-supplemented group, CaR expression increased 39% (P=0.01) and CYP27B1 expression increased 159% (P=0.06). Cholecalciferol 7-17 calcium sensing receptor Homo sapiens 38-41 21395540-3 2011 These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR). Cholecalciferol 43-53 nuclear receptor subfamily 1 group I member 3 Homo sapiens 173-205 21395540-3 2011 These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR). Cholecalciferol 43-53 nuclear receptor subfamily 1 group I member 3 Homo sapiens 207-210 21395540-3 2011 These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR). Cholecalciferol 43-53 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 155-165 21395540-3 2011 These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR). Cholecalciferol 43-53 nuclear receptor subfamily 1 group H member 4 Homo sapiens 235-238 21395540-3 2011 These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR). Cholecalciferol 43-53 vitamin D receptor Homo sapiens 244-262 21395540-3 2011 These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR). Cholecalciferol 43-53 vitamin D receptor Homo sapiens 264-267 20490785-7 2011 Serum 1,25 (OH)(2) vitamin D3 was associated with higher urinary excretion of calcium and phosphorus in ASF patients. Cholecalciferol 19-29 arylsulfatase F Homo sapiens 104-107 20490785-5 2011 Serum 1,25 (OH)(2) vitamin D3 levels in the ASF and control groups were 127 +- 40 and 93 +- 35 pmol/l (p < 0.001). Cholecalciferol 19-29 arylsulfatase F Homo sapiens 44-47 21084270-7 2011 In the vitamin D3-supplemented group, CaR expression increased 39% (P=0.01) and CYP27B1 expression increased 159% (P=0.06). Cholecalciferol 7-17 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 80-87 21084270-8 2011 In patients supplemented with both calcium and vitamin D3, VDR expression increased 19% (P=0.13) and CaR expression increased 24% (P=0.05). Cholecalciferol 47-57 vitamin D receptor Homo sapiens 59-62 21084270-8 2011 In patients supplemented with both calcium and vitamin D3, VDR expression increased 19% (P=0.13) and CaR expression increased 24% (P=0.05). Cholecalciferol 47-57 calcium sensing receptor Homo sapiens 101-104 21422528-6 2011 The results obtained indicate that a vitamin D3-enriched diet correlates with a decrease in the number of amyloid plaques, a decrease in Abeta peptides, a decrease in inflammation, and an increase in NGF in the brains of AbetaPP mice. Cholecalciferol 37-47 nerve growth factor Mus musculus 200-203 21307571-5 2011 We have identified the 1alpha(OH)ase gene, which uses a novel expression cloning method derived from VDR deficient mice that have excess amounts of active vitamin D3 in the serum. Cholecalciferol 155-165 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 23-36 21307571-5 2011 We have identified the 1alpha(OH)ase gene, which uses a novel expression cloning method derived from VDR deficient mice that have excess amounts of active vitamin D3 in the serum. Cholecalciferol 155-165 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 101-104 21307571-6 2011 Identification of 1alpha(OH)ase gene had lead us to understand not only the biological significance of active vitamin D3 synthesis, but also a novel mechanism of VDR-mediated transcriptional regulation. Cholecalciferol 110-120 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 18-31 21307571-7 2011 The gene expression of 1alpha(OH)ase is positively and negatively regulated by parathyroid hormone (PTH) and active vitamin D3 respectively. Cholecalciferol 116-126 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 23-36 21041166-3 2011 RESULTS: A 48-year-old woman with a history of postsurgical hypoparathyroidism who was taking calcium carbonate, 1500 mg 3 times daily, and cholecalciferol, 1200 IU daily, presented with a generalized seizure in the setting of hypocalcemia 12 days after initiating therapy with the proton pump inhibitor lansoprazole. Cholecalciferol 140-155 ATPase H+/K+ transporting non-gastric alpha2 subunit Homo sapiens 282-293 20714323-3 2011 In this study, we show that 1,25 vitamin D3 and its analogues EB1089 and KH1060 potently inhibit CEACAM1 expression in cancer cells. Cholecalciferol 33-43 CEA cell adhesion molecule 1 Homo sapiens 97-104 21253537-12 2011 Normal PTH levels were more frequently found in case of calcium and vitamin D3 use (RR 14.3, CI 3.6-56.5, P < .001). Cholecalciferol 68-78 parathyroid hormone Homo sapiens 7-10 21253537-14 2011 This study demonstrates interrelationships between semi-quantified fecal scores, PTH levels, and the compliance of taking calcium/vitamin D3 suppletion. Cholecalciferol 130-140 parathyroid hormone Homo sapiens 81-84 20654640-2 2010 The aim of this study was to determine whether mitogen-activated protein kinase (MAPK) pathways are associated with 1,25-D(3)-induced cell death in breast cancer. Cholecalciferol 121-125 mitogen-activated protein kinase 3 Homo sapiens 81-85 22180837-1 2011 Derivatives of vitamin D(3) containing a second side-chain emanating at C-20 are known as gemini and act as vitamin D receptor agonists. Cholecalciferol 15-27 vitamin D receptor Homo sapiens 108-126 21041072-0 2011 Expression and vitamin D3 regulation of long-chain fatty-acid-CoA ligase 3 in human prostate cancer cells. Cholecalciferol 15-25 acyl-CoA synthetase long chain family member 3 Homo sapiens 40-74 20560977-1 2010 In human monocytes, Toll-like receptor (TLR) 2/1 activation leads to vitamin D3-dependent antimycobacterial activities, but the molecular mechanisms by which TLR2/1 stimulation induces antimicrobial activities against mycobacteria remain unclear. Cholecalciferol 69-79 toll like receptor 1 Homo sapiens 40-43 20971925-4 2010 Treatment with a Cox-2 selective inhibitor (SC-58125) or Cox-2 small interfering RNA attenuated hBD2 and hBD3 production in NHEKs when stimulated with macrophage-activating lipopeptide-2, polyinosinic-polycytidylic acid, or UVB (15 mJ/cm(2)), but it did not attenuate vitamin D3-induced cathelicidin. Cholecalciferol 268-278 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 20149622-7 2010 Data showed that either vitamin D (cholecalciferol or calcitriol) or a low Ca(2+) diet increases mMDH activity. Cholecalciferol 35-50 malate dehydrogenase 2, NAD (mitochondrial) Mus musculus 97-101 20872152-10 2010 High-dose cholecalciferol is safe and effective in correcting vitamin D insufficiency and results in a significant reduction in PTH levels in vitamin D-insufficient children. Cholecalciferol 10-25 parathyroid hormone Homo sapiens 128-131 21050239-0 2010 Vitamin D3 treatment of Crohn"s disease patients increases stimulated T cell IL-6 production and proliferation. Cholecalciferol 0-10 interleukin 6 Homo sapiens 77-81 21050239-1 2010 BACKGROUND: Vitamin D3 has shown immune-modulating effects in CD4+ T cells from Crohn"s disease patients in vitro. Cholecalciferol 12-22 CD4 molecule Homo sapiens 62-65 21050239-6 2010 Vitamin D3 treatment increased interleukin-6 production (delta = 188 pg/mL, range: -444 to 4071) compared with a decrease in the placebo group (delta = -896 pg/mL, range: -3841 to 1323) (P < 0.02, Wilcoxon rank sum test). Cholecalciferol 0-10 interleukin 6 Homo sapiens 31-44 21050239-7 2010 Interestingly, vitamin D3 increased the amount of proliferating stimulated CD4+ T cells from median 41% (range: 10-75%) to 56% (range: 26-77%) (P = 0.02, Wilcoxon rank sum test). Cholecalciferol 15-25 CD4 molecule Homo sapiens 75-78 21050239-8 2010 CONCLUSIONS: Vitamin D3 treatment of Crohn"s disease patients increased the IL-6 levels. Cholecalciferol 13-23 interleukin 6 Homo sapiens 76-80 21050239-9 2010 Interestingly, vitamin D3 treatment enhanced the CD4+ T cell proliferation. Cholecalciferol 15-25 CD4 molecule Homo sapiens 49-52 21067953-3 2010 Immune cells that produce calcitriol also express the vitamin D receptor (VDR) and the enzymes needed to metabolize vitamin D3 (1alpha-, 25-, and 24-hydroxylases). Cholecalciferol 116-126 vitamin D receptor Homo sapiens 54-72 21067953-3 2010 Immune cells that produce calcitriol also express the vitamin D receptor (VDR) and the enzymes needed to metabolize vitamin D3 (1alpha-, 25-, and 24-hydroxylases). Cholecalciferol 116-126 vitamin D receptor Homo sapiens 74-77 20667458-2 2010 The dopamine receptor DRD3 gene is a strong candidate in genetic studies of SCZ because of the dopamine hypothesis of SCZ and the selective expression of D(3) in areas of the limbic system implicated in the disease. Cholecalciferol 154-158 dopamine receptor D3 Homo sapiens 22-26 20560977-1 2010 In human monocytes, Toll-like receptor (TLR) 2/1 activation leads to vitamin D3-dependent antimycobacterial activities, but the molecular mechanisms by which TLR2/1 stimulation induces antimicrobial activities against mycobacteria remain unclear. Cholecalciferol 69-79 toll like receptor 2 Homo sapiens 158-164 20660032-12 2010 CONCLUSIONS: A single oral dose of 600,000 IU of cholecalciferol rapidly enhances 25(OH)D and reduces PTH in young people with vitamin D deficiency. Cholecalciferol 49-64 parathyroid hormone Homo sapiens 102-105 21105150-0 2010 A novel targeting modality for renal cell carcinoma: human osteocalcin promoter-mediated gene therapy synergistically induced by vitamin C and vitamin D3. Cholecalciferol 143-153 bone gamma-carboxyglutamate protein Homo sapiens 59-70 20398751-1 2010 25-hydroxyvitamin D3 24-hydroxylase (CYP24A1), the catabolizing enzyme of the active vitamin D3, is often overexpressed in solid tumors. Cholecalciferol 10-20 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 37-44 20642435-1 2010 Vitamin-D-receptor (VDR) mediates immunomodulatory effects of vitamin-D3 (VD3). Cholecalciferol 62-72 vitamin D receptor Homo sapiens 0-18 20642435-1 2010 Vitamin-D-receptor (VDR) mediates immunomodulatory effects of vitamin-D3 (VD3). Cholecalciferol 62-72 vitamin D receptor Homo sapiens 20-23 20664979-4 2010 The NDRG1/Cap43 expression in MG63 and U2OS was significantly enhanced by vitamin D3, which also induced the production of osteocalcin, a differentiation marker of osteoblasts. Cholecalciferol 74-84 N-myc downstream regulated 1 Homo sapiens 4-9 20664979-4 2010 The NDRG1/Cap43 expression in MG63 and U2OS was significantly enhanced by vitamin D3, which also induced the production of osteocalcin, a differentiation marker of osteoblasts. Cholecalciferol 74-84 N-myc downstream regulated 1 Homo sapiens 10-15 20664979-4 2010 The NDRG1/Cap43 expression in MG63 and U2OS was significantly enhanced by vitamin D3, which also induced the production of osteocalcin, a differentiation marker of osteoblasts. Cholecalciferol 74-84 bone gamma-carboxyglutamate protein Homo sapiens 123-134 20635334-3 2010 Patched 1 regulates the activity of Smoothened (1) via Vitamin D3, which inhibits Smoothened in the absence of hedgehog ligand or (2) via oxysterols, which activate Smoothened in the presence of hedgehog ligand. Cholecalciferol 55-65 smoothened Drosophila melanogaster 36-46 20635334-3 2010 Patched 1 regulates the activity of Smoothened (1) via Vitamin D3, which inhibits Smoothened in the absence of hedgehog ligand or (2) via oxysterols, which activate Smoothened in the presence of hedgehog ligand. Cholecalciferol 55-65 smoothened Drosophila melanogaster 82-92 20635334-3 2010 Patched 1 regulates the activity of Smoothened (1) via Vitamin D3, which inhibits Smoothened in the absence of hedgehog ligand or (2) via oxysterols, which activate Smoothened in the presence of hedgehog ligand. Cholecalciferol 55-65 smoothened Drosophila melanogaster 82-92 20557314-3 2010 Vitamin D3 contributes to host immune responses against Mycobacterium tuberculosis through LL-37/hCAP-18, which is the only cathelicidin identified to date in humans. Cholecalciferol 0-10 cathelicidin antimicrobial peptide Homo sapiens 97-104 20574005-3 2010 We studied the role of TNF in the induction of Ag-specific regulatory T cells (Tregs) by tolerogenic vitamin D3-modulated human dendritic cells (VD3-DCs), which previously were shown to release high amounts of soluble TNF (sTNF) upon maturation with LPS. Cholecalciferol 101-111 tumor necrosis factor Homo sapiens 23-26 20574005-3 2010 We studied the role of TNF in the induction of Ag-specific regulatory T cells (Tregs) by tolerogenic vitamin D3-modulated human dendritic cells (VD3-DCs), which previously were shown to release high amounts of soluble TNF (sTNF) upon maturation with LPS. Cholecalciferol 101-111 tumor necrosis factor Homo sapiens 218-221 20495364-4 2010 Vitamin D3 was found to inhibit cell growth specifically through inactivation of Smo and the downstream Hh pathway, rather than activation of the vitamin D3 receptor. Cholecalciferol 0-10 smoothened, frizzled class receptor Mus musculus 81-84 20171278-7 2010 Here, we briefly summarize our findings for all the VDR/RXR cis-acting transcriptional elements (VDR/RXR cistrome) in pre-osteoblastic cells, MC3T3-E1, provide a few examples of this dynamic control by VDR and 1,25(OH)2D3, and demonstrate that distal transcriptional control contributes to the majority of vitamin D3-mediated transcription. Cholecalciferol 306-316 vitamin D receptor Homo sapiens 52-55 20171278-7 2010 Here, we briefly summarize our findings for all the VDR/RXR cis-acting transcriptional elements (VDR/RXR cistrome) in pre-osteoblastic cells, MC3T3-E1, provide a few examples of this dynamic control by VDR and 1,25(OH)2D3, and demonstrate that distal transcriptional control contributes to the majority of vitamin D3-mediated transcription. Cholecalciferol 306-316 retinoid X receptor alpha Homo sapiens 56-59 20171278-7 2010 Here, we briefly summarize our findings for all the VDR/RXR cis-acting transcriptional elements (VDR/RXR cistrome) in pre-osteoblastic cells, MC3T3-E1, provide a few examples of this dynamic control by VDR and 1,25(OH)2D3, and demonstrate that distal transcriptional control contributes to the majority of vitamin D3-mediated transcription. Cholecalciferol 306-316 vitamin D receptor Homo sapiens 97-100 20171278-7 2010 Here, we briefly summarize our findings for all the VDR/RXR cis-acting transcriptional elements (VDR/RXR cistrome) in pre-osteoblastic cells, MC3T3-E1, provide a few examples of this dynamic control by VDR and 1,25(OH)2D3, and demonstrate that distal transcriptional control contributes to the majority of vitamin D3-mediated transcription. Cholecalciferol 306-316 retinoid X receptor alpha Homo sapiens 101-104 20171278-7 2010 Here, we briefly summarize our findings for all the VDR/RXR cis-acting transcriptional elements (VDR/RXR cistrome) in pre-osteoblastic cells, MC3T3-E1, provide a few examples of this dynamic control by VDR and 1,25(OH)2D3, and demonstrate that distal transcriptional control contributes to the majority of vitamin D3-mediated transcription. Cholecalciferol 306-316 vitamin D receptor Homo sapiens 97-100 20722932-0 2010 Effects of vitamin D3 on expression of tumor necrosis factor-alpha and chemokines by monocytes. Cholecalciferol 11-21 tumor necrosis factor Homo sapiens 39-66 20435648-0 2010 Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Cholecalciferol 0-10 toll like receptor 9 Homo sapiens 40-60 20435648-0 2010 Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Cholecalciferol 0-10 toll like receptor 9 Homo sapiens 76-96 20435648-0 2010 Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Cholecalciferol 0-10 interleukin 6 Homo sapiens 105-109 20193763-1 2010 CYP27B1 catalyzes the 1alpha-hydroxylation of 25-hydroxyvitamin D3 to 1alpha,25-dihydroxyvitamin D3, the hormonally active form of vitamin D3. Cholecalciferol 56-66 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 0-7 20040518-2 2010 Ectopic expression of BRAP2 in transfected African green monkey kidney COS-7 cells was found to significantly reduce nuclear localization signal (NLS)-dependent nuclear accumulation of either simian virus SV40 large-tumor antigen (T-ag) or human cytomegalovirus DNA polymerase processivity factor ppUL44; this was also observed in HL-60 human promyelocytic leukemia cells on induction of BRAP2 expression by vitamin D3 treatment. Cholecalciferol 408-418 BRCA1 associated protein Homo sapiens 22-27 19878298-9 2010 We have shown that exposure to UVB, sufficient to produce vitamin D(3), upregulates hCAP18 in human skin in vivo. Cholecalciferol 58-70 cathelicidin antimicrobial peptide Homo sapiens 84-90 19878298-12 2010 Our results further support the role of vitamin D(3) as a key physiologic regulator of hCAP18/LL-37 in human skin. Cholecalciferol 40-52 cathelicidin antimicrobial peptide Homo sapiens 87-93 19878298-12 2010 Our results further support the role of vitamin D(3) as a key physiologic regulator of hCAP18/LL-37 in human skin. Cholecalciferol 40-52 cathelicidin antimicrobial peptide Homo sapiens 94-99 19603526-2 2010 In fact, vitamin D3 regulates vitamin D receptor and nerve growth factor expression, modulates brain development, and reverses experimental autoimmune encephalomyelitis. Cholecalciferol 9-19 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 30-48 19603526-6 2010 We found that the translocation of vitamin D3 from cytoplasm to the nucleus is transient, as the maximal nuclear concentration is reached after 10 h of incubation with (3)H-vitamin D3 and decreases to control values by 12 h. The appearance of differentiation markers such as Bcl2, NGF, STAT3, and the decrease of proliferation markers such as cyclin-1 and PCNA are late events. Cholecalciferol 35-45 B cell leukemia/lymphoma 2 Mus musculus 275-279 19603526-6 2010 We found that the translocation of vitamin D3 from cytoplasm to the nucleus is transient, as the maximal nuclear concentration is reached after 10 h of incubation with (3)H-vitamin D3 and decreases to control values by 12 h. The appearance of differentiation markers such as Bcl2, NGF, STAT3, and the decrease of proliferation markers such as cyclin-1 and PCNA are late events. Cholecalciferol 35-45 signal transducer and activator of transcription 3 Mus musculus 286-291 19603526-6 2010 We found that the translocation of vitamin D3 from cytoplasm to the nucleus is transient, as the maximal nuclear concentration is reached after 10 h of incubation with (3)H-vitamin D3 and decreases to control values by 12 h. The appearance of differentiation markers such as Bcl2, NGF, STAT3, and the decrease of proliferation markers such as cyclin-1 and PCNA are late events. Cholecalciferol 35-45 proliferating cell nuclear antigen Mus musculus 356-360 20096724-1 2010 The study was to find out the effect of Vitamin D3 supplementation on preventing the altered gene expression of cholinergic, dopaminergic, insulin receptors and GLUT3 gene expression in cerebellum of diabetic rats. Cholecalciferol 40-50 solute carrier family 2 member 3 Rattus norvegicus 161-166 20096724-9 2010 Our study showed Vitamin D3 functional regulation through dopaminergic, cholinergic and insulin receptors and glucose transport mechanism through GLUT3 in the cerebellum of diabetic rats which play a major role in neuroprotection in diabetes which has clinical application. Cholecalciferol 17-27 solute carrier family 2 member 3 Rattus norvegicus 146-151 20227041-0 2010 Modulation of the vitamin D3 response by cancer-associated mutant p53. Cholecalciferol 18-28 tumor protein p53 Homo sapiens 66-69 20089776-6 2010 Endpoint serum PTH was lower (P < 0.05) in the 3 cholecalciferol-supplemented groups compared with that in the placebo group in > or = 64-y olds, but cholecalciferol supplementation did not affect other markers in either cohort and there was no significant interaction with VDR genotype. Cholecalciferol 52-67 vitamin D receptor Homo sapiens 280-283 20360850-1 2010 BACKGROUND: Cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,23(OH)(2)D3, as well as 1-hydroxyvitamin D3 to 1alpha,20-dihydroxyvitamin D3 (1,20(OH)(2)D3). Cholecalciferol 51-53 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 12-30 20360850-0 2010 Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity. Cholecalciferol 12-22 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 61-79 20360850-1 2010 BACKGROUND: Cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,23(OH)(2)D3, as well as 1-hydroxyvitamin D3 to 1alpha,20-dihydroxyvitamin D3 (1,20(OH)(2)D3). Cholecalciferol 43-53 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 12-30 20684247-2 2010 Activity of vitamin D3 25-hydroxylase enzymes of hepatocytes is regulated by cholecalciferol and alpha-tocopherol. Cholecalciferol 77-92 cytochrome P450, family 27, subfamily a, polypeptide 1 Rattus norvegicus 12-37 20056760-0 2010 A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Cholecalciferol 22-37 parathyroid hormone Homo sapiens 74-93 19885846-5 2010 Here, we demonstrate that in osteoblastic cells, the VDR binds to the nuclear matrix in a vitamin D(3)-dependent manner. Cholecalciferol 90-102 vitamin D receptor Homo sapiens 53-56 19809375-3 2010 Thioredoxin binding protein-2 (TBP-2), which is identical to vitamin D3 up-regulated protein (VDUP1) and thioredoxin interacting protein (Txnip), was recently reported to be a key transcriptional factor controlling glucose metabolism. Cholecalciferol 61-71 thioredoxin interacting protein Mus musculus 0-29 20007751-3 2010 Cholecalciferol therapy increased serum 25(OH)D levels four-fold, monocyte vitamin D receptor expression three-fold, and 24-hydroxylase expression; therapy decreased monocyte 1alpha-hydroxylase levels. Cholecalciferol 0-15 vitamin D receptor Homo sapiens 75-93 20007751-4 2010 The CD16(+) "inflammatory" monocyte subset responded to 25(OH)D repletion the most, demonstrating the greatest increase in vitamin D receptor expression after cholecalciferol. Cholecalciferol 159-174 Fc gamma receptor IIIa Homo sapiens 4-8 20007751-5 2010 Cholecalciferol therapy reduced circulating levels of inflammatory cytokines, including IL-8, IL-6, and TNF. Cholecalciferol 0-15 C-X-C motif chemokine ligand 8 Homo sapiens 88-92 20007751-5 2010 Cholecalciferol therapy reduced circulating levels of inflammatory cytokines, including IL-8, IL-6, and TNF. Cholecalciferol 0-15 interleukin 6 Homo sapiens 94-98 19809375-3 2010 Thioredoxin binding protein-2 (TBP-2), which is identical to vitamin D3 up-regulated protein (VDUP1) and thioredoxin interacting protein (Txnip), was recently reported to be a key transcriptional factor controlling glucose metabolism. Cholecalciferol 61-71 thioredoxin interacting protein Mus musculus 31-36 19809375-3 2010 Thioredoxin binding protein-2 (TBP-2), which is identical to vitamin D3 up-regulated protein (VDUP1) and thioredoxin interacting protein (Txnip), was recently reported to be a key transcriptional factor controlling glucose metabolism. Cholecalciferol 61-71 thioredoxin interacting protein Mus musculus 94-99 19809375-3 2010 Thioredoxin binding protein-2 (TBP-2), which is identical to vitamin D3 up-regulated protein (VDUP1) and thioredoxin interacting protein (Txnip), was recently reported to be a key transcriptional factor controlling glucose metabolism. Cholecalciferol 61-71 thioredoxin interacting protein Mus musculus 138-143 19415373-10 2010 To address the question whether a normalization of calcium homeostasis improves BMD in NF1 patients, we treated four patients with cholecalciferol for 1 year, which resulted in a significant increase of BMD. Cholecalciferol 131-146 neurofibromin 1 Homo sapiens 87-90 19766150-3 2010 In this study, we investigated in rats whether CST inhibits vascular calcification induced by vitamin D3 and nicotine treatment in vivo and calcification of cultured rat vascular smooth muscular cells (VSMCs) induced by beta-glycerophosphate in vitro and the underlying mechanism. Cholecalciferol 94-104 cortistatin Rattus norvegicus 47-50 20510731-5 2010 Type-1 T regulatory (Tr1) cells, CD46-stimulated IL-10-secreting T cells, and IL-10-secreting T cells induced by vitamin D3 (VitD3) and dexamethasone (Dex) are induced populations with significant regulatory activities. Cholecalciferol 113-123 interleukin 10 Homo sapiens 78-83 19733911-3 2009 The secondary bile acid lithocholic acid (LCA) is a ligand of the vitamin D receptor (VDR) and can carry out in vivo functions of vitamin D3. Cholecalciferol 130-140 vitamin D receptor Homo sapiens 66-84 19647104-8 2009 RESULTS: After one year, VDR gene polymorphisms using Bsm1 and TaqI restriction enzymes were associated with percent changes in bone area, BMC and BMD at multiple skeletal sites in the Vitamin D3 group but not in the placebo group. Cholecalciferol 185-195 vitamin D receptor Homo sapiens 25-28 20097959-0 2009 Vitamin D3 affects expression of thyroid hormone receptor alpha and deiodinase activity in liver of MNU-treated Sprague-Dawley rats. Cholecalciferol 0-10 thyroid hormone receptor alpha Rattus norvegicus 33-63 19701245-0 2009 Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Cholecalciferol 114-124 interleukin 1 beta Homo sapiens 19-27 19701245-6 2009 Vitamin D3, an effective chemopreventive agent, interrupted this crosstalk by blocking the constitutive activation of STAT1 and the production of IL-1beta in macrophages, and therefore-in a vitamin D receptor-dependent manner-inhibited the ability of macrophages to activate Wnt signaling in colon carcinoma cells. Cholecalciferol 0-10 signal transducer and activator of transcription 1 Homo sapiens 118-123 19701245-6 2009 Vitamin D3, an effective chemopreventive agent, interrupted this crosstalk by blocking the constitutive activation of STAT1 and the production of IL-1beta in macrophages, and therefore-in a vitamin D receptor-dependent manner-inhibited the ability of macrophages to activate Wnt signaling in colon carcinoma cells. Cholecalciferol 0-10 interleukin 1 beta Homo sapiens 146-154 19701245-6 2009 Vitamin D3, an effective chemopreventive agent, interrupted this crosstalk by blocking the constitutive activation of STAT1 and the production of IL-1beta in macrophages, and therefore-in a vitamin D receptor-dependent manner-inhibited the ability of macrophages to activate Wnt signaling in colon carcinoma cells. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 190-208 19666701-0 2009 Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter. Cholecalciferol 0-10 solute carrier family 46 member 1 Homo sapiens 86-119 19721012-10 2009 Moreover, ectopic GATA-1 expression stabilizes the moDC phenotype under monocyte-promoting conditions in the presence of vitamin D3 (VD3). Cholecalciferol 121-131 GATA binding protein 1 Homo sapiens 18-24 19660988-1 2009 Paricalcitol (19-nor-1,25/OH(2)/D(2)), a second generation vitamin D receptor (VDR) activator, is a synthetic analogue of vitamin D3. Cholecalciferol 122-132 nuclear receptor subfamily 4 group A member 3 Homo sapiens 17-22 19660988-1 2009 Paricalcitol (19-nor-1,25/OH(2)/D(2)), a second generation vitamin D receptor (VDR) activator, is a synthetic analogue of vitamin D3. Cholecalciferol 122-132 vitamin D receptor Homo sapiens 59-77 19660988-1 2009 Paricalcitol (19-nor-1,25/OH(2)/D(2)), a second generation vitamin D receptor (VDR) activator, is a synthetic analogue of vitamin D3. Cholecalciferol 122-132 vitamin D receptor Homo sapiens 79-82 19733911-3 2009 The secondary bile acid lithocholic acid (LCA) is a ligand of the vitamin D receptor (VDR) and can carry out in vivo functions of vitamin D3. Cholecalciferol 130-140 vitamin D receptor Homo sapiens 86-89 19538496-9 2009 Existing therapies including corticosteroids and allergen immunotherapy act on Tregs, in part to increase IL-10 production, while vitamin D3 and long-acting beta-agonists enhance IL-10 Treg function. Cholecalciferol 130-140 interleukin 10 Homo sapiens 179-184 19667150-2 2009 From research on the synthesis of 1,25(OH)2D3 analogs with the goal of separating these biological activities, we have already reported two characteristic analogs of active vitamin D3, namely 1alpha,25-dihydroxy-22-oxavitamin D3 (OCT) and 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy) vitamin D3 (ED-71). Cholecalciferol 173-183 plexin A2 Homo sapiens 230-233 19538461-1 2009 Genetic or vitamin D3-induced overexpression of thymic stromal lymphopoietin (TSLP) by keratinocytes results in an atopic dermatitis (AD)-like inflammatory phenotype in mice echoing the discovery of high TSLP expression in epidermis from AD patients. Cholecalciferol 11-21 thymic stromal lymphopoietin Mus musculus 78-82 19382910-0 2009 Vitamin D3 signalling in the brain enhances the function of phosphoprotein enriched in astrocytes--15 kD (PEA-15). Cholecalciferol 0-10 proliferation and apoptosis adaptor protein 15 Homo sapiens 106-112 20387647-7 2009 The mechanism of vitaminE participation in the vitamin D3 metabolism under D-hypovitaminosis and D-hypervitaminosis may be its influence on the activity of different vitamin D3 25-hydroxylase systems of hepatocytes. Cholecalciferol 47-57 cytochrome P450, family 27, subfamily a, polypeptide 1 Rattus norvegicus 166-191 19018785-7 2009 Serum 25OHD significantly increased at 4 and 8 weeks in both treatment groups (P < 0.001), whereas PTH(1-84) declined significantly in subjects treated with cholecalciferol (P < 0.007) and tended to decrease following ergocalciferol (P < 0.09). Cholecalciferol 160-175 parathyroid hormone Homo sapiens 102-105 19282837-5 2009 Bcl-3 silencing enhanced vitamin D3 (1,25D3)-induced gene expression of cathelicidin AMP in keratinocytes, suggesting a negative regulatory function on cathelicidin transcription. Cholecalciferol 25-35 BCL3 transcription coactivator Homo sapiens 0-5 19390510-7 2009 The stimulatory effect of D(3) on ETB receptor mRNA and protein expression was also blocked by nicardipine. Cholecalciferol 26-30 endothelin receptor type B Rattus norvegicus 34-37 19538461-1 2009 Genetic or vitamin D3-induced overexpression of thymic stromal lymphopoietin (TSLP) by keratinocytes results in an atopic dermatitis (AD)-like inflammatory phenotype in mice echoing the discovery of high TSLP expression in epidermis from AD patients. Cholecalciferol 11-21 thymic stromal lymphopoietin Mus musculus 204-208 19543524-0 2009 20-Hydroxycholecalciferol, product of vitamin D3 hydroxylation by P450scc, decreases NF-kappaB activity by increasing IkappaB alpha levels in human keratinocytes. Cholecalciferol 38-48 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 66-73 19644632-1 2009 INTRODUCTION: This study aims to compare Ki-67 antigen expression and K-ras mutation in lung tumours induced by the interfering effects of urethane followed by sodium nitrite, sodium chloride and vitamin D3. Cholecalciferol 196-206 antigen identified by monoclonal antibody Ki 67 Mus musculus 41-46 19644632-1 2009 INTRODUCTION: This study aims to compare Ki-67 antigen expression and K-ras mutation in lung tumours induced by the interfering effects of urethane followed by sodium nitrite, sodium chloride and vitamin D3. Cholecalciferol 196-206 Kirsten rat sarcoma viral oncogene homolog Mus musculus 70-75 19543524-1 2009 The side chain of vitamin D3 is hydroxylated in a sequential manner by cytochrome P450scc (CYP11A1) to form 20-hydroxycholecalciferol, which can induce growth arrest and differentiation of both primary and immortalized epidermal keratinocytes. Cholecalciferol 18-28 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 82-89 19543524-1 2009 The side chain of vitamin D3 is hydroxylated in a sequential manner by cytochrome P450scc (CYP11A1) to form 20-hydroxycholecalciferol, which can induce growth arrest and differentiation of both primary and immortalized epidermal keratinocytes. Cholecalciferol 18-28 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 91-98 19517319-1 2009 Elocalcitol, which had been under development by BioXell SpA, is a synthetic derivative of vitamin D3 that regulates cell proliferation and apoptosis via its binding to the vitamin D receptor. Cholecalciferol 91-101 surfactant protein A1 Homo sapiens 57-60 19517319-1 2009 Elocalcitol, which had been under development by BioXell SpA, is a synthetic derivative of vitamin D3 that regulates cell proliferation and apoptosis via its binding to the vitamin D receptor. Cholecalciferol 91-101 vitamin D receptor Homo sapiens 173-191 19244278-11 2009 Thus, AhR activation by BaP stimulates vitamin D3 catabolism. Cholecalciferol 39-49 aryl hydrocarbon receptor Homo sapiens 6-9 19539561-10 2009 UV-induced regulatory T cells are expanded by UV-exposed cutaneous LC and recently, epidermal expression of vitamin D3 or RANKL (CD254) has been shown to connect the environment to the immune system via expansion of CD4(+)CD25(+) regulatory T cells. Cholecalciferol 108-118 CD4 molecule Homo sapiens 216-219 19185400-0 2009 The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Cholecalciferol 35-45 parathyroid hormone Homo sapiens 78-97 19244278-0 2009 The aryl hydrocarbon receptor activator benzo[a]pyrene enhances vitamin D3 catabolism in macrophages. Cholecalciferol 64-74 aryl hydrocarbon receptor Homo sapiens 4-29 19244278-2 2009 1,25-Dihydroxyvitamin D3 [1,25(OH)2D3], a potent ligand for the nuclear receptor vitamin D receptor (VDR), has been shown to decrease the risk of osteoporosis, some types of cancer and cardiovascular disease, suggesting an opposing effect of vitamin D3 to cigarette smoking. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 101-104 19102726-0 2009 Lysine-specific gingipain promotes lipopolysaccharide- and active-vitamin D3-induced osteoclast differentiation by degrading osteoprotegerin. Cholecalciferol 66-76 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Mus musculus 125-140 18991184-17 2009 Vitamin D3 had greater potency than equimolar vitamin D2, with a higher, sustained serum 25(OH)D response and efficacious PTH suppression. Cholecalciferol 0-10 parathyroid hormone Homo sapiens 122-125 19034928-0 2009 Butyrate and vitamin D3 induce transcriptional attenuation at the cyclin D1 locus in colonic carcinoma cells. Cholecalciferol 13-23 cyclin D1 Homo sapiens 66-75 19188585-3 2009 In the present study, we show that induced expression of thymic stromal lymphopoietin (TSLP) in mouse epidermal keratinocytes upon topical application of MC903 (a low calcemic analogue of vitamin D3) not only triggers AD as we previously reported but also aggravates experimental allergic asthma induced by ovalbumin sensitization and challenge. Cholecalciferol 188-198 thymic stromal lymphopoietin Mus musculus 57-85 19188585-3 2009 In the present study, we show that induced expression of thymic stromal lymphopoietin (TSLP) in mouse epidermal keratinocytes upon topical application of MC903 (a low calcemic analogue of vitamin D3) not only triggers AD as we previously reported but also aggravates experimental allergic asthma induced by ovalbumin sensitization and challenge. Cholecalciferol 188-198 thymic stromal lymphopoietin Mus musculus 87-91 19056929-0 2009 PPARdelta is a ligand-dependent negative regulator of vitamin D3-induced monocyte differentiation. Cholecalciferol 54-64 peroxisome proliferator activated receptor delta Homo sapiens 0-9 19058874-0 2009 Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. Cholecalciferol 14-24 AKT serine/threonine kinase 1 Homo sapiens 0-3 19058874-0 2009 Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. Cholecalciferol 14-24 zinc fingers and homeoboxes 2 Homo sapiens 78-81 19058874-0 2009 Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. Cholecalciferol 14-24 mitogen-activated protein kinase kinase 7 Homo sapiens 82-85 19058874-0 2009 Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. Cholecalciferol 14-24 mitogen-activated protein kinase 1 Homo sapiens 86-89 19058874-0 2009 Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. Cholecalciferol 14-24 mitogen-activated protein kinase 1 Homo sapiens 90-94 19058874-2 2009 Here, we show that vitamin D3 induced functional differentiation by Akt through Raf/MEK/ERK MAPK signaling. Cholecalciferol 19-29 AKT serine/threonine kinase 1 Homo sapiens 68-71 19058874-2 2009 Here, we show that vitamin D3 induced functional differentiation by Akt through Raf/MEK/ERK MAPK signaling. Cholecalciferol 19-29 zinc fingers and homeoboxes 2 Homo sapiens 80-83 19058874-2 2009 Here, we show that vitamin D3 induced functional differentiation by Akt through Raf/MEK/ERK MAPK signaling. Cholecalciferol 19-29 mitogen-activated protein kinase kinase 7 Homo sapiens 84-87 19058874-2 2009 Here, we show that vitamin D3 induced functional differentiation by Akt through Raf/MEK/ERK MAPK signaling. Cholecalciferol 19-29 mitogen-activated protein kinase 1 Homo sapiens 88-91 19058874-2 2009 Here, we show that vitamin D3 induced functional differentiation by Akt through Raf/MEK/ERK MAPK signaling. Cholecalciferol 19-29 mitogen-activated protein kinase 1 Homo sapiens 92-96 19058874-3 2009 Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway. Cholecalciferol 0-10 AKT serine/threonine kinase 1 Homo sapiens 25-28 19058874-3 2009 Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway. Cholecalciferol 0-10 AKT serine/threonine kinase 1 Homo sapiens 39-42 19058874-3 2009 Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway. Cholecalciferol 0-10 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 43-47 19058874-3 2009 Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway. Cholecalciferol 0-10 zinc fingers and homeoboxes 2 Homo sapiens 43-46 19058874-3 2009 Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway. Cholecalciferol 0-10 mitogen-activated protein kinase kinase 7 Homo sapiens 96-99 19058874-3 2009 Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway. Cholecalciferol 0-10 mitogen-activated protein kinase 1 Homo sapiens 100-103 19058874-3 2009 Vitamin D3 downregulated Akt, weakened Akt-Raf1 interaction, and subsequently activated the Raf/MEK/ERK MAPK pathway. Cholecalciferol 0-10 mitogen-activated protein kinase 1 Homo sapiens 104-108 19058874-4 2009 Pharmacological inhibition of MEK/ERK crippled differentiation in response to vitamin D3. Cholecalciferol 78-88 mitogen-activated protein kinase kinase 7 Homo sapiens 30-33 19058874-4 2009 Pharmacological inhibition of MEK/ERK crippled differentiation in response to vitamin D3. Cholecalciferol 78-88 mitogen-activated protein kinase 1 Homo sapiens 34-37 19058874-5 2009 Ectopic overexpression of Akt inhibited MAPK signaling, downregulated cyclin-dependent kinase (CDK) inhibitors p21(Wip1/Cip1) and p27(Kip1) and blunted differentiation in response to vitamin D3 while knockdown of Akt by RNA interference gave reverse effects. Cholecalciferol 183-193 AKT serine/threonine kinase 1 Homo sapiens 26-29 19058874-7 2009 Vitamin D3-induced MAPK signaling mediated upregulation of the CDK inhibitors and Rb, disassociation of Raf1 and Rb, and dephosphorylation of Rb, resulting in Rb binding to transcription factor E2F1 and subsequent differentiation. Cholecalciferol 0-10 mitogen-activated protein kinase 1 Homo sapiens 19-23 19058874-7 2009 Vitamin D3-induced MAPK signaling mediated upregulation of the CDK inhibitors and Rb, disassociation of Raf1 and Rb, and dephosphorylation of Rb, resulting in Rb binding to transcription factor E2F1 and subsequent differentiation. Cholecalciferol 0-10 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 104-108 19058874-7 2009 Vitamin D3-induced MAPK signaling mediated upregulation of the CDK inhibitors and Rb, disassociation of Raf1 and Rb, and dephosphorylation of Rb, resulting in Rb binding to transcription factor E2F1 and subsequent differentiation. Cholecalciferol 0-10 E2F transcription factor 1 Homo sapiens 194-198 19058874-10 2009 Taken together, our data suggest that vitamin D3-triggered differentiation of human myeloid leukemia cells depends on downregulation of Akt, which dissociates from Raf1 and activates MAPK signaling leading to CDK inhibitor upregulation, Raf1 disassociation from Rb, and Rb upregulation and hypophosphorylation coupled to E2F1 binding. Cholecalciferol 38-48 AKT serine/threonine kinase 1 Homo sapiens 136-139 19058874-10 2009 Taken together, our data suggest that vitamin D3-triggered differentiation of human myeloid leukemia cells depends on downregulation of Akt, which dissociates from Raf1 and activates MAPK signaling leading to CDK inhibitor upregulation, Raf1 disassociation from Rb, and Rb upregulation and hypophosphorylation coupled to E2F1 binding. Cholecalciferol 38-48 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 164-168 19058874-10 2009 Taken together, our data suggest that vitamin D3-triggered differentiation of human myeloid leukemia cells depends on downregulation of Akt, which dissociates from Raf1 and activates MAPK signaling leading to CDK inhibitor upregulation, Raf1 disassociation from Rb, and Rb upregulation and hypophosphorylation coupled to E2F1 binding. Cholecalciferol 38-48 mitogen-activated protein kinase 1 Homo sapiens 183-187 19058874-10 2009 Taken together, our data suggest that vitamin D3-triggered differentiation of human myeloid leukemia cells depends on downregulation of Akt, which dissociates from Raf1 and activates MAPK signaling leading to CDK inhibitor upregulation, Raf1 disassociation from Rb, and Rb upregulation and hypophosphorylation coupled to E2F1 binding. Cholecalciferol 38-48 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 237-241 19058874-10 2009 Taken together, our data suggest that vitamin D3-triggered differentiation of human myeloid leukemia cells depends on downregulation of Akt, which dissociates from Raf1 and activates MAPK signaling leading to CDK inhibitor upregulation, Raf1 disassociation from Rb, and Rb upregulation and hypophosphorylation coupled to E2F1 binding. Cholecalciferol 38-48 E2F transcription factor 1 Homo sapiens 321-325 19225217-0 2009 Osteocalcin attenuates T3- and increases vitamin D3-induced expression of MMP-13 in mouse osteoblasts. Cholecalciferol 41-51 bone gamma-carboxyglutamate protein 2 Mus musculus 0-11 18683889-6 2009 Vitamin D(3) was also shown to induce the expression of the osteoblast-specific markers, alkaline phosphatase and osteocalcin, in a dose-dependent manner in human dermal fibroblasts. Cholecalciferol 0-12 bone gamma-carboxyglutamate protein Homo sapiens 114-125 19012883-4 2009 In addition, 18 h after sensitisation, the lymph node populations in the vitamin D3-deficient and normal male mice showed similar proliferation and IFN-gamma production. Cholecalciferol 73-83 interferon gamma Mus musculus 148-157 19068548-4 2009 RECENT FINDINGS: Recent studies advanced our understanding of the mechanisms controlling LL-37 expression, demonstrating the key involvement of the vitamin D3 and the hypoxia response pathways, and the impacts of commensal and pathogenic microorganisms on its production. Cholecalciferol 148-158 cathelicidin antimicrobial peptide Homo sapiens 89-94 19125756-0 2009 A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Cholecalciferol 81-91 insulin Homo sapiens 111-118 19125756-8 2009 CONCLUSION: The trial indicates that vitamin D(3) supplementation improves postprandial insulin sensitivity (OGIS) in apparently healthy men likely to have insulin resistance (centrally obese but non-diabetic). Cholecalciferol 37-49 insulin Homo sapiens 88-95 18971286-4 2009 Here, we investigated whether human tolDC, generated with dexamethasone and the active form of vitamin D3, maintained their tolerogenic function upon activation with LPS (LPS-tolDC), while acquiring the ability to present exogenous autoantigen and to migrate in response to the CCR7 ligand CCL19. Cholecalciferol 95-105 interferon regulatory factor 6 Homo sapiens 166-169 18971286-4 2009 Here, we investigated whether human tolDC, generated with dexamethasone and the active form of vitamin D3, maintained their tolerogenic function upon activation with LPS (LPS-tolDC), while acquiring the ability to present exogenous autoantigen and to migrate in response to the CCR7 ligand CCL19. Cholecalciferol 95-105 interferon regulatory factor 6 Homo sapiens 171-180 18971286-4 2009 Here, we investigated whether human tolDC, generated with dexamethasone and the active form of vitamin D3, maintained their tolerogenic function upon activation with LPS (LPS-tolDC), while acquiring the ability to present exogenous autoantigen and to migrate in response to the CCR7 ligand CCL19. Cholecalciferol 95-105 C-C motif chemokine receptor 7 Homo sapiens 278-282 18971286-4 2009 Here, we investigated whether human tolDC, generated with dexamethasone and the active form of vitamin D3, maintained their tolerogenic function upon activation with LPS (LPS-tolDC), while acquiring the ability to present exogenous autoantigen and to migrate in response to the CCR7 ligand CCL19. Cholecalciferol 95-105 C-C motif chemokine ligand 19 Homo sapiens 290-295 18981260-0 2009 Nuclear xenobiotic receptor pregnane X receptor locks corepressor silencing mediator for retinoid and thyroid hormone receptors (SMRT) onto the CYP24A1 promoter to attenuate vitamin D3 activation. Cholecalciferol 174-184 nuclear receptor subfamily 1, group I, member 2 Mus musculus 28-47 18981260-0 2009 Nuclear xenobiotic receptor pregnane X receptor locks corepressor silencing mediator for retinoid and thyroid hormone receptors (SMRT) onto the CYP24A1 promoter to attenuate vitamin D3 activation. Cholecalciferol 174-184 nuclear receptor co-repressor 2 Mus musculus 129-133 18981260-0 2009 Nuclear xenobiotic receptor pregnane X receptor locks corepressor silencing mediator for retinoid and thyroid hormone receptors (SMRT) onto the CYP24A1 promoter to attenuate vitamin D3 activation. Cholecalciferol 174-184 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 144-151 20429425-8 2009 Activation and expansion ofantigen-specific CD4+CD25+ Tregs in vivo using adjuvants such as IL-10 or pharmacological agents such as low dose steroids or vitamin D3 could represent novel approaches to induce antigen-specific tolerance in immune-mediated conditions such as allergic asthma, autoimmune disease and the rejection of transplanted organs in man. Cholecalciferol 153-163 CD4 molecule Homo sapiens 44-47 19125756-8 2009 CONCLUSION: The trial indicates that vitamin D(3) supplementation improves postprandial insulin sensitivity (OGIS) in apparently healthy men likely to have insulin resistance (centrally obese but non-diabetic). Cholecalciferol 37-49 insulin Homo sapiens 156-163 19225217-0 2009 Osteocalcin attenuates T3- and increases vitamin D3-induced expression of MMP-13 in mouse osteoblasts. Cholecalciferol 41-51 matrix metallopeptidase 13 Mus musculus 74-80 19094444-1 2008 Catalase (antioxidant enzyme) activity in erythrocytes and serum levels of trace elements (copper, iron, zinc), heavy metals (cadmium, cobalt) and vitamins A (retinol), D (cholecalciferol) and E (alpha-tocopherol) were measured in 145 subjects comprising 47 pre-eclamptic pregnant women (PE), 48 healthy pregnant women (HP) and 50 healthy non-pregnant controls (NP). Cholecalciferol 172-187 catalase Homo sapiens 0-8 19050268-0 2008 IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. Cholecalciferol 16-26 interleukin 17A Homo sapiens 0-6 19050268-0 2008 IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. Cholecalciferol 16-26 cathelicidin antimicrobial peptide Homo sapiens 49-83 19075789-8 2008 Activation and expansion of antigen-specific CD4(+)CD25(+) T(Regs) in vivo using adjuvants or pharmacological agents such as low dose steroids or vitamin D3 could represent novel approaches to induce antigen-specific tolerance in human diseases including allergic asthma, autoimmune disease and the rejection of transplanted organs. Cholecalciferol 146-156 CD4 molecule Homo sapiens 45-48 19000766-1 2008 Cytochrome P450scc (CYP11A1) metabolizes vitamin D3 to 20-hydroxyvitamin D3 as the major product, with subsequent production of dihydroxy and trihydroxy derivatives. Cholecalciferol 41-51 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 0-18 19000766-1 2008 Cytochrome P450scc (CYP11A1) metabolizes vitamin D3 to 20-hydroxyvitamin D3 as the major product, with subsequent production of dihydroxy and trihydroxy derivatives. Cholecalciferol 41-51 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 20-27 19000766-5 2008 The Km for 1alpha-hydroxyvitamin D3 determined for P450scc incorporated into phospholipid vesicles was 1.4 mol substrate/mol phospholipid, half that observed for vitamin D3. Cholecalciferol 25-35 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 51-58 19000766-6 2008 The kcat was 3.0 mol/min/mol P450scc, 6-fold lower than that for vitamin D3. Cholecalciferol 65-75 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 29-36 18997319-0 2008 Structure of the ligand-binding domain of rat VDR in complex with the nonsecosteroidal vitamin D3 analogue YR301. Cholecalciferol 87-97 vitamin D receptor Rattus norvegicus 46-49 18839328-11 2009 PTH and vitamin D3 were independent predictors of FGF23 in the study group. Cholecalciferol 8-18 fibroblast growth factor 23 Homo sapiens 50-55 19075641-4 2008 Several studies have reported that Trx-1 activity can be modulated by the interaction with vitamin D3-upregulated protein (VDUP-1) (also called Txnip for thioredoxin interacting protein-1 or TBP-2 for Trx-binding protein-2). Cholecalciferol 91-101 thioredoxin 1 Mus musculus 35-40 19075641-4 2008 Several studies have reported that Trx-1 activity can be modulated by the interaction with vitamin D3-upregulated protein (VDUP-1) (also called Txnip for thioredoxin interacting protein-1 or TBP-2 for Trx-binding protein-2). Cholecalciferol 91-101 thioredoxin interacting protein Mus musculus 123-129 19075641-4 2008 Several studies have reported that Trx-1 activity can be modulated by the interaction with vitamin D3-upregulated protein (VDUP-1) (also called Txnip for thioredoxin interacting protein-1 or TBP-2 for Trx-binding protein-2). Cholecalciferol 91-101 thioredoxin interacting protein Mus musculus 144-149 19075641-4 2008 Several studies have reported that Trx-1 activity can be modulated by the interaction with vitamin D3-upregulated protein (VDUP-1) (also called Txnip for thioredoxin interacting protein-1 or TBP-2 for Trx-binding protein-2). Cholecalciferol 91-101 thioredoxin interacting protein Mus musculus 191-196 19075641-4 2008 Several studies have reported that Trx-1 activity can be modulated by the interaction with vitamin D3-upregulated protein (VDUP-1) (also called Txnip for thioredoxin interacting protein-1 or TBP-2 for Trx-binding protein-2). Cholecalciferol 91-101 thioredoxin 1 Mus musculus 35-38 18814144-0 2008 Modulation of mouse RANKL gene expression by Runx2 and vitamin D3. Cholecalciferol 55-65 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 20-25 19112416-3 2008 MDB entails the use of anti-proliferative molecules such as somatostatine, prolactin, and estrogen inhibitors, along with differentiating and apoptotic molecules such as melatonin, retinoids, vitamins C, D3, and E, calcium, and amino-sugars, combined with minimal doses of chemotherapy. Cholecalciferol 204-206 ABR activator of RhoGEF and GTPase Homo sapiens 0-3 18754805-5 2008 RESULTS: After 24 weeks, cholecalciferol supplementation significantly increased 25(OH)D3 and 1,25(OH)2D3 levels and decreased PTH and insulin sensitivity. Cholecalciferol 25-40 parathyroid hormone Homo sapiens 127-130 18616960-4 2008 A recently described analog of vitamin D3, 2-methylene-19-nor-20(S)-1alpha-hydroxy-bishomopregnacalciferol [20(S)-2MbisP], suppresses PTH levels, but is unable to stimulate intestinal calcium absorption or bone resorption in rats. Cholecalciferol 31-41 parathyroid hormone Rattus norvegicus 134-137 18940664-0 2008 Superagonistic fluorinated vitamin D3 analogs stabilize helix 12 of the vitamin D receptor. Cholecalciferol 27-37 vitamin D receptor a Danio rerio 72-90 18754805-0 2008 The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. Cholecalciferol 14-29 insulin Homo sapiens 70-77 18754805-5 2008 RESULTS: After 24 weeks, cholecalciferol supplementation significantly increased 25(OH)D3 and 1,25(OH)2D3 levels and decreased PTH and insulin sensitivity. Cholecalciferol 25-40 insulin Homo sapiens 135-142 18754805-9 2008 Cholecalciferol dosages of > or =2000 IU are necessary to achieve 1,25(OH)2D3 levels that significantly decrease PTH, but also negatively affect insulin sensitivity. Cholecalciferol 0-15 parathyroid hormone Homo sapiens 116-119 18754805-9 2008 Cholecalciferol dosages of > or =2000 IU are necessary to achieve 1,25(OH)2D3 levels that significantly decrease PTH, but also negatively affect insulin sensitivity. Cholecalciferol 0-15 insulin Homo sapiens 148-155 18768889-1 2008 The epithelial-derived cytokine thymic stromal lymphopoietin (TSLP) is sufficient to induce asthma or atopic dermatitis-like phenotypes when selectively overexpressed in transgenic mice, or when driven by topical application of vitamin D3 or low-calcemic analogues. Cholecalciferol 228-238 thymic stromal lymphopoietin Mus musculus 32-60 18768889-1 2008 The epithelial-derived cytokine thymic stromal lymphopoietin (TSLP) is sufficient to induce asthma or atopic dermatitis-like phenotypes when selectively overexpressed in transgenic mice, or when driven by topical application of vitamin D3 or low-calcemic analogues. Cholecalciferol 228-238 thymic stromal lymphopoietin Mus musculus 62-66 18628207-8 2008 Knockdown of Beclin1 eliminates vitamin D3-induced autophagy and inhibits differentiation but activates apoptosis, suggesting that Beclin1 is required for both autophagy and differentiation, and autophagy cooperates with differentiation but excludes apoptosis, in which Beclin1 acts as an interface for these three different cascades. Cholecalciferol 32-42 beclin 1 Homo sapiens 131-138 18628207-8 2008 Knockdown of Beclin1 eliminates vitamin D3-induced autophagy and inhibits differentiation but activates apoptosis, suggesting that Beclin1 is required for both autophagy and differentiation, and autophagy cooperates with differentiation but excludes apoptosis, in which Beclin1 acts as an interface for these three different cascades. Cholecalciferol 32-42 beclin 1 Homo sapiens 131-138 18628207-6 2008 Vitamin D3 up-regulates Beclin1, which binds to class III phosphatidylinositol 3-kinase to trigger autophagy. Cholecalciferol 0-10 beclin 1 Homo sapiens 24-31 18716166-0 2008 Dietary calcium and cholecalciferol modulate cyclin D1 expression, apoptosis, and tumorigenesis in intestine of adenomatous polyposis coli1638N/+ mice. Cholecalciferol 20-35 cyclin D1 Mus musculus 45-54 18628207-7 2008 Vitamin D3 phosphorylates Bad in its BH3 domain, resulting in disassociation of the apoptotic Bad-Bcl-xL complex and association of Bcl-xL with Beclin1 and ultimate suppression of apoptotic signaling. Cholecalciferol 0-10 BCL2 like 1 Homo sapiens 98-104 18628207-7 2008 Vitamin D3 phosphorylates Bad in its BH3 domain, resulting in disassociation of the apoptotic Bad-Bcl-xL complex and association of Bcl-xL with Beclin1 and ultimate suppression of apoptotic signaling. Cholecalciferol 0-10 BCL2 like 1 Homo sapiens 132-138 18628207-7 2008 Vitamin D3 phosphorylates Bad in its BH3 domain, resulting in disassociation of the apoptotic Bad-Bcl-xL complex and association of Bcl-xL with Beclin1 and ultimate suppression of apoptotic signaling. Cholecalciferol 0-10 beclin 1 Homo sapiens 144-151 18628207-8 2008 Knockdown of Beclin1 eliminates vitamin D3-induced autophagy and inhibits differentiation but activates apoptosis, suggesting that Beclin1 is required for both autophagy and differentiation, and autophagy cooperates with differentiation but excludes apoptosis, in which Beclin1 acts as an interface for these three different cascades. Cholecalciferol 32-42 beclin 1 Homo sapiens 13-20 18252022-11 2008 Thus, with 8 weeks of cholecalciferol supplementation in Asian Indians with chronic hypovitaminosis D, mean serum 25(OH)D levels would be normalized and serum PTH value would be reduced to half. Cholecalciferol 22-37 parathyroid hormone Homo sapiens 159-162 18368131-0 2008 20-Hydroxyvitamin D3, a product of vitamin D3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation. Cholecalciferol 10-20 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 74-81 18368131-1 2008 It has been shown that mammalian cytochrome P450scc can metabolize vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,22(OH)2D3. Cholecalciferol 67-77 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 44-51 18368131-1 2008 It has been shown that mammalian cytochrome P450scc can metabolize vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,22(OH)2D3. Cholecalciferol 67-77 MIA SH3 domain ER export factor 3 Homo sapiens 99-111 18368131-12 2008 These data imply that the previously unreported pathway of vitamin D3 metabolism by P450scc may have wider biological implications depending, for example, on the extent of adrenal gland or cutaneous metabolism. Cholecalciferol 59-69 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 84-91 18716166-9 2008 Importantly, Apc(1638N/+) mice fed the WD/Ca/VitD3 diet did not develop colonic tumors, further indicating that dietary calcium and cholecalciferol have a key role in the chemoprevention of colorectal neoplasia in this mouse model of human colon cancer. Cholecalciferol 132-147 APC, WNT signaling pathway regulator Mus musculus 13-16 18492750-10 2008 At 60 d, the form of vitamin (cholecalciferol) significantly lowers PTH levels (P = 0.037). Cholecalciferol 30-45 parathyroid hormone Homo sapiens 68-71 18489902-0 2008 Novel vitamin D3 analogs, 1alpha, 25(OH)2D(3)-26, 23-lactam (DLAMs), antagonize bone resorption via suppressing RANKL expression in osteoblasts. Cholecalciferol 6-16 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 112-117 18410379-0 2008 Pathways and products for the metabolism of vitamin D3 by cytochrome P450scc. Cholecalciferol 44-54 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 58-76 18547426-3 2008 METHODS: Over 12-months, 136 women out of 184 randomized (T-score spine < -1.5) completed the study and received, daily, 1000 mg Ca and 20 microg cholecalciferol (Vit D3) and three different ch-OSA doses (3, 6 and 12 mg Si) or placebo. Cholecalciferol 149-164 vitrin Homo sapiens 166-169 18537536-2 2008 Starting in 1999 when the orphan nuclear receptor FXR was shown to be specifically activated by bile acids, these compounds became part of the arsenal of ligands of the steroid hormone superfamily of nuclear receptors, including receptors of Vitamin D3, retinoids (RAR, RXR), and thyroid hormone. Cholecalciferol 242-252 nuclear receptor subfamily 1 group H member 4 Homo sapiens 50-53 18487663-0 2008 Blood mineral, hormone, and osteocalcin responses of multiparous Jersey cows to an oral dose of 25-hydroxyvitamin D3 or vitamin D3 before parturition. Cholecalciferol 106-116 bone gamma-carboxyglutamate protein Bos taurus 28-39 18410337-3 2008 In recent years, vitamin D3 analogs and a new formulation containing 8% clobetasol-17-propionate in a colourless nail lacquer vehicle have produced good results for the control of nail psoriasis. Cholecalciferol 17-27 CD244 molecule Homo sapiens 180-184 18511070-0 2008 Structural analysis of CYP2R1 in complex with vitamin D3. Cholecalciferol 46-56 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 23-29 18511070-4 2008 To understand the narrow substrate specificity of CYP2R1 we obtained the hemeprotein in a highly purified state, confirmed the enzyme as a vitamin D 25-hydroxylase, and solved the crystal structure of CYP2R1 in complex with vitamin D3. Cholecalciferol 224-234 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 50-56 18511070-4 2008 To understand the narrow substrate specificity of CYP2R1 we obtained the hemeprotein in a highly purified state, confirmed the enzyme as a vitamin D 25-hydroxylase, and solved the crystal structure of CYP2R1 in complex with vitamin D3. Cholecalciferol 224-234 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 139-163 18511070-4 2008 To understand the narrow substrate specificity of CYP2R1 we obtained the hemeprotein in a highly purified state, confirmed the enzyme as a vitamin D 25-hydroxylase, and solved the crystal structure of CYP2R1 in complex with vitamin D3. Cholecalciferol 224-234 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 201-207 18411217-9 2008 TNF-alpha synthesis was also decreased upon TLR ligand stimulation in vitamin D(3)-treated monocytes. Cholecalciferol 70-82 tumor necrosis factor Homo sapiens 0-9 18004750-0 2008 Crystal structure of a secondary vitamin D3 binding site of milk beta-lactoglobulin. Cholecalciferol 33-43 beta-lactoglobulin Bos taurus 65-83 18004750-13 2008 Atomic coordinates for the crystal structure of beta-LG-vitamin D(3) complex described in this work have been deposited in the PDB (access code 2GJ5). Cholecalciferol 56-68 beta-lactoglobulin Bos taurus 48-55 18410379-1 2008 Cytochrome P450scc (CYP11A1) can hydroxylate vitamin D3 to produce 20-hydroxyvitamin D3 and other poorly characterized hydroxylated products. Cholecalciferol 45-55 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 0-18 18410379-1 2008 Cytochrome P450scc (CYP11A1) can hydroxylate vitamin D3 to produce 20-hydroxyvitamin D3 and other poorly characterized hydroxylated products. Cholecalciferol 45-55 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 20-27 18410379-2 2008 The present study aimed to identify all the products of vitamin D3 metabolism by P450scc, as well as the pathways leading to their formation. Cholecalciferol 56-66 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 81-88 18410379-9 2008 We conclude that the major pathway of vitamin D3 metabolism by P450scc is: vitamin D3 --> 20-hydroxyvitamin D3 --> 20,23-dihydroxyvitamin D3 --> 17alpha,20,23-trihydroxyvitamin D3. Cholecalciferol 38-48 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 63-70 18410379-9 2008 We conclude that the major pathway of vitamin D3 metabolism by P450scc is: vitamin D3 --> 20-hydroxyvitamin D3 --> 20,23-dihydroxyvitamin D3 --> 17alpha,20,23-trihydroxyvitamin D3. Cholecalciferol 75-85 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 63-70 18410379-11 2008 Our new identification of the major dihydroxyvitamin D3 product as 20,23-dihydroxyvitamin D3, rather than 20,22-dihydroxyvitamin D3, explains why there is no cleavage of the vitamin D3 side chain, unlike the metabolism of cholesterol by P450scc. Cholecalciferol 45-55 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 237-244 18226257-8 2008 Previously reviewed mechanisms include that 1) low vitamin D3, may impair insulin action, glucose metabolism and various other metabolic processes in adipose and lean tissue 2) fat soluble-vitamin D3 is sequestered in the large adipose compartment, and low in serum, 3) obese people may be sensitive about their body shape, minimising their skin exposure to view and sunlight (not tested). Cholecalciferol 51-61 insulin Homo sapiens 74-81 18483314-0 2008 Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. Cholecalciferol 0-10 cyclin dependent kinase inhibitor 1C Homo sapiens 102-105 18358842-2 2008 Overexpression of Tob2 in stromal cells repressed vitamin D(3)-induced osteoclasts formation. Cholecalciferol 50-62 transducer of ERBB2, 2 Mus musculus 18-22 18591157-0 2008 Regulation of the vitamin D receptor and cornifin beta expression in vaginal epithelium of the rats through vitamin D3. Cholecalciferol 108-118 vitamin D receptor Rattus norvegicus 18-36 18591157-0 2008 Regulation of the vitamin D receptor and cornifin beta expression in vaginal epithelium of the rats through vitamin D3. Cholecalciferol 108-118 small proline-rich protein 1B Rattus norvegicus 41-54 18248997-0 2008 The 2alpha-(3-hydroxypropyl) group as an active motif in vitamin D3 analogues as agonists of the mutant vitamin D receptor (Arg274Leu). Cholecalciferol 57-67 vitamin D receptor Homo sapiens 104-122 18424365-12 2008 Lowered exocrine pancreatic function with lowered fecal elastase 1 seems to be relevant as a reason for reduced levels of circulating vitamin D3 metabolites being an appropriate additional cause for predominant osteoporosis. Cholecalciferol 134-144 chymotrypsin like elastase 3B Homo sapiens 50-66 18411844-4 2008 The N,S-heterodisubstituted o-carborane containing a mercapto group, 1-(2"-pyridyl)-2-SH-1,2-closo-C2B10H10, 1, is one of the two examples of a rigid bidentate chelating (pyridine)N-C-C-C-S(H) motif having been structurally fully characterized. Cholecalciferol 184-189 secretoglobin family 2B member 3, pseudogene Homo sapiens 99-110 17881271-0 2008 Vitamin D3 cannot revert desensitization of growth hormone (GH)-induced STAT5-signaling in GH-overexpressing mice non-calcemic tissues. Cholecalciferol 0-10 growth hormone Mus musculus 44-58 17881271-0 2008 Vitamin D3 cannot revert desensitization of growth hormone (GH)-induced STAT5-signaling in GH-overexpressing mice non-calcemic tissues. Cholecalciferol 0-10 growth hormone Mus musculus 60-62 17881271-0 2008 Vitamin D3 cannot revert desensitization of growth hormone (GH)-induced STAT5-signaling in GH-overexpressing mice non-calcemic tissues. Cholecalciferol 0-10 signal transducer and activator of transcription 5A Mus musculus 72-77 17881271-5 2008 Vitamin D3 has been shown to inhibit GH-induced expression of CIS and SOCS-3 and therefore prolong GH signaling in osteoblast-like cells. Cholecalciferol 0-10 growth hormone Mus musculus 37-39 17881271-5 2008 Vitamin D3 has been shown to inhibit GH-induced expression of CIS and SOCS-3 and therefore prolong GH signaling in osteoblast-like cells. Cholecalciferol 0-10 suppressor of cytokine signaling 3 Mus musculus 70-76 17881271-5 2008 Vitamin D3 has been shown to inhibit GH-induced expression of CIS and SOCS-3 and therefore prolong GH signaling in osteoblast-like cells. Cholecalciferol 0-10 growth hormone Mus musculus 99-101 17881271-6 2008 The purpose of the present study is to determine if vitamin D3 could attenuate CIS expression in GH-overexpressing mice, and consequently allow GH JAK2/STAT5 signaling in GH-responsive tissues in these animals. Cholecalciferol 52-62 growth hormone Mus musculus 97-99 17881271-6 2008 The purpose of the present study is to determine if vitamin D3 could attenuate CIS expression in GH-overexpressing mice, and consequently allow GH JAK2/STAT5 signaling in GH-responsive tissues in these animals. Cholecalciferol 52-62 growth hormone Mus musculus 144-146 17881271-6 2008 The purpose of the present study is to determine if vitamin D3 could attenuate CIS expression in GH-overexpressing mice, and consequently allow GH JAK2/STAT5 signaling in GH-responsive tissues in these animals. Cholecalciferol 52-62 Janus kinase 2 Mus musculus 147-151 17881271-6 2008 The purpose of the present study is to determine if vitamin D3 could attenuate CIS expression in GH-overexpressing mice, and consequently allow GH JAK2/STAT5 signaling in GH-responsive tissues in these animals. Cholecalciferol 52-62 signal transducer and activator of transcription 5A Mus musculus 152-157 17881271-6 2008 The purpose of the present study is to determine if vitamin D3 could attenuate CIS expression in GH-overexpressing mice, and consequently allow GH JAK2/STAT5 signaling in GH-responsive tissues in these animals. Cholecalciferol 52-62 growth hormone Mus musculus 144-146 18178294-2 2008 Herein, we report that murine DCs exposed to TLR3/TLR4 ligands upregulate their expression of 1 alpha-hydroxylase, the enzyme that converts circulating 25(OH)D3 to calcitriol, the active form of vitamin D3. Cholecalciferol 195-205 toll-like receptor 3 Mus musculus 45-49 18178294-2 2008 Herein, we report that murine DCs exposed to TLR3/TLR4 ligands upregulate their expression of 1 alpha-hydroxylase, the enzyme that converts circulating 25(OH)D3 to calcitriol, the active form of vitamin D3. Cholecalciferol 195-205 toll-like receptor 4 Mus musculus 50-54 18178824-6 2008 PHA and IL-2 stimulation as well as vitamin D3/dexamethasone and anti-CD2/CD16 mAbs are demonstrated to induce IL-10 expression in NK cells. Cholecalciferol 36-46 interleukin 10 Homo sapiens 111-116 18175915-0 2008 Differential regulation of extracellular signal-related kinase phosphorylation by vitamin D3 analogs. Cholecalciferol 82-92 mitogen-activated protein kinase 1 Homo sapiens 27-62 18573681-6 2008 20-Hydroxyvitamin D3 was further hydroxylated by P450scc in vesicles, producing primarily 20,23-dihydroxyvitamin D3, with Km and kcat values 22- and 6-fold lower than those for vitamin D3, respectively. Cholecalciferol 10-20 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 49-56 18238736-1 2008 OBJECTIVE: To investigate the efficacy of cholecalciferol (vitamin D3) in raising serum 25-hydroxyvitamin D (25[OH)]D) levels and reducing parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD). Cholecalciferol 42-57 parathyroid hormone Homo sapiens 139-158 18238736-1 2008 OBJECTIVE: To investigate the efficacy of cholecalciferol (vitamin D3) in raising serum 25-hydroxyvitamin D (25[OH)]D) levels and reducing parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD). Cholecalciferol 42-57 parathyroid hormone Homo sapiens 160-163 18238736-1 2008 OBJECTIVE: To investigate the efficacy of cholecalciferol (vitamin D3) in raising serum 25-hydroxyvitamin D (25[OH)]D) levels and reducing parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD). Cholecalciferol 59-69 parathyroid hormone Homo sapiens 139-158 18238736-1 2008 OBJECTIVE: To investigate the efficacy of cholecalciferol (vitamin D3) in raising serum 25-hydroxyvitamin D (25[OH)]D) levels and reducing parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD). Cholecalciferol 59-69 parathyroid hormone Homo sapiens 160-163 18238736-11 2008 As-treated analysis indicated a trend toward lower PTH levels among cholecalciferol-treated participants (P = .07). Cholecalciferol 68-83 parathyroid hormone Homo sapiens 51-54 17949889-1 2008 OBJECTIVE: The roles of phosphatidylinositol 3 (PI3K) and mitogen-activated protein kinases (MAPK) have been widely studied in terms of the differentiation process induced by several drugs (phorbol ester, vitamin D-3, retinoic acid, etc. Cholecalciferol 205-216 mitogen-activated protein kinase 1 Homo sapiens 93-97 18573681-0 2008 Kinetics of vitamin D3 metabolism by cytochrome P450scc (CYP11A1) in phospholipid vesicles and cyclodextrin. Cholecalciferol 12-22 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 48-55 18573681-0 2008 Kinetics of vitamin D3 metabolism by cytochrome P450scc (CYP11A1) in phospholipid vesicles and cyclodextrin. Cholecalciferol 12-22 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 57-64 18573681-1 2008 Vitamin D3 can be hydroxylated sequentially by cytochrome P450scc (CYP11A1) producing 20-hydroxyvitamin D3, 20,23-dihydroxyvitamin D3 and 17,20,23-trihydroxyvitamin D3. Cholecalciferol 0-10 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 58-65 18573681-9 2008 This study shows that vitamin D3 quantitatively associates with phospholipid vesicles, can exchange between membranes, and can be hydroxylated by membrane-associated P450scc but with lower efficiency than for cholesterol hydroxylation. Cholecalciferol 22-32 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 166-173 18573681-1 2008 Vitamin D3 can be hydroxylated sequentially by cytochrome P450scc (CYP11A1) producing 20-hydroxyvitamin D3, 20,23-dihydroxyvitamin D3 and 17,20,23-trihydroxyvitamin D3. Cholecalciferol 0-10 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 67-74 18387750-6 2008 The central nervous system converts vitamin D3 into 1,25-dihydroxyvitamin D3 (1,25-(OH)2 D3), a biologically active hormone with anti-inflammatory and neuro-protective functions that depend on IL-10-producing regulatory lymphocytes. Cholecalciferol 36-46 interleukin 10 Homo sapiens 193-198 18573681-2 2008 The aim of this study was to characterize the ability of vitamin D3 to associate with phospholipid vesicles and to determine the kinetics of metabolism of vitamin D3 by P450scc in vesicles and in 2-hydroxypropyl-beta-cyclodextrin (cyclodextrin). Cholecalciferol 155-165 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 169-176 18573681-5 2008 The Km of P450scc for vitamin D3 in vesicles was 3.3 mol vitamin D3/mol phospholipid and the rate of conversion of vitamin D3 to 20-hydroxyvitamin D3 was first order with respect to the vitamin D3 concentration for the range of concentrations of vitamin D3 that could be incorporated into the vesicle membrane. Cholecalciferol 22-32 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 10-17 18573681-5 2008 The Km of P450scc for vitamin D3 in vesicles was 3.3 mol vitamin D3/mol phospholipid and the rate of conversion of vitamin D3 to 20-hydroxyvitamin D3 was first order with respect to the vitamin D3 concentration for the range of concentrations of vitamin D3 that could be incorporated into the vesicle membrane. Cholecalciferol 57-67 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 10-17 18573681-5 2008 The Km of P450scc for vitamin D3 in vesicles was 3.3 mol vitamin D3/mol phospholipid and the rate of conversion of vitamin D3 to 20-hydroxyvitamin D3 was first order with respect to the vitamin D3 concentration for the range of concentrations of vitamin D3 that could be incorporated into the vesicle membrane. Cholecalciferol 57-67 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 10-17 18573681-5 2008 The Km of P450scc for vitamin D3 in vesicles was 3.3 mol vitamin D3/mol phospholipid and the rate of conversion of vitamin D3 to 20-hydroxyvitamin D3 was first order with respect to the vitamin D3 concentration for the range of concentrations of vitamin D3 that could be incorporated into the vesicle membrane. Cholecalciferol 57-67 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 10-17 18573681-5 2008 The Km of P450scc for vitamin D3 in vesicles was 3.3 mol vitamin D3/mol phospholipid and the rate of conversion of vitamin D3 to 20-hydroxyvitamin D3 was first order with respect to the vitamin D3 concentration for the range of concentrations of vitamin D3 that could be incorporated into the vesicle membrane. Cholecalciferol 57-67 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 10-17 17910894-3 2008 Vitamin A (retinoic acid [RA]) and the active form of vitamin D3 (1,25 dihydroxyvitamin D3 [1,25D(3)]) have been used to treat certain T cell-mediated inflammatory skin diseases, as well as cutaneous T-cell lymphomas; however, their effect on CLA expression has not been studied. Cholecalciferol 54-64 selectin P ligand Homo sapiens 243-246 18979160-0 2008 The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit. Cholecalciferol 51-66 parathyroid hormone Homo sapiens 110-129 18387750-9 2008 We hypothesize that vIL-10 may induce a dysfunction of IL-10-producing regulatory lymphocytes, thereby undermining the protective functions of sunlight, vitamin D3, and 1,25-(OH)2 D3. Cholecalciferol 153-163 interleukin 10 Homo sapiens 21-26 17707062-1 2007 PURPOSE: The active form of vitamin D3, that is 1alpha,25-dihydroxyvitamin D3, binds with vitamin D receptor, which forms a complex with retinoid X receptors alpha, beta and gamma to manifest antitumor effects. Cholecalciferol 28-38 vitamin D receptor Homo sapiens 90-108 17607662-2 2007 CYP2R1, a cytochrome P450 enzyme, catalyzes the formation of vitamin D3 to 25-hydroxyvitamin D3 (25(OH)D3), the main circulating vitamin D metabolite. Cholecalciferol 61-71 cytochrome P450 family 2 subfamily R member 1 Homo sapiens 0-6 17699781-1 2007 Here, we show that the platelet-derived growth factor receptor (PDGFR) regulates myeloid and monocytic differentiation of HL-60 myeloblastic leukemia cells in response to retinoic acid (RA) and vitamin D3 (D3), respectively. Cholecalciferol 194-204 platelet derived growth factor receptor beta Homo sapiens 23-62 17621647-5 2007 The data indicate that dexamethasone and vitamin D3 ameliorated the age-related increase in IFNgamma and suggest that IFNgamma may be the trigger leading to microglial activation, since it increases MHCII mRNA and IL-1beta release from cultured glia. Cholecalciferol 41-51 interleukin 18 Rattus norvegicus 92-100 17621647-5 2007 The data indicate that dexamethasone and vitamin D3 ameliorated the age-related increase in IFNgamma and suggest that IFNgamma may be the trigger leading to microglial activation, since it increases MHCII mRNA and IL-1beta release from cultured glia. Cholecalciferol 41-51 interleukin 18 Rattus norvegicus 118-126 17621647-5 2007 The data indicate that dexamethasone and vitamin D3 ameliorated the age-related increase in IFNgamma and suggest that IFNgamma may be the trigger leading to microglial activation, since it increases MHCII mRNA and IL-1beta release from cultured glia. Cholecalciferol 41-51 interleukin 1 beta Rattus norvegicus 214-222 17621647-6 2007 In parallel with its ability to decrease microglial activation in vivo, we report that treatment of cultured glia with dexamethasone and vitamin D3 blocked the lipopolysaccharide increased MHCII mRNA and IL-1beta concentration, while the IL-1beta-induced increases in activation of JNK and caspase 3 in cultured neurons were also reversed by treatment with dexamethasone and vitamin D3. Cholecalciferol 137-147 interleukin 1 beta Rattus norvegicus 204-212 17621647-6 2007 In parallel with its ability to decrease microglial activation in vivo, we report that treatment of cultured glia with dexamethasone and vitamin D3 blocked the lipopolysaccharide increased MHCII mRNA and IL-1beta concentration, while the IL-1beta-induced increases in activation of JNK and caspase 3 in cultured neurons were also reversed by treatment with dexamethasone and vitamin D3. Cholecalciferol 137-147 interleukin 1 beta Rattus norvegicus 238-246 17621647-6 2007 In parallel with its ability to decrease microglial activation in vivo, we report that treatment of cultured glia with dexamethasone and vitamin D3 blocked the lipopolysaccharide increased MHCII mRNA and IL-1beta concentration, while the IL-1beta-induced increases in activation of JNK and caspase 3 in cultured neurons were also reversed by treatment with dexamethasone and vitamin D3. Cholecalciferol 137-147 mitogen-activated protein kinase 8 Rattus norvegicus 282-285 17621647-6 2007 In parallel with its ability to decrease microglial activation in vivo, we report that treatment of cultured glia with dexamethasone and vitamin D3 blocked the lipopolysaccharide increased MHCII mRNA and IL-1beta concentration, while the IL-1beta-induced increases in activation of JNK and caspase 3 in cultured neurons were also reversed by treatment with dexamethasone and vitamin D3. Cholecalciferol 137-147 caspase 3 Rattus norvegicus 290-299 17956020-3 2007 In the bones treated with vitamin D3 plus vitamin K2, osteocalcin production and the ratio of the mineralization of osteoblasts were increased. Cholecalciferol 26-36 bone gamma-carboxyglutamate protein Homo sapiens 54-65 17699781-1 2007 Here, we show that the platelet-derived growth factor receptor (PDGFR) regulates myeloid and monocytic differentiation of HL-60 myeloblastic leukemia cells in response to retinoic acid (RA) and vitamin D3 (D3), respectively. Cholecalciferol 194-204 platelet derived growth factor receptor beta Homo sapiens 64-69 17440494-3 2007 In this study, we examined the ability of 1,25 dihydroxyvitamin D3 (1,25(OH)(2)D3) to regulate the expression of the vasculoprotective natriuretic peptide receptor-A gene in these cells in culture. Cholecalciferol 64-66 natriuretic peptide receptor 1 Homo sapiens 135-165 17352718-5 2007 Thus, results from our study indicate that IPL-RF irradiation in combination with topical application of vitamin D(3) ointment would be useful as new modalities, especially for treatment of numerous small pigmented lesions in patients with NF1. Cholecalciferol 105-117 neurofibromin 1 Homo sapiens 240-243 17487855-8 2007 Treatment with 1,25(OH)(2)D(3), an active metabolite of vitamin D3, in the CCA cell lines with high expression of VDR significantly reduced cell proliferation in a dose-dependent manner. Cholecalciferol 56-66 vitamin D receptor Homo sapiens 114-117 17433303-0 2007 Mechanism of vitamin D3-induced transcription of phospholipase D1 in HaCat human keratinocytes. Cholecalciferol 13-23 phospholipase D1 Homo sapiens 49-65 17325131-0 2007 Vitamin D3 derivatives with adamantane or lactone ring side chains are cell type-selective vitamin D receptor modulators. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 91-109 17290304-5 2007 How 1,25D3 could participate in the injury response was explained by findings that the levels of CYP27B1, which converts 25OH vitamin D3 (25D3) to active 1,25D3, were increased in wounds and induced in keratinocytes in response to TGF-beta1. Cholecalciferol 126-136 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 97-104 17290304-5 2007 How 1,25D3 could participate in the injury response was explained by findings that the levels of CYP27B1, which converts 25OH vitamin D3 (25D3) to active 1,25D3, were increased in wounds and induced in keratinocytes in response to TGF-beta1. Cholecalciferol 126-136 transforming growth factor beta 1 Homo sapiens 231-240 17283131-6 2007 The silencing was manifested in an inability to activate the normal expression of INK4b RNA as shown in vitamin D3-treated U937 cells expressing CBFbeta-SMMHC. Cholecalciferol 104-114 core-binding factor subunit beta Homo sapiens 145-152 17259988-3 2007 We show here that 1,25(OH)(2)D(3), the active form of vitamin D3, signaled T cells to express CC chemokine receptor 10, which enabled them to migrate to the skin-specific chemokine CCL27 secreted by keratinocytes of the epidermis. Cholecalciferol 54-64 C-C motif chemokine receptor 10 Homo sapiens 94-118 17259988-3 2007 We show here that 1,25(OH)(2)D(3), the active form of vitamin D3, signaled T cells to express CC chemokine receptor 10, which enabled them to migrate to the skin-specific chemokine CCL27 secreted by keratinocytes of the epidermis. Cholecalciferol 54-64 C-C motif chemokine ligand 27 Homo sapiens 181-186 17326835-4 2007 Osteoblasts were incubated in the presence of vitamin D3 (50 nM), which is an inducer of osteocalcin, encoded by an osteoblast terminal differentiation gene. Cholecalciferol 46-56 bone gamma-carboxyglutamate protein Homo sapiens 89-100 17203216-11 2007 In conclusion, decitabine synergizes with Vitamin D3 to induce CD11b and CD14 expression, likely by enhancing PU.1/c-jun and Sp1 transcriptional activity. Cholecalciferol 42-52 integrin subunit alpha M Homo sapiens 63-68 17203216-11 2007 In conclusion, decitabine synergizes with Vitamin D3 to induce CD11b and CD14 expression, likely by enhancing PU.1/c-jun and Sp1 transcriptional activity. Cholecalciferol 42-52 CD14 molecule Homo sapiens 73-77 17203216-11 2007 In conclusion, decitabine synergizes with Vitamin D3 to induce CD11b and CD14 expression, likely by enhancing PU.1/c-jun and Sp1 transcriptional activity. Cholecalciferol 42-52 Spi-1 proto-oncogene Homo sapiens 110-114 17203216-11 2007 In conclusion, decitabine synergizes with Vitamin D3 to induce CD11b and CD14 expression, likely by enhancing PU.1/c-jun and Sp1 transcriptional activity. Cholecalciferol 42-52 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 115-120 17156784-2 2007 The vitamin D3 action is mediated by the vitamin D3 receptor (VDR). Cholecalciferol 4-14 vitamin D (1,25- dihydroxyvitamin D3) receptor Gallus gallus 41-60 17156784-2 2007 The vitamin D3 action is mediated by the vitamin D3 receptor (VDR). Cholecalciferol 4-14 vitamin D (1,25- dihydroxyvitamin D3) receptor Gallus gallus 62-65 17156784-10 2007 The differential VDR expression in the epididymal region segments reveals that several extratesticular ducts may be target for vitamin D3 action and suggests that vitamin D3 may have a regional-specific function, such as calcium transport, that is modulated through VDR activity. Cholecalciferol 127-137 vitamin D (1,25- dihydroxyvitamin D3) receptor Gallus gallus 17-20 17156784-10 2007 The differential VDR expression in the epididymal region segments reveals that several extratesticular ducts may be target for vitamin D3 action and suggests that vitamin D3 may have a regional-specific function, such as calcium transport, that is modulated through VDR activity. Cholecalciferol 163-173 vitamin D (1,25- dihydroxyvitamin D3) receptor Gallus gallus 17-20 17156784-10 2007 The differential VDR expression in the epididymal region segments reveals that several extratesticular ducts may be target for vitamin D3 action and suggests that vitamin D3 may have a regional-specific function, such as calcium transport, that is modulated through VDR activity. Cholecalciferol 163-173 vitamin D (1,25- dihydroxyvitamin D3) receptor Gallus gallus 266-269 17326835-11 2007 The vitamin D3 induced osteocalcin was strongly inhibited in a dose-dependent manner in the presence of gal-3, at both the mRNA and protein levels. Cholecalciferol 4-14 bone gamma-carboxyglutamate protein Homo sapiens 23-34 17326835-11 2007 The vitamin D3 induced osteocalcin was strongly inhibited in a dose-dependent manner in the presence of gal-3, at both the mRNA and protein levels. Cholecalciferol 4-14 galectin 3 Homo sapiens 104-109 17996099-8 2007 Under vitamin D3, these drugs also showed a decrease in RANKL level, which, however, did not reach statistical significance. Cholecalciferol 6-16 TNF superfamily member 11 Homo sapiens 56-61 17996099-6 2007 Interestingly, OPG expression and production under basal conditions or vitamin D3 treatment were upregulated by CS and by both CS and GS incubated together. Cholecalciferol 71-81 TNF receptor superfamily member 11b Homo sapiens 15-18 17426122-1 2007 The human 25-hydroxyvitamin D3 (25(OH)D3) 1alpha-hydroxylase, which is encoded by the CYP27B1 gene, catalyzes the metabolic activation of the 25(OH)D3 into 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the most biologically potent vitamin D3 metabolite. Cholecalciferol 20-30 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 86-93 16902422-2 2007 In the research presented here, we have investigated the influence of UVB-triggered calcitriol production on gene expression of the vitamin D3 hydroxylating enzymes catabolic 25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), active vitamin-D3-25-hydroxylase (CYP27A1), and 25-hydroxyvitamin-D3-1alpha-hydroxylase (CYP27B1) using real-time PCR. Cholecalciferol 132-142 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 212-219 16902422-2 2007 In the research presented here, we have investigated the influence of UVB-triggered calcitriol production on gene expression of the vitamin D3 hydroxylating enzymes catabolic 25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), active vitamin-D3-25-hydroxylase (CYP27A1), and 25-hydroxyvitamin-D3-1alpha-hydroxylase (CYP27B1) using real-time PCR. Cholecalciferol 132-142 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 256-263 16902422-2 2007 In the research presented here, we have investigated the influence of UVB-triggered calcitriol production on gene expression of the vitamin D3 hydroxylating enzymes catabolic 25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), active vitamin-D3-25-hydroxylase (CYP27A1), and 25-hydroxyvitamin-D3-1alpha-hydroxylase (CYP27B1) using real-time PCR. Cholecalciferol 132-142 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 270-309 16902422-2 2007 In the research presented here, we have investigated the influence of UVB-triggered calcitriol production on gene expression of the vitamin D3 hydroxylating enzymes catabolic 25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), active vitamin-D3-25-hydroxylase (CYP27A1), and 25-hydroxyvitamin-D3-1alpha-hydroxylase (CYP27B1) using real-time PCR. Cholecalciferol 132-142 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 311-318 17217059-5 2007 First, TRPV5 gene expression is regulated by calciotropic hormones such as vitamin D3 and parathyroid hormone. Cholecalciferol 75-85 transient receptor potential cation channel, subfamily V, member 5 Mus musculus 7-12 17217059-10 2007 Inactivation of TRPV5 in mice leads to severe hypercalciuria, which is compensated by increased intestinal Ca2+ absorption due to augmented vitamin D3 levels. Cholecalciferol 140-150 transient receptor potential cation channel, subfamily V, member 5 Mus musculus 16-21 17217060-2 2007 Transcriptional regulation of TRPV6 messenger RNA (mRNA) is controlled by 1,25-dihydroxyvitamin D, which is the active hormonal form of vitamin D3, and by additional calcium-dependent and vitamin D3-independent mechanisms. Cholecalciferol 136-146 transient receptor potential cation channel subfamily V member 6 Homo sapiens 30-35 17217060-2 2007 Transcriptional regulation of TRPV6 messenger RNA (mRNA) is controlled by 1,25-dihydroxyvitamin D, which is the active hormonal form of vitamin D3, and by additional calcium-dependent and vitamin D3-independent mechanisms. Cholecalciferol 188-198 transient receptor potential cation channel subfamily V member 6 Homo sapiens 30-35 17261502-3 2007 CD33 expression in the Liu01 cell line, a subclone of U266 cells, and in vitamin D3-treated ILKM3 cells, correlated with a monocytoid morphology featuring convoluted nuclei and with increased C/EBPalpha expression. Cholecalciferol 73-83 CD33 molecule Homo sapiens 0-4 17261502-3 2007 CD33 expression in the Liu01 cell line, a subclone of U266 cells, and in vitamin D3-treated ILKM3 cells, correlated with a monocytoid morphology featuring convoluted nuclei and with increased C/EBPalpha expression. Cholecalciferol 73-83 CCAAT enhancer binding protein alpha Homo sapiens 192-202 17721071-4 2007 NPT2 is crucial for the Pi reabsorption and is modulated by several hormones (PTH and vitamin D3, phosphatonins) and non-hormonal factors. Cholecalciferol 86-96 solute carrier family 34 member 1 Homo sapiens 0-4 16598763-3 2006 THP-1 macrophages and preconfluent CaCo-2 cells contain the vitamin D receptor (VDR), possess 25-hydroxylase (CYP2R1 and CYP27A1) and 1alpha-hydroxylase (CYP27B1) activity, and survive the low UVB doses essential for vitamin D3 photoproduction. Cholecalciferol 217-227 GLI family zinc finger 2 Homo sapiens 0-5 16879968-1 2006 The synthesis of a new class of vitamin D3 analogues in which two units of 1alpha,25-dihydroxyvitamin D3 are linked at the C-3 position by a dicarbamate functionality of variable length is described. Cholecalciferol 32-42 complement C3 Homo sapiens 123-126 16930540-1 2006 CYP27A1 catalyses hydroxylations in the biosynthesis of bile acids and the bioactivation of vitamin D3. Cholecalciferol 92-102 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 0-7 16824767-5 2006 Nevertheless, dermal fibroblasts produce inactive vitamin D3 metabolites that can be activated by epidermal keratinocytes as CYP24 mRNA is induced in epidermal keratinocytes but not in dermal fibroblasts after transfer of medium or cellular suspensions from BM15766-pretreated, UVB-irradiated fibroblasts. Cholecalciferol 50-60 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 125-130 16842832-8 2006 Interestingly, human CYP2J2 hydroxylated vitamin D2, an exogenous vitamin D, at a higher rate than it did vitamin D3, an endogenous vitamin D, whereas, rat CYP2J3 hydroxylated vitamin D3 (1.4 min(-1)) more efficiently than vitamin D2 (0.86 min(-1)). Cholecalciferol 106-116 cytochrome P450 family 2 subfamily J member 2 Homo sapiens 21-27 16842832-8 2006 Interestingly, human CYP2J2 hydroxylated vitamin D2, an exogenous vitamin D, at a higher rate than it did vitamin D3, an endogenous vitamin D, whereas, rat CYP2J3 hydroxylated vitamin D3 (1.4 min(-1)) more efficiently than vitamin D2 (0.86 min(-1)). Cholecalciferol 176-186 cytochrome P450 family 2 subfamily J member 2 Homo sapiens 21-27 16842832-8 2006 Interestingly, human CYP2J2 hydroxylated vitamin D2, an exogenous vitamin D, at a higher rate than it did vitamin D3, an endogenous vitamin D, whereas, rat CYP2J3 hydroxylated vitamin D3 (1.4 min(-1)) more efficiently than vitamin D2 (0.86 min(-1)). Cholecalciferol 176-186 cytochrome P450, family 2, subfamily j, polypeptide 3 Rattus norvegicus 156-162 16842832-10 2006 CYP2J2 and CYP2J3 exhibit distinct preferences toward vitamin D3 and D2. Cholecalciferol 54-64 cytochrome P450, family 2, subfamily j, polypeptide 4 Rattus norvegicus 0-6 16842832-10 2006 CYP2J2 and CYP2J3 exhibit distinct preferences toward vitamin D3 and D2. Cholecalciferol 54-64 cytochrome P450, family 2, subfamily j, polypeptide 3 Rattus norvegicus 11-17 16598763-3 2006 THP-1 macrophages and preconfluent CaCo-2 cells contain the vitamin D receptor (VDR), possess 25-hydroxylase (CYP2R1 and CYP27A1) and 1alpha-hydroxylase (CYP27B1) activity, and survive the low UVB doses essential for vitamin D3 photoproduction. Cholecalciferol 217-227 vitamin D receptor Homo sapiens 60-78 16598763-3 2006 THP-1 macrophages and preconfluent CaCo-2 cells contain the vitamin D receptor (VDR), possess 25-hydroxylase (CYP2R1 and CYP27A1) and 1alpha-hydroxylase (CYP27B1) activity, and survive the low UVB doses essential for vitamin D3 photoproduction. Cholecalciferol 217-227 vitamin D receptor Homo sapiens 80-83 16518840-1 2006 Our previous study demonstrate that vitamin D3 induces the binding of vitamin D3 receptor (VDR) to Sp1 transcription factor and stimulates p27Kip1 expression via the Sp1 consensus sequences in the promoter. Cholecalciferol 36-46 vitamin D receptor Homo sapiens 70-89 16924108-3 2006 We report that OX40 ligand (OX40L) completely inhibited the generation of IL-10-producing Tr1 cells from naive and memory CD4(+) T cells induced by the immunosuppressive drugs dexamethasone and vitamin D3. Cholecalciferol 194-204 TNF superfamily member 4 Homo sapiens 15-26 16924108-3 2006 We report that OX40 ligand (OX40L) completely inhibited the generation of IL-10-producing Tr1 cells from naive and memory CD4(+) T cells induced by the immunosuppressive drugs dexamethasone and vitamin D3. Cholecalciferol 194-204 TNF superfamily member 4 Homo sapiens 28-33 16924108-3 2006 We report that OX40 ligand (OX40L) completely inhibited the generation of IL-10-producing Tr1 cells from naive and memory CD4(+) T cells induced by the immunosuppressive drugs dexamethasone and vitamin D3. Cholecalciferol 194-204 interleukin 10 Homo sapiens 74-79 16518840-1 2006 Our previous study demonstrate that vitamin D3 induces the binding of vitamin D3 receptor (VDR) to Sp1 transcription factor and stimulates p27Kip1 expression via the Sp1 consensus sequences in the promoter. Cholecalciferol 36-46 vitamin D receptor Homo sapiens 91-94 16518840-1 2006 Our previous study demonstrate that vitamin D3 induces the binding of vitamin D3 receptor (VDR) to Sp1 transcription factor and stimulates p27Kip1 expression via the Sp1 consensus sequences in the promoter. Cholecalciferol 36-46 cyclin dependent kinase inhibitor 1B Homo sapiens 139-146 16518840-3 2006 To address this issue, we constructed the AF-2 deletion mutant of VDR and tested the effect of vitamin D3 on p27Kip1 expression. Cholecalciferol 95-105 cyclin dependent kinase inhibitor 1B Homo sapiens 109-116 16518840-4 2006 In consistent with our previous results, we found that expression of wild-type VDR in SW620 colon cancer cells, which expressed very low level of endogenous VDR, increased vitamin D3-stimulated p27Kip1 promoter activity and protein expression. Cholecalciferol 172-182 vitamin D receptor Homo sapiens 79-82 16518840-4 2006 In consistent with our previous results, we found that expression of wild-type VDR in SW620 colon cancer cells, which expressed very low level of endogenous VDR, increased vitamin D3-stimulated p27Kip1 promoter activity and protein expression. Cholecalciferol 172-182 cyclin dependent kinase inhibitor 1B Homo sapiens 194-201 16518840-6 2006 DNA affinity precipitation assay (DAPA) showed that both wild-type and deletion mutant of VDR bound to the DNA probe corresponding to the Sp1 binding site in the p27Kip1 promoter in a vitamin D3-dependent manner indicating deletion of AF-2 domain does not affect the interaction between VDR and Sp1. Cholecalciferol 184-194 vitamin D receptor Homo sapiens 90-93 16772287-2 2006 Two nuclease-hypersensitive sites span the key regulatory elements that control basal tissue-specific and vitamin D3-enhanced OC gene transcription. Cholecalciferol 106-116 bone gamma-carboxyglutamate protein Homo sapiens 126-128 16772287-5 2006 This interaction results in inhibition of both basal and vitamin D3-enhanced OC gene transcription and a marked decrease in nuclease hypersensitivity. Cholecalciferol 57-67 bone gamma-carboxyglutamate protein Homo sapiens 77-79 16518840-6 2006 DNA affinity precipitation assay (DAPA) showed that both wild-type and deletion mutant of VDR bound to the DNA probe corresponding to the Sp1 binding site in the p27Kip1 promoter in a vitamin D3-dependent manner indicating deletion of AF-2 domain does not affect the interaction between VDR and Sp1. Cholecalciferol 184-194 cyclin dependent kinase inhibitor 1B Homo sapiens 162-169 16886688-3 2006 MATERIALS AND METHODS: Vitamin D receptor (VDR)- positive MCF-7 cells in culture were stimulated with the vitamin D metabolites vitamin D3, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 for 24, 48; 72 and 96 hours in physiological and supraphysiological concentrations. Cholecalciferol 128-138 vitamin D receptor Homo sapiens 23-41 16777406-8 2006 Inhibition of the Akt-mTOR pathway represents a novel mechanism by which vitamin D3 analogs may modulate the expression and activity of proteins involved in cancer cell proliferation. Cholecalciferol 73-83 AKT serine/threonine kinase 1 Homo sapiens 18-21 16777406-8 2006 Inhibition of the Akt-mTOR pathway represents a novel mechanism by which vitamin D3 analogs may modulate the expression and activity of proteins involved in cancer cell proliferation. Cholecalciferol 73-83 mechanistic target of rapamycin kinase Homo sapiens 22-26 16777406-0 2006 Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway. Cholecalciferol 13-23 AKT serine/threonine kinase 1 Homo sapiens 76-79 16777406-0 2006 Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway. Cholecalciferol 13-23 mechanistic target of rapamycin kinase Homo sapiens 80-84 16880407-0 2006 Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Cholecalciferol 8-18 thymic stromal lymphopoietin Mus musculus 51-79 16886665-6 2006 Vitamin D3 up-regulated 25(OH)D-24R-hydroxylase and IGFBP3, two 1alpha,25(OH)2D-responsive genes, in prostate cells. Cholecalciferol 0-10 insulin like growth factor binding protein 3 Homo sapiens 52-58 16886688-3 2006 MATERIALS AND METHODS: Vitamin D receptor (VDR)- positive MCF-7 cells in culture were stimulated with the vitamin D metabolites vitamin D3, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 for 24, 48; 72 and 96 hours in physiological and supraphysiological concentrations. Cholecalciferol 128-138 vitamin D receptor Homo sapiens 43-46 16614077-2 2006 The increase in OPG mRNA noted with dexamethasone was in contrast to 1,25(OH)(2)-vitamin D3 (D3) treatment, which decreased OPG expression. Cholecalciferol 81-91 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Mus musculus 124-127 16895439-7 2006 Vitamin D3 bound to Smo with high affinity in a cyclopamine-sensitive manner. Cholecalciferol 0-10 smoothened, frizzled class receptor Danio rerio 20-23 16672909-0 2006 Kidney-specific upregulation of vitamin D3 target genes in ClC-5 KO mice. Cholecalciferol 32-42 chloride channel, voltage-sensitive 5 Mus musculus 59-64 16895439-0 2006 Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. Cholecalciferol 52-62 smoothened, frizzled class receptor Danio rerio 14-24 16895439-8 2006 Treating zebrafish embryos with vitamin D3 mimicked the smo(-/-) phenotype, confirming the inhibitory action in vivo. Cholecalciferol 32-42 smoothened, frizzled class receptor Danio rerio 56-59 16696936-10 2006 Our data suggest that ch25h could be a vitamin D3 target gene and may partly mediate anti-proliferative action of vitamin D3 in human primary prostate stromal cells. Cholecalciferol 39-49 cholesterol 25-hydroxylase Homo sapiens 22-27 16696936-10 2006 Our data suggest that ch25h could be a vitamin D3 target gene and may partly mediate anti-proliferative action of vitamin D3 in human primary prostate stromal cells. Cholecalciferol 114-124 cholesterol 25-hydroxylase Homo sapiens 22-27 16690021-6 2006 The data suggest that VDR-mediated inhibition of 25-hydroxylase(s) by vitamin D3 metabolites at the transcriptional level may play an important role in the regulation of 25-hydroxyvitamin D3 production in liver and other tissues. Cholecalciferol 70-80 vitamin D receptor Homo sapiens 22-25 16651407-6 2006 Among them, we focused on the vitamin D receptor (VDR) gene because vitamin D3 has recently been used for chemoprevention of human tumors. Cholecalciferol 68-78 vitamin D receptor Homo sapiens 30-48 16696936-0 2006 Regulation of cholesterol 25-hydroxylase expression by vitamin D3 metabolites in human prostate stromal cells. Cholecalciferol 55-65 cholesterol 25-hydroxylase Homo sapiens 14-40 16205781-2 2006 In the present study, we investigated the effects of the novel D(3)-selective antagonist NGB 2904 (N-(4-[4-{2,3-dichlorophenyl}-1-piperazinyl]butyl)-3-fluorenylcarboxamide) on cocaine self-administration, cocaine-enhanced brain stimulation reward (BSR), and cocaine-triggered reinstatement of drug-seeking behavior in male Long-Evans rats. Cholecalciferol 63-67 neuroglobin Rattus norvegicus 89-92 16205781-5 2006 Overall, these data show that the novel D(3)-selective antagonist NGB 2904 attenuates cocaine"s rewarding effects as assessed by PR self-administration, BSR, and cocaine-triggered reinstatement of cocaine-seeking behavior. Cholecalciferol 40-44 neuroglobin Rattus norvegicus 66-69 16800739-9 2006 In some breast cancer cell lines, KLK6 expression could be restored by the vitamin D3 analog EB1089. Cholecalciferol 75-85 kallikrein related peptidase 6 Homo sapiens 34-38 16508948-0 2006 Vitamin D3 suppresses the androgen-stimulated growth of mouse mammary carcinoma SC-3 cells by transcriptional repression of fibroblast growth factor 8. Cholecalciferol 0-10 fibroblast growth factor 8 Homo sapiens 124-150 16508948-5 2006 Importantly, fgf8 was markedly repressed in response to vitamin D3. Cholecalciferol 56-66 fibroblast growth factor 8 Homo sapiens 13-17 16508948-6 2006 The exogenous addition of FGF8 canceled the growth suppression by vitamin D3 in SC-3 cells, suggesting that the repression of fgf8 is an indispensable step in vitamin D3-mediated growth inhibition. Cholecalciferol 66-76 fibroblast growth factor 8 Homo sapiens 26-30 16508948-6 2006 The exogenous addition of FGF8 canceled the growth suppression by vitamin D3 in SC-3 cells, suggesting that the repression of fgf8 is an indispensable step in vitamin D3-mediated growth inhibition. Cholecalciferol 66-76 fibroblast growth factor 8 Homo sapiens 126-130 16508948-6 2006 The exogenous addition of FGF8 canceled the growth suppression by vitamin D3 in SC-3 cells, suggesting that the repression of fgf8 is an indispensable step in vitamin D3-mediated growth inhibition. Cholecalciferol 159-169 fibroblast growth factor 8 Homo sapiens 26-30 16508948-6 2006 The exogenous addition of FGF8 canceled the growth suppression by vitamin D3 in SC-3 cells, suggesting that the repression of fgf8 is an indispensable step in vitamin D3-mediated growth inhibition. Cholecalciferol 159-169 fibroblast growth factor 8 Homo sapiens 126-130 16508948-10 2006 All these findings strongly suggest that vitamin D3 serves as a negative regulator for both androgen-related and fgf8 transcriptions. Cholecalciferol 41-51 fibroblast growth factor 8 Homo sapiens 113-117 16521124-0 2006 Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. Cholecalciferol 8-18 vitamin D receptor Rattus norvegicus 109-127 16521124-1 2006 The vitamin D receptor (VDR) is believed to mediate different biologic actions of vitamin D3, an active metabolite of vitamin D, through regulation of gene expression after binding to specific DNA-response element (VDRE) on target genes. Cholecalciferol 82-92 vitamin D receptor Rattus norvegicus 4-22 16521124-1 2006 The vitamin D receptor (VDR) is believed to mediate different biologic actions of vitamin D3, an active metabolite of vitamin D, through regulation of gene expression after binding to specific DNA-response element (VDRE) on target genes. Cholecalciferol 82-92 vitamin D receptor Rattus norvegicus 24-27 16521124-5 2006 Chronic treatment of vitamin D3 increased the expression of microtubule-associated protein-2, growth-associated protein-43 and synapsin-1 in cultured rat cortical neurons, suggesting a trophic role of vitamin D3 in differentiation and maturation of neurons. Cholecalciferol 21-31 microtubule-associated protein 2 Rattus norvegicus 60-92 16521124-5 2006 Chronic treatment of vitamin D3 increased the expression of microtubule-associated protein-2, growth-associated protein-43 and synapsin-1 in cultured rat cortical neurons, suggesting a trophic role of vitamin D3 in differentiation and maturation of neurons. Cholecalciferol 21-31 growth associated protein 43 Rattus norvegicus 94-122 16521124-5 2006 Chronic treatment of vitamin D3 increased the expression of microtubule-associated protein-2, growth-associated protein-43 and synapsin-1 in cultured rat cortical neurons, suggesting a trophic role of vitamin D3 in differentiation and maturation of neurons. Cholecalciferol 21-31 synapsin I Rattus norvegicus 127-137 16521124-7 2006 Parallel studies showed that VDR mRNA was significantly upregulated 12-24 hr after brief glutamate exposure in cultured neurons chronically treated with vitamin D3, but not in those with vehicle alone. Cholecalciferol 153-163 vitamin D receptor Rattus norvegicus 29-32 16521124-8 2006 Our results suggest that vitamin D3 may play a role in mechanisms relevant to protective properties against the neurotoxicity of glutamate through upregulation of VDR expression in cultured rat cortical neurons. Cholecalciferol 25-35 vitamin D receptor Rattus norvegicus 163-166 16651407-6 2006 Among them, we focused on the vitamin D receptor (VDR) gene because vitamin D3 has recently been used for chemoprevention of human tumors. Cholecalciferol 68-78 vitamin D receptor Homo sapiens 50-53 16651407-9 2006 In addition, p53 induced VDR target genes in a vitamin D3-dependent manner. Cholecalciferol 47-57 tumor protein p53 Homo sapiens 13-16 16651407-9 2006 In addition, p53 induced VDR target genes in a vitamin D3-dependent manner. Cholecalciferol 47-57 vitamin D receptor Homo sapiens 25-28 16549446-5 2006 Furthermore, HMEC cultures were dose dependently growth inhibited by physiological concentrations of 25(OH)D3, suggesting that CYP27B1 converts this precursor cholecalciferol metabolite to 1alpha,25(OH)2D3, the ligand for the vitamin D receptor (VDR). Cholecalciferol 159-174 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 127-134 16555680-1 2006 Vitamin D3 is modified by vitamin D3 25-hydroxylase in the liver, and by 25-hydroxyvitamin D3 1alpha-hydroxylase (CYP27B1) in the kidney, to form the active metabolite 1alpha,25-dihydroxyvitamin D3. Cholecalciferol 0-10 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 26-51 16502013-4 2006 The aim of this study was to examine whether the biologically active vitamin D3-metabolite 1alpha,25-dihydroxyvitamin D3 (1,25-D3), influences the expression of inducible cyclooxygenase-2 in photothrombotically lesioned brain or is part of an independent neuroprotective mechanism. Cholecalciferol 69-79 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 171-187 16555680-1 2006 Vitamin D3 is modified by vitamin D3 25-hydroxylase in the liver, and by 25-hydroxyvitamin D3 1alpha-hydroxylase (CYP27B1) in the kidney, to form the active metabolite 1alpha,25-dihydroxyvitamin D3. Cholecalciferol 0-10 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 73-112 16555680-1 2006 Vitamin D3 is modified by vitamin D3 25-hydroxylase in the liver, and by 25-hydroxyvitamin D3 1alpha-hydroxylase (CYP27B1) in the kidney, to form the active metabolite 1alpha,25-dihydroxyvitamin D3. Cholecalciferol 0-10 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 114-121 16491287-1 2006 UNLABELLED: In this 2-year randomized controlled study of 167 men >50 years of age, supplementation with calcium-vitamin D3-fortified milk providing an additional 1000 mg of calcium and 800 IU of vitamin D3 per day was effective for suppressing PTH and stopping or slowing bone loss at several clinically important skeletal sites at risk for fracture. Cholecalciferol 116-126 parathyroid hormone Homo sapiens 248-251 16269462-0 2006 Thioredoxin-binding protein-2-like inducible membrane protein is a novel vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling. Cholecalciferol 73-83 peroxisome proliferator activated receptor gamma Homo sapiens 180-189 16483768-0 2006 Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 45-48 16251181-11 2006 In osteoblasts isolated from calvariae, both an increase in RANKL mRNA and a decrease in OPG mRNA and protein elicited by vitamin D3 were reversed by IL-4 and IL-13. Cholecalciferol 122-132 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Mus musculus 89-92 16251181-11 2006 In osteoblasts isolated from calvariae, both an increase in RANKL mRNA and a decrease in OPG mRNA and protein elicited by vitamin D3 were reversed by IL-4 and IL-13. Cholecalciferol 122-132 interleukin 4 Mus musculus 150-154 16251181-11 2006 In osteoblasts isolated from calvariae, both an increase in RANKL mRNA and a decrease in OPG mRNA and protein elicited by vitamin D3 were reversed by IL-4 and IL-13. Cholecalciferol 122-132 interleukin 13 Mus musculus 159-164 16234363-3 2006 In addition, forced expression of TEL2 but not TEL blocks vitamin D3-induced differentiation of U937 and HL60 myeloid cells. Cholecalciferol 58-68 ETS variant transcription factor 7 Homo sapiens 34-38 16234363-3 2006 In addition, forced expression of TEL2 but not TEL blocks vitamin D3-induced differentiation of U937 and HL60 myeloid cells. Cholecalciferol 58-68 ETS variant transcription factor 6 Homo sapiens 34-37 16316664-8 2006 Skin of the vitamin D3 pretreated group demonstrated stronger immunoreactivity for VDR compared to irradiation alone group. Cholecalciferol 12-22 vitamin D receptor Rattus norvegicus 83-86 16269462-0 2006 Thioredoxin-binding protein-2-like inducible membrane protein is a novel vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling. Cholecalciferol 73-83 thioredoxin Homo sapiens 0-11 16355272-1 2006 UNLABELLED: Monocytes express 1alpha-hydroxylase, the enzyme responsible for final hydroxylation of vitamin D3, in response to IFNgamma and CD14/TLR4 activation. Cholecalciferol 100-110 interferon gamma Homo sapiens 127-135 17163485-10 2006 hCAR inhibited hVDR-mediated vitamin D3 induction of hSULT2A1 but not methotrexate induction of hSULT2A1. Cholecalciferol 29-39 CXADR Ig-like cell adhesion molecule Homo sapiens 0-4 17163485-10 2006 hCAR inhibited hVDR-mediated vitamin D3 induction of hSULT2A1 but not methotrexate induction of hSULT2A1. Cholecalciferol 29-39 vitamin D receptor Homo sapiens 15-19 17163485-10 2006 hCAR inhibited hVDR-mediated vitamin D3 induction of hSULT2A1 but not methotrexate induction of hSULT2A1. Cholecalciferol 29-39 sulfotransferase family 2A member 1 Homo sapiens 53-61 16402404-3 2006 We report here that vitamin D3 [1alpha,25-dihydroxycholecalciferol, 1,25(OH)(2)D3] suppresses the expression of TLR2 and TLR4 protein and mRNA in human monocytes in a time- and dose-dependent fashion. Cholecalciferol 20-30 toll like receptor 2 Homo sapiens 112-116 16402404-3 2006 We report here that vitamin D3 [1alpha,25-dihydroxycholecalciferol, 1,25(OH)(2)D3] suppresses the expression of TLR2 and TLR4 protein and mRNA in human monocytes in a time- and dose-dependent fashion. Cholecalciferol 20-30 toll like receptor 4 Homo sapiens 121-125 16402404-3 2006 We report here that vitamin D3 [1alpha,25-dihydroxycholecalciferol, 1,25(OH)(2)D3] suppresses the expression of TLR2 and TLR4 protein and mRNA in human monocytes in a time- and dose-dependent fashion. Cholecalciferol 78-81 toll like receptor 2 Homo sapiens 112-116 16402404-3 2006 We report here that vitamin D3 [1alpha,25-dihydroxycholecalciferol, 1,25(OH)(2)D3] suppresses the expression of TLR2 and TLR4 protein and mRNA in human monocytes in a time- and dose-dependent fashion. Cholecalciferol 78-81 toll like receptor 4 Homo sapiens 121-125 16380433-7 2006 Finally, BSPRY expression in kidney was increased in 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice, suggesting an inverse regulation by vitamin D3. Cholecalciferol 63-73 B-box and SPRY domain containing Mus musculus 9-14 16502129-6 2006 However, recent evidence indicates that bone matrix proteins such as osteopontin, matrix Gla protein (MGP), and osteocalcin are expressed in calcified atherosclerotic lesions, and that calcium-regulating hormones such as vitamin D3 and parathyroid hormone-related protein regulate vascular calcification in in vitro vascular calcification models based on cultured aortic smooth muscle cells. Cholecalciferol 221-231 parathyroid hormone like hormone Homo sapiens 236-271 16355272-1 2006 UNLABELLED: Monocytes express 1alpha-hydroxylase, the enzyme responsible for final hydroxylation of vitamin D3, in response to IFNgamma and CD14/TLR4 activation. Cholecalciferol 100-110 CD14 molecule Homo sapiens 140-144 16341266-1 2006 We previously reported that human CD4+ Tregs secrete high levels of IL-10 when stimulated in the presence of dexamethasone and calcitriol (vitamin D3). Cholecalciferol 139-149 CD4 molecule Homo sapiens 34-37 16341266-7 2006 Vitamin D3 significantly overcame the inhibition of glucocorticoid-receptor expression by dexamethasone while IL-10 upregulated glucocorticoid-receptor expression by CD4+ T cells, suggesting potential mechanisms whereby these treatments may overcome poor glucocorticoid responsiveness. Cholecalciferol 0-10 nuclear receptor subfamily 3 group C member 1 Homo sapiens 52-75 16355272-1 2006 UNLABELLED: Monocytes express 1alpha-hydroxylase, the enzyme responsible for final hydroxylation of vitamin D3, in response to IFNgamma and CD14/TLR4 activation. Cholecalciferol 100-110 toll like receptor 4 Homo sapiens 145-149 16341266-8 2006 We show here that administration of vitamin D3 to healthy individuals and SR asthmatic patients enhanced subsequent responsiveness to dexamethasone for induction of IL-10. Cholecalciferol 36-46 interleukin 10 Homo sapiens 165-170 16341266-1 2006 We previously reported that human CD4+ Tregs secrete high levels of IL-10 when stimulated in the presence of dexamethasone and calcitriol (vitamin D3). Cholecalciferol 139-149 interleukin 10 Homo sapiens 68-73 16341266-5 2006 Addition of vitamin D3 with dexamethasone to cultures of SR CD4+ T cells enhanced IL-10 synthesis to levels observed in cells from glucocorticoid-sensitive patients cultured with dexamethasone alone. Cholecalciferol 12-22 CD4 molecule Homo sapiens 60-63 16336217-4 2006 Interestingly, pre-treating HIB5 with vitamin D3 significantly reduced these effects of Dex and, in addition, lowered the transactivational function of the glucocorticoid receptor (GR) in transient reporter gene assays. Cholecalciferol 38-48 nuclear receptor subfamily 3, group C, member 1 Rattus norvegicus 156-179 16341266-5 2006 Addition of vitamin D3 with dexamethasone to cultures of SR CD4+ T cells enhanced IL-10 synthesis to levels observed in cells from glucocorticoid-sensitive patients cultured with dexamethasone alone. Cholecalciferol 12-22 interleukin 10 Homo sapiens 82-87 16336217-4 2006 Interestingly, pre-treating HIB5 with vitamin D3 significantly reduced these effects of Dex and, in addition, lowered the transactivational function of the glucocorticoid receptor (GR) in transient reporter gene assays. Cholecalciferol 38-48 nuclear receptor subfamily 3, group C, member 1 Rattus norvegicus 181-183 16336217-5 2006 A further impact of vitamin D3 on glucocorticoid effects was observed in a rat primary hippocampal culture known to be particularly sensitive to prolonged GR activation. Cholecalciferol 20-30 nuclear receptor subfamily 3, group C, member 1 Rattus norvegicus 155-157 19079903-4 2005 It is suggested that the relationship between vitamin D and low-intensity chronic inflammation and insulin resistance in T2DM can be mediated in part by the immune-modulating properties of the active form of vitamin D (1-alpha,25-dihydroxyvitamin D3; 1,25(OH)2D3), which is able to down regulate the production of pro-inflammatory cytokines - particularly TNF-alpha, and IL-6. Cholecalciferol 247-249 insulin Homo sapiens 99-106 16844314-8 2006 We present an example from our own studies by showing that vitamin D3 has the potential to de-methylate the osteocalcin-promoter in MG63 osteosarcoma cells. Cholecalciferol 59-69 bone gamma-carboxyglutamate protein Homo sapiens 108-119 15904991-3 2005 Here, we present results of the effect of PRP on Vitamin D3-induced phenotypic (CD11b and CD14) and functional (phagocytic) differentiation/maturation of monocytes/macrophages using the premonocytic HL-60 cell line as a model. Cholecalciferol 49-59 integrin subunit alpha M Homo sapiens 80-85 16172800-8 2005 Furthermore, serum levels of 1.25 vitamin D3 and PTH were negatively correlated with disease activity and TNFalpha. Cholecalciferol 34-44 tumor necrosis factor Homo sapiens 106-114 15904991-3 2005 Here, we present results of the effect of PRP on Vitamin D3-induced phenotypic (CD11b and CD14) and functional (phagocytic) differentiation/maturation of monocytes/macrophages using the premonocytic HL-60 cell line as a model. Cholecalciferol 49-59 CD14 molecule Homo sapiens 90-94 16239345-6 2005 Association of HDAC3 and HDAC1 with the relB VDR-binding site was observed, but only HDAC3 was reciprocally modulated by D(3) analog and LPS. Cholecalciferol 121-125 histone deacetylase 3 Mus musculus 85-90 16239345-8 2005 Depletion of HDAC3 attenuated relB suppression by D(3) analog. Cholecalciferol 50-54 histone deacetylase 3 Mus musculus 13-18 16239345-8 2005 Depletion of HDAC3 attenuated relB suppression by D(3) analog. Cholecalciferol 50-54 avian reticuloendotheliosis viral (v-rel) oncogene related B Mus musculus 30-34 16042547-4 2005 In this paper, we provide evidence to suggest that vitamin D3 acts as an anti-inflammatory agent and reverses the age-related increase in microglial activation and the accompanying increase in IL-1beta (interleukin-1beta) concentration. Cholecalciferol 51-61 interleukin 1 beta Rattus norvegicus 193-201 16148162-6 2005 Correlating with reduced EAE, the intact, vitamin D(3)-fed female mice had significantly more 1,25-dihydroxyvitamin D(3) and fewer CYP24A1 transcripts, encoding the 1,25-dihydroxyvitamin D(3)-inactivating enzyme, in the spinal cord than the other groups of mice. Cholecalciferol 42-54 cytochrome P450, family 24, subfamily a, polypeptide 1 Mus musculus 131-138 16284441-3 2005 Despite the severity of her condition, oral administration of vitamin D3 (alphacalcido) has stalled both the tumor growth and further increases of serum thyroglobulin (Tg) level, and has led to a good preservation of quality of life for the last two years. Cholecalciferol 62-72 thyroglobulin Homo sapiens 153-166 16284441-3 2005 Despite the severity of her condition, oral administration of vitamin D3 (alphacalcido) has stalled both the tumor growth and further increases of serum thyroglobulin (Tg) level, and has led to a good preservation of quality of life for the last two years. Cholecalciferol 62-72 thyroglobulin Homo sapiens 168-170 16091841-3 2005 Osteocalcin production was evaluated by cultured cells in neridronate 10(-4) M and 10(-6) M, both under basal conditions and after vitamin D3 stimulation. Cholecalciferol 131-141 bone gamma-carboxyglutamate protein Homo sapiens 0-11 16091841-4 2005 In the absence of neridronate, vitamin D3 increased osteocalcin production in all cell cultures; under the same conditions, and in the absence of vitamin D3, OA osteoblasts showed a significantly higher osteocalcin production whereas OP osteoblasts showed a significantly lower osteocalcin production compared to the normal osteoblasts, respectively. Cholecalciferol 31-41 bone gamma-carboxyglutamate protein Homo sapiens 52-63 16091841-4 2005 In the absence of neridronate, vitamin D3 increased osteocalcin production in all cell cultures; under the same conditions, and in the absence of vitamin D3, OA osteoblasts showed a significantly higher osteocalcin production whereas OP osteoblasts showed a significantly lower osteocalcin production compared to the normal osteoblasts, respectively. Cholecalciferol 31-41 bone gamma-carboxyglutamate protein Homo sapiens 203-214 16091841-4 2005 In the absence of neridronate, vitamin D3 increased osteocalcin production in all cell cultures; under the same conditions, and in the absence of vitamin D3, OA osteoblasts showed a significantly higher osteocalcin production whereas OP osteoblasts showed a significantly lower osteocalcin production compared to the normal osteoblasts, respectively. Cholecalciferol 31-41 bone gamma-carboxyglutamate protein Homo sapiens 203-214 16042547-4 2005 In this paper, we provide evidence to suggest that vitamin D3 acts as an anti-inflammatory agent and reverses the age-related increase in microglial activation and the accompanying increase in IL-1beta (interleukin-1beta) concentration. Cholecalciferol 51-61 interleukin 1 beta Rattus norvegicus 203-220 16922635-6 2005 However, Caco-2 cells may be induced to express higher levels of CYP3A4 by treatment with vitamin D3. Cholecalciferol 90-100 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 65-71 15809060-6 2005 Furthermore, the expression of CD14 in U937 cells expressing the DeltaC-C mutant in response to vitamin D3 was markedly higher than in cells expressing PML-RARalpha. Cholecalciferol 96-106 CD14 molecule Homo sapiens 31-35 16098191-0 2005 The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism. Cholecalciferol 60-70 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 4-22 16098191-1 2005 We show that cytochrome P450scc (CYP11A1) in either a reconstituted system or in isolated adrenal mitochondria can metabolize vitamin D3. Cholecalciferol 126-136 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 13-31 16098191-1 2005 We show that cytochrome P450scc (CYP11A1) in either a reconstituted system or in isolated adrenal mitochondria can metabolize vitamin D3. Cholecalciferol 126-136 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 33-40 16098191-4 2005 Based on NMR analysis and known properties of P450scc we propose that hydroxylation of vitamin D3 by P450scc occurs sequentially and stereospecifically with initial formation of 20(S)-hydroxyvitamin D3. Cholecalciferol 87-97 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 46-53 16098191-4 2005 Based on NMR analysis and known properties of P450scc we propose that hydroxylation of vitamin D3 by P450scc occurs sequentially and stereospecifically with initial formation of 20(S)-hydroxyvitamin D3. Cholecalciferol 87-97 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 101-108 16098191-8 2005 It therefore appears that non-P450scc enzymes present in the adrenal cortex to some extent contribute to metabolism of vitamin D3. Cholecalciferol 119-129 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 30-37 16098191-9 2005 We conclude that purified P450scc in a reconstituted system or P450scc in adrenal mitochondria can add one hydroxyl group to vitamin D3 with subsequent hydroxylation being observed for reconstituted enzyme but not for adrenal mitochondria. Cholecalciferol 125-135 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 26-33 16098191-9 2005 We conclude that purified P450scc in a reconstituted system or P450scc in adrenal mitochondria can add one hydroxyl group to vitamin D3 with subsequent hydroxylation being observed for reconstituted enzyme but not for adrenal mitochondria. Cholecalciferol 125-135 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 63-70 15988048-5 2005 Amplifying CD11b, CD11c, and CD14 mRNAs, as specific markers of differentiation, by the real-time RT-PCR assay we could detect both retinoic acid (RA) and vitamin D3 and human transforming growth factor beta1 (VitD3/TGFbeta1) induced cellular maturation more precociously than the canonical flow-cytofluorimetric assay. Cholecalciferol 155-165 integrin subunit alpha M Homo sapiens 11-16 15988048-5 2005 Amplifying CD11b, CD11c, and CD14 mRNAs, as specific markers of differentiation, by the real-time RT-PCR assay we could detect both retinoic acid (RA) and vitamin D3 and human transforming growth factor beta1 (VitD3/TGFbeta1) induced cellular maturation more precociously than the canonical flow-cytofluorimetric assay. Cholecalciferol 155-165 CD14 molecule Homo sapiens 29-33 15864137-0 2005 Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. Cholecalciferol 113-123 vitamin D receptor Homo sapiens 0-18 16158969-0 2005 Correlation between VDR expression and antiproliferative activity of vitamin D3 compounds in combination with cytostatics. Cholecalciferol 69-79 vitamin D receptor Homo sapiens 20-23 15752725-0 2005 Measurement and characterization of C-3 epimerization activity toward vitamin D3. Cholecalciferol 70-80 complement C3 Homo sapiens 36-39 15863722-0 2005 Regulation of the human cyclin C gene via multiple vitamin D3-responsive regions in its promoter. Cholecalciferol 51-61 cyclin C Homo sapiens 24-32 15585593-4 2005 CYP2C11 had the greatest activity with these substrates, except vitamin D3, which had the same activity as four of the other enzymes. Cholecalciferol 64-74 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 0-7 15585593-5 2005 The descending order of 25-hydroxylation by CYP2C11 was 1alphaOHD3 > 1alphaOHD2 > vitamin D2 > vitamin D3. Cholecalciferol 104-114 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 44-51 15585593-15 2005 It is concluded that CYP2C11 is a male-specific hepatic microsomal vitamin D 25-hydroxylase that hydroxylates vitamin D2, vitamin D3, 1alphaOHD2, and 1alphaOHD3. Cholecalciferol 122-132 cytochrome P450, subfamily 2, polypeptide 11 Rattus norvegicus 21-28 15585593-15 2005 It is concluded that CYP2C11 is a male-specific hepatic microsomal vitamin D 25-hydroxylase that hydroxylates vitamin D2, vitamin D3, 1alphaOHD2, and 1alphaOHD3. Cholecalciferol 122-132 cytochrome P450, family 2, subfamily r, polypeptide 1 Rattus norvegicus 67-91 15707954-0 2005 Negative regulation of human parathyroid hormone gene promoter by vitamin D3 through nuclear factor Y. Cholecalciferol 66-76 parathyroid hormone Homo sapiens 29-48 15707954-1 2005 The negative regulation of the human parathyroid hormone (PTH) gene by biologically active vitamin D3 (1,25-dihydroxyvitamin D3; 1,25(OH)2D3) was studied in rat pituitary GH4C1 cells, which express factors needed for the negative regulation. Cholecalciferol 91-101 parathyroid hormone Homo sapiens 37-56 15707954-1 2005 The negative regulation of the human parathyroid hormone (PTH) gene by biologically active vitamin D3 (1,25-dihydroxyvitamin D3; 1,25(OH)2D3) was studied in rat pituitary GH4C1 cells, which express factors needed for the negative regulation. Cholecalciferol 91-101 parathyroid hormone Homo sapiens 58-61 16158254-0 2005 Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Cholecalciferol 38-53 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 55-82 15816500-1 2005 Vitamin D3 is modified by vitamin D3-25-hydroxylase in the liver, and 25-hydroxyvitamin D3-1alpha-hydroxylase in the kidney, to form the active metabolite, 1,25-dihydroxyvitamin D3. Cholecalciferol 0-10 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 26-51 15638502-5 2005 The same phenomenon demonstrating massive denaturation and aggregation was observed for a greater than 500-fold excess of D(3) with respect to Fbg after 20 h of incubation. Cholecalciferol 122-126 fibrinogen beta chain Homo sapiens 143-146 16158255-7 2005 Cholecalciferol has effects similar to those of calcitriol on growth, MMP activity, and VDR. Cholecalciferol 0-15 vitamin D receptor Homo sapiens 88-91 16158255-8 2005 The ability of CYP27A1 to catalyze the conversion of cholecalciferol to 25(OH)D(3) and of 25(OH)D(3) to calcitriol has been reported. Cholecalciferol 53-68 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 15-22 15766397-0 2005 [Expression of CD14 protein in U937 cells induced by vitamin D3]. Cholecalciferol 53-63 CD14 molecule Homo sapiens 15-19 15746971-0 2005 Influence of mechanical and biological signals on gene expression in human MG-63 cells: evidence for a complex interplay between hydrostatic compression and vitamin D3 or TGF-beta1 on MMP-1 and MMP-3 mRNA levels. Cholecalciferol 157-167 matrix metallopeptidase 1 Homo sapiens 184-189 15746971-0 2005 Influence of mechanical and biological signals on gene expression in human MG-63 cells: evidence for a complex interplay between hydrostatic compression and vitamin D3 or TGF-beta1 on MMP-1 and MMP-3 mRNA levels. Cholecalciferol 157-167 matrix metallopeptidase 3 Homo sapiens 194-199 15785827-6 2005 RANKL expression can be upregulated by bone-resorbing factors such as glucocorticoids, vitamin D3, interleukin 1 (IL-1), IL-6, IL-11, IL-17, tumor necrosis factor-alpha, prostaglandin E2, or parathyroid hormone-related peptide. Cholecalciferol 87-97 TNF superfamily member 11 Homo sapiens 0-5 16158255-7 2005 Cholecalciferol has effects similar to those of calcitriol on growth, MMP activity, and VDR. Cholecalciferol 0-15 matrix metallopeptidase 2 Homo sapiens 70-73 16158254-0 2005 Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Cholecalciferol 38-53 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 84-91 16158254-6 2005 Results show that cholecalciferol, at physiological levels: (i) inhibits anchorage-dependent growth (ii) induces differentiation by increasing PSA expression and (iii) exerts its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptors (RXRs), and androgen receptor (AR). Cholecalciferol 18-33 vitamin D receptor Homo sapiens 204-222 16158254-6 2005 Results show that cholecalciferol, at physiological levels: (i) inhibits anchorage-dependent growth (ii) induces differentiation by increasing PSA expression and (iii) exerts its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptors (RXRs), and androgen receptor (AR). Cholecalciferol 18-33 vitamin D receptor Homo sapiens 224-227 16158254-6 2005 Results show that cholecalciferol, at physiological levels: (i) inhibits anchorage-dependent growth (ii) induces differentiation by increasing PSA expression and (iii) exerts its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptors (RXRs), and androgen receptor (AR). Cholecalciferol 18-33 androgen receptor Homo sapiens 263-280 16158254-6 2005 Results show that cholecalciferol, at physiological levels: (i) inhibits anchorage-dependent growth (ii) induces differentiation by increasing PSA expression and (iii) exerts its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptors (RXRs), and androgen receptor (AR). Cholecalciferol 18-33 androgen receptor Homo sapiens 282-284 16158254-7 2005 Furthermore, we discovered that human prostate epithelial cells constitutively express appreciable levels of 25-hydroxylase CYP27A1 protein, the enzyme which catalyzes the conversion of cholecalciferol to 25(OH)D(3), and that CYP27A1 is up-regulated by cholecalciferol. Cholecalciferol 186-201 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 124-131 16158254-7 2005 Furthermore, we discovered that human prostate epithelial cells constitutively express appreciable levels of 25-hydroxylase CYP27A1 protein, the enzyme which catalyzes the conversion of cholecalciferol to 25(OH)D(3), and that CYP27A1 is up-regulated by cholecalciferol. Cholecalciferol 186-201 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 226-233 16158254-7 2005 Furthermore, we discovered that human prostate epithelial cells constitutively express appreciable levels of 25-hydroxylase CYP27A1 protein, the enzyme which catalyzes the conversion of cholecalciferol to 25(OH)D(3), and that CYP27A1 is up-regulated by cholecalciferol. Cholecalciferol 253-268 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 124-131 16158255-0 2005 Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Cholecalciferol 0-15 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 113-120 16158255-0 2005 Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Cholecalciferol 17-27 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 113-120 16158255-4 2005 Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner. Cholecalciferol 0-15 vimentin Homo sapiens 144-152 16158255-4 2005 Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner. Cholecalciferol 0-15 matrix metallopeptidase 9 Homo sapiens 232-237 16158255-4 2005 Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner. Cholecalciferol 0-15 matrix metallopeptidase 2 Homo sapiens 242-247 16158255-4 2005 Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner. Cholecalciferol 0-15 vitamin D receptor Homo sapiens 342-360 16158255-4 2005 Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner. Cholecalciferol 0-15 vitamin D receptor Homo sapiens 362-365 16158255-4 2005 Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner. Cholecalciferol 0-15 retinoid X receptor alpha Homo sapiens 368-393 16158255-4 2005 Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner. Cholecalciferol 0-15 retinoid X receptor alpha Homo sapiens 395-404 16158255-4 2005 Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner. Cholecalciferol 0-15 androgen receptor Homo sapiens 411-428 16158255-4 2005 Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner. Cholecalciferol 0-15 androgen receptor Homo sapiens 430-432 16158255-6 2005 Clin Exp Metast 2005; 22: 265-73), constitutively express the enzyme 25-hydroxylase CYP27A1 which is markedly up-regulated by cholecalciferol. Cholecalciferol 126-141 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 84-91 15574355-3 2005 Upon analyses of the metabolites of vitamin D3 by the reconstituted system, CYP27A1 surprisingly produced at least seven forms of minor metabolites including 1alpha,25(OH)2D3 in addition to the major metabolite 25(OH)D3. Cholecalciferol 36-46 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 76-83 15574355-4 2005 These results indicated that human CYP27A1 catalyzes multiple reactions involved in the vitamin D3 metabolism. Cholecalciferol 88-98 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 35-42 15574355-6 2005 Enzymatic studies on substrate specificity of CYP27B1 suggest that the 1alpha-hydroxylase activity of CYP27B1 requires the presence of 25-hydroxyl group of vitamin D3 and is enhanced by 24-hydroxyl group while the presence of 23-hydroxyl group greatly reduced the activity. Cholecalciferol 156-166 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 46-53 15574355-6 2005 Enzymatic studies on substrate specificity of CYP27B1 suggest that the 1alpha-hydroxylase activity of CYP27B1 requires the presence of 25-hydroxyl group of vitamin D3 and is enhanced by 24-hydroxyl group while the presence of 23-hydroxyl group greatly reduced the activity. Cholecalciferol 156-166 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 102-109 15749627-3 2005 We investigated the effect of the nutrient vitamin D (cholecalciferol), a biochemical precursor of calcitriol, on PSA levels and the rate of rise of PSA in these patients. Cholecalciferol 54-69 kallikrein related peptidase 3 Homo sapiens 114-117 15601870-3 2005 The CCAAT box on the ODF gene is required for its transcriptional induction by vitamin D3, suggesting that NF-Y coregulates this promoter along with VDR. Cholecalciferol 79-89 TNF superfamily member 11 Homo sapiens 21-24 15601870-3 2005 The CCAAT box on the ODF gene is required for its transcriptional induction by vitamin D3, suggesting that NF-Y coregulates this promoter along with VDR. Cholecalciferol 79-89 vitamin D receptor Homo sapiens 149-152 15601870-5 2005 Stimulation with vitamin D3 facilitates the recruitment of VDR and p300 onto the ODF promoter, resulting in acetylation of histone H4 in an NF-Y-independent manner. Cholecalciferol 17-27 vitamin D receptor Homo sapiens 59-62 15601870-5 2005 Stimulation with vitamin D3 facilitates the recruitment of VDR and p300 onto the ODF promoter, resulting in acetylation of histone H4 in an NF-Y-independent manner. Cholecalciferol 17-27 E1A binding protein p300 Homo sapiens 67-71 15601870-5 2005 Stimulation with vitamin D3 facilitates the recruitment of VDR and p300 onto the ODF promoter, resulting in acetylation of histone H4 in an NF-Y-independent manner. Cholecalciferol 17-27 TNF superfamily member 11 Homo sapiens 81-84 15749627-0 2005 Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Cholecalciferol 42-57 kallikrein related peptidase 3 Homo sapiens 76-79 15749627-5 2005 In 9 patients, PSA levels decreased or remained unchanged after the commencement of cholecalciferol. Cholecalciferol 84-99 kallikrein related peptidase 3 Homo sapiens 15-18 15749627-7 2005 Also, there was a statistically significant decrease in the rate of PSA rise after administration of cholecalciferol (P = 0.005) compared with that before cholecalciferol. Cholecalciferol 101-116 kallikrein related peptidase 3 Homo sapiens 68-71 15749627-8 2005 The median PSA doubling time increased from 14.3 mo prior to commencing cholecalciferol to 25 mo after commencing cholecalciferol. Cholecalciferol 72-87 kallikrein related peptidase 3 Homo sapiens 11-14 15749627-8 2005 The median PSA doubling time increased from 14.3 mo prior to commencing cholecalciferol to 25 mo after commencing cholecalciferol. Cholecalciferol 114-129 kallikrein related peptidase 3 Homo sapiens 11-14 15749627-9 2005 Fourteen of 15 patients had a prolongation of PSA doubling time after commencing cholecalciferol. Cholecalciferol 81-96 kallikrein related peptidase 3 Homo sapiens 46-49 15319350-0 2004 Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Cholecalciferol 0-10 dynactin 6 Mus musculus 42-45 16152990-8 2005 On grouping patients according to their mean OPG levels, we observed significantly lower serum IGF-1, vitamin D3 concentrations, and lumbar spine and hip bone mineral density in the high OPG groups. Cholecalciferol 102-112 TNF receptor superfamily member 11b Homo sapiens 45-48 16152990-8 2005 On grouping patients according to their mean OPG levels, we observed significantly lower serum IGF-1, vitamin D3 concentrations, and lumbar spine and hip bone mineral density in the high OPG groups. Cholecalciferol 102-112 TNF receptor superfamily member 11b Homo sapiens 187-190 15801068-0 2004 Osteocalcin synthesis by human osteoblasts from normal and osteoarthritic bone after vitamin D3 stimulation. Cholecalciferol 85-95 bone gamma-carboxyglutamate protein Homo sapiens 0-11 15801068-3 2004 In this study we correlated osteocalcin production from human osteoblasts isolated from healthy and osteoarthritic subjects to the degree of cartilage damage, before and after stimulation with 1,25(OH)2-vitamin D3, the active metabolite of vitamin D3. Cholecalciferol 203-213 bone gamma-carboxyglutamate protein Homo sapiens 28-39 15801068-5 2004 We determined the osteocalcin production in normal and osteoarthritic osteoblasts from maximal and minimal cartilage damage areas both under basal conditions and after vitamin D3 stimulation. Cholecalciferol 168-178 bone gamma-carboxyglutamate protein Homo sapiens 18-29 15801068-8 2004 The response of osteoblasts to vitamin D3 stimulation appeared to be proportional to the degree of joint damage, as the vitamin D3-induced increase in osteocalcin is proportionally greater in maximally damaged osteoblasts compared to minimally damaged ones. Cholecalciferol 31-41 bone gamma-carboxyglutamate protein Homo sapiens 151-162 15801068-8 2004 The response of osteoblasts to vitamin D3 stimulation appeared to be proportional to the degree of joint damage, as the vitamin D3-induced increase in osteocalcin is proportionally greater in maximally damaged osteoblasts compared to minimally damaged ones. Cholecalciferol 120-130 bone gamma-carboxyglutamate protein Homo sapiens 151-162 15801068-9 2004 Thus, after vitamin D3 stimulation, a significant increase in osteocalcin production by maximally damaged osteoblasts compared to the minimally damaged ones was observed. Cholecalciferol 12-22 bone gamma-carboxyglutamate protein Homo sapiens 62-73 15488475-2 2004 It remains to be determined whether CYP24A1 has the ability to hydroxylate vitamin D3 compounds at C-25. Cholecalciferol 75-85 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 36-43 15556626-0 2004 Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells. Cholecalciferol 0-10 fatty acid synthase Homo sapiens 20-39 15556626-0 2004 Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells. Cholecalciferol 0-10 acyl-CoA synthetase long chain family member 3 Homo sapiens 84-118 15556626-2 2004 In our previous studies, we found that FAS and FACL3 genes were vitamin D3-regulated and involved in the antiproliferative effect of 1alpha,25(OH)2D3 in the human prostate cancer LNCaP cells. Cholecalciferol 72-74 acyl-CoA synthetase long chain family member 3 Homo sapiens 47-52 15556626-6 2004 This suggests that the downregulation of FAS expression by vitamin D3 is mediated by vitamin D3 upregulation of FACL3 expression. Cholecalciferol 59-69 acyl-CoA synthetase long chain family member 3 Homo sapiens 112-117 15556626-6 2004 This suggests that the downregulation of FAS expression by vitamin D3 is mediated by vitamin D3 upregulation of FACL3 expression. Cholecalciferol 85-95 acyl-CoA synthetase long chain family member 3 Homo sapiens 112-117 15556626-7 2004 Myristic acid, one of the substrates preferential for FACL3, enhanced the repression of FAS expression by vitamin D3. Cholecalciferol 106-116 acyl-CoA synthetase long chain family member 3 Homo sapiens 54-59 15556626-8 2004 The action of myristic acid was abrogated by inhibition of FACL3 activity, suggesting that the enhancement in the downregulation of FAS expression by vitamin D3 is due to the formation of myristoyl-CoA. Cholecalciferol 150-160 acyl-CoA synthetase long chain family member 3 Homo sapiens 59-64 15556626-9 2004 The data suggest that vitamin D3-repression of FAS mRNA expression is the consequence of feedback inhibition of FAS expression by long chain fatty acyl-CoAs, which are formed by FACL3 during its upregulation by vitamin D3 in human prostate cancer LNCaP cells. Cholecalciferol 22-32 acyl-CoA synthetase long chain family member 3 Homo sapiens 178-183 15556626-9 2004 The data suggest that vitamin D3-repression of FAS mRNA expression is the consequence of feedback inhibition of FAS expression by long chain fatty acyl-CoAs, which are formed by FACL3 during its upregulation by vitamin D3 in human prostate cancer LNCaP cells. Cholecalciferol 211-221 acyl-CoA synthetase long chain family member 3 Homo sapiens 178-183 15521896-1 2004 AIMS: This study was undertaken to evaluate removal of 22-oxacalcitriol (OCT), an active and intravenously used vitamin D3 analogue with less calcaemic activity, by polysulphone haemodialyser in vivo and in vitro. Cholecalciferol 112-122 plexin A2 Homo sapiens 73-76 15876428-2 2004 Vitamin D receptor (VDR) belongs to a nuclear receptor super-family that mediates the genomic actions of vitamin D3 and regulates gene expression by binding with vitamin D response elements in the promoter region of the cognate gene. Cholecalciferol 105-115 vitamin D receptor Homo sapiens 0-18 15876428-2 2004 Vitamin D receptor (VDR) belongs to a nuclear receptor super-family that mediates the genomic actions of vitamin D3 and regulates gene expression by binding with vitamin D response elements in the promoter region of the cognate gene. Cholecalciferol 105-115 vitamin D receptor Homo sapiens 20-23 15876428-5 2004 The biologically active form of vitamin D3, 1alpha,25-dihydroxy vitamin D3 [1,25(OH)2D3], induced VDR in THP-1 cells after 24 h treatment, and LPS inhibited 1,25(OH)2D3-mediated VDR induction. Cholecalciferol 32-42 vitamin D receptor Homo sapiens 178-181 15876428-5 2004 The biologically active form of vitamin D3, 1alpha,25-dihydroxy vitamin D3 [1,25(OH)2D3], induced VDR in THP-1 cells after 24 h treatment, and LPS inhibited 1,25(OH)2D3-mediated VDR induction. Cholecalciferol 32-42 vitamin D receptor Homo sapiens 98-101 15876428-5 2004 The biologically active form of vitamin D3, 1alpha,25-dihydroxy vitamin D3 [1,25(OH)2D3], induced VDR in THP-1 cells after 24 h treatment, and LPS inhibited 1,25(OH)2D3-mediated VDR induction. Cholecalciferol 32-42 GLI family zinc finger 2 Homo sapiens 105-110 15511223-3 2004 Moreover, purified mammalian P450scc enzyme and, most importantly, mitochondria isolated from placenta and adrenals produced robust transformation of 7-dehydrocholesterol (7-DHC; precursor to cholesterol and vitamin D3) to 7-dehydropregnenolone (7-DHP). Cholecalciferol 208-218 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 29-36 15511223-7 2004 In the skin, 5,7-steroidal dienes (7-DHP and its hydroxy derivatives), whether synthesized locally or delivered by the circulation, may undergo UVB-induced intramolecular rearrangements to vitamin D3-like derivatives. Cholecalciferol 189-199 dihydropyrimidinase Homo sapiens 37-40 15369780-7 2004 Based on these results and the fact that human CYP27A1 and Streptomyces CYP105A1 also convert vitamin D3 to 1alpha,25(OH)D3, 1alpha-hydroxylation, and 25-hydroxylation of vitamin D3 appear to be closely linked together. Cholecalciferol 94-104 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 47-54 15369780-7 2004 Based on these results and the fact that human CYP27A1 and Streptomyces CYP105A1 also convert vitamin D3 to 1alpha,25(OH)D3, 1alpha-hydroxylation, and 25-hydroxylation of vitamin D3 appear to be closely linked together. Cholecalciferol 171-181 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 47-54 15369780-2 2004 To reveal the enzymatic properties of CYP27B1, we measured its hydroxylation activity toward vitamin D3 and 1alpha-hydroxyvitamin D3 (1alpha(OH)D3) in addition to the physiological substrate 25(OH)D3. Cholecalciferol 93-103 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 38-45 15369780-3 2004 Surprisingly, CYP27B1 converted vitamin D3 to 1alpha,25(OH)D3. Cholecalciferol 32-42 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 14-21 15342392-6 2004 Overexpression of TEL2 in U937 cells inhibited differentiation induced by vitamin D3. Cholecalciferol 74-84 ETS variant transcription factor 7 Homo sapiens 18-22 15375610-9 2004 The complete human Osteocalcin promoter and the bone-sialoprotein promoter were partially induced by vitamin D3 or C respectively while the pAd.3r-luc activity could be shut down by doxycyclin. Cholecalciferol 101-111 bone gamma-carboxyglutamate protein Homo sapiens 19-30 15368355-2 2004 Vitamin D3 (VD3) exerts its biological actions by binding within cells to VDR. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 74-77 15331408-0 2004 Vitamin D3 induces caspase-14 expression in psoriatic lesions and enhances caspase-14 processing in organotypic skin cultures. Cholecalciferol 0-10 caspase 14 Homo sapiens 19-29 15331408-0 2004 Vitamin D3 induces caspase-14 expression in psoriatic lesions and enhances caspase-14 processing in organotypic skin cultures. Cholecalciferol 0-10 caspase 14 Homo sapiens 75-85 15331408-4 2004 Topical treatment of psoriatic lesions with a vitamin D3 analogue resulted in a decrease of the psoriatic phenotype and an increase in caspase-14 expression in the parakeratotic plugs. Cholecalciferol 46-56 caspase 14 Homo sapiens 135-145 15331408-6 2004 1alpha,25-Dihydroxycholecalciferol, the biologically active form of vitamin D3, increased caspase-14 expression, whereas retinoic acid inhibited it. Cholecalciferol 68-78 caspase 14 Homo sapiens 90-100 15331408-7 2004 Moreover, retinoic acid repressed the vitamin D3-induced caspase-14 expression level. Cholecalciferol 38-48 caspase 14 Homo sapiens 57-67 15357841-12 2004 From the results, it has become evident that Vitamin D3 induces EDNRB expression by NCCmelb4 cells. Cholecalciferol 45-55 endothelin receptor type B Mus musculus 64-69 15371984-9 2004 Moreover, intrinsic clearance of CYP3A4-mediated verapamil metabolism in homogenates of simultaneously collected shed enterocytes correlated with in vivo E GI of d0-verapamil 15 min /d3-verapamil 240 min (r = 0.62, P =.03). Cholecalciferol 183-185 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 33-39 15503649-4 2004 Vitamin D3 exerts its effects through the vitamin D3 receptor (VDR), a ligand-activated nuclear receptor expressed in a wide array of tissue and cell types. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 42-61 15503649-4 2004 Vitamin D3 exerts its effects through the vitamin D3 receptor (VDR), a ligand-activated nuclear receptor expressed in a wide array of tissue and cell types. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 63-66 15450141-9 2004 A possible explanation is mentioned in the literature by an increase in PGP level and multi-drug resistance, so we suggest that it may play a role in impaired Tc-99m MIBI uptake in the thyroid phase and recommend cessation of vitamin D3 metabolites before performing parathyroid scintigraphy. Cholecalciferol 226-236 phosphoglycolate phosphatase Homo sapiens 72-75 15178414-0 2004 The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth. Cholecalciferol 50-60 acyl-CoA synthetase long chain family member 3 Homo sapiens 12-46 15328373-8 2004 Mad1-expression, however, neither enforced spontaneous differentiation nor enhanced differentiation induced by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate, retinoic acid (RA), or vitamin D3 but rather led to delayed RA-stimulated differentiation. Cholecalciferol 190-200 MAX dimerization protein 1 Homo sapiens 0-4 15207715-4 2004 As mammalian mitochondrial CYP27A1 catalyzes a similar two-step hydroxylation towards vitamin D3, the enzymatic properties of CYP105A1 were compared with those of human CYP27A1. Cholecalciferol 86-96 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 27-34 15232218-2 2004 In the present study we showed that expression of RANK was strongly induced by phorbol-12-myristate-13-acetate (PMA) during monocyte differentiation of U937 cells, and was enhanced by concomitant treatment with vitamin D3. Cholecalciferol 211-221 TNF receptor superfamily member 11a Homo sapiens 50-54 15064717-0 2004 Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3. Cholecalciferol 87-97 vitamin D receptor Homo sapiens 0-19 15064717-0 2004 Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3. Cholecalciferol 87-97 cyclin dependent kinase inhibitor 1B Homo sapiens 65-72 15064717-1 2004 1alpha,25-dihydroxyvitamin D3 (vitamin D3) has been shown to upregulate p27Kip1 expression via Sp1 and NF-Y binding sites in the p27Kip1 promoter. Cholecalciferol 19-29 cyclin dependent kinase inhibitor 1B Homo sapiens 72-79 15064717-1 2004 1alpha,25-dihydroxyvitamin D3 (vitamin D3) has been shown to upregulate p27Kip1 expression via Sp1 and NF-Y binding sites in the p27Kip1 promoter. Cholecalciferol 19-29 cyclin dependent kinase inhibitor 1B Homo sapiens 129-136 15064717-3 2004 In this study, we demonstrated that expression of VDR in SW620 cells, which exhibited low level of endogenous VDR, increased vitamin D3-stimulated p27Kip1 promoter activity. Cholecalciferol 125-135 vitamin D receptor Homo sapiens 50-53 15064717-3 2004 In this study, we demonstrated that expression of VDR in SW620 cells, which exhibited low level of endogenous VDR, increased vitamin D3-stimulated p27Kip1 promoter activity. Cholecalciferol 125-135 vitamin D receptor Homo sapiens 110-113 15064717-3 2004 In this study, we demonstrated that expression of VDR in SW620 cells, which exhibited low level of endogenous VDR, increased vitamin D3-stimulated p27Kip1 promoter activity. Cholecalciferol 125-135 cyclin dependent kinase inhibitor 1B Homo sapiens 147-154 15064717-4 2004 On the contrary, suppression of Sp1 expression by small interference RNA reduced the stimulation of p27Kip1 promoter activity by vitamin D3 in LNCaP cells. Cholecalciferol 129-139 cyclin dependent kinase inhibitor 1B Homo sapiens 100-107 15064717-7 2004 Collectively, our results suggest that VDR is involved in the induction of p27Kip1 by vitamin D3 and may interact with Sp1 to modulate the expression of target genes that lack VDR response element (VDRE) in their promoters. Cholecalciferol 86-96 vitamin D receptor Homo sapiens 39-42 15064717-7 2004 Collectively, our results suggest that VDR is involved in the induction of p27Kip1 by vitamin D3 and may interact with Sp1 to modulate the expression of target genes that lack VDR response element (VDRE) in their promoters. Cholecalciferol 86-96 cyclin dependent kinase inhibitor 1B Homo sapiens 75-82 15225839-5 2004 In addition, we found that TNF-alpha potently increases the conversion rate of Vitamin D(3) (cholecalciferol) to calcitriol in this cell system. Cholecalciferol 79-91 tumor necrosis factor Homo sapiens 27-36 15149692-0 2004 Design and synthesis of dysidiolide analogs from vitamin D3: novel class of Cdc25A inhibitors. Cholecalciferol 49-59 cell division cycle 25A Homo sapiens 76-82 15026419-10 2004 Purified recombinant CYP2J3 showed strong 25-hydroxylation activities toward vitamin D3 and 1alpha-hydroxyvitamin D3 with turnover numbers of 3.3 and 22, respectively, which were markedly higher than those of P450s previously characterized as 25-hydroxylases. Cholecalciferol 77-87 cytochrome P450, family 2, subfamily j, polypeptide 3 Rattus norvegicus 21-27 15026419-12 2004 These results strongly suggest that CYP2J3 is the principal P450 responsible for vitamin D3 25-hydroxylation in rat liver. Cholecalciferol 81-91 cytochrome P450, family 2, subfamily j, polypeptide 3 Rattus norvegicus 36-42 15225755-0 2004 Model of three-dimensional structure of VDR bound with Vitamin D3 analogs substituted at carbon-2. Cholecalciferol 55-65 vitamin D receptor Homo sapiens 40-43 15173382-4 2004 Here, we show that Alien and Sin3A reside together in vivo with the vitamin D3 receptor on the human 24-hydroxylase (CYP24) promoter containing vitamin D3 response elements by chromatin immunoprecipitation. Cholecalciferol 68-78 COP9 signalosome subunit 2 Homo sapiens 19-24 15173382-4 2004 Here, we show that Alien and Sin3A reside together in vivo with the vitamin D3 receptor on the human 24-hydroxylase (CYP24) promoter containing vitamin D3 response elements by chromatin immunoprecipitation. Cholecalciferol 68-78 SIN3 transcription regulator family member A Homo sapiens 29-34 15173382-4 2004 Here, we show that Alien and Sin3A reside together in vivo with the vitamin D3 receptor on the human 24-hydroxylase (CYP24) promoter containing vitamin D3 response elements by chromatin immunoprecipitation. Cholecalciferol 68-78 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 117-122 15225744-0 2004 Cell specificity and properties of the C-3 epimerization of Vitamin D3 metabolites. Cholecalciferol 60-70 complement C3 Homo sapiens 39-42 15225744-2 2004 We investigated the C-3 epimerization of Vitamin D3 metabolites in various cultured cells and basic properties of the enzyme responsible for the C-3 epimerization. Cholecalciferol 41-51 complement C3 Rattus norvegicus 20-23 15225744-7 2004 Based on these results, the enzyme responsible for the C-3 epimerization of Vitamin D3 are thought to be different from already-known cytochrome P450-related Vitamin D metabolic enzymes and HSE. Cholecalciferol 76-86 complement C3 Homo sapiens 55-58 15225744-7 2004 Based on these results, the enzyme responsible for the C-3 epimerization of Vitamin D3 are thought to be different from already-known cytochrome P450-related Vitamin D metabolic enzymes and HSE. Cholecalciferol 76-86 hydroxysteroid 17-beta dehydrogenase 6 Homo sapiens 190-193 15225746-0 2004 Different effects of physiologically and pharmacologically increased growth hormone levels on cholecalciferol metabolism at prepubertal age. Cholecalciferol 94-109 somatotropin Canis lupus familiaris 69-83 15225746-1 2004 The aim of the study was to investigate the influence of physiologically and pharmacologically increased plasma growth hormone (GH) levels on cholecalciferol metabolism at prepubertal age. Cholecalciferol 142-157 somatotropin Canis lupus familiaris 112-126 15225839-5 2004 In addition, we found that TNF-alpha potently increases the conversion rate of Vitamin D(3) (cholecalciferol) to calcitriol in this cell system. Cholecalciferol 93-108 tumor necrosis factor Homo sapiens 27-36 14757768-0 2004 C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation. Cholecalciferol 21-31 complement C3 Sus scrofa 0-3 14757768-2 2004 We now report the isolation and structural assignment of 3-epi-25-hydroxyvitamin D3 (3-epi-25(OH)D3 as a major metabolite of 25-hydroxyvitamin D3 (25(OH)D3) and the further metabolism of C-3 epimers of vitamin D3 metabolites. Cholecalciferol 73-83 complement C3 Sus scrofa 187-190 14757768-10 2004 These results indicate that C-3 epimerization may be a common metabolic pathway for the major metabolites of vitamin D3. Cholecalciferol 109-119 complement C3 Sus scrofa 28-31 14583431-3 2004 Vitamin D3 (VitD) is known to increase PMCA expression and activity in Ca2+-transporting tissues such as the intestine, as well as in osteoblasts and Madin-Darby bovine kidney epithelial cells. Cholecalciferol 0-10 ATPase plasma membrane Ca2+ transporting 1 Bos taurus 39-43 15005856-11 2004 CYP3A4 25-hydroxylase activity was four times higher with 1alpha(OH)D2 than with 1alpha(OH)D3 as substrate, was much less with vitamin D2, and was not detected with vitamin D3. Cholecalciferol 165-175 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 15165715-2 2004 Our work was aimed to explore the production of ADM, changes and pathophysiological significance of ADM mRNA and ADM receptor components--calcitonin receptor like receptor (CRLR) and receptor activity modifying proteins (RAMPs) mRNA in calcified myocardium and aorta of rats induced by Vitamin D3 plus nicotine. Cholecalciferol 286-296 adrenomedullin Rattus norvegicus 48-51 15165715-2 2004 Our work was aimed to explore the production of ADM, changes and pathophysiological significance of ADM mRNA and ADM receptor components--calcitonin receptor like receptor (CRLR) and receptor activity modifying proteins (RAMPs) mRNA in calcified myocardium and aorta of rats induced by Vitamin D3 plus nicotine. Cholecalciferol 286-296 adrenomedullin Rattus norvegicus 100-103 15165715-2 2004 Our work was aimed to explore the production of ADM, changes and pathophysiological significance of ADM mRNA and ADM receptor components--calcitonin receptor like receptor (CRLR) and receptor activity modifying proteins (RAMPs) mRNA in calcified myocardium and aorta of rats induced by Vitamin D3 plus nicotine. Cholecalciferol 286-296 adrenomedullin Rattus norvegicus 100-103 14672955-9 2004 However, although adherence induced in response to D(3) was sensitive to silencing of p110alpha, LPS-induced adherence was not. Cholecalciferol 51-55 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha Homo sapiens 86-95 15083599-1 2004 Vitamin D3 is modified by vitamin D3-25-hydroxylase in the liver and 25-hydroxyvitamin D3-1 alpha-hydroxylase in the kidney to form the active metabolite 1 alpha,25-dihydroxyvitamin D3. Cholecalciferol 0-10 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 26-51 15083599-1 2004 Vitamin D3 is modified by vitamin D3-25-hydroxylase in the liver and 25-hydroxyvitamin D3-1 alpha-hydroxylase in the kidney to form the active metabolite 1 alpha,25-dihydroxyvitamin D3. Cholecalciferol 0-10 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 69-109 15214747-0 2004 The effect of vitamin D3 on CD34 progenitor cells in vitamin D deficiency rickets. Cholecalciferol 14-24 CD34 molecule Homo sapiens 28-32 14657394-0 2003 A pathway for the metabolism of vitamin D3: unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1). Cholecalciferol 32-42 cytochrome P450 family 11 subfamily A member 1 Homo sapiens 125-132 14753364-3 2004 A trend existed for pigs receiving the highest concentration of vitamin D3 supplementation to have a lower (P = 0.08) ADG (0.77 kg/d) compared with pigs fed either the 40-diet (0.88 kg/d) or control (0.92 kg/d). Cholecalciferol 64-74 ADG Sus scrofa 118-121 14696037-2 2004 Studies on the function of the hormonal form of vitamin D3, 1alpha,25-dihydroxyvitamin D3, have been greatly accelerated by the molecular cloning and structural analysis of the vitamin D3 receptor, which is a ligand-activated regulator of gene transcription. Cholecalciferol 48-58 vitamin D receptor Homo sapiens 177-196 14531785-2 2003 The condition of vitamin D insufficiency is defined as the level of serum 25(OH)vitamin D at which vitamin D2 or D3 supplementation leads to a reduction of levels of parathyroid hormone (PTH). Cholecalciferol 113-115 parathyroid hormone Homo sapiens 166-185 14507914-2 2003 In this study, inhibition of RelB expression in DCs exposed to an analog of the active form of vitamin D3 (1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3)) was observed and shown to be mediated by the vitamin D receptor (VDR). Cholecalciferol 95-105 RELB proto-oncogene, NF-kB subunit Homo sapiens 29-33 14507914-2 2003 In this study, inhibition of RelB expression in DCs exposed to an analog of the active form of vitamin D3 (1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3)) was observed and shown to be mediated by the vitamin D receptor (VDR). Cholecalciferol 95-105 vitamin D receptor Homo sapiens 203-221 14507914-2 2003 In this study, inhibition of RelB expression in DCs exposed to an analog of the active form of vitamin D3 (1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3)) was observed and shown to be mediated by the vitamin D receptor (VDR). Cholecalciferol 95-105 vitamin D receptor Homo sapiens 223-226 14531785-2 2003 The condition of vitamin D insufficiency is defined as the level of serum 25(OH)vitamin D at which vitamin D2 or D3 supplementation leads to a reduction of levels of parathyroid hormone (PTH). Cholecalciferol 113-115 parathyroid hormone Homo sapiens 187-190 14505649-3 2003 Therefore, 6-deoxy-5a-carba-beta-D-galactopyranosylamine (D-3) might be a promising lead compound for further design of new carba sugar-type beta-galactosidase inhibitors. Cholecalciferol 58-61 galactosidase beta 1 Homo sapiens 141-159 12893883-3 2003 Here, we show a unique facet of the intermolecular RXR-VDR interaction, in which RXR actively participates in vitamin D3-dependent gene transcription. Cholecalciferol 110-120 retinoid X receptor alpha Homo sapiens 51-54 12893883-3 2003 Here, we show a unique facet of the intermolecular RXR-VDR interaction, in which RXR actively participates in vitamin D3-dependent gene transcription. Cholecalciferol 110-120 vitamin D receptor Homo sapiens 55-58 12893883-3 2003 Here, we show a unique facet of the intermolecular RXR-VDR interaction, in which RXR actively participates in vitamin D3-dependent gene transcription. Cholecalciferol 110-120 retinoid X receptor alpha Homo sapiens 81-84 12893883-7 2003 These results confirm and extend the previous observations suggesting that RXR is a significant contributor to VDR-mediated gene expression and provide a mechanism by which RXR acts as a major contributor to vitamin D3-dependent transcription. Cholecalciferol 208-218 retinoid X receptor alpha Homo sapiens 75-78 12893883-7 2003 These results confirm and extend the previous observations suggesting that RXR is a significant contributor to VDR-mediated gene expression and provide a mechanism by which RXR acts as a major contributor to vitamin D3-dependent transcription. Cholecalciferol 208-218 vitamin D receptor Homo sapiens 111-114 12893883-7 2003 These results confirm and extend the previous observations suggesting that RXR is a significant contributor to VDR-mediated gene expression and provide a mechanism by which RXR acts as a major contributor to vitamin D3-dependent transcription. Cholecalciferol 208-218 retinoid X receptor alpha Homo sapiens 173-176 12972373-1 2003 The aim of the study was to investigate the influence of growth hormone (GH) on Vitamin D3 metabolism and the subsequent effects on calcium (Ca) homeostasis and skeletal growth in growing dogs. Cholecalciferol 80-90 somatotropin Canis lupus familiaris 73-75 12842807-5 2003 Vitamin D3-differentiated THP-1 cells and peripheral blood mononuclear cells were stimulated in vitro with several concentrations of SP-A for different incubation times. Cholecalciferol 0-10 surfactant protein A1 Homo sapiens 133-137 14550285-0 2003 Vitamin D3-dependent pathway regulates TACO gene transcription. Cholecalciferol 0-10 coronin 1A Homo sapiens 39-43 12867411-7 2003 Co-expression of CYP2R1 with vitamin D 1alpha-hydroxylase (CYP27B1) elicited additive activation of vitamin D3, whereas co-expression with vitamin D 24-hydroxylase (CYP24A1) caused inactivation. Cholecalciferol 100-110 cytochrome P450, family 2, subfamily r, polypeptide 1 Mus musculus 17-23 12867411-7 2003 Co-expression of CYP2R1 with vitamin D 1alpha-hydroxylase (CYP27B1) elicited additive activation of vitamin D3, whereas co-expression with vitamin D 24-hydroxylase (CYP24A1) caused inactivation. Cholecalciferol 100-110 cytochrome P450, family 27, subfamily b, polypeptide 1 Mus musculus 59-66 12907249-0 2003 Inhibition of MG-63 cell cycle progression by synthetic vitamin D3 analogs mediated by p27, Cdk2, cyclin E, and the retinoblastoma protein. Cholecalciferol 56-66 interferon alpha inducible protein 27 Homo sapiens 87-90 12907249-0 2003 Inhibition of MG-63 cell cycle progression by synthetic vitamin D3 analogs mediated by p27, Cdk2, cyclin E, and the retinoblastoma protein. Cholecalciferol 56-66 cyclin dependent kinase 2 Homo sapiens 92-96 12972373-0 2003 Growth hormone modulates cholecalciferol metabolism with moderate effects on intestinal mineral absorption and specific effects on bone formation in growing dogs raised on balanced food. Cholecalciferol 25-40 somatotropin Canis lupus familiaris 0-14 12972373-1 2003 The aim of the study was to investigate the influence of growth hormone (GH) on Vitamin D3 metabolism and the subsequent effects on calcium (Ca) homeostasis and skeletal growth in growing dogs. Cholecalciferol 80-90 somatotropin Canis lupus familiaris 57-71 12916707-0 2003 IL-1beta induces and TGF-beta reduces vitamin D3-induced bone resorption in mouse calvarial bone cells. Cholecalciferol 38-48 transforming growth factor, beta 1 Mus musculus 21-29 12916707-6 2003 TGF-beta reduced basal bone resorption and inhibited vitamin D3 [1,25(OH)2D3]-induced bone resorption in rat long bone cells. Cholecalciferol 53-63 transforming growth factor, beta 1 Rattus norvegicus 0-8 12892157-3 2003 This study aimed to determine whether supplementation with vitamin D3 to healthy children during the winter affects bone turnover in healthy children measured by serum osteocalcin, PICP, PINP or ICTP. Cholecalciferol 59-69 bone gamma-carboxyglutamate protein Homo sapiens 168-179 12697832-4 2003 Therefore, we addressed p300 control of basal and vitamin D(3)-enhanced activity of the OC promoter. Cholecalciferol 50-62 E1A binding protein p300 Homo sapiens 24-28 12858342-0 2003 Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. Cholecalciferol 0-10 TNF superfamily member 11 Homo sapiens 90-95 12890894-0 2003 Selective inhibition of mammalian DNA polymerase alpha by vitamin D2 and D3. Cholecalciferol 73-75 DNA polymerase alpha 1, catalytic subunit Homo sapiens 34-54 12736715-4 2003 Our results indicate that cells with endogenous or transfected exogenous c-myc overexpression (SW613-12A1 and -2G1mycP2Tu1 cell lines, respectively), activate the apoptotic machinery in response to the treatment with etoposide, doxorubicin and vitamin D3, which induce apoptosis through the death receptor Fas. Cholecalciferol 244-254 MYC proto-oncogene, bHLH transcription factor Homo sapiens 73-78 12727200-7 2003 We raise a possibility that a conformational change of VDR through its phosphorylation mediated by DNA-PKcs underlies the mechanism of gene repression by 1,25 vitamin D3-bound VDR. Cholecalciferol 159-169 vitamin D receptor Homo sapiens 55-58 12727200-7 2003 We raise a possibility that a conformational change of VDR through its phosphorylation mediated by DNA-PKcs underlies the mechanism of gene repression by 1,25 vitamin D3-bound VDR. Cholecalciferol 159-169 protein kinase, DNA-activated, catalytic subunit Homo sapiens 99-107 12727200-7 2003 We raise a possibility that a conformational change of VDR through its phosphorylation mediated by DNA-PKcs underlies the mechanism of gene repression by 1,25 vitamin D3-bound VDR. Cholecalciferol 159-169 vitamin D receptor Homo sapiens 176-179 12697832-4 2003 Therefore, we addressed p300 control of basal and vitamin D(3)-enhanced activity of the OC promoter. Cholecalciferol 50-62 bone gamma-carboxyglutamate protein Homo sapiens 88-90 12697832-5 2003 We find that transient overexpression of p300 results in a significant dose-dependent increase of both basal and vitamin D(3)-stimulated OC gene activity. Cholecalciferol 113-125 E1A binding protein p300 Homo sapiens 41-45 12697832-5 2003 We find that transient overexpression of p300 results in a significant dose-dependent increase of both basal and vitamin D(3)-stimulated OC gene activity. Cholecalciferol 113-125 bone gamma-carboxyglutamate protein Homo sapiens 137-139 12759887-7 2003 Furthermore, fecal elastase 1 of patients correlated the same way with both D(3)-vitamins (P <.01), as well as with parameters of BMD (P <.01). Cholecalciferol 76-89 chymotrypsin like elastase 3B Homo sapiens 13-29 12446453-0 2003 The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Cholecalciferol 4-14 tumor protein p53 Homo sapiens 53-56 12800453-0 2003 The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Cholecalciferol 14-24 insulin Homo sapiens 28-35 12800453-1 2003 The aim of this study was to evaluate the effect of vitamin D3 supplementation on insulin secretion and insulin resistance. Cholecalciferol 52-62 insulin Homo sapiens 82-89 12800453-14 2003 Bearing in mind that the main defects in type 2 diabetes mellitus are reduced FPIS and insulin resistance, and the favourable effect vitamin D3 had on them, we suggest vitamin D3 deficiency may at least partly contribute to the impairment of insulin secretion and probably of insulin action. Cholecalciferol 168-178 insulin Homo sapiens 87-94 12800453-14 2003 Bearing in mind that the main defects in type 2 diabetes mellitus are reduced FPIS and insulin resistance, and the favourable effect vitamin D3 had on them, we suggest vitamin D3 deficiency may at least partly contribute to the impairment of insulin secretion and probably of insulin action. Cholecalciferol 168-178 insulin Homo sapiens 242-249 12446453-0 2003 The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Cholecalciferol 4-14 mitogen-activated protein kinase 14 Homo sapiens 89-92 12446453-0 2003 The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Cholecalciferol 4-14 mitogen-activated protein kinase 1 Homo sapiens 134-137 12757166-10 2003 Therefore, ERCP and fecal elastase 1 verify the severity grade of a chronic pancreatitis, and thus show a vitamin D3 deficiency, depending on the progress of the disease. Cholecalciferol 106-116 chymotrypsin like elastase 3B Homo sapiens 20-36 12788662-0 2003 Melatonin and vitamin D3 increase TGF-beta1 release and induce growth inhibition in breast cancer cell cultures. Cholecalciferol 14-24 transforming growth factor, beta 1 Mus musculus 34-43 12577313-5 2003 The 1,25(OH)(2)D(3)-induced phosphorylation was abolished by GF109203X, a general PKC inhibitor, in both cell types, confirming that the secosteroid induced PKC activity. Cholecalciferol 15-19 protein kinase C, alpha Mus musculus 82-85 12577313-5 2003 The 1,25(OH)(2)D(3)-induced phosphorylation was abolished by GF109203X, a general PKC inhibitor, in both cell types, confirming that the secosteroid induced PKC activity. Cholecalciferol 15-19 protein kinase C, alpha Mus musculus 157-160 15758368-10 2003 Our data suggest that long-term treatment with calcium and 1,25(OH)(2) vitamin D3 supplements in hypoPTH patients on suppressive LT4 therapy results in increased BMD when compared with patients with normal PTH levels. Cholecalciferol 71-81 parathyroid hormone Homo sapiens 101-104 12649563-0 2003 Vitamin D receptor is expressed in pancreatic cancer cells and a vitamin D3 analogue decreases cell number. Cholecalciferol 65-75 vitamin D receptor Homo sapiens 0-18 12520525-0 2003 Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. Cholecalciferol 121-131 vitamin D receptor Homo sapiens 63-81 12711004-0 2003 Induction of apoptosis by 1,25-dihydroxyvitamin D3 in MCF-7 Vitamin D3-resistant variant can be sensitized by TPA. Cholecalciferol 60-70 plasminogen activator, tissue type Homo sapiens 110-113 12711004-6 2003 TPA pretreatment greatly enhances 1,25-(OH)(2)D(3) stimulated 24-hydroxylase luciferase activity and VDR protein expression, although transactivation is lower in the MCF-7(D(3)Res) cells compared to the parental cell line. Cholecalciferol 46-49 plasminogen activator, tissue type Homo sapiens 0-3 12711004-6 2003 TPA pretreatment greatly enhances 1,25-(OH)(2)D(3) stimulated 24-hydroxylase luciferase activity and VDR protein expression, although transactivation is lower in the MCF-7(D(3)Res) cells compared to the parental cell line. Cholecalciferol 46-49 vitamin D receptor Homo sapiens 101-104 12899518-1 2003 Calcitriol (1alpha,25(OH)2D3), the hormonally active form of vitamin D3 (D3) is produced by a cascade of reactions, including photochemical D3 synthesis in the skin and subsequent hydroxylation at the C-25 atom in the liver and finally at C-1alpha position in the kidney. Cholecalciferol 61-71 endogenous retrovirus group K member 1 Homo sapiens 239-247 12573816-0 2002 Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue. Cholecalciferol 79-89 insulin like growth factor 1 Homo sapiens 10-15 12371967-0 2002 Expression profiling confirms the role of endocytic receptor megalin in renal vitamin D3 metabolism. Cholecalciferol 78-88 low density lipoprotein receptor-related protein 2 Mus musculus 61-68 12399436-1 2002 The active form of vitamin D3 can regulate epidermal keratinization by inducing terminal differentiation; and mice lacking the vitamin D receptor display defects leading to postnatal alopecia. Cholecalciferol 19-29 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 127-145 12599478-0 2002 Rational design of vitamin D3 analogues which selectively restore activity to a vitamin D receptor mutant associated with rickets. Cholecalciferol 19-29 vitamin D receptor Homo sapiens 80-98 12599478-1 2002 [formula: see text] Vitamin D3-resistant rickets (VDRR) is associated with mutations to the Vitamin D receptor (VDR) which effect ligand-dependent transactivation. Cholecalciferol 20-30 vitamin D receptor Homo sapiens 92-110 12599478-1 2002 [formula: see text] Vitamin D3-resistant rickets (VDRR) is associated with mutations to the Vitamin D receptor (VDR) which effect ligand-dependent transactivation. Cholecalciferol 20-30 vitamin D receptor Homo sapiens 50-53 12018917-8 2002 These findings indicate that vitamin D3 regulates Na+/H+ exchange activity in rat ileum by influencing the mRNA levels of NHE3, the predominant luminal membrane isoform involved in vectorial Na+ transport. Cholecalciferol 29-39 solute carrier family 9 member A3 Rattus norvegicus 122-126 12400159-0 2002 [Analysis of molecular mechanism of cancer cell differentiation and apoptosis induced by vitamin D3 analogs on the basis of molecular recognition of vitamin D receptor ligand binding domain]. Cholecalciferol 89-99 vitamin D receptor Homo sapiens 149-167 12174089-11 2002 The lines of evidence for an effect of vitamin D3 in systemic cancer are the laboratory demonstration of relevant effects on cellular growth, differentiation, apoptosis, malignant cell invasion and metastasis; epidemiological findings of an association of the occurrence and outcome of cancers with derangements of vitamin D3/1,25(OH)2D3 and the association of functional polymorphisms of the VDR with the occurrence of certain cancers. Cholecalciferol 39-49 vitamin D receptor Homo sapiens 393-396 12363040-6 2002 The appearance of CD10 on the cell surface was blocked by preincubation of the cells with the monocytic/macrophage-differentiating agents vitamin D3 and phorbol 12-myristate 13-acetate, but not by the granulocytic differentiating agents retinoic acid or dimethyl sulfoxide. Cholecalciferol 138-148 membrane metalloendopeptidase Homo sapiens 18-22 12022443-2 2002 In human osteoblasts, we showed that vitamin D3 analogue, 1,25(OH)2D3, had a stimulatory effect on ALP activity after 3 days, compared with control. Cholecalciferol 37-47 ATHS Homo sapiens 99-102 11811942-3 2002 In the present study, we investigated whether vitamin D3 induces vascular endothelial growth factor (VEGF) release in aortic smooth muscle A10 cells. Cholecalciferol 46-56 vascular endothelial growth factor A Homo sapiens 65-99 11811942-3 2002 In the present study, we investigated whether vitamin D3 induces vascular endothelial growth factor (VEGF) release in aortic smooth muscle A10 cells. Cholecalciferol 46-56 vascular endothelial growth factor A Homo sapiens 101-105 11811942-4 2002 1,25-Dihydroxyvitamin D3 (1,25(OH)2VD3), an active form of vitamin D3, stimulated the VEGF release while 24,25-dihydroxyvitamin D3 (24,25(OH)2VD3), an inactive form of vitamin D3, had little effect on the release. Cholecalciferol 14-24 vascular endothelial growth factor A Homo sapiens 86-90 11811942-4 2002 1,25-Dihydroxyvitamin D3 (1,25(OH)2VD3), an active form of vitamin D3, stimulated the VEGF release while 24,25-dihydroxyvitamin D3 (24,25(OH)2VD3), an inactive form of vitamin D3, had little effect on the release. Cholecalciferol 59-69 vascular endothelial growth factor A Homo sapiens 86-90 12064463-0 2002 Signaling of monocytic differentiation by a non-hypercalcemic analog of vitamin D3, 1,25(OH)2-5,6 trans-16-ene-vitamin D3, involves nuclear vitamin D receptor (nVDR) and non-nVDR-mediated pathways. Cholecalciferol 72-82 vitamin D receptor Homo sapiens 140-158 12064463-0 2002 Signaling of monocytic differentiation by a non-hypercalcemic analog of vitamin D3, 1,25(OH)2-5,6 trans-16-ene-vitamin D3, involves nuclear vitamin D receptor (nVDR) and non-nVDR-mediated pathways. Cholecalciferol 111-121 vitamin D receptor Homo sapiens 140-158 11875645-0 2002 Effect of vitamin D3 on the increased expression of Bcl-xL in psoriasis. Cholecalciferol 10-20 BCL2 like 1 Homo sapiens 52-58 11801650-0 2002 Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes. Cholecalciferol 54-64 Fas cell surface death receptor Homo sapiens 23-27 11799400-1 2002 The human serum vitamin D-binding protein (DBP) has many physiologically important functions, ranging from transporting vitamin D3 metabolites, binding and sequestering globular actin and binding fatty acids to functioning in the immune system. Cholecalciferol 120-130 GC vitamin D binding protein Homo sapiens 16-41 11799400-1 2002 The human serum vitamin D-binding protein (DBP) has many physiologically important functions, ranging from transporting vitamin D3 metabolites, binding and sequestering globular actin and binding fatty acids to functioning in the immune system. Cholecalciferol 120-130 D-box binding PAR bZIP transcription factor Homo sapiens 43-46 11799400-2 2002 Here we report the 2.3 A crystal structure of DBP in complex with 25-hydroxyvitamin D3, a vitamin D3 metabolite, which reveals the vitamin D-binding site in the N-terminal part of domain I. Cholecalciferol 76-86 D-box binding PAR bZIP transcription factor Homo sapiens 46-49 11799400-3 2002 To more explicitly explore this, we also studied the structure of DBP in complex with a vitamin D3 analog. Cholecalciferol 88-98 D-box binding PAR bZIP transcription factor Homo sapiens 66-69 11799400-5 2002 These observed structural differences explain the unique vitamin D3-binding property of DBP. Cholecalciferol 57-67 D-box binding PAR bZIP transcription factor Homo sapiens 88-91 12022443-6 2002 These results also show that the vitamin D3 analogue stimulates ERK1 activation in primary human osteoblasts. Cholecalciferol 33-43 mitogen-activated protein kinase 3 Homo sapiens 64-68 11814331-5 2002 Treatment of ROS cells with Go6976, an inhibitor of PKC alpha and beta isozymes, produced similar effects as lead on vitamin D3-dependent osteocalcin production, while activation of PKC by phorbol-12-myristate-13-acetate (TPA) did not reverse or mimic this effect of lead. Cholecalciferol 117-127 bone gamma-carboxyglutamate protein Homo sapiens 138-149 11814331-2 2002 To explain this clinical observation, we investigated the mechanism of action of lead on vitamin D3-dependent osteocalcin production. Cholecalciferol 89-99 bone gamma-carboxyglutamate protein Homo sapiens 110-121 11814331-3 2002 Lead (5-20 microM) blocked the stimulating effects of vitamin D3 on osteocalcin production in cultured rat osteosarcoma cells (ROS 17/2.8). Cholecalciferol 54-64 bone gamma-carboxyglutamate protein Rattus norvegicus 68-79 12362981-2 2002 PRI-1906, an analog of vitamin D2, and PRI-2191, an analog of vitamin D3 bind nuclear vitamin D receptor (nVDR) with substantially lower affinity than 1,25-dihydroxyvitamin D3 (1,25-D3), but have higher differentiation-inducing activity as estimated in HL-60 leukemia cellmodel. Cholecalciferol 62-72 vitamin D receptor Homo sapiens 86-104 11748459-3 2002 The microarray showed that the most strongly up-regulated gene by 5-FU was vitamin D3 up-regulated protein 1 (VDUP1), an interesting stress response gene, which was originally reported as a vitamin D3 inducible gene in HL-60. Cholecalciferol 75-85 thioredoxin interacting protein Homo sapiens 110-115 12112004-0 2002 Differential regulation of Cbfa1/Runx2 and osteocalcin gene expression by vitamin-D3, dexamethasone, and local growth factors in primary human osteoblasts. Cholecalciferol 74-84 RUNX family transcription factor 2 Homo sapiens 27-32 12112004-0 2002 Differential regulation of Cbfa1/Runx2 and osteocalcin gene expression by vitamin-D3, dexamethasone, and local growth factors in primary human osteoblasts. Cholecalciferol 74-84 RUNX family transcription factor 2 Homo sapiens 33-38 12112004-0 2002 Differential regulation of Cbfa1/Runx2 and osteocalcin gene expression by vitamin-D3, dexamethasone, and local growth factors in primary human osteoblasts. Cholecalciferol 74-84 bone gamma-carboxyglutamate protein Homo sapiens 43-54 12903199-2 2002 The osteoblastic ROS17/2.8 cells abundantly express VDR and have been used for the promoter analysis of many of vitamin D3 target genes. Cholecalciferol 112-122 vitamin D receptor Rattus norvegicus 52-55 12112009-8 2002 These studies, together with our previous findings of auto-suppression of the Runx2 promoter and negative regulation by 1,25(OH)(2) Vitamin D3, suggest that physiological control of Runx2 gene expression is mediated by a series of intricate regulatory mechanisms. Cholecalciferol 132-142 RUNX family transcription factor 2 Rattus norvegicus 182-187 11602520-8 2001 The retinoic acid receptor ligand all-trans-retinoic acid augmented the 1,25-(OH)(2)-D(3)-mediated induction of CYP3A4 catalytic activity up to 2-fold in Caco-2 cells, while having no demonstrable effect on levels of CYP3A4 mRNA or protein. Cholecalciferol 85-89 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 112-118 11850224-1 2001 We investigated the effects of a nuclear receptor system constituted by retinoid X receptor (RXR) and its heterodimer partner on the aromatase activity in a cultured MCF-7 human breast cancer cell line and also in human ovarian granulosa cells, using each selective ligand for retinoic acid receptor, RAR (TTNPB), retinoid X receptor, RXR (LG100268), PPARgamma (troglitazone), and vitamin D3 receptor (cholecalciferol). Cholecalciferol 402-417 retinoid X receptor alpha Homo sapiens 93-96 11805636-13 2002 CONCLUSIONS: Posterior longitudinal ligament cells from the three North American white patients with ossification of the posterior longitudinal ligament, when cultured in vitro, synthesized osteocalcin on vitamin D3 priming, confirming their osteoblastic phenotype, whereas posterior longitudinal ligament cells from four white patients with isolated spondylosis did not. Cholecalciferol 205-215 bone gamma-carboxyglutamate protein Homo sapiens 190-201 11755212-1 2001 We have recently shown that the hormonal form of vitamin D3, 1,25(OH)2-vitamin D3 (1,25(OH)2D3), stimulates the enzymatic activity of the non-receptor protein tyrosine kinase c-Src in skeletal muscle cells. Cholecalciferol 49-59 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 175-180 11562285-9 2001 The discovery of novel vitamin D3 analogs along with an increased understanding of the biological functions and mechanisms of action of VDR are likely to result in improved treatments for responsive indications. Cholecalciferol 23-33 vitamin D receptor Homo sapiens 136-139 11602520-8 2001 The retinoic acid receptor ligand all-trans-retinoic acid augmented the 1,25-(OH)(2)-D(3)-mediated induction of CYP3A4 catalytic activity up to 2-fold in Caco-2 cells, while having no demonstrable effect on levels of CYP3A4 mRNA or protein. Cholecalciferol 85-89 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 217-223 11745731-3 2001 Surprisingly, only transformed cell lines were induced by 1alpha,25-dihydroxy vitamin D3 (D3) to express high amounts of CYP3A4. Cholecalciferol 86-88 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 121-127 11473365-0 2001 Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. Cholecalciferol 37-47 transforming growth factor beta 1 Homo sapiens 10-17 11473365-1 2001 In this study, we address whether TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in nonmalignant and malignant breast cells. Cholecalciferol 61-71 transforming growth factor beta 1 Homo sapiens 34-41 11473365-4 2001 Thus, the sensitivity to the vitamin D3 analogs correlated with the sensitivity to TGFbeta. Cholecalciferol 29-39 transforming growth factor beta 1 Homo sapiens 83-90 11473365-7 2001 These results are consistent with the idea that autocrine TGFbeta signaling mediates the anti-proliferative effects of the vitamin D3 analogs in these cells. Cholecalciferol 123-133 transforming growth factor beta 1 Homo sapiens 58-65 11473365-8 2001 The expression of TGFbeta isoforms and/or TGFbeta receptors was induced by the analogs in the vitamin D3 and TGFbeta sensitive cells. Cholecalciferol 94-104 transforming growth factor beta 1 Homo sapiens 18-25 11473365-8 2001 The expression of TGFbeta isoforms and/or TGFbeta receptors was induced by the analogs in the vitamin D3 and TGFbeta sensitive cells. Cholecalciferol 94-104 transforming growth factor beta 1 Homo sapiens 42-49 11473365-8 2001 The expression of TGFbeta isoforms and/or TGFbeta receptors was induced by the analogs in the vitamin D3 and TGFbeta sensitive cells. Cholecalciferol 94-104 transforming growth factor beta 1 Homo sapiens 42-49 11473365-14 2001 These results indicate that Smad3 coactivates VDR to further enhance TGFbeta signaling and vitamin D3 signaling in the sensitive 184A1 cells. Cholecalciferol 91-101 SMAD family member 3 Homo sapiens 28-33 11473365-14 2001 These results indicate that Smad3 coactivates VDR to further enhance TGFbeta signaling and vitamin D3 signaling in the sensitive 184A1 cells. Cholecalciferol 91-101 vitamin D receptor Homo sapiens 46-49 11493580-10 2001 Vitamin D3 supplementation causes a decrease of the serum PTH concentration, a decrease of bone turnover, and an increase of bone mineral density. Cholecalciferol 0-10 parathyroid hormone Homo sapiens 58-61 11376942-1 2001 VDUP1 encodes a vitamin D3-inducible gene product that has been shown to be down-regulated in chemically-induced mammary tumors in rats. Cholecalciferol 16-26 thioredoxin interacting protein Rattus norvegicus 0-5 11572331-0 2001 Stathmin levels in growth plate chondrocytes are modulated by vitamin D3 metabolites and transforming growth factor-beta1 and are associated with proliferation. Cholecalciferol 62-72 stathmin 1 Homo sapiens 0-8 11572331-14 2001 Inhibition of PKC with chelerythrine had no effect on the response of RC cells to 1alpha,25-(OH)2D3 but it blocked the effect of rhTGF-beta1, indicating that decreases in stathmin by vitamin D3 metabolites may not be modulated by PKC, whereas increases in stathmin via rhTGF-beta1 may be regulated via a PKC-dependent mechanism. Cholecalciferol 183-193 stathmin 1 Homo sapiens 171-179 11464105-0 2001 Tacalcitol, an active vitamin D3, induces nerve growth factor production in human epidermal keratinocytes. Cholecalciferol 22-32 nerve growth factor Homo sapiens 42-61 11464105-5 2001 These results suggest that active vitamin D3 could treat peripheral neuropathy by inducing NGF production in the skin. Cholecalciferol 34-44 nerve growth factor Homo sapiens 91-94 11516412-2 2001 Recent studies have shown that 1,25-dihydroxyvitamin D(3) (D3) enhances endogenous GDNF expression in vitro and in vivo. Cholecalciferol 59-61 glial cell derived neurotrophic factor Rattus norvegicus 83-87 11246549-1 2001 1Alpha,25-dihydroxyvitamin D3 (active form of vitamin D3; vitamin D3) has been reported to induce the upregulation of thrombomodulin and downregulation of tissue factor (TF) on monocytes. Cholecalciferol 19-29 coagulation factor III, tissue factor Rattus norvegicus 155-168 11339831-5 2001 Cells treated with D(3) or ATRA start to express CD11b after 9--14 h, before completing the first maturation division. Cholecalciferol 19-23 integrin subunit alpha M Homo sapiens 49-54 11332696-1 2001 In calcium homeostasis, vitamin D3 is a potent serum calcium-raising agent which in vivo regulates both calcitonin (CT) and parathyroid hormone (PTH) gene expression. Cholecalciferol 24-34 calcitonin-related polypeptide alpha Rattus norvegicus 104-114 11332696-1 2001 In calcium homeostasis, vitamin D3 is a potent serum calcium-raising agent which in vivo regulates both calcitonin (CT) and parathyroid hormone (PTH) gene expression. Cholecalciferol 24-34 calcitonin-related polypeptide alpha Rattus norvegicus 116-118 11332696-1 2001 In calcium homeostasis, vitamin D3 is a potent serum calcium-raising agent which in vivo regulates both calcitonin (CT) and parathyroid hormone (PTH) gene expression. Cholecalciferol 24-34 parathyroid hormone Rattus norvegicus 124-143 11332696-1 2001 In calcium homeostasis, vitamin D3 is a potent serum calcium-raising agent which in vivo regulates both calcitonin (CT) and parathyroid hormone (PTH) gene expression. Cholecalciferol 24-34 parathyroid hormone Rattus norvegicus 145-148 11332696-8 2001 Our results show, that, in rats, long term administration of vitamin D3 results in a decrease in hormone biosynthetic activities of both PTH and CT-producing cells, albeit at different magnitudes. Cholecalciferol 61-71 parathyroid hormone Rattus norvegicus 137-140 11332696-8 2001 Our results show, that, in rats, long term administration of vitamin D3 results in a decrease in hormone biosynthetic activities of both PTH and CT-producing cells, albeit at different magnitudes. Cholecalciferol 61-71 calcitonin-related polypeptide alpha Rattus norvegicus 145-147 11315990-0 2001 Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements. Cholecalciferol 31-41 vitamin D receptor Homo sapiens 55-74 11315990-0 2001 Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements. Cholecalciferol 31-41 retinoid X receptor alpha Homo sapiens 75-94 11332745-0 2001 Nongenomic vitamin D3 analogs activating ERK2 in HL-60 cells show that retinoic acid-induced differentiation and cell cycle arrest require early concurrent MAPK and RAR and RXR activation. Cholecalciferol 11-21 mitogen-activated protein kinase 1 Homo sapiens 41-45 11332745-0 2001 Nongenomic vitamin D3 analogs activating ERK2 in HL-60 cells show that retinoic acid-induced differentiation and cell cycle arrest require early concurrent MAPK and RAR and RXR activation. Cholecalciferol 11-21 RAB40B, member RAS oncogene family Homo sapiens 165-168 11332745-0 2001 Nongenomic vitamin D3 analogs activating ERK2 in HL-60 cells show that retinoic acid-induced differentiation and cell cycle arrest require early concurrent MAPK and RAR and RXR activation. Cholecalciferol 11-21 retinoid X receptor alpha Homo sapiens 173-176 11246549-1 2001 1Alpha,25-dihydroxyvitamin D3 (active form of vitamin D3; vitamin D3) has been reported to induce the upregulation of thrombomodulin and downregulation of tissue factor (TF) on monocytes. Cholecalciferol 19-29 coagulation factor III, tissue factor Rattus norvegicus 170-172 11246549-1 2001 1Alpha,25-dihydroxyvitamin D3 (active form of vitamin D3; vitamin D3) has been reported to induce the upregulation of thrombomodulin and downregulation of tissue factor (TF) on monocytes. Cholecalciferol 46-56 coagulation factor III, tissue factor Rattus norvegicus 155-168 11246549-1 2001 1Alpha,25-dihydroxyvitamin D3 (active form of vitamin D3; vitamin D3) has been reported to induce the upregulation of thrombomodulin and downregulation of tissue factor (TF) on monocytes. Cholecalciferol 46-56 coagulation factor III, tissue factor Rattus norvegicus 170-172 11270487-11 2001 Our results demonstrate that the biologically active form of vitamin D3 directly regulates the expression of p21 and p27, inducing a G0/G1 phase arrest: one mechanism by which 1,25(OH)2D3 controls cell proliferation inSCCHN. Cholecalciferol 61-71 H3 histone pseudogene 16 Homo sapiens 109-112 11270487-11 2001 Our results demonstrate that the biologically active form of vitamin D3 directly regulates the expression of p21 and p27, inducing a G0/G1 phase arrest: one mechanism by which 1,25(OH)2D3 controls cell proliferation inSCCHN. Cholecalciferol 61-71 interferon alpha inducible protein 27 Homo sapiens 117-120 11702003-6 2001 In conclusion, stanniocalcin 1 was expressed in the apical membrane of distal nephron segments and enhanced by vitamin D3. Cholecalciferol 111-121 stanniocalcin 1 Rattus norvegicus 15-30 11686044-1 2001 The key enzymes of vitamin D3 metabolism, renal 25-hydroxyvitamin D3 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24) were expressed in Escherichia coli, and their enzymatic properties were revealed. Cholecalciferol 19-29 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 119-124 11686044-4 2001 Enzymatic studies on substrate specificity of CYP27B1 revealed that 25-hydroxyl group of vitamin D3 was essential for the 1 alpha-hydroxylase activity, and 24-hydroxyl group enhanced the activity, but, 23-hydroxyl group greatly reduced the activity. Cholecalciferol 89-99 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 46-53 11702003-0 2001 Distribution of stanniocalcin 1 in rat kidney and its regulation by vitamin D3. Cholecalciferol 68-78 stanniocalcin 1 Rattus norvegicus 16-31 10944439-4 2000 The 5"-flanking region of ECAC1 contains four putative vitamin D(3)-responsive elements. Cholecalciferol 55-67 transient receptor potential cation channel subfamily V member 5 Homo sapiens 26-31 11374031-3 2001 We found that MGP transcription is downregulated by retinoic acid and transforming growth factor beta (TGF beta) whereas it is upregulated by vitamin D3 and cyclic AMP. Cholecalciferol 142-152 matrix Gla protein Rattus norvegicus 14-17 11122013-3 2000 Objectives Here we report the response of the TGF-beta regulation system to 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3], an active vitamin D3 analogue Patients/methods We studied two types of fibroblasts derived from normal and psoriatic lesional skin, using an enzyme-linked immunosorbent assay and Northern blotting techniques. Cholecalciferol 95-105 transforming growth factor beta 1 Homo sapiens 46-54 11089522-0 2000 A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1. Cholecalciferol 2-12 cyclin dependent kinase 2 Homo sapiens 76-80 11089522-0 2000 A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1. Cholecalciferol 2-12 cyclin dependent kinase 6 Homo sapiens 85-89 11089522-0 2000 A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1. Cholecalciferol 2-12 cyclin dependent kinase inhibitor 1B Homo sapiens 123-130 11080586-2 2000 As a unique member of the protein tyrosine phosphatase (PTP) superfamily, osteotesticular PTP (OST-PTP) is a receptor protein whose expression is highly regulated during osteoblast differentiation and in response to modulators of bone remodeling such as parathyroid hormone and vitamin D3. Cholecalciferol 278-288 protein tyrosine phosphatase, receptor type, U Mus musculus 26-54 11080586-2 2000 As a unique member of the protein tyrosine phosphatase (PTP) superfamily, osteotesticular PTP (OST-PTP) is a receptor protein whose expression is highly regulated during osteoblast differentiation and in response to modulators of bone remodeling such as parathyroid hormone and vitamin D3. Cholecalciferol 278-288 protein tyrosine phosphatase, receptor type, U Mus musculus 56-59 11080586-2 2000 As a unique member of the protein tyrosine phosphatase (PTP) superfamily, osteotesticular PTP (OST-PTP) is a receptor protein whose expression is highly regulated during osteoblast differentiation and in response to modulators of bone remodeling such as parathyroid hormone and vitamin D3. Cholecalciferol 278-288 protein tyrosine phosphatase, receptor type, U Mus musculus 90-93 11080586-2 2000 As a unique member of the protein tyrosine phosphatase (PTP) superfamily, osteotesticular PTP (OST-PTP) is a receptor protein whose expression is highly regulated during osteoblast differentiation and in response to modulators of bone remodeling such as parathyroid hormone and vitamin D3. Cholecalciferol 278-288 protein tyrosine phosphatase, receptor type, V Mus musculus 95-102 11140269-6 2000 The conversion of vitamin D3 generated after UVB irradiation to calcitriol is inhibited by ketoconazole indicating the involvement of P450 mixed function oxidases in this chemical reaction. Cholecalciferol 18-28 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 134-138 11046111-6 2000 Two markers of monocyte differentiation, Mac-1 expression and nitroblue tetrazolium reduction, are increased in arsenite-exposed, D(3)-costimulated cells. Cholecalciferol 130-134 integrin subunit alpha M Homo sapiens 41-46 10777696-4 2000 VIP, PACAP-27, and PACAP-38, at concentrations of 10(-6) M, all significantly inhibited formation of tartrate-resistant acid phosphatase-positive multinuclear cells (TRAP + MNC) in mouse bone marrow cultures stimulated by 1, 25(OH)(2)-vitamin D3 (D3; 10(-8) M). Cholecalciferol 235-245 vasoactive intestinal polypeptide Mus musculus 0-3 10951230-4 2000 We also studied the regulation of Fas and Fas ligand in skin cells by retinoic acid, vitamin D3, and dexamethasone as well as various cytokines. Cholecalciferol 85-95 Fas ligand Homo sapiens 42-52 12903442-0 2000 [The regulation of vitamin D3 and 9-cis-retinoic acid and their receptors on human hsp90 beta gene]. Cholecalciferol 19-29 heat shock protein 90 alpha family class B member 1 Homo sapiens 83-93 12903442-1 2000 OBJECTIVE: To study the effects of vitamin D3(VD3), 9-cis-retinoic acid (9-cis-RA) and their receptors on the regulation of human hsp90 beta gene. Cholecalciferol 35-45 heat shock protein 90 alpha family class B member 1 Homo sapiens 130-140 12903442-8 2000 In addition, EMSA results showed that unliganded VDR and RXR simultaneously bound to the vitamin D3 response element (VDRE) of hsp90 beta gene. Cholecalciferol 89-99 vitamin D receptor Homo sapiens 49-52 12903442-8 2000 In addition, EMSA results showed that unliganded VDR and RXR simultaneously bound to the vitamin D3 response element (VDRE) of hsp90 beta gene. Cholecalciferol 89-99 retinoid X receptor alpha Homo sapiens 57-60 12903442-8 2000 In addition, EMSA results showed that unliganded VDR and RXR simultaneously bound to the vitamin D3 response element (VDRE) of hsp90 beta gene. Cholecalciferol 89-99 heat shock protein 90 alpha family class B member 1 Homo sapiens 127-137 10886207-0 2000 Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Cholecalciferol 26-36 caspase 3 Homo sapiens 97-106 10886207-0 2000 Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Cholecalciferol 26-36 mitogen-activated protein kinase 14 Homo sapiens 111-114 10876100-0 2000 An evaluation of the biologic activity and vitamin D receptor binding affinity of the photoisomers of vitamin D3 and previtamin D3. Cholecalciferol 102-112 vitamin D receptor Homo sapiens 43-61 10777696-4 2000 VIP, PACAP-27, and PACAP-38, at concentrations of 10(-6) M, all significantly inhibited formation of tartrate-resistant acid phosphatase-positive multinuclear cells (TRAP + MNC) in mouse bone marrow cultures stimulated by 1, 25(OH)(2)-vitamin D3 (D3; 10(-8) M). Cholecalciferol 235-245 adenylate cyclase activating polypeptide 1 Mus musculus 19-24 11778232-0 2000 [Modulating effect of vitamin D3 in vitro on EGFR mRNA expression of human breast cancer cell lines]. Cholecalciferol 22-32 epidermal growth factor receptor Homo sapiens 45-49 10762037-0 2000 Synthesis of a novel class of cdc25A inhibitors from vitamin D3. Cholecalciferol 53-63 cell division cycle 25A Homo sapiens 30-36 11778232-1 2000 OBJECTIVE: To assess the modulating effects of vitamin D3, combined with or without tamoxifen, on cell proliferation and EGFR mRNA level of human breast cancer. Cholecalciferol 47-57 epidermal growth factor receptor Homo sapiens 121-125 11778232-5 2000 The growth inhibitory effect on the 2 cell lines could be augmented and accompanied by a decrease in EGFR mRNA level after combined treatment with IC50 dose of tamoxifen and 10(-10)-10(-9) mol/L vitamin D3. Cholecalciferol 195-205 epidermal growth factor receptor Homo sapiens 101-105 10702588-0 2000 Improved cholecalciferol nutrition in rats is noncalcemic, suppresses parathyroid hormone and increases responsiveness to 1, 25-dihydroxycholecalciferol. Cholecalciferol 9-24 parathyroid hormone Rattus norvegicus 70-89 10706136-0 2000 SN-1, a novel leukemic cell line with t(11;16)(q23;p13): myeloid characteristics and resistance to retinoids and vitamin D3. Cholecalciferol 113-123 solute carrier family 38 member 3 Homo sapiens 0-4 10712807-4 2000 At the same concentration, 9-cis RA and cholecalciferol induced ALP of chondroblast and osteoblast cells, respectively; ATRA, 9-cis RA and cholecalciferol induced PIP of chondroblast and undifferentiated cells. Cholecalciferol 40-55 alkaline phosphatase, biomineralization associated Canis lupus familiaris 64-67 10712807-4 2000 At the same concentration, 9-cis RA and cholecalciferol induced ALP of chondroblast and osteoblast cells, respectively; ATRA, 9-cis RA and cholecalciferol induced PIP of chondroblast and undifferentiated cells. Cholecalciferol 40-55 prolactin induced protein Canis lupus familiaris 163-166 10712807-4 2000 At the same concentration, 9-cis RA and cholecalciferol induced ALP of chondroblast and osteoblast cells, respectively; ATRA, 9-cis RA and cholecalciferol induced PIP of chondroblast and undifferentiated cells. Cholecalciferol 139-154 alkaline phosphatase, biomineralization associated Canis lupus familiaris 64-67 10712807-4 2000 At the same concentration, 9-cis RA and cholecalciferol induced ALP of chondroblast and osteoblast cells, respectively; ATRA, 9-cis RA and cholecalciferol induced PIP of chondroblast and undifferentiated cells. Cholecalciferol 139-154 prolactin induced protein Canis lupus familiaris 163-166 10623885-7 2000 A low concentration of D(3) synergistically stimulated IL-4-induced TRAP-positive MGC formation, whereas a high concentration of D(3) inhibited it. Cholecalciferol 23-27 interleukin 4 Homo sapiens 55-59 10676652-8 2000 In agreement with the recent identification of nuclear receptors for bile acids, our data suggest that functional interactions between nuclear bile acid signaling pathways, PKC, and nuclear receptors for retinoic acid and vitamin D3 are involved in the down-regulation of the myeloblastin gene and the induction of cell differentiation in human leukemic cells. Cholecalciferol 222-232 proteinase 3 Homo sapiens 276-288 10587349-4 1999 Furthermore, induction of CD14 expression in response to D(3) was abrogated by (a) the PI 3-kinase inhibitors LY294002 and wortmannin; (b) antisense oligonucleotides to mRNA for the p110 catalytic subunit of PI 3-kinase; and (c) a dominant negative mutant of PI 3-kinase. Cholecalciferol 57-61 CD14 molecule Homo sapiens 26-30 10721822-1 2000 Retinoic acid, vitamin D3 and triiodothyronine regulate keratinocyte proliferation and differentiation--processes that are disturbed in psoriatic skin--via binding to nuclear receptors for retinoic acid (RAR-alpha,-gamma), vitamin D3 (VDR), thyroid hormone (TR-alpha,-beta) plus the common heterodimer partners, the 9-cis-retinoic acid receptors (RXR-alpha,-beta). Cholecalciferol 15-25 retinoic acid receptor alpha Homo sapiens 204-256 10721822-1 2000 Retinoic acid, vitamin D3 and triiodothyronine regulate keratinocyte proliferation and differentiation--processes that are disturbed in psoriatic skin--via binding to nuclear receptors for retinoic acid (RAR-alpha,-gamma), vitamin D3 (VDR), thyroid hormone (TR-alpha,-beta) plus the common heterodimer partners, the 9-cis-retinoic acid receptors (RXR-alpha,-beta). Cholecalciferol 15-25 T cell receptor alpha locus Homo sapiens 258-266 10721822-1 2000 Retinoic acid, vitamin D3 and triiodothyronine regulate keratinocyte proliferation and differentiation--processes that are disturbed in psoriatic skin--via binding to nuclear receptors for retinoic acid (RAR-alpha,-gamma), vitamin D3 (VDR), thyroid hormone (TR-alpha,-beta) plus the common heterodimer partners, the 9-cis-retinoic acid receptors (RXR-alpha,-beta). Cholecalciferol 15-25 retinoid X receptor alpha Homo sapiens 347-356 11322510-4 2000 We also report on the permissive effects of Vitamin D3 and the Vitamin D3 analog EB 1089 in the promotion of apoptosis in p53-wild-type cells. Cholecalciferol 44-54 tumor protein p53 Homo sapiens 122-125 11322510-4 2000 We also report on the permissive effects of Vitamin D3 and the Vitamin D3 analog EB 1089 in the promotion of apoptosis in p53-wild-type cells. Cholecalciferol 63-73 tumor protein p53 Homo sapiens 122-125 10687144-0 2000 Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy. Cholecalciferol 0-10 CD34 antigen Mus musculus 66-70 10687144-2 2000 Using a metastatic Lewis lung carcinoma (LLC-LN7) tumor model, these CD34+ NS cells were shown to be present within the s.c. primary tumor tissue, but their levels declined after treatment with the inducer of myeloid cell differentiation, vitamin D3. Cholecalciferol 239-249 CD34 antigen Mus musculus 69-73 10687144-3 2000 Therefore, studies determined whether vitamin D3 treatment to diminish the CD34+ NS cell levels in LLC-LN7-bearing mice would enhance (a) intratumoral immune reactivity and (b) the antitumor activity of adoptive therapy consisting of tumor-reactive lymph node cells. Cholecalciferol 38-48 CD34 antigen Mus musculus 75-79 10687144-4 2000 The results showed that vitamin D3 treatment alone increased the intratumoral CD8+ cell content and the activity of the intratumoral infiltrate, as detected by production of interferon-gamma and expression of the p55 IL-2 receptor. Cholecalciferol 24-34 interferon gamma Mus musculus 174-190 10687144-7 2000 These studies demonstrate that vitamin D3 treatment increases intratumoral T-cell immune reactivity, and that coupling vitamin D3 treatment to diminish levels of CD34+ NS cells with adoptive immunotherapy enhances the effectiveness of the adoptively transferred tumor-reactive lymph node cells at limiting both metastasis and locoregional tumor recurrence. Cholecalciferol 119-129 CD34 antigen Mus musculus 162-166 10587349-5 1999 In THP-1 cells, induction of CD11b expression by D(3) was also abrogated by LY294002 and wortmannin. Cholecalciferol 49-53 integrin subunit alpha M Homo sapiens 29-34 10587349-6 1999 Similarly, LY294002 and wortmannin inhibited D(3)-induced expression of both CD14 and CD11b in peripheral blood monocytes. Cholecalciferol 45-49 CD14 molecule Homo sapiens 77-81 10587349-6 1999 Similarly, LY294002 and wortmannin inhibited D(3)-induced expression of both CD14 and CD11b in peripheral blood monocytes. Cholecalciferol 45-49 integrin subunit alpha M Homo sapiens 86-91 10554525-5 1999 The cytosolic GPx isoenzyme (cGPx) and thioredoxin reductase alpha (TrxR alpha) are upregulated during the process of differentiation and under the influence of 1.25 (OH)2 vitamin D3. Cholecalciferol 172-182 thioredoxin Homo sapiens 39-50 10674883-10 1999 Northern analysis demonstrated that RAR-alpha was down-regulated by dexamethasone, ICI, and TPA, whereas vitamin D3 and E2 up-regulated RAR-alpha. Cholecalciferol 105-115 retinoic acid receptor alpha Homo sapiens 136-145 10552213-5 1999 The augmented expression of CD86 induced by NiCl(2) and DNCB was significantly suppressed by DEX at concentrations in the range 10(-8) to 10(-5) M, which include concentrations less than its therapeutically effective concentration of 10(-7) M. Vit D3 also significantly suppressed NiCl(2)- and DNCB-induced augmented expression of CD86, at concentrations in the ranges 10(-9) to 10(-7) M and 10(-10) to 10(-7) M, respectively. Cholecalciferol 244-250 CD86 molecule Homo sapiens 28-32 10552213-8 1999 Only DEX suppressed HLA-DR antigen expression at 10(-5) M. TNFalpha secretion by stimulated DCs was suppressed by DEX and Vit D3, although their effects were not statistically significant. Cholecalciferol 122-128 tumor necrosis factor Homo sapiens 59-67 10541881-0 1999 Expression of vitamin D3 25-hydroxylase (CYP27) mRNA after induction by vitamin D3 or UVB radiation in keratinocytes of human skin equivalents--a preliminary study. Cholecalciferol 14-24 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 41-46 10517670-4 1999 In human skin nuclear extracts, VDR exclusively bound to DNA containing vitamin D3 response elements as heterodimers with retinoid X receptors. Cholecalciferol 72-82 vitamin D receptor Homo sapiens 32-35 10509435-7 1999 These results indicate that 25-OH-D3 is safe for use in laying hen feed as a source of vitamin D3 at 82.5 micrograms/kg feed (1x), with a margin of safety of approximately 5x between the proposed 1x level and the 5x level (412.5 micrograms/kg feed) that constitutes threshold toxicity in layers. Cholecalciferol 87-97 dopamine receptor D3 Gallus gallus 28-36 10541881-5 1999 CYP27 mRNA in keratinocytes is not constitutively expressed but is inducible both by vitamin D3 (780 nM) and by UVB radiation (300 nm, 30 mJ/cm2). Cholecalciferol 85-95 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 0-5 10438943-2 1999 B. burgdorferi induced secretion of IL-8 by vitamin D3-matured THP-1 cells, which was inhibited by a CD14-specific mAb known to block cellular activation by LPS and the prototypic spirochetal lipoprotein, outer surface protein A. Cholecalciferol 44-54 CD14 molecule Homo sapiens 101-105 10359826-4 1999 By using luciferase reporter gene constructs of truncated forms of the 1alpha-OHase promoter transfected into a modified pig kidney cell line, AOK-B50, we identified regulatory regions of the 1.4-kb 1alpha-OHase promoter for parathyroid hormone 1-34 [PTH(1-34)], forskolin, and 1,25-hydroxyvitamin D3 [1,25(OH)2D3]. Cholecalciferol 298-300 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 71-83 10373554-1 1999 Coexpression of the human TATA-binding protein (TBP)-associated factor 28 (hTAFII28) with the altered-specificity mutant TBP spm3 synergistically enhances transcriptional activation by the activation function 2 of the nuclear receptors (NRs) for estrogen and vitamin D3 from a reporter plasmid containing a TGTA element in mammalian cells. Cholecalciferol 259-269 TATA-box binding protein Homo sapiens 26-46 10373554-1 1999 Coexpression of the human TATA-binding protein (TBP)-associated factor 28 (hTAFII28) with the altered-specificity mutant TBP spm3 synergistically enhances transcriptional activation by the activation function 2 of the nuclear receptors (NRs) for estrogen and vitamin D3 from a reporter plasmid containing a TGTA element in mammalian cells. Cholecalciferol 259-269 TATA-box binding protein Homo sapiens 48-51 10373554-1 1999 Coexpression of the human TATA-binding protein (TBP)-associated factor 28 (hTAFII28) with the altered-specificity mutant TBP spm3 synergistically enhances transcriptional activation by the activation function 2 of the nuclear receptors (NRs) for estrogen and vitamin D3 from a reporter plasmid containing a TGTA element in mammalian cells. Cholecalciferol 259-269 TATA-box binding protein associated factor 11 Homo sapiens 75-83 10373554-1 1999 Coexpression of the human TATA-binding protein (TBP)-associated factor 28 (hTAFII28) with the altered-specificity mutant TBP spm3 synergistically enhances transcriptional activation by the activation function 2 of the nuclear receptors (NRs) for estrogen and vitamin D3 from a reporter plasmid containing a TGTA element in mammalian cells. Cholecalciferol 259-269 TATA-box binding protein Homo sapiens 121-124 10359826-4 1999 By using luciferase reporter gene constructs of truncated forms of the 1alpha-OHase promoter transfected into a modified pig kidney cell line, AOK-B50, we identified regulatory regions of the 1.4-kb 1alpha-OHase promoter for parathyroid hormone 1-34 [PTH(1-34)], forskolin, and 1,25-hydroxyvitamin D3 [1,25(OH)2D3]. Cholecalciferol 298-300 cytochrome P450 family 27 subfamily B member 1 Homo sapiens 199-211 10347174-0 1999 Differential regulation of direct repeat 3 vitamin D3 and direct repeat 4 thyroid hormone signaling pathways by the human TR4 orphan receptor. Cholecalciferol 43-53 nuclear receptor subfamily 2 group C member 2 Homo sapiens 122-125 10347174-1 1999 In situ hybridization analysis demonstrated that abundant testicular orphan receptor (TR4) transcripts were detected in kidney, intestine, and bone, which are vitamin D3 target organs. Cholecalciferol 159-169 nuclear receptor subfamily 2 group C member 2 Homo sapiens 86-89 10347174-2 1999 Cell transfection studies also demonstrated that the expression of the vitamin D3 target gene, 25-hydroxyvitamin D3 24-hydroxylase, can be repressed by TR4 through high affinity binding (Kd = 1.32 nM) to the direct repeat 3 vitamin D3 receptor response element (DR3VDRE). Cholecalciferol 71-81 nuclear receptor subfamily 2 group C member 2 Homo sapiens 152-155 10380891-3 1999 Furthermore, TRANCE is expressed on osteoblasts stimulated with vitamin D3, dexamethasone, and parathyroid hormone. Cholecalciferol 64-74 TNF superfamily member 11 Homo sapiens 13-19 10362505-4 1999 PLC gamma2 nuclear translocation increased progressively until 96 hours of vitamin D3 administration. Cholecalciferol 75-85 phospholipase C gamma 2 Homo sapiens 0-10 10362505-5 1999 A fourth PLC isozyme, beta2, present in the cytoplasm of untreated cells, translocates to the cytoplasm after vitamin D3 addition and reaches the highest concentration at the end of monocytic differentiation. Cholecalciferol 110-120 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 22-27 10365915-5 1999 We chose two conditions under which osteocalcin expression is known to be upregulated: exposure of osteoblastic cells to differentiation-promoting medium and to vitamin D3. Cholecalciferol 161-171 bone gamma-carboxyglutamate protein Rattus norvegicus 36-47 10365915-7 1999 Vitamin D3 treatment resulted in upregulation of osteocalcin activity without a corresponding change in p53 transactivation activity or expression. Cholecalciferol 0-10 bone gamma-carboxyglutamate protein Rattus norvegicus 49-60 10330159-0 1999 A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun. Cholecalciferol 24-34 colony stimulating factor 2 Homo sapiens 78-126 10330159-0 1999 A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun. Cholecalciferol 24-34 vitamin D receptor Homo sapiens 133-151 10330159-0 1999 A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun. Cholecalciferol 24-34 nuclear factor of activated T cells 2 Homo sapiens 182-187 10330159-0 1999 A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun. Cholecalciferol 24-34 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 203-208 10470102-5 1999 1,25(OH)2D3 mediates its biological activities through specific binding to the vitamin D3 receptor (VDR) and subsequent association with vitamin D3 response elements (VDRE) in genes modulated by 1,25(OH)2D3. Cholecalciferol 79-89 vitamin D receptor Homo sapiens 100-103 10383375-0 1999 Expression of c-erbB-4/HER4 is regulated in T47D breast carcinoma cells by retinoids and vitamin D3. Cholecalciferol 89-99 erb-b2 receptor tyrosine kinase 4 Homo sapiens 23-27 10231362-1 1999 Previously we expressed rat 25-hydroxyvitamin D3 24-hydroxylase (CYP24) cDNA in Escherichia coli JM109 and showed that CYP24 catalyses three-step monooxygenation towards 25-hydroxyvitamin D3 and 1alpha,25-dihydroxyvitamin D3 [Akiyoshi-Shibata, M., Sakaki, T., Ohyama, Y., Noshiro, M., Okuda, K. & Yabusaki, Y. Cholecalciferol 46-48 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 65-70 10231362-1 1999 Previously we expressed rat 25-hydroxyvitamin D3 24-hydroxylase (CYP24) cDNA in Escherichia coli JM109 and showed that CYP24 catalyses three-step monooxygenation towards 25-hydroxyvitamin D3 and 1alpha,25-dihydroxyvitamin D3 [Akiyoshi-Shibata, M., Sakaki, T., Ohyama, Y., Noshiro, M., Okuda, K. & Yabusaki, Y. Cholecalciferol 46-48 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 119-124 10426559-0 1999 In vivo and in vitro pharmacokinetics and metabolism studies of 26,26,26,27,27,27-F6-1,25(OH)2 vitamin D3 (Falecalcitriol) in rat: induction of vitamin D3-24-hydroxylase (CYP24) responsible for 23S-hydroxylation in target tissues and the drop in serum levels. Cholecalciferol 95-105 cytochrome P450, family 24, subfamily a, polypeptide 1 Rattus norvegicus 144-169 10203416-6 1999 The time course study, in the presence of 10(-8) M vitamin D3 (vit D3) showed a marked increase (fourfold) in ALP activity with a peak at day 3. Cholecalciferol 51-61 alkaline phosphatase, placental Homo sapiens 110-113 10203416-6 1999 The time course study, in the presence of 10(-8) M vitamin D3 (vit D3) showed a marked increase (fourfold) in ALP activity with a peak at day 3. Cholecalciferol 63-69 alkaline phosphatase, placental Homo sapiens 110-113 10203416-10 1999 In contrast, treatment with vit D3 induced a marked increase of ALP and OC transcripts. Cholecalciferol 28-34 alkaline phosphatase, placental Homo sapiens 64-67 10203416-10 1999 In contrast, treatment with vit D3 induced a marked increase of ALP and OC transcripts. Cholecalciferol 28-34 bone gamma-carboxyglutamate protein Homo sapiens 72-74 10470102-7 1999 To clarify the mechanism by which nine of these vitamin D3 analogs mediate their remarkably potent biological activities, we have investigated their abilities in PC-3 prostate cancer cells to transactivate a chroramphenicol acetyl transferase (CAT) reporter gene containing a VDRE from the human osteocalcin gene attached to a thymidine kinase minimal promoter. Cholecalciferol 48-58 chromobox 8 Homo sapiens 162-166 10470102-11 1999 In summary, this is the first report of a potent series of 20-cyclopropyl-cholecalciferol vitamin D3 analogs with the ability to inhibit proliferation of LNCaP, PC-3, DU-145, MCF-7 and HL-60 cell lines. Cholecalciferol 90-100 chromobox 8 Homo sapiens 161-165 10343528-1 1999 OBJECTIVES: The active form of vitamin D3, 1 alpha,25 dihydroxyvitamin D3 (1,25D3), through its interaction with vitamin D receptors (VDR), is reported to effect a variety of anabolic and catabolic events, especially in bone and cartilage tissues. Cholecalciferol 31-41 vitamin D receptor Homo sapiens 113-132 10200351-8 1999 The results of these experiments show that the newly developed 19-nor synthetic vitamin D3 analog, Ro 25-6760, as well as 1, 25-dihydroxyvitamin D3, induced the expression of p21waf1, resulted in a significant G1/G0 cell cycle arrest leading to impressive growth inhibition and induction of apoptosis associated with proteolytic cleavage of poly(ADP-ribose) polymerase (PARP) showing a possible involvement of apoptosis-specific activation of the ICE/CED-3 proteolitic pathway. Cholecalciferol 80-90 poly(ADP-ribose) polymerase 1 Homo sapiens 341-368 10200351-8 1999 The results of these experiments show that the newly developed 19-nor synthetic vitamin D3 analog, Ro 25-6760, as well as 1, 25-dihydroxyvitamin D3, induced the expression of p21waf1, resulted in a significant G1/G0 cell cycle arrest leading to impressive growth inhibition and induction of apoptosis associated with proteolytic cleavage of poly(ADP-ribose) polymerase (PARP) showing a possible involvement of apoptosis-specific activation of the ICE/CED-3 proteolitic pathway. Cholecalciferol 80-90 poly(ADP-ribose) polymerase 1 Homo sapiens 370-374 10090931-5 1999 The cyclin-dependent kinase (cdk) inhibitor p21(WAF1/CIP1) has a vitamin D3-responsive element (VDRE) in its promoter, and 1,25(OH)2D3 enhances the expression of p21(WAF1/CIP1) and induces differentiation of selected myeloid leukemic cell lines. Cholecalciferol 65-75 cyclin dependent kinase inhibitor 1A Homo sapiens 44-47 10090931-5 1999 The cyclin-dependent kinase (cdk) inhibitor p21(WAF1/CIP1) has a vitamin D3-responsive element (VDRE) in its promoter, and 1,25(OH)2D3 enhances the expression of p21(WAF1/CIP1) and induces differentiation of selected myeloid leukemic cell lines. Cholecalciferol 65-75 cyclin dependent kinase inhibitor 1A Homo sapiens 48-57 10090931-5 1999 The cyclin-dependent kinase (cdk) inhibitor p21(WAF1/CIP1) has a vitamin D3-responsive element (VDRE) in its promoter, and 1,25(OH)2D3 enhances the expression of p21(WAF1/CIP1) and induces differentiation of selected myeloid leukemic cell lines. Cholecalciferol 65-75 cyclin dependent kinase inhibitor 1A Homo sapiens 162-165 10090931-5 1999 The cyclin-dependent kinase (cdk) inhibitor p21(WAF1/CIP1) has a vitamin D3-responsive element (VDRE) in its promoter, and 1,25(OH)2D3 enhances the expression of p21(WAF1/CIP1) and induces differentiation of selected myeloid leukemic cell lines. Cholecalciferol 65-75 cyclin dependent kinase inhibitor 1A Homo sapiens 48-52 10090931-5 1999 The cyclin-dependent kinase (cdk) inhibitor p21(WAF1/CIP1) has a vitamin D3-responsive element (VDRE) in its promoter, and 1,25(OH)2D3 enhances the expression of p21(WAF1/CIP1) and induces differentiation of selected myeloid leukemic cell lines. Cholecalciferol 65-75 cyclin dependent kinase inhibitor 1A Homo sapiens 53-57 10399884-1 1999 In this article, we describe the development of a general synthetic strategy to functionalize the C-6 position of vitamin D3 and its biologically important metabolites, i.e. 25-hydroxyvitamin D3 (25-OH-D3) and 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3]. Cholecalciferol 114-124 complement C6 Homo sapiens 98-101 10399884-2 1999 We employed Mazur"s cyclovitamin D method to synthesize vitamin D3 analogs with several functionalities at the C-6 position. Cholecalciferol 56-66 complement C6 Homo sapiens 111-114 10424403-2 1999 In our study, HC-11 cells exhibited specific vitamin D3 receptors (VDR) determined by Northern analysis or flow cytometry and responded to 10 nM vitamin D3 treatment displaying strong growth inhibition, arrest in G0/G1 phase without evidence of apoptosis, and VDR mRNA reduction, although the percentage of cells expressing VDR protein remained unchanged. Cholecalciferol 45-55 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 67-70 10424403-4 1999 A down-regulation of VDR expression was observed after Ha-ras transformation of HC-11 cells which desensitized the cells to the growth inhibitory effects of vitamin D3. Cholecalciferol 157-167 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 21-24 10424403-4 1999 A down-regulation of VDR expression was observed after Ha-ras transformation of HC-11 cells which desensitized the cells to the growth inhibitory effects of vitamin D3. Cholecalciferol 157-167 Harvey rat sarcoma virus oncogene Mus musculus 55-61 10219964-2 1999 Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by 12 recombinant human cytochrome P450 (P450 or CYP) enzymes and by human liver microsomes have been investigated. Cholecalciferol 72-87 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 147-175 10219964-7 1999 Retinol, retinoic acid and cholecalciferol were strong inhibitors for xenobiotic oxidations catalysed by recombinant CYP1A1, 2C8 and 2C19. Cholecalciferol 27-42 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 117-123 10219964-9 1999 Dixon plots of inhibitions of CYP1A1-, 1A2-, 2C8- and 2C19-dependent xenobiotic oxidations by arachidonic acid, of CYP1A1-, 2B6- and 2C19-dependent activities by retinol, and of CYP1A1- and 2C19-dependent activities by cholecalciferol indicated that these chemicals inhibit P450 activities mainly through a competitive mechanism. Cholecalciferol 219-234 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 30-36 10219964-9 1999 Dixon plots of inhibitions of CYP1A1-, 1A2-, 2C8- and 2C19-dependent xenobiotic oxidations by arachidonic acid, of CYP1A1-, 2B6- and 2C19-dependent activities by retinol, and of CYP1A1- and 2C19-dependent activities by cholecalciferol indicated that these chemicals inhibit P450 activities mainly through a competitive mechanism. Cholecalciferol 219-234 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 115-121 10219964-9 1999 Dixon plots of inhibitions of CYP1A1-, 1A2-, 2C8- and 2C19-dependent xenobiotic oxidations by arachidonic acid, of CYP1A1-, 2B6- and 2C19-dependent activities by retinol, and of CYP1A1- and 2C19-dependent activities by cholecalciferol indicated that these chemicals inhibit P450 activities mainly through a competitive mechanism. Cholecalciferol 219-234 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 115-121 10232681-3 1999 In the present study, porcine CYP27B cDNA was cloned, and the effects of cAMP and vitamin D3 on the regulation of CYP27B1 mRNA expression in LLC-PK1 cells were examined. Cholecalciferol 82-92 cytochrome P450 family 27 subfamily B member 1 Sus scrofa 114-121 10205176-3 1999 PSU1 interacts in a ligand-dependent manner with the LBD of several NRs, including retinoic acid (RARalpha), retinoid X (RXRalpha), thyroid hormone (TRalpha), vitamin D3 (VDR) and oestrogen (ERalpha) receptors. Cholecalciferol 159-169 decapping enzyme complex catalytic subunit Saccharomyces cerevisiae S288C 0-4 10223184-13 1999 Thus the loss of the growth inhibitory effect of vitamin D3 in HBL100 cells may be caused by the expression of the large T antigen in the cells, and provide further evidence that VDR is required for efficient growth inhibition by vitamin D3. Cholecalciferol 230-240 vitamin D receptor Homo sapiens 179-182 10460008-1 1999 To examine whether synthetic vitamin D3 analog, 22-oxa-1,25(OH)2D3 (OCT) has an inhibitory effect on the growth of thyroid carcinoma, we tested the in vitro and in vivo effects of OCT on the growth of a well-differentiated thyroid cancer cell line, NPA. Cholecalciferol 29-39 plexin A2 Homo sapiens 68-71 9952315-0 1999 Greater synergism of retinoic acid receptor (RAR) agonists with vitamin D3 than that of retinoid X receptor (RXR) agonists with regard to growth inhibition and differentiation induction in monoblastic leukemia cells. Cholecalciferol 64-74 retinoic acid receptor alpha Homo sapiens 21-43 9952315-0 1999 Greater synergism of retinoic acid receptor (RAR) agonists with vitamin D3 than that of retinoid X receptor (RXR) agonists with regard to growth inhibition and differentiation induction in monoblastic leukemia cells. Cholecalciferol 64-74 retinoic acid receptor alpha Homo sapiens 45-48 10064589-3 1999 Here, we report a novel cytoplasmic localization of p21(Cip1/WAF1) in peripheral blood monocytes (PBMs) and in U937 cells undergoing monocytic differentiation by in vitro treatment with vitamin D3 or ectopic expression of p21(Cip1/WAF1), and analyze the biological consequences of this cytoplasmic expression. Cholecalciferol 186-196 cyclin dependent kinase inhibitor 1A Homo sapiens 52-55 10064589-3 1999 Here, we report a novel cytoplasmic localization of p21(Cip1/WAF1) in peripheral blood monocytes (PBMs) and in U937 cells undergoing monocytic differentiation by in vitro treatment with vitamin D3 or ectopic expression of p21(Cip1/WAF1), and analyze the biological consequences of this cytoplasmic expression. Cholecalciferol 186-196 cyclin dependent kinase inhibitor 1A Homo sapiens 56-60 10064589-3 1999 Here, we report a novel cytoplasmic localization of p21(Cip1/WAF1) in peripheral blood monocytes (PBMs) and in U937 cells undergoing monocytic differentiation by in vitro treatment with vitamin D3 or ectopic expression of p21(Cip1/WAF1), and analyze the biological consequences of this cytoplasmic expression. Cholecalciferol 186-196 cyclin dependent kinase inhibitor 1A Homo sapiens 61-65 10450176-3 1999 Immunohistochemistry using the specific monoclonal antibody 9A7 gamma directed against the nuclear vitamin D receptor was used to identify receptors for the active metabolite of vitamin D3 (1,25-dihydroxyvitamin D3). Cholecalciferol 178-188 vitamin D receptor Homo sapiens 99-117 10450176-7 1999 CONCLUSIONS: Colorectal cancer tissue expresses the nuclear vitamin D receptor and this could act as a potential therapeutic target for synthetic vitamin D3 differentiating agents. Cholecalciferol 146-156 vitamin D receptor Homo sapiens 60-78 10231710-1 1999 The solution structure of a biologically active modified linear endothelin-1 analogue, ET1-21[Cys(Acm)1,15, Aib3,11, Leu7], has been determined for the first time by two-dimensional nuclear magnetic resonance spectroscopy in a methanol-d3/water solvent mixture. Cholecalciferol 236-238 endothelin 1 Homo sapiens 64-76 10231710-1 1999 The solution structure of a biologically active modified linear endothelin-1 analogue, ET1-21[Cys(Acm)1,15, Aib3,11, Leu7], has been determined for the first time by two-dimensional nuclear magnetic resonance spectroscopy in a methanol-d3/water solvent mixture. Cholecalciferol 236-238 endothelin 1 Homo sapiens 87-90 10343528-1 1999 OBJECTIVES: The active form of vitamin D3, 1 alpha,25 dihydroxyvitamin D3 (1,25D3), through its interaction with vitamin D receptors (VDR), is reported to effect a variety of anabolic and catabolic events, especially in bone and cartilage tissues. Cholecalciferol 31-41 vitamin D receptor Homo sapiens 134-137 11056661-1 1999 INTRODUCTION: 1alpha,25-dihydroxyvitamin D(3)[1alpha,25(OH)(2)D(3)], the biologically active metabolite of vitamin D3, acts through an intracellular vitamin D receptor (VDR) and has several immunostimulatory effects. Cholecalciferol 107-117 vitamin D receptor Homo sapiens 149-167 9927498-0 1999 Vitamin D3 differentially regulates parathyroid hormone/parathyroid hormone-related peptide receptor expression in bone and cartilage. Cholecalciferol 0-10 parathyroid hormone 1 receptor Mus musculus 36-100 9933476-11 1999 In situ hybridization using mouse cRNA probes revealed that the increased BSP expression and decreased OPN expression in the vitamin D3-deficient mice was primarily in osteoblastic cells on the surface of calvariae and endosteal spaces of alveolar bone, on newly formed epiphyseal bone, and in cementoblasts and in hypertrophic chondrocytes. Cholecalciferol 125-135 secreted phosphoprotein 1 Mus musculus 103-106 9933476-12 1999 These studies are the first to show that BSP and OPN are differentially regulated by vitamin D3 in vivo, reflecting the diverse roles of these protein in bone remodeling. Cholecalciferol 85-95 black spleen Mus musculus 41-44 9933476-12 1999 These studies are the first to show that BSP and OPN are differentially regulated by vitamin D3 in vivo, reflecting the diverse roles of these protein in bone remodeling. Cholecalciferol 85-95 secreted phosphoprotein 1 Mus musculus 49-52 9933476-13 1999 Moreover, the increased expression of the BSP transgene in the rachitic mice demonstrates that vitamin D3 regulation of BSP expression is mediated, in part, by element(s) within the 2.7 kb promoter region. Cholecalciferol 95-105 black spleen Mus musculus 42-45 9933476-13 1999 Moreover, the increased expression of the BSP transgene in the rachitic mice demonstrates that vitamin D3 regulation of BSP expression is mediated, in part, by element(s) within the 2.7 kb promoter region. Cholecalciferol 95-105 black spleen Mus musculus 120-123 11056661-1 1999 INTRODUCTION: 1alpha,25-dihydroxyvitamin D(3)[1alpha,25(OH)(2)D(3)], the biologically active metabolite of vitamin D3, acts through an intracellular vitamin D receptor (VDR) and has several immunostimulatory effects. Cholecalciferol 107-117 vitamin D receptor Homo sapiens 169-172 9870260-3 1998 The affinity of these three vitamin D3 derivatives to the vitamin D receptor (VDR) and was determined. Cholecalciferol 28-38 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 58-76 9886497-0 1999 Transforming growth factor-beta1 is an autocrine mediator of U937 cell growth arrest and differentiation induced by vitamin D3 and retinoids. Cholecalciferol 116-126 transforming growth factor beta 1 Homo sapiens 0-32 10025676-0 1999 Vitamin D3 metabolites regulate LTBP1 and latent TGF-beta1 expression and latent TGF-beta1 incorporation in the extracellular matrix of chondrocytes. Cholecalciferol 0-10 latent transforming growth factor beta binding protein 1 Rattus norvegicus 32-37 10025676-0 1999 Vitamin D3 metabolites regulate LTBP1 and latent TGF-beta1 expression and latent TGF-beta1 incorporation in the extracellular matrix of chondrocytes. Cholecalciferol 0-10 transforming growth factor, beta 1 Rattus norvegicus 49-58 10025676-18 1999 Thus, vitamin D3 metabolites may play a role in regulating the availability of TGF-beta1 by modulating LTBP1 production. Cholecalciferol 6-16 transforming growth factor, beta 1 Rattus norvegicus 79-88 10025676-18 1999 Thus, vitamin D3 metabolites may play a role in regulating the availability of TGF-beta1 by modulating LTBP1 production. Cholecalciferol 6-16 latent transforming growth factor beta binding protein 1 Rattus norvegicus 103-108 9874511-4 1998 Northern analysis showed modulation of the expression of BMP-2 and BMP-4 mRNAs in two human osteosarcoma cell lines, MG63 and Saos-2, by prostaglandin E2 (PGE2), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), interferon-alpha (IFN-alpha), retinoic acid and 1,25(OH)2 vitamin D3. Cholecalciferol 280-282 bone morphogenetic protein 2 Homo sapiens 57-62 9874511-4 1998 Northern analysis showed modulation of the expression of BMP-2 and BMP-4 mRNAs in two human osteosarcoma cell lines, MG63 and Saos-2, by prostaglandin E2 (PGE2), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), interferon-alpha (IFN-alpha), retinoic acid and 1,25(OH)2 vitamin D3. Cholecalciferol 280-282 bone morphogenetic protein 4 Homo sapiens 67-72 9874511-10 1998 In Saos-2 cells only 1,25(OH)2 vitamin D3 had any great effect on BMP-2 expression, which was down-regulated to approximately 60% of control values. Cholecalciferol 31-41 bone morphogenetic protein 2 Homo sapiens 66-71 9870260-3 1998 The affinity of these three vitamin D3 derivatives to the vitamin D receptor (VDR) and was determined. Cholecalciferol 28-38 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 78-81 9795371-17 1998 Furthermore, biochemical markers indicating bone loss (ICTP) and increased bone turnover (PTH, OSC) correlated positively with IGFBP-1 and IGFBP-4 but negatively with IGF-I, IGFBP-3 and IGFBP-5, while the opposite was observed with bone formation markers (PICP, B-ALP) and vitamin D3 metabolites. Cholecalciferol 273-283 lanosterol synthase Homo sapiens 95-98 9764845-4 1998 Although cPLA2 mRNA and protein were constitutively expressed in untreated HaCaT cells, expression levels did not increase in response to cholecalciferol treatment; however, unlike COX-1 and cPLA2 expression, COX-2 mRNA and COX-2 protein expression increased in response to cholecalciferol treatment. Cholecalciferol 274-289 phospholipase A2 group IVA Homo sapiens 9-14 9764845-5 1998 Calphostin C, a potent protein kinase C inhibitor, significantly reduced cholecalciferol-induced PGE2 production by inhibiting cholecalciferol-enhanced COX-2 mRNA and protein expression. Cholecalciferol 73-88 mitochondrially encoded cytochrome c oxidase II Homo sapiens 152-157 9764845-5 1998 Calphostin C, a potent protein kinase C inhibitor, significantly reduced cholecalciferol-induced PGE2 production by inhibiting cholecalciferol-enhanced COX-2 mRNA and protein expression. Cholecalciferol 127-142 mitochondrially encoded cytochrome c oxidase II Homo sapiens 152-157 9764845-6 1998 These results indicate that (i) 1alpha,25(OH)2D3 does not induce PGE2 biosynthesis in keratinocytes, (ii) cholecalciferol-induced PGE2 production is primarily COX-2 dependent, and (iii) cholecalciferol enhances both COX-2 mRNA and protein expression, via a protein kinase C-dependent mechanism in human keratinocytes. Cholecalciferol 106-121 mitochondrially encoded cytochrome c oxidase II Homo sapiens 159-164 9764845-6 1998 These results indicate that (i) 1alpha,25(OH)2D3 does not induce PGE2 biosynthesis in keratinocytes, (ii) cholecalciferol-induced PGE2 production is primarily COX-2 dependent, and (iii) cholecalciferol enhances both COX-2 mRNA and protein expression, via a protein kinase C-dependent mechanism in human keratinocytes. Cholecalciferol 106-121 mitochondrially encoded cytochrome c oxidase II Homo sapiens 216-221 9753201-1 1998 The vitamin D receptor (VDR) is a nuclear receptor that mediates the effect of the active metabolite of vitamin D3, the 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3). Cholecalciferol 104-114 vitamin D receptor Rattus norvegicus 4-22 9733889-3 1998 Vitamin D3 did not induce NF-kappaB activation but selectively upregulated CXCR4 expression in minus clones. Cholecalciferol 0-10 C-X-C motif chemokine receptor 4 Homo sapiens 75-80 9733889-4 1998 The CXCR4 ligand stromal-cell derived factor-1 induced Ca2+ fluxes and inhibited both constitutive and vitamin D3-enhanced HIV replication in minus clones. Cholecalciferol 103-113 C-X-C motif chemokine receptor 4 Homo sapiens 4-9 9733889-4 1998 The CXCR4 ligand stromal-cell derived factor-1 induced Ca2+ fluxes and inhibited both constitutive and vitamin D3-enhanced HIV replication in minus clones. Cholecalciferol 103-113 C-X-C motif chemokine ligand 12 Homo sapiens 17-46 9808170-0 1998 Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Cholecalciferol 0-10 interferon gamma Homo sapiens 47-63 9753201-1 1998 The vitamin D receptor (VDR) is a nuclear receptor that mediates the effect of the active metabolite of vitamin D3, the 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3). Cholecalciferol 104-114 vitamin D receptor Rattus norvegicus 24-27 9703220-4 1998 The vitamin D3 metabolite increased ALP activity in these cells, whereas no effect of the hormone was observed on gamma-glutamyltranspeptidase and acid phosphatase activities. Cholecalciferol 4-14 ALPA Sus scrofa 36-39 9801993-0 1998 Vitamin D3 inhibits proliferation and increases c-myc expression in fibroblasts from psoriatic patients. Cholecalciferol 0-10 MYC proto-oncogene, bHLH transcription factor Homo sapiens 48-53 9677345-7 1998 Moreover, vitamin D3 enhanced calbindin-D28K synthesis as well as OC synthesis and alkaline phosphatase activity. Cholecalciferol 10-20 bone gamma-carboxyglutamate protein Homo sapiens 66-68 9773502-1 1998 In contrast to vitamin D3-dependent gene expression of calbindin (CaBP-D28k) in intestine and kidney, the cerebellar mRNA expression seems independent of vitamin D3. Cholecalciferol 15-25 calbindin 1 Gallus gallus 55-64 9714336-0 1998 p53-independent induction of WAF1/Cip1 is correlated with osteoblastic differentiation by vitamin D3. Cholecalciferol 90-100 tumor protein p53 Homo sapiens 0-3 9714336-0 1998 p53-independent induction of WAF1/Cip1 is correlated with osteoblastic differentiation by vitamin D3. Cholecalciferol 90-100 cyclin dependent kinase inhibitor 1A Homo sapiens 29-33 9714336-0 1998 p53-independent induction of WAF1/Cip1 is correlated with osteoblastic differentiation by vitamin D3. Cholecalciferol 90-100 cyclin dependent kinase inhibitor 1A Homo sapiens 34-38 9723955-0 1998 Regulation of RANTES and IL-8 production in normal human dermal fibroblasts by active vitamin D3 (tacalcitol). Cholecalciferol 86-96 C-C motif chemokine ligand 5 Homo sapiens 14-20 9723955-0 1998 Regulation of RANTES and IL-8 production in normal human dermal fibroblasts by active vitamin D3 (tacalcitol). Cholecalciferol 86-96 C-X-C motif chemokine ligand 8 Homo sapiens 25-29 9723955-11 1998 Three active vitamin D3 compounds, tacalcitol, 1alpha,25-dihydroxyvitamin D3 and MC903 (calcipotriol), inhibited the production of RANTES and IL-8, with very similar potencies. Cholecalciferol 13-23 C-C motif chemokine ligand 5 Homo sapiens 131-137 9723955-11 1998 Three active vitamin D3 compounds, tacalcitol, 1alpha,25-dihydroxyvitamin D3 and MC903 (calcipotriol), inhibited the production of RANTES and IL-8, with very similar potencies. Cholecalciferol 13-23 C-X-C motif chemokine ligand 8 Homo sapiens 142-146 9680096-2 1998 Progressive decreases in the steady-state levels of the mRNAs for thymidylate synthase, topoisomerase II, and hypoxanthine guanine phosphoribosyltransferase occurred following exposure to TPA or vitamin D3. Cholecalciferol 195-205 thymidylate synthetase Homo sapiens 66-86 9680096-2 1998 Progressive decreases in the steady-state levels of the mRNAs for thymidylate synthase, topoisomerase II, and hypoxanthine guanine phosphoribosyltransferase occurred following exposure to TPA or vitamin D3. Cholecalciferol 195-205 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 110-156 9680096-3 1998 In contrast, the steady-state levels of the mRNAs for thymidine kinase, topoisomerase I, and DNA polymerase-alpha did not decrease until days 3-5 of treatment with vitamin D3 and then progressively declined thereafter. Cholecalciferol 164-174 DNA polymerase alpha 1, catalytic subunit Homo sapiens 93-113 9551426-9 1998 Active vitamin D3 and platelet activating factor inhibit Pgp transport and are possible endogenous substrates in proximal tubule and mesangial cells, respectively. Cholecalciferol 7-17 phosphoglycolate phosphatase Homo sapiens 57-60 9673393-6 1998 Vitamin D3 analogs (10 nM) significantly counteracted the growth stimulation induced by TGF-a and IGF-I as well as the paracrine stimulation observed in co-cultures. Cholecalciferol 0-10 transforming growth factor alpha Homo sapiens 88-93 9673393-6 1998 Vitamin D3 analogs (10 nM) significantly counteracted the growth stimulation induced by TGF-a and IGF-I as well as the paracrine stimulation observed in co-cultures. Cholecalciferol 0-10 insulin like growth factor 1 Homo sapiens 98-103 11327011-5 1998 The vitamin D3 in products was extracted with chloroform and separated with mu-Bondapak C18 column(300 mm x 3.9 mm i.d.) Cholecalciferol 4-14 Bardet-Biedl syndrome 9 Homo sapiens 88-91 9678721-7 1998 CD14+ cell numbers were maintained, or recovered, in cultures supplemented with vitamin D3 (59% at day 7), and CD15+ cell numbers, too, remained unchanged in the presence of retinoic acid (67%) or vitamin D3 (66%). Cholecalciferol 80-90 CD14 molecule Homo sapiens 0-4 9705080-4 1998 The integrity of OLCs was confirmed by their ability to produce alkaline phosphatase and osteocalcin in response to vitamin D3 and also by their ability to deposit mineral. Cholecalciferol 116-126 bone gamma-carboxyglutamate protein Homo sapiens 89-100 9568710-1 1998 The ligand for osteoprotegerin has been identified, and it is a TNF-related cytokine that replaces the requirement for stromal cells, vitamin D3, and glucocorticoids in the coculture model of in vitro osteoclastogenesis. Cholecalciferol 134-144 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Mus musculus 15-30 9568645-0 1998 Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels. Cholecalciferol 128-138 CD34 antigen Mus musculus 161-165 9568645-6 1998 Similarly, treatment of LLC-LN7-bearing mice with vitamin D3 alone diminished the levels of CD34+ NS cells within regional lymph nodes, spleens and tumors. Cholecalciferol 50-60 CD34 antigen Mus musculus 92-96 9568645-10 1998 The results of this study show that treatment of tumor bearers with vitamin D3 to eliminate CD34+ NS cells improves the anti-tumor effectiveness of adoptively transferred tumor-reactive lymph node cells. Cholecalciferol 68-78 CD34 antigen Mus musculus 92-96 9528762-0 1998 A differential screen for ligand-regulated genes: identification of HoxA10 as a target of vitamin D3 induction in myeloid leukemic cells. Cholecalciferol 90-100 homeobox A10 Homo sapiens 68-74 9566710-0 1998 Enhancement by antisense oligonucleotides to NF-kappaB of the differentiation of HL-60 promyelocytic leukemia cells induced by vitamin D3. Cholecalciferol 127-137 nuclear factor kappa B subunit 1 Homo sapiens 45-54 9586948-9 1998 It is therefore possible that RXR-specific ligands may counteract certain biological actions of vitamin D3. Cholecalciferol 96-106 retinoid X receptor alpha Homo sapiens 30-33 9566710-2 1998 We have also shown that a variety of agents which inhibit NF-kappaB, including vitamin E and related antioxidants, curcumin and several non-steroidal anti-inflammatory agents, significantly enhanced the differentiation of HL-60 leukemia cells when combined with low levels of 1,25-dihydroxyvitamin D3 (vitamin D3). Cholecalciferol 290-300 nuclear factor kappa B subunit 1 Homo sapiens 58-67 9566710-3 1998 To provide further evidence that interference with the activation of NF-kappaB affects the maturation of HL-60 leukemia cells by creating an environment conducive to terminal differentiation, we measured the effects of phosphorothioate antisense oligonucleotides to the various subunits of NF-kappaB on the differentiation of HL-60 cells produced by low levels of vitamin D3. Cholecalciferol 364-374 nuclear factor kappa B subunit 1 Homo sapiens 69-78 9566710-5 1998 However, the antisense oligomer to the Rel A subunit of NF-kappaB markedly increased the extent of differentiation produced by low levels of vitamin D3. Cholecalciferol 141-151 RELA proto-oncogene, NF-kB subunit Homo sapiens 39-44 9566710-5 1998 However, the antisense oligomer to the Rel A subunit of NF-kappaB markedly increased the extent of differentiation produced by low levels of vitamin D3. Cholecalciferol 141-151 nuclear factor kappa B subunit 1 Homo sapiens 56-65 9566710-6 1998 An enhancement of the differentiation of HL-60 cells induced by vitamin D3 was also obtained by several transcription factor decoys designed to mimic the consensus sequences of genes activated by Rel A. Cholecalciferol 64-74 RELA proto-oncogene, NF-kB subunit Homo sapiens 196-201 9437041-1 1998 The ratio of baseline level/maximum level of serum parathyroid hormone (PTH) is high in PTH-deficient hypoparathyroidism and it decreases after vitamin D3 treatment. Cholecalciferol 144-154 parathyroid hormone Homo sapiens 51-70 9504637-1 1998 The effect of differentiating doses of all-trans retinoic acid (ATRA, 10(-6) M) and vitamin D3 (10(-7) M) was investigated on the nuclear levels of endogenous ceramide and protein kinase C-zeta (PKC-zeta) catalytic activity in HL-60 myeloid cells. Cholecalciferol 84-94 protein kinase C zeta Homo sapiens 172-193 9504637-1 1998 The effect of differentiating doses of all-trans retinoic acid (ATRA, 10(-6) M) and vitamin D3 (10(-7) M) was investigated on the nuclear levels of endogenous ceramide and protein kinase C-zeta (PKC-zeta) catalytic activity in HL-60 myeloid cells. Cholecalciferol 84-94 protein kinase C zeta Homo sapiens 195-203 9504637-3 1998 On the other hand, vitamin D3 increased the levels of nuclear ceramide and PKC-zeta activity to a lesser extent and with a delayed kinetics compared to ATRA (peak at 96 h). Cholecalciferol 19-29 protein kinase C zeta Homo sapiens 75-83 9492037-5 1998 All three vitamin D3 compounds decreased both basal and serum- and EGF-induced steady state PTHrP messenger RNA and secreted peptide levels. Cholecalciferol 10-20 epidermal growth factor Homo sapiens 67-70 9492037-5 1998 All three vitamin D3 compounds decreased both basal and serum- and EGF-induced steady state PTHrP messenger RNA and secreted peptide levels. Cholecalciferol 10-20 parathyroid hormone like hormone Homo sapiens 92-97 9484784-5 1998 Although U937 cells expressing WT1 were hampered in their ability to differentiate on incubation with retinoic acid and vitamin D3, the induced G1/G0-accumulation was similar to differentiating control cells treated with inducers. Cholecalciferol 120-130 WT1 transcription factor Homo sapiens 31-34 9602865-2 1998 The effects of vitamin D3 are mediated through the vitamin D3 receptor (VDR). Cholecalciferol 15-25 vitamin D receptor Homo sapiens 51-70 9602865-2 1998 The effects of vitamin D3 are mediated through the vitamin D3 receptor (VDR). Cholecalciferol 15-25 vitamin D receptor Homo sapiens 72-75 9602865-4 1998 In the present study the levels of VDR and RXR in involved and uninvolved psoriatic skin were determined by immunoblotting, and the binding of the VDR-RXR complex to a vitamin D3 response element (VDRE) consisting of two hexanucleotides spaced by three nucleotides (DR-3) by the electrophoretic mobility shift assay. Cholecalciferol 168-178 vitamin D receptor Homo sapiens 147-150 9781285-2 1998 In this paper we show that Cholecalciferol, a poor ligand of the vitamin D receptor, also induces cell death of HU197 human glioblastoma cell line and early passages cultures derived from a recurrent human glioblastoma. Cholecalciferol 27-42 vitamin D receptor Homo sapiens 65-83 9602865-4 1998 In the present study the levels of VDR and RXR in involved and uninvolved psoriatic skin were determined by immunoblotting, and the binding of the VDR-RXR complex to a vitamin D3 response element (VDRE) consisting of two hexanucleotides spaced by three nucleotides (DR-3) by the electrophoretic mobility shift assay. Cholecalciferol 168-178 retinoid X receptor alpha Homo sapiens 151-154 9625456-4 1998 Based on the fact that PTH requires vitamin D3 to take effect on calcium mobilization from bone, it is possible that VDR polymorphism may influence the PTH action on bone. Cholecalciferol 36-46 parathyroid hormone Homo sapiens 23-26 9625456-4 1998 Based on the fact that PTH requires vitamin D3 to take effect on calcium mobilization from bone, it is possible that VDR polymorphism may influence the PTH action on bone. Cholecalciferol 36-46 vitamin D receptor Homo sapiens 117-120 9457545-7 1998 As indicated by increased alkaline phosphatase-specific activity, increased cell-surface and matrix-associated protein, and 1.25 (OH2) vitamin D3-stimulated osteocalcin production, a more differentiated osteoblast-like phenotype was observed on the sintered HA surfaces compared to the as-received HA and calcined HA surfaces. Cholecalciferol 135-145 bone gamma-carboxyglutamate protein Homo sapiens 157-168 9570559-7 1998 Similarly, pretreatment of cells with either alphaIR3 or an IGF-binding protein, IGFBP-3, led to a 75% inhibition of CD11b expression when cells were cultured with vitamin D3 in serum-containing medium. Cholecalciferol 164-174 insulin like growth factor binding protein 3 Homo sapiens 81-88 9570559-7 1998 Similarly, pretreatment of cells with either alphaIR3 or an IGF-binding protein, IGFBP-3, led to a 75% inhibition of CD11b expression when cells were cultured with vitamin D3 in serum-containing medium. Cholecalciferol 164-174 integrin subunit alpha M Homo sapiens 117-122 9578149-0 1998 Effect of vitamin D3 on interleukin-6 synthesis induced by prostaglandins in osteoblasts. Cholecalciferol 10-20 interleukin 6 Mus musculus 24-37 9578149-2 1998 In the present study, we investigated the effect of vitamin D3 on IL-6 synthesis in MC3T3-E1 cells. Cholecalciferol 52-62 interleukin 6 Mus musculus 66-70 9578149-3 1998 1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), an active form of vitamin D3, inhibited the IL-6 synthesis induced by PGF2alpha or PGE1. Cholecalciferol 14-24 interleukin 6 Mus musculus 85-89 9578149-7 1998 These results strongly suggest that 1,25-(OH)2D3, an active form of vitamin D3, inhibits IL-6 synthesis at both the protein kinase C pathway and the protein kinase A pathway in osteoblasts. Cholecalciferol 68-78 interleukin 6 Mus musculus 89-93 9781285-5 1998 We determined the levels of sphingomyelin ceramide and ganglioside GD3 in Hu197 cells after treatment with cholecalciferol. Cholecalciferol 107-122 GRDX Homo sapiens 67-70 9503046-0 1998 Elevated PTH levels in hypovitaminosis D are more rapidly suppressed by the administration of 1,25-dihydroxy-vitamin D3 than by vitamin D3. Cholecalciferol 109-119 parathyroid hormone Homo sapiens 9-12 9541257-2 1998 Expression of BSP is suppressed by the osteotropic hormone, 1,25-dihydroxyvitamin D3 (vitamin D3), which regulates bone remodelling. Cholecalciferol 74-84 integrin-binding sialoprotein Rattus norvegicus 14-17 9541257-9 1998 These studies demonstrate that subtle differences in the nucleotide sequence of VDREs affect VDR binding, which mediates the vitamin D3 response. Cholecalciferol 125-135 vitamin D receptor Rattus norvegicus 80-83 9536224-0 1998 RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol). Cholecalciferol 128-138 C-C motif chemokine ligand 5 Homo sapiens 55-61 9536224-0 1998 RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol). Cholecalciferol 128-138 C-X-C motif chemokine ligand 8 Homo sapiens 66-70 9536224-13 1998 Tacalcitol (1 alpha,24(R)-dihydroxyvitamin D3), an active vitamin D3 analogue, inhibited RANTES and IL-8 production in cultured normal epidermal keratinocytes. Cholecalciferol 35-45 C-C motif chemokine ligand 5 Homo sapiens 89-95 9536224-13 1998 Tacalcitol (1 alpha,24(R)-dihydroxyvitamin D3), an active vitamin D3 analogue, inhibited RANTES and IL-8 production in cultured normal epidermal keratinocytes. Cholecalciferol 35-45 C-X-C motif chemokine ligand 8 Homo sapiens 100-104 21528312-3 1997 Addition of 10 nM and 100 nM vitamin D-3 to HL-60 cells cultured in the serum-free, chemically defined medium of insulin/transferrin/selenium (ITS) effected cell growth differently than cells maintained in a fetal bovine serum-supplemented medium. Cholecalciferol 29-40 insulin Homo sapiens 113-120 9425298-5 1997 Transfection of the vitamin D3 25-hydroxylase cDNA into simian COS cells resulted in the synthesis of an enzyme that was recognized by a monoclonal antibody raised against purified vitamin D3 25-hydroxylase and catalyzed 25-hydroxylation in the bioactivation of vitamin D3. Cholecalciferol 20-30 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 181-206 9437792-7 1998 The elucidation of the structure-function relationships at the DBP-binding-sites could have major impact on the development of new vitamin D3 derivatives with extended serum half-life. Cholecalciferol 131-141 D site albumin promoter binding protein Mus musculus 63-66 9390178-0 1997 Identification of the subdomain in the nuclear receptor for the hormonal form of vitamin D3, 1 alpha,25-dihydroxyvitamin D3, vitamin D receptor, that is covalently modified by an affinity labeling reagent. Cholecalciferol 81-91 vitamin D receptor Homo sapiens 125-143 9390178-1 1997 Multiple physiological actions of the hormonal form of vitamin D3, 1 alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), are mediated by a genomic pathway which is initiated by the highly specific recognition and binding by its cognate receptor (vitamin D receptor, VDR) in the target cells. Cholecalciferol 55-65 vitamin D receptor Homo sapiens 238-256 9390178-1 1997 Multiple physiological actions of the hormonal form of vitamin D3, 1 alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), are mediated by a genomic pathway which is initiated by the highly specific recognition and binding by its cognate receptor (vitamin D receptor, VDR) in the target cells. Cholecalciferol 55-65 vitamin D receptor Homo sapiens 258-261 9417865-4 1997 Consistent with macrophage specificity, HC gp-39 expression is also induced upon selective stimulation of the pluripotent promyelocytic leukemia cell line HL-60 toward the monocyte/macrophage lineage with vitamin D3 or phorbol 12-myristate 13-acetate (PMA), while treatments stimulating granulocyte and eosinophilic pathways do not induce expression. Cholecalciferol 205-215 chitinase 3 like 1 Homo sapiens 40-48 9417865-5 1997 Furthermore, HC gp-39 expression levels correlate with the degree of morphological differentiation induced by PMA and vitamin D3 treatments. Cholecalciferol 118-128 chitinase 3 like 1 Homo sapiens 13-21 21528312-3 1997 Addition of 10 nM and 100 nM vitamin D-3 to HL-60 cells cultured in the serum-free, chemically defined medium of insulin/transferrin/selenium (ITS) effected cell growth differently than cells maintained in a fetal bovine serum-supplemented medium. Cholecalciferol 29-40 transferrin Homo sapiens 121-132 9333117-6 1997 To investigate further the mechanism for the apparent species difference in vitamin D3 induction of mouse and human osteocalcin, we examined the effect of 1,25(OH)2D3 in an MC3T3-E1 cell line (MC4) containing a stably integrated 3900 bp osteocalcin promoter-luciferase construct. Cholecalciferol 76-86 bone gamma-carboxyglutamate protein Homo sapiens 116-127 9326225-9 1997 Similarly, Western blot analysis showed that expression of C/EBP epsilon protein was either unchanged or decreased slightly as the promyelocytic cell line NB4 differentiated down the macrophage-like pathway after treatment with a potent vitamin D3 analog (KH1060). Cholecalciferol 237-247 CCAAT enhancer binding protein epsilon Homo sapiens 59-72 9467970-1 1997 To understand the structural requirements for the biological activity of endothelin peptides and to develop receptor selective endothelin analogues further, the solution structure of the bicyclic 21 amino acid residue vasoactive peptide, endothelin-1, has been determined in methanol-d3/water using high-resolution 1H-NMR spectroscopy. Cholecalciferol 284-286 endothelin 1 Homo sapiens 238-250 9380407-2 1997 EB1089 treatment of the breast cancer cell lines MCF-7 E, BT20, T47D, and ZR75 demonstrated a correlation between a reduction in Cdk2 kinase activity towards phosphorylation of histone H1 and a decrease in DNA synthesis, while no modulation of Cdk2 activity was observed in the vitamin D3 and EB1089 resistant cell line MCF-7 L. This was accompanied by a time dependent decrease in the percentage of S phase cells in the responsive lines. Cholecalciferol 278-288 cyclin dependent kinase 2 Homo sapiens 129-133 9344190-5 1997 RESULTS: The vitamin D receptor has been detected in most skin cells, which means that keratinization, hair growth, melanogenesis, fibrogenesis, angiogenesis, and immune-mediated processes are potential targets for vitamin D3. Cholecalciferol 215-225 vitamin D receptor Homo sapiens 13-31 9302649-3 1997 The present study was conducted to determine whether a new vitamin D3 analogue, 22-oxacalcitriol, could be effective in inhibiting the proliferation and IL-8 secretion of normal human epidermal keratinocytes. Cholecalciferol 59-69 C-X-C motif chemokine ligand 8 Homo sapiens 153-157 9302649-9 1997 The inhibition of IL-8 secretion from keratinocytes by vitamin D3 could modulate the behaviour of immunocompetent cells infiltrating in the skin. Cholecalciferol 55-65 C-X-C motif chemokine ligand 8 Homo sapiens 18-22 9260973-7 1997 This discussion presents the hypothesis that reduced epidermal vitamin D3 photosynthesis associated with high skin melanin content and/or decreased UV light intensity at distances from the equator, alone or when coupled with decreased dietary calcium and vitamin D, may be associated with reduced vitamin D stores and increased parathyroid hormone secretion. Cholecalciferol 63-73 parathyroid hormone Homo sapiens 328-347 9430985-0 1997 [Serum bone Gla-protein increases following short-term oral administration of active vitamin D3 in the elderly with vitamin D deficiency]. Cholecalciferol 85-95 bone gamma-carboxyglutamate protein Homo sapiens 7-23 9430985-2 1997 It is well known that serum BGP levels increase after oral administration of active vitamin D3 in postmenopausal women and patients with chronic renal failure before dialysis. Cholecalciferol 84-94 bone gamma-carboxyglutamate protein Homo sapiens 28-31 9430985-3 1997 These findings indicate that active vitamin D3 increases the BGP production by osteoblasts. Cholecalciferol 36-46 bone gamma-carboxyglutamate protein Homo sapiens 61-64 9258754-2 1997 In this study, we examined the effect of vitamin D3 supplementation on BMD at the femoral neck in relation to VDR genotype. Cholecalciferol 41-51 vitamin D receptor Homo sapiens 110-113 9182762-5 1997 Osf2/Cbfa1 expression is initiated in the mesenchymal condensations of the developing skeleton, is strictly restricted to cells of the osteoblast lineage thereafter, and is regulated by BMP7 and vitamin D3. Cholecalciferol 195-205 RUNX family transcription factor 2 Homo sapiens 0-4 9207192-6 1997 Both biochemical and immunohistochemical analyses show proportionately greater increased presence of AR in the nucleus, accompanied by relatively reduced AR in the cytosol, following treatment of LNCaP cells with vitamin D3. Cholecalciferol 213-223 androgen receptor Homo sapiens 101-103 9207192-6 1997 Both biochemical and immunohistochemical analyses show proportionately greater increased presence of AR in the nucleus, accompanied by relatively reduced AR in the cytosol, following treatment of LNCaP cells with vitamin D3. Cholecalciferol 213-223 androgen receptor Homo sapiens 154-156 9207192-8 1997 These results suggest that vitamin D3 promotes the translocation of AR from the cytosol to the nucleus. Cholecalciferol 27-37 androgen receptor Homo sapiens 68-70 9196026-4 1997 While the expression of the TGM1 gene is markedly affected by the calcium concentration of the medium, all trans retinoic acid, vitamin D3, and TPA treatment, the expression of the RABGGTA gene was unaffected by these reagents. Cholecalciferol 128-138 transglutaminase 1 Homo sapiens 28-32 9278857-1 1997 We have synthesized and studied the ability of a series of seven novel 1 alpha,25(OH)2 vitamin D3 analogues to inhibit clonal growth of prostate cancer cells (LNCaP, PC-3 and DU-145). Cholecalciferol 87-97 chromobox 8 Homo sapiens 166-170 9192867-0 1997 Human TAF(II)135 potentiates transcriptional activation by the AF-2s of the retinoic acid, vitamin D3, and thyroid hormone receptors in mammalian cells. Cholecalciferol 91-101 TATA-box binding protein associated factor 4 Homo sapiens 6-16 9182762-5 1997 Osf2/Cbfa1 expression is initiated in the mesenchymal condensations of the developing skeleton, is strictly restricted to cells of the osteoblast lineage thereafter, and is regulated by BMP7 and vitamin D3. Cholecalciferol 195-205 RUNX family transcription factor 2 Homo sapiens 5-10 9108352-6 1997 The vitamin D3 suppression of HES-1 mRNA level was blocked by actinomycin D as well as cycloheximide, suggesting the involvement of transcriptional control, which requires new protein synthesis. Cholecalciferol 4-14 hes family bHLH transcription factor 1 Rattus norvegicus 30-35 9209684-2 1997 The actions of 1,25(OH)2D3 are mediated through the intracellular vitamin D receptor (VDR), and the level of VDR is believed to determine the cellular responsiveness to vitamin D3. Cholecalciferol 169-179 vitamin D receptor Homo sapiens 109-112 9148917-1 1997 A subset of nuclear receptors, including those for thyroid hormone (TR), retinoic acid, vitamin D3, and eicosanoids, can form heterodimers with the retinoid X receptor (RXR) on DNA regulatory elements in the absence of their cognate ligands. Cholecalciferol 88-98 retinoid X receptor alpha Homo sapiens 148-167 9148917-1 1997 A subset of nuclear receptors, including those for thyroid hormone (TR), retinoic acid, vitamin D3, and eicosanoids, can form heterodimers with the retinoid X receptor (RXR) on DNA regulatory elements in the absence of their cognate ligands. Cholecalciferol 88-98 retinoid X receptor alpha Homo sapiens 169-172 9184230-4 1997 Moreover, DR3 and DR4 elements which mediate vitamin D3 and thyroid hormone responses, respectively, in other contexts, are converted to exclusive RAR response elements when placed in the RARbeta2 promoter and EC cell context. Cholecalciferol 45-55 TNF receptor superfamily member 25 Homo sapiens 10-13 9184230-4 1997 Moreover, DR3 and DR4 elements which mediate vitamin D3 and thyroid hormone responses, respectively, in other contexts, are converted to exclusive RAR response elements when placed in the RARbeta2 promoter and EC cell context. Cholecalciferol 45-55 retinoic acid receptor alpha Homo sapiens 147-150 9125573-4 1997 Whereas tumor necrosis factor alpha, gamma interferon, bufalin, or granulocyte-macrophage colony-stimulating factor only marginally increased the ability of monocytic MonoMac-6 and myelomonocytic JOSK-M cells to interact with the bacteria, retinoic acid and vitamin D3 treatment for 2 to 4 days led to highly phagocytic cells that internalized gonococci in an Opa protein-specific manner. Cholecalciferol 258-268 colony stimulating factor 2 Homo sapiens 37-115 9108352-11 1997 These results indicate that HES-1 is expressed in osteoblastic cells and is involved in vitamin D3 regulation of osteoblastic gene expression. Cholecalciferol 88-98 hes family bHLH transcription factor 1 Rattus norvegicus 28-33 9073553-0 1997 Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. Cholecalciferol 25-35 alpha-N-acetylgalactosaminidase Homo sapiens 55-86 9176036-2 1997 The active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3, controls calcium absorption in the human duodenum, an effect that is mediated by mucosal vitamin D receptor expression. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 152-170 9130647-0 1997 Chemoattractant receptors for interleukin-8 and C5a: expression on peripheral blood leukocytes and differential regulation on HL-60 and AML-193 cells by vitamin D3 and all-trans retinoic acid. Cholecalciferol 153-163 C-X-C motif chemokine ligand 8 Homo sapiens 30-43 9130647-0 1997 Chemoattractant receptors for interleukin-8 and C5a: expression on peripheral blood leukocytes and differential regulation on HL-60 and AML-193 cells by vitamin D3 and all-trans retinoic acid. Cholecalciferol 153-163 complement C5a receptor 1 Homo sapiens 48-51 9130647-9 1997 Vitamin D3 (250 ng/ml, 7 days), which has been shown to induce differentiation of AML-193 and HL-60 cells into the monocytic phenotype, led to an up-regulation of IL-8RB and C5aR in both cell lines in the absence of any expression of IL-8RA. Cholecalciferol 0-10 C-X-C motif chemokine receptor 2 Homo sapiens 163-169 9130647-9 1997 Vitamin D3 (250 ng/ml, 7 days), which has been shown to induce differentiation of AML-193 and HL-60 cells into the monocytic phenotype, led to an up-regulation of IL-8RB and C5aR in both cell lines in the absence of any expression of IL-8RA. Cholecalciferol 0-10 complement C5a receptor 1 Homo sapiens 174-178 9130647-9 1997 Vitamin D3 (250 ng/ml, 7 days), which has been shown to induce differentiation of AML-193 and HL-60 cells into the monocytic phenotype, led to an up-regulation of IL-8RB and C5aR in both cell lines in the absence of any expression of IL-8RA. Cholecalciferol 0-10 C-X-C motif chemokine receptor 1 Homo sapiens 234-240 9077482-2 1997 In vitro, RXR and VDR-specific antibodies identified endogenous RXR and VDR bound to a vitamin D3-responsive element (DR3) as heterodimers (VDR-RXR). Cholecalciferol 87-97 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 72-75 9077482-2 1997 In vitro, RXR and VDR-specific antibodies identified endogenous RXR and VDR bound to a vitamin D3-responsive element (DR3) as heterodimers (VDR-RXR). Cholecalciferol 87-97 tumor necrosis factor receptor superfamily, member 25 Mus musculus 118-121 9077482-2 1997 In vitro, RXR and VDR-specific antibodies identified endogenous RXR and VDR bound to a vitamin D3-responsive element (DR3) as heterodimers (VDR-RXR). Cholecalciferol 87-97 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 72-75 9077482-2 1997 In vitro, RXR and VDR-specific antibodies identified endogenous RXR and VDR bound to a vitamin D3-responsive element (DR3) as heterodimers (VDR-RXR). Cholecalciferol 87-97 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 18-21 9126352-4 1997 The efficient concentration ranges of other vitamin D3 metabolites suggest a mediation through the VD nuclear receptor (VDR). Cholecalciferol 44-54 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 99-118 9126352-4 1997 The efficient concentration ranges of other vitamin D3 metabolites suggest a mediation through the VD nuclear receptor (VDR). Cholecalciferol 44-54 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 120-123 9192071-2 1997 We previously reported that 24 h treatment with 1 alpha, 25-dihydroxyvitamin D3 (1,25-D3), the active form of vitamin D3, induces calbindin-D28K and activates protein kinase C (PKC) in MDBK (Madin-Darby bovine kidney) cells. Cholecalciferol 69-79 protein kinase C alpha Bos taurus 177-180 9426846-11 1997 In our study, treatment with intravenous vitamin D3 led to significant suppression of PTH secretion. Cholecalciferol 41-51 parathyroid hormone Homo sapiens 86-89 9081214-0 1997 Paxillin increases as retinoic acid or vitamin D3 induce HL-60 cell differentiation. Cholecalciferol 39-49 paxillin Homo sapiens 0-8 8978456-0 1996 Regulation of rat interstitial collagenase gene expression in growth cartilage and chondrocytes by vitamin D3, interleukin-1 beta, and okadaic acid. Cholecalciferol 99-109 matrix metallopeptidase 13 Rattus norvegicus 18-42 9112257-2 1997 Synergistic induction of differentiation as measured by the above markers was observed when 1-10 muM curcumin was combined with 10-100 nM all-trans retinoic acid (RA) or with 100 nM 1 alpha, 25-dihydroxyvitamin D3 (vitamin D3). Cholecalciferol 203-213 latexin Homo sapiens 97-100 9018097-0 1996 Vitamin D3 reduces the apoptotic effect of IFN-gamma but does not facilitate HLA class II inducibility in RB-defective cells. Cholecalciferol 0-10 interferon gamma Homo sapiens 43-52 9018097-6 1996 Our results indicated that cotreating the RB-defective S4 cells with IFN-gamma and Vitamin D3 decreased the number of cells containing subdiploid DNA compared to cells treated with IFN-gamma alone, suggesting that Vitamin D3 reduced IFN-gamma-mediated apoptosis. Cholecalciferol 214-224 interferon gamma Homo sapiens 69-78 9018097-6 1996 Our results indicated that cotreating the RB-defective S4 cells with IFN-gamma and Vitamin D3 decreased the number of cells containing subdiploid DNA compared to cells treated with IFN-gamma alone, suggesting that Vitamin D3 reduced IFN-gamma-mediated apoptosis. Cholecalciferol 214-224 interferon gamma Homo sapiens 181-190 9018097-6 1996 Our results indicated that cotreating the RB-defective S4 cells with IFN-gamma and Vitamin D3 decreased the number of cells containing subdiploid DNA compared to cells treated with IFN-gamma alone, suggesting that Vitamin D3 reduced IFN-gamma-mediated apoptosis. Cholecalciferol 214-224 interferon gamma Homo sapiens 181-190 9018097-7 1996 S4 cells cotreated with Vitamin D3 and IFN-gamma also had decreased cell detachment, further indicating that Vitamin D3 decreased IFN-gamma induced apoptosis. Cholecalciferol 24-34 interferon gamma Homo sapiens 130-139 9018097-7 1996 S4 cells cotreated with Vitamin D3 and IFN-gamma also had decreased cell detachment, further indicating that Vitamin D3 decreased IFN-gamma induced apoptosis. Cholecalciferol 109-119 interferon gamma Homo sapiens 39-48 9018097-7 1996 S4 cells cotreated with Vitamin D3 and IFN-gamma also had decreased cell detachment, further indicating that Vitamin D3 decreased IFN-gamma induced apoptosis. Cholecalciferol 109-119 interferon gamma Homo sapiens 130-139 8977425-8 1997 Similarly, the alpha IR-3 mAb abrogated vitamin D3-induced differentiation of the HL-60 cells into macrophages in serum-free medium, as assessed by expression of the leucam surface protein, CD11b. Cholecalciferol 40-50 integrin subunit alpha M Homo sapiens 190-195 8980292-8 1997 These results suggest that EGF-treated HaCaT keratinocytes could serve for further studies of the vitamin D3 pathway and its relationship to proliferation and differentiation, but differences in calcitriol synthesis and catabolism from those in cultured primary keratinocytes or other cell lines must be considered. Cholecalciferol 98-108 epidermal growth factor Homo sapiens 27-30 8977259-0 1996 Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Cholecalciferol 98-108 interleukin 6 Homo sapiens 43-56 8940196-2 1996 We reported previously that the induced differentiation of the myelomonocytic cell line U937 by vitamin D3 is facilitated by the transcriptional induction of the p21(WAF1/CIP1) gene by the vitamin D3 receptor (Liu, M., Lee, M.-H., Cohen, M., and Freedman, L. P. (1996) Genes Dev. Cholecalciferol 96-106 cyclin dependent kinase inhibitor 1A Homo sapiens 162-165 8940196-2 1996 We reported previously that the induced differentiation of the myelomonocytic cell line U937 by vitamin D3 is facilitated by the transcriptional induction of the p21(WAF1/CIP1) gene by the vitamin D3 receptor (Liu, M., Lee, M.-H., Cohen, M., and Freedman, L. P. (1996) Genes Dev. Cholecalciferol 96-106 cyclin dependent kinase inhibitor 1A Homo sapiens 166-175 8940196-2 1996 We reported previously that the induced differentiation of the myelomonocytic cell line U937 by vitamin D3 is facilitated by the transcriptional induction of the p21(WAF1/CIP1) gene by the vitamin D3 receptor (Liu, M., Lee, M.-H., Cohen, M., and Freedman, L. P. (1996) Genes Dev. Cholecalciferol 96-106 vitamin D receptor Homo sapiens 189-208 9027335-5 1996 Elements allowing regulation by vitamin D3, pituitary-specific factors and Pit-1-dependent response to retinoic acid are well conserved. Cholecalciferol 32-42 POU class 1 homeobox 1 Rattus norvegicus 75-80 8906031-1 1996 OBJECTIVE: To evaluate the in vivo efficacy and clinical toxic effects of the 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in beta-luteinizing hormone-Tag (LH beta-Tag) transgenic mice with heritable retinoblastoma. Cholecalciferol 107-117 temporal alpha-galactosidase Mus musculus 155-158 8906031-1 1996 OBJECTIVE: To evaluate the in vivo efficacy and clinical toxic effects of the 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in beta-luteinizing hormone-Tag (LH beta-Tag) transgenic mice with heritable retinoblastoma. Cholecalciferol 107-117 luteinizing hormone beta Mus musculus 160-167 9167334-9 1996 Although many other topical treatments for psoriasis (occlusive therapy and vitamin D3 analogues) result in a prominent reduction in the amount of transglutaminase and involucrin positive cell layers, the effect of dithranol on these markers is minimal. Cholecalciferol 76-86 involucrin Homo sapiens 168-178 8895322-10 1996 Vitamin D3 also increased osteocalcin secretion in a dose-dependent manner when the clone was maintained at 34 C (approximately 6-fold), and this stimulation was enhanced > 5 fold at 40 C. In contrast to the low expression of alkaline phosphatase, the cells secreted high amounts of osteocalcin in response to vitamin D3 (approximately 15 ng/mg cell protein); this biochemical profile also resembled that of preosteocytes. Cholecalciferol 0-10 bone gamma-carboxyglutamate protein Homo sapiens 26-37 8895322-10 1996 Vitamin D3 also increased osteocalcin secretion in a dose-dependent manner when the clone was maintained at 34 C (approximately 6-fold), and this stimulation was enhanced > 5 fold at 40 C. In contrast to the low expression of alkaline phosphatase, the cells secreted high amounts of osteocalcin in response to vitamin D3 (approximately 15 ng/mg cell protein); this biochemical profile also resembled that of preosteocytes. Cholecalciferol 0-10 bone gamma-carboxyglutamate protein Homo sapiens 286-297 8839845-3 1996 M-CSF was found to induce substantial bone resorption and osteoclast formation in a dose-responsive and time-dependent manner above that induced by 1,25 dihydroxyvitamin D3 (1,25 vitamin D3) in cultures of human bone marrow (BM) stromal cells sedimented onto devitalized bone. Cholecalciferol 162-172 colony stimulating factor 1 Homo sapiens 0-5 8806764-1 1996 Vitamin D binding protein (DBP) plays an essential role in the vitamin D hormone endocrine system in sequestering vitamin D3 and its metabolites with high affinity, and transporting them to various target organs and tissues. Cholecalciferol 114-124 GC, vitamin D binding protein Rattus norvegicus 0-25 8806764-1 1996 Vitamin D binding protein (DBP) plays an essential role in the vitamin D hormone endocrine system in sequestering vitamin D3 and its metabolites with high affinity, and transporting them to various target organs and tissues. Cholecalciferol 114-124 D-box binding PAR bZIP transcription factor Rattus norvegicus 27-30 8841046-1 1996 In order to assess the effect of vitamin D receptor (VDR) gene polymorphisms on vitamin D3 therapy for postmenopausal bone loss. Cholecalciferol 80-90 vitamin D receptor Homo sapiens 33-51 8947586-0 1996 Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogs. Cholecalciferol 159-169 retinoic acid receptor alpha Homo sapiens 45-73 8877104-0 1996 Vitamin D3- and retinoic acid-induced monocytic differentiation: interactions between the endogenous vitamin D3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cells. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 101-120 8816911-0 1996 Vitamin D3 regulation of stromelysin-1 (MMP-3) in chondrocyte cultures is mediated by protein kinase C. Matrix metalloproteinases (MMPs) are a group of enzymes with the potential to degrade extracellular matrix proteins. Cholecalciferol 0-10 matrix metallopeptidase 3 Rattus norvegicus 25-38 8816911-0 1996 Vitamin D3 regulation of stromelysin-1 (MMP-3) in chondrocyte cultures is mediated by protein kinase C. Matrix metalloproteinases (MMPs) are a group of enzymes with the potential to degrade extracellular matrix proteins. Cholecalciferol 0-10 matrix metallopeptidase 3 Rattus norvegicus 40-45 8816911-0 1996 Vitamin D3 regulation of stromelysin-1 (MMP-3) in chondrocyte cultures is mediated by protein kinase C. Matrix metalloproteinases (MMPs) are a group of enzymes with the potential to degrade extracellular matrix proteins. Cholecalciferol 0-10 matrix metallopeptidase 3 Homo sapiens 131-135 8947586-8 1996 This mutation in the retinoic acid receptor alpha of the HL-60/RA cells may be responsible for drug resistance to ATRA and 9-cis-retinoic acid and increased sensitivity to vitamin D3 analogs. Cholecalciferol 172-182 retinoic acid receptor alpha Homo sapiens 21-49 8841046-1 1996 In order to assess the effect of vitamin D receptor (VDR) gene polymorphisms on vitamin D3 therapy for postmenopausal bone loss. Cholecalciferol 80-90 vitamin D receptor Homo sapiens 53-56 8806877-4 1996 We have demonstrated marked stimulation of chromaffin cell proliferation by vitamin D3, a potent stimulus to Ca2+ absorption not previously associated with adrenal medullary toxicity. Cholecalciferol 76-86 carbonic anhydrase 2 Rattus norvegicus 109-112 8761475-0 1996 Identification of a vitamin D3-response element that overlaps a unique inverted TATA box in the rat bone sialoprotein gene. Cholecalciferol 20-30 integrin-binding sialoprotein Rattus norvegicus 100-117 8931118-2 1996 We have previously shown that interleukin 1 beta (IL-1 beta) induces PGE2 production in synovial fibroblast cultures and that this effect is suppressed by the active metabolite of vitamin D3, 1,25-(OH)2D3. Cholecalciferol 180-190 interleukin 1 beta Homo sapiens 30-48 8931118-2 1996 We have previously shown that interleukin 1 beta (IL-1 beta) induces PGE2 production in synovial fibroblast cultures and that this effect is suppressed by the active metabolite of vitamin D3, 1,25-(OH)2D3. Cholecalciferol 180-190 interleukin 1 beta Homo sapiens 50-59